{"doc_id": 0, "doc": {"question": "下列常用口服adrenocorticoids藥，何者脂溶性最大？", "A": "prednisolone", "B": "triamcinolone", "C": "dexamethasone", "D": "hydrocortisone", "answer": "C", "questions": "下列常用口服adrenocorticoids藥，何者脂溶性最大？", "choices": ["prednisolone", "triamcinolone", "dexamethasone", "hydrocortisone"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列常用口服adrenocorticoids藥，何者脂溶性最大？\nA. prednisolone\nB. triamcinolone\nC. dexamethasone\nD. hydrocortisone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列常用口服adrenocorticoids藥，何者脂溶性最大？\nA. prednisolone\nB. triamcinolone\nC. dexamethasone\nD. hydrocortisone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列常用口服adrenocorticoids藥，何者脂溶性最大？\nA. prednisolone\nB. triamcinolone\nC. dexamethasone\nD. hydrocortisone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列常用口服adrenocorticoids藥，何者脂溶性最大？\nA. prednisolone\nB. triamcinolone\nC. dexamethasone\nD. hydrocortisone\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.125", "False"]], [["-5.625", "False"]], [["-0.00738525390625", "True"]], [["-7.625", "False"]]], "filtered_resps": [["-6.125", "False"], ["-5.625", "False"], ["-0.00738525390625", "True"], ["-7.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d8a0be96f32b96a9c5a47c6d69a6890cbb29edda2aadb3e0c97e7b4daf40aab6", "prompt_hash": "045d40ae9b13548f515bcef3b1dfb593d8e27de055e68965538ed99fbbf179f6", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 1, "doc": {"question": "下列何者在體內會進行Hofmann elimination而失去活性？", "A": "rocuronium", "B": "mivacurium", "C": "atracurium", "D": "doxacurium", "answer": "C", "questions": "下列何者在體內會進行Hofmann elimination而失去活性？", "choices": ["rocuronium", "mivacurium", "atracurium", "doxacurium"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者在體內會進行Hofmann elimination而失去活性？\nA. rocuronium\nB. mivacurium\nC. atracurium\nD. doxacurium\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者在體內會進行Hofmann elimination而失去活性？\nA. rocuronium\nB. mivacurium\nC. atracurium\nD. doxacurium\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者在體內會進行Hofmann elimination而失去活性？\nA. rocuronium\nB. mivacurium\nC. atracurium\nD. doxacurium\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者在體內會進行Hofmann elimination而失去活性？\nA. rocuronium\nB. mivacurium\nC. atracurium\nD. doxacurium\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.65625", "False"]], [["-5.78125", "False"]], [["-0.027099609375", "True"]], [["-5.65625", "False"]]], "filtered_resps": [["-5.65625", "False"], ["-5.78125", "False"], ["-0.027099609375", "True"], ["-5.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6bb27abf7403db716bb39e8887cdc45b18e0bced7129b3c6dbcf3bb1217d6f20", "prompt_hash": "65a151f8445be12faad3029f07edf5becb089166faf22e65597dec08ddfe6e4f", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 2, "doc": {"question": "下列有關warfarin的敘述，何者錯誤？", "A": "溶液狀態下會產生不具活性的cyclic hemiketal結構", "B": "具有lactone結構", "C": "會抑制vitamine K 2,3-epoxide reductase complex 1（VKORC1）", "D": "結構中的-OH基團有助於製成鹽類製劑", "answer": "A", "questions": "下列有關warfarin的敘述，何者錯誤？", "choices": ["溶液狀態下會產生不具活性的cyclic hemiketal結構", "具有lactone結構", "會抑制vitamine K 2,3-epoxide reductase complex 1（VKORC1）", "結構中的-OH基團有助於製成鹽類製劑"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關warfarin的敘述，何者錯誤？\nA. 溶液狀態下會產生不具活性的cyclic hemiketal結構\nB. 具有lactone結構\nC. 會抑制vitamine K 2,3-epoxide reductase complex 1（VKORC1）\nD. 結構中的-OH基團有助於製成鹽類製劑\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關warfarin的敘述，何者錯誤？\nA. 溶液狀態下會產生不具活性的cyclic hemiketal結構\nB. 具有lactone結構\nC. 會抑制vitamine K 2,3-epoxide reductase complex 1（VKORC1）\nD. 結構中的-OH基團有助於製成鹽類製劑\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關warfarin的敘述，何者錯誤？\nA. 溶液狀態下會產生不具活性的cyclic hemiketal結構\nB. 具有lactone結構\nC. 會抑制vitamine K 2,3-epoxide reductase complex 1（VKORC1）\nD. 結構中的-OH基團有助於製成鹽類製劑\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關warfarin的敘述，何者錯誤？\nA. 溶液狀態下會產生不具活性的cyclic hemiketal結構\nB. 具有lactone結構\nC. 會抑制vitamine K 2,3-epoxide reductase complex 1（VKORC1）\nD. 結構中的-OH基團有助於製成鹽類製劑\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.57421875", "True"]], [["-1.453125", "False"]], [["-3.953125", "False"]], [["-1.703125", "False"]]], "filtered_resps": [["-0.57421875", "True"], ["-1.453125", "False"], ["-3.953125", "False"], ["-1.703125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6019f353377014ebae6ae86489f1e239287c5627b643409848472f0026aff5b4", "prompt_hash": "10b822e0dff5f173e0bbbb97088e40c5457a8fad5d9e0d6a2e31fa8d48ae09a9", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 3, "doc": {"question": "Digoxin對於下列何種病因所造成的心臟衰竭具有最好的治療效果？", "A": "甲狀腺機能亢進", "B": "原發性高血壓", "C": "動脈瘤", "D": "貧血", "answer": "B", "questions": "Digoxin對於下列何種病因所造成的心臟衰竭具有最好的治療效果？", "choices": ["甲狀腺機能亢進", "原發性高血壓", "動脈瘤", "貧血"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nDigoxin對於下列何種病因所造成的心臟衰竭具有最好的治療效果？\nA. 甲狀腺機能亢進\nB. 原發性高血壓\nC. 動脈瘤\nD. 貧血\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nDigoxin對於下列何種病因所造成的心臟衰竭具有最好的治療效果？\nA. 甲狀腺機能亢進\nB. 原發性高血壓\nC. 動脈瘤\nD. 貧血\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nDigoxin對於下列何種病因所造成的心臟衰竭具有最好的治療效果？\nA. 甲狀腺機能亢進\nB. 原發性高血壓\nC. 動脈瘤\nD. 貧血\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nDigoxin對於下列何種病因所造成的心臟衰竭具有最好的治療效果？\nA. 甲狀腺機能亢進\nB. 原發性高血壓\nC. 動脈瘤\nD. 貧血\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.29296875", "True"]], [["-3.046875", "False"]], [["-4.03125", "False"]], [["-1.671875", "False"]]], "filtered_resps": [["-0.29296875", "True"], ["-3.046875", "False"], ["-4.03125", "False"], ["-1.671875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bf4eba1ea4ed3a8e1733f4ba4109acd13565caf0609851d9e4cbc78d1250a2f1", "prompt_hash": "ca145cc24fb148bd253f4d7d105b07664b25a964e2789ec91eea0674ad9a4877", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 4, "doc": {"question": "下列有關最小肺泡麻醉劑濃度（MAC）的敘述，何者正確？", "A": "一氧化二氮（N2 O）可輕易達到1個 MAC", "B": "體溫低的年老病人，其MAC值較低", "C": "長期使用中樞抑制劑，如酒精，MAC值會降低", "D": "同時併用嗎啡類止痛藥，MAC值會增加", "answer": "B", "questions": "下列有關最小肺泡麻醉劑濃度（MAC）的敘述，何者正確？", "choices": ["一氧化二氮（N2 O）可輕易達到1個 MAC", "體溫低的年老病人，其MAC值較低", "長期使用中樞抑制劑，如酒精，MAC值會降低", "同時併用嗎啡類止痛藥，MAC值會增加"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關最小肺泡麻醉劑濃度（MAC）的敘述，何者正確？\nA. 一氧化二氮（N2 O）可輕易達到1個 MAC\nB. 體溫低的年老病人，其MAC值較低\nC. 長期使用中樞抑制劑，如酒精，MAC值會降低\nD. 同時併用嗎啡類止痛藥，MAC值會增加\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關最小肺泡麻醉劑濃度（MAC）的敘述，何者正確？\nA. 一氧化二氮（N2 O）可輕易達到1個 MAC\nB. 體溫低的年老病人，其MAC值較低\nC. 長期使用中樞抑制劑，如酒精，MAC值會降低\nD. 同時併用嗎啡類止痛藥，MAC值會增加\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關最小肺泡麻醉劑濃度（MAC）的敘述，何者正確？\nA. 一氧化二氮（N2 O）可輕易達到1個 MAC\nB. 體溫低的年老病人，其MAC值較低\nC. 長期使用中樞抑制劑，如酒精，MAC值會降低\nD. 同時併用嗎啡類止痛藥，MAC值會增加\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關最小肺泡麻醉劑濃度（MAC）的敘述，何者正確？\nA. 一氧化二氮（N2 O）可輕易達到1個 MAC\nB. 體溫低的年老病人，其MAC值較低\nC. 長期使用中樞抑制劑，如酒精，MAC值會降低\nD. 同時併用嗎啡類止痛藥，MAC值會增加\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.109375", "False"]], [["-0.484375", "True"]], [["-2.234375", "False"]], [["-1.859375", "False"]]], "filtered_resps": [["-2.109375", "False"], ["-0.484375", "True"], ["-2.234375", "False"], ["-1.859375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5fdf8bc33aad3d1a4b1600d55235a722edee03001b250d086bd405f181aeb143", "prompt_hash": "eb43900ae00c9a7716479056ba09de49b3d24cd8cadaf94a0111fbdae96dcda6", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 5, "doc": {"question": "下列有關Pyrazinamide的敘述，何者錯誤？", "A": "主要副作用是肝毒性", "B": "它本身是Prodrug，其活性型是Pyrazinoic acid", "C": "它對肺結核的活性，在pH值偏鹼性的環境下抑制作用較強", "D": "高尿酸症的病人可能會誘發急性痛風關節炎", "answer": "C", "questions": "下列有關Pyrazinamide的敘述，何者錯誤？", "choices": ["主要副作用是肝毒性", "它本身是Prodrug，其活性型是Pyrazinoic acid", "它對肺結核的活性，在pH值偏鹼性的環境下抑制作用較強", "高尿酸症的病人可能會誘發急性痛風關節炎"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Pyrazinamide的敘述，何者錯誤？\nA. 主要副作用是肝毒性\nB. 它本身是Prodrug，其活性型是Pyrazinoic acid\nC. 它對肺結核的活性，在pH值偏鹼性的環境下抑制作用較強\nD. 高尿酸症的病人可能會誘發急性痛風關節炎\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Pyrazinamide的敘述，何者錯誤？\nA. 主要副作用是肝毒性\nB. 它本身是Prodrug，其活性型是Pyrazinoic acid\nC. 它對肺結核的活性，在pH值偏鹼性的環境下抑制作用較強\nD. 高尿酸症的病人可能會誘發急性痛風關節炎\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Pyrazinamide的敘述，何者錯誤？\nA. 主要副作用是肝毒性\nB. 它本身是Prodrug，其活性型是Pyrazinoic acid\nC. 它對肺結核的活性，在pH值偏鹼性的環境下抑制作用較強\nD. 高尿酸症的病人可能會誘發急性痛風關節炎\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Pyrazinamide的敘述，何者錯誤？\nA. 主要副作用是肝毒性\nB. 它本身是Prodrug，其活性型是Pyrazinoic acid\nC. 它對肺結核的活性，在pH值偏鹼性的環境下抑制作用較強\nD. 高尿酸症的病人可能會誘發急性痛風關節炎\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.0", "False"]], [["-1.7578125", "False"]], [["-0.259765625", "True"]], [["-3.265625", "False"]]], "filtered_resps": [["-4.0", "False"], ["-1.7578125", "False"], ["-0.259765625", "True"], ["-3.265625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a51ab0a4936ca1b41876a24319f7fa67f7c9ba2bea527ba4d2245beed874e2ce", "prompt_hash": "026453e43a21520c78670c40e993db4985272ff756f553e20139b44afdb20693", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 6, "doc": {"question": "Rosuvastatin具下列何種雜環結構？", "A": "pyrazole", "B": "pyrrole", "C": "imidazole", "D": "pyrimidine", "answer": "D", "questions": "Rosuvastatin具下列何種雜環結構？", "choices": ["pyrazole", "pyrrole", "imidazole", "pyrimidine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRosuvastatin具下列何種雜環結構？\nA. pyrazole\nB. pyrrole\nC. imidazole\nD. pyrimidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRosuvastatin具下列何種雜環結構？\nA. pyrazole\nB. pyrrole\nC. imidazole\nD. pyrimidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRosuvastatin具下列何種雜環結構？\nA. pyrazole\nB. pyrrole\nC. imidazole\nD. pyrimidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRosuvastatin具下列何種雜環結構？\nA. pyrazole\nB. pyrrole\nC. imidazole\nD. pyrimidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.671875", "False"]], [["-2.046875", "False"]], [["-2.921875", "False"]], [["-0.29296875", "True"]]], "filtered_resps": [["-2.671875", "False"], ["-2.046875", "False"], ["-2.921875", "False"], ["-0.29296875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4d0777f0e18eecf43a2e86c43126ed39c73007b531678dce7c9e15f3dd1e9c34", "prompt_hash": "b65c486a24e4a6826fe50692ae35084c9d2250a3d81d8299163da7ffc904bc17", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 7, "doc": {"question": "下列有關fosphenytoin相較於phenytoin 的敘述，何者錯誤？", "A": "口服給藥", "B": "水溶性較佳", "C": "為前驅藥", "D": "分子量較大", "answer": "A", "questions": "下列有關fosphenytoin相較於phenytoin 的敘述，何者錯誤？", "choices": ["口服給藥", "水溶性較佳", "為前驅藥", "分子量較大"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fosphenytoin相較於phenytoin 的敘述，何者錯誤？\nA. 口服給藥\nB. 水溶性較佳\nC. 為前驅藥\nD. 分子量較大\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fosphenytoin相較於phenytoin 的敘述，何者錯誤？\nA. 口服給藥\nB. 水溶性較佳\nC. 為前驅藥\nD. 分子量較大\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fosphenytoin相較於phenytoin 的敘述，何者錯誤？\nA. 口服給藥\nB. 水溶性較佳\nC. 為前驅藥\nD. 分子量較大\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fosphenytoin相較於phenytoin 的敘述，何者錯誤？\nA. 口服給藥\nB. 水溶性較佳\nC. 為前驅藥\nD. 分子量較大\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.08154296875", "True"]], [["-3.703125", "False"]], [["-4.09375", "False"]], [["-3.328125", "False"]]], "filtered_resps": [["-0.08154296875", "True"], ["-3.703125", "False"], ["-4.09375", "False"], ["-3.328125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "685639f966553f1220fbac3078443d40cce93b4ce37bb13923d057a3d40b39d0", "prompt_hash": "cad34eb60cf46bcd5cb3d1efb5e662669a2bdbd0f93e0c36c1289b02d5eed5e5", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 8, "doc": {"question": "下列何種化療藥物的作用原理（機制）與其它不同？", "A": "eribulin", "B": "imatinib", "C": "vincristine", "D": "paclitaxel", "answer": "B", "questions": "下列何種化療藥物的作用原理（機制）與其它不同？", "choices": ["eribulin", "imatinib", "vincristine", "paclitaxel"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種化療藥物的作用原理（機制）與其它不同？\nA. eribulin\nB. imatinib\nC. vincristine\nD. paclitaxel\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種化療藥物的作用原理（機制）與其它不同？\nA. eribulin\nB. imatinib\nC. vincristine\nD. paclitaxel\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種化療藥物的作用原理（機制）與其它不同？\nA. eribulin\nB. imatinib\nC. vincristine\nD. paclitaxel\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種化療藥物的作用原理（機制）與其它不同？\nA. eribulin\nB. imatinib\nC. vincristine\nD. paclitaxel\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.125", "False"]], [["-0.01031494140625", "True"]], [["-7.25", "False"]], [["-6.875", "False"]]], "filtered_resps": [["-7.125", "False"], ["-0.01031494140625", "True"], ["-7.25", "False"], ["-6.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "565e1a9f31342ed7c0ecd610ef95e4dd3852c76364419bb5f595a86658b4a2f6", "prompt_hash": "6ed22a6951e1a5890bff8c4f6ee3c9e6db2133d81c71c5ad4d244c69008ceda2", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 9, "doc": {"question": "選擇性5-HT3拮抗劑bemesetron的核心結構，源自下列何者？", "A": "cocaine", "B": "serotonin", "C": "aspirin", "D": "quinine", "answer": "A", "questions": "選擇性5-HT3拮抗劑bemesetron的核心結構，源自下列何者？", "choices": ["cocaine", "serotonin", "aspirin", "quinine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性5-HT3拮抗劑bemesetron的核心結構，源自下列何者？\nA. cocaine\nB. serotonin\nC. aspirin\nD. quinine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性5-HT3拮抗劑bemesetron的核心結構，源自下列何者？\nA. cocaine\nB. serotonin\nC. aspirin\nD. quinine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性5-HT3拮抗劑bemesetron的核心結構，源自下列何者？\nA. cocaine\nB. serotonin\nC. aspirin\nD. quinine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性5-HT3拮抗劑bemesetron的核心結構，源自下列何者？\nA. cocaine\nB. serotonin\nC. aspirin\nD. quinine\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.6484375", "False"]], [["-2.140625", "False"]], [["-4.15625", "False"]], [["-0.39453125", "True"]]], "filtered_resps": [["-1.6484375", "False"], ["-2.140625", "False"], ["-4.15625", "False"], ["-0.39453125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6768c7a93b45d4a2f48bef868b10d8ca73a841cf37b488c093846a57f897ee7a", "prompt_hash": "d2c501947e9db998ec98ed9235223c3d97cd2e6ef6ec8e43de941c5852ab299f", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 10, "doc": {"question": "關於嗎啡之藥理性質，那一項錯誤？", "A": "促進呼吸作用", "B": "具成癮性", "C": "有鎮咳作用", "D": "產生便秘", "answer": "A", "questions": "關於嗎啡之藥理性質，那一項錯誤？", "choices": ["促進呼吸作用", "具成癮性", "有鎮咳作用", "產生便秘"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於嗎啡之藥理性質，那一項錯誤？\nA. 促進呼吸作用\nB. 具成癮性\nC. 有鎮咳作用\nD. 產生便秘\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於嗎啡之藥理性質，那一項錯誤？\nA. 促進呼吸作用\nB. 具成癮性\nC. 有鎮咳作用\nD. 產生便秘\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於嗎啡之藥理性質，那一項錯誤？\nA. 促進呼吸作用\nB. 具成癮性\nC. 有鎮咳作用\nD. 產生便秘\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於嗎啡之藥理性質，那一項錯誤？\nA. 促進呼吸作用\nB. 具成癮性\nC. 有鎮咳作用\nD. 產生便秘\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0179443359375", "True"]], [["-4.90625", "False"]], [["-6.28125", "False"]], [["-4.90625", "False"]]], "filtered_resps": [["-0.0179443359375", "True"], ["-4.90625", "False"], ["-6.28125", "False"], ["-4.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6147f15ef4967bc83fe78e8efd7cb65f32cd797a7fc71146170112b1b91b1290", "prompt_hash": "f7cac06410555d0eaa90405b6ea80b003e932108bff621a6fba9d60158d62180", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 11, "doc": {"question": "下列有關antibody-drug conjugates（ADC）設計通則之敘述，何者正確？", "A": "高專一性抗體搭配低細胞毒性的小分子藥物", "B": "高專一性抗體搭配高細胞毒性的小分子藥物", "C": "低專一性抗體搭配高細胞毒性的小分子藥物", "D": "低專一性抗體搭配低細胞毒性的小分子藥物", "answer": "B", "questions": "下列有關antibody-drug conjugates（ADC）設計通則之敘述，何者正確？", "choices": ["高專一性抗體搭配低細胞毒性的小分子藥物", "高專一性抗體搭配高細胞毒性的小分子藥物", "低專一性抗體搭配高細胞毒性的小分子藥物", "低專一性抗體搭配低細胞毒性的小分子藥物"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關antibody-drug conjugates（ADC）設計通則之敘述，何者正確？\nA. 高專一性抗體搭配低細胞毒性的小分子藥物\nB. 高專一性抗體搭配高細胞毒性的小分子藥物\nC. 低專一性抗體搭配高細胞毒性的小分子藥物\nD. 低專一性抗體搭配低細胞毒性的小分子藥物\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關antibody-drug conjugates（ADC）設計通則之敘述，何者正確？\nA. 高專一性抗體搭配低細胞毒性的小分子藥物\nB. 高專一性抗體搭配高細胞毒性的小分子藥物\nC. 低專一性抗體搭配高細胞毒性的小分子藥物\nD. 低專一性抗體搭配低細胞毒性的小分子藥物\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關antibody-drug conjugates（ADC）設計通則之敘述，何者正確？\nA. 高專一性抗體搭配低細胞毒性的小分子藥物\nB. 高專一性抗體搭配高細胞毒性的小分子藥物\nC. 低專一性抗體搭配高細胞毒性的小分子藥物\nD. 低專一性抗體搭配低細胞毒性的小分子藥物\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關antibody-drug conjugates（ADC）設計通則之敘述，何者正確？\nA. 高專一性抗體搭配低細胞毒性的小分子藥物\nB. 高專一性抗體搭配高細胞毒性的小分子藥物\nC. 低專一性抗體搭配高細胞毒性的小分子藥物\nD. 低專一性抗體搭配低細胞毒性的小分子藥物\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.125", "False"]], [["-0.00506591796875", "True"]], [["-6.625", "False"]], [["-6.375", "False"]]], "filtered_resps": [["-7.125", "False"], ["-0.00506591796875", "True"], ["-6.625", "False"], ["-6.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e9152bfa3fcbbb3e491490f41abafac16ed8d739ebf601ec726bc0216ab7b3f0", "prompt_hash": "7dd429485c7cc26eef144ac713481d4c0f334999f35ecc2cd71bac3177d89070", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 12, "doc": {"question": "下列藥物何者口服吸收效果差？", "A": "nafcillin", "B": "dicloxacillin", "C": "amoxicillin", "D": "ampicillin", "answer": "A", "questions": "下列藥物何者口服吸收效果差？", "choices": ["nafcillin", "dicloxacillin", "amoxicillin", "ampicillin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者口服吸收效果差？\nA. nafcillin\nB. dicloxacillin\nC. amoxicillin\nD. ampicillin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者口服吸收效果差？\nA. nafcillin\nB. dicloxacillin\nC. amoxicillin\nD. ampicillin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者口服吸收效果差？\nA. nafcillin\nB. dicloxacillin\nC. amoxicillin\nD. ampicillin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者口服吸收效果差？\nA. nafcillin\nB. dicloxacillin\nC. amoxicillin\nD. ampicillin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.01385498046875", "True"]], [["-5.25", "False"]], [["-6.875", "False"]], [["-5.0", "False"]]], "filtered_resps": [["-0.01385498046875", "True"], ["-5.25", "False"], ["-6.875", "False"], ["-5.0", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "647076208ecdc6bcee089f4e454646b567f28289d711bb2c4a7a681db1f47d19", "prompt_hash": "d55eec2fec7116ac0973b2440bc855cc10c3268b0d771c324b7c139c8b5cdc94", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 13, "doc": {"question": "Vinblastine與paclitaxel共同點，下列何者錯誤？", "A": "皆會有骨髓抑制不良反應", "B": "可由肝臟中P450系統代謝", "C": "作用在有絲分裂期而抑制癌細胞分裂", "D": "皆能抑制微管蛋白聚合（tubulin polymerization）", "answer": "D", "questions": "Vinblastine與paclitaxel共同點，下列何者錯誤？", "choices": ["皆會有骨髓抑制不良反應", "可由肝臟中P450系統代謝", "作用在有絲分裂期而抑制癌細胞分裂", "皆能抑制微管蛋白聚合（tubulin polymerization）"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nVinblastine與paclitaxel共同點，下列何者錯誤？\nA. 皆會有骨髓抑制不良反應\nB. 可由肝臟中P450系統代謝\nC. 作用在有絲分裂期而抑制癌細胞分裂\nD. 皆能抑制微管蛋白聚合（tubulin polymerization）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nVinblastine與paclitaxel共同點，下列何者錯誤？\nA. 皆會有骨髓抑制不良反應\nB. 可由肝臟中P450系統代謝\nC. 作用在有絲分裂期而抑制癌細胞分裂\nD. 皆能抑制微管蛋白聚合（tubulin polymerization）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nVinblastine與paclitaxel共同點，下列何者錯誤？\nA. 皆會有骨髓抑制不良反應\nB. 可由肝臟中P450系統代謝\nC. 作用在有絲分裂期而抑制癌細胞分裂\nD. 皆能抑制微管蛋白聚合（tubulin polymerization）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nVinblastine與paclitaxel共同點，下列何者錯誤？\nA. 皆會有骨髓抑制不良反應\nB. 可由肝臟中P450系統代謝\nC. 作用在有絲分裂期而抑制癌細胞分裂\nD. 皆能抑制微管蛋白聚合（tubulin polymerization）\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.8125", "False"]], [["-0.5703125", "True"]], [["-3.3125", "False"]], [["-0.9453125", "False"]]], "filtered_resps": [["-4.8125", "False"], ["-0.5703125", "True"], ["-3.3125", "False"], ["-0.9453125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1ef8a50499d0c103a5ea85b2ffd0a059f8dcb034d128f5f6db812dea0b0bfc8c", "prompt_hash": "411251a3ce00285f739b7b8a1afdae34e5c77d39463193d0ac311ef27ba9e6bf", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 14, "doc": {"question": "下列有關acarbose之敘述，何者錯誤？", "A": "常見有胃腸道刺激、脹氣等副作用", "B": "主要以原型由胃腸道排出", "C": "可補充蔗糖來改善低血糖問題", "D": "可抑制glucoamylase", "answer": "C", "questions": "下列有關acarbose之敘述，何者錯誤？", "choices": ["常見有胃腸道刺激、脹氣等副作用", "主要以原型由胃腸道排出", "可補充蔗糖來改善低血糖問題", "可抑制glucoamylase"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關acarbose之敘述，何者錯誤？\nA. 常見有胃腸道刺激、脹氣等副作用\nB. 主要以原型由胃腸道排出\nC. 可補充蔗糖來改善低血糖問題\nD. 可抑制glucoamylase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關acarbose之敘述，何者錯誤？\nA. 常見有胃腸道刺激、脹氣等副作用\nB. 主要以原型由胃腸道排出\nC. 可補充蔗糖來改善低血糖問題\nD. 可抑制glucoamylase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關acarbose之敘述，何者錯誤？\nA. 常見有胃腸道刺激、脹氣等副作用\nB. 主要以原型由胃腸道排出\nC. 可補充蔗糖來改善低血糖問題\nD. 可抑制glucoamylase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關acarbose之敘述，何者錯誤？\nA. 常見有胃腸道刺激、脹氣等副作用\nB. 主要以原型由胃腸道排出\nC. 可補充蔗糖來改善低血糖問題\nD. 可抑制glucoamylase\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.4375", "False"]], [["-3.8125", "False"]], [["-0.062255859375", "True"]], [["-3.6875", "False"]]], "filtered_resps": [["-4.4375", "False"], ["-3.8125", "False"], ["-0.062255859375", "True"], ["-3.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "26b9ae024a4213f5d4b18d781aa7f150d0a50967c804760f51603e336521fb04", "prompt_hash": "1a80208a245fac3f1e902d2bbf5433c0a60043062d203e3b557ea04c14b3bf53", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 15, "doc": {"question": "臨床上使用降血脂藥物，下列何者可能會降低葡萄糖耐受性？", "A": "Gemfibrozil", "B": "Niacin", "C": "Atorvastatin", "D": "Ezetimibe", "answer": "B", "questions": "臨床上使用降血脂藥物，下列何者可能會降低葡萄糖耐受性？", "choices": ["Gemfibrozil", "Niacin", "Atorvastatin", "Ezetimibe"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上使用降血脂藥物，下列何者可能會降低葡萄糖耐受性？\nA. Gemfibrozil\nB. Niacin\nC. Atorvastatin\nD. Ezetimibe\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上使用降血脂藥物，下列何者可能會降低葡萄糖耐受性？\nA. Gemfibrozil\nB. Niacin\nC. Atorvastatin\nD. Ezetimibe\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上使用降血脂藥物，下列何者可能會降低葡萄糖耐受性？\nA. Gemfibrozil\nB. Niacin\nC. Atorvastatin\nD. Ezetimibe\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上使用降血脂藥物，下列何者可能會降低葡萄糖耐受性？\nA. Gemfibrozil\nB. Niacin\nC. Atorvastatin\nD. Ezetimibe\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.75", "False"]], [["-0.006988525390625", "True"]], [["-6.0", "False"]], [["-7.125", "False"]]], "filtered_resps": [["-5.75", "False"], ["-0.006988525390625", "True"], ["-6.0", "False"], ["-7.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ff33606a861756ff531026db01f934e4dbb7d398434f7d6c0c9f1fff493b5554", "prompt_hash": "2dc2546013eaf05a8f6671aba95814a89eaf5c8278570f5ee1ac7c1e07ef0866", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 16, "doc": {"question": "β-blockers用於治療心律不整之機制，下列何者正確？", "A": "活化鉀離子通道，增加AV node再極化程度", "B": "延長AV conduction time及有效不反應期", "C": "降低鈉離子通道活化閾值，增加同步興奮性", "D": "抑制交感興奮，縮短動作電位有效不反應期", "answer": "B", "questions": "β-blockers用於治療心律不整之機制，下列何者正確？", "choices": ["活化鉀離子通道，增加AV node再極化程度", "延長AV conduction time及有效不反應期", "降低鈉離子通道活化閾值，增加同步興奮性", "抑制交感興奮，縮短動作電位有效不反應期"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nβ-blockers用於治療心律不整之機制，下列何者正確？\nA. 活化鉀離子通道，增加AV node再極化程度\nB. 延長AV conduction time及有效不反應期\nC. 降低鈉離子通道活化閾值，增加同步興奮性\nD. 抑制交感興奮，縮短動作電位有效不反應期\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nβ-blockers用於治療心律不整之機制，下列何者正確？\nA. 活化鉀離子通道，增加AV node再極化程度\nB. 延長AV conduction time及有效不反應期\nC. 降低鈉離子通道活化閾值，增加同步興奮性\nD. 抑制交感興奮，縮短動作電位有效不反應期\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nβ-blockers用於治療心律不整之機制，下列何者正確？\nA. 活化鉀離子通道，增加AV node再極化程度\nB. 延長AV conduction time及有效不反應期\nC. 降低鈉離子通道活化閾值，增加同步興奮性\nD. 抑制交感興奮，縮短動作電位有效不反應期\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nβ-blockers用於治療心律不整之機制，下列何者正確？\nA. 活化鉀離子通道，增加AV node再極化程度\nB. 延長AV conduction time及有效不反應期\nC. 降低鈉離子通道活化閾值，增加同步興奮性\nD. 抑制交感興奮，縮短動作電位有效不反應期\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.8125", "False"]], [["-0.04931640625", "True"]], [["-5.9375", "False"]], [["-3.171875", "False"]]], "filtered_resps": [["-5.8125", "False"], ["-0.04931640625", "True"], ["-5.9375", "False"], ["-3.171875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7282e1de01482e6e9962cf550e9a71b2e02abf5232854f45caca6805741947b7", "prompt_hash": "df4bb9349cdd004efd75c95d72b2ab3e98207927aa1b972a15660764de90b6cb", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 17, "doc": {"question": "造成penicillin產生抗藥性的原因，下列何者錯誤？", "A": "增進penicillin排除", "B": "β–lactamase的存在", "C": "無法結合到penicillin結合蛋白", "D": "在格蘭氏陽性菌株外膜因為膜孔蛋白（porin）表現量下降，使藥物不易進入", "answer": "D", "questions": "造成penicillin產生抗藥性的原因，下列何者錯誤？", "choices": ["增進penicillin排除", "β–lactamase的存在", "無法結合到penicillin結合蛋白", "在格蘭氏陽性菌株外膜因為膜孔蛋白（porin）表現量下降，使藥物不易進入"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n造成penicillin產生抗藥性的原因，下列何者錯誤？\nA. 增進penicillin排除\nB. β–lactamase的存在\nC. 無法結合到penicillin結合蛋白\nD. 在格蘭氏陽性菌株外膜因為膜孔蛋白（porin）表現量下降，使藥物不易進入\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n造成penicillin產生抗藥性的原因，下列何者錯誤？\nA. 增進penicillin排除\nB. β–lactamase的存在\nC. 無法結合到penicillin結合蛋白\nD. 在格蘭氏陽性菌株外膜因為膜孔蛋白（porin）表現量下降，使藥物不易進入\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n造成penicillin產生抗藥性的原因，下列何者錯誤？\nA. 增進penicillin排除\nB. β–lactamase的存在\nC. 無法結合到penicillin結合蛋白\nD. 在格蘭氏陽性菌株外膜因為膜孔蛋白（porin）表現量下降，使藥物不易進入\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n造成penicillin產生抗藥性的原因，下列何者錯誤？\nA. 增進penicillin排除\nB. β–lactamase的存在\nC. 無法結合到penicillin結合蛋白\nD. 在格蘭氏陽性菌株外膜因為膜孔蛋白（porin）表現量下降，使藥物不易進入\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.125", "False"]], [["-3.75", "False"]], [["-1.125", "False"]], [["-0.62890625", "True"]]], "filtered_resps": [["-2.125", "False"], ["-3.75", "False"], ["-1.125", "False"], ["-0.62890625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0070a0a0ac9ccc1421935f4ef03ad68ab437e4d43150da239edd10a6e456448b", "prompt_hash": "93ef485225637f099f06cf1e9e21a048a19ab6922d4156042cd3fdea62954420", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 18, "doc": {"question": "下列何者於外科手術時，可作為全身麻醉劑之輔助藥可作為全身麻醉劑之輔助藥？", "A": "enflurane", "B": "propofol", "C": "pancuronium", "D": "etomidate", "answer": "C", "questions": "下列何者於外科手術時，可作為全身麻醉劑之輔助藥可作為全身麻醉劑之輔助藥？", "choices": ["enflurane", "propofol", "pancuronium", "etomidate"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者於外科手術時，可作為全身麻醉劑之輔助藥可作為全身麻醉劑之輔助藥？\nA. enflurane\nB. propofol\nC. pancuronium\nD. etomidate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者於外科手術時，可作為全身麻醉劑之輔助藥可作為全身麻醉劑之輔助藥？\nA. enflurane\nB. propofol\nC. pancuronium\nD. etomidate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者於外科手術時，可作為全身麻醉劑之輔助藥可作為全身麻醉劑之輔助藥？\nA. enflurane\nB. propofol\nC. pancuronium\nD. etomidate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者於外科手術時，可作為全身麻醉劑之輔助藥可作為全身麻醉劑之輔助藥？\nA. enflurane\nB. propofol\nC. pancuronium\nD. etomidate\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.9375", "False"]], [["-4.3125", "False"]], [["-0.059326171875", "True"]], [["-3.4375", "False"]]], "filtered_resps": [["-4.9375", "False"], ["-4.3125", "False"], ["-0.059326171875", "True"], ["-3.4375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "69cd3e2619512d90bffd1f75a873ba6d84c937de85186beb8a9bc784a9567c0c", "prompt_hash": "4bfc2c5ae6716f36bf2f3566783cf4be24f04cb1cbda47a15d38315a66c244f8", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 19, "doc": {"question": "下列藥物何者不適用於治療腎臟癌？", "A": "Imatinib", "B": "Bevacizumab", "C": "Sunitinib", "D": "Sorafenib", "answer": "A", "questions": "下列藥物何者不適用於治療腎臟癌？", "choices": ["Imatinib", "Bevacizumab", "Sunitinib", "Sorafenib"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不適用於治療腎臟癌？\nA. Imatinib\nB. Bevacizumab\nC. Sunitinib\nD. Sorafenib\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不適用於治療腎臟癌？\nA. Imatinib\nB. Bevacizumab\nC. Sunitinib\nD. Sorafenib\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不適用於治療腎臟癌？\nA. Imatinib\nB. Bevacizumab\nC. Sunitinib\nD. Sorafenib\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不適用於治療腎臟癌？\nA. Imatinib\nB. Bevacizumab\nC. Sunitinib\nD. Sorafenib\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.00567626953125", "True"]], [["-6.0", "False"]], [["-8.125", "False"]], [["-7.625", "False"]]], "filtered_resps": [["-0.00567626953125", "True"], ["-6.0", "False"], ["-8.125", "False"], ["-7.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b83f6b761c7d87f615ba08b44726baecf34efca8633943012f60436d2bfc419d", "prompt_hash": "98dc6b9d4f3d06fa6ee00fa22711a78152a782bd2823c140bbc63f485ae5c1e6", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 20, "doc": {"question": "下列何種藥物具有carbamate基團？", "A": "cyclophosphamide", "B": "estramustine", "C": "melphalan", "D": "chlorambucil", "answer": "B", "questions": "下列何種藥物具有carbamate基團？", "choices": ["cyclophosphamide", "estramustine", "melphalan", "chlorambucil"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物具有carbamate基團？\nA. cyclophosphamide\nB. estramustine\nC. melphalan\nD. chlorambucil\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物具有carbamate基團？\nA. cyclophosphamide\nB. estramustine\nC. melphalan\nD. chlorambucil\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物具有carbamate基團？\nA. cyclophosphamide\nB. estramustine\nC. melphalan\nD. chlorambucil\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物具有carbamate基團？\nA. cyclophosphamide\nB. estramustine\nC. melphalan\nD. chlorambucil\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.8125", "False"]], [["-0.0654296875", "True"]], [["-7.1875", "False"]], [["-6.1875", "False"]]], "filtered_resps": [["-2.8125", "False"], ["-0.0654296875", "True"], ["-7.1875", "False"], ["-6.1875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "135d3641c7db16d5f2f62ef07194681d08ab8bba2d13c8d7b2e96ffa6f8e31bb", "prompt_hash": "55c6f6abf2afc573bb0d65e51aea1dc1cb35477ed0678cd5230f6a7739778ef6", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 21, "doc": {"question": "Clonidine之pKa為8.3，於正常生理之pH值下，其解離度約為多少？", "A": "60%", "B": "40%", "C": "20%", "D": "80%", "answer": "D", "questions": "Clonidine之pKa為8.3，於正常生理之pH值下，其解離度約為多少？", "choices": ["60%", "40%", "20%", "80%"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClonidine之pKa為8.3，於正常生理之pH值下，其解離度約為多少？\nA. 60%\nB. 40%\nC. 20%\nD. 80%\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClonidine之pKa為8.3，於正常生理之pH值下，其解離度約為多少？\nA. 60%\nB. 40%\nC. 20%\nD. 80%\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClonidine之pKa為8.3，於正常生理之pH值下，其解離度約為多少？\nA. 60%\nB. 40%\nC. 20%\nD. 80%\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClonidine之pKa為8.3，於正常生理之pH值下，其解離度約為多少？\nA. 60%\nB. 40%\nC. 20%\nD. 80%\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.265625", "False"]], [["-1.265625", "False"]], [["-0.76953125", "True"]], [["-1.890625", "False"]]], "filtered_resps": [["-2.265625", "False"], ["-1.265625", "False"], ["-0.76953125", "True"], ["-1.890625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "58c5ca071a7ac359157ea2a558f5554b6f026d9a55f5c84d797295eba33a35b2", "prompt_hash": "4082723930d7f4880b3e31d994871f5b7b3e5c50b3fce1a7a9bf038df16f90cb", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 22, "doc": {"question": "某酸性藥的pKa為5.4，下列何者為該藥在血液中最可能的解離態與未解離態比例？", "A": "1：100", "B": "100：1", "C": "1：10", "D": "10：1", "answer": "B", "questions": "某酸性藥的pKa為5.4，下列何者為該藥在血液中最可能的解離態與未解離態比例？", "choices": ["1：100", "100：1", "1：10", "10：1"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n某酸性藥的pKa為5.4，下列何者為該藥在血液中最可能的解離態與未解離態比例？\nA. 1：100\nB. 100：1\nC. 1：10\nD. 10：1\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n某酸性藥的pKa為5.4，下列何者為該藥在血液中最可能的解離態與未解離態比例？\nA. 1：100\nB. 100：1\nC. 1：10\nD. 10：1\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n某酸性藥的pKa為5.4，下列何者為該藥在血液中最可能的解離態與未解離態比例？\nA. 1：100\nB. 100：1\nC. 1：10\nD. 10：1\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n某酸性藥的pKa為5.4，下列何者為該藥在血液中最可能的解離態與未解離態比例？\nA. 1：100\nB. 100：1\nC. 1：10\nD. 10：1\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.109375", "False"]], [["-1.9765625", "False"]], [["-1.3515625", "False"]], [["-0.73046875", "True"]]], "filtered_resps": [["-2.109375", "False"], ["-1.9765625", "False"], ["-1.3515625", "False"], ["-0.73046875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3fbecf3b418eb503b73d1f1a923e2d06a260d16d0d181638e2d5bc5296757ab5", "prompt_hash": "7b81a77ca6260a12c08a2976c28eda78c662f9b3911eddf98dcb2aeba528d009", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 23, "doc": {"question": "關於抗甲狀腺藥thioamides之敘述，下列何者正確？", "A": "propylthiouracil可抑制甲狀腺素釋放", "B": "propylthiouracil較methimazole容易通過胎盤影響胎兒之甲狀腺功能，較不適合給孕婦使用", "C": "methimazole無法有效抑制thyroxine（T4）去碘化作用，所以不適合用於治療甲狀腺風暴", "D": "methimazole可抑制iodide進入甲狀腺細胞", "answer": "C", "questions": "關於抗甲狀腺藥thioamides之敘述，下列何者正確？", "choices": ["propylthiouracil可抑制甲狀腺素釋放", "propylthiouracil較methimazole容易通過胎盤影響胎兒之甲狀腺功能，較不適合給孕婦使用", "methimazole無法有效抑制thyroxine（T4）去碘化作用，所以不適合用於治療甲狀腺風暴", "methimazole可抑制iodide進入甲狀腺細胞"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於抗甲狀腺藥thioamides之敘述，下列何者正確？\nA. propylthiouracil可抑制甲狀腺素釋放\nB. propylthiouracil較methimazole容易通過胎盤影響胎兒之甲狀腺功能，較不適合給孕婦使用\nC. methimazole無法有效抑制thyroxine（T4）去碘化作用，所以不適合用於治療甲狀腺風暴\nD. methimazole可抑制iodide進入甲狀腺細胞\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於抗甲狀腺藥thioamides之敘述，下列何者正確？\nA. propylthiouracil可抑制甲狀腺素釋放\nB. propylthiouracil較methimazole容易通過胎盤影響胎兒之甲狀腺功能，較不適合給孕婦使用\nC. methimazole無法有效抑制thyroxine（T4）去碘化作用，所以不適合用於治療甲狀腺風暴\nD. methimazole可抑制iodide進入甲狀腺細胞\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於抗甲狀腺藥thioamides之敘述，下列何者正確？\nA. propylthiouracil可抑制甲狀腺素釋放\nB. propylthiouracil較methimazole容易通過胎盤影響胎兒之甲狀腺功能，較不適合給孕婦使用\nC. methimazole無法有效抑制thyroxine（T4）去碘化作用，所以不適合用於治療甲狀腺風暴\nD. methimazole可抑制iodide進入甲狀腺細胞\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於抗甲狀腺藥thioamides之敘述，下列何者正確？\nA. propylthiouracil可抑制甲狀腺素釋放\nB. propylthiouracil較methimazole容易通過胎盤影響胎兒之甲狀腺功能，較不適合給孕婦使用\nC. methimazole無法有效抑制thyroxine（T4）去碘化作用，所以不適合用於治療甲狀腺風暴\nD. methimazole可抑制iodide進入甲狀腺細胞\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.921875", "False"]], [["-0.421875", "True"]], [["-2.671875", "False"]], [["-2.046875", "False"]]], "filtered_resps": [["-1.921875", "False"], ["-0.421875", "True"], ["-2.671875", "False"], ["-2.046875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "84eb92f027aebb0c1cd34cb8816af8f7cd59fb7b18b3c89f7b733ca7a6442ecc", "prompt_hash": "49d4209e804142e2bdf86b7ac04943d77f47d96040f76eb900362618666b6880", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 24, "doc": {"question": "下列何者不是Loop diuretics（利尿劑）之臨床適應症？", "A": "高尿酸血症（hyperuricemia）", "B": "急性腎衰竭（acute renal failure）", "C": "陰離子過量（anion overdose）", "D": "高血鉀症（hyperkalemia）", "answer": "A", "questions": "下列何者不是Loop diuretics（利尿劑）之臨床適應症？", "choices": ["高尿酸血症（hyperuricemia）", "急性腎衰竭（acute renal failure）", "陰離子過量（anion overdose）", "高血鉀症（hyperkalemia）"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是Loop diuretics（利尿劑）之臨床適應症？\nA. 高尿酸血症（hyperuricemia）\nB. 急性腎衰竭（acute renal failure）\nC. 陰離子過量（anion overdose）\nD. 高血鉀症（hyperkalemia）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是Loop diuretics（利尿劑）之臨床適應症？\nA. 高尿酸血症（hyperuricemia）\nB. 急性腎衰竭（acute renal failure）\nC. 陰離子過量（anion overdose）\nD. 高血鉀症（hyperkalemia）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是Loop diuretics（利尿劑）之臨床適應症？\nA. 高尿酸血症（hyperuricemia）\nB. 急性腎衰竭（acute renal failure）\nC. 陰離子過量（anion overdose）\nD. 高血鉀症（hyperkalemia）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是Loop diuretics（利尿劑）之臨床適應症？\nA. 高尿酸血症（hyperuricemia）\nB. 急性腎衰竭（acute renal failure）\nC. 陰離子過量（anion overdose）\nD. 高血鉀症（hyperkalemia）\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.1796875", "False"]], [["-0.427734375", "True"]], [["-6.0625", "False"]], [["-3.296875", "False"]]], "filtered_resps": [["-1.1796875", "False"], ["-0.427734375", "True"], ["-6.0625", "False"], ["-3.296875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2a8c314e9fc6d759fe3c740a292a0659ec6c022b79e0abc06812c666410dcf61", "prompt_hash": "76e4cd77584b85125a6f77783dbb53982078a9bc284167f1b475e8e617ea99ff", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 25, "doc": {"question": "神經性退化疾病阿茲海默症病因之一為腦中乙醯膽鹼濃度不足，下列可用於緩解輕／中度阿茲海默症患者症狀之乙醯膽鹼酯酶抑制劑中，何者具有明顯肝毒性？", "A": "tacrine", "B": "donepezil", "C": "rivastigmine", "D": "galantamine", "answer": "A", "questions": "神經性退化疾病阿茲海默症病因之一為腦中乙醯膽鹼濃度不足，下列可用於緩解輕／中度阿茲海默症患者症狀之乙醯膽鹼酯酶抑制劑中，何者具有明顯肝毒性？", "choices": ["tacrine", "donepezil", "rivastigmine", "galantamine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n神經性退化疾病阿茲海默症病因之一為腦中乙醯膽鹼濃度不足，下列可用於緩解輕／中度阿茲海默症患者症狀之乙醯膽鹼酯酶抑制劑中，何者具有明顯肝毒性？\nA. tacrine\nB. donepezil\nC. rivastigmine\nD. galantamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n神經性退化疾病阿茲海默症病因之一為腦中乙醯膽鹼濃度不足，下列可用於緩解輕／中度阿茲海默症患者症狀之乙醯膽鹼酯酶抑制劑中，何者具有明顯肝毒性？\nA. tacrine\nB. donepezil\nC. rivastigmine\nD. galantamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n神經性退化疾病阿茲海默症病因之一為腦中乙醯膽鹼濃度不足，下列可用於緩解輕／中度阿茲海默症患者症狀之乙醯膽鹼酯酶抑制劑中，何者具有明顯肝毒性？\nA. tacrine\nB. donepezil\nC. rivastigmine\nD. galantamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n神經性退化疾病阿茲海默症病因之一為腦中乙醯膽鹼濃度不足，下列可用於緩解輕／中度阿茲海默症患者症狀之乙醯膽鹼酯酶抑制劑中，何者具有明顯肝毒性？\nA. tacrine\nB. donepezil\nC. rivastigmine\nD. galantamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.005157470703125", "True"]], [["-6.5", "False"]], [["-6.625", "False"]], [["-6.75", "False"]]], "filtered_resps": [["-0.005157470703125", "True"], ["-6.5", "False"], ["-6.625", "False"], ["-6.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "cf1ddef2897e5206f2ec72912be471accaacca3184912c4a6f97be54c573f75f", "prompt_hash": "1a46fc7ed20bbb9bef86af5ae4c6d30e57d0c561eb0c77c7015aba935d3aa2ec", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 26, "doc": {"question": "下列何者可抑制D-alanine racemase和D-alanine ligase，干擾結核分枝桿菌細胞壁的合成？", "A": "cycloserine", "B": "L-alanine", "C": "ethionamide", "D": "capreomycin", "answer": "A", "questions": "下列何者可抑制D-alanine racemase和D-alanine ligase，干擾結核分枝桿菌細胞壁的合成？", "choices": ["cycloserine", "L-alanine", "ethionamide", "capreomycin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可抑制D-alanine racemase和D-alanine ligase，干擾結核分枝桿菌細胞壁的合成？\nA. cycloserine\nB. L-alanine\nC. ethionamide\nD. capreomycin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可抑制D-alanine racemase和D-alanine ligase，干擾結核分枝桿菌細胞壁的合成？\nA. cycloserine\nB. L-alanine\nC. ethionamide\nD. capreomycin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可抑制D-alanine racemase和D-alanine ligase，干擾結核分枝桿菌細胞壁的合成？\nA. cycloserine\nB. L-alanine\nC. ethionamide\nD. capreomycin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可抑制D-alanine racemase和D-alanine ligase，干擾結核分枝桿菌細胞壁的合成？\nA. cycloserine\nB. L-alanine\nC. ethionamide\nD. capreomycin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0301513671875", "True"]], [["-4.28125", "False"]], [["-5.78125", "False"]], [["-4.65625", "False"]]], "filtered_resps": [["-0.0301513671875", "True"], ["-4.28125", "False"], ["-5.78125", "False"], ["-4.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4040908d9542e8cd5e0914e0eba06e9043e925643d9607e42c96c567b3290113", "prompt_hash": "67c3e60489a8466ce324fcc56c5e4b8945eca1593bd130416ac06b5d1b572afd", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 27, "doc": {"question": "下列藥物何者屬於血栓溶解作用（fibrinolysis）之抑制劑？", "A": "antithrombin III", "B": "heparin", "C": "anistreplase", "D": "aminocaproic acid", "answer": "D", "questions": "下列藥物何者屬於血栓溶解作用（fibrinolysis）之抑制劑？", "choices": ["antithrombin III", "heparin", "anistreplase", "aminocaproic acid"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者屬於血栓溶解作用（fibrinolysis）之抑制劑？\nA. antithrombin III\nB. heparin\nC. anistreplase\nD. aminocaproic acid\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者屬於血栓溶解作用（fibrinolysis）之抑制劑？\nA. antithrombin III\nB. heparin\nC. anistreplase\nD. aminocaproic acid\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者屬於血栓溶解作用（fibrinolysis）之抑制劑？\nA. antithrombin III\nB. heparin\nC. anistreplase\nD. aminocaproic acid\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者屬於血栓溶解作用（fibrinolysis）之抑制劑？\nA. antithrombin III\nB. heparin\nC. anistreplase\nD. aminocaproic acid\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.25", "False"]], [["-6.25", "False"]], [["-5.625", "False"]], [["-0.00836181640625", "True"]]], "filtered_resps": [["-6.25", "False"], ["-6.25", "False"], ["-5.625", "False"], ["-0.00836181640625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d4b3566e538588db0c457d37fadc3b431a6e9bf66c70561d49ea6057b22c7fda", "prompt_hash": "6fd891316dd0602487f0552640b87454aeea6625520228d5bc6066d8c235b011", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 28, "doc": {"question": "Zafirlucast 結構中，何種基團可產生陰離子與何種基團可產生陰離子與 cysteinyl leukotriene 受體之陽離子結合？受體之陽離子結合", "A": "indole", "B": "sulfonamide", "C": "carbamate", "D": "tetrazole", "answer": "B", "questions": "Zafirlucast 結構中，何種基團可產生陰離子與何種基團可產生陰離子與 cysteinyl leukotriene 受體之陽離子結合？受體之陽離子結合", "choices": ["indole", "sulfonamide", "carbamate", "tetrazole"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nZafirlucast 結構中，何種基團可產生陰離子與何種基團可產生陰離子與 cysteinyl leukotriene 受體之陽離子結合？受體之陽離子結合\nA. indole\nB. sulfonamide\nC. carbamate\nD. tetrazole\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nZafirlucast 結構中，何種基團可產生陰離子與何種基團可產生陰離子與 cysteinyl leukotriene 受體之陽離子結合？受體之陽離子結合\nA. indole\nB. sulfonamide\nC. carbamate\nD. tetrazole\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nZafirlucast 結構中，何種基團可產生陰離子與何種基團可產生陰離子與 cysteinyl leukotriene 受體之陽離子結合？受體之陽離子結合\nA. indole\nB. sulfonamide\nC. carbamate\nD. tetrazole\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nZafirlucast 結構中，何種基團可產生陰離子與何種基團可產生陰離子與 cysteinyl leukotriene 受體之陽離子結合？受體之陽離子結合\nA. indole\nB. sulfonamide\nC. carbamate\nD. tetrazole\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.65625", "False"]], [["-0.154296875", "True"]], [["-4.53125", "False"]], [["-2.28125", "False"]]], "filtered_resps": [["-3.65625", "False"], ["-0.154296875", "True"], ["-4.53125", "False"], ["-2.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "48321de556f3469cc966646769184318aec9d19128d9fa0d64060c690d499948", "prompt_hash": "7bb856565c950ed349d25e646ab0c81265fbb69c45ddeb7f4f34a5a08688b936", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 29, "doc": {"question": "反義（antisense）藥物fomivirsen是屬於何種oligodeoxynucleotide？", "A": "phosphoramide", "B": "phosphorothioate", "C": "phosphodiester", "D": "methylphosphonate", "answer": "B", "questions": "反義（antisense）藥物fomivirsen是屬於何種oligodeoxynucleotide？", "choices": ["phosphoramide", "phosphorothioate", "phosphodiester", "methylphosphonate"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n反義（antisense）藥物fomivirsen是屬於何種oligodeoxynucleotide？\nA. phosphoramide\nB. phosphorothioate\nC. phosphodiester\nD. methylphosphonate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n反義（antisense）藥物fomivirsen是屬於何種oligodeoxynucleotide？\nA. phosphoramide\nB. phosphorothioate\nC. phosphodiester\nD. methylphosphonate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n反義（antisense）藥物fomivirsen是屬於何種oligodeoxynucleotide？\nA. phosphoramide\nB. phosphorothioate\nC. phosphodiester\nD. methylphosphonate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n反義（antisense）藥物fomivirsen是屬於何種oligodeoxynucleotide？\nA. phosphoramide\nB. phosphorothioate\nC. phosphodiester\nD. methylphosphonate\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.78125", "False"]], [["-0.0269775390625", "True"]], [["-7.15625", "False"]], [["-3.78125", "False"]]], "filtered_resps": [["-6.78125", "False"], ["-0.0269775390625", "True"], ["-7.15625", "False"], ["-3.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "01934bc11bcc8c41ddd3b88b6dd2b56831f3d0165f186939ed93043942843615", "prompt_hash": "627fe36f6234cdc6a0cfcdc9c0ef0501f469edd2bdbd0532973c939d3d8bf7ce", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 30, "doc": {"question": "有關抗凝血藥物（anticoagulants）heparin之副作用，下列敘述何者錯誤？", "A": "出血（bleeding）", "B": "表皮壞死（cutaneous necrosis）", "C": "骨質疏鬆及骨折（osteoporosis and spontaneous fractures）", "D": "血小板減少症（thrombocytopenia）", "answer": "B", "questions": "有關抗凝血藥物（anticoagulants）heparin之副作用，下列敘述何者錯誤？", "choices": ["出血（bleeding）", "表皮壞死（cutaneous necrosis）", "骨質疏鬆及骨折（osteoporosis and spontaneous fractures）", "血小板減少症（thrombocytopenia）"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗凝血藥物（anticoagulants）heparin之副作用，下列敘述何者錯誤？\nA. 出血（bleeding）\nB. 表皮壞死（cutaneous necrosis）\nC. 骨質疏鬆及骨折（osteoporosis and spontaneous fractures）\nD. 血小板減少症（thrombocytopenia）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗凝血藥物（anticoagulants）heparin之副作用，下列敘述何者錯誤？\nA. 出血（bleeding）\nB. 表皮壞死（cutaneous necrosis）\nC. 骨質疏鬆及骨折（osteoporosis and spontaneous fractures）\nD. 血小板減少症（thrombocytopenia）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗凝血藥物（anticoagulants）heparin之副作用，下列敘述何者錯誤？\nA. 出血（bleeding）\nB. 表皮壞死（cutaneous necrosis）\nC. 骨質疏鬆及骨折（osteoporosis and spontaneous fractures）\nD. 血小板減少症（thrombocytopenia）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗凝血藥物（anticoagulants）heparin之副作用，下列敘述何者錯誤？\nA. 出血（bleeding）\nB. 表皮壞死（cutaneous necrosis）\nC. 骨質疏鬆及骨折（osteoporosis and spontaneous fractures）\nD. 血小板減少症（thrombocytopenia）\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-0.154296875", "True"]], [["-2.15625", "False"]], [["-3.78125", "False"]]], "filtered_resps": [["-5.78125", "False"], ["-0.154296875", "True"], ["-2.15625", "False"], ["-3.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "059051c24b013416a5fcd074e1a4d1b29545008e36d947178ad5aceda2610339", "prompt_hash": "38656b6a625799f61ab5a1a946bcc38b3b375672ed0eaeb8ffa2f7f89288441b", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 31, "doc": {"question": "下列那一種全身麻醉劑的誘導期間最短，且其恢復作用也最快？", "A": "Isoflurane", "B": "Halothane", "C": "Sevoflurane", "D": "Methoxyflurane", "answer": "C", "questions": "下列那一種全身麻醉劑的誘導期間最短，且其恢復作用也最快？", "choices": ["Isoflurane", "Halothane", "Sevoflurane", "Methoxyflurane"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種全身麻醉劑的誘導期間最短，且其恢復作用也最快？\nA. Isoflurane\nB. Halothane\nC. Sevoflurane\nD. Methoxyflurane\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種全身麻醉劑的誘導期間最短，且其恢復作用也最快？\nA. Isoflurane\nB. Halothane\nC. Sevoflurane\nD. Methoxyflurane\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種全身麻醉劑的誘導期間最短，且其恢復作用也最快？\nA. Isoflurane\nB. Halothane\nC. Sevoflurane\nD. Methoxyflurane\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種全身麻醉劑的誘導期間最短，且其恢復作用也最快？\nA. Isoflurane\nB. Halothane\nC. Sevoflurane\nD. Methoxyflurane\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.0", "False"]], [["-6.25", "False"]], [["-0.0087890625", "True"]], [["-6.75", "False"]]], "filtered_resps": [["-6.0", "False"], ["-6.25", "False"], ["-0.0087890625", "True"], ["-6.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "24c81f612ad16615ea4268e45a501ad135e77aefbd4c93d3056ecab3ab7d1a6d", "prompt_hash": "94ae191bafc8994a184956500dac6e019490f74525c648c0680e40ad8886004f", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 32, "doc": {"question": "下列有關神經肌肉疾病用藥的交互作用或禁忌的敘述，何者錯誤？", "A": "alemtuzumab用於多發性硬化症，可降低黑色素瘤（melanoma）的風險", "B": "rasagiline若與ciprofloxacin併用，需減低rasagiline劑量", "C": "carisoprodol併用omeprazole，可降低carisoprodol的代謝", "D": "carbidopa與鐵鹽併用，會降低其生體可用率", "answer": "A", "questions": "下列有關神經肌肉疾病用藥的交互作用或禁忌的敘述，何者錯誤？", "choices": ["alemtuzumab用於多發性硬化症，可降低黑色素瘤（melanoma）的風險", "rasagiline若與ciprofloxacin併用，需減低rasagiline劑量", "carisoprodol併用omeprazole，可降低carisoprodol的代謝", "carbidopa與鐵鹽併用，會降低其生體可用率"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關神經肌肉疾病用藥的交互作用或禁忌的敘述，何者錯誤？\nA. alemtuzumab用於多發性硬化症，可降低黑色素瘤（melanoma）的風險\nB. rasagiline若與ciprofloxacin併用，需減低rasagiline劑量\nC. carisoprodol併用omeprazole，可降低carisoprodol的代謝\nD. carbidopa與鐵鹽併用，會降低其生體可用率\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關神經肌肉疾病用藥的交互作用或禁忌的敘述，何者錯誤？\nA. alemtuzumab用於多發性硬化症，可降低黑色素瘤（melanoma）的風險\nB. rasagiline若與ciprofloxacin併用，需減低rasagiline劑量\nC. carisoprodol併用omeprazole，可降低carisoprodol的代謝\nD. carbidopa與鐵鹽併用，會降低其生體可用率\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關神經肌肉疾病用藥的交互作用或禁忌的敘述，何者錯誤？\nA. alemtuzumab用於多發性硬化症，可降低黑色素瘤（melanoma）的風險\nB. rasagiline若與ciprofloxacin併用，需減低rasagiline劑量\nC. carisoprodol併用omeprazole，可降低carisoprodol的代謝\nD. carbidopa與鐵鹽併用，會降低其生體可用率\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關神經肌肉疾病用藥的交互作用或禁忌的敘述，何者錯誤？\nA. alemtuzumab用於多發性硬化症，可降低黑色素瘤（melanoma）的風險\nB. rasagiline若與ciprofloxacin併用，需減低rasagiline劑量\nC. carisoprodol併用omeprazole，可降低carisoprodol的代謝\nD. carbidopa與鐵鹽併用，會降低其生體可用率\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.375", "False"]], [["-1.25", "False"]], [["-1.125", "True"]], [["-2.0", "False"]]], "filtered_resps": [["-1.375", "False"], ["-1.25", "False"], ["-1.125", "True"], ["-2.0", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c0b4e7dcb1150a710f85eae7af1d621af733c4fbd0464c968341722ef22e6916", "prompt_hash": "b0bb16a48d74cb0da5c86933bf4e9bf2f7368c66df0a0df1b56ffb57107e3021", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 33, "doc": {"question": "併用下列何種藥物，能減少因使用大劑量organic nitrates治療穩定型心絞痛時反而產生刺激心臟惡化心絞痛的發生？", "A": "beta blocker", "B": "alpha blocker", "C": "muscarinic blocker", "D": "calcium channel blocker", "answer": "A", "questions": "併用下列何種藥物，能減少因使用大劑量organic nitrates治療穩定型心絞痛時反而產生刺激心臟惡化心絞痛的發生？", "choices": ["beta blocker", "alpha blocker", "muscarinic blocker", "calcium channel blocker"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n併用下列何種藥物，能減少因使用大劑量organic nitrates治療穩定型心絞痛時反而產生刺激心臟惡化心絞痛的發生？\nA. beta blocker\nB. alpha blocker\nC. muscarinic blocker\nD. calcium channel blocker\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n併用下列何種藥物，能減少因使用大劑量organic nitrates治療穩定型心絞痛時反而產生刺激心臟惡化心絞痛的發生？\nA. beta blocker\nB. alpha blocker\nC. muscarinic blocker\nD. calcium channel blocker\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n併用下列何種藥物，能減少因使用大劑量organic nitrates治療穩定型心絞痛時反而產生刺激心臟惡化心絞痛的發生？\nA. beta blocker\nB. alpha blocker\nC. muscarinic blocker\nD. calcium channel blocker\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n併用下列何種藥物，能減少因使用大劑量organic nitrates治療穩定型心絞痛時反而產生刺激心臟惡化心絞痛的發生？\nA. beta blocker\nB. alpha blocker\nC. muscarinic blocker\nD. calcium channel blocker\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1171875", "True"]], [["-2.609375", "False"]], [["-4.75", "False"]], [["-3.609375", "False"]]], "filtered_resps": [["-0.1171875", "True"], ["-2.609375", "False"], ["-4.75", "False"], ["-3.609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "91a71e2789ed52fb7d38f1918a8dfec2c1175d7d773c827ba664fdf0e108dec9", "prompt_hash": "ecb22b2e8101b8791bcae57f88f3513958484b5f843403e636de62cdc892f009", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 34, "doc": {"question": "下列抗黴菌藥物中，何者可抑制黴菌之細胞壁合成？", "A": "micafungin", "B": "amphotericin B", "C": "fluconazole", "D": "flucytosine", "answer": "A", "questions": "下列抗黴菌藥物中，何者可抑制黴菌之細胞壁合成？", "choices": ["micafungin", "amphotericin B", "fluconazole", "flucytosine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗黴菌藥物中，何者可抑制黴菌之細胞壁合成？\nA. micafungin\nB. amphotericin B\nC. fluconazole\nD. flucytosine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗黴菌藥物中，何者可抑制黴菌之細胞壁合成？\nA. micafungin\nB. amphotericin B\nC. fluconazole\nD. flucytosine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗黴菌藥物中，何者可抑制黴菌之細胞壁合成？\nA. micafungin\nB. amphotericin B\nC. fluconazole\nD. flucytosine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗黴菌藥物中，何者可抑制黴菌之細胞壁合成？\nA. micafungin\nB. amphotericin B\nC. fluconazole\nD. flucytosine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0269775390625", "True"]], [["-4.78125", "False"]], [["-6.40625", "False"]], [["-4.15625", "False"]]], "filtered_resps": [["-0.0269775390625", "True"], ["-4.78125", "False"], ["-6.40625", "False"], ["-4.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "799eac68be8e18bd5096f0a6ef48a103dd69b42078bc9d7ca87703499d96417b", "prompt_hash": "0a0b72cee49fa1b3d4368c6e8538045cd9dbda255cc4b252ae4d9e1fb3eea29d", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 35, "doc": {"question": "有關carbidopa的敘述，下列何者正確？", "A": "會減少levodopa在周邊系統的代謝作用", "B": "會通透血腦障壁（blood-brain barrier）", "C": "經常單獨使用來治療帕金森氏症的患者", "D": "會抑制單胺氧化酶B（MAO-B）的活性，進而減少dopamine的代謝作用", "answer": "A", "questions": "有關carbidopa的敘述，下列何者正確？", "choices": ["會減少levodopa在周邊系統的代謝作用", "會通透血腦障壁（blood-brain barrier）", "經常單獨使用來治療帕金森氏症的患者", "會抑制單胺氧化酶B（MAO-B）的活性，進而減少dopamine的代謝作用"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關carbidopa的敘述，下列何者正確？\nA. 會減少levodopa在周邊系統的代謝作用\nB. 會通透血腦障壁（blood-brain barrier）\nC. 經常單獨使用來治療帕金森氏症的患者\nD. 會抑制單胺氧化酶B（MAO-B）的活性，進而減少dopamine的代謝作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關carbidopa的敘述，下列何者正確？\nA. 會減少levodopa在周邊系統的代謝作用\nB. 會通透血腦障壁（blood-brain barrier）\nC. 經常單獨使用來治療帕金森氏症的患者\nD. 會抑制單胺氧化酶B（MAO-B）的活性，進而減少dopamine的代謝作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關carbidopa的敘述，下列何者正確？\nA. 會減少levodopa在周邊系統的代謝作用\nB. 會通透血腦障壁（blood-brain barrier）\nC. 經常單獨使用來治療帕金森氏症的患者\nD. 會抑制單胺氧化酶B（MAO-B）的活性，進而減少dopamine的代謝作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關carbidopa的敘述，下列何者正確？\nA. 會減少levodopa在周邊系統的代謝作用\nB. 會通透血腦障壁（blood-brain barrier）\nC. 經常單獨使用來治療帕金森氏症的患者\nD. 會抑制單胺氧化酶B（MAO-B）的活性，進而減少dopamine的代謝作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.042236328125", "True"]], [["-3.421875", "False"]], [["-6.40625", "False"]], [["-5.15625", "False"]]], "filtered_resps": [["-0.042236328125", "True"], ["-3.421875", "False"], ["-6.40625", "False"], ["-5.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "819249382072c5146a49bb13c469a8301fab0adc7c0b9093eb7398a535046eef", "prompt_hash": "f7b102472f40a85396ff95a3f8b378f1bc5b4d36c2341bb2fd97d243333efa77", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 36, "doc": {"question": "下列藥物，何者具有 3,4-dimethoxyphenyl 結構？", "A": "verapamil", "B": "velpatasvir", "C": "valsartan", "D": "venetoclax", "answer": "A", "questions": "下列藥物，何者具有 3,4-dimethoxyphenyl 結構？", "choices": ["verapamil", "velpatasvir", "valsartan", "venetoclax"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者具有 3,4-dimethoxyphenyl 結構？\nA. verapamil\nB. velpatasvir\nC. valsartan\nD. venetoclax\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者具有 3,4-dimethoxyphenyl 結構？\nA. verapamil\nB. velpatasvir\nC. valsartan\nD. venetoclax\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者具有 3,4-dimethoxyphenyl 結構？\nA. verapamil\nB. velpatasvir\nC. valsartan\nD. venetoclax\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者具有 3,4-dimethoxyphenyl 結構？\nA. verapamil\nB. velpatasvir\nC. valsartan\nD. venetoclax\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0908203125", "True"]], [["-4.96875", "False"]], [["-3.09375", "False"]], [["-3.46875", "False"]]], "filtered_resps": [["-0.0908203125", "True"], ["-4.96875", "False"], ["-3.09375", "False"], ["-3.46875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5157384b32a41ac0da06881fe7dcf23f9c0357721994df0394635a20711ef091", "prompt_hash": "8d4f939ba2e102243d3be68c83890f6f9d61687eb93affdccd9a0d1ac678fcb6", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 37, "doc": {"question": "下列有關擬交感神經作用劑產生之反應，何者錯誤？", "A": "phenylephrine可活化心臟alpha1受體，增加心收縮力", "B": "isoproterenol非選擇性活化心臟上beta受體，增加心收縮力、心臟輸出及心跳速率", "C": "clonidine可活化中樞和周邊神經系統之alpha2受體，產生抑制交感神經張力（sympathetic tone），血壓下降現象", "D": "phenylephrine可活化廣泛存在血管壁上alpha1受體，形成血管收縮，血壓上升現象", "answer": "C", "questions": "下列有關擬交感神經作用劑產生之反應，何者錯誤？", "choices": ["phenylephrine可活化心臟alpha1受體，增加心收縮力", "isoproterenol非選擇性活化心臟上beta受體，增加心收縮力、心臟輸出及心跳速率", "clonidine可活化中樞和周邊神經系統之alpha2受體，產生抑制交感神經張力（sympathetic tone），血壓下降現象", "phenylephrine可活化廣泛存在血管壁上alpha1受體，形成血管收縮，血壓上升現象"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關擬交感神經作用劑產生之反應，何者錯誤？\nA. phenylephrine可活化心臟alpha1受體，增加心收縮力\nB. isoproterenol非選擇性活化心臟上beta受體，增加心收縮力、心臟輸出及心跳速率\nC. clonidine可活化中樞和周邊神經系統之alpha2受體，產生抑制交感神經張力（sympathetic tone），血壓下降現象\nD. phenylephrine可活化廣泛存在血管壁上alpha1受體，形成血管收縮，血壓上升現象\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關擬交感神經作用劑產生之反應，何者錯誤？\nA. phenylephrine可活化心臟alpha1受體，增加心收縮力\nB. isoproterenol非選擇性活化心臟上beta受體，增加心收縮力、心臟輸出及心跳速率\nC. clonidine可活化中樞和周邊神經系統之alpha2受體，產生抑制交感神經張力（sympathetic tone），血壓下降現象\nD. phenylephrine可活化廣泛存在血管壁上alpha1受體，形成血管收縮，血壓上升現象\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關擬交感神經作用劑產生之反應，何者錯誤？\nA. phenylephrine可活化心臟alpha1受體，增加心收縮力\nB. isoproterenol非選擇性活化心臟上beta受體，增加心收縮力、心臟輸出及心跳速率\nC. clonidine可活化中樞和周邊神經系統之alpha2受體，產生抑制交感神經張力（sympathetic tone），血壓下降現象\nD. phenylephrine可活化廣泛存在血管壁上alpha1受體，形成血管收縮，血壓上升現象\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關擬交感神經作用劑產生之反應，何者錯誤？\nA. phenylephrine可活化心臟alpha1受體，增加心收縮力\nB. isoproterenol非選擇性活化心臟上beta受體，增加心收縮力、心臟輸出及心跳速率\nC. clonidine可活化中樞和周邊神經系統之alpha2受體，產生抑制交感神經張力（sympathetic tone），血壓下降現象\nD. phenylephrine可活化廣泛存在血管壁上alpha1受體，形成血管收縮，血壓上升現象\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.15625", "False"]], [["-0.042724609375", "True"]], [["-3.671875", "False"]], [["-4.65625", "False"]]], "filtered_resps": [["-5.15625", "False"], ["-0.042724609375", "True"], ["-3.671875", "False"], ["-4.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "054b26b474a51f783979b7cd678002f9763f067c2a807422ce13dbbf5efb4d8e", "prompt_hash": "7ef220f41ed53d43c3630e917e8f55c5f6ef487b26689fc0af3a18f2978beebf", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 38, "doc": {"question": "下列有關finasteride與dutasteride的敘述，何者錯誤？", "A": "dutasteride抑制5α-reductase作用較強", "B": "dutasteride脂溶性較大", "C": "finasteride之血漿蛋白結合力較低", "D": "兩者都會產生活性代謝物", "answer": "D", "questions": "下列有關finasteride與dutasteride的敘述，何者錯誤？", "choices": ["dutasteride抑制5α-reductase作用較強", "dutasteride脂溶性較大", "finasteride之血漿蛋白結合力較低", "兩者都會產生活性代謝物"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關finasteride與dutasteride的敘述，何者錯誤？\nA. dutasteride抑制5α-reductase作用較強\nB. dutasteride脂溶性較大\nC. finasteride之血漿蛋白結合力較低\nD. 兩者都會產生活性代謝物\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關finasteride與dutasteride的敘述，何者錯誤？\nA. dutasteride抑制5α-reductase作用較強\nB. dutasteride脂溶性較大\nC. finasteride之血漿蛋白結合力較低\nD. 兩者都會產生活性代謝物\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關finasteride與dutasteride的敘述，何者錯誤？\nA. dutasteride抑制5α-reductase作用較強\nB. dutasteride脂溶性較大\nC. finasteride之血漿蛋白結合力較低\nD. 兩者都會產生活性代謝物\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關finasteride與dutasteride的敘述，何者錯誤？\nA. dutasteride抑制5α-reductase作用較強\nB. dutasteride脂溶性較大\nC. finasteride之血漿蛋白結合力較低\nD. 兩者都會產生活性代謝物\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.7734375", "False"]], [["-1.1484375", "False"]], [["-3.015625", "False"]], [["-0.76953125", "True"]]], "filtered_resps": [["-1.7734375", "False"], ["-1.1484375", "False"], ["-3.015625", "False"], ["-0.76953125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e3838e2d7f82e753541e9eeb264d076dd9ada27b814f42b4fd9e60ab789c5e53", "prompt_hash": "7b05430d22240a08f66546bdb045fb7e7be6a89a25016f0809fbbbd611c42040", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 39, "doc": {"question": "腎組織之水孔（Aquaporin）有1、2、3、4型，Vasopressin作用劑Desmopressin主要是活化那一型水孔，使水分在腎臟吸收量增加而用於尿崩症？", "A": "Aquaporin 3", "B": "Aquaporin 2", "C": "Aquaporin 4", "D": "Aquaporin 1", "answer": "B", "questions": "腎組織之水孔（Aquaporin）有1、2、3、4型，Vasopressin作用劑Desmopressin主要是活化那一型水孔，使水分在腎臟吸收量增加而用於尿崩症？", "choices": ["Aquaporin 3", "Aquaporin 2", "Aquaporin 4", "Aquaporin 1"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎組織之水孔（Aquaporin）有1、2、3、4型，Vasopressin作用劑Desmopressin主要是活化那一型水孔，使水分在腎臟吸收量增加而用於尿崩症？\nA. Aquaporin 3\nB. Aquaporin 2\nC. Aquaporin 4\nD. Aquaporin 1\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎組織之水孔（Aquaporin）有1、2、3、4型，Vasopressin作用劑Desmopressin主要是活化那一型水孔，使水分在腎臟吸收量增加而用於尿崩症？\nA. Aquaporin 3\nB. Aquaporin 2\nC. Aquaporin 4\nD. Aquaporin 1\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎組織之水孔（Aquaporin）有1、2、3、4型，Vasopressin作用劑Desmopressin主要是活化那一型水孔，使水分在腎臟吸收量增加而用於尿崩症？\nA. Aquaporin 3\nB. Aquaporin 2\nC. Aquaporin 4\nD. Aquaporin 1\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎組織之水孔（Aquaporin）有1、2、3、4型，Vasopressin作用劑Desmopressin主要是活化那一型水孔，使水分在腎臟吸收量增加而用於尿崩症？\nA. Aquaporin 3\nB. Aquaporin 2\nC. Aquaporin 4\nD. Aquaporin 1\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.375", "False"]], [["-0.0024261474609375", "True"]], [["-7.625", "False"]], [["-6.875", "False"]]], "filtered_resps": [["-7.375", "False"], ["-0.0024261474609375", "True"], ["-7.625", "False"], ["-6.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a814c7ffb3916433bc2dc7d5e3b9b4bbaa9301d1742858d908980a32d96193cb", "prompt_hash": "199b6284155c662e5edbed4dda3194e29bccd2738c32a98bc0e81b61174e192b", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 40, "doc": {"question": "下列何種抗癌藥為topoisomerase I之抑制劑？", "A": "doxorubicin", "B": "topotecan", "C": "etoposide", "D": "mitoxantrone", "answer": "B", "questions": "下列何種抗癌藥為topoisomerase I之抑制劑？", "choices": ["doxorubicin", "topotecan", "etoposide", "mitoxantrone"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥為topoisomerase I之抑制劑？\nA. doxorubicin\nB. topotecan\nC. etoposide\nD. mitoxantrone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥為topoisomerase I之抑制劑？\nA. doxorubicin\nB. topotecan\nC. etoposide\nD. mitoxantrone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥為topoisomerase I之抑制劑？\nA. doxorubicin\nB. topotecan\nC. etoposide\nD. mitoxantrone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥為topoisomerase I之抑制劑？\nA. doxorubicin\nB. topotecan\nC. etoposide\nD. mitoxantrone\nAnswer:", "arg_1": " D"}}, "resps": [[["-8.625", "False"]], [["-0.0020904541015625", "True"]], [["-7.875", "False"]], [["-7.25", "False"]]], "filtered_resps": [["-8.625", "False"], ["-0.0020904541015625", "True"], ["-7.875", "False"], ["-7.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "986b64de50e7b3696b7bf3288648eb081b26bf6ddc568ab8abcfdbdae65b6e0d", "prompt_hash": "89bb592cde0f30cffe791add26d38e8db568c9f93bd590b6fa73bb89409d3dce", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 41, "doc": {"question": "有關Tetracyclines類抗生素之敘述，下列何者正確？", "A": "屬於殺菌型抗生素", "B": "和細菌之50S核醣體結合而抑制其功能", "C": "副作用少，適合用於治療孕婦或幼童之感染", "D": "是治療披衣菌（chlamydiae）及立克次體（rickettsiae）感染的首選藥物", "answer": "D", "questions": "有關Tetracyclines類抗生素之敘述，下列何者正確？", "choices": ["屬於殺菌型抗生素", "和細菌之50S核醣體結合而抑制其功能", "副作用少，適合用於治療孕婦或幼童之感染", "是治療披衣菌（chlamydiae）及立克次體（rickettsiae）感染的首選藥物"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關Tetracyclines類抗生素之敘述，下列何者正確？\nA. 屬於殺菌型抗生素\nB. 和細菌之50S核醣體結合而抑制其功能\nC. 副作用少，適合用於治療孕婦或幼童之感染\nD. 是治療披衣菌（chlamydiae）及立克次體（rickettsiae）感染的首選藥物\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關Tetracyclines類抗生素之敘述，下列何者正確？\nA. 屬於殺菌型抗生素\nB. 和細菌之50S核醣體結合而抑制其功能\nC. 副作用少，適合用於治療孕婦或幼童之感染\nD. 是治療披衣菌（chlamydiae）及立克次體（rickettsiae）感染的首選藥物\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關Tetracyclines類抗生素之敘述，下列何者正確？\nA. 屬於殺菌型抗生素\nB. 和細菌之50S核醣體結合而抑制其功能\nC. 副作用少，適合用於治療孕婦或幼童之感染\nD. 是治療披衣菌（chlamydiae）及立克次體（rickettsiae）感染的首選藥物\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關Tetracyclines類抗生素之敘述，下列何者正確？\nA. 屬於殺菌型抗生素\nB. 和細菌之50S核醣體結合而抑制其功能\nC. 副作用少，適合用於治療孕婦或幼童之感染\nD. 是治療披衣菌（chlamydiae）及立克次體（rickettsiae）感染的首選藥物\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.75", "False"]], [["-3.625", "False"]], [["-3.875", "False"]], [["-0.251953125", "True"]]], "filtered_resps": [["-1.75", "False"], ["-3.625", "False"], ["-3.875", "False"], ["-0.251953125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "38a48e6d7f22a25ee8458d4de3116d4cf02eb39a9714ed36d71f72b8f87b5f4c", "prompt_hash": "f4c6db5020c2fefa76ff4f409a4d6bd02743ac25487e7f9ea5191acf004f08f5", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 42, "doc": {"question": "下列非固醇類抗發炎藥 (NSAID)，何者是oxicam之衍生物？", "A": "diclofenac", "B": "indomethacin", "C": "piroxicam", "D": "aspirin", "answer": "C", "questions": "下列非固醇類抗發炎藥 (NSAID)，何者是oxicam之衍生物？", "choices": ["diclofenac", "indomethacin", "piroxicam", "aspirin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列非固醇類抗發炎藥 (NSAID)，何者是oxicam之衍生物？\nA. diclofenac\nB. indomethacin\nC. piroxicam\nD. aspirin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列非固醇類抗發炎藥 (NSAID)，何者是oxicam之衍生物？\nA. diclofenac\nB. indomethacin\nC. piroxicam\nD. aspirin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列非固醇類抗發炎藥 (NSAID)，何者是oxicam之衍生物？\nA. diclofenac\nB. indomethacin\nC. piroxicam\nD. aspirin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列非固醇類抗發炎藥 (NSAID)，何者是oxicam之衍生物？\nA. diclofenac\nB. indomethacin\nC. piroxicam\nD. aspirin\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.0625", "False"]], [["-4.4375", "False"]], [["-0.051025390625", "True"]], [["-4.6875", "False"]]], "filtered_resps": [["-4.0625", "False"], ["-4.4375", "False"], ["-0.051025390625", "True"], ["-4.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "244f6dcb6c9601440fadd2d21d60561c538557e45aabb09121733c202fecd9f1", "prompt_hash": "75c6fb3aa72df2f1b16ca6ee73ab3b91b4031fcc2d97e498db0deaaabe921084", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 43, "doc": {"question": "下列血清胺（serotonin）受體中，何者屬於離子通道（ion channel）型？", "A": "5-HT3", "B": "5-HT1", "C": "5-HT4", "D": "5-HT2", "answer": "A", "questions": "下列血清胺（serotonin）受體中，何者屬於離子通道（ion channel）型？", "choices": ["5-HT3", "5-HT1", "5-HT4", "5-HT2"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列血清胺（serotonin）受體中，何者屬於離子通道（ion channel）型？\nA. 5-HT3\nB. 5-HT1\nC. 5-HT4\nD. 5-HT2\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列血清胺（serotonin）受體中，何者屬於離子通道（ion channel）型？\nA. 5-HT3\nB. 5-HT1\nC. 5-HT4\nD. 5-HT2\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列血清胺（serotonin）受體中，何者屬於離子通道（ion channel）型？\nA. 5-HT3\nB. 5-HT1\nC. 5-HT4\nD. 5-HT2\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列血清胺（serotonin）受體中，何者屬於離子通道（ion channel）型？\nA. 5-HT3\nB. 5-HT1\nC. 5-HT4\nD. 5-HT2\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1298828125", "True"]], [["-4.625", "False"]], [["-5.0", "False"]], [["-2.25", "False"]]], "filtered_resps": [["-0.1298828125", "True"], ["-4.625", "False"], ["-5.0", "False"], ["-2.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ba8012fa168fe9a4a938581da504a0f75e40758c3f2d16acfaba16d1396d9c4b", "prompt_hash": "b36ce98b63f2f9e85336fc3f72661dae1d80e440af8ed179c9c53744032dd4bb", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 44, "doc": {"question": "下列有關gene transfer所用之Adenovirus載體（vector）之敘述，何者錯誤？", "A": "容易產生免疫反應", "B": "相較於Retrovirus vector，Adenovirus vector有較久之DNA表現（expression）作用", "C": "可轉殖到不分裂之細胞", "D": "優點為高效率之DNA transfer", "answer": "B", "questions": "下列有關gene transfer所用之Adenovirus載體（vector）之敘述，何者錯誤？", "choices": ["容易產生免疫反應", "相較於Retrovirus vector，Adenovirus vector有較久之DNA表現（expression）作用", "可轉殖到不分裂之細胞", "優點為高效率之DNA transfer"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關gene transfer所用之Adenovirus載體（vector）之敘述，何者錯誤？\nA. 容易產生免疫反應\nB. 相較於Retrovirus vector，Adenovirus vector有較久之DNA表現（expression）作用\nC. 可轉殖到不分裂之細胞\nD. 優點為高效率之DNA transfer\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關gene transfer所用之Adenovirus載體（vector）之敘述，何者錯誤？\nA. 容易產生免疫反應\nB. 相較於Retrovirus vector，Adenovirus vector有較久之DNA表現（expression）作用\nC. 可轉殖到不分裂之細胞\nD. 優點為高效率之DNA transfer\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關gene transfer所用之Adenovirus載體（vector）之敘述，何者錯誤？\nA. 容易產生免疫反應\nB. 相較於Retrovirus vector，Adenovirus vector有較久之DNA表現（expression）作用\nC. 可轉殖到不分裂之細胞\nD. 優點為高效率之DNA transfer\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關gene transfer所用之Adenovirus載體（vector）之敘述，何者錯誤？\nA. 容易產生免疫反應\nB. 相較於Retrovirus vector，Adenovirus vector有較久之DNA表現（expression）作用\nC. 可轉殖到不分裂之細胞\nD. 優點為高效率之DNA transfer\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.453125", "False"]], [["-0.1982421875", "True"]], [["-2.203125", "False"]], [["-3.328125", "False"]]], "filtered_resps": [["-3.453125", "False"], ["-0.1982421875", "True"], ["-2.203125", "False"], ["-3.328125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e7e92be2decbd36c37fab9c3ed76f6a4986d8ba1d80949f4c8d32e855cfe4e02", "prompt_hash": "07317b28598baf6128e86f9b64939c2a9ed9d2eb26e17880a27e32e57f8dceab", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 45, "doc": {"question": "Bleomycin之抗癌作用機轉為何？", "A": "DNA cross-linking", "B": "DNA alkylation", "C": "DNA binding and cleavage", "D": "mitosis inhibition", "answer": "C", "questions": "Bleomycin之抗癌作用機轉為何？", "choices": ["DNA cross-linking", "DNA alkylation", "DNA binding and cleavage", "mitosis inhibition"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBleomycin之抗癌作用機轉為何？\nA. DNA cross-linking\nB. DNA alkylation\nC. DNA binding and cleavage\nD. mitosis inhibition\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBleomycin之抗癌作用機轉為何？\nA. DNA cross-linking\nB. DNA alkylation\nC. DNA binding and cleavage\nD. mitosis inhibition\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBleomycin之抗癌作用機轉為何？\nA. DNA cross-linking\nB. DNA alkylation\nC. DNA binding and cleavage\nD. mitosis inhibition\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBleomycin之抗癌作用機轉為何？\nA. DNA cross-linking\nB. DNA alkylation\nC. DNA binding and cleavage\nD. mitosis inhibition\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.375", "False"]], [["-5.875", "False"]], [["-0.1279296875", "True"]], [["-5.25", "False"]]], "filtered_resps": [["-2.375", "False"], ["-5.875", "False"], ["-0.1279296875", "True"], ["-5.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "501e5794f6d74da2669f31f849c4a06ec1c23c7bf88b66857bf5d615fde5ca11", "prompt_hash": "4acd161a7bdf338dc018ba2c9e080f0fbbda19dd88264dac62c34ba5043bb6d6", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 46, "doc": {"question": "下列肌肉鬆弛劑中，何者屬於glycerol monoether衍生物？", "A": "cyclobenzaprine", "B": "meprobamate", "C": "mephenesin", "D": "orphenadrine", "answer": "C", "questions": "下列肌肉鬆弛劑中，何者屬於glycerol monoether衍生物？", "choices": ["cyclobenzaprine", "meprobamate", "mephenesin", "orphenadrine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列肌肉鬆弛劑中，何者屬於glycerol monoether衍生物？\nA. cyclobenzaprine\nB. meprobamate\nC. mephenesin\nD. orphenadrine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列肌肉鬆弛劑中，何者屬於glycerol monoether衍生物？\nA. cyclobenzaprine\nB. meprobamate\nC. mephenesin\nD. orphenadrine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列肌肉鬆弛劑中，何者屬於glycerol monoether衍生物？\nA. cyclobenzaprine\nB. meprobamate\nC. mephenesin\nD. orphenadrine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列肌肉鬆弛劑中，何者屬於glycerol monoether衍生物？\nA. cyclobenzaprine\nB. meprobamate\nC. mephenesin\nD. orphenadrine\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.53125", "False"]], [["-7.28125", "False"]], [["-0.02587890625", "True"]], [["-5.28125", "False"]]], "filtered_resps": [["-6.53125", "False"], ["-7.28125", "False"], ["-0.02587890625", "True"], ["-5.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "af38c0c0c2e4f57fc8dff2530a893b7372c769f0914fb106e717073421482a3f", "prompt_hash": "0803907832affd17823f0f025be02ec10127839086e57d8dcc792d628c1c436e", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 47, "doc": {"question": "下列關於mifepristone之敘述，何者錯誤？", "A": "可拮抗子宮之progesterone受體", "B": "只能在懷孕七週內產生墮胎效果", "C": "常和PGI2製劑合併使用以增強墮胎效果", "D": "可當作性行為後避孕藥", "answer": "C", "questions": "下列關於mifepristone之敘述，何者錯誤？", "choices": ["可拮抗子宮之progesterone受體", "只能在懷孕七週內產生墮胎效果", "常和PGI2製劑合併使用以增強墮胎效果", "可當作性行為後避孕藥"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於mifepristone之敘述，何者錯誤？\nA. 可拮抗子宮之progesterone受體\nB. 只能在懷孕七週內產生墮胎效果\nC. 常和PGI2製劑合併使用以增強墮胎效果\nD. 可當作性行為後避孕藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於mifepristone之敘述，何者錯誤？\nA. 可拮抗子宮之progesterone受體\nB. 只能在懷孕七週內產生墮胎效果\nC. 常和PGI2製劑合併使用以增強墮胎效果\nD. 可當作性行為後避孕藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於mifepristone之敘述，何者錯誤？\nA. 可拮抗子宮之progesterone受體\nB. 只能在懷孕七週內產生墮胎效果\nC. 常和PGI2製劑合併使用以增強墮胎效果\nD. 可當作性行為後避孕藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於mifepristone之敘述，何者錯誤？\nA. 可拮抗子宮之progesterone受體\nB. 只能在懷孕七週內產生墮胎效果\nC. 常和PGI2製劑合併使用以增強墮胎效果\nD. 可當作性行為後避孕藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.9375", "False"]], [["-3.921875", "False"]], [["-0.048828125", "True"]], [["-3.796875", "False"]]], "filtered_resps": [["-5.9375", "False"], ["-3.921875", "False"], ["-0.048828125", "True"], ["-3.796875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0faa4ac4365e7630774a76a2227d7a386a627bce5cfaef3cf8b7cd88f0c0346b", "prompt_hash": "697d93a58aef46c62be70349fdceb05a8e0d4cdbeb180890152567e1206b36d2", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 48, "doc": {"question": "下列有關降血壓藥aliskiren的結構與活性描述，何者錯誤？", "A": "結構模擬serine protease活性作用位置", "B": "與高脂食物併服會降低吸收", "C": "口服吸收差", "D": "作用標的為腎素（renin）", "answer": "A", "questions": "下列有關降血壓藥aliskiren的結構與活性描述，何者錯誤？", "choices": ["結構模擬serine protease活性作用位置", "與高脂食物併服會降低吸收", "口服吸收差", "作用標的為腎素（renin）"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血壓藥aliskiren的結構與活性描述，何者錯誤？\nA. 結構模擬serine protease活性作用位置\nB. 與高脂食物併服會降低吸收\nC. 口服吸收差\nD. 作用標的為腎素（renin）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血壓藥aliskiren的結構與活性描述，何者錯誤？\nA. 結構模擬serine protease活性作用位置\nB. 與高脂食物併服會降低吸收\nC. 口服吸收差\nD. 作用標的為腎素（renin）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血壓藥aliskiren的結構與活性描述，何者錯誤？\nA. 結構模擬serine protease活性作用位置\nB. 與高脂食物併服會降低吸收\nC. 口服吸收差\nD. 作用標的為腎素（renin）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血壓藥aliskiren的結構與活性描述，何者錯誤？\nA. 結構模擬serine protease活性作用位置\nB. 與高脂食物併服會降低吸收\nC. 口服吸收差\nD. 作用標的為腎素（renin）\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.15234375", "True"]], [["-2.40625", "False"]], [["-4.03125", "False"]], [["-3.53125", "False"]]], "filtered_resps": [["-0.15234375", "True"], ["-2.40625", "False"], ["-4.03125", "False"], ["-3.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b5040ae2f17b0f362cb03bf06aa6832600c6b1260c6d8c7c44391c0a48bf1817", "prompt_hash": "38a808dbfaaccd30c8ea5348b2bc11c6610b76f824456ff858e06dc4c2441c14", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 49, "doc": {"question": "改變gonadotropin-releasing hormone（GnRH）的C-terminus，並以D-amino acid置換結構中那個胺基酸可得到GnRH superagonist？", "A": "Pro 9", "B": "Gly 19", "C": "Gly 6", "D": "Tyr 5", "answer": "C", "questions": "改變gonadotropin-releasing hormone（GnRH）的C-terminus，並以D-amino acid置換結構中那個胺基酸可得到GnRH superagonist？", "choices": ["Pro 9", "Gly 19", "Gly 6", "Tyr 5"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n改變gonadotropin-releasing hormone（GnRH）的C-terminus，並以D-amino acid置換結構中那個胺基酸可得到GnRH superagonist？\nA. Pro 9\nB. Gly 19\nC. Gly 6\nD. Tyr 5\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n改變gonadotropin-releasing hormone（GnRH）的C-terminus，並以D-amino acid置換結構中那個胺基酸可得到GnRH superagonist？\nA. Pro 9\nB. Gly 19\nC. Gly 6\nD. Tyr 5\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n改變gonadotropin-releasing hormone（GnRH）的C-terminus，並以D-amino acid置換結構中那個胺基酸可得到GnRH superagonist？\nA. Pro 9\nB. Gly 19\nC. Gly 6\nD. Tyr 5\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n改變gonadotropin-releasing hormone（GnRH）的C-terminus，並以D-amino acid置換結構中那個胺基酸可得到GnRH superagonist？\nA. Pro 9\nB. Gly 19\nC. Gly 6\nD. Tyr 5\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.71875", "False"]], [["-0.84375", "True"]], [["-2.34375", "False"]], [["-1.21875", "False"]]], "filtered_resps": [["-1.71875", "False"], ["-0.84375", "True"], ["-2.34375", "False"], ["-1.21875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6d0973c22dc0a82716657987cb7ef94c4c21a4bf8ef174b64b4722615a11fed5", "prompt_hash": "53196b7f3e7b18f4890239e807bf52522f4fa1caccc581a743aafa0cff26c68d", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 50, "doc": {"question": "下列抗黴菌藥中，何者不屬於squalene epoxidase抑制劑？", "A": "tolnaftate", "B": "amorolfine", "C": "butenafine", "D": "naftifine", "answer": "B", "questions": "下列抗黴菌藥中，何者不屬於squalene epoxidase抑制劑？", "choices": ["tolnaftate", "amorolfine", "butenafine", "naftifine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗黴菌藥中，何者不屬於squalene epoxidase抑制劑？\nA. tolnaftate\nB. amorolfine\nC. butenafine\nD. naftifine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗黴菌藥中，何者不屬於squalene epoxidase抑制劑？\nA. tolnaftate\nB. amorolfine\nC. butenafine\nD. naftifine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗黴菌藥中，何者不屬於squalene epoxidase抑制劑？\nA. tolnaftate\nB. amorolfine\nC. butenafine\nD. naftifine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗黴菌藥中，何者不屬於squalene epoxidase抑制劑？\nA. tolnaftate\nB. amorolfine\nC. butenafine\nD. naftifine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-0.0128173828125", "True"]], [["-5.625", "False"]], [["-5.125", "False"]]], "filtered_resps": [["-5.875", "False"], ["-0.0128173828125", "True"], ["-5.625", "False"], ["-5.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c1a52f374f1ac4b0b38ff0b8bb5b25c1e7859b05f36b91ed645aa52f0af60ac6", "prompt_hash": "ad9cfeb2bedb087834079e32ceb9a20b759be052588c0c1a19efa69ced72db95", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 51, "doc": {"question": "下列何者不是碳酸酐酶（carbonic anhydrase）抑制劑之臨床適應症？", "A": "尿液鹼化（urinary alkalinization）", "B": "急性高山症（acute mountain sickness）", "C": "代謝性酸中毒（metabolic acidosis）", "D": "青光眼（glaucoma）", "answer": "C", "questions": "下列何者不是碳酸酐酶（carbonic anhydrase）抑制劑之臨床適應症？", "choices": ["尿液鹼化（urinary alkalinization）", "急性高山症（acute mountain sickness）", "代謝性酸中毒（metabolic acidosis）", "青光眼（glaucoma）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是碳酸酐酶（carbonic anhydrase）抑制劑之臨床適應症？\nA. 尿液鹼化（urinary alkalinization）\nB. 急性高山症（acute mountain sickness）\nC. 代謝性酸中毒（metabolic acidosis）\nD. 青光眼（glaucoma）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是碳酸酐酶（carbonic anhydrase）抑制劑之臨床適應症？\nA. 尿液鹼化（urinary alkalinization）\nB. 急性高山症（acute mountain sickness）\nC. 代謝性酸中毒（metabolic acidosis）\nD. 青光眼（glaucoma）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是碳酸酐酶（carbonic anhydrase）抑制劑之臨床適應症？\nA. 尿液鹼化（urinary alkalinization）\nB. 急性高山症（acute mountain sickness）\nC. 代謝性酸中毒（metabolic acidosis）\nD. 青光眼（glaucoma）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是碳酸酐酶（carbonic anhydrase）抑制劑之臨床適應症？\nA. 尿液鹼化（urinary alkalinization）\nB. 急性高山症（acute mountain sickness）\nC. 代謝性酸中毒（metabolic acidosis）\nD. 青光眼（glaucoma）\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.15625", "False"]], [["-1.5234375", "False"]], [["-0.275390625", "True"]], [["-4.03125", "False"]]], "filtered_resps": [["-6.15625", "False"], ["-1.5234375", "False"], ["-0.275390625", "True"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "69ae91380b9d1192a33589123ec7780b119dd0278c2e6ddf5090bd1852f82d32", "prompt_hash": "45b26a1950569ad1e1bf6757d776afa5248d6a4c61072e203621add03a1bb6e6", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 52, "doc": {"question": "Ranolazine用於心絞痛治療的藥理機制為何？", "A": "block late component of calcium channel", "B": "block ryanodine calcium release channel", "C": "block funny current", "D": "block late component of sodium current", "answer": "D", "questions": "Ranolazine用於心絞痛治療的藥理機制為何？", "choices": ["block late component of calcium channel", "block ryanodine calcium release channel", "block funny current", "block late component of sodium current"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRanolazine用於心絞痛治療的藥理機制為何？\nA. block late component of calcium channel\nB. block ryanodine calcium release channel\nC. block funny current\nD. block late component of sodium current\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRanolazine用於心絞痛治療的藥理機制為何？\nA. block late component of calcium channel\nB. block ryanodine calcium release channel\nC. block funny current\nD. block late component of sodium current\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRanolazine用於心絞痛治療的藥理機制為何？\nA. block late component of calcium channel\nB. block ryanodine calcium release channel\nC. block funny current\nD. block late component of sodium current\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRanolazine用於心絞痛治療的藥理機制為何？\nA. block late component of calcium channel\nB. block ryanodine calcium release channel\nC. block funny current\nD. block late component of sodium current\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.671875", "False"]], [["-4.6875", "False"]], [["-5.1875", "False"]], [["-0.05078125", "True"]]], "filtered_resps": [["-3.671875", "False"], ["-4.6875", "False"], ["-5.1875", "False"], ["-0.05078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "17bab6b666e046d331dec929598d4ee5bc9968c055c21fc1157b1e5b7c88771a", "prompt_hash": "ddc8b8e02503185f497998aa5561abd2b86490455099406f8dea549f14b1e92b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 53, "doc": {"question": "下列藥物何者較適合用於治療前列腺癌（prostatic carcinoma）？", "A": "oxandrolone", "B": "flutamide", "C": "exemestane", "D": "fulvestrant", "answer": "B", "questions": "下列藥物何者較適合用於治療前列腺癌（prostatic carcinoma）？", "choices": ["oxandrolone", "flutamide", "exemestane", "fulvestrant"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者較適合用於治療前列腺癌（prostatic carcinoma）？\nA. oxandrolone\nB. flutamide\nC. exemestane\nD. fulvestrant\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者較適合用於治療前列腺癌（prostatic carcinoma）？\nA. oxandrolone\nB. flutamide\nC. exemestane\nD. fulvestrant\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者較適合用於治療前列腺癌（prostatic carcinoma）？\nA. oxandrolone\nB. flutamide\nC. exemestane\nD. fulvestrant\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者較適合用於治療前列腺癌（prostatic carcinoma）？\nA. oxandrolone\nB. flutamide\nC. exemestane\nD. fulvestrant\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.125", "False"]], [["-0.01251220703125", "True"]], [["-7.875", "False"]], [["-6.125", "False"]]], "filtered_resps": [["-7.125", "False"], ["-0.01251220703125", "True"], ["-7.875", "False"], ["-6.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "402c39e2abc0159d649b76724cf2e1baaa57a381fe7a59a1ced6dfa77df9a913", "prompt_hash": "6714f97c1cb997306ee88b527ef49ac1c3fbab3d49a8aa7636b1ef64885aad35", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 54, "doc": {"question": "下列何者為抗組織胺藥carbinoxamine、clemastine及setastine的共同結構？", "A": "ethanolamine ether", "B": "phenothiazine", "C": "piperazine", "D": "ethylenediamine", "answer": "A", "questions": "下列何者為抗組織胺藥carbinoxamine、clemastine及setastine的共同結構？", "choices": ["ethanolamine ether", "phenothiazine", "piperazine", "ethylenediamine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗組織胺藥carbinoxamine、clemastine及setastine的共同結構？\nA. ethanolamine ether\nB. phenothiazine\nC. piperazine\nD. ethylenediamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗組織胺藥carbinoxamine、clemastine及setastine的共同結構？\nA. ethanolamine ether\nB. phenothiazine\nC. piperazine\nD. ethylenediamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗組織胺藥carbinoxamine、clemastine及setastine的共同結構？\nA. ethanolamine ether\nB. phenothiazine\nC. piperazine\nD. ethylenediamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗組織胺藥carbinoxamine、clemastine及setastine的共同結構？\nA. ethanolamine ether\nB. phenothiazine\nC. piperazine\nD. ethylenediamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.10986328125", "True"]], [["-4.125", "False"]], [["-5.125", "False"]], [["-2.609375", "False"]]], "filtered_resps": [["-0.10986328125", "True"], ["-4.125", "False"], ["-5.125", "False"], ["-2.609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "503e4f80de0105e0295853dca6209f5575bb11d2a671ecbc41dc87627e2e271a", "prompt_hash": "2d87c9dc3cfeb8758446b55e61bfdd8a7a908f85bcfe7be1d7c4199d47d20557", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 55, "doc": {"question": "下列何者為兒茶酚胺－磺胺（catecholamine-sulfonamide）之衍生物？", "A": "finasteride", "B": "tamsulosin", "C": "medrogesterone", "D": "doxazosin", "answer": "B", "questions": "下列何者為兒茶酚胺－磺胺（catecholamine-sulfonamide）之衍生物？", "choices": ["finasteride", "tamsulosin", "medrogesterone", "doxazosin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為兒茶酚胺－磺胺（catecholamine-sulfonamide）之衍生物？\nA. finasteride\nB. tamsulosin\nC. medrogesterone\nD. doxazosin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為兒茶酚胺－磺胺（catecholamine-sulfonamide）之衍生物？\nA. finasteride\nB. tamsulosin\nC. medrogesterone\nD. doxazosin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為兒茶酚胺－磺胺（catecholamine-sulfonamide）之衍生物？\nA. finasteride\nB. tamsulosin\nC. medrogesterone\nD. doxazosin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為兒茶酚胺－磺胺（catecholamine-sulfonamide）之衍生物？\nA. finasteride\nB. tamsulosin\nC. medrogesterone\nD. doxazosin\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.40625", "False"]], [["-0.142578125", "True"]], [["-3.640625", "False"]], [["-2.390625", "False"]]], "filtered_resps": [["-4.40625", "False"], ["-0.142578125", "True"], ["-3.640625", "False"], ["-2.390625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5b09710b31f67444e8c596d80d28759c5539161ab4621a84607d7eb7fef549a1", "prompt_hash": "2dc714cba3497e41cdc18e59aeb0b16c32312f61d52feeb218760cc222af69f0", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 56, "doc": {"question": "下列有關Itraconazole抗黴菌藥物的敘述，何者錯誤？", "A": "其進入腦脊髓液的能力差", "B": "Cimetidine會減低其吸收", "C": "其吸收會被食物減低", "D": "Rifamycins類藥物會減低它的生體可用率", "answer": "C", "questions": "下列有關Itraconazole抗黴菌藥物的敘述，何者錯誤？", "choices": ["其進入腦脊髓液的能力差", "Cimetidine會減低其吸收", "其吸收會被食物減低", "Rifamycins類藥物會減低它的生體可用率"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Itraconazole抗黴菌藥物的敘述，何者錯誤？\nA. 其進入腦脊髓液的能力差\nB. Cimetidine會減低其吸收\nC. 其吸收會被食物減低\nD. Rifamycins類藥物會減低它的生體可用率\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Itraconazole抗黴菌藥物的敘述，何者錯誤？\nA. 其進入腦脊髓液的能力差\nB. Cimetidine會減低其吸收\nC. 其吸收會被食物減低\nD. Rifamycins類藥物會減低它的生體可用率\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Itraconazole抗黴菌藥物的敘述，何者錯誤？\nA. 其進入腦脊髓液的能力差\nB. Cimetidine會減低其吸收\nC. 其吸收會被食物減低\nD. Rifamycins類藥物會減低它的生體可用率\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Itraconazole抗黴菌藥物的敘述，何者錯誤？\nA. 其進入腦脊髓液的能力差\nB. Cimetidine會減低其吸收\nC. 其吸收會被食物減低\nD. Rifamycins類藥物會減低它的生體可用率\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.75", "False"]], [["-0.6328125", "True"]], [["-1.1328125", "False"]], [["-2.5", "False"]]], "filtered_resps": [["-2.75", "False"], ["-0.6328125", "True"], ["-1.1328125", "False"], ["-2.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6263d0f94fc5d44bac752c77e81a9722e9416486f6c1b352519ac192c565e329", "prompt_hash": "d6222875156d5718dbc18937c5dd2f0bcd95f015b94079d5f7f0b8efb184c80a", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 57, "doc": {"question": "下列有關fondaparinux及heparin的敘述，何者正確？", "A": "fondaparinux是pentapeptide，heparin為polypeptide", "B": "fondaparinux是pentasaccharide，heparin為polypeptide", "C": "fondaparinux是pentasaccharide，heparin為polysaccharide", "D": "fondaparinux是pentapeptide，heparin為polysaccharide", "answer": "C", "questions": "下列有關fondaparinux及heparin的敘述，何者正確？", "choices": ["fondaparinux是pentapeptide，heparin為polypeptide", "fondaparinux是pentasaccharide，heparin為polypeptide", "fondaparinux是pentasaccharide，heparin為polysaccharide", "fondaparinux是pentapeptide，heparin為polysaccharide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fondaparinux及heparin的敘述，何者正確？\nA. fondaparinux是pentapeptide，heparin為polypeptide\nB. fondaparinux是pentasaccharide，heparin為polypeptide\nC. fondaparinux是pentasaccharide，heparin為polysaccharide\nD. fondaparinux是pentapeptide，heparin為polysaccharide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fondaparinux及heparin的敘述，何者正確？\nA. fondaparinux是pentapeptide，heparin為polypeptide\nB. fondaparinux是pentasaccharide，heparin為polypeptide\nC. fondaparinux是pentasaccharide，heparin為polysaccharide\nD. fondaparinux是pentapeptide，heparin為polysaccharide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fondaparinux及heparin的敘述，何者正確？\nA. fondaparinux是pentapeptide，heparin為polypeptide\nB. fondaparinux是pentasaccharide，heparin為polypeptide\nC. fondaparinux是pentasaccharide，heparin為polysaccharide\nD. fondaparinux是pentapeptide，heparin為polysaccharide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fondaparinux及heparin的敘述，何者正確？\nA. fondaparinux是pentapeptide，heparin為polypeptide\nB. fondaparinux是pentasaccharide，heparin為polypeptide\nC. fondaparinux是pentasaccharide，heparin為polysaccharide\nD. fondaparinux是pentapeptide，heparin為polysaccharide\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.0625", "False"]], [["-1.8046875", "False"]], [["-0.30078125", "True"]], [["-2.421875", "False"]]], "filtered_resps": [["-5.0625", "False"], ["-1.8046875", "False"], ["-0.30078125", "True"], ["-2.421875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a432c179ccfb6b2b04f63df4d22f91f3875c477037e6348e636938de640023eb", "prompt_hash": "37d1b15af1b729245e578177db81b3a5734b9092de16ec0da46f0e8c3bb4ddfb", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 58, "doc": {"question": "Erythromycin結構中的C-6 hydroxy基團以methyl ether取代後的產物為：", "A": "dirithromycin", "B": "azithromycin", "C": "clarithromycin", "D": "telithromycin", "answer": "C", "questions": "Erythromycin結構中的C-6 hydroxy基團以methyl ether取代後的產物為：", "choices": ["dirithromycin", "azithromycin", "clarithromycin", "telithromycin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nErythromycin結構中的C-6 hydroxy基團以methyl ether取代後的產物為：\nA. dirithromycin\nB. azithromycin\nC. clarithromycin\nD. telithromycin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nErythromycin結構中的C-6 hydroxy基團以methyl ether取代後的產物為：\nA. dirithromycin\nB. azithromycin\nC. clarithromycin\nD. telithromycin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nErythromycin結構中的C-6 hydroxy基團以methyl ether取代後的產物為：\nA. dirithromycin\nB. azithromycin\nC. clarithromycin\nD. telithromycin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nErythromycin結構中的C-6 hydroxy基團以methyl ether取代後的產物為：\nA. dirithromycin\nB. azithromycin\nC. clarithromycin\nD. telithromycin\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.984375", "False"]], [["-4.34375", "False"]], [["-0.1064453125", "True"]], [["-3.484375", "False"]]], "filtered_resps": [["-2.984375", "False"], ["-4.34375", "False"], ["-0.1064453125", "True"], ["-3.484375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "eb56c6787f5a747aea0bb03073e01bbfa67435d216f237fbf55966a399ba1f23", "prompt_hash": "6714b0ac00bae01b5a0814b61a240be35fcec4e274a91c0f065340d753f1f775", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 59, "doc": {"question": "下列何種抗生素可抑制細菌細胞壁的生合成？", "A": "spectinomycin", "B": "vancomycin", "C": "erythromycin", "D": "chloramphenicol", "answer": "B", "questions": "下列何種抗生素可抑制細菌細胞壁的生合成？", "choices": ["spectinomycin", "vancomycin", "erythromycin", "chloramphenicol"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗生素可抑制細菌細胞壁的生合成？\nA. spectinomycin\nB. vancomycin\nC. erythromycin\nD. chloramphenicol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗生素可抑制細菌細胞壁的生合成？\nA. spectinomycin\nB. vancomycin\nC. erythromycin\nD. chloramphenicol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗生素可抑制細菌細胞壁的生合成？\nA. spectinomycin\nB. vancomycin\nC. erythromycin\nD. chloramphenicol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗生素可抑制細菌細胞壁的生合成？\nA. spectinomycin\nB. vancomycin\nC. erythromycin\nD. chloramphenicol\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-0.007110595703125", "True"]], [["-6.125", "False"]], [["-7.75", "False"]]], "filtered_resps": [["-5.875", "False"], ["-0.007110595703125", "True"], ["-6.125", "False"], ["-7.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6a6af2bc4f486fbb7880c2ebdec36843dab77b7c739a420a8eb0316ef103bb3e", "prompt_hash": "68fc3f17f4174f865ac3d6b17d312dd93d79cc1b176cc0e6649c9401557527e6", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 60, "doc": {"question": "下列何者不是基因突變（mutation）常見的現象？", "A": "取代（substitution）", "B": "刪除（deletion）", "C": "加成（addition）", "D": "封頂（capping）", "answer": "D", "questions": "下列何者不是基因突變（mutation）常見的現象？", "choices": ["取代（substitution）", "刪除（deletion）", "加成（addition）", "封頂（capping）"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是基因突變（mutation）常見的現象？\nA. 取代（substitution）\nB. 刪除（deletion）\nC. 加成（addition）\nD. 封頂（capping）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是基因突變（mutation）常見的現象？\nA. 取代（substitution）\nB. 刪除（deletion）\nC. 加成（addition）\nD. 封頂（capping）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是基因突變（mutation）常見的現象？\nA. 取代（substitution）\nB. 刪除（deletion）\nC. 加成（addition）\nD. 封頂（capping）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是基因突變（mutation）常見的現象？\nA. 取代（substitution）\nB. 刪除（deletion）\nC. 加成（addition）\nD. 封頂（capping）\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.71875", "False"]], [["-7.21875", "False"]], [["-2.59375", "False"]], [["-0.0908203125", "True"]]], "filtered_resps": [["-4.71875", "False"], ["-7.21875", "False"], ["-2.59375", "False"], ["-0.0908203125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "85c9d224377dc930f27d3c9ba8d534f5128c7be9721860411bfa0b5079cc29ac", "prompt_hash": "2e3106b73e8499b0f152999dc6a81fb4675c7c1a554cd156b8fa0a5dfdce33b9", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 61, "doc": {"question": "下列有關 PDE5 抑制劑之敘述，何者正確 ?", "A": "藥效最長者為 sildenafil", "B": "tadalafil 具活性代謝物", "C": "活性依序為 vardenafil＞sildenafil＞tadalafil", "D": "sildenafil 與 vardenafil 均具 pyrazolopyrimidinone結構", "answer": "C", "questions": "下列有關 PDE5 抑制劑之敘述，何者正確 ?", "choices": ["藥效最長者為 sildenafil", "tadalafil 具活性代謝物", "活性依序為 vardenafil＞sildenafil＞tadalafil", "sildenafil 與 vardenafil 均具 pyrazolopyrimidinone結構"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 PDE5 抑制劑之敘述，何者正確 ?\nA. 藥效最長者為 sildenafil\nB. tadalafil 具活性代謝物\nC. 活性依序為 vardenafil＞sildenafil＞tadalafil\nD. sildenafil 與 vardenafil 均具 pyrazolopyrimidinone結構\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 PDE5 抑制劑之敘述，何者正確 ?\nA. 藥效最長者為 sildenafil\nB. tadalafil 具活性代謝物\nC. 活性依序為 vardenafil＞sildenafil＞tadalafil\nD. sildenafil 與 vardenafil 均具 pyrazolopyrimidinone結構\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 PDE5 抑制劑之敘述，何者正確 ?\nA. 藥效最長者為 sildenafil\nB. tadalafil 具活性代謝物\nC. 活性依序為 vardenafil＞sildenafil＞tadalafil\nD. sildenafil 與 vardenafil 均具 pyrazolopyrimidinone結構\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 PDE5 抑制劑之敘述，何者正確 ?\nA. 藥效最長者為 sildenafil\nB. tadalafil 具活性代謝物\nC. 活性依序為 vardenafil＞sildenafil＞tadalafil\nD. sildenafil 與 vardenafil 均具 pyrazolopyrimidinone結構\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.109375", "False"]], [["-1.359375", "False"]], [["-1.109375", "True"]], [["-1.234375", "False"]]], "filtered_resps": [["-2.109375", "False"], ["-1.359375", "False"], ["-1.109375", "True"], ["-1.234375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f0fb577c03d7d38e0bcc8d3a06000e02ca00aadcee4869d475e475a1961b73ea", "prompt_hash": "7b66c42aaa6d8a9dbf4d20a3690832d32eca4465b8236bf58824767f7e08339d", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 62, "doc": {"question": "下列抗高血壓藥物，何者較少產生直立性低血壓的副作用？", "A": "Methyldopa", "B": "Hydralazine", "C": "Prazosin", "D": "Hydrochlorothiazide", "answer": "D", "questions": "下列抗高血壓藥物，何者較少產生直立性低血壓的副作用？", "choices": ["Methyldopa", "Hydralazine", "Prazosin", "Hydrochlorothiazide"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗高血壓藥物，何者較少產生直立性低血壓的副作用？\nA. Methyldopa\nB. Hydralazine\nC. Prazosin\nD. Hydrochlorothiazide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗高血壓藥物，何者較少產生直立性低血壓的副作用？\nA. Methyldopa\nB. Hydralazine\nC. Prazosin\nD. Hydrochlorothiazide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗高血壓藥物，何者較少產生直立性低血壓的副作用？\nA. Methyldopa\nB. Hydralazine\nC. Prazosin\nD. Hydrochlorothiazide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗高血壓藥物，何者較少產生直立性低血壓的副作用？\nA. Methyldopa\nB. Hydralazine\nC. Prazosin\nD. Hydrochlorothiazide\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.125", "False"]], [["-5.125", "False"]], [["-6.125", "False"]], [["-0.0147705078125", "True"]]], "filtered_resps": [["-5.125", "False"], ["-5.125", "False"], ["-6.125", "False"], ["-0.0147705078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e319fd5711f2ae3a67eb95b9eaca95f3e422061c4c87bcf07b4395c5d953842f", "prompt_hash": "59ab486874fd4ca396257730a33ecb1fa4faa4c1acaa198d0b0068dd0cc3bf1c", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 63, "doc": {"question": "當使用β blockers中毒時，下列何者為常用之解毒劑？", "A": "esmolol", "B": "glucagon", "C": "fomepizole", "D": "naloxone", "answer": "B", "questions": "當使用β blockers中毒時，下列何者為常用之解毒劑？", "choices": ["esmolol", "glucagon", "fomepizole", "naloxone"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當使用β blockers中毒時，下列何者為常用之解毒劑？\nA. esmolol\nB. glucagon\nC. fomepizole\nD. naloxone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當使用β blockers中毒時，下列何者為常用之解毒劑？\nA. esmolol\nB. glucagon\nC. fomepizole\nD. naloxone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當使用β blockers中毒時，下列何者為常用之解毒劑？\nA. esmolol\nB. glucagon\nC. fomepizole\nD. naloxone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當使用β blockers中毒時，下列何者為常用之解毒劑？\nA. esmolol\nB. glucagon\nC. fomepizole\nD. naloxone\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.703125", "False"]], [["-0.08544921875", "True"]], [["-4.96875", "False"]], [["-4.96875", "False"]]], "filtered_resps": [["-2.703125", "False"], ["-0.08544921875", "True"], ["-4.96875", "False"], ["-4.96875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6bc6d3fe5f476ac5333f3c555a22f2410cf0d65e437589fdd64b599e7f2a3c79", "prompt_hash": "aa09e5f2562fc560583fc3f2cbfa27441b97dc56a50c3526da5939407ee5a142", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 64, "doc": {"question": "下列何種局部麻醉劑因結構中含有thiophene環，而使其易於穿透細胞膜？", "A": "articaine", "B": "bupivacaine", "C": "mepivacaine", "D": "ropivacaine", "answer": "A", "questions": "下列何種局部麻醉劑因結構中含有thiophene環，而使其易於穿透細胞膜？", "choices": ["articaine", "bupivacaine", "mepivacaine", "ropivacaine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種局部麻醉劑因結構中含有thiophene環，而使其易於穿透細胞膜？\nA. articaine\nB. bupivacaine\nC. mepivacaine\nD. ropivacaine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種局部麻醉劑因結構中含有thiophene環，而使其易於穿透細胞膜？\nA. articaine\nB. bupivacaine\nC. mepivacaine\nD. ropivacaine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種局部麻醉劑因結構中含有thiophene環，而使其易於穿透細胞膜？\nA. articaine\nB. bupivacaine\nC. mepivacaine\nD. ropivacaine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種局部麻醉劑因結構中含有thiophene環，而使其易於穿透細胞膜？\nA. articaine\nB. bupivacaine\nC. mepivacaine\nD. ropivacaine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.06591796875", "True"]], [["-5.3125", "False"]], [["-3.4375", "False"]], [["-4.0625", "False"]]], "filtered_resps": [["-0.06591796875", "True"], ["-5.3125", "False"], ["-3.4375", "False"], ["-4.0625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d8a1aae9f8bebd6275aaa455bd1fea45ea717a02c3fbb3ea67b885e8fc5dce39", "prompt_hash": "549eed0ce3c18742e9e9a84aaef4189c335bc830aa9416a076495363ebc31fc9", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 65, "doc": {"question": "下列何種抗癌藥對DNA生合成具有抑制作用？", "A": "idarubicin", "B": "mitomycin", "C": "methotrexate", "D": "dacarbazine", "answer": "C", "questions": "下列何種抗癌藥對DNA生合成具有抑制作用？", "choices": ["idarubicin", "mitomycin", "methotrexate", "dacarbazine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥對DNA生合成具有抑制作用？\nA. idarubicin\nB. mitomycin\nC. methotrexate\nD. dacarbazine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥對DNA生合成具有抑制作用？\nA. idarubicin\nB. mitomycin\nC. methotrexate\nD. dacarbazine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥對DNA生合成具有抑制作用？\nA. idarubicin\nB. mitomycin\nC. methotrexate\nD. dacarbazine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥對DNA生合成具有抑制作用？\nA. idarubicin\nB. mitomycin\nC. methotrexate\nD. dacarbazine\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.40625", "False"]], [["-4.53125", "False"]], [["-0.0279541015625", "True"]], [["-5.40625", "False"]]], "filtered_resps": [["-6.40625", "False"], ["-4.53125", "False"], ["-0.0279541015625", "True"], ["-5.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9b5467904bacc03eb79d1f9c7d35ad089cb7597cbc95227102f0c1823a88ee85", "prompt_hash": "d3c4620325cc6d502e6c10eb128fe83b71ee5899dcb0c1f18704b7cf908f665e", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 66, "doc": {"question": "下列何者不是長期使用haloperidol所造成的多巴胺神經性的副作用？", "A": "高泌乳症", "B": "帕金森氏症", "C": "Tonic-clonic seizure", "D": "Tardive dyskinesia", "answer": "C", "questions": "下列何者不是長期使用haloperidol所造成的多巴胺神經性的副作用？", "choices": ["高泌乳症", "帕金森氏症", "Tonic-clonic seizure", "Tardive dyskinesia"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是長期使用haloperidol所造成的多巴胺神經性的副作用？\nA. 高泌乳症\nB. 帕金森氏症\nC. Tonic-clonic seizure\nD. Tardive dyskinesia\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是長期使用haloperidol所造成的多巴胺神經性的副作用？\nA. 高泌乳症\nB. 帕金森氏症\nC. Tonic-clonic seizure\nD. Tardive dyskinesia\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是長期使用haloperidol所造成的多巴胺神經性的副作用？\nA. 高泌乳症\nB. 帕金森氏症\nC. Tonic-clonic seizure\nD. Tardive dyskinesia\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是長期使用haloperidol所造成的多巴胺神經性的副作用？\nA. 高泌乳症\nB. 帕金森氏症\nC. Tonic-clonic seizure\nD. Tardive dyskinesia\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.25", "False"]], [["-5.125", "False"]], [["-0.130859375", "True"]], [["-4.75", "False"]]], "filtered_resps": [["-2.25", "False"], ["-5.125", "False"], ["-0.130859375", "True"], ["-4.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "55fcdd5ddb7ee876217b7872abc3b1b45e6dc031aa1cb6d746870e7a784f227f", "prompt_hash": "32a2cc65c59e15be8f3d2360e7be936a6320c5d3192a4d1d576c66dcbe7fffba", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 67, "doc": {"question": "下列那一種降血壓藥物會引起關節痛、肌肉酸痛、皮膚疹、發燒等類似紅斑性狼瘡之副作用？", "A": "Hydralazine", "B": "Losartan", "C": "Enalapril", "D": "Clonidine", "answer": "A", "questions": "下列那一種降血壓藥物會引起關節痛、肌肉酸痛、皮膚疹、發燒等類似紅斑性狼瘡之副作用？", "choices": ["Hydralazine", "Losartan", "Enalapril", "Clonidine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種降血壓藥物會引起關節痛、肌肉酸痛、皮膚疹、發燒等類似紅斑性狼瘡之副作用？\nA. Hydralazine\nB. Losartan\nC. Enalapril\nD. Clonidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種降血壓藥物會引起關節痛、肌肉酸痛、皮膚疹、發燒等類似紅斑性狼瘡之副作用？\nA. Hydralazine\nB. Losartan\nC. Enalapril\nD. Clonidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種降血壓藥物會引起關節痛、肌肉酸痛、皮膚疹、發燒等類似紅斑性狼瘡之副作用？\nA. Hydralazine\nB. Losartan\nC. Enalapril\nD. Clonidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種降血壓藥物會引起關節痛、肌肉酸痛、皮膚疹、發燒等類似紅斑性狼瘡之副作用？\nA. Hydralazine\nB. Losartan\nC. Enalapril\nD. Clonidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0264892578125", "True"]], [["-4.78125", "False"]], [["-4.90625", "False"]], [["-5.28125", "False"]]], "filtered_resps": [["-0.0264892578125", "True"], ["-4.78125", "False"], ["-4.90625", "False"], ["-5.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d49f4044f0fbaea5bbc13d1e6c04b9cb56affc3cb321e056f8bacedaf94008c2", "prompt_hash": "3469b3ea44dbb2d9a2d41530369f5311f4bd5ffbd9fd18d568fbce492542bda3", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 68, "doc": {"question": "鹼性藥物phenylpropanolamine（pKa＝9.4）在pH＝7.4溶液中之解離度大約為多少？", "A": "60～80%", "B": "90%以上", "C": "30～50%", "D": "10%以下", "answer": "B", "questions": "鹼性藥物phenylpropanolamine（pKa＝9.4）在pH＝7.4溶液中之解離度大約為多少？", "choices": ["60～80%", "90%以上", "30～50%", "10%以下"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n鹼性藥物phenylpropanolamine（pKa＝9.4）在pH＝7.4溶液中之解離度大約為多少？\nA. 60～80%\nB. 90%以上\nC. 30～50%\nD. 10%以下\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n鹼性藥物phenylpropanolamine（pKa＝9.4）在pH＝7.4溶液中之解離度大約為多少？\nA. 60～80%\nB. 90%以上\nC. 30～50%\nD. 10%以下\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n鹼性藥物phenylpropanolamine（pKa＝9.4）在pH＝7.4溶液中之解離度大約為多少？\nA. 60～80%\nB. 90%以上\nC. 30～50%\nD. 10%以下\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n鹼性藥物phenylpropanolamine（pKa＝9.4）在pH＝7.4溶液中之解離度大約為多少？\nA. 60～80%\nB. 90%以上\nC. 30～50%\nD. 10%以下\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.4375", "False"]], [["-0.69140625", "True"]], [["-2.6875", "False"]], [["-1.0703125", "False"]]], "filtered_resps": [["-2.4375", "False"], ["-0.69140625", "True"], ["-2.6875", "False"], ["-1.0703125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "702977f8682aa95bd74c974bdd9f56beeffea256947dd39e9caacba5d1038533", "prompt_hash": "9dbbc2411fa7ec808729164a145579e0a7ef9aea50f895f0f1cb9c8fa6119b81", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 69, "doc": {"question": "下列給藥方式中，何者的生體可用率（bioavailability）最高？", "A": "吸入法", "B": "肌肉注射法", "C": "口服", "D": "靜脈注射法", "answer": "D", "questions": "下列給藥方式中，何者的生體可用率（bioavailability）最高？", "choices": ["吸入法", "肌肉注射法", "口服", "靜脈注射法"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式中，何者的生體可用率（bioavailability）最高？\nA. 吸入法\nB. 肌肉注射法\nC. 口服\nD. 靜脈注射法\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式中，何者的生體可用率（bioavailability）最高？\nA. 吸入法\nB. 肌肉注射法\nC. 口服\nD. 靜脈注射法\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式中，何者的生體可用率（bioavailability）最高？\nA. 吸入法\nB. 肌肉注射法\nC. 口服\nD. 靜脈注射法\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式中，何者的生體可用率（bioavailability）最高？\nA. 吸入法\nB. 肌肉注射法\nC. 口服\nD. 靜脈注射法\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.421875", "False"]], [["-4.5625", "False"]], [["-5.5625", "False"]], [["-0.296875", "True"]]], "filtered_resps": [["-1.421875", "False"], ["-4.5625", "False"], ["-5.5625", "False"], ["-0.296875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d9da45ccbc2d07a4b635a17594a290ebc82cd19609ccce69f9b59fc784689458", "prompt_hash": "e7b2db3c34e0b436741c08e62b9cd6931fc1bc2b296383924b81148fa32c44dd", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 70, "doc": {"question": "下列何者並非使用嗎啡（Morphine）時常見的副作用？", "A": "瞳孔放大", "B": "呼吸抑制作用", "C": "抑制免疫活性", "D": "便秘作用", "answer": "A", "questions": "下列何者並非使用嗎啡（Morphine）時常見的副作用？", "choices": ["瞳孔放大", "呼吸抑制作用", "抑制免疫活性", "便秘作用"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非使用嗎啡（Morphine）時常見的副作用？\nA. 瞳孔放大\nB. 呼吸抑制作用\nC. 抑制免疫活性\nD. 便秘作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非使用嗎啡（Morphine）時常見的副作用？\nA. 瞳孔放大\nB. 呼吸抑制作用\nC. 抑制免疫活性\nD. 便秘作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非使用嗎啡（Morphine）時常見的副作用？\nA. 瞳孔放大\nB. 呼吸抑制作用\nC. 抑制免疫活性\nD. 便秘作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非使用嗎啡（Morphine）時常見的副作用？\nA. 瞳孔放大\nB. 呼吸抑制作用\nC. 抑制免疫活性\nD. 便秘作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.04931640625", "True"]], [["-3.671875", "False"]], [["-4.4375", "False"]], [["-4.6875", "False"]]], "filtered_resps": [["-0.04931640625", "True"], ["-3.671875", "False"], ["-4.4375", "False"], ["-4.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "757f6b59002472b5907a520d6032f4eda7acea62c4ed73329a827719cc060ecc", "prompt_hash": "4a6a28b59d5ff53cbfe59c8e16da4f12f2a8105e48b8baabe3c16fcd7757a8f4", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 71, "doc": {"question": "下列有關肺結核治療劑isoniazid之敘述，何者正確？", "A": "併用pyridoxine可預防肝炎副作用", "B": "可抑制細胞壁成分mycolic acid之生合成", "C": "主要以原型由腎臟排出", "D": "為抑菌型抗生素", "answer": "B", "questions": "下列有關肺結核治療劑isoniazid之敘述，何者正確？", "choices": ["併用pyridoxine可預防肝炎副作用", "可抑制細胞壁成分mycolic acid之生合成", "主要以原型由腎臟排出", "為抑菌型抗生素"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關肺結核治療劑isoniazid之敘述，何者正確？\nA. 併用pyridoxine可預防肝炎副作用\nB. 可抑制細胞壁成分mycolic acid之生合成\nC. 主要以原型由腎臟排出\nD. 為抑菌型抗生素\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關肺結核治療劑isoniazid之敘述，何者正確？\nA. 併用pyridoxine可預防肝炎副作用\nB. 可抑制細胞壁成分mycolic acid之生合成\nC. 主要以原型由腎臟排出\nD. 為抑菌型抗生素\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關肺結核治療劑isoniazid之敘述，何者正確？\nA. 併用pyridoxine可預防肝炎副作用\nB. 可抑制細胞壁成分mycolic acid之生合成\nC. 主要以原型由腎臟排出\nD. 為抑菌型抗生素\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關肺結核治療劑isoniazid之敘述，何者正確？\nA. 併用pyridoxine可預防肝炎副作用\nB. 可抑制細胞壁成分mycolic acid之生合成\nC. 主要以原型由腎臟排出\nD. 為抑菌型抗生素\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.03125", "False"]], [["-1.0234375", "False"]], [["-3.03125", "False"]], [["-0.77734375", "True"]]], "filtered_resps": [["-2.03125", "False"], ["-1.0234375", "False"], ["-3.03125", "False"], ["-0.77734375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2197121f06a605030b62b24243ab44465e45ca0aa23a31a3bb7cdc6ee7175451", "prompt_hash": "33f5fbdb3f6c582f4f837915260a924cc014410ce565d54dbd1104c23f123bb6", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 72, "doc": {"question": "下列何者不是在新藥開發進入臨床試驗前的必備項目？", "A": "證明藥效的藥理實驗數據", "B": "預測藥物作用的電腦模擬數據", "C": "證明安全性的毒理實驗數據", "D": "獲得足量符合品質的原料藥", "answer": "B", "questions": "下列何者不是在新藥開發進入臨床試驗前的必備項目？", "choices": ["證明藥效的藥理實驗數據", "預測藥物作用的電腦模擬數據", "證明安全性的毒理實驗數據", "獲得足量符合品質的原料藥"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是在新藥開發進入臨床試驗前的必備項目？\nA. 證明藥效的藥理實驗數據\nB. 預測藥物作用的電腦模擬數據\nC. 證明安全性的毒理實驗數據\nD. 獲得足量符合品質的原料藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是在新藥開發進入臨床試驗前的必備項目？\nA. 證明藥效的藥理實驗數據\nB. 預測藥物作用的電腦模擬數據\nC. 證明安全性的毒理實驗數據\nD. 獲得足量符合品質的原料藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是在新藥開發進入臨床試驗前的必備項目？\nA. 證明藥效的藥理實驗數據\nB. 預測藥物作用的電腦模擬數據\nC. 證明安全性的毒理實驗數據\nD. 獲得足量符合品質的原料藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是在新藥開發進入臨床試驗前的必備項目？\nA. 證明藥效的藥理實驗數據\nB. 預測藥物作用的電腦模擬數據\nC. 證明安全性的毒理實驗數據\nD. 獲得足量符合品質的原料藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.0", "False"]], [["-0.003570556640625", "True"]], [["-8.25", "False"]], [["-6.375", "False"]]], "filtered_resps": [["-7.0", "False"], ["-0.003570556640625", "True"], ["-8.25", "False"], ["-6.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f7ffc9eace197a670e64efe5e605fc17f6a8f4e8977b0bcf2a7b71974bacb459", "prompt_hash": "23a2d748387b1070b9600210b8a550a3d61fa6c70d064e55f7e460d1c93b9c99", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 73, "doc": {"question": "下列何藥用於治療食道靜脈曲張之出血？", "A": "Lactulose", "B": "Ursodiol", "C": "Ergotamine", "D": "Octreotide", "answer": "D", "questions": "下列何藥用於治療食道靜脈曲張之出血？", "choices": ["Lactulose", "Ursodiol", "Ergotamine", "Octreotide"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何藥用於治療食道靜脈曲張之出血？\nA. Lactulose\nB. Ursodiol\nC. Ergotamine\nD. Octreotide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何藥用於治療食道靜脈曲張之出血？\nA. Lactulose\nB. Ursodiol\nC. Ergotamine\nD. Octreotide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何藥用於治療食道靜脈曲張之出血？\nA. Lactulose\nB. Ursodiol\nC. Ergotamine\nD. Octreotide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何藥用於治療食道靜脈曲張之出血？\nA. Lactulose\nB. Ursodiol\nC. Ergotamine\nD. Octreotide\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.0", "False"]], [["-6.0", "False"]], [["-6.375", "False"]], [["-0.00848388671875", "True"]]], "filtered_resps": [["-6.0", "False"], ["-6.0", "False"], ["-6.375", "False"], ["-0.00848388671875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3486e559c5eb15d82a7566d9e2e08da8c1091612c60b520b6e3f34747943800d", "prompt_hash": "19d3fdb4a645baa2eeec401b8b1acc1677b367e6818374eaef9f48f9561c18d8", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 74, "doc": {"question": "有關Heparin引致血小板減少症（thrombocytopenia）時之處理方式，下列何者錯誤？", "A": "不可使用Fondaparinux治療", "B": "不能使用Warfarin治療", "C": "停止使用Heparin", "D": "可使用Lepirudin治療", "answer": "A", "questions": "有關Heparin引致血小板減少症（thrombocytopenia）時之處理方式，下列何者錯誤？", "choices": ["不可使用Fondaparinux治療", "不能使用Warfarin治療", "停止使用Heparin", "可使用Lepirudin治療"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關Heparin引致血小板減少症（thrombocytopenia）時之處理方式，下列何者錯誤？\nA. 不可使用Fondaparinux治療\nB. 不能使用Warfarin治療\nC. 停止使用Heparin\nD. 可使用Lepirudin治療\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關Heparin引致血小板減少症（thrombocytopenia）時之處理方式，下列何者錯誤？\nA. 不可使用Fondaparinux治療\nB. 不能使用Warfarin治療\nC. 停止使用Heparin\nD. 可使用Lepirudin治療\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關Heparin引致血小板減少症（thrombocytopenia）時之處理方式，下列何者錯誤？\nA. 不可使用Fondaparinux治療\nB. 不能使用Warfarin治療\nC. 停止使用Heparin\nD. 可使用Lepirudin治療\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關Heparin引致血小板減少症（thrombocytopenia）時之處理方式，下列何者錯誤？\nA. 不可使用Fondaparinux治療\nB. 不能使用Warfarin治療\nC. 停止使用Heparin\nD. 可使用Lepirudin治療\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.298828125", "True"]], [["-2.171875", "False"]], [["-4.1875", "False"]], [["-2.046875", "False"]]], "filtered_resps": [["-0.298828125", "True"], ["-2.171875", "False"], ["-4.1875", "False"], ["-2.046875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2e05453c1c61c85e827d49e3a020f0043a1de169656e2070a77c8b93f1682e70", "prompt_hash": "9cd52d62603668fa678e25afe4d9573fc55d3898d3f369ca337ed58e9dcd7468", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 75, "doc": {"question": "下列抗生素中，何者脂溶性最大且最容易通過中樞血腦屏障（blood brain barrier），可用於治療meningitis？", "A": "tetracycline", "B": "azithromycin", "C": "cefepime", "D": "amikacin", "answer": "C", "questions": "下列抗生素中，何者脂溶性最大且最容易通過中樞血腦屏障（blood brain barrier），可用於治療meningitis？", "choices": ["tetracycline", "azithromycin", "cefepime", "amikacin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者脂溶性最大且最容易通過中樞血腦屏障（blood brain barrier），可用於治療meningitis？\nA. tetracycline\nB. azithromycin\nC. cefepime\nD. amikacin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者脂溶性最大且最容易通過中樞血腦屏障（blood brain barrier），可用於治療meningitis？\nA. tetracycline\nB. azithromycin\nC. cefepime\nD. amikacin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者脂溶性最大且最容易通過中樞血腦屏障（blood brain barrier），可用於治療meningitis？\nA. tetracycline\nB. azithromycin\nC. cefepime\nD. amikacin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者脂溶性最大且最容易通過中樞血腦屏障（blood brain barrier），可用於治療meningitis？\nA. tetracycline\nB. azithromycin\nC. cefepime\nD. amikacin\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.4375", "False"]], [["-0.44921875", "True"]], [["-1.078125", "False"]], [["-4.4375", "False"]]], "filtered_resps": [["-5.4375", "False"], ["-0.44921875", "True"], ["-1.078125", "False"], ["-4.4375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5c6acf9d4d4848ff9bc853435115ed6732f3410cc085fd3d4cfe37b67ee26522", "prompt_hash": "99e6d7dc43bc633097da82ed3ae7cf1b82b398b2f75d66a9db394ecfdfb4b203", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 76, "doc": {"question": "下列抗肺結核藥物中，何者能干擾葉酸之合成？", "A": "PAS", "B": "INH", "C": "pyrazinamide", "D": "ethionamide", "answer": "A", "questions": "下列抗肺結核藥物中，何者能干擾葉酸之合成？", "choices": ["PAS", "INH", "pyrazinamide", "ethionamide"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗肺結核藥物中，何者能干擾葉酸之合成？\nA. PAS\nB. INH\nC. pyrazinamide\nD. ethionamide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗肺結核藥物中，何者能干擾葉酸之合成？\nA. PAS\nB. INH\nC. pyrazinamide\nD. ethionamide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗肺結核藥物中，何者能干擾葉酸之合成？\nA. PAS\nB. INH\nC. pyrazinamide\nD. ethionamide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗肺結核藥物中，何者能干擾葉酸之合成？\nA. PAS\nB. INH\nC. pyrazinamide\nD. ethionamide\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.10498046875", "True"]], [["-3.734375", "False"]], [["-4.59375", "False"]], [["-2.734375", "False"]]], "filtered_resps": [["-0.10498046875", "True"], ["-3.734375", "False"], ["-4.59375", "False"], ["-2.734375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "952de2a38a34246d3b7d8a18acd6bc15137b5947b2e353bac40425cefbb374d4", "prompt_hash": "28100bf499c1ab8921f61335ac6cec97b2353474f412ce61b6fcb3c42cca4b42", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 77, "doc": {"question": "下列藥物何者臨床上用於治療銅中毒？", "A": "penicillamine", "B": "pralidoxime", "C": "dimercaprol", "D": "succimer", "answer": "A", "questions": "下列藥物何者臨床上用於治療銅中毒？", "choices": ["penicillamine", "pralidoxime", "dimercaprol", "succimer"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者臨床上用於治療銅中毒？\nA. penicillamine\nB. pralidoxime\nC. dimercaprol\nD. succimer\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者臨床上用於治療銅中毒？\nA. penicillamine\nB. pralidoxime\nC. dimercaprol\nD. succimer\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者臨床上用於治療銅中毒？\nA. penicillamine\nB. pralidoxime\nC. dimercaprol\nD. succimer\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者臨床上用於治療銅中毒？\nA. penicillamine\nB. pralidoxime\nC. dimercaprol\nD. succimer\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.025634765625", "True"]], [["-6.03125", "False"]], [["-4.40625", "False"]], [["-4.90625", "False"]]], "filtered_resps": [["-0.025634765625", "True"], ["-6.03125", "False"], ["-4.40625", "False"], ["-4.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "33549e79c1e68a61d8f8a2e8102b4299676c5f7eb0214da7ad96a0ba0c7b35d4", "prompt_hash": "b6f3c88f4c4b5193228a28ece11ff356e04892aac52278504ed1c82451b0eea0", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 78, "doc": {"question": "兒茶酚胺（catecholamine）再回收抑制劑臨床應用廣泛，下列敘述何者錯誤？", "A": "sibutramine可降低食慾", "B": "reboxetine可用於治療重度憂鬱", "C": "milnacipran可治療肌纖維疼痛", "D": "atomoxetine可用來治療姿態性低血壓", "answer": "D", "questions": "兒茶酚胺（catecholamine）再回收抑制劑臨床應用廣泛，下列敘述何者錯誤？", "choices": ["sibutramine可降低食慾", "reboxetine可用於治療重度憂鬱", "milnacipran可治療肌纖維疼痛", "atomoxetine可用來治療姿態性低血壓"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n兒茶酚胺（catecholamine）再回收抑制劑臨床應用廣泛，下列敘述何者錯誤？\nA. sibutramine可降低食慾\nB. reboxetine可用於治療重度憂鬱\nC. milnacipran可治療肌纖維疼痛\nD. atomoxetine可用來治療姿態性低血壓\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n兒茶酚胺（catecholamine）再回收抑制劑臨床應用廣泛，下列敘述何者錯誤？\nA. sibutramine可降低食慾\nB. reboxetine可用於治療重度憂鬱\nC. milnacipran可治療肌纖維疼痛\nD. atomoxetine可用來治療姿態性低血壓\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n兒茶酚胺（catecholamine）再回收抑制劑臨床應用廣泛，下列敘述何者錯誤？\nA. sibutramine可降低食慾\nB. reboxetine可用於治療重度憂鬱\nC. milnacipran可治療肌纖維疼痛\nD. atomoxetine可用來治療姿態性低血壓\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n兒茶酚胺（catecholamine）再回收抑制劑臨床應用廣泛，下列敘述何者錯誤？\nA. sibutramine可降低食慾\nB. reboxetine可用於治療重度憂鬱\nC. milnacipran可治療肌纖維疼痛\nD. atomoxetine可用來治療姿態性低血壓\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.625", "False"]], [["-5.875", "False"]], [["-6.125", "False"]], [["-0.0069580078125", "True"]]], "filtered_resps": [["-6.625", "False"], ["-5.875", "False"], ["-6.125", "False"], ["-0.0069580078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "053ed2933511a978bbc2bad11ae34feac237d18ba4afea6577900201b8cf430e", "prompt_hash": "b9777140cf232f84434016524f3c4bd0d7312fd173e5247e8fa17bf8a66d1038", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 79, "doc": {"question": "使用succimer作為重金屬解毒劑時，下列敘述何者錯誤？", "A": "可以口服給藥", "B": "可治療鉛中毒", "C": "可治療砷中毒", "D": "為高脂溶性藥物", "answer": "D", "questions": "使用succimer作為重金屬解毒劑時，下列敘述何者錯誤？", "choices": ["可以口服給藥", "可治療鉛中毒", "可治療砷中毒", "為高脂溶性藥物"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用succimer作為重金屬解毒劑時，下列敘述何者錯誤？\nA. 可以口服給藥\nB. 可治療鉛中毒\nC. 可治療砷中毒\nD. 為高脂溶性藥物\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用succimer作為重金屬解毒劑時，下列敘述何者錯誤？\nA. 可以口服給藥\nB. 可治療鉛中毒\nC. 可治療砷中毒\nD. 為高脂溶性藥物\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用succimer作為重金屬解毒劑時，下列敘述何者錯誤？\nA. 可以口服給藥\nB. 可治療鉛中毒\nC. 可治療砷中毒\nD. 為高脂溶性藥物\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用succimer作為重金屬解毒劑時，下列敘述何者錯誤？\nA. 可以口服給藥\nB. 可治療鉛中毒\nC. 可治療砷中毒\nD. 為高脂溶性藥物\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.3125", "False"]], [["-3.921875", "False"]], [["-4.3125", "False"]], [["-0.0498046875", "True"]]], "filtered_resps": [["-4.3125", "False"], ["-3.921875", "False"], ["-4.3125", "False"], ["-0.0498046875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "75b9b6f237f1ed278db84bfa9f545ec6e178acd37a1b68e5bb4cead436aafcd0", "prompt_hash": "4e5ced6a85227db5c4a6dbcfddc5479a0465ab7e60c6c513ac25d5c088d5e27a", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 80, "doc": {"question": "下列有關penicillamine的敘述，何者錯誤？", "A": "治療類風溼性關節炎", "B": "D-Penicillamine比L-Penicillamine毒性小", "C": "治療鐵中毒", "D": "為水溶性penicillin derivative", "answer": "C", "questions": "下列有關penicillamine的敘述，何者錯誤？", "choices": ["治療類風溼性關節炎", "D-Penicillamine比L-Penicillamine毒性小", "治療鐵中毒", "為水溶性penicillin derivative"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關penicillamine的敘述，何者錯誤？\nA. 治療類風溼性關節炎\nB. D-Penicillamine比L-Penicillamine毒性小\nC. 治療鐵中毒\nD. 為水溶性penicillin derivative\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關penicillamine的敘述，何者錯誤？\nA. 治療類風溼性關節炎\nB. D-Penicillamine比L-Penicillamine毒性小\nC. 治療鐵中毒\nD. 為水溶性penicillin derivative\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關penicillamine的敘述，何者錯誤？\nA. 治療類風溼性關節炎\nB. D-Penicillamine比L-Penicillamine毒性小\nC. 治療鐵中毒\nD. 為水溶性penicillin derivative\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關penicillamine的敘述，何者錯誤？\nA. 治療類風溼性關節炎\nB. D-Penicillamine比L-Penicillamine毒性小\nC. 治療鐵中毒\nD. 為水溶性penicillin derivative\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.96875", "False"]], [["-0.71484375", "True"]], [["-2.21875", "False"]], [["-0.96484375", "False"]]], "filtered_resps": [["-3.96875", "False"], ["-0.71484375", "True"], ["-2.21875", "False"], ["-0.96484375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a42110f43111329c694382bf32fcae84ae9577204437f54c0825095a422d3256", "prompt_hash": "280c5bd3f3316826addec363d62a69a0e7fc0cbb56f8f2f12e1f1ad2ae96ba3e", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 81, "doc": {"question": "麥角鹼（ergot alkaloids）引起周邊血管痙攣時，可用下列何種藥物治療？", "A": "Nitroprusside", "B": "Verapamil", "C": "Amlodipine", "D": "Timolol", "answer": "A", "questions": "麥角鹼（ergot alkaloids）引起周邊血管痙攣時，可用下列何種藥物治療？", "choices": ["Nitroprusside", "Verapamil", "Amlodipine", "Timolol"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n麥角鹼（ergot alkaloids）引起周邊血管痙攣時，可用下列何種藥物治療？\nA. Nitroprusside\nB. Verapamil\nC. Amlodipine\nD. Timolol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n麥角鹼（ergot alkaloids）引起周邊血管痙攣時，可用下列何種藥物治療？\nA. Nitroprusside\nB. Verapamil\nC. Amlodipine\nD. Timolol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n麥角鹼（ergot alkaloids）引起周邊血管痙攣時，可用下列何種藥物治療？\nA. Nitroprusside\nB. Verapamil\nC. Amlodipine\nD. Timolol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n麥角鹼（ergot alkaloids）引起周邊血管痙攣時，可用下列何種藥物治療？\nA. Nitroprusside\nB. Verapamil\nC. Amlodipine\nD. Timolol\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.046875", "True"]], [["-4.03125", "False"]], [["-4.28125", "False"]], [["-4.90625", "False"]]], "filtered_resps": [["-0.046875", "True"], ["-4.03125", "False"], ["-4.28125", "False"], ["-4.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1aa0491c76c35f7240bda4e2578609e639c4dc3dc757a2ad4f436e4d5da2afe0", "prompt_hash": "0cd6fbf7c83449c30010803dbfabd13ada1d466680a9066febabbad7341c9283", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 82, "doc": {"question": "下列何種骨骼肌鬆弛劑適用於肝腎疾病之患者？", "A": "vecuronium", "B": "atracurium", "C": "doxacurium", "D": "pancuronium", "answer": "B", "questions": "下列何種骨骼肌鬆弛劑適用於肝腎疾病之患者？", "choices": ["vecuronium", "atracurium", "doxacurium", "pancuronium"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種骨骼肌鬆弛劑適用於肝腎疾病之患者？\nA. vecuronium\nB. atracurium\nC. doxacurium\nD. pancuronium\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種骨骼肌鬆弛劑適用於肝腎疾病之患者？\nA. vecuronium\nB. atracurium\nC. doxacurium\nD. pancuronium\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種骨骼肌鬆弛劑適用於肝腎疾病之患者？\nA. vecuronium\nB. atracurium\nC. doxacurium\nD. pancuronium\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種骨骼肌鬆弛劑適用於肝腎疾病之患者？\nA. vecuronium\nB. atracurium\nC. doxacurium\nD. pancuronium\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.375", "False"]], [["-0.007293701171875", "True"]], [["-7.5", "False"]], [["-7.5", "False"]]], "filtered_resps": [["-7.375", "False"], ["-0.007293701171875", "True"], ["-7.5", "False"], ["-7.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d7b5cfd7b73ff61608bd1b8751f0a40a2f69fbc5bca9fb6d36b7eb17e60ebba4", "prompt_hash": "1150c0aa898248828272b01b6a3d88cbb6831b866e73e11186f6d39feea45744", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 83, "doc": {"question": "下列何者是ARB類藥物之重要基團，用以模擬angiotensin II N-terminal Asp之COOH，可提高脂溶性與生體可用率？", "A": "phosphate", "B": "tetrazole", "C": "imidazole", "D": "sulfhydryl", "answer": "B", "questions": "下列何者是ARB類藥物之重要基團，用以模擬angiotensin II N-terminal Asp之COOH，可提高脂溶性與生體可用率？", "choices": ["phosphate", "tetrazole", "imidazole", "sulfhydryl"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是ARB類藥物之重要基團，用以模擬angiotensin II N-terminal Asp之COOH，可提高脂溶性與生體可用率？\nA. phosphate\nB. tetrazole\nC. imidazole\nD. sulfhydryl\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是ARB類藥物之重要基團，用以模擬angiotensin II N-terminal Asp之COOH，可提高脂溶性與生體可用率？\nA. phosphate\nB. tetrazole\nC. imidazole\nD. sulfhydryl\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是ARB類藥物之重要基團，用以模擬angiotensin II N-terminal Asp之COOH，可提高脂溶性與生體可用率？\nA. phosphate\nB. tetrazole\nC. imidazole\nD. sulfhydryl\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是ARB類藥物之重要基團，用以模擬angiotensin II N-terminal Asp之COOH，可提高脂溶性與生體可用率？\nA. phosphate\nB. tetrazole\nC. imidazole\nD. sulfhydryl\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.59375", "False"]], [["-0.10205078125", "True"]], [["-2.859375", "False"]], [["-3.359375", "False"]]], "filtered_resps": [["-5.59375", "False"], ["-0.10205078125", "True"], ["-2.859375", "False"], ["-3.359375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "57de7229ba4e08310f3d01306853479e42bd4d50c1c67a3f9828561022450674", "prompt_hash": "6e06e3fbc5af71a122bba32a3dbcc56bf88d1020937e6556e4843be92e05be70", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 84, "doc": {"question": "Phenylephrine在活體引起的心搏徐緩（bradycardia），可以下列何種藥物預處理而消失？", "A": "Esmolol", "B": "Atenolol", "C": "Trimethaphan", "D": "Propranolol", "answer": "C", "questions": "Phenylephrine在活體引起的心搏徐緩（bradycardia），可以下列何種藥物預處理而消失？", "choices": ["Esmolol", "Atenolol", "Trimethaphan", "Propranolol"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPhenylephrine在活體引起的心搏徐緩（bradycardia），可以下列何種藥物預處理而消失？\nA. Esmolol\nB. Atenolol\nC. Trimethaphan\nD. Propranolol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPhenylephrine在活體引起的心搏徐緩（bradycardia），可以下列何種藥物預處理而消失？\nA. Esmolol\nB. Atenolol\nC. Trimethaphan\nD. Propranolol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPhenylephrine在活體引起的心搏徐緩（bradycardia），可以下列何種藥物預處理而消失？\nA. Esmolol\nB. Atenolol\nC. Trimethaphan\nD. Propranolol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPhenylephrine在活體引起的心搏徐緩（bradycardia），可以下列何種藥物預處理而消失？\nA. Esmolol\nB. Atenolol\nC. Trimethaphan\nD. Propranolol\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.15625", "False"]], [["-6.15625", "False"]], [["-0.0172119140625", "True"]], [["-6.03125", "False"]]], "filtered_resps": [["-5.15625", "False"], ["-6.15625", "False"], ["-0.0172119140625", "True"], ["-6.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "df7a9ca09d1e645f087a694b24b61bc689fc2d6b106d37920108f71678aebdf0", "prompt_hash": "cbec27ee7082d64d77b8f5a3a3a2cdde409f713a4e74e3863645dbb69f84de59", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 85, "doc": {"question": "下列治療肺結核的藥物，何者作用機轉為抑制D-alanine racemase與D-alanine ligase？", "A": "cycloserine", "B": "ethambutol", "C": "pyrazinamide", "D": "p-aminosalicylic acid", "answer": "A", "questions": "下列治療肺結核的藥物，何者作用機轉為抑制D-alanine racemase與D-alanine ligase？", "choices": ["cycloserine", "ethambutol", "pyrazinamide", "p-aminosalicylic acid"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療肺結核的藥物，何者作用機轉為抑制D-alanine racemase與D-alanine ligase？\nA. cycloserine\nB. ethambutol\nC. pyrazinamide\nD. p-aminosalicylic acid\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療肺結核的藥物，何者作用機轉為抑制D-alanine racemase與D-alanine ligase？\nA. cycloserine\nB. ethambutol\nC. pyrazinamide\nD. p-aminosalicylic acid\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療肺結核的藥物，何者作用機轉為抑制D-alanine racemase與D-alanine ligase？\nA. cycloserine\nB. ethambutol\nC. pyrazinamide\nD. p-aminosalicylic acid\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療肺結核的藥物，何者作用機轉為抑制D-alanine racemase與D-alanine ligase？\nA. cycloserine\nB. ethambutol\nC. pyrazinamide\nD. p-aminosalicylic acid\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0198974609375", "True"]], [["-4.78125", "False"]], [["-6.65625", "False"]], [["-4.78125", "False"]]], "filtered_resps": [["-0.0198974609375", "True"], ["-4.78125", "False"], ["-6.65625", "False"], ["-4.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5bdd6e32b061838bd834cc432ac7bfe25eb72a97c1794152497cdda45b6f012c", "prompt_hash": "66074878e3fb395333e0625060316127f35d6e09192094e2dc7e6846a1248bcd", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 86, "doc": {"question": "關於乳癌的治療，下列何者錯誤？", "A": "trastuzumab適用於有表達estrogen及progesterone受體，但HER-2/neu受體沒有表達的患者", "B": "在使用tamoxifen藥物5年後建議以anastrozole來做為替代藥物繼續治療", "C": "fluorouracil, doxorubicin, cyclophosphamide（FAC）對於第二期乳癌淋巴結轉移數少於三顆者有顯著效用", "D": "在有過度表達HER-2及EGFR之情形下，可以用lapatinib來治療轉移性乳癌", "answer": "A", "questions": "關於乳癌的治療，下列何者錯誤？", "choices": ["trastuzumab適用於有表達estrogen及progesterone受體，但HER-2/neu受體沒有表達的患者", "在使用tamoxifen藥物5年後建議以anastrozole來做為替代藥物繼續治療", "fluorouracil, doxorubicin, cyclophosphamide（FAC）對於第二期乳癌淋巴結轉移數少於三顆者有顯著效用", "在有過度表達HER-2及EGFR之情形下，可以用lapatinib來治療轉移性乳癌"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於乳癌的治療，下列何者錯誤？\nA. trastuzumab適用於有表達estrogen及progesterone受體，但HER-2/neu受體沒有表達的患者\nB. 在使用tamoxifen藥物5年後建議以anastrozole來做為替代藥物繼續治療\nC. fluorouracil, doxorubicin, cyclophosphamide（FAC）對於第二期乳癌淋巴結轉移數少於三顆者有顯著效用\nD. 在有過度表達HER-2及EGFR之情形下，可以用lapatinib來治療轉移性乳癌\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於乳癌的治療，下列何者錯誤？\nA. trastuzumab適用於有表達estrogen及progesterone受體，但HER-2/neu受體沒有表達的患者\nB. 在使用tamoxifen藥物5年後建議以anastrozole來做為替代藥物繼續治療\nC. fluorouracil, doxorubicin, cyclophosphamide（FAC）對於第二期乳癌淋巴結轉移數少於三顆者有顯著效用\nD. 在有過度表達HER-2及EGFR之情形下，可以用lapatinib來治療轉移性乳癌\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於乳癌的治療，下列何者錯誤？\nA. trastuzumab適用於有表達estrogen及progesterone受體，但HER-2/neu受體沒有表達的患者\nB. 在使用tamoxifen藥物5年後建議以anastrozole來做為替代藥物繼續治療\nC. fluorouracil, doxorubicin, cyclophosphamide（FAC）對於第二期乳癌淋巴結轉移數少於三顆者有顯著效用\nD. 在有過度表達HER-2及EGFR之情形下，可以用lapatinib來治療轉移性乳癌\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於乳癌的治療，下列何者錯誤？\nA. trastuzumab適用於有表達estrogen及progesterone受體，但HER-2/neu受體沒有表達的患者\nB. 在使用tamoxifen藥物5年後建議以anastrozole來做為替代藥物繼續治療\nC. fluorouracil, doxorubicin, cyclophosphamide（FAC）對於第二期乳癌淋巴結轉移數少於三顆者有顯著效用\nD. 在有過度表達HER-2及EGFR之情形下，可以用lapatinib來治療轉移性乳癌\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.078125", "True"]], [["-3.953125", "False"]], [["-4.8125", "False"]], [["-3.078125", "False"]]], "filtered_resps": [["-0.078125", "True"], ["-3.953125", "False"], ["-4.8125", "False"], ["-3.078125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8dcdb5464641c2d72bb6f5debc64fc0a5f45aa5c45f2d27a66573a7f0270f546", "prompt_hash": "473e52da3bf1d6c5b67efd254f9886c6010352aebaa4496039a61fd152c1497a", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 87, "doc": {"question": "下列何者不是theophylline的藥理作用？", "A": "神經緊張", "B": "降低血液黏稠度", "C": "改善呼吸道換氣", "D": "抑制胃酸分泌", "answer": "D", "questions": "下列何者不是theophylline的藥理作用？", "choices": ["神經緊張", "降低血液黏稠度", "改善呼吸道換氣", "抑制胃酸分泌"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是theophylline的藥理作用？\nA. 神經緊張\nB. 降低血液黏稠度\nC. 改善呼吸道換氣\nD. 抑制胃酸分泌\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是theophylline的藥理作用？\nA. 神經緊張\nB. 降低血液黏稠度\nC. 改善呼吸道換氣\nD. 抑制胃酸分泌\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是theophylline的藥理作用？\nA. 神經緊張\nB. 降低血液黏稠度\nC. 改善呼吸道換氣\nD. 抑制胃酸分泌\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是theophylline的藥理作用？\nA. 神經緊張\nB. 降低血液黏稠度\nC. 改善呼吸道換氣\nD. 抑制胃酸分泌\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.25", "False"]], [["-4.5", "False"]], [["-6.25", "False"]], [["-0.1279296875", "True"]]], "filtered_resps": [["-2.25", "False"], ["-4.5", "False"], ["-6.25", "False"], ["-0.1279296875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "cacf89ef749bd56ede4fbf56ad2c5b5e84f125e5032111cb474f86a232ce02ac", "prompt_hash": "97ab54541fa99f103200ef381212cc0e139e4d8f51f8ec7666548dd53dae1796", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 88, "doc": {"question": "Paclitaxel經下列何種酵素氧化，可產生6α-hydroxypaclitaxel？", "A": "CYP3A4", "B": "CYP3A2", "C": "CYP2C6", "D": "CYP2C8", "answer": "D", "questions": "Paclitaxel經下列何種酵素氧化，可產生6α-hydroxypaclitaxel？", "choices": ["CYP3A4", "CYP3A2", "CYP2C6", "CYP2C8"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPaclitaxel經下列何種酵素氧化，可產生6α-hydroxypaclitaxel？\nA. CYP3A4\nB. CYP3A2\nC. CYP2C6\nD. CYP2C8\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPaclitaxel經下列何種酵素氧化，可產生6α-hydroxypaclitaxel？\nA. CYP3A4\nB. CYP3A2\nC. CYP2C6\nD. CYP2C8\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPaclitaxel經下列何種酵素氧化，可產生6α-hydroxypaclitaxel？\nA. CYP3A4\nB. CYP3A2\nC. CYP2C6\nD. CYP2C8\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPaclitaxel經下列何種酵素氧化，可產生6α-hydroxypaclitaxel？\nA. CYP3A4\nB. CYP3A2\nC. CYP2C6\nD. CYP2C8\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.5390625", "False"]], [["-4.90625", "False"]], [["-3.65625", "False"]], [["-0.28515625", "True"]]], "filtered_resps": [["-1.5390625", "False"], ["-4.90625", "False"], ["-3.65625", "False"], ["-0.28515625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "507b93932758ced306e0fb2c811eb6c2994fd9bfb28253d1b74d86f8382671a4", "prompt_hash": "376857225081cbb2c0c6d853da2d62547bf7ea9b55d2b5e3ca633eee0cafe835", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 89, "doc": {"question": "下列止痛藥物，何者並沒有抗發炎之效用？", "A": "piroxicam", "B": "acetaminophen", "C": "ibuprofen", "D": "diclofenac", "answer": "B", "questions": "下列止痛藥物，何者並沒有抗發炎之效用？", "choices": ["piroxicam", "acetaminophen", "ibuprofen", "diclofenac"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列止痛藥物，何者並沒有抗發炎之效用？\nA. piroxicam\nB. acetaminophen\nC. ibuprofen\nD. diclofenac\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列止痛藥物，何者並沒有抗發炎之效用？\nA. piroxicam\nB. acetaminophen\nC. ibuprofen\nD. diclofenac\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列止痛藥物，何者並沒有抗發炎之效用？\nA. piroxicam\nB. acetaminophen\nC. ibuprofen\nD. diclofenac\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列止痛藥物，何者並沒有抗發炎之效用？\nA. piroxicam\nB. acetaminophen\nC. ibuprofen\nD. diclofenac\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.875", "False"]], [["-0.002288818359375", "True"]], [["-8.4375", "False"]], [["-8.5625", "False"]]], "filtered_resps": [["-7.875", "False"], ["-0.002288818359375", "True"], ["-8.4375", "False"], ["-8.5625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "837e248f07c8b69e19da0a9ebabb3b8eabe19d10723219f945d9474c5df329bb", "prompt_hash": "09003c2a32871eec26c234b90737b442127ec989200863c42f69800b30bc7580", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 90, "doc": {"question": "使用下列那個止痛劑會造成Reye's syndrome？", "A": "prednisolone", "B": "diclofenac", "C": "aspirin", "D": "acetaminophen", "answer": "C", "questions": "使用下列那個止痛劑會造成Reye's syndrome？", "choices": ["prednisolone", "diclofenac", "aspirin", "acetaminophen"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用下列那個止痛劑會造成Reye's syndrome？\nA. prednisolone\nB. diclofenac\nC. aspirin\nD. acetaminophen\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用下列那個止痛劑會造成Reye's syndrome？\nA. prednisolone\nB. diclofenac\nC. aspirin\nD. acetaminophen\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用下列那個止痛劑會造成Reye's syndrome？\nA. prednisolone\nB. diclofenac\nC. aspirin\nD. acetaminophen\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用下列那個止痛劑會造成Reye's syndrome？\nA. prednisolone\nB. diclofenac\nC. aspirin\nD. acetaminophen\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.0", "False"]], [["-6.875", "False"]], [["-0.0037078857421875", "True"]], [["-7.375", "False"]]], "filtered_resps": [["-7.0", "False"], ["-6.875", "False"], ["-0.0037078857421875", "True"], ["-7.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7d49449965d5c3947c02bc3f3d200d88912abd5dd879d75e3700cc5a979fbf5f", "prompt_hash": "1d902c2e476dd34b94777c8b469f3bbf9c1d08919e29c6c193c7bd216c2b26b3", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 91, "doc": {"question": "有關臨床劑量之嗎啡作用的敘述，下列何者正確？", "A": "降低疼痛閾值（threshold）", "B": "使瞳孔放大", "C": "抑制呼吸", "D": "使血壓上升", "answer": "C", "questions": "有關臨床劑量之嗎啡作用的敘述，下列何者正確？", "choices": ["降低疼痛閾值（threshold）", "使瞳孔放大", "抑制呼吸", "使血壓上升"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關臨床劑量之嗎啡作用的敘述，下列何者正確？\nA. 降低疼痛閾值（threshold）\nB. 使瞳孔放大\nC. 抑制呼吸\nD. 使血壓上升\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關臨床劑量之嗎啡作用的敘述，下列何者正確？\nA. 降低疼痛閾值（threshold）\nB. 使瞳孔放大\nC. 抑制呼吸\nD. 使血壓上升\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關臨床劑量之嗎啡作用的敘述，下列何者正確？\nA. 降低疼痛閾值（threshold）\nB. 使瞳孔放大\nC. 抑制呼吸\nD. 使血壓上升\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關臨床劑量之嗎啡作用的敘述，下列何者正確？\nA. 降低疼痛閾值（threshold）\nB. 使瞳孔放大\nC. 抑制呼吸\nD. 使血壓上升\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.78125", "False"]], [["-3.15625", "False"]], [["-0.1572265625", "True"]], [["-2.53125", "False"]]], "filtered_resps": [["-3.78125", "False"], ["-3.15625", "False"], ["-0.1572265625", "True"], ["-2.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f535fe8c8a3c8f5f2e8c1967fe26ae9bfcd14977dc4e30c240b09c61c26fa504", "prompt_hash": "eec1d296b996a76c91fda1d7fff84af7735153633ebb77cb05ab08c86b4f5dad", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 92, "doc": {"question": "下列何者為teniposide最主要之代謝反應？", "A": "esterification", "B": "reduction", "C": "hydrolysis", "D": "demethylation", "answer": "C", "questions": "下列何者為teniposide最主要之代謝反應？", "choices": ["esterification", "reduction", "hydrolysis", "demethylation"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為teniposide最主要之代謝反應？\nA. esterification\nB. reduction\nC. hydrolysis\nD. demethylation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為teniposide最主要之代謝反應？\nA. esterification\nB. reduction\nC. hydrolysis\nD. demethylation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為teniposide最主要之代謝反應？\nA. esterification\nB. reduction\nC. hydrolysis\nD. demethylation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為teniposide最主要之代謝反應？\nA. esterification\nB. reduction\nC. hydrolysis\nD. demethylation\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.5", "False"]], [["-3.875", "False"]], [["-0.1279296875", "True"]], [["-2.75", "False"]]], "filtered_resps": [["-3.5", "False"], ["-3.875", "False"], ["-0.1279296875", "True"], ["-2.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "050c486e09d1fc135c18ecd6ddfbf5fc68dae5ac137fd7d70d53df0cc03eb516", "prompt_hash": "5817ed7e64ea0f383a91f3b47cde368f3f52ff47e9e72a2e612bf451fac090a6", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 93, "doc": {"question": "下列藥物何者不適用於治療非小細胞肺癌？", "A": "docetaxel", "B": "cytarabine", "C": "carboplatin", "D": "erlotinib", "answer": "B", "questions": "下列藥物何者不適用於治療非小細胞肺癌？", "choices": ["docetaxel", "cytarabine", "carboplatin", "erlotinib"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不適用於治療非小細胞肺癌？\nA. docetaxel\nB. cytarabine\nC. carboplatin\nD. erlotinib\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不適用於治療非小細胞肺癌？\nA. docetaxel\nB. cytarabine\nC. carboplatin\nD. erlotinib\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不適用於治療非小細胞肺癌？\nA. docetaxel\nB. cytarabine\nC. carboplatin\nD. erlotinib\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不適用於治療非小細胞肺癌？\nA. docetaxel\nB. cytarabine\nC. carboplatin\nD. erlotinib\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.5", "False"]], [["-0.0029144287109375", "True"]], [["-8.625", "False"]], [["-6.625", "False"]]], "filtered_resps": [["-7.5", "False"], ["-0.0029144287109375", "True"], ["-8.625", "False"], ["-6.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6553f7ef083e41facdb8b9635993ffa2349efb9cdd44649650679ba6db3ec9a0", "prompt_hash": "0438718515e60fa6b73a3cf1d68110ea6c68abe68d9da9fcc6ee901ede859108", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 94, "doc": {"question": "有關藥物清除率（clearance）的敘述，下列何者錯誤？", "A": "清除率會依病情的嚴重度而改變", "B": "清除率會受藥物合用的影響", "C": "藥物以靜脈注射時，清除率較其他給藥路徑高", "D": "可以由藥物的吸收量除以 AUC（area under the curve），得知清除率", "answer": "C", "questions": "有關藥物清除率（clearance）的敘述，下列何者錯誤？", "choices": ["清除率會依病情的嚴重度而改變", "清除率會受藥物合用的影響", "藥物以靜脈注射時，清除率較其他給藥路徑高", "可以由藥物的吸收量除以 AUC（area under the curve），得知清除率"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關藥物清除率（clearance）的敘述，下列何者錯誤？\nA. 清除率會依病情的嚴重度而改變\nB. 清除率會受藥物合用的影響\nC. 藥物以靜脈注射時，清除率較其他給藥路徑高\nD. 可以由藥物的吸收量除以 AUC（area under the curve），得知清除率\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關藥物清除率（clearance）的敘述，下列何者錯誤？\nA. 清除率會依病情的嚴重度而改變\nB. 清除率會受藥物合用的影響\nC. 藥物以靜脈注射時，清除率較其他給藥路徑高\nD. 可以由藥物的吸收量除以 AUC（area under the curve），得知清除率\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關藥物清除率（clearance）的敘述，下列何者錯誤？\nA. 清除率會依病情的嚴重度而改變\nB. 清除率會受藥物合用的影響\nC. 藥物以靜脈注射時，清除率較其他給藥路徑高\nD. 可以由藥物的吸收量除以 AUC（area under the curve），得知清除率\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關藥物清除率（clearance）的敘述，下列何者錯誤？\nA. 清除率會依病情的嚴重度而改變\nB. 清除率會受藥物合用的影響\nC. 藥物以靜脈注射時，清除率較其他給藥路徑高\nD. 可以由藥物的吸收量除以 AUC（area under the curve），得知清除率\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.703125", "False"]], [["-1.953125", "False"]], [["-2.203125", "False"]], [["-0.326171875", "True"]]], "filtered_resps": [["-3.703125", "False"], ["-1.953125", "False"], ["-2.203125", "False"], ["-0.326171875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "10ec744cf4c8e0077777b4abc98c78ee517d7cc1b5aba38bcf0342a86c7c3a93", "prompt_hash": "a1e53681c1137106937413c2460ef7d66d80292b42083c143e2e84b28d83a32d", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 95, "doc": {"question": "下列何者是organic nitrates類抗心絞痛藥物在體內的活性代謝物？", "A": "nitrite", "B": "sulfhydryl", "C": "nitric oxide", "D": "nitrate", "answer": "C", "questions": "下列何者是organic nitrates類抗心絞痛藥物在體內的活性代謝物？", "choices": ["nitrite", "sulfhydryl", "nitric oxide", "nitrate"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是organic nitrates類抗心絞痛藥物在體內的活性代謝物？\nA. nitrite\nB. sulfhydryl\nC. nitric oxide\nD. nitrate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是organic nitrates類抗心絞痛藥物在體內的活性代謝物？\nA. nitrite\nB. sulfhydryl\nC. nitric oxide\nD. nitrate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是organic nitrates類抗心絞痛藥物在體內的活性代謝物？\nA. nitrite\nB. sulfhydryl\nC. nitric oxide\nD. nitrate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是organic nitrates類抗心絞痛藥物在體內的活性代謝物？\nA. nitrite\nB. sulfhydryl\nC. nitric oxide\nD. nitrate\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.28125", "False"]], [["-5.28125", "False"]], [["-0.0279541015625", "True"]], [["-5.15625", "False"]]], "filtered_resps": [["-4.28125", "False"], ["-5.28125", "False"], ["-0.0279541015625", "True"], ["-5.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1e87e3e8c1b915f95b5db4af6d545669a31c4f818276634ffd7b29190f1d216c", "prompt_hash": "35c789c117fbe249a74fa9fb10cc675debe1cadaaf9960e77072c60bc1e4a52a", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 96, "doc": {"question": "下列何者為phenoxybenzamine與α-adrenoceptors間主要之作用力？", "A": "共價鍵", "B": "氫鍵", "C": "離子鍵", "D": "凡得瓦爾力", "answer": "A", "questions": "下列何者為phenoxybenzamine與α-adrenoceptors間主要之作用力？", "choices": ["共價鍵", "氫鍵", "離子鍵", "凡得瓦爾力"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為phenoxybenzamine與α-adrenoceptors間主要之作用力？\nA. 共價鍵\nB. 氫鍵\nC. 離子鍵\nD. 凡得瓦爾力\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為phenoxybenzamine與α-adrenoceptors間主要之作用力？\nA. 共價鍵\nB. 氫鍵\nC. 離子鍵\nD. 凡得瓦爾力\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為phenoxybenzamine與α-adrenoceptors間主要之作用力？\nA. 共價鍵\nB. 氫鍵\nC. 離子鍵\nD. 凡得瓦爾力\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為phenoxybenzamine與α-adrenoceptors間主要之作用力？\nA. 共價鍵\nB. 氫鍵\nC. 離子鍵\nD. 凡得瓦爾力\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0849609375", "True"]], [["-4.21875", "False"]], [["-4.84375", "False"]], [["-2.953125", "False"]]], "filtered_resps": [["-0.0849609375", "True"], ["-4.21875", "False"], ["-4.84375", "False"], ["-2.953125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6f0e346498ed4d1e89a7ed0d1bfc71cf5eade027acd1829827674b8d99b3994c", "prompt_hash": "459d15581efa368e8aa4d78449cdb06edfc85209782b251afecd2bd5d3cbc01c", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 97, "doc": {"question": "下列抑制細胞壁合成的抗生素中，何者經由抑制transpeptidase所催化之peptidoglycan橫向連結（crosslinking）？", "A": "Teicoplanin", "B": "Aztreonam", "C": "Cycloserine", "D": "Bacitracin", "answer": "B", "questions": "下列抑制細胞壁合成的抗生素中，何者經由抑制transpeptidase所催化之peptidoglycan橫向連結（crosslinking）？", "choices": ["Teicoplanin", "Aztreonam", "Cycloserine", "Bacitracin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抑制細胞壁合成的抗生素中，何者經由抑制transpeptidase所催化之peptidoglycan橫向連結（crosslinking）？\nA. Teicoplanin\nB. Aztreonam\nC. Cycloserine\nD. Bacitracin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抑制細胞壁合成的抗生素中，何者經由抑制transpeptidase所催化之peptidoglycan橫向連結（crosslinking）？\nA. Teicoplanin\nB. Aztreonam\nC. Cycloserine\nD. Bacitracin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抑制細胞壁合成的抗生素中，何者經由抑制transpeptidase所催化之peptidoglycan橫向連結（crosslinking）？\nA. Teicoplanin\nB. Aztreonam\nC. Cycloserine\nD. Bacitracin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抑制細胞壁合成的抗生素中，何者經由抑制transpeptidase所催化之peptidoglycan橫向連結（crosslinking）？\nA. Teicoplanin\nB. Aztreonam\nC. Cycloserine\nD. Bacitracin\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.46875", "False"]], [["-0.2177734375", "True"]], [["-1.96875", "False"]], [["-2.96875", "False"]]], "filtered_resps": [["-5.46875", "False"], ["-0.2177734375", "True"], ["-1.96875", "False"], ["-2.96875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0374b21aadc63d9aced4ff7ab946ae6b8904adb1b05d070cfe454ebfcac227e0", "prompt_hash": "c07bc2fd7e35552c0584a07b1004cdf59045dcee17e16ae9a1444adcecdf8a8c", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 98, "doc": {"question": "下列何種痛風治療藥之作用機制為增加尿酸降解？", "A": "febuxostat", "B": "allopurinol", "C": "probenecid", "D": "pegloticase", "answer": "D", "questions": "下列何種痛風治療藥之作用機制為增加尿酸降解？", "choices": ["febuxostat", "allopurinol", "probenecid", "pegloticase"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種痛風治療藥之作用機制為增加尿酸降解？\nA. febuxostat\nB. allopurinol\nC. probenecid\nD. pegloticase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種痛風治療藥之作用機制為增加尿酸降解？\nA. febuxostat\nB. allopurinol\nC. probenecid\nD. pegloticase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種痛風治療藥之作用機制為增加尿酸降解？\nA. febuxostat\nB. allopurinol\nC. probenecid\nD. pegloticase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種痛風治療藥之作用機制為增加尿酸降解？\nA. febuxostat\nB. allopurinol\nC. probenecid\nD. pegloticase\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.875", "False"]], [["-7.75", "False"]], [["-8.0", "False"]], [["-0.0015411376953125", "True"]]], "filtered_resps": [["-7.875", "False"], ["-7.75", "False"], ["-8.0", "False"], ["-0.0015411376953125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "16d080ae8182b94b510d2466812bfc37d02eae477edc21019fdafe154b0aa110", "prompt_hash": "a52326b53090a35892276ea10477519ab603c859397d51ffcbd5824896d3f0c7", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 99, "doc": {"question": "下列何者為手術期間可用來抑制心律不整發生的短效型β-blocker？", "A": "atenolol", "B": "nebivolol", "C": "esmolol", "D": "propranolol", "answer": "C", "questions": "下列何者為手術期間可用來抑制心律不整發生的短效型β-blocker？", "choices": ["atenolol", "nebivolol", "esmolol", "propranolol"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為手術期間可用來抑制心律不整發生的短效型β-blocker？\nA. atenolol\nB. nebivolol\nC. esmolol\nD. propranolol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為手術期間可用來抑制心律不整發生的短效型β-blocker？\nA. atenolol\nB. nebivolol\nC. esmolol\nD. propranolol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為手術期間可用來抑制心律不整發生的短效型β-blocker？\nA. atenolol\nB. nebivolol\nC. esmolol\nD. propranolol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為手術期間可用來抑制心律不整發生的短效型β-blocker？\nA. atenolol\nB. nebivolol\nC. esmolol\nD. propranolol\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.625", "False"]], [["-7.625", "False"]], [["-0.01007080078125", "True"]], [["-6.125", "False"]]], "filtered_resps": [["-6.625", "False"], ["-7.625", "False"], ["-0.01007080078125", "True"], ["-6.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4374da7812ac2af1d3857bc0d3bae724a923aaaa376240f2a33731a1d5c99e9e", "prompt_hash": "1fee6d381968f759987452c927d1d3296ba47e72597337644a992c3f23601a6a", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 100, "doc": {"question": "下列何者antibody-drug conjugate（ADC），使用不可切斷性（noncleavable）之linker？", "A": "gemtuzumab ozogamicin", "B": "inotuzumab ozogamicin", "C": "trastuzumab emtansine", "D": "brentuximab vedotin", "answer": "C", "questions": "下列何者antibody-drug conjugate（ADC），使用不可切斷性（noncleavable）之linker？", "choices": ["gemtuzumab ozogamicin", "inotuzumab ozogamicin", "trastuzumab emtansine", "brentuximab vedotin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者antibody-drug conjugate（ADC），使用不可切斷性（noncleavable）之linker？\nA. gemtuzumab ozogamicin\nB. inotuzumab ozogamicin\nC. trastuzumab emtansine\nD. brentuximab vedotin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者antibody-drug conjugate（ADC），使用不可切斷性（noncleavable）之linker？\nA. gemtuzumab ozogamicin\nB. inotuzumab ozogamicin\nC. trastuzumab emtansine\nD. brentuximab vedotin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者antibody-drug conjugate（ADC），使用不可切斷性（noncleavable）之linker？\nA. gemtuzumab ozogamicin\nB. inotuzumab ozogamicin\nC. trastuzumab emtansine\nD. brentuximab vedotin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者antibody-drug conjugate（ADC），使用不可切斷性（noncleavable）之linker？\nA. gemtuzumab ozogamicin\nB. inotuzumab ozogamicin\nC. trastuzumab emtansine\nD. brentuximab vedotin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.5234375", "True"]], [["-1.7734375", "False"]], [["-2.03125", "False"]], [["-2.28125", "False"]]], "filtered_resps": [["-0.5234375", "True"], ["-1.7734375", "False"], ["-2.03125", "False"], ["-2.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6f7380bbb93d224aa8cc0f0d4589f17a62a760bf7d335b7aee91ca92fc110cbc", "prompt_hash": "87eb1d2fae456228e3da3bff0dfdb561f644c53996d5b502b3a36bb361030cfc", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 101, "doc": {"question": "下列何者不屬於cocaine之水解產物？", "A": "tropic acid", "B": "methanol", "C": "ecgonine", "D": "benzoic acid", "answer": "A", "questions": "下列何者不屬於cocaine之水解產物？", "choices": ["tropic acid", "methanol", "ecgonine", "benzoic acid"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不屬於cocaine之水解產物？\nA. tropic acid\nB. methanol\nC. ecgonine\nD. benzoic acid\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不屬於cocaine之水解產物？\nA. tropic acid\nB. methanol\nC. ecgonine\nD. benzoic acid\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不屬於cocaine之水解產物？\nA. tropic acid\nB. methanol\nC. ecgonine\nD. benzoic acid\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不屬於cocaine之水解產物？\nA. tropic acid\nB. methanol\nC. ecgonine\nD. benzoic acid\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.62109375", "True"]], [["-0.99609375", "False"]], [["-5.0", "False"]], [["-2.5", "False"]]], "filtered_resps": [["-0.62109375", "True"], ["-0.99609375", "False"], ["-5.0", "False"], ["-2.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0e4017b9a2be28e479c9592b7d003fe37856d5d8e934ec7663dfc3eb8438c65d", "prompt_hash": "c737a16d8ae121582bd7178833c177f961c4120c7ecd2354b183b201be3dc22b", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 102, "doc": {"question": "下列何種免疫抑制劑，是屬於融合TNF受體蛋白（fusion protein）藥物？", "A": "infliximab", "B": "etanercept", "C": "golimumab", "D": "adalimumab", "answer": "B", "questions": "下列何種免疫抑制劑，是屬於融合TNF受體蛋白（fusion protein）藥物？", "choices": ["infliximab", "etanercept", "golimumab", "adalimumab"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種免疫抑制劑，是屬於融合TNF受體蛋白（fusion protein）藥物？\nA. infliximab\nB. etanercept\nC. golimumab\nD. adalimumab\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種免疫抑制劑，是屬於融合TNF受體蛋白（fusion protein）藥物？\nA. infliximab\nB. etanercept\nC. golimumab\nD. adalimumab\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種免疫抑制劑，是屬於融合TNF受體蛋白（fusion protein）藥物？\nA. infliximab\nB. etanercept\nC. golimumab\nD. adalimumab\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種免疫抑制劑，是屬於融合TNF受體蛋白（fusion protein）藥物？\nA. infliximab\nB. etanercept\nC. golimumab\nD. adalimumab\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.828125", "False"]], [["-0.078125", "True"]], [["-5.4375", "False"]], [["-4.6875", "False"]]], "filtered_resps": [["-2.828125", "False"], ["-0.078125", "True"], ["-5.4375", "False"], ["-4.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2cfc717a2bc2566bc3f4b5f719321d658ea7c740727f06a2b8de522a1d0720cd", "prompt_hash": "ff128fd75eb1a376856e67af6bc48fab96d1425cd6a440baeb224792df2855be", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 103, "doc": {"question": "在ceftaroline fosamil 結構中，不具下列何種雜環？", "A": "pyrrolidine", "B": "pyridine", "C": "thiadiazole", "D": "thiazole", "answer": "A", "questions": "在ceftaroline fosamil 結構中，不具下列何種雜環？", "choices": ["pyrrolidine", "pyridine", "thiadiazole", "thiazole"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在ceftaroline fosamil 結構中，不具下列何種雜環？\nA. pyrrolidine\nB. pyridine\nC. thiadiazole\nD. thiazole\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在ceftaroline fosamil 結構中，不具下列何種雜環？\nA. pyrrolidine\nB. pyridine\nC. thiadiazole\nD. thiazole\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在ceftaroline fosamil 結構中，不具下列何種雜環？\nA. pyrrolidine\nB. pyridine\nC. thiadiazole\nD. thiazole\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在ceftaroline fosamil 結構中，不具下列何種雜環？\nA. pyrrolidine\nB. pyridine\nC. thiadiazole\nD. thiazole\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.71875", "False"]], [["-3.21875", "False"]], [["-0.21484375", "True"]], [["-2.46875", "False"]]], "filtered_resps": [["-2.71875", "False"], ["-3.21875", "False"], ["-0.21484375", "True"], ["-2.46875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bc56a4181d55bbb20675e088f9e11e3bc37b58673e432bdb925973354f038faf", "prompt_hash": "89e46cf26080d370401306c7b0e32317ab9cb4669c910c1b7e4786a882bc5820", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 104, "doc": {"question": "下列lactam-antibiotics中，何者對酸不穩定，因此不可口服？", "A": "oxacillin", "B": "ampicillin", "C": "amoxicillin", "D": "methicillin", "answer": "D", "questions": "下列lactam-antibiotics中，何者對酸不穩定，因此不可口服？", "choices": ["oxacillin", "ampicillin", "amoxicillin", "methicillin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列lactam-antibiotics中，何者對酸不穩定，因此不可口服？\nA. oxacillin\nB. ampicillin\nC. amoxicillin\nD. methicillin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列lactam-antibiotics中，何者對酸不穩定，因此不可口服？\nA. oxacillin\nB. ampicillin\nC. amoxicillin\nD. methicillin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列lactam-antibiotics中，何者對酸不穩定，因此不可口服？\nA. oxacillin\nB. ampicillin\nC. amoxicillin\nD. methicillin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列lactam-antibiotics中，何者對酸不穩定，因此不可口服？\nA. oxacillin\nB. ampicillin\nC. amoxicillin\nD. methicillin\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.734375", "False"]], [["-2.734375", "False"]], [["-1.984375", "False"]], [["-0.48046875", "True"]]], "filtered_resps": [["-1.734375", "False"], ["-2.734375", "False"], ["-1.984375", "False"], ["-0.48046875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5b90e1a5776b5639ec3a7b72d3037d79bd9970f0782de6115264be59566d0a21", "prompt_hash": "47f1c965917efd8f75819e4663d0cd85992b9368a2557a1a953d3107a2966bcd", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 105, "doc": {"question": "糖尿病治療用藥metformin，主要是藉由活化肝臟細胞內之下列何種機轉，而抑制糖質新生作用（gluconeogenesis）？", "A": "AMP-activated protein kinase", "B": "α-glucosidase", "C": "aromatase", "D": "ATP-sensitive potassium channels", "answer": "A", "questions": "糖尿病治療用藥metformin，主要是藉由活化肝臟細胞內之下列何種機轉，而抑制糖質新生作用（gluconeogenesis）？", "choices": ["AMP-activated protein kinase", "α-glucosidase", "aromatase", "ATP-sensitive potassium channels"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n糖尿病治療用藥metformin，主要是藉由活化肝臟細胞內之下列何種機轉，而抑制糖質新生作用（gluconeogenesis）？\nA. AMP-activated protein kinase\nB. α-glucosidase\nC. aromatase\nD. ATP-sensitive potassium channels\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n糖尿病治療用藥metformin，主要是藉由活化肝臟細胞內之下列何種機轉，而抑制糖質新生作用（gluconeogenesis）？\nA. AMP-activated protein kinase\nB. α-glucosidase\nC. aromatase\nD. ATP-sensitive potassium channels\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n糖尿病治療用藥metformin，主要是藉由活化肝臟細胞內之下列何種機轉，而抑制糖質新生作用（gluconeogenesis）？\nA. AMP-activated protein kinase\nB. α-glucosidase\nC. aromatase\nD. ATP-sensitive potassium channels\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n糖尿病治療用藥metformin，主要是藉由活化肝臟細胞內之下列何種機轉，而抑制糖質新生作用（gluconeogenesis）？\nA. AMP-activated protein kinase\nB. α-glucosidase\nC. aromatase\nD. ATP-sensitive potassium channels\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.01214599609375", "True"]], [["-6.5", "False"]], [["-7.375", "False"]], [["-4.875", "False"]]], "filtered_resps": [["-0.01214599609375", "True"], ["-6.5", "False"], ["-7.375", "False"], ["-4.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "838937d1d536a737f778bd14bd3a7552b0980a71f49a7c006d94bea03f4c999a", "prompt_hash": "9c13fd5f9e694f2ea9490527ac1263cc1f35c3303a245465aef0f92a1e03f964", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 106, "doc": {"question": "下列何者為全身麻醉劑isoflurane的代謝物？", "A": "CH3 CH2 COOH", "B": "CF3 COOH", "C": "CHCl2 COOH", "D": "HOCH2 COOH", "answer": "B", "questions": "下列何者為全身麻醉劑isoflurane的代謝物？", "choices": ["CH3 CH2 COOH", "CF3 COOH", "CHCl2 COOH", "HOCH2 COOH"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為全身麻醉劑isoflurane的代謝物？\nA. CH3 CH2 COOH\nB. CF3 COOH\nC. CHCl2 COOH\nD. HOCH2 COOH\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為全身麻醉劑isoflurane的代謝物？\nA. CH3 CH2 COOH\nB. CF3 COOH\nC. CHCl2 COOH\nD. HOCH2 COOH\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為全身麻醉劑isoflurane的代謝物？\nA. CH3 CH2 COOH\nB. CF3 COOH\nC. CHCl2 COOH\nD. HOCH2 COOH\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為全身麻醉劑isoflurane的代謝物？\nA. CH3 CH2 COOH\nB. CF3 COOH\nC. CHCl2 COOH\nD. HOCH2 COOH\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.3125", "False"]], [["-0.07568359375", "True"]], [["-3.703125", "False"]], [["-3.453125", "False"]]], "filtered_resps": [["-4.3125", "False"], ["-0.07568359375", "True"], ["-3.703125", "False"], ["-3.453125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d3d83f29fec04322ef8c06f6103fa0dace6ae67dafd8f5d50ecb9fe8bffa287c", "prompt_hash": "37f49938b35dc85eb207c78ba67cd5e0d59a3216a9d57119bd11a29456486b3a", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 107, "doc": {"question": "下列有關ethinyl estradiol的敘述，何者錯誤？", "A": "mestranol為其前驅藥", "B": "將C-3的hydroxyl group修飾成methyl ether，則得到mestranol", "C": "在estradiol結構導入17β-C≡CH，阻礙17α-hydroxyl group氧化", "D": "可以口服", "answer": "C", "questions": "下列有關ethinyl estradiol的敘述，何者錯誤？", "choices": ["mestranol為其前驅藥", "將C-3的hydroxyl group修飾成methyl ether，則得到mestranol", "在estradiol結構導入17β-C≡CH，阻礙17α-hydroxyl group氧化", "可以口服"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ethinyl estradiol的敘述，何者錯誤？\nA. mestranol為其前驅藥\nB. 將C-3的hydroxyl group修飾成methyl ether，則得到mestranol\nC. 在estradiol結構導入17β-C≡CH，阻礙17α-hydroxyl group氧化\nD. 可以口服\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ethinyl estradiol的敘述，何者錯誤？\nA. mestranol為其前驅藥\nB. 將C-3的hydroxyl group修飾成methyl ether，則得到mestranol\nC. 在estradiol結構導入17β-C≡CH，阻礙17α-hydroxyl group氧化\nD. 可以口服\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ethinyl estradiol的敘述，何者錯誤？\nA. mestranol為其前驅藥\nB. 將C-3的hydroxyl group修飾成methyl ether，則得到mestranol\nC. 在estradiol結構導入17β-C≡CH，阻礙17α-hydroxyl group氧化\nD. 可以口服\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ethinyl estradiol的敘述，何者錯誤？\nA. mestranol為其前驅藥\nB. 將C-3的hydroxyl group修飾成methyl ether，則得到mestranol\nC. 在estradiol結構導入17β-C≡CH，阻礙17α-hydroxyl group氧化\nD. 可以口服\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.3125", "False"]], [["-2.1875", "False"]], [["-0.1884765625", "True"]], [["-4.0625", "False"]]], "filtered_resps": [["-3.3125", "False"], ["-2.1875", "False"], ["-0.1884765625", "True"], ["-4.0625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "76b81f76ccb397da084f43116249731b25d5985ba62003a91d7c9ff7e3c4783b", "prompt_hash": "ba1db2aeeb9632057b088975f33d746c270355d438b9f75023e55885c1e3f6b0", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 108, "doc": {"question": "下列何者不具 mu 受體之拮抗作用？", "A": "butorphanol", "B": "nalbuphine", "C": "levorphanol", "D": "naloxegol", "answer": "C", "questions": "下列何者不具 mu 受體之拮抗作用？", "choices": ["butorphanol", "nalbuphine", "levorphanol", "naloxegol"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不具 mu 受體之拮抗作用？\nA. butorphanol\nB. nalbuphine\nC. levorphanol\nD. naloxegol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不具 mu 受體之拮抗作用？\nA. butorphanol\nB. nalbuphine\nC. levorphanol\nD. naloxegol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不具 mu 受體之拮抗作用？\nA. butorphanol\nB. nalbuphine\nC. levorphanol\nD. naloxegol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不具 mu 受體之拮抗作用？\nA. butorphanol\nB. nalbuphine\nC. levorphanol\nD. naloxegol\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.03125", "False"]], [["-6.53125", "False"]], [["-0.0167236328125", "True"]], [["-4.53125", "False"]]], "filtered_resps": [["-6.03125", "False"], ["-6.53125", "False"], ["-0.0167236328125", "True"], ["-4.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "539b6cdfa0fc50e2272f05184f791bc045050d29d773da11b828525d1827d935", "prompt_hash": "f891fbcdf5a78ba4642a3a8abe4d8e04c6683bd17a363ce7bc208a9222a6d547", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 109, "doc": {"question": "下列有關治療威爾森氏症（Wilson's disease）之敘述，何者錯誤？", "A": "血中銅離子太多", "B": "腦和內臟銅離子多", "C": "口服zinc acetate可以增加銅離子之排除", "D": "penicillamine是首選之藥", "answer": "A", "questions": "下列有關治療威爾森氏症（Wilson's disease）之敘述，何者錯誤？", "choices": ["血中銅離子太多", "腦和內臟銅離子多", "口服zinc acetate可以增加銅離子之排除", "penicillamine是首選之藥"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關治療威爾森氏症（Wilson's disease）之敘述，何者錯誤？\nA. 血中銅離子太多\nB. 腦和內臟銅離子多\nC. 口服zinc acetate可以增加銅離子之排除\nD. penicillamine是首選之藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關治療威爾森氏症（Wilson's disease）之敘述，何者錯誤？\nA. 血中銅離子太多\nB. 腦和內臟銅離子多\nC. 口服zinc acetate可以增加銅離子之排除\nD. penicillamine是首選之藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關治療威爾森氏症（Wilson's disease）之敘述，何者錯誤？\nA. 血中銅離子太多\nB. 腦和內臟銅離子多\nC. 口服zinc acetate可以增加銅離子之排除\nD. penicillamine是首選之藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關治療威爾森氏症（Wilson's disease）之敘述，何者錯誤？\nA. 血中銅離子太多\nB. 腦和內臟銅離子多\nC. 口服zinc acetate可以增加銅離子之排除\nD. penicillamine是首選之藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.90625", "False"]], [["-2.65625", "False"]], [["-0.5234375", "True"]], [["-1.1484375", "False"]]], "filtered_resps": [["-3.90625", "False"], ["-2.65625", "False"], ["-0.5234375", "True"], ["-1.1484375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fcc8bea8768fa6ea72111fb06e65e2d7cf04c29a69f6c27d7cd8ff26a4a9bd6b", "prompt_hash": "223c8c6436f9976cdb7bf55be42fb88e0a75ff74304869a05c8b39a59aae2ecc", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 110, "doc": {"question": "下列那一種鎮靜－安眠（sedative-hypnotic）藥物，通常以靜脈注射的方式投藥，用於外科手術麻醉前的誘導作用？", "A": "Secobarbital", "B": "Pentobarbital", "C": "Thiopental", "D": "Amobarbital", "answer": "C", "questions": "下列那一種鎮靜－安眠（sedative-hypnotic）藥物，通常以靜脈注射的方式投藥，用於外科手術麻醉前的誘導作用？", "choices": ["Secobarbital", "Pentobarbital", "Thiopental", "Amobarbital"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種鎮靜－安眠（sedative-hypnotic）藥物，通常以靜脈注射的方式投藥，用於外科手術麻醉前的誘導作用？\nA. Secobarbital\nB. Pentobarbital\nC. Thiopental\nD. Amobarbital\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種鎮靜－安眠（sedative-hypnotic）藥物，通常以靜脈注射的方式投藥，用於外科手術麻醉前的誘導作用？\nA. Secobarbital\nB. Pentobarbital\nC. Thiopental\nD. Amobarbital\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種鎮靜－安眠（sedative-hypnotic）藥物，通常以靜脈注射的方式投藥，用於外科手術麻醉前的誘導作用？\nA. Secobarbital\nB. Pentobarbital\nC. Thiopental\nD. Amobarbital\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種鎮靜－安眠（sedative-hypnotic）藥物，通常以靜脈注射的方式投藥，用於外科手術麻醉前的誘導作用？\nA. Secobarbital\nB. Pentobarbital\nC. Thiopental\nD. Amobarbital\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.25", "False"]], [["-7.1875", "False"]], [["-0.01025390625", "True"]], [["-5.625", "False"]]], "filtered_resps": [["-6.25", "False"], ["-7.1875", "False"], ["-0.01025390625", "True"], ["-5.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f59d1418473a61ab793b8aaa492c444d8d572e7072d8b414efb775b96de1ce43", "prompt_hash": "28fe7140f33a22f35d76eb79c3d2cfd925cf44149afb59606956b98847d83251", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 111, "doc": {"question": "下列何種降血脂藥物可用於處理毛地黃毒性？", "A": "Colestipol", "B": "Fenofibrate", "C": "Niacin", "D": "Rosuvastatin", "answer": "A", "questions": "下列何種降血脂藥物可用於處理毛地黃毒性？", "choices": ["Colestipol", "Fenofibrate", "Niacin", "Rosuvastatin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種降血脂藥物可用於處理毛地黃毒性？\nA. Colestipol\nB. Fenofibrate\nC. Niacin\nD. Rosuvastatin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種降血脂藥物可用於處理毛地黃毒性？\nA. Colestipol\nB. Fenofibrate\nC. Niacin\nD. Rosuvastatin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種降血脂藥物可用於處理毛地黃毒性？\nA. Colestipol\nB. Fenofibrate\nC. Niacin\nD. Rosuvastatin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種降血脂藥物可用於處理毛地黃毒性？\nA. Colestipol\nB. Fenofibrate\nC. Niacin\nD. Rosuvastatin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.31640625", "True"]], [["-2.1875", "False"]], [["-2.3125", "False"]], [["-2.8125", "False"]]], "filtered_resps": [["-0.31640625", "True"], ["-2.1875", "False"], ["-2.3125", "False"], ["-2.8125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a285b3efb2427627ddae2a2b9f7415a93e9262ca71a754c31350cc5407765472", "prompt_hash": "f2132c7bc10104c69705e6908662a1db53aab0f91701e0170f503bdd1f9cb971", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 112, "doc": {"question": "下列Parkinson's disease治療藥的結構，何者不具手性中心（chiral center）？", "A": "selegiline", "B": "apomorphine", "C": "ropinirole", "D": "carbidopa", "answer": "C", "questions": "下列Parkinson's disease治療藥的結構，何者不具手性中心（chiral center）？", "choices": ["selegiline", "apomorphine", "ropinirole", "carbidopa"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列Parkinson's disease治療藥的結構，何者不具手性中心（chiral center）？\nA. selegiline\nB. apomorphine\nC. ropinirole\nD. carbidopa\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列Parkinson's disease治療藥的結構，何者不具手性中心（chiral center）？\nA. selegiline\nB. apomorphine\nC. ropinirole\nD. carbidopa\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列Parkinson's disease治療藥的結構，何者不具手性中心（chiral center）？\nA. selegiline\nB. apomorphine\nC. ropinirole\nD. carbidopa\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列Parkinson's disease治療藥的結構，何者不具手性中心（chiral center）？\nA. selegiline\nB. apomorphine\nC. ropinirole\nD. carbidopa\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.03125", "False"]], [["-5.78125", "False"]], [["-0.025634765625", "True"]], [["-4.15625", "False"]]], "filtered_resps": [["-6.03125", "False"], ["-5.78125", "False"], ["-0.025634765625", "True"], ["-4.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b661e4627939ebf0a8f15c96a69d48f041da0f45d0a9039a1d3f767f952b2593", "prompt_hash": "2101be56473fdd19e7200a884eb464d174c2e3d3d2c6920b83db20865c32ed6b", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 113, "doc": {"question": "下列全身麻醉劑中，何者對肝腎的毒性最低？", "A": "enflurane", "B": "halothane", "C": "isoflurane", "D": "methoxyflurane", "answer": "C", "questions": "下列全身麻醉劑中，何者對肝腎的毒性最低？", "choices": ["enflurane", "halothane", "isoflurane", "methoxyflurane"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者對肝腎的毒性最低？\nA. enflurane\nB. halothane\nC. isoflurane\nD. methoxyflurane\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者對肝腎的毒性最低？\nA. enflurane\nB. halothane\nC. isoflurane\nD. methoxyflurane\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者對肝腎的毒性最低？\nA. enflurane\nB. halothane\nC. isoflurane\nD. methoxyflurane\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者對肝腎的毒性最低？\nA. enflurane\nB. halothane\nC. isoflurane\nD. methoxyflurane\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.28125", "False"]], [["-4.53125", "False"]], [["-0.042236328125", "True"]], [["-4.28125", "False"]]], "filtered_resps": [["-4.28125", "False"], ["-4.53125", "False"], ["-0.042236328125", "True"], ["-4.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bc32c810b046ff1e3fd86551adab1541574bba76d32f20dc3e708f0e307add2c", "prompt_hash": "2d0f46aefee10b3671bec2436107a00b4be2f4a1bcea1b123be165ec2180a55b", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 114, "doc": {"question": "下列那一類降血壓藥可能會增加血中renin及angiotensin II濃度，並可能減少aldosterone分泌？", "A": "candesartan", "B": "captopril", "C": "propranolol", "D": "aliskiren", "answer": "A", "questions": "下列那一類降血壓藥可能會增加血中renin及angiotensin II濃度，並可能減少aldosterone分泌？", "choices": ["candesartan", "captopril", "propranolol", "aliskiren"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一類降血壓藥可能會增加血中renin及angiotensin II濃度，並可能減少aldosterone分泌？\nA. candesartan\nB. captopril\nC. propranolol\nD. aliskiren\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一類降血壓藥可能會增加血中renin及angiotensin II濃度，並可能減少aldosterone分泌？\nA. candesartan\nB. captopril\nC. propranolol\nD. aliskiren\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一類降血壓藥可能會增加血中renin及angiotensin II濃度，並可能減少aldosterone分泌？\nA. candesartan\nB. captopril\nC. propranolol\nD. aliskiren\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一類降血壓藥可能會增加血中renin及angiotensin II濃度，並可能減少aldosterone分泌？\nA. candesartan\nB. captopril\nC. propranolol\nD. aliskiren\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.154296875", "True"]], [["-2.65625", "False"]], [["-3.53125", "False"]], [["-3.15625", "False"]]], "filtered_resps": [["-0.154296875", "True"], ["-2.65625", "False"], ["-3.53125", "False"], ["-3.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6716501ed3182415563be3044e183ab2beab0d542fea512ebdc0f9e953a873c3", "prompt_hash": "92c3a26edc6c4fdcc35feff15b873adfeb71b909c3b86fea5638629381d2314f", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 115, "doc": {"question": "下列關於藥物的吸收或代謝之敘述，何者正確？", "A": "脂溶性藥物較水溶性藥物易由乳汁分泌", "B": "鹼性藥物的酸解離常數（acid dissociation constant）小於酸性藥物", "C": "酸性藥物中毒時可以使用NH4Cl", "D": "酸性藥物較鹼性藥物不易在胃部吸收", "answer": "A", "questions": "下列關於藥物的吸收或代謝之敘述，何者正確？", "choices": ["脂溶性藥物較水溶性藥物易由乳汁分泌", "鹼性藥物的酸解離常數（acid dissociation constant）小於酸性藥物", "酸性藥物中毒時可以使用NH4Cl", "酸性藥物較鹼性藥物不易在胃部吸收"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於藥物的吸收或代謝之敘述，何者正確？\nA. 脂溶性藥物較水溶性藥物易由乳汁分泌\nB. 鹼性藥物的酸解離常數（acid dissociation constant）小於酸性藥物\nC. 酸性藥物中毒時可以使用NH4Cl\nD. 酸性藥物較鹼性藥物不易在胃部吸收\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於藥物的吸收或代謝之敘述，何者正確？\nA. 脂溶性藥物較水溶性藥物易由乳汁分泌\nB. 鹼性藥物的酸解離常數（acid dissociation constant）小於酸性藥物\nC. 酸性藥物中毒時可以使用NH4Cl\nD. 酸性藥物較鹼性藥物不易在胃部吸收\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於藥物的吸收或代謝之敘述，何者正確？\nA. 脂溶性藥物較水溶性藥物易由乳汁分泌\nB. 鹼性藥物的酸解離常數（acid dissociation constant）小於酸性藥物\nC. 酸性藥物中毒時可以使用NH4Cl\nD. 酸性藥物較鹼性藥物不易在胃部吸收\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於藥物的吸收或代謝之敘述，何者正確？\nA. 脂溶性藥物較水溶性藥物易由乳汁分泌\nB. 鹼性藥物的酸解離常數（acid dissociation constant）小於酸性藥物\nC. 酸性藥物中毒時可以使用NH4Cl\nD. 酸性藥物較鹼性藥物不易在胃部吸收\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.015625", "False"]], [["-2.515625", "False"]], [["-1.3828125", "False"]], [["-0.63671875", "True"]]], "filtered_resps": [["-2.015625", "False"], ["-2.515625", "False"], ["-1.3828125", "False"], ["-0.63671875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e59c77400cbf027e7a1a3384ed2caa03b3623cd48b09be5da6d31a039a491d6b", "prompt_hash": "6fabdb9ab20c715f04f9f210acfd2a2b44fc2415a624b11cade758918394fab3", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 116, "doc": {"question": "下列何者是直接作用在serine/threonine kinase receptor？", "A": "PDGF", "B": "EGF", "C": "ANP", "D": "TGF-beta", "answer": "D", "questions": "下列何者是直接作用在serine/threonine kinase receptor？", "choices": ["PDGF", "EGF", "ANP", "TGF-beta"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是直接作用在serine/threonine kinase receptor？\nA. PDGF\nB. EGF\nC. ANP\nD. TGF-beta\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是直接作用在serine/threonine kinase receptor？\nA. PDGF\nB. EGF\nC. ANP\nD. TGF-beta\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是直接作用在serine/threonine kinase receptor？\nA. PDGF\nB. EGF\nC. ANP\nD. TGF-beta\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是直接作用在serine/threonine kinase receptor？\nA. PDGF\nB. EGF\nC. ANP\nD. TGF-beta\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-6.75", "False"]], [["-6.625", "False"]], [["-0.006591796875", "True"]]], "filtered_resps": [["-5.875", "False"], ["-6.75", "False"], ["-6.625", "False"], ["-0.006591796875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c416756d45ed775f60924dd073f07666a50f1a143f98ef230894f1cf402eb05f", "prompt_hash": "18a2c64d8219fb8f6c84fad9b4a9294a30e0515c0e5943ce2914742da6d9cc0b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 117, "doc": {"question": "含氨基之雙磷酸鹽類藥物（amino bisphosphonates），例如alendronate，可以藉由抑制下列何種機制而降低噬骨細胞（osteoclast）的活性？", "A": "Ca2+-sensing receptor", "B": "farnesyl pyrophosphate synthase", "C": "HMG-CoA reductase", "D": "ATP-dependent potassium channels", "answer": "B", "questions": "含氨基之雙磷酸鹽類藥物（amino bisphosphonates），例如alendronate，可以藉由抑制下列何種機制而降低噬骨細胞（osteoclast）的活性？", "choices": ["Ca2+-sensing receptor", "farnesyl pyrophosphate synthase", "HMG-CoA reductase", "ATP-dependent potassium channels"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n含氨基之雙磷酸鹽類藥物（amino bisphosphonates），例如alendronate，可以藉由抑制下列何種機制而降低噬骨細胞（osteoclast）的活性？\nA. Ca2+-sensing receptor\nB. farnesyl pyrophosphate synthase\nC. HMG-CoA reductase\nD. ATP-dependent potassium channels\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n含氨基之雙磷酸鹽類藥物（amino bisphosphonates），例如alendronate，可以藉由抑制下列何種機制而降低噬骨細胞（osteoclast）的活性？\nA. Ca2+-sensing receptor\nB. farnesyl pyrophosphate synthase\nC. HMG-CoA reductase\nD. ATP-dependent potassium channels\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n含氨基之雙磷酸鹽類藥物（amino bisphosphonates），例如alendronate，可以藉由抑制下列何種機制而降低噬骨細胞（osteoclast）的活性？\nA. Ca2+-sensing receptor\nB. farnesyl pyrophosphate synthase\nC. HMG-CoA reductase\nD. ATP-dependent potassium channels\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n含氨基之雙磷酸鹽類藥物（amino bisphosphonates），例如alendronate，可以藉由抑制下列何種機制而降低噬骨細胞（osteoclast）的活性？\nA. Ca2+-sensing receptor\nB. farnesyl pyrophosphate synthase\nC. HMG-CoA reductase\nD. ATP-dependent potassium channels\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.9375", "False"]], [["-0.048583984375", "True"]], [["-6.5625", "False"]], [["-3.296875", "False"]]], "filtered_resps": [["-4.9375", "False"], ["-0.048583984375", "True"], ["-6.5625", "False"], ["-3.296875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "02613ad8da6cfb324cab1ead474eaee6129482a1fa809c55ff20a4fe99bb562f", "prompt_hash": "f91d7e62545c8089eb6e3b990eb3a98f1ae87f5457d908ac556e0e24bef29c6f", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 118, "doc": {"question": "下列那一藥物不是作用在GABAA受體？", "A": "ramelteon", "B": "carisoprodol", "C": "zolpidem", "D": "triazolam", "answer": "A", "questions": "下列那一藥物不是作用在GABAA受體？", "choices": ["ramelteon", "carisoprodol", "zolpidem", "triazolam"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一藥物不是作用在GABAA受體？\nA. ramelteon\nB. carisoprodol\nC. zolpidem\nD. triazolam\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一藥物不是作用在GABAA受體？\nA. ramelteon\nB. carisoprodol\nC. zolpidem\nD. triazolam\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一藥物不是作用在GABAA受體？\nA. ramelteon\nB. carisoprodol\nC. zolpidem\nD. triazolam\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一藥物不是作用在GABAA受體？\nA. ramelteon\nB. carisoprodol\nC. zolpidem\nD. triazolam\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1513671875", "True"]], [["-2.28125", "False"]], [["-4.15625", "False"]], [["-3.90625", "False"]]], "filtered_resps": [["-0.1513671875", "True"], ["-2.28125", "False"], ["-4.15625", "False"], ["-3.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fa73a3ae13ba59956fbc00d1d3497f5ec141162c79e86fa1096a13f2394fdb58", "prompt_hash": "3337e234a7ddf0ca95a72a3a9ac2e6d0bdeac558d0c8d2338352c85e0d680646", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 119, "doc": {"question": "一位心臟功能不良的年長病人，將接受膽囊切除手術，麻醉醫師最可能給予對心臟具有興奮作用的靜脈麻醉劑為何？", "A": "Thiopental", "B": "Propofol", "C": "Midazolam", "D": "Ketamine", "answer": "D", "questions": "一位心臟功能不良的年長病人，將接受膽囊切除手術，麻醉醫師最可能給予對心臟具有興奮作用的靜脈麻醉劑為何？", "choices": ["Thiopental", "Propofol", "Midazolam", "Ketamine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位心臟功能不良的年長病人，將接受膽囊切除手術，麻醉醫師最可能給予對心臟具有興奮作用的靜脈麻醉劑為何？\nA. Thiopental\nB. Propofol\nC. Midazolam\nD. Ketamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位心臟功能不良的年長病人，將接受膽囊切除手術，麻醉醫師最可能給予對心臟具有興奮作用的靜脈麻醉劑為何？\nA. Thiopental\nB. Propofol\nC. Midazolam\nD. Ketamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位心臟功能不良的年長病人，將接受膽囊切除手術，麻醉醫師最可能給予對心臟具有興奮作用的靜脈麻醉劑為何？\nA. Thiopental\nB. Propofol\nC. Midazolam\nD. Ketamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位心臟功能不良的年長病人，將接受膽囊切除手術，麻醉醫師最可能給予對心臟具有興奮作用的靜脈麻醉劑為何？\nA. Thiopental\nB. Propofol\nC. Midazolam\nD. Ketamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.5", "False"]], [["-5.75", "False"]], [["-5.875", "False"]], [["-0.01031494140625", "True"]]], "filtered_resps": [["-5.5", "False"], ["-5.75", "False"], ["-5.875", "False"], ["-0.01031494140625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c9ca29c296a6b2b468f1de85797946a0e7cbd3d23b5bfae5ab2cb4a81ceeec14", "prompt_hash": "8f6e274cea18f8a8dfefa71f85e3da7d18d12b5d8d55c02f9e8988eb59fbc386", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 120, "doc": {"question": "下列比較 levodopa 和 pramipexole 之藥理作用，何者錯誤？", "A": "pramipexole 大多以原型排出；levodopa 會產生 dopamine 和 dopamine 代謝產物", "B": "pramipexole 可以直接過血腦屏障；levodopa 需要經由 transporters 進入中樞神經系統", "C": "pramipexole 直接作用在突觸後的 dopamine 受體；levodopa 需要有神經細胞的代謝為 dopamine", "D": "pramipexole 選擇性作用在 D2 受體；levodopa 代謝為 dopamine，對不同 dopamine 受體無選擇性的差異", "answer": "D", "questions": "下列比較 levodopa 和 pramipexole 之藥理作用，何者錯誤？", "choices": ["pramipexole 大多以原型排出；levodopa 會產生 dopamine 和 dopamine 代謝產物", "pramipexole 可以直接過血腦屏障；levodopa 需要經由 transporters 進入中樞神經系統", "pramipexole 直接作用在突觸後的 dopamine 受體；levodopa 需要有神經細胞的代謝為 dopamine", "pramipexole 選擇性作用在 D2 受體；levodopa 代謝為 dopamine，對不同 dopamine 受體無選擇性的差異"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列比較 levodopa 和 pramipexole 之藥理作用，何者錯誤？\nA. pramipexole 大多以原型排出；levodopa 會產生 dopamine 和 dopamine 代謝產物\nB. pramipexole 可以直接過血腦屏障；levodopa 需要經由 transporters 進入中樞神經系統\nC. pramipexole 直接作用在突觸後的 dopamine 受體；levodopa 需要有神經細胞的代謝為 dopamine\nD. pramipexole 選擇性作用在 D2 受體；levodopa 代謝為 dopamine，對不同 dopamine 受體無選擇性的差異\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列比較 levodopa 和 pramipexole 之藥理作用，何者錯誤？\nA. pramipexole 大多以原型排出；levodopa 會產生 dopamine 和 dopamine 代謝產物\nB. pramipexole 可以直接過血腦屏障；levodopa 需要經由 transporters 進入中樞神經系統\nC. pramipexole 直接作用在突觸後的 dopamine 受體；levodopa 需要有神經細胞的代謝為 dopamine\nD. pramipexole 選擇性作用在 D2 受體；levodopa 代謝為 dopamine，對不同 dopamine 受體無選擇性的差異\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列比較 levodopa 和 pramipexole 之藥理作用，何者錯誤？\nA. pramipexole 大多以原型排出；levodopa 會產生 dopamine 和 dopamine 代謝產物\nB. pramipexole 可以直接過血腦屏障；levodopa 需要經由 transporters 進入中樞神經系統\nC. pramipexole 直接作用在突觸後的 dopamine 受體；levodopa 需要有神經細胞的代謝為 dopamine\nD. pramipexole 選擇性作用在 D2 受體；levodopa 代謝為 dopamine，對不同 dopamine 受體無選擇性的差異\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列比較 levodopa 和 pramipexole 之藥理作用，何者錯誤？\nA. pramipexole 大多以原型排出；levodopa 會產生 dopamine 和 dopamine 代謝產物\nB. pramipexole 可以直接過血腦屏障；levodopa 需要經由 transporters 進入中樞神經系統\nC. pramipexole 直接作用在突觸後的 dopamine 受體；levodopa 需要有神經細胞的代謝為 dopamine\nD. pramipexole 選擇性作用在 D2 受體；levodopa 代謝為 dopamine，對不同 dopamine 受體無選擇性的差異\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.0625", "False"]], [["-3.5625", "False"]], [["-3.9375", "False"]], [["-0.06787109375", "True"]]], "filtered_resps": [["-4.0625", "False"], ["-3.5625", "False"], ["-3.9375", "False"], ["-0.06787109375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "803145dd6f707f607be4bd26643433e8ea0e94be33a62237fb554d3d9a88027b", "prompt_hash": "e34b010aa19e2d6cf190cfec43ce3646e3f704e3eb48acd4efc868cfdbdb06bd", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 121, "doc": {"question": "下列何種藥物主要以acetylation的方式代謝？", "A": "acetaminophen", "B": "lidocaine", "C": "indomethacin", "D": "procainamide", "answer": "D", "questions": "下列何種藥物主要以acetylation的方式代謝？", "choices": ["acetaminophen", "lidocaine", "indomethacin", "procainamide"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物主要以acetylation的方式代謝？\nA. acetaminophen\nB. lidocaine\nC. indomethacin\nD. procainamide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物主要以acetylation的方式代謝？\nA. acetaminophen\nB. lidocaine\nC. indomethacin\nD. procainamide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物主要以acetylation的方式代謝？\nA. acetaminophen\nB. lidocaine\nC. indomethacin\nD. procainamide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物主要以acetylation的方式代謝？\nA. acetaminophen\nB. lidocaine\nC. indomethacin\nD. procainamide\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.125", "False"]], [["-5.625", "False"]], [["-5.75", "False"]], [["-0.01190185546875", "True"]]], "filtered_resps": [["-6.125", "False"], ["-5.625", "False"], ["-5.75", "False"], ["-0.01190185546875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "30981212c9dd9d84d5895b65f1c0943de7afc4dd6122c037fe61b7d2158ecfc0", "prompt_hash": "47e9a57cbf87b5f7f2d46d0b17ef6e6a14183c9ab224934aa442d0ed6049786b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 122, "doc": {"question": "重組之活化型凝血因子VIIa（rFVIIa）用於對抗下列何者的使用過量而引致之流血？", "A": "heparin", "B": "ticlopidine", "C": "aspirin", "D": "warfarin", "answer": "D", "questions": "重組之活化型凝血因子VIIa（rFVIIa）用於對抗下列何者的使用過量而引致之流血？", "choices": ["heparin", "ticlopidine", "aspirin", "warfarin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n重組之活化型凝血因子VIIa（rFVIIa）用於對抗下列何者的使用過量而引致之流血？\nA. heparin\nB. ticlopidine\nC. aspirin\nD. warfarin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n重組之活化型凝血因子VIIa（rFVIIa）用於對抗下列何者的使用過量而引致之流血？\nA. heparin\nB. ticlopidine\nC. aspirin\nD. warfarin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n重組之活化型凝血因子VIIa（rFVIIa）用於對抗下列何者的使用過量而引致之流血？\nA. heparin\nB. ticlopidine\nC. aspirin\nD. warfarin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n重組之活化型凝血因子VIIa（rFVIIa）用於對抗下列何者的使用過量而引致之流血？\nA. heparin\nB. ticlopidine\nC. aspirin\nD. warfarin\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.65625", "False"]], [["-3.15625", "False"]], [["-1.40625", "False"]], [["-0.65625", "True"]]], "filtered_resps": [["-1.65625", "False"], ["-3.15625", "False"], ["-1.40625", "False"], ["-0.65625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b040a6687f85fbe45acadb21ffc2f955509184b8020231759d0aae189b8fb882", "prompt_hash": "b3352030aabac75c0e82cd02dd9478683a3b867ef639b1f9355ee6c103bdcbae", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 123, "doc": {"question": "Omeprazole主要代謝物的生成，最主要是經由下列何種代謝酵素？", "A": "CYP3A4", "B": "CYP2D6", "C": "CYP2C19", "D": "CYP2C9", "answer": "C", "questions": "Omeprazole主要代謝物的生成，最主要是經由下列何種代謝酵素？", "choices": ["CYP3A4", "CYP2D6", "CYP2C19", "CYP2C9"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nOmeprazole主要代謝物的生成，最主要是經由下列何種代謝酵素？\nA. CYP3A4\nB. CYP2D6\nC. CYP2C19\nD. CYP2C9\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nOmeprazole主要代謝物的生成，最主要是經由下列何種代謝酵素？\nA. CYP3A4\nB. CYP2D6\nC. CYP2C19\nD. CYP2C9\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nOmeprazole主要代謝物的生成，最主要是經由下列何種代謝酵素？\nA. CYP3A4\nB. CYP2D6\nC. CYP2C19\nD. CYP2C9\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nOmeprazole主要代謝物的生成，最主要是經由下列何種代謝酵素？\nA. CYP3A4\nB. CYP2D6\nC. CYP2C19\nD. CYP2C9\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.828125", "False"]], [["-5.5625", "False"]], [["-0.0712890625", "True"]], [["-3.203125", "False"]]], "filtered_resps": [["-3.828125", "False"], ["-5.5625", "False"], ["-0.0712890625", "True"], ["-3.203125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2d9c9cf31494cc7a28ee2eacd89269b6c098ca681b80f8c78c97fe4521fd196e", "prompt_hash": "f02e8691b4e43ada3cba7ebc1826d9481e7c500a81f3e47bc0e70be202c961d9", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 124, "doc": {"question": "下列有關chloroprocaine之敘述，何者錯誤？", "A": "易受血漿中cholinesterase代謝", "B": "結構中的氯取代基位於苯環上羰基（carbonyl）之間位（meta）", "C": "屬於酯類結構", "D": "不可與磺胺藥併用", "answer": "B", "questions": "下列有關chloroprocaine之敘述，何者錯誤？", "choices": ["易受血漿中cholinesterase代謝", "結構中的氯取代基位於苯環上羰基（carbonyl）之間位（meta）", "屬於酯類結構", "不可與磺胺藥併用"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關chloroprocaine之敘述，何者錯誤？\nA. 易受血漿中cholinesterase代謝\nB. 結構中的氯取代基位於苯環上羰基（carbonyl）之間位（meta）\nC. 屬於酯類結構\nD. 不可與磺胺藥併用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關chloroprocaine之敘述，何者錯誤？\nA. 易受血漿中cholinesterase代謝\nB. 結構中的氯取代基位於苯環上羰基（carbonyl）之間位（meta）\nC. 屬於酯類結構\nD. 不可與磺胺藥併用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關chloroprocaine之敘述，何者錯誤？\nA. 易受血漿中cholinesterase代謝\nB. 結構中的氯取代基位於苯環上羰基（carbonyl）之間位（meta）\nC. 屬於酯類結構\nD. 不可與磺胺藥併用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關chloroprocaine之敘述，何者錯誤？\nA. 易受血漿中cholinesterase代謝\nB. 結構中的氯取代基位於苯環上羰基（carbonyl）之間位（meta）\nC. 屬於酯類結構\nD. 不可與磺胺藥併用\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.8125", "False"]], [["-0.0634765625", "True"]], [["-4.5625", "False"]], [["-3.5625", "False"]]], "filtered_resps": [["-3.8125", "False"], ["-0.0634765625", "True"], ["-4.5625", "False"], ["-3.5625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ffc09bb2e365e993a88e49fa700305174e8edcf84cf85129c22248109552cefc", "prompt_hash": "ebfad1c7c7562d686078f58f33ec28998517487e35f429fa9905f48f87d37f92", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 125, "doc": {"question": "一位頭頸癌病患接受合併手術切除與放射治療後，產生顯著唾液分泌減少與口乾副作用，下列藥物何者無法緩解該副作用？", "A": "pilocarpine", "B": "cevimeline", "C": "atropine", "D": "neostigmine", "answer": "C", "questions": "一位頭頸癌病患接受合併手術切除與放射治療後，產生顯著唾液分泌減少與口乾副作用，下列藥物何者無法緩解該副作用？", "choices": ["pilocarpine", "cevimeline", "atropine", "neostigmine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位頭頸癌病患接受合併手術切除與放射治療後，產生顯著唾液分泌減少與口乾副作用，下列藥物何者無法緩解該副作用？\nA. pilocarpine\nB. cevimeline\nC. atropine\nD. neostigmine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位頭頸癌病患接受合併手術切除與放射治療後，產生顯著唾液分泌減少與口乾副作用，下列藥物何者無法緩解該副作用？\nA. pilocarpine\nB. cevimeline\nC. atropine\nD. neostigmine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位頭頸癌病患接受合併手術切除與放射治療後，產生顯著唾液分泌減少與口乾副作用，下列藥物何者無法緩解該副作用？\nA. pilocarpine\nB. cevimeline\nC. atropine\nD. neostigmine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位頭頸癌病患接受合併手術切除與放射治療後，產生顯著唾液分泌減少與口乾副作用，下列藥物何者無法緩解該副作用？\nA. pilocarpine\nB. cevimeline\nC. atropine\nD. neostigmine\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.875", "False"]], [["-7.375", "False"]], [["-0.0037994384765625", "True"]], [["-6.375", "False"]]], "filtered_resps": [["-7.875", "False"], ["-7.375", "False"], ["-0.0037994384765625", "True"], ["-6.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fb86d2cba21cb5fc9588904e2280aa6c0f7e0ae2a812029bc266ef88db9396d5", "prompt_hash": "a012861cee24776842547b9ba5d180159623a18c238741ce1d4215368e60f75f", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 126, "doc": {"question": "下列有關抗癲癇藥gabapentin特性之敘述，何者錯誤？", "A": "其胺基之pKa約為10.7", "B": "水溶解度可達10 mg/mL", "C": "透過被動運輸穿入血腦障壁", "D": "屬於電雙性（zwitterionic）化合物", "answer": "C", "questions": "下列有關抗癲癇藥gabapentin特性之敘述，何者錯誤？", "choices": ["其胺基之pKa約為10.7", "水溶解度可達10 mg/mL", "透過被動運輸穿入血腦障壁", "屬於電雙性（zwitterionic）化合物"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗癲癇藥gabapentin特性之敘述，何者錯誤？\nA. 其胺基之pKa約為10.7\nB. 水溶解度可達10 mg/mL\nC. 透過被動運輸穿入血腦障壁\nD. 屬於電雙性（zwitterionic）化合物\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗癲癇藥gabapentin特性之敘述，何者錯誤？\nA. 其胺基之pKa約為10.7\nB. 水溶解度可達10 mg/mL\nC. 透過被動運輸穿入血腦障壁\nD. 屬於電雙性（zwitterionic）化合物\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗癲癇藥gabapentin特性之敘述，何者錯誤？\nA. 其胺基之pKa約為10.7\nB. 水溶解度可達10 mg/mL\nC. 透過被動運輸穿入血腦障壁\nD. 屬於電雙性（zwitterionic）化合物\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗癲癇藥gabapentin特性之敘述，何者錯誤？\nA. 其胺基之pKa約為10.7\nB. 水溶解度可達10 mg/mL\nC. 透過被動運輸穿入血腦障壁\nD. 屬於電雙性（zwitterionic）化合物\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.015625", "False"]], [["-2.765625", "False"]], [["-0.1376953125", "True"]], [["-4.125", "False"]]], "filtered_resps": [["-3.015625", "False"], ["-2.765625", "False"], ["-0.1376953125", "True"], ["-4.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ad214d1e1a3dd4dca78422a65c6ce34317f04fe6246318622f4651cce9973fd3", "prompt_hash": "cefb141f7fb49b7c26c9e5d68d91eccc7177be5cfb4992eb6cdff4eafc3b35f4", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 127, "doc": {"question": "下列那一種局部麻醉劑的作用時間最短？", "A": "Bupivacaine", "B": "Lidocaine", "C": "Tetracaine", "D": "Procaine", "answer": "D", "questions": "下列那一種局部麻醉劑的作用時間最短？", "choices": ["Bupivacaine", "Lidocaine", "Tetracaine", "Procaine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種局部麻醉劑的作用時間最短？\nA. Bupivacaine\nB. Lidocaine\nC. Tetracaine\nD. Procaine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種局部麻醉劑的作用時間最短？\nA. Bupivacaine\nB. Lidocaine\nC. Tetracaine\nD. Procaine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種局部麻醉劑的作用時間最短？\nA. Bupivacaine\nB. Lidocaine\nC. Tetracaine\nD. Procaine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種局部麻醉劑的作用時間最短？\nA. Bupivacaine\nB. Lidocaine\nC. Tetracaine\nD. Procaine\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.125", "False"]], [["-6.25", "False"]], [["-7.5", "False"]], [["-0.0036773681640625", "True"]]], "filtered_resps": [["-7.125", "False"], ["-6.25", "False"], ["-7.5", "False"], ["-0.0036773681640625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "787017991227113b338120378c0b2df6b1b321fbd908e1b72c61c960d2ceacce", "prompt_hash": "379f5ca8fa58c6b0cd66108a4370175121ea32ce4b7606b07864eadb7c6fb4ea", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 128, "doc": {"question": "Fluticasone結構中具有幾個氟原子？", "A": "2", "B": "4", "C": "3", "D": "5", "answer": "C", "questions": "Fluticasone結構中具有幾個氟原子？", "choices": ["2", "4", "3", "5"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFluticasone結構中具有幾個氟原子？\nA. 2\nB. 4\nC. 3\nD. 5\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFluticasone結構中具有幾個氟原子？\nA. 2\nB. 4\nC. 3\nD. 5\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFluticasone結構中具有幾個氟原子？\nA. 2\nB. 4\nC. 3\nD. 5\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFluticasone結構中具有幾個氟原子？\nA. 2\nB. 4\nC. 3\nD. 5\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.515625", "False"]], [["-0.515625", "True"]], [["-2.265625", "False"]], [["-1.515625", "False"]]], "filtered_resps": [["-2.515625", "False"], ["-0.515625", "True"], ["-2.265625", "False"], ["-1.515625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "abb714f1a345794a97225120268d623dd4496581c23f17ce3a983887c1b2dd6d", "prompt_hash": "b8b30f10c5f0ac397c4b83c97017a1e9503aa82e0fc4ce48da2e28c561389a69", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 129, "doc": {"question": "下列何種抗人類免疫缺乏病毒（HIV）藥物最不適用在懷孕婦女?", "A": "abacavir", "B": "etravirine", "C": "darunavir", "D": "raltegravir", "answer": "B", "questions": "下列何種抗人類免疫缺乏病毒（HIV）藥物最不適用在懷孕婦女?", "choices": ["abacavir", "etravirine", "darunavir", "raltegravir"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗人類免疫缺乏病毒（HIV）藥物最不適用在懷孕婦女?\nA. abacavir\nB. etravirine\nC. darunavir\nD. raltegravir\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗人類免疫缺乏病毒（HIV）藥物最不適用在懷孕婦女?\nA. abacavir\nB. etravirine\nC. darunavir\nD. raltegravir\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗人類免疫缺乏病毒（HIV）藥物最不適用在懷孕婦女?\nA. abacavir\nB. etravirine\nC. darunavir\nD. raltegravir\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗人類免疫缺乏病毒（HIV）藥物最不適用在懷孕婦女?\nA. abacavir\nB. etravirine\nC. darunavir\nD. raltegravir\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.28125", "False"]], [["-0.016357421875", "True"]], [["-5.78125", "False"]], [["-5.15625", "False"]]], "filtered_resps": [["-5.28125", "False"], ["-0.016357421875", "True"], ["-5.78125", "False"], ["-5.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d92ae80ed5a1fb341708def5d22d3ea050a090ed2f7df5f757916ffb6cfbd16c", "prompt_hash": "6b7a3770c72fdda57e923d2ab55f9ee5ca9adedb324d474c4b43183b856ee26f", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 130, "doc": {"question": "Galantamine最適宜治療下列何種疾病？", "A": "廣角型青光眼", "B": "帕金森氏症", "C": "重症肌無力", "D": "老年癡呆症", "answer": "D", "questions": "Galantamine最適宜治療下列何種疾病？", "choices": ["廣角型青光眼", "帕金森氏症", "重症肌無力", "老年癡呆症"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGalantamine最適宜治療下列何種疾病？\nA. 廣角型青光眼\nB. 帕金森氏症\nC. 重症肌無力\nD. 老年癡呆症\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGalantamine最適宜治療下列何種疾病？\nA. 廣角型青光眼\nB. 帕金森氏症\nC. 重症肌無力\nD. 老年癡呆症\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGalantamine最適宜治療下列何種疾病？\nA. 廣角型青光眼\nB. 帕金森氏症\nC. 重症肌無力\nD. 老年癡呆症\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGalantamine最適宜治療下列何種疾病？\nA. 廣角型青光眼\nB. 帕金森氏症\nC. 重症肌無力\nD. 老年癡呆症\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.5", "False"]], [["-5.375", "False"]], [["-5.75", "False"]], [["-0.01190185546875", "True"]]], "filtered_resps": [["-6.5", "False"], ["-5.375", "False"], ["-5.75", "False"], ["-0.01190185546875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fd94bb2d7044112dd25caeec7ba55cd67d498d28bff66c32223880553e3efa80", "prompt_hash": "59af36f203a5fb4d062bcfdfdeefd833e52eb35ca9b2938fff68a971c67908eb", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 131, "doc": {"question": "Interferons等蛋白藥物製劑中，加入白蛋白（albumin）的主要目的為何？", "A": "減少玻璃管壁的吸附", "B": "增加安定性", "C": "減少凝集（aggregation）", "D": "用來稀釋藥物濃度", "answer": "A", "questions": "Interferons等蛋白藥物製劑中，加入白蛋白（albumin）的主要目的為何？", "choices": ["減少玻璃管壁的吸附", "增加安定性", "減少凝集（aggregation）", "用來稀釋藥物濃度"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nInterferons等蛋白藥物製劑中，加入白蛋白（albumin）的主要目的為何？\nA. 減少玻璃管壁的吸附\nB. 增加安定性\nC. 減少凝集（aggregation）\nD. 用來稀釋藥物濃度\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nInterferons等蛋白藥物製劑中，加入白蛋白（albumin）的主要目的為何？\nA. 減少玻璃管壁的吸附\nB. 增加安定性\nC. 減少凝集（aggregation）\nD. 用來稀釋藥物濃度\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nInterferons等蛋白藥物製劑中，加入白蛋白（albumin）的主要目的為何？\nA. 減少玻璃管壁的吸附\nB. 增加安定性\nC. 減少凝集（aggregation）\nD. 用來稀釋藥物濃度\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nInterferons等蛋白藥物製劑中，加入白蛋白（albumin）的主要目的為何？\nA. 減少玻璃管壁的吸附\nB. 增加安定性\nC. 減少凝集（aggregation）\nD. 用來稀釋藥物濃度\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.54296875", "True"]], [["-1.2890625", "False"]], [["-2.921875", "False"]], [["-2.421875", "False"]]], "filtered_resps": [["-0.54296875", "True"], ["-1.2890625", "False"], ["-2.921875", "False"], ["-2.421875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fd2e2feb7e3e8bf2bddb26a72c6a146ae36c1b9a6e219d09722a34d655a4d1b8", "prompt_hash": "627dbbe63875ee05436190accadbaf45a80cf4586e870abbaaa45fb8414d52b6", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 132, "doc": {"question": "Zafirlucast 結構中，何種基團可產生陰離子與cysteinyl leukotriene 受體之陽離子結合?", "A": "carbamate", "B": "indole", "C": "sulfonamide", "D": "tetrazole", "answer": "C", "questions": "Zafirlucast 結構中，何種基團可產生陰離子與cysteinyl leukotriene 受體之陽離子結合?", "choices": ["carbamate", "indole", "sulfonamide", "tetrazole"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nZafirlucast 結構中，何種基團可產生陰離子與cysteinyl leukotriene 受體之陽離子結合?\nA. carbamate\nB. indole\nC. sulfonamide\nD. tetrazole\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nZafirlucast 結構中，何種基團可產生陰離子與cysteinyl leukotriene 受體之陽離子結合?\nA. carbamate\nB. indole\nC. sulfonamide\nD. tetrazole\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nZafirlucast 結構中，何種基團可產生陰離子與cysteinyl leukotriene 受體之陽離子結合?\nA. carbamate\nB. indole\nC. sulfonamide\nD. tetrazole\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nZafirlucast 結構中，何種基團可產生陰離子與cysteinyl leukotriene 受體之陽離子結合?\nA. carbamate\nB. indole\nC. sulfonamide\nD. tetrazole\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.0625", "False"]], [["-4.1875", "False"]], [["-0.072265625", "True"]], [["-3.203125", "False"]]], "filtered_resps": [["-5.0625", "False"], ["-4.1875", "False"], ["-0.072265625", "True"], ["-3.203125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e29707213cba12902f9746ac6422afc1261feb664910f72e804af7bec01e193d", "prompt_hash": "7842e1dcc5bd350d4dc6bf6fe7e8c2c0c65ea25ef092744023d25a0a4ff1dddb", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 133, "doc": {"question": "下列何種藥物之類固醇結構骨架中，，不具 9α-氟取代基？", "A": "methylprednisolone", "B": "betamethasone", "C": "triamcinolone", "D": "dexamethasone", "answer": "A", "questions": "下列何種藥物之類固醇結構骨架中，，不具 9α-氟取代基？", "choices": ["methylprednisolone", "betamethasone", "triamcinolone", "dexamethasone"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之類固醇結構骨架中，，不具 9α-氟取代基？\nA. methylprednisolone\nB. betamethasone\nC. triamcinolone\nD. dexamethasone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之類固醇結構骨架中，，不具 9α-氟取代基？\nA. methylprednisolone\nB. betamethasone\nC. triamcinolone\nD. dexamethasone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之類固醇結構骨架中，，不具 9α-氟取代基？\nA. methylprednisolone\nB. betamethasone\nC. triamcinolone\nD. dexamethasone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之類固醇結構骨架中，，不具 9α-氟取代基？\nA. methylprednisolone\nB. betamethasone\nC. triamcinolone\nD. dexamethasone\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.162109375", "True"]], [["-4.03125", "False"]], [["-2.40625", "False"]], [["-3.15625", "False"]]], "filtered_resps": [["-0.162109375", "True"], ["-4.03125", "False"], ["-2.40625", "False"], ["-3.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c36869907cfc4469d562428ddf531e1bb55059102b055964678c0ea6423d8dcf", "prompt_hash": "12e472169c8393add5d3df05c239e5d4c445240248291bc18da2583b190a72c0", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 134, "doc": {"question": "關於sucralfate的敘述，下列何者正確？", "A": "應該在空腹時使用", "B": "主要作用機制是抑制胃酸分泌", "C": "腹瀉是常見的副作用", "D": "與氫離子幫浦抑制劑（proton pump inhibitors）合用可增强其作用", "answer": "A", "questions": "關於sucralfate的敘述，下列何者正確？", "choices": ["應該在空腹時使用", "主要作用機制是抑制胃酸分泌", "腹瀉是常見的副作用", "與氫離子幫浦抑制劑（proton pump inhibitors）合用可增强其作用"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於sucralfate的敘述，下列何者正確？\nA. 應該在空腹時使用\nB. 主要作用機制是抑制胃酸分泌\nC. 腹瀉是常見的副作用\nD. 與氫離子幫浦抑制劑（proton pump inhibitors）合用可增强其作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於sucralfate的敘述，下列何者正確？\nA. 應該在空腹時使用\nB. 主要作用機制是抑制胃酸分泌\nC. 腹瀉是常見的副作用\nD. 與氫離子幫浦抑制劑（proton pump inhibitors）合用可增强其作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於sucralfate的敘述，下列何者正確？\nA. 應該在空腹時使用\nB. 主要作用機制是抑制胃酸分泌\nC. 腹瀉是常見的副作用\nD. 與氫離子幫浦抑制劑（proton pump inhibitors）合用可增强其作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於sucralfate的敘述，下列何者正確？\nA. 應該在空腹時使用\nB. 主要作用機制是抑制胃酸分泌\nC. 腹瀉是常見的副作用\nD. 與氫離子幫浦抑制劑（proton pump inhibitors）合用可增强其作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.453125", "False"]], [["-4.09375", "False"]], [["-0.45703125", "True"]], [["-1.3359375", "False"]]], "filtered_resps": [["-2.453125", "False"], ["-4.09375", "False"], ["-0.45703125", "True"], ["-1.3359375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8e4d7063be7adcba6faa3ded74bc7fa219ab8194756f9e7049fd242c1c85e2cc", "prompt_hash": "d154115a9145b20bea24cd9d06e7e3b477e03e292f06f4849af8f8863f2e48c2", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 135, "doc": {"question": "下列何者為pyrazinamide在體內之主要代謝反應？", "A": "N-oxidation", "B": "sulfation", "C": "hydrolysis", "D": "deacetylation", "answer": "C", "questions": "下列何者為pyrazinamide在體內之主要代謝反應？", "choices": ["N-oxidation", "sulfation", "hydrolysis", "deacetylation"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pyrazinamide在體內之主要代謝反應？\nA. N-oxidation\nB. sulfation\nC. hydrolysis\nD. deacetylation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pyrazinamide在體內之主要代謝反應？\nA. N-oxidation\nB. sulfation\nC. hydrolysis\nD. deacetylation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pyrazinamide在體內之主要代謝反應？\nA. N-oxidation\nB. sulfation\nC. hydrolysis\nD. deacetylation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pyrazinamide在體內之主要代謝反應？\nA. N-oxidation\nB. sulfation\nC. hydrolysis\nD. deacetylation\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.09375", "False"]], [["-3.84375", "False"]], [["-0.0888671875", "True"]], [["-3.34375", "False"]]], "filtered_resps": [["-4.09375", "False"], ["-3.84375", "False"], ["-0.0888671875", "True"], ["-3.34375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f1dba7d06aa9c05cdfa6b37f435464d6b5a2e13ee605a14a028eeeeb9fc40d36", "prompt_hash": "e0bca28a21efa467dec3e8290f539676b367a84e69edf4a7016b64ffeaa10a0e", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 136, "doc": {"question": "下列何種四環素之結構，在C-9具有glycylamido基團？", "A": "tigecycline", "B": "doxycycline", "C": "oxytetracycline", "D": "minocycline", "answer": "A", "questions": "下列何種四環素之結構，在C-9具有glycylamido基團？", "choices": ["tigecycline", "doxycycline", "oxytetracycline", "minocycline"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種四環素之結構，在C-9具有glycylamido基團？\nA. tigecycline\nB. doxycycline\nC. oxytetracycline\nD. minocycline\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種四環素之結構，在C-9具有glycylamido基團？\nA. tigecycline\nB. doxycycline\nC. oxytetracycline\nD. minocycline\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種四環素之結構，在C-9具有glycylamido基團？\nA. tigecycline\nB. doxycycline\nC. oxytetracycline\nD. minocycline\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種四環素之結構，在C-9具有glycylamido基團？\nA. tigecycline\nB. doxycycline\nC. oxytetracycline\nD. minocycline\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0291748046875", "True"]], [["-5.15625", "False"]], [["-5.65625", "False"]], [["-4.15625", "False"]]], "filtered_resps": [["-0.0291748046875", "True"], ["-5.15625", "False"], ["-5.65625", "False"], ["-4.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "09f71c0af0c01bb25c55b85f1dd2199514e29dbb2be75d4326fe44063f5b5885", "prompt_hash": "369040942c894ed1ef144f0c589a55a2fd8e05e77847a28eac9ba91c121030d7", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 137, "doc": {"question": "下列何者為B lymphocytes抗體藥物，用於類風濕關節炎的治療？", "A": "infliximab", "B": "adalimumab", "C": "tocilizumab", "D": "rituximab", "answer": "D", "questions": "下列何者為B lymphocytes抗體藥物，用於類風濕關節炎的治療？", "choices": ["infliximab", "adalimumab", "tocilizumab", "rituximab"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為B lymphocytes抗體藥物，用於類風濕關節炎的治療？\nA. infliximab\nB. adalimumab\nC. tocilizumab\nD. rituximab\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為B lymphocytes抗體藥物，用於類風濕關節炎的治療？\nA. infliximab\nB. adalimumab\nC. tocilizumab\nD. rituximab\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為B lymphocytes抗體藥物，用於類風濕關節炎的治療？\nA. infliximab\nB. adalimumab\nC. tocilizumab\nD. rituximab\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為B lymphocytes抗體藥物，用於類風濕關節炎的治療？\nA. infliximab\nB. adalimumab\nC. tocilizumab\nD. rituximab\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.53125", "False"]], [["-4.53125", "False"]], [["-5.78125", "False"]], [["-0.0205078125", "True"]]], "filtered_resps": [["-5.53125", "False"], ["-4.53125", "False"], ["-5.78125", "False"], ["-0.0205078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b03b5459cc2550c8e1d5e1fbd1b4e1af237bebb52f4220cdfc26e5bc9bfec0c7", "prompt_hash": "e887d6a56ae25044cc090b22297c50830807597dc59c26812fc507a36728e845", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 138, "doc": {"question": "下列有關saxagliptin之敘述，何者錯誤？", "A": "為不可逆抑制劑", "B": "為α-aminoacylpyrrolidines之衍生物", "C": "作用於dipeptidyl peptidase-4 (DPP4)", "D": "結構中pyrrolidine環上有nitro基團", "answer": "D", "questions": "下列有關saxagliptin之敘述，何者錯誤？", "choices": ["為不可逆抑制劑", "為α-aminoacylpyrrolidines之衍生物", "作用於dipeptidyl peptidase-4 (DPP4)", "結構中pyrrolidine環上有nitro基團"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關saxagliptin之敘述，何者錯誤？\nA. 為不可逆抑制劑\nB. 為α-aminoacylpyrrolidines之衍生物\nC. 作用於dipeptidyl peptidase-4 (DPP4)\nD. 結構中pyrrolidine環上有nitro基團\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關saxagliptin之敘述，何者錯誤？\nA. 為不可逆抑制劑\nB. 為α-aminoacylpyrrolidines之衍生物\nC. 作用於dipeptidyl peptidase-4 (DPP4)\nD. 結構中pyrrolidine環上有nitro基團\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關saxagliptin之敘述，何者錯誤？\nA. 為不可逆抑制劑\nB. 為α-aminoacylpyrrolidines之衍生物\nC. 作用於dipeptidyl peptidase-4 (DPP4)\nD. 結構中pyrrolidine環上有nitro基團\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關saxagliptin之敘述，何者錯誤？\nA. 為不可逆抑制劑\nB. 為α-aminoacylpyrrolidines之衍生物\nC. 作用於dipeptidyl peptidase-4 (DPP4)\nD. 結構中pyrrolidine環上有nitro基團\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.40625", "False"]], [["-4.53125", "False"]], [["-5.15625", "False"]], [["-0.030517578125", "True"]]], "filtered_resps": [["-4.40625", "False"], ["-4.53125", "False"], ["-5.15625", "False"], ["-0.030517578125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "745853911136003c2fd62ffe071a1324f8afedcae9f03e515c32c980bbbbd7ee", "prompt_hash": "7a84c60a54eacdcd561a4ea92b6979883eb9cc2d93f9150ab5532d36ce9fdd99", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 139, "doc": {"question": "下列類固醇藥物，何者抗發炎效果最差？", "A": "prednisolone", "B": "betamethasone", "C": "dexamethasone", "D": "hydrocortisone", "answer": "D", "questions": "下列類固醇藥物，何者抗發炎效果最差？", "choices": ["prednisolone", "betamethasone", "dexamethasone", "hydrocortisone"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列類固醇藥物，何者抗發炎效果最差？\nA. prednisolone\nB. betamethasone\nC. dexamethasone\nD. hydrocortisone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列類固醇藥物，何者抗發炎效果最差？\nA. prednisolone\nB. betamethasone\nC. dexamethasone\nD. hydrocortisone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列類固醇藥物，何者抗發炎效果最差？\nA. prednisolone\nB. betamethasone\nC. dexamethasone\nD. hydrocortisone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列類固醇藥物，何者抗發炎效果最差？\nA. prednisolone\nB. betamethasone\nC. dexamethasone\nD. hydrocortisone\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-6.875", "False"]], [["-6.75", "False"]], [["-0.0079345703125", "True"]]], "filtered_resps": [["-5.875", "False"], ["-6.875", "False"], ["-6.75", "False"], ["-0.0079345703125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ded44151ed403416d52c1b5e231f5548a8336b90c20b81a01a915a338370cee7", "prompt_hash": "ead2a2c4dea91977269efd94a46c444d8a0dda5c1dd01113a9c2a52894856ed8", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 140, "doc": {"question": "下列何者為pure estrogen receptor antagonist，臨床上主要用於治療乳癌？", "A": "tamoxifen", "B": "fulvestrant", "C": "anastrozole", "D": "danazol", "answer": "B", "questions": "下列何者為pure estrogen receptor antagonist，臨床上主要用於治療乳癌？", "choices": ["tamoxifen", "fulvestrant", "anastrozole", "danazol"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pure estrogen receptor antagonist，臨床上主要用於治療乳癌？\nA. tamoxifen\nB. fulvestrant\nC. anastrozole\nD. danazol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pure estrogen receptor antagonist，臨床上主要用於治療乳癌？\nA. tamoxifen\nB. fulvestrant\nC. anastrozole\nD. danazol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pure estrogen receptor antagonist，臨床上主要用於治療乳癌？\nA. tamoxifen\nB. fulvestrant\nC. anastrozole\nD. danazol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pure estrogen receptor antagonist，臨床上主要用於治療乳癌？\nA. tamoxifen\nB. fulvestrant\nC. anastrozole\nD. danazol\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.578125", "False"]], [["-0.080078125", "True"]], [["-4.84375", "False"]], [["-3.203125", "False"]]], "filtered_resps": [["-3.578125", "False"], ["-0.080078125", "True"], ["-4.84375", "False"], ["-3.203125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b7f310021c937d039bb121d4683356fce6914fdedf36b24658ac9fe6e48f0e0e", "prompt_hash": "96179f63b8894ddedc9efe3696b120794e1f8f323ccc95621c95d594cc1f2c47", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 141, "doc": {"question": "下列何者對於開發治療癲癇（Epilepsy）藥物的策略而言，是錯誤的？", "A": "阻斷麩胺酸（Glutamate）受體（Receptor）", "B": "增加GABA的代謝", "C": "抑制丘腦（Thalamic）的T-型鈣離子管道（Ca2+ channel）", "D": "減少興奮性麩胺酸（Glutamate）的神經傳遞作用", "answer": "B", "questions": "下列何者對於開發治療癲癇（Epilepsy）藥物的策略而言，是錯誤的？", "choices": ["阻斷麩胺酸（Glutamate）受體（Receptor）", "增加GABA的代謝", "抑制丘腦（Thalamic）的T-型鈣離子管道（Ca2+ channel）", "減少興奮性麩胺酸（Glutamate）的神經傳遞作用"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者對於開發治療癲癇（Epilepsy）藥物的策略而言，是錯誤的？\nA. 阻斷麩胺酸（Glutamate）受體（Receptor）\nB. 增加GABA的代謝\nC. 抑制丘腦（Thalamic）的T-型鈣離子管道（Ca2+ channel）\nD. 減少興奮性麩胺酸（Glutamate）的神經傳遞作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者對於開發治療癲癇（Epilepsy）藥物的策略而言，是錯誤的？\nA. 阻斷麩胺酸（Glutamate）受體（Receptor）\nB. 增加GABA的代謝\nC. 抑制丘腦（Thalamic）的T-型鈣離子管道（Ca2+ channel）\nD. 減少興奮性麩胺酸（Glutamate）的神經傳遞作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者對於開發治療癲癇（Epilepsy）藥物的策略而言，是錯誤的？\nA. 阻斷麩胺酸（Glutamate）受體（Receptor）\nB. 增加GABA的代謝\nC. 抑制丘腦（Thalamic）的T-型鈣離子管道（Ca2+ channel）\nD. 減少興奮性麩胺酸（Glutamate）的神經傳遞作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者對於開發治療癲癇（Epilepsy）藥物的策略而言，是錯誤的？\nA. 阻斷麩胺酸（Glutamate）受體（Receptor）\nB. 增加GABA的代謝\nC. 抑制丘腦（Thalamic）的T-型鈣離子管道（Ca2+ channel）\nD. 減少興奮性麩胺酸（Glutamate）的神經傳遞作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.734375", "False"]], [["-0.11279296875", "True"]], [["-2.984375", "False"]], [["-3.484375", "False"]]], "filtered_resps": [["-3.734375", "False"], ["-0.11279296875", "True"], ["-2.984375", "False"], ["-3.484375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "86e82821ce872b09f384a893e237a05ed60e230a2f737913cd158c613d92fbff", "prompt_hash": "cd74b28a45a883c748727439c4a56ff8a9374396d6c7c4ac7e5a37e980ece585", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 142, "doc": {"question": "阿珍已經懷孕四個月，但是她卻患了廣泛性焦慮症，根據美國FDA懷孕用藥指示，下列何種鎮靜安眠藥物最安全？", "A": "diazepam", "B": "triazolam", "C": "pentobarbital", "D": "buspirone", "answer": "D", "questions": "阿珍已經懷孕四個月，但是她卻患了廣泛性焦慮症，根據美國FDA懷孕用藥指示，下列何種鎮靜安眠藥物最安全？", "choices": ["diazepam", "triazolam", "pentobarbital", "buspirone"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿珍已經懷孕四個月，但是她卻患了廣泛性焦慮症，根據美國FDA懷孕用藥指示，下列何種鎮靜安眠藥物最安全？\nA. diazepam\nB. triazolam\nC. pentobarbital\nD. buspirone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿珍已經懷孕四個月，但是她卻患了廣泛性焦慮症，根據美國FDA懷孕用藥指示，下列何種鎮靜安眠藥物最安全？\nA. diazepam\nB. triazolam\nC. pentobarbital\nD. buspirone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿珍已經懷孕四個月，但是她卻患了廣泛性焦慮症，根據美國FDA懷孕用藥指示，下列何種鎮靜安眠藥物最安全？\nA. diazepam\nB. triazolam\nC. pentobarbital\nD. buspirone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿珍已經懷孕四個月，但是她卻患了廣泛性焦慮症，根據美國FDA懷孕用藥指示，下列何種鎮靜安眠藥物最安全？\nA. diazepam\nB. triazolam\nC. pentobarbital\nD. buspirone\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.625", "False"]], [["-5.875", "False"]], [["-7.625", "False"]], [["-0.006805419921875", "True"]]], "filtered_resps": [["-6.625", "False"], ["-5.875", "False"], ["-7.625", "False"], ["-0.006805419921875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "07323acfb5aea4fb0dfe5b8ad279e8f6291a8e63409538d5e393294adb7f5ec5", "prompt_hash": "b3b60f944693b17b8899fdc3ac5359cc21a48f0b9b2d9e7bce508a6da06feca0", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 143, "doc": {"question": "抗病毒藥foscarnet sodium結構中有幾個鈉離子？", "A": "2", "B": "3", "C": "4", "D": "1", "answer": "B", "questions": "抗病毒藥foscarnet sodium結構中有幾個鈉離子？", "choices": ["2", "3", "4", "1"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗病毒藥foscarnet sodium結構中有幾個鈉離子？\nA. 2\nB. 3\nC. 4\nD. 1\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗病毒藥foscarnet sodium結構中有幾個鈉離子？\nA. 2\nB. 3\nC. 4\nD. 1\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗病毒藥foscarnet sodium結構中有幾個鈉離子？\nA. 2\nB. 3\nC. 4\nD. 1\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗病毒藥foscarnet sodium結構中有幾個鈉離子？\nA. 2\nB. 3\nC. 4\nD. 1\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.6171875", "False"]], [["-1.4921875", "False"]], [["-1.8671875", "False"]], [["-0.8671875", "True"]]], "filtered_resps": [["-1.6171875", "False"], ["-1.4921875", "False"], ["-1.8671875", "False"], ["-0.8671875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ad54a620c911e4186933b277eb1875842d05413f82b9e4ad0a500ca3b5ce6a83", "prompt_hash": "e85d167d663b7f04e1724ad157d68c0821729156329b97dc2ca1daba3b356573", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 144, "doc": {"question": "Clomiphene主要透過下列何種機轉而促使卵巢排卵？", "A": "活化卵巢細胞之luteinizing hormone（LH）受體", "B": "活化下視丘之progesterone受體", "C": "拮抗卵巢細胞之androgen受體", "D": "拮抗下視丘之estrogen受體", "answer": "D", "questions": "Clomiphene主要透過下列何種機轉而促使卵巢排卵？", "choices": ["活化卵巢細胞之luteinizing hormone（LH）受體", "活化下視丘之progesterone受體", "拮抗卵巢細胞之androgen受體", "拮抗下視丘之estrogen受體"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClomiphene主要透過下列何種機轉而促使卵巢排卵？\nA. 活化卵巢細胞之luteinizing hormone（LH）受體\nB. 活化下視丘之progesterone受體\nC. 拮抗卵巢細胞之androgen受體\nD. 拮抗下視丘之estrogen受體\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClomiphene主要透過下列何種機轉而促使卵巢排卵？\nA. 活化卵巢細胞之luteinizing hormone（LH）受體\nB. 活化下視丘之progesterone受體\nC. 拮抗卵巢細胞之androgen受體\nD. 拮抗下視丘之estrogen受體\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClomiphene主要透過下列何種機轉而促使卵巢排卵？\nA. 活化卵巢細胞之luteinizing hormone（LH）受體\nB. 活化下視丘之progesterone受體\nC. 拮抗卵巢細胞之androgen受體\nD. 拮抗下視丘之estrogen受體\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClomiphene主要透過下列何種機轉而促使卵巢排卵？\nA. 活化卵巢細胞之luteinizing hormone（LH）受體\nB. 活化下視丘之progesterone受體\nC. 拮抗卵巢細胞之androgen受體\nD. 拮抗下視丘之estrogen受體\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.25", "False"]], [["-8.75", "False"]], [["-7.625", "False"]], [["-0.004852294921875", "True"]]], "filtered_resps": [["-6.25", "False"], ["-8.75", "False"], ["-7.625", "False"], ["-0.004852294921875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fa23a487e2688dfaa3eb4983b05242402c2cde50ab8ab4cf382dc401d730c5bf", "prompt_hash": "75024aac2c385362799fc764813f804e0a1b9e662e0bc552d81b71c1bf3e952b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 145, "doc": {"question": "下列關於治療帕金森氏症（Parkinson's disease）藥物的敘述，何者錯誤？", "A": "levodopa和carbidopa凝膠劑型，經由持久的胃造瘻給藥，以治療患帕金森氏症的重症病人", "B": "selegiline的藥理機制是抑制dopamine D2受體", "C": "levodopa和carbidopa合併使用是為了減少周邊levodopa轉變成dopamine", "D": "Rytary是一長效劑型，減少藥物血中濃度之變動（fluctuation）", "answer": "B", "questions": "下列關於治療帕金森氏症（Parkinson's disease）藥物的敘述，何者錯誤？", "choices": ["levodopa和carbidopa凝膠劑型，經由持久的胃造瘻給藥，以治療患帕金森氏症的重症病人", "selegiline的藥理機制是抑制dopamine D2受體", "levodopa和carbidopa合併使用是為了減少周邊levodopa轉變成dopamine", "Rytary是一長效劑型，減少藥物血中濃度之變動（fluctuation）"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於治療帕金森氏症（Parkinson's disease）藥物的敘述，何者錯誤？\nA. levodopa和carbidopa凝膠劑型，經由持久的胃造瘻給藥，以治療患帕金森氏症的重症病人\nB. selegiline的藥理機制是抑制dopamine D2受體\nC. levodopa和carbidopa合併使用是為了減少周邊levodopa轉變成dopamine\nD. Rytary是一長效劑型，減少藥物血中濃度之變動（fluctuation）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於治療帕金森氏症（Parkinson's disease）藥物的敘述，何者錯誤？\nA. levodopa和carbidopa凝膠劑型，經由持久的胃造瘻給藥，以治療患帕金森氏症的重症病人\nB. selegiline的藥理機制是抑制dopamine D2受體\nC. levodopa和carbidopa合併使用是為了減少周邊levodopa轉變成dopamine\nD. Rytary是一長效劑型，減少藥物血中濃度之變動（fluctuation）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於治療帕金森氏症（Parkinson's disease）藥物的敘述，何者錯誤？\nA. levodopa和carbidopa凝膠劑型，經由持久的胃造瘻給藥，以治療患帕金森氏症的重症病人\nB. selegiline的藥理機制是抑制dopamine D2受體\nC. levodopa和carbidopa合併使用是為了減少周邊levodopa轉變成dopamine\nD. Rytary是一長效劑型，減少藥物血中濃度之變動（fluctuation）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於治療帕金森氏症（Parkinson's disease）藥物的敘述，何者錯誤？\nA. levodopa和carbidopa凝膠劑型，經由持久的胃造瘻給藥，以治療患帕金森氏症的重症病人\nB. selegiline的藥理機制是抑制dopamine D2受體\nC. levodopa和carbidopa合併使用是為了減少周邊levodopa轉變成dopamine\nD. Rytary是一長效劑型，減少藥物血中濃度之變動（fluctuation）\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.875", "False"]], [["-0.005706787109375", "True"]], [["-6.375", "False"]], [["-6.75", "False"]]], "filtered_resps": [["-6.875", "False"], ["-0.005706787109375", "True"], ["-6.375", "False"], ["-6.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d830f0eca49ce3671a391f6c566133a3e8394dbf72eb90c355b8173ed39e354e", "prompt_hash": "6ad55c011ce6de5da6d24644047aa3e7aec381c301f8d0dd57ac95d4e01b3af9", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 146, "doc": {"question": "下列消化性潰瘍治療藥物，何者是結合到腸胃道潰瘍部位的蛋白質來保護受損黏膜？", "A": "sucralfate", "B": "omeprazole", "C": "cimetidine", "D": "antacids", "answer": "A", "questions": "下列消化性潰瘍治療藥物，何者是結合到腸胃道潰瘍部位的蛋白質來保護受損黏膜？", "choices": ["sucralfate", "omeprazole", "cimetidine", "antacids"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列消化性潰瘍治療藥物，何者是結合到腸胃道潰瘍部位的蛋白質來保護受損黏膜？\nA. sucralfate\nB. omeprazole\nC. cimetidine\nD. antacids\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列消化性潰瘍治療藥物，何者是結合到腸胃道潰瘍部位的蛋白質來保護受損黏膜？\nA. sucralfate\nB. omeprazole\nC. cimetidine\nD. antacids\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列消化性潰瘍治療藥物，何者是結合到腸胃道潰瘍部位的蛋白質來保護受損黏膜？\nA. sucralfate\nB. omeprazole\nC. cimetidine\nD. antacids\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列消化性潰瘍治療藥物，何者是結合到腸胃道潰瘍部位的蛋白質來保護受損黏膜？\nA. sucralfate\nB. omeprazole\nC. cimetidine\nD. antacids\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0279541015625", "True"]], [["-5.65625", "False"]], [["-5.78125", "False"]], [["-4.78125", "False"]]], "filtered_resps": [["-0.0279541015625", "True"], ["-5.65625", "False"], ["-5.78125", "False"], ["-4.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "96ae169e409ea4e288fdba00131fde2f9c1197ae17c6e443d1d114c138bb3f82", "prompt_hash": "b6499e1cd38ee44f7ab55033177d3fa29b39044cce9056308e334a7a14f8ffca", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 147, "doc": {"question": "Saxagliptin結構中cyano 基團，可與DPP-IV 酵素的何種胺基酸殘基結合？", "A": "cysteine", "B": "methionine", "C": "threonine", "D": "serine", "answer": "D", "questions": "Saxagliptin結構中cyano 基團，可與DPP-IV 酵素的何種胺基酸殘基結合？", "choices": ["cysteine", "methionine", "threonine", "serine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSaxagliptin結構中cyano 基團，可與DPP-IV 酵素的何種胺基酸殘基結合？\nA. cysteine\nB. methionine\nC. threonine\nD. serine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSaxagliptin結構中cyano 基團，可與DPP-IV 酵素的何種胺基酸殘基結合？\nA. cysteine\nB. methionine\nC. threonine\nD. serine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSaxagliptin結構中cyano 基團，可與DPP-IV 酵素的何種胺基酸殘基結合？\nA. cysteine\nB. methionine\nC. threonine\nD. serine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSaxagliptin結構中cyano 基團，可與DPP-IV 酵素的何種胺基酸殘基結合？\nA. cysteine\nB. methionine\nC. threonine\nD. serine\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.53125", "False"]], [["-4.78125", "False"]], [["-4.90625", "False"]], [["-0.029052734375", "True"]]], "filtered_resps": [["-4.53125", "False"], ["-4.78125", "False"], ["-4.90625", "False"], ["-0.029052734375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d74e83c6f0a54f652d93d9aafbe8d35effe645fd9a79d61f100714b25a4dbc69", "prompt_hash": "0ff550dfce5bfc4587112c82e1c37d509934ff1e7c8c0b19a6e927eb9f1549d9", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 148, "doc": {"question": "下列藥物中何者之主要作用細胞，與其它藥物作用之細胞不同？", "A": "afatinib", "B": "basiliximab", "C": "alefacept", "D": "nivolumab", "answer": "A", "questions": "下列藥物中何者之主要作用細胞，與其它藥物作用之細胞不同？", "choices": ["afatinib", "basiliximab", "alefacept", "nivolumab"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中何者之主要作用細胞，與其它藥物作用之細胞不同？\nA. afatinib\nB. basiliximab\nC. alefacept\nD. nivolumab\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中何者之主要作用細胞，與其它藥物作用之細胞不同？\nA. afatinib\nB. basiliximab\nC. alefacept\nD. nivolumab\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中何者之主要作用細胞，與其它藥物作用之細胞不同？\nA. afatinib\nB. basiliximab\nC. alefacept\nD. nivolumab\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中何者之主要作用細胞，與其它藥物作用之細胞不同？\nA. afatinib\nB. basiliximab\nC. alefacept\nD. nivolumab\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.140625", "False"]], [["-2.140625", "False"]], [["-3.265625", "False"]], [["-0.64453125", "True"]]], "filtered_resps": [["-1.140625", "False"], ["-2.140625", "False"], ["-3.265625", "False"], ["-0.64453125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "83134e40c67933cb6e36709bd9193f06cd5db8cf78299eef2a3eca6d8f75356c", "prompt_hash": "08b9052c35a8440f71cdd930609e197436b4dd3d6d96a377feb06c4c9e8fe32d", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 149, "doc": {"question": "下列那一種藥物最不適合用來作為急性高血壓病人之初期治療藥物？", "A": "Sodium Nitroprusside", "B": "Fenoldopam", "C": "Thiazide", "D": "Diazoxide", "answer": "C", "questions": "下列那一種藥物最不適合用來作為急性高血壓病人之初期治療藥物？", "choices": ["Sodium Nitroprusside", "Fenoldopam", "Thiazide", "Diazoxide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種藥物最不適合用來作為急性高血壓病人之初期治療藥物？\nA. Sodium Nitroprusside\nB. Fenoldopam\nC. Thiazide\nD. Diazoxide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種藥物最不適合用來作為急性高血壓病人之初期治療藥物？\nA. Sodium Nitroprusside\nB. Fenoldopam\nC. Thiazide\nD. Diazoxide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種藥物最不適合用來作為急性高血壓病人之初期治療藥物？\nA. Sodium Nitroprusside\nB. Fenoldopam\nC. Thiazide\nD. Diazoxide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種藥物最不適合用來作為急性高血壓病人之初期治療藥物？\nA. Sodium Nitroprusside\nB. Fenoldopam\nC. Thiazide\nD. Diazoxide\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.15625", "False"]], [["-5.28125", "False"]], [["-0.016845703125", "True"]], [["-5.28125", "False"]]], "filtered_resps": [["-7.15625", "False"], ["-5.28125", "False"], ["-0.016845703125", "True"], ["-5.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a35637ae8774668a54ac541ef8f2ccf6eff26a9d7ba871625a8c71cff2e92b43", "prompt_hash": "a919c20f0e31a602796d6566c5c8c57344bac4cd3cd4756a585a72706e2f45be", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 150, "doc": {"question": "下列何者不是神經病變疼痛（ neuropathic pain）的第一線用藥？", "A": "desipramine", "B": "lidocaine", "C": "gabapentin", "D": "duloxetine", "answer": "B", "questions": "下列何者不是神經病變疼痛（ neuropathic pain）的第一線用藥？", "choices": ["desipramine", "lidocaine", "gabapentin", "duloxetine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是神經病變疼痛（ neuropathic pain）的第一線用藥？\nA. desipramine\nB. lidocaine\nC. gabapentin\nD. duloxetine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是神經病變疼痛（ neuropathic pain）的第一線用藥？\nA. desipramine\nB. lidocaine\nC. gabapentin\nD. duloxetine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是神經病變疼痛（ neuropathic pain）的第一線用藥？\nA. desipramine\nB. lidocaine\nC. gabapentin\nD. duloxetine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是神經病變疼痛（ neuropathic pain）的第一線用藥？\nA. desipramine\nB. lidocaine\nC. gabapentin\nD. duloxetine\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.125", "False"]], [["-0.01556396484375", "True"]], [["-7.375", "False"]], [["-4.75", "False"]]], "filtered_resps": [["-6.125", "False"], ["-0.01556396484375", "True"], ["-7.375", "False"], ["-4.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d925ca164e338babcb2ef4244d6b863c6bbf5c1e4195028acef9c152f116e300", "prompt_hash": "ea80cd5ea3c9ef4fee873d85c8c8ec5833bab848d1e4030407ac7b5d231acffd", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 151, "doc": {"question": "Clonidine容易產生withdrawal hypertensive crisis，此作用的主要原因為何？", "A": "降低alpha2 -adrenoceptor表現量", "B": "增加alpha1 -adrenoceptor的intrinsic activity", "C": "降低alpha2 -adrenoceptor的intrinsic activity", "D": "增加alpha1 -adrenoceptor表現量", "answer": "A", "questions": "Clonidine容易產生withdrawal hypertensive crisis，此作用的主要原因為何？", "choices": ["降低alpha2 -adrenoceptor表現量", "增加alpha1 -adrenoceptor的intrinsic activity", "降低alpha2 -adrenoceptor的intrinsic activity", "增加alpha1 -adrenoceptor表現量"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClonidine容易產生withdrawal hypertensive crisis，此作用的主要原因為何？\nA. 降低alpha2 -adrenoceptor表現量\nB. 增加alpha1 -adrenoceptor的intrinsic activity\nC. 降低alpha2 -adrenoceptor的intrinsic activity\nD. 增加alpha1 -adrenoceptor表現量\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClonidine容易產生withdrawal hypertensive crisis，此作用的主要原因為何？\nA. 降低alpha2 -adrenoceptor表現量\nB. 增加alpha1 -adrenoceptor的intrinsic activity\nC. 降低alpha2 -adrenoceptor的intrinsic activity\nD. 增加alpha1 -adrenoceptor表現量\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClonidine容易產生withdrawal hypertensive crisis，此作用的主要原因為何？\nA. 降低alpha2 -adrenoceptor表現量\nB. 增加alpha1 -adrenoceptor的intrinsic activity\nC. 降低alpha2 -adrenoceptor的intrinsic activity\nD. 增加alpha1 -adrenoceptor表現量\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClonidine容易產生withdrawal hypertensive crisis，此作用的主要原因為何？\nA. 降低alpha2 -adrenoceptor表現量\nB. 增加alpha1 -adrenoceptor的intrinsic activity\nC. 降低alpha2 -adrenoceptor的intrinsic activity\nD. 增加alpha1 -adrenoceptor表現量\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.140625", "False"]], [["-0.640625", "True"]], [["-1.515625", "False"]], [["-2.015625", "False"]]], "filtered_resps": [["-2.140625", "False"], ["-0.640625", "True"], ["-1.515625", "False"], ["-2.015625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8ae1433b73a6dadbdcb9aa9081e8390cfda0e5597d32a432a94503a2d64cb118", "prompt_hash": "023ca58621b29fc081b6c895df19217d2616ae973510ea44a74e9f30047b613e", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 152, "doc": {"question": "那一種利尿劑較不會增加腎血流量？", "A": "Furosemide", "B": "Ethacrynic acid", "C": "Trichlormethiazide", "D": "Bumetanide", "answer": "C", "questions": "那一種利尿劑較不會增加腎血流量？", "choices": ["Furosemide", "Ethacrynic acid", "Trichlormethiazide", "Bumetanide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種利尿劑較不會增加腎血流量？\nA. Furosemide\nB. Ethacrynic acid\nC. Trichlormethiazide\nD. Bumetanide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種利尿劑較不會增加腎血流量？\nA. Furosemide\nB. Ethacrynic acid\nC. Trichlormethiazide\nD. Bumetanide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種利尿劑較不會增加腎血流量？\nA. Furosemide\nB. Ethacrynic acid\nC. Trichlormethiazide\nD. Bumetanide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種利尿劑較不會增加腎血流量？\nA. Furosemide\nB. Ethacrynic acid\nC. Trichlormethiazide\nD. Bumetanide\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.125", "False"]], [["-6.25", "False"]], [["-0.007568359375", "True"]], [["-6.25", "False"]]], "filtered_resps": [["-7.125", "False"], ["-6.25", "False"], ["-0.007568359375", "True"], ["-6.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "08d6ca8528958a2f7e1b4fba722b3f550cbcafc2275a37793884353aebf057ee", "prompt_hash": "e37b28a028cedc63570aba42d7f17b50d5ec00fd05d253226e69cdcad074f14b", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 153, "doc": {"question": "Silver sulfadiazine的結構含有下列那一種雜環？", "A": "pyrimidine", "B": "pyridazine", "C": "pyridine", "D": "isoxazole", "answer": "A", "questions": "Silver sulfadiazine的結構含有下列那一種雜環？", "choices": ["pyrimidine", "pyridazine", "pyridine", "isoxazole"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSilver sulfadiazine的結構含有下列那一種雜環？\nA. pyrimidine\nB. pyridazine\nC. pyridine\nD. isoxazole\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSilver sulfadiazine的結構含有下列那一種雜環？\nA. pyrimidine\nB. pyridazine\nC. pyridine\nD. isoxazole\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSilver sulfadiazine的結構含有下列那一種雜環？\nA. pyrimidine\nB. pyridazine\nC. pyridine\nD. isoxazole\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSilver sulfadiazine的結構含有下列那一種雜環？\nA. pyrimidine\nB. pyridazine\nC. pyridine\nD. isoxazole\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.10205078125", "True"]], [["-4.21875", "False"]], [["-4.09375", "False"]], [["-2.734375", "False"]]], "filtered_resps": [["-0.10205078125", "True"], ["-4.21875", "False"], ["-4.09375", "False"], ["-2.734375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7f0d70a119c03970057d68b1e9c2ffec521bf829c3d3a1d531218b2d3de452b8", "prompt_hash": "c1a21a533b018b03c10cfb0b642bd66f0e77ae9ff0fb96cabf470a6fe7dd05a3", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 154, "doc": {"question": "下列何種DPP-IV抑制劑具有xanthine結構？", "A": "linagliptin", "B": "vildagliptin", "C": "saxagliptin", "D": "alogliptin", "answer": "A", "questions": "下列何種DPP-IV抑制劑具有xanthine結構？", "choices": ["linagliptin", "vildagliptin", "saxagliptin", "alogliptin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種DPP-IV抑制劑具有xanthine結構？\nA. linagliptin\nB. vildagliptin\nC. saxagliptin\nD. alogliptin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種DPP-IV抑制劑具有xanthine結構？\nA. linagliptin\nB. vildagliptin\nC. saxagliptin\nD. alogliptin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種DPP-IV抑制劑具有xanthine結構？\nA. linagliptin\nB. vildagliptin\nC. saxagliptin\nD. alogliptin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種DPP-IV抑制劑具有xanthine結構？\nA. linagliptin\nB. vildagliptin\nC. saxagliptin\nD. alogliptin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.03515625", "True"]], [["-4.78125", "False"]], [["-4.65625", "False"]], [["-4.28125", "False"]]], "filtered_resps": [["-0.03515625", "True"], ["-4.78125", "False"], ["-4.65625", "False"], ["-4.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6b1693bd3864565f149500f65e3e6f92470fc32149f4624eff3dfb8dea6c95c6", "prompt_hash": "94f491d09c5048ed42a8ff1a98af61e1958c6b6898bdcedc23d8290c8f273660", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 155, "doc": {"question": "下列有關降血脂fibrates類藥物之敘述，何者錯誤？", "A": "具有加強抗凝血藥物（anticoagulant）之作用", "B": "fenofibrate可與statin一起併用", "C": "適用於肝臟及腎臟缺損之病人", "D": "可導致膽結石（gallstones）形成", "answer": "C", "questions": "下列有關降血脂fibrates類藥物之敘述，何者錯誤？", "choices": ["具有加強抗凝血藥物（anticoagulant）之作用", "fenofibrate可與statin一起併用", "適用於肝臟及腎臟缺損之病人", "可導致膽結石（gallstones）形成"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血脂fibrates類藥物之敘述，何者錯誤？\nA. 具有加強抗凝血藥物（anticoagulant）之作用\nB. fenofibrate可與statin一起併用\nC. 適用於肝臟及腎臟缺損之病人\nD. 可導致膽結石（gallstones）形成\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血脂fibrates類藥物之敘述，何者錯誤？\nA. 具有加強抗凝血藥物（anticoagulant）之作用\nB. fenofibrate可與statin一起併用\nC. 適用於肝臟及腎臟缺損之病人\nD. 可導致膽結石（gallstones）形成\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血脂fibrates類藥物之敘述，何者錯誤？\nA. 具有加強抗凝血藥物（anticoagulant）之作用\nB. fenofibrate可與statin一起併用\nC. 適用於肝臟及腎臟缺損之病人\nD. 可導致膽結石（gallstones）形成\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血脂fibrates類藥物之敘述，何者錯誤？\nA. 具有加強抗凝血藥物（anticoagulant）之作用\nB. fenofibrate可與statin一起併用\nC. 適用於肝臟及腎臟缺損之病人\nD. 可導致膽結石（gallstones）形成\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.546875", "False"]], [["-5.28125", "False"]], [["-0.041259765625", "True"]], [["-8.3125", "False"]]], "filtered_resps": [["-3.546875", "False"], ["-5.28125", "False"], ["-0.041259765625", "True"], ["-8.3125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3a9c3eefd17bf65f89ffdf63e4f9ceb0f665f9f932adc8256b288ac796410dd2", "prompt_hash": "f267219c7b5b7a4aa4c6c1bb1a8b9ae29e597bddf814af6b70931424ab2a4cb6", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 156, "doc": {"question": "下列何者經CYP3A4作用後的代謝產物為fexofenadine？", "A": "acrivastine", "B": "loratadine", "C": "hydroxyzine", "D": "terfenadine", "answer": "D", "questions": "下列何者經CYP3A4作用後的代謝產物為fexofenadine？", "choices": ["acrivastine", "loratadine", "hydroxyzine", "terfenadine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者經CYP3A4作用後的代謝產物為fexofenadine？\nA. acrivastine\nB. loratadine\nC. hydroxyzine\nD. terfenadine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者經CYP3A4作用後的代謝產物為fexofenadine？\nA. acrivastine\nB. loratadine\nC. hydroxyzine\nD. terfenadine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者經CYP3A4作用後的代謝產物為fexofenadine？\nA. acrivastine\nB. loratadine\nC. hydroxyzine\nD. terfenadine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者經CYP3A4作用後的代謝產物為fexofenadine？\nA. acrivastine\nB. loratadine\nC. hydroxyzine\nD. terfenadine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.1875", "False"]], [["-3.0625", "False"]], [["-6.3125", "False"]], [["-0.056396484375", "True"]]], "filtered_resps": [["-5.1875", "False"], ["-3.0625", "False"], ["-6.3125", "False"], ["-0.056396484375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0c6570585510f7aef7bdacaef5d93cea95400379299d25dbd7aad35e8af37418", "prompt_hash": "7d6bd214e34b9da25ef9f6a050c3acb5d04d11366db88c73666307ca6186c260", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 157, "doc": {"question": "使用heparin做為治療深層靜脈栓塞症若發生肝素引起血小板低下（heparin-induced thrombocytopenia, HIT） 時，應停用heparin，可改以下列何者作替代抗凝劑？", "A": "danaparoid", "B": "argatroban", "C": "enoxaparin", "D": "dalteparin", "answer": "B", "questions": "使用heparin做為治療深層靜脈栓塞症若發生肝素引起血小板低下（heparin-induced thrombocytopenia, HIT） 時，應停用heparin，可改以下列何者作替代抗凝劑？", "choices": ["danaparoid", "argatroban", "enoxaparin", "dalteparin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用heparin做為治療深層靜脈栓塞症若發生肝素引起血小板低下（heparin-induced thrombocytopenia, HIT） 時，應停用heparin，可改以下列何者作替代抗凝劑？\nA. danaparoid\nB. argatroban\nC. enoxaparin\nD. dalteparin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用heparin做為治療深層靜脈栓塞症若發生肝素引起血小板低下（heparin-induced thrombocytopenia, HIT） 時，應停用heparin，可改以下列何者作替代抗凝劑？\nA. danaparoid\nB. argatroban\nC. enoxaparin\nD. dalteparin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用heparin做為治療深層靜脈栓塞症若發生肝素引起血小板低下（heparin-induced thrombocytopenia, HIT） 時，應停用heparin，可改以下列何者作替代抗凝劑？\nA. danaparoid\nB. argatroban\nC. enoxaparin\nD. dalteparin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用heparin做為治療深層靜脈栓塞症若發生肝素引起血小板低下（heparin-induced thrombocytopenia, HIT） 時，應停用heparin，可改以下列何者作替代抗凝劑？\nA. danaparoid\nB. argatroban\nC. enoxaparin\nD. dalteparin\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.375", "False"]], [["-0.007537841796875", "True"]], [["-8.125", "False"]], [["-6.625", "False"]]], "filtered_resps": [["-5.375", "False"], ["-0.007537841796875", "True"], ["-8.125", "False"], ["-6.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ef4ac48ce5b5bdbc6e8183d7278abc1b6466b18a5a7d3135d91289d3f78fbcab", "prompt_hash": "ddbb32ca08cf3656ebefc1ba42c8310324af00ca7ce1ab72d0bf006ec9cc4158", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 158, "doc": {"question": "下列何者為gonadotropin-releasing hormone（GnRH）受體拮抗劑，可以作為前列腺癌之治療用藥？", "A": "abarelix", "B": "abaloparatide", "C": "abatacept", "D": "abacavir", "answer": "A", "questions": "下列何者為gonadotropin-releasing hormone（GnRH）受體拮抗劑，可以作為前列腺癌之治療用藥？", "choices": ["abarelix", "abaloparatide", "abatacept", "abacavir"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為gonadotropin-releasing hormone（GnRH）受體拮抗劑，可以作為前列腺癌之治療用藥？\nA. abarelix\nB. abaloparatide\nC. abatacept\nD. abacavir\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為gonadotropin-releasing hormone（GnRH）受體拮抗劑，可以作為前列腺癌之治療用藥？\nA. abarelix\nB. abaloparatide\nC. abatacept\nD. abacavir\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為gonadotropin-releasing hormone（GnRH）受體拮抗劑，可以作為前列腺癌之治療用藥？\nA. abarelix\nB. abaloparatide\nC. abatacept\nD. abacavir\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為gonadotropin-releasing hormone（GnRH）受體拮抗劑，可以作為前列腺癌之治療用藥？\nA. abarelix\nB. abaloparatide\nC. abatacept\nD. abacavir\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0029449462890625", "True"]], [["-7.0", "False"]], [["-8.625", "False"]], [["-7.25", "False"]]], "filtered_resps": [["-0.0029449462890625", "True"], ["-7.0", "False"], ["-8.625", "False"], ["-7.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8fcd7a583d7cf0025bd0020b75e2afb6b62552cc7d799a9c01f9e7182320544e", "prompt_hash": "4482fe4e14c814daaa16acd2f01e7c130b671430e6d7af2c1469d2c33f8f42e6", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 159, "doc": {"question": "下列何者不屬於cysteinyl leukotrienes？", "A": "LTC4", "B": "LTB4", "C": "LTE4", "D": "LTD4", "answer": "B", "questions": "下列何者不屬於cysteinyl leukotrienes？", "choices": ["LTC4", "LTB4", "LTE4", "LTD4"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不屬於cysteinyl leukotrienes？\nA. LTC4\nB. LTB4\nC. LTE4\nD. LTD4\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不屬於cysteinyl leukotrienes？\nA. LTC4\nB. LTB4\nC. LTE4\nD. LTD4\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不屬於cysteinyl leukotrienes？\nA. LTC4\nB. LTB4\nC. LTE4\nD. LTD4\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不屬於cysteinyl leukotrienes？\nA. LTC4\nB. LTB4\nC. LTE4\nD. LTD4\nAnswer:", "arg_1": " D"}}, "resps": [[["-8.875", "False"]], [["-0.003204345703125", "True"]], [["-8.0", "False"]], [["-7.75", "False"]]], "filtered_resps": [["-8.875", "False"], ["-0.003204345703125", "True"], ["-8.0", "False"], ["-7.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a12b03833694b76455df33babc02b588161414b802928dccfe8a6d7e6db0a16f", "prompt_hash": "a5110dfd62c10b3208395cb53617dfbd1fe7c417cbe6a6252e55726968dcf739", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 160, "doc": {"question": "安非他命（amphetamine）是間接作用型擬交感神經藥物，造成突觸間隙生物胺神經傳導物質正腎上腺素或多巴胺濃度上升，增強其效應。下列作用機轉何者錯誤？", "A": "安非他命抑制正腎上腺素或多巴胺代謝酵素monoamine oxidase", "B": "安非他命藉由抑制細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET），抑制突觸間隙之正腎上腺素被突觸前神經末梢再回收", "C": "安非他命可藉由細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET）進入突觸前神經末梢，促使突觸前神經末梢內生物胺神經傳導物質排空", "D": "安非他命在突觸前神經末梢內，可藉由抑制突觸小囊之單胺類轉運體（vesicular monoamine transporter, VMAT），導致生物胺類神經傳導物不易進入突觸小囊", "answer": "B", "questions": "安非他命（amphetamine）是間接作用型擬交感神經藥物，造成突觸間隙生物胺神經傳導物質正腎上腺素或多巴胺濃度上升，增強其效應。下列作用機轉何者錯誤？", "choices": ["安非他命抑制正腎上腺素或多巴胺代謝酵素monoamine oxidase", "安非他命藉由抑制細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET），抑制突觸間隙之正腎上腺素被突觸前神經末梢再回收", "安非他命可藉由細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET）進入突觸前神經末梢，促使突觸前神經末梢內生物胺神經傳導物質排空", "安非他命在突觸前神經末梢內，可藉由抑制突觸小囊之單胺類轉運體（vesicular monoamine transporter, VMAT），導致生物胺類神經傳導物不易進入突觸小囊"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n安非他命（amphetamine）是間接作用型擬交感神經藥物，造成突觸間隙生物胺神經傳導物質正腎上腺素或多巴胺濃度上升，增強其效應。下列作用機轉何者錯誤？\nA. 安非他命抑制正腎上腺素或多巴胺代謝酵素monoamine oxidase\nB. 安非他命藉由抑制細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET），抑制突觸間隙之正腎上腺素被突觸前神經末梢再回收\nC. 安非他命可藉由細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET）進入突觸前神經末梢，促使突觸前神經末梢內生物胺神經傳導物質排空\nD. 安非他命在突觸前神經末梢內，可藉由抑制突觸小囊之單胺類轉運體（vesicular monoamine transporter, VMAT），導致生物胺類神經傳導物不易進入突觸小囊\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n安非他命（amphetamine）是間接作用型擬交感神經藥物，造成突觸間隙生物胺神經傳導物質正腎上腺素或多巴胺濃度上升，增強其效應。下列作用機轉何者錯誤？\nA. 安非他命抑制正腎上腺素或多巴胺代謝酵素monoamine oxidase\nB. 安非他命藉由抑制細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET），抑制突觸間隙之正腎上腺素被突觸前神經末梢再回收\nC. 安非他命可藉由細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET）進入突觸前神經末梢，促使突觸前神經末梢內生物胺神經傳導物質排空\nD. 安非他命在突觸前神經末梢內，可藉由抑制突觸小囊之單胺類轉運體（vesicular monoamine transporter, VMAT），導致生物胺類神經傳導物不易進入突觸小囊\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n安非他命（amphetamine）是間接作用型擬交感神經藥物，造成突觸間隙生物胺神經傳導物質正腎上腺素或多巴胺濃度上升，增強其效應。下列作用機轉何者錯誤？\nA. 安非他命抑制正腎上腺素或多巴胺代謝酵素monoamine oxidase\nB. 安非他命藉由抑制細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET），抑制突觸間隙之正腎上腺素被突觸前神經末梢再回收\nC. 安非他命可藉由細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET）進入突觸前神經末梢，促使突觸前神經末梢內生物胺神經傳導物質排空\nD. 安非他命在突觸前神經末梢內，可藉由抑制突觸小囊之單胺類轉運體（vesicular monoamine transporter, VMAT），導致生物胺類神經傳導物不易進入突觸小囊\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n安非他命（amphetamine）是間接作用型擬交感神經藥物，造成突觸間隙生物胺神經傳導物質正腎上腺素或多巴胺濃度上升，增強其效應。下列作用機轉何者錯誤？\nA. 安非他命抑制正腎上腺素或多巴胺代謝酵素monoamine oxidase\nB. 安非他命藉由抑制細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET），抑制突觸間隙之正腎上腺素被突觸前神經末梢再回收\nC. 安非他命可藉由細胞膜上之正腎上腺素轉運體（norepinephrine transporter, NET）進入突觸前神經末梢，促使突觸前神經末梢內生物胺神經傳導物質排空\nD. 安非他命在突觸前神經末梢內，可藉由抑制突觸小囊之單胺類轉運體（vesicular monoamine transporter, VMAT），導致生物胺類神經傳導物不易進入突觸小囊\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.5625", "False"]], [["-2.3125", "False"]], [["-1.1875", "False"]], [["-0.56640625", "True"]]], "filtered_resps": [["-3.5625", "False"], ["-2.3125", "False"], ["-1.1875", "False"], ["-0.56640625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fe0f8577fb26cc042977d481f1748b202011a17a31bc50a8876dfd074ae859f5", "prompt_hash": "70b0715832f269825cd3b9ea1f8be80e15acb8263890889b49ef11cd138f830c", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 161, "doc": {"question": "下列有關lomitapide之敘述，何者錯誤？", "A": "可抑制microsomal triglyceride transport protein", "B": "可降低VLDL生成", "C": "服藥時，宜避免飲用葡萄柚汁", "D": "具高水溶性與高生體可用率", "answer": "D", "questions": "下列有關lomitapide之敘述，何者錯誤？", "choices": ["可抑制microsomal triglyceride transport protein", "可降低VLDL生成", "服藥時，宜避免飲用葡萄柚汁", "具高水溶性與高生體可用率"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關lomitapide之敘述，何者錯誤？\nA. 可抑制microsomal triglyceride transport protein\nB. 可降低VLDL生成\nC. 服藥時，宜避免飲用葡萄柚汁\nD. 具高水溶性與高生體可用率\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關lomitapide之敘述，何者錯誤？\nA. 可抑制microsomal triglyceride transport protein\nB. 可降低VLDL生成\nC. 服藥時，宜避免飲用葡萄柚汁\nD. 具高水溶性與高生體可用率\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關lomitapide之敘述，何者錯誤？\nA. 可抑制microsomal triglyceride transport protein\nB. 可降低VLDL生成\nC. 服藥時，宜避免飲用葡萄柚汁\nD. 具高水溶性與高生體可用率\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關lomitapide之敘述，何者錯誤？\nA. 可抑制microsomal triglyceride transport protein\nB. 可降低VLDL生成\nC. 服藥時，宜避免飲用葡萄柚汁\nD. 具高水溶性與高生體可用率\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.15625", "False"]], [["-4.28125", "False"]], [["-5.53125", "False"]], [["-0.0341796875", "True"]]], "filtered_resps": [["-4.15625", "False"], ["-4.28125", "False"], ["-5.53125", "False"], ["-0.0341796875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9ff8d36a17a8a0fb26f084791069915ba47290955f1da63f877efde5d7325ab7", "prompt_hash": "8e2701d14dfc03617335548a4beaca75c47a2af249616b3349905993196bda7e", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 162, "doc": {"question": "下列與糖尿病用藥相關的敘述，何者錯誤？", "A": "amylin可與insulin共用，調控餐後血糖濃度", "B": "源自rDNA的human glucagon可避免狂牛病之風險", "C": "glucagon的作用與insulin相反", "D": "pramlintide與insulin併用，可以縮短胃排空時間", "answer": "D", "questions": "下列與糖尿病用藥相關的敘述，何者錯誤？", "choices": ["amylin可與insulin共用，調控餐後血糖濃度", "源自rDNA的human glucagon可避免狂牛病之風險", "glucagon的作用與insulin相反", "pramlintide與insulin併用，可以縮短胃排空時間"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列與糖尿病用藥相關的敘述，何者錯誤？\nA. amylin可與insulin共用，調控餐後血糖濃度\nB. 源自rDNA的human glucagon可避免狂牛病之風險\nC. glucagon的作用與insulin相反\nD. pramlintide與insulin併用，可以縮短胃排空時間\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列與糖尿病用藥相關的敘述，何者錯誤？\nA. amylin可與insulin共用，調控餐後血糖濃度\nB. 源自rDNA的human glucagon可避免狂牛病之風險\nC. glucagon的作用與insulin相反\nD. pramlintide與insulin併用，可以縮短胃排空時間\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列與糖尿病用藥相關的敘述，何者錯誤？\nA. amylin可與insulin共用，調控餐後血糖濃度\nB. 源自rDNA的human glucagon可避免狂牛病之風險\nC. glucagon的作用與insulin相反\nD. pramlintide與insulin併用，可以縮短胃排空時間\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列與糖尿病用藥相關的敘述，何者錯誤？\nA. amylin可與insulin共用，調控餐後血糖濃度\nB. 源自rDNA的human glucagon可避免狂牛病之風險\nC. glucagon的作用與insulin相反\nD. pramlintide與insulin併用，可以縮短胃排空時間\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.125", "False"]], [["-5.875", "False"]], [["-8.75", "False"]], [["-0.005584716796875", "True"]]], "filtered_resps": [["-6.125", "False"], ["-5.875", "False"], ["-8.75", "False"], ["-0.005584716796875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "799dd373d67b1afa6e4525b0786a2fcf3d47fa7d3063f6b10e0ee48376084527", "prompt_hash": "71fc5a7b1e07c42ed68dcb428090000d749d2cb11c6f1df2b5035d332f06fb56", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 163, "doc": {"question": "下列藥物分子量大小的比較，何者正確？", "A": "heparin＞fondaparinux＞dalteparin", "B": "heparin＞dalteparin＞fondaparinux", "C": "fondaparinux＞heparin＞dalteparin", "D": "dalteparin＞heparin＞fondaparinux", "answer": "B", "questions": "下列藥物分子量大小的比較，何者正確？", "choices": ["heparin＞fondaparinux＞dalteparin", "heparin＞dalteparin＞fondaparinux", "fondaparinux＞heparin＞dalteparin", "dalteparin＞heparin＞fondaparinux"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物分子量大小的比較，何者正確？\nA. heparin＞fondaparinux＞dalteparin\nB. heparin＞dalteparin＞fondaparinux\nC. fondaparinux＞heparin＞dalteparin\nD. dalteparin＞heparin＞fondaparinux\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物分子量大小的比較，何者正確？\nA. heparin＞fondaparinux＞dalteparin\nB. heparin＞dalteparin＞fondaparinux\nC. fondaparinux＞heparin＞dalteparin\nD. dalteparin＞heparin＞fondaparinux\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物分子量大小的比較，何者正確？\nA. heparin＞fondaparinux＞dalteparin\nB. heparin＞dalteparin＞fondaparinux\nC. fondaparinux＞heparin＞dalteparin\nD. dalteparin＞heparin＞fondaparinux\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物分子量大小的比較，何者正確？\nA. heparin＞fondaparinux＞dalteparin\nB. heparin＞dalteparin＞fondaparinux\nC. fondaparinux＞heparin＞dalteparin\nD. dalteparin＞heparin＞fondaparinux\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.25", "False"]], [["-1.0078125", "False"]], [["-0.75390625", "True"]], [["-2.875", "False"]]], "filtered_resps": [["-2.25", "False"], ["-1.0078125", "False"], ["-0.75390625", "True"], ["-2.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "30fc1f539b522620d591f6752c75b9abc156575f51cc0054936a29a8d2e09a02", "prompt_hash": "3ad5c890534cf0e7d24a51f956aca52f5ca39824b2198620c3e34f285ff1e409", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 164, "doc": {"question": "關於選擇性第二型環氧酶（cyclooxygenase-2）抑制劑之敘述，下列何者錯誤？", "A": "不易產生胃潰瘍", "B": "不易引起血管栓塞的風險", "C": "celecoxib受CYP2C9代謝", "D": "仍具有腎毒性的副作用", "answer": "B", "questions": "關於選擇性第二型環氧酶（cyclooxygenase-2）抑制劑之敘述，下列何者錯誤？", "choices": ["不易產生胃潰瘍", "不易引起血管栓塞的風險", "celecoxib受CYP2C9代謝", "仍具有腎毒性的副作用"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於選擇性第二型環氧酶（cyclooxygenase-2）抑制劑之敘述，下列何者錯誤？\nA. 不易產生胃潰瘍\nB. 不易引起血管栓塞的風險\nC. celecoxib受CYP2C9代謝\nD. 仍具有腎毒性的副作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於選擇性第二型環氧酶（cyclooxygenase-2）抑制劑之敘述，下列何者錯誤？\nA. 不易產生胃潰瘍\nB. 不易引起血管栓塞的風險\nC. celecoxib受CYP2C9代謝\nD. 仍具有腎毒性的副作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於選擇性第二型環氧酶（cyclooxygenase-2）抑制劑之敘述，下列何者錯誤？\nA. 不易產生胃潰瘍\nB. 不易引起血管栓塞的風險\nC. celecoxib受CYP2C9代謝\nD. 仍具有腎毒性的副作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於選擇性第二型環氧酶（cyclooxygenase-2）抑制劑之敘述，下列何者錯誤？\nA. 不易產生胃潰瘍\nB. 不易引起血管栓塞的風險\nC. celecoxib受CYP2C9代謝\nD. 仍具有腎毒性的副作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.171875", "False"]], [["-0.054443359375", "True"]], [["-5.1875", "False"]], [["-5.1875", "False"]]], "filtered_resps": [["-3.171875", "False"], ["-0.054443359375", "True"], ["-5.1875", "False"], ["-5.1875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2db92f52d60b0f3da33a2fcd074151685e253d3684a35918a3dae4bd7452fd22", "prompt_hash": "586368b2e32c44d45f75b63e6278a747e180937a14815b6f285908320f0b09f7", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 165, "doc": {"question": "下列何種藥不產生p-aminobenzoic acid代謝物，因此不易造成過敏現象？", "A": "lidocaine", "B": "benzocaine", "C": "procaine", "D": "chloroprocaine", "answer": "A", "questions": "下列何種藥不產生p-aminobenzoic acid代謝物，因此不易造成過敏現象？", "choices": ["lidocaine", "benzocaine", "procaine", "chloroprocaine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥不產生p-aminobenzoic acid代謝物，因此不易造成過敏現象？\nA. lidocaine\nB. benzocaine\nC. procaine\nD. chloroprocaine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥不產生p-aminobenzoic acid代謝物，因此不易造成過敏現象？\nA. lidocaine\nB. benzocaine\nC. procaine\nD. chloroprocaine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥不產生p-aminobenzoic acid代謝物，因此不易造成過敏現象？\nA. lidocaine\nB. benzocaine\nC. procaine\nD. chloroprocaine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥不產生p-aminobenzoic acid代謝物，因此不易造成過敏現象？\nA. lidocaine\nB. benzocaine\nC. procaine\nD. chloroprocaine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.22265625", "True"]], [["-2.59375", "False"]], [["-3.21875", "False"]], [["-2.46875", "False"]]], "filtered_resps": [["-0.22265625", "True"], ["-2.59375", "False"], ["-3.21875", "False"], ["-2.46875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f5ef382638fca9ed95f8535ade7cf37a3ec27df4cbfade6f6b1f32af457bdc23", "prompt_hash": "a74d1583f492544afcf655c92b35bb9bda736ca10e17ac1d3ad459f1b2191d91", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 166, "doc": {"question": "下列有關glucagon之敘述，何者正確？", "A": "藉由β-adrenoceptor呈現強心作用", "B": "一般劑量下，抑制胰島素釋放", "C": "常用於改善鬱血性心衰竭", "D": "可拮抗β-blocker之心臟症狀", "answer": "D", "questions": "下列有關glucagon之敘述，何者正確？", "choices": ["藉由β-adrenoceptor呈現強心作用", "一般劑量下，抑制胰島素釋放", "常用於改善鬱血性心衰竭", "可拮抗β-blocker之心臟症狀"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關glucagon之敘述，何者正確？\nA. 藉由β-adrenoceptor呈現強心作用\nB. 一般劑量下，抑制胰島素釋放\nC. 常用於改善鬱血性心衰竭\nD. 可拮抗β-blocker之心臟症狀\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關glucagon之敘述，何者正確？\nA. 藉由β-adrenoceptor呈現強心作用\nB. 一般劑量下，抑制胰島素釋放\nC. 常用於改善鬱血性心衰竭\nD. 可拮抗β-blocker之心臟症狀\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關glucagon之敘述，何者正確？\nA. 藉由β-adrenoceptor呈現強心作用\nB. 一般劑量下，抑制胰島素釋放\nC. 常用於改善鬱血性心衰竭\nD. 可拮抗β-blocker之心臟症狀\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關glucagon之敘述，何者正確？\nA. 藉由β-adrenoceptor呈現強心作用\nB. 一般劑量下，抑制胰島素釋放\nC. 常用於改善鬱血性心衰竭\nD. 可拮抗β-blocker之心臟症狀\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.8125", "False"]], [["-3.3125", "False"]], [["-4.8125", "False"]], [["-0.06982421875", "True"]]], "filtered_resps": [["-3.8125", "False"], ["-3.3125", "False"], ["-4.8125", "False"], ["-0.06982421875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f61cd7dd4a2c793ea4a95b0fc8485c9df1fc96ec03e99d6b19a943aa168a75c5", "prompt_hash": "00fafb653b1d1e04905dd0166ebaa8b52e978be0ef9104e02513e3eb4ba76033", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 167, "doc": {"question": "Misoprostol為下列何者之半合成衍生物？", "A": "PGJ2", "B": "PGE2", "C": "PGE1", "D": "PGD2", "answer": "C", "questions": "Misoprostol為下列何者之半合成衍生物？", "choices": ["PGJ2", "PGE2", "PGE1", "PGD2"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMisoprostol為下列何者之半合成衍生物？\nA. PGJ2\nB. PGE2\nC. PGE1\nD. PGD2\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMisoprostol為下列何者之半合成衍生物？\nA. PGJ2\nB. PGE2\nC. PGE1\nD. PGD2\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMisoprostol為下列何者之半合成衍生物？\nA. PGJ2\nB. PGE2\nC. PGE1\nD. PGD2\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMisoprostol為下列何者之半合成衍生物？\nA. PGJ2\nB. PGE2\nC. PGE1\nD. PGD2\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.59375", "False"]], [["-2.984375", "False"]], [["-0.10791015625", "True"]], [["-3.359375", "False"]]], "filtered_resps": [["-4.59375", "False"], ["-2.984375", "False"], ["-0.10791015625", "True"], ["-3.359375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "cd4b2009b06bdf18faab5644cc54f55cde633f733daf6e46851f8cfb2b107a9c", "prompt_hash": "73c7bfdcaf4d61a5702cad8de8b0c785d82048e98fffca8e5f0f9ad837fdac80", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 168, "doc": {"question": "下列化學治療藥物，何者不是抑制thymidylate synthase？", "A": "Capecitabine", "B": "5-Fluorouracil", "C": "Pemetrexed", "D": "Cytarabine", "answer": "D", "questions": "下列化學治療藥物，何者不是抑制thymidylate synthase？", "choices": ["Capecitabine", "5-Fluorouracil", "Pemetrexed", "Cytarabine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者不是抑制thymidylate synthase？\nA. Capecitabine\nB. 5-Fluorouracil\nC. Pemetrexed\nD. Cytarabine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者不是抑制thymidylate synthase？\nA. Capecitabine\nB. 5-Fluorouracil\nC. Pemetrexed\nD. Cytarabine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者不是抑制thymidylate synthase？\nA. Capecitabine\nB. 5-Fluorouracil\nC. Pemetrexed\nD. Cytarabine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者不是抑制thymidylate synthase？\nA. Capecitabine\nB. 5-Fluorouracil\nC. Pemetrexed\nD. Cytarabine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.625", "False"]], [["-6.875", "False"]], [["-6.625", "False"]], [["-0.007537841796875", "True"]]], "filtered_resps": [["-5.625", "False"], ["-6.875", "False"], ["-6.625", "False"], ["-0.007537841796875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fbca5f78ae76b9ee6bc8ae998eec790503aae397b6b144d05023001459f9feba", "prompt_hash": "aab8b5c9ed4c8570d989d5221ddbd264b46bba71d67733b3cc10a893ffe58711", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 169, "doc": {"question": "下列何者不是clorazepate的代謝途徑？", "A": "N-demethylation", "B": "3-hydroxylation", "C": "glucuronidation", "D": "decarboxylation", "answer": "A", "questions": "下列何者不是clorazepate的代謝途徑？", "choices": ["N-demethylation", "3-hydroxylation", "glucuronidation", "decarboxylation"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是clorazepate的代謝途徑？\nA. N-demethylation\nB. 3-hydroxylation\nC. glucuronidation\nD. decarboxylation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是clorazepate的代謝途徑？\nA. N-demethylation\nB. 3-hydroxylation\nC. glucuronidation\nD. decarboxylation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是clorazepate的代謝途徑？\nA. N-demethylation\nB. 3-hydroxylation\nC. glucuronidation\nD. decarboxylation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是clorazepate的代謝途徑？\nA. N-demethylation\nB. 3-hydroxylation\nC. glucuronidation\nD. decarboxylation\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.953125", "False"]], [["-0.451171875", "True"]], [["-2.578125", "False"]], [["-1.453125", "False"]]], "filtered_resps": [["-3.953125", "False"], ["-0.451171875", "True"], ["-2.578125", "False"], ["-1.453125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4054b332aed42f89105bffcdce5e76fe1be727675ab02e53500860a2f00999cd", "prompt_hash": "b20aa3950f417d2ae5802fafdb8813541ed0c88883a1687c4b0543c3723c6dee", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 170, "doc": {"question": "下列何者為微生物ubiquinone reductase的抑制劑？", "A": "atovaquone", "B": "diloxanide furoate", "C": "pentamidine", "D": "eflornithine", "answer": "A", "questions": "下列何者為微生物ubiquinone reductase的抑制劑？", "choices": ["atovaquone", "diloxanide furoate", "pentamidine", "eflornithine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為微生物ubiquinone reductase的抑制劑？\nA. atovaquone\nB. diloxanide furoate\nC. pentamidine\nD. eflornithine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為微生物ubiquinone reductase的抑制劑？\nA. atovaquone\nB. diloxanide furoate\nC. pentamidine\nD. eflornithine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為微生物ubiquinone reductase的抑制劑？\nA. atovaquone\nB. diloxanide furoate\nC. pentamidine\nD. eflornithine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為微生物ubiquinone reductase的抑制劑？\nA. atovaquone\nB. diloxanide furoate\nC. pentamidine\nD. eflornithine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.01611328125", "True"]], [["-5.65625", "False"]], [["-5.90625", "False"]], [["-5.15625", "False"]]], "filtered_resps": [["-0.01611328125", "True"], ["-5.65625", "False"], ["-5.90625", "False"], ["-5.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "373d66beb0ef6f3efed4ed0756409b143bb45cb1c8d7cdf2dbdbfa96ea67bfc1", "prompt_hash": "ee5aa2fa470c116f2aee23b4e4d4b996705ae1969729f7275c98714946c59837", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 171, "doc": {"question": "下列化學治療藥物，何者可以抑制tubulin polymerization？", "A": "vinorelbine", "B": "paclitaxel", "C": "cladribine", "D": "topotecan", "answer": "A", "questions": "下列化學治療藥物，何者可以抑制tubulin polymerization？", "choices": ["vinorelbine", "paclitaxel", "cladribine", "topotecan"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者可以抑制tubulin polymerization？\nA. vinorelbine\nB. paclitaxel\nC. cladribine\nD. topotecan\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者可以抑制tubulin polymerization？\nA. vinorelbine\nB. paclitaxel\nC. cladribine\nD. topotecan\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者可以抑制tubulin polymerization？\nA. vinorelbine\nB. paclitaxel\nC. cladribine\nD. topotecan\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者可以抑制tubulin polymerization？\nA. vinorelbine\nB. paclitaxel\nC. cladribine\nD. topotecan\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.033447265625", "True"]], [["-3.78125", "False"]], [["-6.15625", "False"]], [["-5.40625", "False"]]], "filtered_resps": [["-0.033447265625", "True"], ["-3.78125", "False"], ["-6.15625", "False"], ["-5.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b65ab37954a57b286a41da0e9eb2d7357324d68b9f3666dcd1a2d045653878d1", "prompt_hash": "f736a04414cd341f6c98e460b8d60d8baa841c84649f9f1b3525bedada4abf49", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 172, "doc": {"question": "下列第三代cephalosporin中，何者結構無C-3側鏈？", "A": "ceftriaxone", "B": "cefdinir", "C": "cefixime", "D": "ceftibuten", "answer": "D", "questions": "下列第三代cephalosporin中，何者結構無C-3側鏈？", "choices": ["ceftriaxone", "cefdinir", "cefixime", "ceftibuten"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列第三代cephalosporin中，何者結構無C-3側鏈？\nA. ceftriaxone\nB. cefdinir\nC. cefixime\nD. ceftibuten\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列第三代cephalosporin中，何者結構無C-3側鏈？\nA. ceftriaxone\nB. cefdinir\nC. cefixime\nD. ceftibuten\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列第三代cephalosporin中，何者結構無C-3側鏈？\nA. ceftriaxone\nB. cefdinir\nC. cefixime\nD. ceftibuten\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列第三代cephalosporin中，何者結構無C-3側鏈？\nA. ceftriaxone\nB. cefdinir\nC. cefixime\nD. ceftibuten\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.640625", "False"]], [["-2.640625", "False"]], [["-3.265625", "False"]], [["-0.146484375", "True"]]], "filtered_resps": [["-3.640625", "False"], ["-2.640625", "False"], ["-3.265625", "False"], ["-0.146484375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "91b1d51d93270c00032416d438d175fa7cceffcfb7c4a3bc13a9dc0073b5f385", "prompt_hash": "01df6ebd423d6f8e0c252556a39ccb5be273d3f1fb0fd914c15d5ff1c2b763e0", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 173, "doc": {"question": "下列何種藥物可用以治療懼曠症（agoraphobia）？", "A": "Alprazolam", "B": "Buspirone", "C": "Zaleplon", "D": "Propranolol", "answer": "A", "questions": "下列何種藥物可用以治療懼曠症（agoraphobia）？", "choices": ["Alprazolam", "Buspirone", "Zaleplon", "Propranolol"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可用以治療懼曠症（agoraphobia）？\nA. Alprazolam\nB. Buspirone\nC. Zaleplon\nD. Propranolol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可用以治療懼曠症（agoraphobia）？\nA. Alprazolam\nB. Buspirone\nC. Zaleplon\nD. Propranolol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可用以治療懼曠症（agoraphobia）？\nA. Alprazolam\nB. Buspirone\nC. Zaleplon\nD. Propranolol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可用以治療懼曠症（agoraphobia）？\nA. Alprazolam\nB. Buspirone\nC. Zaleplon\nD. Propranolol\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.09765625", "True"]], [["-6.34375", "False"]], [["-5.71875", "False"]], [["-2.46875", "False"]]], "filtered_resps": [["-0.09765625", "True"], ["-6.34375", "False"], ["-5.71875", "False"], ["-2.46875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b92dbff47b7365b929eb71268e2fa68876b4008e4d641fc8b689e701a02e7c37", "prompt_hash": "3e18cbc3417a03fc66f4996610f54c12712bbcae4cdf245f7c2430f9fe75f83c", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 174, "doc": {"question": "下列何者為局部麻醉劑tetracaine活性明顯高於procaine之主因？", "A": "烷胺上取代基不同", "B": "芳香胺上取代基不同", "C": "pKa不同", "D": "酯與烷胺間碳鏈長度不同", "answer": "B", "questions": "下列何者為局部麻醉劑tetracaine活性明顯高於procaine之主因？", "choices": ["烷胺上取代基不同", "芳香胺上取代基不同", "pKa不同", "酯與烷胺間碳鏈長度不同"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為局部麻醉劑tetracaine活性明顯高於procaine之主因？\nA. 烷胺上取代基不同\nB. 芳香胺上取代基不同\nC. pKa不同\nD. 酯與烷胺間碳鏈長度不同\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為局部麻醉劑tetracaine活性明顯高於procaine之主因？\nA. 烷胺上取代基不同\nB. 芳香胺上取代基不同\nC. pKa不同\nD. 酯與烷胺間碳鏈長度不同\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為局部麻醉劑tetracaine活性明顯高於procaine之主因？\nA. 烷胺上取代基不同\nB. 芳香胺上取代基不同\nC. pKa不同\nD. 酯與烷胺間碳鏈長度不同\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為局部麻醉劑tetracaine活性明顯高於procaine之主因？\nA. 烷胺上取代基不同\nB. 芳香胺上取代基不同\nC. pKa不同\nD. 酯與烷胺間碳鏈長度不同\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.03125", "False"]], [["-0.0159912109375", "True"]], [["-6.53125", "False"]], [["-5.78125", "False"]]], "filtered_resps": [["-5.03125", "False"], ["-0.0159912109375", "True"], ["-6.53125", "False"], ["-5.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c89952eed6b0353adb15a24d91b9d1006d1168b217ab6e39c008c7e73f90f301", "prompt_hash": "9394b855256381372309b0fb3525b60ad6bb07c98e85572df75076ae57e9d4bb", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 175, "doc": {"question": "下列何者為thioamides減少甲狀腺素分泌的機轉？", "A": "抑制甲狀腺球蛋白的合成", "B": "抑制甲狀腺素的合成", "C": "抑制碘離子的吸收", "D": "抑制T3的去碘化作用", "answer": "B", "questions": "下列何者為thioamides減少甲狀腺素分泌的機轉？", "choices": ["抑制甲狀腺球蛋白的合成", "抑制甲狀腺素的合成", "抑制碘離子的吸收", "抑制T3的去碘化作用"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為thioamides減少甲狀腺素分泌的機轉？\nA. 抑制甲狀腺球蛋白的合成\nB. 抑制甲狀腺素的合成\nC. 抑制碘離子的吸收\nD. 抑制T3的去碘化作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為thioamides減少甲狀腺素分泌的機轉？\nA. 抑制甲狀腺球蛋白的合成\nB. 抑制甲狀腺素的合成\nC. 抑制碘離子的吸收\nD. 抑制T3的去碘化作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為thioamides減少甲狀腺素分泌的機轉？\nA. 抑制甲狀腺球蛋白的合成\nB. 抑制甲狀腺素的合成\nC. 抑制碘離子的吸收\nD. 抑制T3的去碘化作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為thioamides減少甲狀腺素分泌的機轉？\nA. 抑制甲狀腺球蛋白的合成\nB. 抑制甲狀腺素的合成\nC. 抑制碘離子的吸收\nD. 抑制T3的去碘化作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.15625", "False"]], [["-0.0277099609375", "True"]], [["-5.28125", "False"]], [["-4.15625", "False"]]], "filtered_resps": [["-5.15625", "False"], ["-0.0277099609375", "True"], ["-5.28125", "False"], ["-4.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0d71ea8c0767ad2fac1563526c12005b9eb9b25c161542230cb457ea20273706", "prompt_hash": "bc814cbb8e7f4e4f7391943e4bcf56c509019e311ceedb7c8c32fb0b42143a86", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 176, "doc": {"question": "下列給藥方式中，何者的bioavailability為100%？", "A": "口服（oral）給藥", "B": "鞘內（intrathecal）給藥", "C": "吸入（inhalation）給藥", "D": "直腸（rectal）給藥", "answer": "B", "questions": "下列給藥方式中，何者的bioavailability為100%？", "choices": ["口服（oral）給藥", "鞘內（intrathecal）給藥", "吸入（inhalation）給藥", "直腸（rectal）給藥"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式中，何者的bioavailability為100%？\nA. 口服（oral）給藥\nB. 鞘內（intrathecal）給藥\nC. 吸入（inhalation）給藥\nD. 直腸（rectal）給藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式中，何者的bioavailability為100%？\nA. 口服（oral）給藥\nB. 鞘內（intrathecal）給藥\nC. 吸入（inhalation）給藥\nD. 直腸（rectal）給藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式中，何者的bioavailability為100%？\nA. 口服（oral）給藥\nB. 鞘內（intrathecal）給藥\nC. 吸入（inhalation）給藥\nD. 直腸（rectal）給藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式中，何者的bioavailability為100%？\nA. 口服（oral）給藥\nB. 鞘內（intrathecal）給藥\nC. 吸入（inhalation）給藥\nD. 直腸（rectal）給藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.75", "False"]], [["-0.01312255859375", "True"]], [["-5.625", "False"]], [["-4.875", "False"]]], "filtered_resps": [["-6.75", "False"], ["-0.01312255859375", "True"], ["-5.625", "False"], ["-4.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d1602f54ad7923aeff82d6c8d73e846a46c46a453d12288aadfd88fef6da6d70", "prompt_hash": "56cea40ffdad8b02d58ef5d6dc6a31f3b72ac2c97375db38e79336e5389a2cd1", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 177, "doc": {"question": "下列關於停經後荷爾蒙治療（postmenopausal hormonal therapy）之敘述，何者錯誤？", "A": "主要是回補黃體素製劑（progestins）而改善停經後所引起之症狀", "B": "可能增加發生子宮內膜癌（endometrial carcinoma）的風險", "C": "可預防停經後骨密度降低", "D": "不會明顯影響血漿中三酸甘油酯濃度", "answer": "A", "questions": "下列關於停經後荷爾蒙治療（postmenopausal hormonal therapy）之敘述，何者錯誤？", "choices": ["主要是回補黃體素製劑（progestins）而改善停經後所引起之症狀", "可能增加發生子宮內膜癌（endometrial carcinoma）的風險", "可預防停經後骨密度降低", "不會明顯影響血漿中三酸甘油酯濃度"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於停經後荷爾蒙治療（postmenopausal hormonal therapy）之敘述，何者錯誤？\nA. 主要是回補黃體素製劑（progestins）而改善停經後所引起之症狀\nB. 可能增加發生子宮內膜癌（endometrial carcinoma）的風險\nC. 可預防停經後骨密度降低\nD. 不會明顯影響血漿中三酸甘油酯濃度\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於停經後荷爾蒙治療（postmenopausal hormonal therapy）之敘述，何者錯誤？\nA. 主要是回補黃體素製劑（progestins）而改善停經後所引起之症狀\nB. 可能增加發生子宮內膜癌（endometrial carcinoma）的風險\nC. 可預防停經後骨密度降低\nD. 不會明顯影響血漿中三酸甘油酯濃度\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於停經後荷爾蒙治療（postmenopausal hormonal therapy）之敘述，何者錯誤？\nA. 主要是回補黃體素製劑（progestins）而改善停經後所引起之症狀\nB. 可能增加發生子宮內膜癌（endometrial carcinoma）的風險\nC. 可預防停經後骨密度降低\nD. 不會明顯影響血漿中三酸甘油酯濃度\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於停經後荷爾蒙治療（postmenopausal hormonal therapy）之敘述，何者錯誤？\nA. 主要是回補黃體素製劑（progestins）而改善停經後所引起之症狀\nB. 可能增加發生子宮內膜癌（endometrial carcinoma）的風險\nC. 可預防停經後骨密度降低\nD. 不會明顯影響血漿中三酸甘油酯濃度\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.54296875", "True"]], [["-4.65625", "False"]], [["-4.78125", "False"]], [["-0.91796875", "False"]]], "filtered_resps": [["-0.54296875", "True"], ["-4.65625", "False"], ["-4.78125", "False"], ["-0.91796875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "75f2908daf1cd6c06458e8e63a208f336baf866fda2db2f79182e1862d0767f8", "prompt_hash": "7ebd6096b6884a581f5916376f020d2e8a9ea7a3381a5daf2e45155075f50757", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 178, "doc": {"question": "下列何種利尿劑易使肝硬化病人造成昏迷？", "A": "Hydrochlorothiazide", "B": "Acetazolamide", "C": "Furosemide", "D": "Amiloride", "answer": "B", "questions": "下列何種利尿劑易使肝硬化病人造成昏迷？", "choices": ["Hydrochlorothiazide", "Acetazolamide", "Furosemide", "Amiloride"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑易使肝硬化病人造成昏迷？\nA. Hydrochlorothiazide\nB. Acetazolamide\nC. Furosemide\nD. Amiloride\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑易使肝硬化病人造成昏迷？\nA. Hydrochlorothiazide\nB. Acetazolamide\nC. Furosemide\nD. Amiloride\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑易使肝硬化病人造成昏迷？\nA. Hydrochlorothiazide\nB. Acetazolamide\nC. Furosemide\nD. Amiloride\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑易使肝硬化病人造成昏迷？\nA. Hydrochlorothiazide\nB. Acetazolamide\nC. Furosemide\nD. Amiloride\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.40625", "False"]], [["-0.022705078125", "True"]], [["-4.78125", "False"]], [["-5.03125", "False"]]], "filtered_resps": [["-5.40625", "False"], ["-0.022705078125", "True"], ["-4.78125", "False"], ["-5.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bdf7dc60366ba8cfa3df5a1538366d179957758c694957b7928f50a17994a6ce", "prompt_hash": "3bad950d4a5756c4e1f12a6839f922d872611a267268c5601e1520e368741f32", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 179, "doc": {"question": "下列有關對 ezetimibe 結構與活性之敘述，何者錯誤？", "A": "具有β-lactam 結構", "B": "phenolic 基團改成 p-methoxyphenyl 仍有活性", "C": "p-fluorophenyl 之 fluoro 取代，可延長作用時間", "D": "aliphatic hydroxyl 改成 aliphatic methoxy 則活性提高", "answer": "D", "questions": "下列有關對 ezetimibe 結構與活性之敘述，何者錯誤？", "choices": ["具有β-lactam 結構", "phenolic 基團改成 p-methoxyphenyl 仍有活性", "p-fluorophenyl 之 fluoro 取代，可延長作用時間", "aliphatic hydroxyl 改成 aliphatic methoxy 則活性提高"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關對 ezetimibe 結構與活性之敘述，何者錯誤？\nA. 具有β-lactam 結構\nB. phenolic 基團改成 p-methoxyphenyl 仍有活性\nC. p-fluorophenyl 之 fluoro 取代，可延長作用時間\nD. aliphatic hydroxyl 改成 aliphatic methoxy 則活性提高\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關對 ezetimibe 結構與活性之敘述，何者錯誤？\nA. 具有β-lactam 結構\nB. phenolic 基團改成 p-methoxyphenyl 仍有活性\nC. p-fluorophenyl 之 fluoro 取代，可延長作用時間\nD. aliphatic hydroxyl 改成 aliphatic methoxy 則活性提高\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關對 ezetimibe 結構與活性之敘述，何者錯誤？\nA. 具有β-lactam 結構\nB. phenolic 基團改成 p-methoxyphenyl 仍有活性\nC. p-fluorophenyl 之 fluoro 取代，可延長作用時間\nD. aliphatic hydroxyl 改成 aliphatic methoxy 則活性提高\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關對 ezetimibe 結構與活性之敘述，何者錯誤？\nA. 具有β-lactam 結構\nB. phenolic 基團改成 p-methoxyphenyl 仍有活性\nC. p-fluorophenyl 之 fluoro 取代，可延長作用時間\nD. aliphatic hydroxyl 改成 aliphatic methoxy 則活性提高\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.73828125", "True"]], [["-2.109375", "False"]], [["-2.609375", "False"]], [["-1.1171875", "False"]]], "filtered_resps": [["-0.73828125", "True"], ["-2.109375", "False"], ["-2.609375", "False"], ["-1.1171875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4c7d747632520a003bc6db95defd767b5a2d4a208f18feed250970855656f868", "prompt_hash": "26d0ff7d74139f990e2b65a84dad810e5f9ac086e2b915f675d6ef84879f050c", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 180, "doc": {"question": "大部分tyrosine kinase抑制劑的作用機制，主要是競爭下列何者在酵素之結合部位？", "A": "GTP", "B": "ADP", "C": "GDP", "D": "ATP", "answer": "D", "questions": "大部分tyrosine kinase抑制劑的作用機制，主要是競爭下列何者在酵素之結合部位？", "choices": ["GTP", "ADP", "GDP", "ATP"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n大部分tyrosine kinase抑制劑的作用機制，主要是競爭下列何者在酵素之結合部位？\nA. GTP\nB. ADP\nC. GDP\nD. ATP\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n大部分tyrosine kinase抑制劑的作用機制，主要是競爭下列何者在酵素之結合部位？\nA. GTP\nB. ADP\nC. GDP\nD. ATP\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n大部分tyrosine kinase抑制劑的作用機制，主要是競爭下列何者在酵素之結合部位？\nA. GTP\nB. ADP\nC. GDP\nD. ATP\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n大部分tyrosine kinase抑制劑的作用機制，主要是競爭下列何者在酵素之結合部位？\nA. GTP\nB. ADP\nC. GDP\nD. ATP\nAnswer:", "arg_1": " D"}}, "resps": [[["-8.0", "False"]], [["-7.125", "False"]], [["-7.625", "False"]], [["-0.0020751953125", "True"]]], "filtered_resps": [["-8.0", "False"], ["-7.125", "False"], ["-7.625", "False"], ["-0.0020751953125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "20aae2de5525dc322433f7ece0c60022386a3d4e928731ccb12dbdb24133fe3c", "prompt_hash": "31aa1191d90ef13c4cf5577a415b300160f83e7ecc1188a3abc3c22d6166c596", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 181, "doc": {"question": "下列有關利尿劑triamterene與amiloride的敘述，何者錯誤？", "A": "amiloride具有aminopyrazine環", "B": "triamterene具有pteridine環", "C": "triamterene的鹼性比amiloride強", "D": "triamterene代謝物4'-hydroxytriamterene仍具利尿活性", "answer": "C", "questions": "下列有關利尿劑triamterene與amiloride的敘述，何者錯誤？", "choices": ["amiloride具有aminopyrazine環", "triamterene具有pteridine環", "triamterene的鹼性比amiloride強", "triamterene代謝物4'-hydroxytriamterene仍具利尿活性"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關利尿劑triamterene與amiloride的敘述，何者錯誤？\nA. amiloride具有aminopyrazine環\nB. triamterene具有pteridine環\nC. triamterene的鹼性比amiloride強\nD. triamterene代謝物4'-hydroxytriamterene仍具利尿活性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關利尿劑triamterene與amiloride的敘述，何者錯誤？\nA. amiloride具有aminopyrazine環\nB. triamterene具有pteridine環\nC. triamterene的鹼性比amiloride強\nD. triamterene代謝物4'-hydroxytriamterene仍具利尿活性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關利尿劑triamterene與amiloride的敘述，何者錯誤？\nA. amiloride具有aminopyrazine環\nB. triamterene具有pteridine環\nC. triamterene的鹼性比amiloride強\nD. triamterene代謝物4'-hydroxytriamterene仍具利尿活性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關利尿劑triamterene與amiloride的敘述，何者錯誤？\nA. amiloride具有aminopyrazine環\nB. triamterene具有pteridine環\nC. triamterene的鹼性比amiloride強\nD. triamterene代謝物4'-hydroxytriamterene仍具利尿活性\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.796875", "False"]], [["-4.4375", "False"]], [["-0.177734375", "True"]], [["-2.046875", "False"]]], "filtered_resps": [["-3.796875", "False"], ["-4.4375", "False"], ["-0.177734375", "True"], ["-2.046875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "62c16ec7a428f84e365e46c4c73a4027acfe4bfc73f1416253e4d8818d80ccab", "prompt_hash": "b04ec5ebfeb0262e0c16bdfa9c8239c4dba222c61a013e76c2775b2f96440846", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 182, "doc": {"question": "下列口服降血糖藥中，何者半衰期（T1/2）最長？", "A": "glyburide", "B": "glimepiride", "C": "chlorpropamide", "D": "acetohexamide", "answer": "C", "questions": "下列口服降血糖藥中，何者半衰期（T1/2）最長？", "choices": ["glyburide", "glimepiride", "chlorpropamide", "acetohexamide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列口服降血糖藥中，何者半衰期（T1/2）最長？\nA. glyburide\nB. glimepiride\nC. chlorpropamide\nD. acetohexamide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列口服降血糖藥中，何者半衰期（T1/2）最長？\nA. glyburide\nB. glimepiride\nC. chlorpropamide\nD. acetohexamide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列口服降血糖藥中，何者半衰期（T1/2）最長？\nA. glyburide\nB. glimepiride\nC. chlorpropamide\nD. acetohexamide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列口服降血糖藥中，何者半衰期（T1/2）最長？\nA. glyburide\nB. glimepiride\nC. chlorpropamide\nD. acetohexamide\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.5625", "False"]], [["-2.4375", "False"]], [["-0.43359375", "True"]], [["-1.6875", "False"]]], "filtered_resps": [["-2.5625", "False"], ["-2.4375", "False"], ["-0.43359375", "True"], ["-1.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fe516f16fc8b106e16689485ba0cb3a1cfa7a33732e4c6ec340f04203acac709", "prompt_hash": "8b630326819553bcd453c3fe8ac5f0e4321976a763459607ccb7d64cedc75ca6", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 183, "doc": {"question": "下列何種藥物可抑制正腎上腺素轉運體（norepinephrine transporter, NET），導致突觸間隙正腎上腺素濃度顯著上升，進而提升自主神經系統反應？", "A": "cannabinoid", "B": "reserpine", "C": "cocaine", "D": "nicotine", "answer": "C", "questions": "下列何種藥物可抑制正腎上腺素轉運體（norepinephrine transporter, NET），導致突觸間隙正腎上腺素濃度顯著上升，進而提升自主神經系統反應？", "choices": ["cannabinoid", "reserpine", "cocaine", "nicotine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可抑制正腎上腺素轉運體（norepinephrine transporter, NET），導致突觸間隙正腎上腺素濃度顯著上升，進而提升自主神經系統反應？\nA. cannabinoid\nB. reserpine\nC. cocaine\nD. nicotine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可抑制正腎上腺素轉運體（norepinephrine transporter, NET），導致突觸間隙正腎上腺素濃度顯著上升，進而提升自主神經系統反應？\nA. cannabinoid\nB. reserpine\nC. cocaine\nD. nicotine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可抑制正腎上腺素轉運體（norepinephrine transporter, NET），導致突觸間隙正腎上腺素濃度顯著上升，進而提升自主神經系統反應？\nA. cannabinoid\nB. reserpine\nC. cocaine\nD. nicotine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可抑制正腎上腺素轉運體（norepinephrine transporter, NET），導致突觸間隙正腎上腺素濃度顯著上升，進而提升自主神經系統反應？\nA. cannabinoid\nB. reserpine\nC. cocaine\nD. nicotine\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.40625", "False"]], [["-4.90625", "False"]], [["-0.018310546875", "True"]], [["-4.65625", "False"]]], "filtered_resps": [["-7.40625", "False"], ["-4.90625", "False"], ["-0.018310546875", "True"], ["-4.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0ad522880dd13b2c7d35237d0e9e647bb78e4ecf1c84d642254e63f668442df4", "prompt_hash": "0c47c36ef93345c397a507240153c8cce6c8eeb154574a6dd7363d409c944bef", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 184, "doc": {"question": "殺蟲劑parathion因使用頻繁，意外中毒事件時有所聞，下列何者最不適合作為治療parathion中毒藥物？", "A": "atropine", "B": "diacetylmonoxime", "C": "carbachol", "D": "pralidoxime", "answer": "C", "questions": "殺蟲劑parathion因使用頻繁，意外中毒事件時有所聞，下列何者最不適合作為治療parathion中毒藥物？", "choices": ["atropine", "diacetylmonoxime", "carbachol", "pralidoxime"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n殺蟲劑parathion因使用頻繁，意外中毒事件時有所聞，下列何者最不適合作為治療parathion中毒藥物？\nA. atropine\nB. diacetylmonoxime\nC. carbachol\nD. pralidoxime\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n殺蟲劑parathion因使用頻繁，意外中毒事件時有所聞，下列何者最不適合作為治療parathion中毒藥物？\nA. atropine\nB. diacetylmonoxime\nC. carbachol\nD. pralidoxime\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n殺蟲劑parathion因使用頻繁，意外中毒事件時有所聞，下列何者最不適合作為治療parathion中毒藥物？\nA. atropine\nB. diacetylmonoxime\nC. carbachol\nD. pralidoxime\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n殺蟲劑parathion因使用頻繁，意外中毒事件時有所聞，下列何者最不適合作為治療parathion中毒藥物？\nA. atropine\nB. diacetylmonoxime\nC. carbachol\nD. pralidoxime\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-4.53125", "False"]], [["-0.0247802734375", "True"]], [["-5.15625", "False"]]], "filtered_resps": [["-5.78125", "False"], ["-4.53125", "False"], ["-0.0247802734375", "True"], ["-5.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "12a48be1cb20bd369b4af6517bb91537d57269770aa977ab39f658be97243878", "prompt_hash": "029d12824982ae4b03b76d6985a76482464c34ed14349262ce93e8f72df04e45", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 185, "doc": {"question": "有一60公斤重之病人，其theophylline之廓清率為0.2 L/kg/hr，其分布體積（volume of distribution）為0.5 L/kg。若要馬上達到血中濃度為15 mg/L，則其loading dose應該是：", "A": "300 mg", "B": "180 mg", "C": "450 mg", "D": "150 mg", "answer": "C", "questions": "有一60公斤重之病人，其theophylline之廓清率為0.2 L/kg/hr，其分布體積（volume of distribution）為0.5 L/kg。若要馬上達到血中濃度為15 mg/L，則其loading dose應該是：", "choices": ["300 mg", "180 mg", "450 mg", "150 mg"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有一60公斤重之病人，其theophylline之廓清率為0.2 L/kg/hr，其分布體積（volume of distribution）為0.5 L/kg。若要馬上達到血中濃度為15 mg/L，則其loading dose應該是：\nA. 300 mg\nB. 180 mg\nC. 450 mg\nD. 150 mg\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有一60公斤重之病人，其theophylline之廓清率為0.2 L/kg/hr，其分布體積（volume of distribution）為0.5 L/kg。若要馬上達到血中濃度為15 mg/L，則其loading dose應該是：\nA. 300 mg\nB. 180 mg\nC. 450 mg\nD. 150 mg\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有一60公斤重之病人，其theophylline之廓清率為0.2 L/kg/hr，其分布體積（volume of distribution）為0.5 L/kg。若要馬上達到血中濃度為15 mg/L，則其loading dose應該是：\nA. 300 mg\nB. 180 mg\nC. 450 mg\nD. 150 mg\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有一60公斤重之病人，其theophylline之廓清率為0.2 L/kg/hr，其分布體積（volume of distribution）為0.5 L/kg。若要馬上達到血中濃度為15 mg/L，則其loading dose應該是：\nA. 300 mg\nB. 180 mg\nC. 450 mg\nD. 150 mg\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.015625", "False"]], [["-1.3828125", "False"]], [["-1.3828125", "False"]], [["-1.0078125", "True"]]], "filtered_resps": [["-2.015625", "False"], ["-1.3828125", "False"], ["-1.3828125", "False"], ["-1.0078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e5637bd9a20e47bfa0114bf420f048626ec6888cb62d9f2e5d86562b6a6af061", "prompt_hash": "aa974367598b696c41f90b6e4f3b753ba67a464072467dcc8e45e1e4c5ddea8c", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 186, "doc": {"question": "下列化學治療藥物，何者抑制骨髓的副作用最小？", "A": "Idarubicin", "B": "Bleomycin", "C": "Paclitaxel", "D": "Vincristine", "answer": "B", "questions": "下列化學治療藥物，何者抑制骨髓的副作用最小？", "choices": ["Idarubicin", "Bleomycin", "Paclitaxel", "Vincristine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者抑制骨髓的副作用最小？\nA. Idarubicin\nB. Bleomycin\nC. Paclitaxel\nD. Vincristine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者抑制骨髓的副作用最小？\nA. Idarubicin\nB. Bleomycin\nC. Paclitaxel\nD. Vincristine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者抑制骨髓的副作用最小？\nA. Idarubicin\nB. Bleomycin\nC. Paclitaxel\nD. Vincristine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列化學治療藥物，何者抑制骨髓的副作用最小？\nA. Idarubicin\nB. Bleomycin\nC. Paclitaxel\nD. Vincristine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.53125", "False"]], [["-0.02197265625", "True"]], [["-4.53125", "False"]], [["-5.15625", "False"]]], "filtered_resps": [["-5.53125", "False"], ["-0.02197265625", "True"], ["-4.53125", "False"], ["-5.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "62220ffb577d410f37fd020d55004411e30d44680fbdca7f5e1a0ee4512bcbf2", "prompt_hash": "993d8bdea81d429fd1e821050e06eca4dc42e897566ef5a126456e7666c67a11", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 187, "doc": {"question": "下列何種基因轉殖方式較易產生宿主免疫反應（host immune reaction）？", "A": "calcium phosphate", "B": "liposome-DNA", "C": "adenovirus", "D": "retrovirus", "answer": "C", "questions": "下列何種基因轉殖方式較易產生宿主免疫反應（host immune reaction）？", "choices": ["calcium phosphate", "liposome-DNA", "adenovirus", "retrovirus"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種基因轉殖方式較易產生宿主免疫反應（host immune reaction）？\nA. calcium phosphate\nB. liposome-DNA\nC. adenovirus\nD. retrovirus\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種基因轉殖方式較易產生宿主免疫反應（host immune reaction）？\nA. calcium phosphate\nB. liposome-DNA\nC. adenovirus\nD. retrovirus\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種基因轉殖方式較易產生宿主免疫反應（host immune reaction）？\nA. calcium phosphate\nB. liposome-DNA\nC. adenovirus\nD. retrovirus\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種基因轉殖方式較易產生宿主免疫反應（host immune reaction）？\nA. calcium phosphate\nB. liposome-DNA\nC. adenovirus\nD. retrovirus\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.9375", "False"]], [["-3.4375", "False"]], [["-0.0634765625", "True"]], [["-4.1875", "False"]]], "filtered_resps": [["-4.9375", "False"], ["-3.4375", "False"], ["-0.0634765625", "True"], ["-4.1875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "52d60f4331ab44a7e4eb45cc42bbb90cef3b324bbdc441a4bfa3a28e303fff22", "prompt_hash": "ac2bc595ae51c4deca7f94738384c7b5d289a120163f1ec5f84393851a535eba", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 188, "doc": {"question": "下列有關citalopram及其serotonin transporter（SERT）抑制活性的描述，何者錯誤？", "A": "主結構具isobenzothiophene環", "B": "對SERT親和力S＞R", "C": "代謝速率S＞R", "D": "對SERT選擇性S＞R", "answer": "A", "questions": "下列有關citalopram及其serotonin transporter（SERT）抑制活性的描述，何者錯誤？", "choices": ["主結構具isobenzothiophene環", "對SERT親和力S＞R", "代謝速率S＞R", "對SERT選擇性S＞R"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關citalopram及其serotonin transporter（SERT）抑制活性的描述，何者錯誤？\nA. 主結構具isobenzothiophene環\nB. 對SERT親和力S＞R\nC. 代謝速率S＞R\nD. 對SERT選擇性S＞R\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關citalopram及其serotonin transporter（SERT）抑制活性的描述，何者錯誤？\nA. 主結構具isobenzothiophene環\nB. 對SERT親和力S＞R\nC. 代謝速率S＞R\nD. 對SERT選擇性S＞R\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關citalopram及其serotonin transporter（SERT）抑制活性的描述，何者錯誤？\nA. 主結構具isobenzothiophene環\nB. 對SERT親和力S＞R\nC. 代謝速率S＞R\nD. 對SERT選擇性S＞R\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關citalopram及其serotonin transporter（SERT）抑制活性的描述，何者錯誤？\nA. 主結構具isobenzothiophene環\nB. 對SERT親和力S＞R\nC. 代謝速率S＞R\nD. 對SERT選擇性S＞R\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.0546875", "False"]], [["-1.8046875", "False"]], [["-0.92578125", "True"]], [["-2.421875", "False"]]], "filtered_resps": [["-1.0546875", "False"], ["-1.8046875", "False"], ["-0.92578125", "True"], ["-2.421875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "437610f9771b0aa0b6f9bf915d17965db230c6518e037503ec06b5869a835a69", "prompt_hash": "027fc535292c86fce800925ca417a2b579aad3a8146859c9129e1c902883fe54", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 189, "doc": {"question": "Heparin透過幾個糖分子上的陰離子，與antithrombin III結合？", "A": "6", "B": "3", "C": "4", "D": "5", "answer": "D", "questions": "Heparin透過幾個糖分子上的陰離子，與antithrombin III結合？", "choices": ["6", "3", "4", "5"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nHeparin透過幾個糖分子上的陰離子，與antithrombin III結合？\nA. 6\nB. 3\nC. 4\nD. 5\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nHeparin透過幾個糖分子上的陰離子，與antithrombin III結合？\nA. 6\nB. 3\nC. 4\nD. 5\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nHeparin透過幾個糖分子上的陰離子，與antithrombin III結合？\nA. 6\nB. 3\nC. 4\nD. 5\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nHeparin透過幾個糖分子上的陰離子，與antithrombin III結合？\nA. 6\nB. 3\nC. 4\nD. 5\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.4375", "False"]], [["-1.5625", "False"]], [["-2.1875", "False"]], [["-0.81640625", "True"]]], "filtered_resps": [["-1.4375", "False"], ["-1.5625", "False"], ["-2.1875", "False"], ["-0.81640625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8a14f6231316fa54411bb5122b6fe228b4e05c13c73ef411ae39035765567350", "prompt_hash": "28450ce415cb3d3d1886c569cac649bd975fec46c6415057e36a0d03610d5a81", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 190, "doc": {"question": "下列藥品在健康人的血液中，何者的解離態比例最高？", "A": "aspirin", "B": "warfarin", "C": "carbamazepine", "D": "acetaminophen", "answer": "A", "questions": "下列藥品在健康人的血液中，何者的解離態比例最高？", "choices": ["aspirin", "warfarin", "carbamazepine", "acetaminophen"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品在健康人的血液中，何者的解離態比例最高？\nA. aspirin\nB. warfarin\nC. carbamazepine\nD. acetaminophen\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品在健康人的血液中，何者的解離態比例最高？\nA. aspirin\nB. warfarin\nC. carbamazepine\nD. acetaminophen\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品在健康人的血液中，何者的解離態比例最高？\nA. aspirin\nB. warfarin\nC. carbamazepine\nD. acetaminophen\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品在健康人的血液中，何者的解離態比例最高？\nA. aspirin\nB. warfarin\nC. carbamazepine\nD. acetaminophen\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.8046875", "False"]], [["-1.6796875", "False"]], [["-2.5625", "False"]], [["-0.55859375", "True"]]], "filtered_resps": [["-1.8046875", "False"], ["-1.6796875", "False"], ["-2.5625", "False"], ["-0.55859375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "131d08acf23c09c7e05aaf572283fcece5e43d2b43d2255867b69a55319d3d0d", "prompt_hash": "2e04a4c25f5260d1b355bd9bdef0ce19513360fbf4cea01469ca755ff7289385", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 191, "doc": {"question": "Glimepiride主要經由何種酵素代謝，產生具有活性的代謝物？", "A": "CYP3A4", "B": "CYP2C19", "C": "CYP2C9", "D": "CYP2D6", "answer": "C", "questions": "Glimepiride主要經由何種酵素代謝，產生具有活性的代謝物？", "choices": ["CYP3A4", "CYP2C19", "CYP2C9", "CYP2D6"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGlimepiride主要經由何種酵素代謝，產生具有活性的代謝物？\nA. CYP3A4\nB. CYP2C19\nC. CYP2C9\nD. CYP2D6\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGlimepiride主要經由何種酵素代謝，產生具有活性的代謝物？\nA. CYP3A4\nB. CYP2C19\nC. CYP2C9\nD. CYP2D6\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGlimepiride主要經由何種酵素代謝，產生具有活性的代謝物？\nA. CYP3A4\nB. CYP2C19\nC. CYP2C9\nD. CYP2D6\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGlimepiride主要經由何種酵素代謝，產生具有活性的代謝物？\nA. CYP3A4\nB. CYP2C19\nC. CYP2C9\nD. CYP2D6\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.28125", "False"]], [["-1.5390625", "False"]], [["-0.287109375", "True"]], [["-4.03125", "False"]]], "filtered_resps": [["-4.28125", "False"], ["-1.5390625", "False"], ["-0.287109375", "True"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "00413d46b006ea400468850fc133a213a174121bc62c85e20b11903101fa1968", "prompt_hash": "0c2a94eaebbc44c50a7a008ae1d107e06434507ad9fa24da9e22b1d1c8cd8515", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 192, "doc": {"question": "Milrinone 具有強心作用可用於心衰竭治療，但亦容易引發心律不整，其作用機制為何？", "A": "phosphodiesterase isozyme 3（PDE3）inhibitor", "B": "calcium channel activator", "C": "cardiac myosin activator", "D": "Na+ /K+ pump inhibitor", "answer": "A", "questions": "Milrinone 具有強心作用可用於心衰竭治療，但亦容易引發心律不整，其作用機制為何？", "choices": ["phosphodiesterase isozyme 3（PDE3）inhibitor", "calcium channel activator", "cardiac myosin activator", "Na+ /K+ pump inhibitor"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMilrinone 具有強心作用可用於心衰竭治療，但亦容易引發心律不整，其作用機制為何？\nA. phosphodiesterase isozyme 3（PDE3）inhibitor\nB. calcium channel activator\nC. cardiac myosin activator\nD. Na+ /K+ pump inhibitor\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMilrinone 具有強心作用可用於心衰竭治療，但亦容易引發心律不整，其作用機制為何？\nA. phosphodiesterase isozyme 3（PDE3）inhibitor\nB. calcium channel activator\nC. cardiac myosin activator\nD. Na+ /K+ pump inhibitor\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMilrinone 具有強心作用可用於心衰竭治療，但亦容易引發心律不整，其作用機制為何？\nA. phosphodiesterase isozyme 3（PDE3）inhibitor\nB. calcium channel activator\nC. cardiac myosin activator\nD. Na+ /K+ pump inhibitor\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMilrinone 具有強心作用可用於心衰竭治療，但亦容易引發心律不整，其作用機制為何？\nA. phosphodiesterase isozyme 3（PDE3）inhibitor\nB. calcium channel activator\nC. cardiac myosin activator\nD. Na+ /K+ pump inhibitor\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.080078125", "True"]], [["-4.21875", "False"]], [["-3.328125", "False"]], [["-3.953125", "False"]]], "filtered_resps": [["-0.080078125", "True"], ["-4.21875", "False"], ["-3.328125", "False"], ["-3.953125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "024069f2cefdd83a99b943306ca8b20ccc3aa1b3a901dfd4a227ed73f1af1b1c", "prompt_hash": "531e222367b893206e13be2aced76426af09049b9c6b72d2df92a468af5f7e27", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 193, "doc": {"question": "下列何者是抗思覺失調症藥物（antipsychotics）產生錐體外毒性（extrapyramidal toxicity）之機制？", "A": "阻斷甲型腎上腺受體（α-adrenergic receptor）活性", "B": "阻斷毒蕈鹼受體（muscarinic receptor）活性", "C": "阻斷組織胺受體（histamine receptor）活性", "D": "阻斷多巴胺受體（dopaminergic receptor）活性", "answer": "D", "questions": "下列何者是抗思覺失調症藥物（antipsychotics）產生錐體外毒性（extrapyramidal toxicity）之機制？", "choices": ["阻斷甲型腎上腺受體（α-adrenergic receptor）活性", "阻斷毒蕈鹼受體（muscarinic receptor）活性", "阻斷組織胺受體（histamine receptor）活性", "阻斷多巴胺受體（dopaminergic receptor）活性"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是抗思覺失調症藥物（antipsychotics）產生錐體外毒性（extrapyramidal toxicity）之機制？\nA. 阻斷甲型腎上腺受體（α-adrenergic receptor）活性\nB. 阻斷毒蕈鹼受體（muscarinic receptor）活性\nC. 阻斷組織胺受體（histamine receptor）活性\nD. 阻斷多巴胺受體（dopaminergic receptor）活性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是抗思覺失調症藥物（antipsychotics）產生錐體外毒性（extrapyramidal toxicity）之機制？\nA. 阻斷甲型腎上腺受體（α-adrenergic receptor）活性\nB. 阻斷毒蕈鹼受體（muscarinic receptor）活性\nC. 阻斷組織胺受體（histamine receptor）活性\nD. 阻斷多巴胺受體（dopaminergic receptor）活性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是抗思覺失調症藥物（antipsychotics）產生錐體外毒性（extrapyramidal toxicity）之機制？\nA. 阻斷甲型腎上腺受體（α-adrenergic receptor）活性\nB. 阻斷毒蕈鹼受體（muscarinic receptor）活性\nC. 阻斷組織胺受體（histamine receptor）活性\nD. 阻斷多巴胺受體（dopaminergic receptor）活性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是抗思覺失調症藥物（antipsychotics）產生錐體外毒性（extrapyramidal toxicity）之機制？\nA. 阻斷甲型腎上腺受體（α-adrenergic receptor）活性\nB. 阻斷毒蕈鹼受體（muscarinic receptor）活性\nC. 阻斷組織胺受體（histamine receptor）活性\nD. 阻斷多巴胺受體（dopaminergic receptor）活性\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.5", "False"]], [["-5.25", "False"]], [["-6.5", "False"]], [["-0.01416015625", "True"]]], "filtered_resps": [["-5.5", "False"], ["-5.25", "False"], ["-6.5", "False"], ["-0.01416015625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6bea9411337afefd79d42b81a54c36a217613b891c5d4fe1a8f8ab705befabfb", "prompt_hash": "54e5d13d27cb22a01ee7311685f82fa5aba7ace757b7e03e01fe9db107cd076c", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 194, "doc": {"question": "服用felodipine同時又飲用葡萄柚汁，下列那些為可能的影響？①felodipine的血中濃度增加 ②felodipine的血中濃度減少 ③葡萄柚汁會活化CYP3A4活性 ④葡萄柚汁會抑制CYP3A4活性", "A": "①④", "B": "①③", "C": "②③", "D": "②④", "answer": "A", "questions": "服用felodipine同時又飲用葡萄柚汁，下列那些為可能的影響？①felodipine的血中濃度增加 ②felodipine的血中濃度減少 ③葡萄柚汁會活化CYP3A4活性 ④葡萄柚汁會抑制CYP3A4活性", "choices": ["①④", "①③", "②③", "②④"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n服用felodipine同時又飲用葡萄柚汁，下列那些為可能的影響？①felodipine的血中濃度增加 ②felodipine的血中濃度減少 ③葡萄柚汁會活化CYP3A4活性 ④葡萄柚汁會抑制CYP3A4活性\nA. ①④\nB. ①③\nC. ②③\nD. ②④\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n服用felodipine同時又飲用葡萄柚汁，下列那些為可能的影響？①felodipine的血中濃度增加 ②felodipine的血中濃度減少 ③葡萄柚汁會活化CYP3A4活性 ④葡萄柚汁會抑制CYP3A4活性\nA. ①④\nB. ①③\nC. ②③\nD. ②④\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n服用felodipine同時又飲用葡萄柚汁，下列那些為可能的影響？①felodipine的血中濃度增加 ②felodipine的血中濃度減少 ③葡萄柚汁會活化CYP3A4活性 ④葡萄柚汁會抑制CYP3A4活性\nA. ①④\nB. ①③\nC. ②③\nD. ②④\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n服用felodipine同時又飲用葡萄柚汁，下列那些為可能的影響？①felodipine的血中濃度增加 ②felodipine的血中濃度減少 ③葡萄柚汁會活化CYP3A4活性 ④葡萄柚汁會抑制CYP3A4活性\nA. ①④\nB. ①③\nC. ②③\nD. ②④\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.6796875", "True"]], [["-2.671875", "False"]], [["-3.546875", "False"]], [["-0.9296875", "False"]]], "filtered_resps": [["-0.6796875", "True"], ["-2.671875", "False"], ["-3.546875", "False"], ["-0.9296875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a16d5802a0374529506008e2afbed3e4e95168b67d633ee769d687194684d275", "prompt_hash": "71e3dfbfc5b7e3a7e3ae6022c243b60fc46a5431826898f1c714d7206dbf352f", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 195, "doc": {"question": "下列情況所產生的拮抗作用，何者是chemical antagonism？", "A": "norepinephrine拮抗迷走神經所產生的心跳減慢作用", "B": "insulin拮抗glucocorticoid所產生的高血糖作用", "C": "nitroprusside拮抗angiotensin II所產生的升壓作用", "D": "protamine拮抗heparin所產生的抗擬血作用", "answer": "D", "questions": "下列情況所產生的拮抗作用，何者是chemical antagonism？", "choices": ["norepinephrine拮抗迷走神經所產生的心跳減慢作用", "insulin拮抗glucocorticoid所產生的高血糖作用", "nitroprusside拮抗angiotensin II所產生的升壓作用", "protamine拮抗heparin所產生的抗擬血作用"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列情況所產生的拮抗作用，何者是chemical antagonism？\nA. norepinephrine拮抗迷走神經所產生的心跳減慢作用\nB. insulin拮抗glucocorticoid所產生的高血糖作用\nC. nitroprusside拮抗angiotensin II所產生的升壓作用\nD. protamine拮抗heparin所產生的抗擬血作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列情況所產生的拮抗作用，何者是chemical antagonism？\nA. norepinephrine拮抗迷走神經所產生的心跳減慢作用\nB. insulin拮抗glucocorticoid所產生的高血糖作用\nC. nitroprusside拮抗angiotensin II所產生的升壓作用\nD. protamine拮抗heparin所產生的抗擬血作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列情況所產生的拮抗作用，何者是chemical antagonism？\nA. norepinephrine拮抗迷走神經所產生的心跳減慢作用\nB. insulin拮抗glucocorticoid所產生的高血糖作用\nC. nitroprusside拮抗angiotensin II所產生的升壓作用\nD. protamine拮抗heparin所產生的抗擬血作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列情況所產生的拮抗作用，何者是chemical antagonism？\nA. norepinephrine拮抗迷走神經所產生的心跳減慢作用\nB. insulin拮抗glucocorticoid所產生的高血糖作用\nC. nitroprusside拮抗angiotensin II所產生的升壓作用\nD. protamine拮抗heparin所產生的抗擬血作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.5", "False"]], [["-3.0", "False"]], [["-3.5", "False"]], [["-0.123046875", "True"]]], "filtered_resps": [["-4.5", "False"], ["-3.0", "False"], ["-3.5", "False"], ["-0.123046875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2c841ae224e38ccf5c89f44be47a4a2a37b9e5c0cdd378ccda91c8eb9c2c45e0", "prompt_hash": "9f16cc0423f63e4526d56b38fab63ae6b0de18517c7ceae4f56c5451d076f7fd", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 196, "doc": {"question": "下列藥物中，何者與warfarin併用會增加抗凝血作用？", "A": "rifampin", "B": "cholestyramine", "C": "primidone", "D": "amiodarone", "answer": "D", "questions": "下列藥物中，何者與warfarin併用會增加抗凝血作用？", "choices": ["rifampin", "cholestyramine", "primidone", "amiodarone"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者與warfarin併用會增加抗凝血作用？\nA. rifampin\nB. cholestyramine\nC. primidone\nD. amiodarone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者與warfarin併用會增加抗凝血作用？\nA. rifampin\nB. cholestyramine\nC. primidone\nD. amiodarone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者與warfarin併用會增加抗凝血作用？\nA. rifampin\nB. cholestyramine\nC. primidone\nD. amiodarone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者與warfarin併用會增加抗凝血作用？\nA. rifampin\nB. cholestyramine\nC. primidone\nD. amiodarone\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.0", "False"]], [["-5.75", "False"]], [["-5.625", "False"]], [["-0.0146484375", "True"]]], "filtered_resps": [["-5.0", "False"], ["-5.75", "False"], ["-5.625", "False"], ["-0.0146484375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a34b2aaf67ac557f1b95675931388b764412320b48fb53d8bfb0581d9eadd54a", "prompt_hash": "66572d24885e369d60f32cafb9f3aeb131f72a8c3183569834b81c60bfc403e9", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 197, "doc": {"question": "有關白血病（leukemia）的治療，下列何者正確？", "A": "急性骨髓性白血病（AML）主要以imatinib治療", "B": "慢性骨髓性白血病（CML）主要以6-mercaptopurine治療", "C": "慢性淋巴性白血病（CLL）主要以cyclophosphamide合併vincristine, prednisone治療", "D": "急性淋巴性白血病（ALL）主要以rituximab治療", "answer": "C", "questions": "有關白血病（leukemia）的治療，下列何者正確？", "choices": ["急性骨髓性白血病（AML）主要以imatinib治療", "慢性骨髓性白血病（CML）主要以6-mercaptopurine治療", "慢性淋巴性白血病（CLL）主要以cyclophosphamide合併vincristine, prednisone治療", "急性淋巴性白血病（ALL）主要以rituximab治療"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關白血病（leukemia）的治療，下列何者正確？\nA. 急性骨髓性白血病（AML）主要以imatinib治療\nB. 慢性骨髓性白血病（CML）主要以6-mercaptopurine治療\nC. 慢性淋巴性白血病（CLL）主要以cyclophosphamide合併vincristine, prednisone治療\nD. 急性淋巴性白血病（ALL）主要以rituximab治療\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關白血病（leukemia）的治療，下列何者正確？\nA. 急性骨髓性白血病（AML）主要以imatinib治療\nB. 慢性骨髓性白血病（CML）主要以6-mercaptopurine治療\nC. 慢性淋巴性白血病（CLL）主要以cyclophosphamide合併vincristine, prednisone治療\nD. 急性淋巴性白血病（ALL）主要以rituximab治療\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關白血病（leukemia）的治療，下列何者正確？\nA. 急性骨髓性白血病（AML）主要以imatinib治療\nB. 慢性骨髓性白血病（CML）主要以6-mercaptopurine治療\nC. 慢性淋巴性白血病（CLL）主要以cyclophosphamide合併vincristine, prednisone治療\nD. 急性淋巴性白血病（ALL）主要以rituximab治療\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關白血病（leukemia）的治療，下列何者正確？\nA. 急性骨髓性白血病（AML）主要以imatinib治療\nB. 慢性骨髓性白血病（CML）主要以6-mercaptopurine治療\nC. 慢性淋巴性白血病（CLL）主要以cyclophosphamide合併vincristine, prednisone治療\nD. 急性淋巴性白血病（ALL）主要以rituximab治療\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.8125", "False"]], [["-2.421875", "False"]], [["-0.92578125", "False"]], [["-0.67578125", "True"]]], "filtered_resps": [["-5.8125", "False"], ["-2.421875", "False"], ["-0.92578125", "False"], ["-0.67578125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f8bae51d0c29a8995de200be4de900286e34488e581ae4dc37184ee9a0161129", "prompt_hash": "623165d292eecb94b926b088f9a595ff81ccab7a7fb121c72b914e2d42e97703", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 198, "doc": {"question": "下列何種抗黴菌藥物結構屬於環狀胜肽類？", "A": "ciclopirox", "B": "nystatin", "C": "tolnaftate", "D": "anidulafungin", "answer": "D", "questions": "下列何種抗黴菌藥物結構屬於環狀胜肽類？", "choices": ["ciclopirox", "nystatin", "tolnaftate", "anidulafungin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗黴菌藥物結構屬於環狀胜肽類？\nA. ciclopirox\nB. nystatin\nC. tolnaftate\nD. anidulafungin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗黴菌藥物結構屬於環狀胜肽類？\nA. ciclopirox\nB. nystatin\nC. tolnaftate\nD. anidulafungin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗黴菌藥物結構屬於環狀胜肽類？\nA. ciclopirox\nB. nystatin\nC. tolnaftate\nD. anidulafungin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗黴菌藥物結構屬於環狀胜肽類？\nA. ciclopirox\nB. nystatin\nC. tolnaftate\nD. anidulafungin\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.75", "False"]], [["-6.25", "False"]], [["-7.375", "False"]], [["-0.00653076171875", "True"]]], "filtered_resps": [["-5.75", "False"], ["-6.25", "False"], ["-7.375", "False"], ["-0.00653076171875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6ff856548cc9ca74c820e8d2f39d9ba9e020e70423f5822bc71f9ca37c2cdf1e", "prompt_hash": "aa6f9456a73e5d018df91a45b7e31e840d0a9f5e71e05de2dca93fae13e35bdb", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 199, "doc": {"question": "下列有關hydrocortisone的結構修飾，何者不會顯著提高其glucocorticoid之活性？", "A": "導入16α-CH3", "B": "導入9α-F", "C": "導入11α-OH", "D": "修飾成∆1 -cortisone", "answer": "C", "questions": "下列有關hydrocortisone的結構修飾，何者不會顯著提高其glucocorticoid之活性？", "choices": ["導入16α-CH3", "導入9α-F", "導入11α-OH", "修飾成∆1 -cortisone"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關hydrocortisone的結構修飾，何者不會顯著提高其glucocorticoid之活性？\nA. 導入16α-CH3\nB. 導入9α-F\nC. 導入11α-OH\nD. 修飾成∆1 -cortisone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關hydrocortisone的結構修飾，何者不會顯著提高其glucocorticoid之活性？\nA. 導入16α-CH3\nB. 導入9α-F\nC. 導入11α-OH\nD. 修飾成∆1 -cortisone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關hydrocortisone的結構修飾，何者不會顯著提高其glucocorticoid之活性？\nA. 導入16α-CH3\nB. 導入9α-F\nC. 導入11α-OH\nD. 修飾成∆1 -cortisone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關hydrocortisone的結構修飾，何者不會顯著提高其glucocorticoid之活性？\nA. 導入16α-CH3\nB. 導入9α-F\nC. 導入11α-OH\nD. 修飾成∆1 -cortisone\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.875", "False"]], [["-3.765625", "False"]], [["-0.13671875", "True"]], [["-2.390625", "False"]]], "filtered_resps": [["-4.875", "False"], ["-3.765625", "False"], ["-0.13671875", "True"], ["-2.390625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ce544cb8a828c98d02f0a17282365ac7a92961fbe874e1af7a8e87b58a0fff3d", "prompt_hash": "63f188926be5a2ce7b7edbd53337e58f49287efbc88248df411cbaf1389540d3", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 200, "doc": {"question": "下列何種類升糖素肽-1受體促效劑（GLP-1 agonists），結構中具有長鏈脂肪酸？", "A": "semaglutide", "B": "exenatide", "C": "dulaglutide", "D": "lixisenatide", "answer": "A", "questions": "下列何種類升糖素肽-1受體促效劑（GLP-1 agonists），結構中具有長鏈脂肪酸？", "choices": ["semaglutide", "exenatide", "dulaglutide", "lixisenatide"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種類升糖素肽-1受體促效劑（GLP-1 agonists），結構中具有長鏈脂肪酸？\nA. semaglutide\nB. exenatide\nC. dulaglutide\nD. lixisenatide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種類升糖素肽-1受體促效劑（GLP-1 agonists），結構中具有長鏈脂肪酸？\nA. semaglutide\nB. exenatide\nC. dulaglutide\nD. lixisenatide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種類升糖素肽-1受體促效劑（GLP-1 agonists），結構中具有長鏈脂肪酸？\nA. semaglutide\nB. exenatide\nC. dulaglutide\nD. lixisenatide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種類升糖素肽-1受體促效劑（GLP-1 agonists），結構中具有長鏈脂肪酸？\nA. semaglutide\nB. exenatide\nC. dulaglutide\nD. lixisenatide\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.040771484375", "True"]], [["-5.03125", "False"]], [["-5.15625", "False"]], [["-3.671875", "False"]]], "filtered_resps": [["-0.040771484375", "True"], ["-5.03125", "False"], ["-5.15625", "False"], ["-3.671875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "34532eeb12cd54b3a226556252c8f4b03add7e1c82bec1dab13aa4829421c227", "prompt_hash": "0be1f29f50534a7a99d4ba8a211afe0a659e4be9ba6a8829d9f4596d93832a90", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 201, "doc": {"question": "服用digoxin之心衰竭患者，若需使用利尿劑以改善水腫，則下列何者最不會增加digoxin之毒性？", "A": "dichlorphenamide", "B": "spironolactone", "C": "metolazone", "D": "bumetanide", "answer": "B", "questions": "服用digoxin之心衰竭患者，若需使用利尿劑以改善水腫，則下列何者最不會增加digoxin之毒性？", "choices": ["dichlorphenamide", "spironolactone", "metolazone", "bumetanide"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n服用digoxin之心衰竭患者，若需使用利尿劑以改善水腫，則下列何者最不會增加digoxin之毒性？\nA. dichlorphenamide\nB. spironolactone\nC. metolazone\nD. bumetanide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n服用digoxin之心衰竭患者，若需使用利尿劑以改善水腫，則下列何者最不會增加digoxin之毒性？\nA. dichlorphenamide\nB. spironolactone\nC. metolazone\nD. bumetanide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n服用digoxin之心衰竭患者，若需使用利尿劑以改善水腫，則下列何者最不會增加digoxin之毒性？\nA. dichlorphenamide\nB. spironolactone\nC. metolazone\nD. bumetanide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n服用digoxin之心衰竭患者，若需使用利尿劑以改善水腫，則下列何者最不會增加digoxin之毒性？\nA. dichlorphenamide\nB. spironolactone\nC. metolazone\nD. bumetanide\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.5", "False"]], [["-0.00921630859375", "True"]], [["-5.5", "False"]], [["-5.75", "False"]]], "filtered_resps": [["-6.5", "False"], ["-0.00921630859375", "True"], ["-5.5", "False"], ["-5.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "889b45e0ce2f10b046082c2738b3e55b1436c6d622113a5c3fa8456f44a9baeb", "prompt_hash": "c59d5e4951ca3252085d35985c46ebc702cb262c0586c392a2c037291607e647", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 202, "doc": {"question": "利尿劑之作用機制依腎小管不同區域而有所差異，下列配對何者錯誤？", "A": "acetazolamide—近曲小管（proximal convoluted tubule）", "B": "thiazide—遠曲小管（distal convoluted tubule）", "C": "furosemide—降支小管（thin descending tubule）", "D": "spironolactone—集尿小管（collecting tubule）", "answer": "C", "questions": "利尿劑之作用機制依腎小管不同區域而有所差異，下列配對何者錯誤？", "choices": ["acetazolamide—近曲小管（proximal convoluted tubule）", "thiazide—遠曲小管（distal convoluted tubule）", "furosemide—降支小管（thin descending tubule）", "spironolactone—集尿小管（collecting tubule）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑之作用機制依腎小管不同區域而有所差異，下列配對何者錯誤？\nA. acetazolamide—近曲小管（proximal convoluted tubule）\nB. thiazide—遠曲小管（distal convoluted tubule）\nC. furosemide—降支小管（thin descending tubule）\nD. spironolactone—集尿小管（collecting tubule）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑之作用機制依腎小管不同區域而有所差異，下列配對何者錯誤？\nA. acetazolamide—近曲小管（proximal convoluted tubule）\nB. thiazide—遠曲小管（distal convoluted tubule）\nC. furosemide—降支小管（thin descending tubule）\nD. spironolactone—集尿小管（collecting tubule）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑之作用機制依腎小管不同區域而有所差異，下列配對何者錯誤？\nA. acetazolamide—近曲小管（proximal convoluted tubule）\nB. thiazide—遠曲小管（distal convoluted tubule）\nC. furosemide—降支小管（thin descending tubule）\nD. spironolactone—集尿小管（collecting tubule）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑之作用機制依腎小管不同區域而有所差異，下列配對何者錯誤？\nA. acetazolamide—近曲小管（proximal convoluted tubule）\nB. thiazide—遠曲小管（distal convoluted tubule）\nC. furosemide—降支小管（thin descending tubule）\nD. spironolactone—集尿小管（collecting tubule）\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.15625", "False"]], [["-8.25", "False"]], [["-0.0167236328125", "True"]], [["-5.03125", "False"]]], "filtered_resps": [["-5.15625", "False"], ["-8.25", "False"], ["-0.0167236328125", "True"], ["-5.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "dd28642fdbbcb4a616793ca6078b83a8cd582a5ccbad5a4c28898bb3a776d94b", "prompt_hash": "38bf23281f1eafe2f231e96175d333280f864b399e30b35f38aeef15178eeb41", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 203, "doc": {"question": "下列有關降血糖藥metformin之敘述，何者錯誤？", "A": "最常見的副作用為腸胃道不適之症狀", "B": "為細胞內AMP-activated protein kinase活化劑", "C": "可以促進insulin自胰臟β細胞釋放", "D": "可以抑制肝臟糖質新生作用（gluconeogenesis）", "answer": "C", "questions": "下列有關降血糖藥metformin之敘述，何者錯誤？", "choices": ["最常見的副作用為腸胃道不適之症狀", "為細胞內AMP-activated protein kinase活化劑", "可以促進insulin自胰臟β細胞釋放", "可以抑制肝臟糖質新生作用（gluconeogenesis）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血糖藥metformin之敘述，何者錯誤？\nA. 最常見的副作用為腸胃道不適之症狀\nB. 為細胞內AMP-activated protein kinase活化劑\nC. 可以促進insulin自胰臟β細胞釋放\nD. 可以抑制肝臟糖質新生作用（gluconeogenesis）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血糖藥metformin之敘述，何者錯誤？\nA. 最常見的副作用為腸胃道不適之症狀\nB. 為細胞內AMP-activated protein kinase活化劑\nC. 可以促進insulin自胰臟β細胞釋放\nD. 可以抑制肝臟糖質新生作用（gluconeogenesis）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血糖藥metformin之敘述，何者錯誤？\nA. 最常見的副作用為腸胃道不適之症狀\nB. 為細胞內AMP-activated protein kinase活化劑\nC. 可以促進insulin自胰臟β細胞釋放\nD. 可以抑制肝臟糖質新生作用（gluconeogenesis）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血糖藥metformin之敘述，何者錯誤？\nA. 最常見的副作用為腸胃道不適之症狀\nB. 為細胞內AMP-activated protein kinase活化劑\nC. 可以促進insulin自胰臟β細胞釋放\nD. 可以抑制肝臟糖質新生作用（gluconeogenesis）\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.40625", "False"]], [["-5.65625", "False"]], [["-0.01806640625", "True"]], [["-5.90625", "False"]]], "filtered_resps": [["-7.40625", "False"], ["-5.65625", "False"], ["-0.01806640625", "True"], ["-5.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1c74d1aaeb2c3e943f607fa998701fb4d4180f57b7dc764a6c0b317c38a988f4", "prompt_hash": "86fd3a26b0579a91640b1cabf2b8189fab42ad64274002bde9d289cc29a66825", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 204, "doc": {"question": "Laudanosine為下列何種藥物經Hofmann elimination所產生的？", "A": "doxacurium", "B": "mivacurium", "C": "atracurium", "D": "pancuronium", "answer": "C", "questions": "Laudanosine為下列何種藥物經Hofmann elimination所產生的？", "choices": ["doxacurium", "mivacurium", "atracurium", "pancuronium"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLaudanosine為下列何種藥物經Hofmann elimination所產生的？\nA. doxacurium\nB. mivacurium\nC. atracurium\nD. pancuronium\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLaudanosine為下列何種藥物經Hofmann elimination所產生的？\nA. doxacurium\nB. mivacurium\nC. atracurium\nD. pancuronium\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLaudanosine為下列何種藥物經Hofmann elimination所產生的？\nA. doxacurium\nB. mivacurium\nC. atracurium\nD. pancuronium\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLaudanosine為下列何種藥物經Hofmann elimination所產生的？\nA. doxacurium\nB. mivacurium\nC. atracurium\nD. pancuronium\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.65625", "False"]], [["-4.90625", "False"]], [["-0.04150390625", "True"]], [["-6.40625", "False"]]], "filtered_resps": [["-6.65625", "False"], ["-4.90625", "False"], ["-0.04150390625", "True"], ["-6.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6946d1c7d4296496dc0621f502518f067f8a47bf3611a194a24435255b83e273", "prompt_hash": "3bbfcb85238c6db570643d3edc1092e493b58870c66efe899428d457dda77321", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 205, "doc": {"question": "嚴重燒傷的病人服用非去極化神經肌肉阻斷劑（nondepolarizing neuromuscular blocking agent），需要如何調整劑量，原因為何？", "A": "增加藥物劑量，因為extrajunctional ACh受體退化", "B": "減少藥物劑量，因為extrajunctional ACh受體過度增生", "C": "增加藥物劑量，因為extrajunctional ACh受體過度增生", "D": "減少藥物劑量，因為extrajunctional ACh受體退化", "answer": "C", "questions": "嚴重燒傷的病人服用非去極化神經肌肉阻斷劑（nondepolarizing neuromuscular blocking agent），需要如何調整劑量，原因為何？", "choices": ["增加藥物劑量，因為extrajunctional ACh受體退化", "減少藥物劑量，因為extrajunctional ACh受體過度增生", "增加藥物劑量，因為extrajunctional ACh受體過度增生", "減少藥物劑量，因為extrajunctional ACh受體退化"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n嚴重燒傷的病人服用非去極化神經肌肉阻斷劑（nondepolarizing neuromuscular blocking agent），需要如何調整劑量，原因為何？\nA. 增加藥物劑量，因為extrajunctional ACh受體退化\nB. 減少藥物劑量，因為extrajunctional ACh受體過度增生\nC. 增加藥物劑量，因為extrajunctional ACh受體過度增生\nD. 減少藥物劑量，因為extrajunctional ACh受體退化\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n嚴重燒傷的病人服用非去極化神經肌肉阻斷劑（nondepolarizing neuromuscular blocking agent），需要如何調整劑量，原因為何？\nA. 增加藥物劑量，因為extrajunctional ACh受體退化\nB. 減少藥物劑量，因為extrajunctional ACh受體過度增生\nC. 增加藥物劑量，因為extrajunctional ACh受體過度增生\nD. 減少藥物劑量，因為extrajunctional ACh受體退化\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n嚴重燒傷的病人服用非去極化神經肌肉阻斷劑（nondepolarizing neuromuscular blocking agent），需要如何調整劑量，原因為何？\nA. 增加藥物劑量，因為extrajunctional ACh受體退化\nB. 減少藥物劑量，因為extrajunctional ACh受體過度增生\nC. 增加藥物劑量，因為extrajunctional ACh受體過度增生\nD. 減少藥物劑量，因為extrajunctional ACh受體退化\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n嚴重燒傷的病人服用非去極化神經肌肉阻斷劑（nondepolarizing neuromuscular blocking agent），需要如何調整劑量，原因為何？\nA. 增加藥物劑量，因為extrajunctional ACh受體退化\nB. 減少藥物劑量，因為extrajunctional ACh受體過度增生\nC. 增加藥物劑量，因為extrajunctional ACh受體過度增生\nD. 減少藥物劑量，因為extrajunctional ACh受體退化\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.875", "False"]], [["-2.75", "False"]], [["-0.126953125", "True"]], [["-3.375", "False"]]], "filtered_resps": [["-3.875", "False"], ["-2.75", "False"], ["-0.126953125", "True"], ["-3.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "56b4450e56327d781d38379f5e190ff6623e226c3e136d1b80af68f25afc1127", "prompt_hash": "e3a35feeb08a23567459de3282e4a05d48fc1714b31056ef7b17a12f0dc25eb0", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 206, "doc": {"question": "下列關於 niacin 之敘述，何者錯誤？", "A": "與 HMG-CoA 還原酶抑制劑併用，會增加肌肉病變發生", "B": "可抑制脂肪組織的 lipolysis", "C": "可增加 HDL", "D": "niacin 引起的潮紅，可用 acetaminophen", "answer": "D", "questions": "下列關於 niacin 之敘述，何者錯誤？", "choices": ["與 HMG-CoA 還原酶抑制劑併用，會增加肌肉病變發生", "可抑制脂肪組織的 lipolysis", "可增加 HDL", "niacin 引起的潮紅，可用 acetaminophen"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於 niacin 之敘述，何者錯誤？\nA. 與 HMG-CoA 還原酶抑制劑併用，會增加肌肉病變發生\nB. 可抑制脂肪組織的 lipolysis\nC. 可增加 HDL\nD. niacin 引起的潮紅，可用 acetaminophen\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於 niacin 之敘述，何者錯誤？\nA. 與 HMG-CoA 還原酶抑制劑併用，會增加肌肉病變發生\nB. 可抑制脂肪組織的 lipolysis\nC. 可增加 HDL\nD. niacin 引起的潮紅，可用 acetaminophen\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於 niacin 之敘述，何者錯誤？\nA. 與 HMG-CoA 還原酶抑制劑併用，會增加肌肉病變發生\nB. 可抑制脂肪組織的 lipolysis\nC. 可增加 HDL\nD. niacin 引起的潮紅，可用 acetaminophen\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於 niacin 之敘述，何者錯誤？\nA. 與 HMG-CoA 還原酶抑制劑併用，會增加肌肉病變發生\nB. 可抑制脂肪組織的 lipolysis\nC. 可增加 HDL\nD. niacin 引起的潮紅，可用 acetaminophen\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.40625", "False"]], [["-1.53125", "False"]], [["-3.53125", "False"]], [["-0.408203125", "True"]]], "filtered_resps": [["-2.40625", "False"], ["-1.53125", "False"], ["-3.53125", "False"], ["-0.408203125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6e55bc52ff8486887cf2f0af7edd323931cfb3d85c08f54f866a75ddcba53d2b", "prompt_hash": "a90be3ff0c1b261db48f249f337f0150603a1b9965828bb697c261ccefc7c0e2", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 207, "doc": {"question": "蛋白質生物製劑不具有下列何種特性？", "A": "genetic instability", "B": "physical instability", "C": "photoinstability", "D": "chemical instability", "answer": "A", "questions": "蛋白質生物製劑不具有下列何種特性？", "choices": ["genetic instability", "physical instability", "photoinstability", "chemical instability"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n蛋白質生物製劑不具有下列何種特性？\nA. genetic instability\nB. physical instability\nC. photoinstability\nD. chemical instability\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n蛋白質生物製劑不具有下列何種特性？\nA. genetic instability\nB. physical instability\nC. photoinstability\nD. chemical instability\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n蛋白質生物製劑不具有下列何種特性？\nA. genetic instability\nB. physical instability\nC. photoinstability\nD. chemical instability\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n蛋白質生物製劑不具有下列何種特性？\nA. genetic instability\nB. physical instability\nC. photoinstability\nD. chemical instability\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.369140625", "True"]], [["-3.0", "False"]], [["-2.875", "False"]], [["-1.6171875", "False"]]], "filtered_resps": [["-0.369140625", "True"], ["-3.0", "False"], ["-2.875", "False"], ["-1.6171875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f6c14897b23196f405a3be85a62a7eaa55ee3b094371d49d620cedff8e401a44", "prompt_hash": "743ae2cb87b1eb0db80c91cc2ca43a8127755d34043fa2f96041184ccfdf49bd", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 208, "doc": {"question": "下列藥物何者主要用於治療鐵中毒？", "A": "dimercaprol", "B": "physostigmine", "C": "deferoxamine", "D": "penicillamine", "answer": "C", "questions": "下列藥物何者主要用於治療鐵中毒？", "choices": ["dimercaprol", "physostigmine", "deferoxamine", "penicillamine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者主要用於治療鐵中毒？\nA. dimercaprol\nB. physostigmine\nC. deferoxamine\nD. penicillamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者主要用於治療鐵中毒？\nA. dimercaprol\nB. physostigmine\nC. deferoxamine\nD. penicillamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者主要用於治療鐵中毒？\nA. dimercaprol\nB. physostigmine\nC. deferoxamine\nD. penicillamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者主要用於治療鐵中毒？\nA. dimercaprol\nB. physostigmine\nC. deferoxamine\nD. penicillamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.328125", "False"]], [["-6.34375", "False"]], [["-0.330078125", "True"]], [["-4.34375", "False"]]], "filtered_resps": [["-1.328125", "False"], ["-6.34375", "False"], ["-0.330078125", "True"], ["-4.34375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "70e80f80051a69a276a603239346a66cf877719ff2bbc77da6f3631c14be5f95", "prompt_hash": "80d1b34b871281fed213a8c7f49e3f7d10dea3170caf318af7669391a7839742", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 209, "doc": {"question": "下列有關naproxen構效關係的敘述，何者錯誤？", "A": "主要以R-(-)-異構物在臨床使用", "B": "核心結構為naphthylpropionic acid", "C": "將methoxy group置換成methylsulfide仍具抗炎活性", "D": "將methoxy group置換成大分子基團會降低抗炎活性", "answer": "A", "questions": "下列有關naproxen構效關係的敘述，何者錯誤？", "choices": ["主要以R-(-)-異構物在臨床使用", "核心結構為naphthylpropionic acid", "將methoxy group置換成methylsulfide仍具抗炎活性", "將methoxy group置換成大分子基團會降低抗炎活性"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關naproxen構效關係的敘述，何者錯誤？\nA. 主要以R-(-)-異構物在臨床使用\nB. 核心結構為naphthylpropionic acid\nC. 將methoxy group置換成methylsulfide仍具抗炎活性\nD. 將methoxy group置換成大分子基團會降低抗炎活性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關naproxen構效關係的敘述，何者錯誤？\nA. 主要以R-(-)-異構物在臨床使用\nB. 核心結構為naphthylpropionic acid\nC. 將methoxy group置換成methylsulfide仍具抗炎活性\nD. 將methoxy group置換成大分子基團會降低抗炎活性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關naproxen構效關係的敘述，何者錯誤？\nA. 主要以R-(-)-異構物在臨床使用\nB. 核心結構為naphthylpropionic acid\nC. 將methoxy group置換成methylsulfide仍具抗炎活性\nD. 將methoxy group置換成大分子基團會降低抗炎活性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關naproxen構效關係的敘述，何者錯誤？\nA. 主要以R-(-)-異構物在臨床使用\nB. 核心結構為naphthylpropionic acid\nC. 將methoxy group置換成methylsulfide仍具抗炎活性\nD. 將methoxy group置換成大分子基團會降低抗炎活性\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.76171875", "True"]], [["-3.015625", "False"]], [["-1.0078125", "False"]], [["-2.140625", "False"]]], "filtered_resps": [["-0.76171875", "True"], ["-3.015625", "False"], ["-1.0078125", "False"], ["-2.140625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4cfeacc021d51767258d4dbf1146ffc3697fbee25b410eacde1bfa4da4f341dd", "prompt_hash": "019c9ffca76d53f5fa4094363ddb2d26bb1b045588cf40d4dc77412cf3a57506", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 210, "doc": {"question": "下列官能基團中，何者可能產生的氫鍵數最少？", "A": "benzene", "B": "alcohol", "C": "amine", "D": "ketone", "answer": "A", "questions": "下列官能基團中，何者可能產生的氫鍵數最少？", "choices": ["benzene", "alcohol", "amine", "ketone"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列官能基團中，何者可能產生的氫鍵數最少？\nA. benzene\nB. alcohol\nC. amine\nD. ketone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列官能基團中，何者可能產生的氫鍵數最少？\nA. benzene\nB. alcohol\nC. amine\nD. ketone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列官能基團中，何者可能產生的氫鍵數最少？\nA. benzene\nB. alcohol\nC. amine\nD. ketone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列官能基團中，何者可能產生的氫鍵數最少？\nA. benzene\nB. alcohol\nC. amine\nD. ketone\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.10498046875", "True"]], [["-4.34375", "False"]], [["-4.09375", "False"]], [["-2.734375", "False"]]], "filtered_resps": [["-0.10498046875", "True"], ["-4.34375", "False"], ["-4.09375", "False"], ["-2.734375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b14de0bba868feea740290288c50c213293134c738831010549d7ab8d686a535", "prompt_hash": "c22a89d82126bead793fe92031c9c1b6b44b4bdcb569621a2d5e26de9bbd26f1", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 211, "doc": {"question": "Methyldopa可用於治療妊娠高血壓，其藥物作用機轉為何？", "A": "代謝物α-methylnorepinephrine可活化α2 -adrenergic receptors產生降壓作用", "B": "可直接活化dopamine β-hydroxylase，減少norepinephrine生成，產生降壓作用", "C": "代謝物α-methylnorepinephrine可抑制DOPA decarboxylase減少norepinephrine生成，產生降壓作用", "D": "可直接活化α2 -adrenergic receptors產生降壓作用", "answer": "A", "questions": "Methyldopa可用於治療妊娠高血壓，其藥物作用機轉為何？", "choices": ["代謝物α-methylnorepinephrine可活化α2 -adrenergic receptors產生降壓作用", "可直接活化dopamine β-hydroxylase，減少norepinephrine生成，產生降壓作用", "代謝物α-methylnorepinephrine可抑制DOPA decarboxylase減少norepinephrine生成，產生降壓作用", "可直接活化α2 -adrenergic receptors產生降壓作用"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethyldopa可用於治療妊娠高血壓，其藥物作用機轉為何？\nA. 代謝物α-methylnorepinephrine可活化α2 -adrenergic receptors產生降壓作用\nB. 可直接活化dopamine β-hydroxylase，減少norepinephrine生成，產生降壓作用\nC. 代謝物α-methylnorepinephrine可抑制DOPA decarboxylase減少norepinephrine生成，產生降壓作用\nD. 可直接活化α2 -adrenergic receptors產生降壓作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethyldopa可用於治療妊娠高血壓，其藥物作用機轉為何？\nA. 代謝物α-methylnorepinephrine可活化α2 -adrenergic receptors產生降壓作用\nB. 可直接活化dopamine β-hydroxylase，減少norepinephrine生成，產生降壓作用\nC. 代謝物α-methylnorepinephrine可抑制DOPA decarboxylase減少norepinephrine生成，產生降壓作用\nD. 可直接活化α2 -adrenergic receptors產生降壓作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethyldopa可用於治療妊娠高血壓，其藥物作用機轉為何？\nA. 代謝物α-methylnorepinephrine可活化α2 -adrenergic receptors產生降壓作用\nB. 可直接活化dopamine β-hydroxylase，減少norepinephrine生成，產生降壓作用\nC. 代謝物α-methylnorepinephrine可抑制DOPA decarboxylase減少norepinephrine生成，產生降壓作用\nD. 可直接活化α2 -adrenergic receptors產生降壓作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethyldopa可用於治療妊娠高血壓，其藥物作用機轉為何？\nA. 代謝物α-methylnorepinephrine可活化α2 -adrenergic receptors產生降壓作用\nB. 可直接活化dopamine β-hydroxylase，減少norepinephrine生成，產生降壓作用\nC. 代謝物α-methylnorepinephrine可抑制DOPA decarboxylase減少norepinephrine生成，產生降壓作用\nD. 可直接活化α2 -adrenergic receptors產生降壓作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.34375", "True"]], [["-1.46875", "False"]], [["-4.09375", "False"]], [["-3.21875", "False"]]], "filtered_resps": [["-0.34375", "True"], ["-1.46875", "False"], ["-4.09375", "False"], ["-3.21875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fd9469766cb1bf37b51e0538aa8deb5bfdd178d61bfa5dd5e13207f4811009e4", "prompt_hash": "1eb50602d340e12162ade8c328c6265b4a3162c3e204c18f68a1c3439d94d0c5", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 212, "doc": {"question": "下列何者為sulfasalazine進行活化代謝的主要部位？", "A": "小腸", "B": "胃", "C": "肝臟", "D": "大腸", "answer": "D", "questions": "下列何者為sulfasalazine進行活化代謝的主要部位？", "choices": ["小腸", "胃", "肝臟", "大腸"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為sulfasalazine進行活化代謝的主要部位？\nA. 小腸\nB. 胃\nC. 肝臟\nD. 大腸\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為sulfasalazine進行活化代謝的主要部位？\nA. 小腸\nB. 胃\nC. 肝臟\nD. 大腸\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為sulfasalazine進行活化代謝的主要部位？\nA. 小腸\nB. 胃\nC. 肝臟\nD. 大腸\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為sulfasalazine進行活化代謝的主要部位？\nA. 小腸\nB. 胃\nC. 肝臟\nD. 大腸\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.3125", "False"]], [["-3.546875", "False"]], [["-4.3125", "False"]], [["-0.0498046875", "True"]]], "filtered_resps": [["-5.3125", "False"], ["-3.546875", "False"], ["-4.3125", "False"], ["-0.0498046875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9a9a58dcae614593f6dcea937a7fb3ff734084fc3be5370429823666b55f5383", "prompt_hash": "4854e36508adaf6f93382f005c659a2350eaf40899f57b1e526eee332d04d6bd", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 213, "doc": {"question": "下列用於心律不整（arrhythmia）之治療藥物，何者能用於緩解糖尿病神經病變之疼痛（diabetic neuropathy pain）？", "A": "mexiletine", "B": "amiodarone", "C": "dofetilide", "D": "verapamil", "answer": "A", "questions": "下列用於心律不整（arrhythmia）之治療藥物，何者能用於緩解糖尿病神經病變之疼痛（diabetic neuropathy pain）？", "choices": ["mexiletine", "amiodarone", "dofetilide", "verapamil"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列用於心律不整（arrhythmia）之治療藥物，何者能用於緩解糖尿病神經病變之疼痛（diabetic neuropathy pain）？\nA. mexiletine\nB. amiodarone\nC. dofetilide\nD. verapamil\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列用於心律不整（arrhythmia）之治療藥物，何者能用於緩解糖尿病神經病變之疼痛（diabetic neuropathy pain）？\nA. mexiletine\nB. amiodarone\nC. dofetilide\nD. verapamil\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列用於心律不整（arrhythmia）之治療藥物，何者能用於緩解糖尿病神經病變之疼痛（diabetic neuropathy pain）？\nA. mexiletine\nB. amiodarone\nC. dofetilide\nD. verapamil\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列用於心律不整（arrhythmia）之治療藥物，何者能用於緩解糖尿病神經病變之疼痛（diabetic neuropathy pain）？\nA. mexiletine\nB. amiodarone\nC. dofetilide\nD. verapamil\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0137939453125", "True"]], [["-5.75", "False"]], [["-7.25", "False"]], [["-5.625", "False"]]], "filtered_resps": [["-0.0137939453125", "True"], ["-5.75", "False"], ["-7.25", "False"], ["-5.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b186b95fce11c09c2f9388d1272564d5dce59a0d173141287f3dc468b270ae2d", "prompt_hash": "731936235324b52e4455ea7f3903cdb35f65cfdd822b1b9a49bb99a39e95f463", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 214, "doc": {"question": "以下有關cyclophosphamide的敘述，何者錯誤？", "A": "藉由CYP2B6進行最初的代謝步驟", "B": "活性代謝物具aziridine結構", "C": "經代謝水解後產生具腎毒性之acrolein", "D": "屬於抗代謝藥", "answer": "D", "questions": "以下有關cyclophosphamide的敘述，何者錯誤？", "choices": ["藉由CYP2B6進行最初的代謝步驟", "活性代謝物具aziridine結構", "經代謝水解後產生具腎毒性之acrolein", "屬於抗代謝藥"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n以下有關cyclophosphamide的敘述，何者錯誤？\nA. 藉由CYP2B6進行最初的代謝步驟\nB. 活性代謝物具aziridine結構\nC. 經代謝水解後產生具腎毒性之acrolein\nD. 屬於抗代謝藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n以下有關cyclophosphamide的敘述，何者錯誤？\nA. 藉由CYP2B6進行最初的代謝步驟\nB. 活性代謝物具aziridine結構\nC. 經代謝水解後產生具腎毒性之acrolein\nD. 屬於抗代謝藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n以下有關cyclophosphamide的敘述，何者錯誤？\nA. 藉由CYP2B6進行最初的代謝步驟\nB. 活性代謝物具aziridine結構\nC. 經代謝水解後產生具腎毒性之acrolein\nD. 屬於抗代謝藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n以下有關cyclophosphamide的敘述，何者錯誤？\nA. 藉由CYP2B6進行最初的代謝步驟\nB. 活性代謝物具aziridine結構\nC. 經代謝水解後產生具腎毒性之acrolein\nD. 屬於抗代謝藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.0625", "False"]], [["-3.4375", "False"]], [["-4.8125", "False"]], [["-0.1845703125", "True"]]], "filtered_resps": [["-2.0625", "False"], ["-3.4375", "False"], ["-4.8125", "False"], ["-0.1845703125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6d87f1f3b9562c5e472959daac1f2e05a1dbb08219ffd2466b921ec980708927", "prompt_hash": "f5f5c25f533df6ec66a36de1221355e7e6e44d759a968b8ef279c33d4a346e73", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 215, "doc": {"question": "下列有關methimazole與propylthiouracil之敘述，何者錯誤？", "A": "methimazole抑制thyroxine生合成，作用較強", "B": "propylthiouracil抑制thyroxine生合成，時間較長", "C": "methimazole無法抑制周邊T4之去碘化作用", "D": "皆有顆粒性白血球缺乏（agranulocytosis）副作用", "answer": "B", "questions": "下列有關methimazole與propylthiouracil之敘述，何者錯誤？", "choices": ["methimazole抑制thyroxine生合成，作用較強", "propylthiouracil抑制thyroxine生合成，時間較長", "methimazole無法抑制周邊T4之去碘化作用", "皆有顆粒性白血球缺乏（agranulocytosis）副作用"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關methimazole與propylthiouracil之敘述，何者錯誤？\nA. methimazole抑制thyroxine生合成，作用較強\nB. propylthiouracil抑制thyroxine生合成，時間較長\nC. methimazole無法抑制周邊T4之去碘化作用\nD. 皆有顆粒性白血球缺乏（agranulocytosis）副作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關methimazole與propylthiouracil之敘述，何者錯誤？\nA. methimazole抑制thyroxine生合成，作用較強\nB. propylthiouracil抑制thyroxine生合成，時間較長\nC. methimazole無法抑制周邊T4之去碘化作用\nD. 皆有顆粒性白血球缺乏（agranulocytosis）副作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關methimazole與propylthiouracil之敘述，何者錯誤？\nA. methimazole抑制thyroxine生合成，作用較強\nB. propylthiouracil抑制thyroxine生合成，時間較長\nC. methimazole無法抑制周邊T4之去碘化作用\nD. 皆有顆粒性白血球缺乏（agranulocytosis）副作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關methimazole與propylthiouracil之敘述，何者錯誤？\nA. methimazole抑制thyroxine生合成，作用較強\nB. propylthiouracil抑制thyroxine生合成，時間較長\nC. methimazole無法抑制周邊T4之去碘化作用\nD. 皆有顆粒性白血球缺乏（agranulocytosis）副作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.40625", "False"]], [["-0.0184326171875", "True"]], [["-4.53125", "False"]], [["-5.15625", "False"]]], "filtered_resps": [["-7.40625", "False"], ["-0.0184326171875", "True"], ["-4.53125", "False"], ["-5.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e87c4734d11bf93bc790cabfa4aa656b86f099d3ca1bfb0223a6ba542ba27de3", "prompt_hash": "02ad3ac08a879d164741b8f8826c7ed1c2cccc70d7e68ddd116e1fe3dbc8d07a", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 216, "doc": {"question": "下列何者為dobutamine主要的代謝酵素？", "A": "monoamine oxidase", "B": "glucosidase", "C": "hydroxylase", "D": "catechol-O-methyltransferase", "answer": "D", "questions": "下列何者為dobutamine主要的代謝酵素？", "choices": ["monoamine oxidase", "glucosidase", "hydroxylase", "catechol-O-methyltransferase"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為dobutamine主要的代謝酵素？\nA. monoamine oxidase\nB. glucosidase\nC. hydroxylase\nD. catechol-O-methyltransferase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為dobutamine主要的代謝酵素？\nA. monoamine oxidase\nB. glucosidase\nC. hydroxylase\nD. catechol-O-methyltransferase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為dobutamine主要的代謝酵素？\nA. monoamine oxidase\nB. glucosidase\nC. hydroxylase\nD. catechol-O-methyltransferase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為dobutamine主要的代謝酵素？\nA. monoamine oxidase\nB. glucosidase\nC. hydroxylase\nD. catechol-O-methyltransferase\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.03125", "False"]], [["-5.28125", "False"]], [["-5.15625", "False"]], [["-0.0185546875", "True"]]], "filtered_resps": [["-5.03125", "False"], ["-5.28125", "False"], ["-5.15625", "False"], ["-0.0185546875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7ee3f46299eae20c7a80a6639fdea0a36b1a23fabdd8df6f4c70a856331a3a4c", "prompt_hash": "749d8c15995f98971995053b2c9ae2f332bcbb5a79cd3b2c796fb9ce86b60265", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 217, "doc": {"question": "下列中樞神經作用藥物，何者最難溶於強鹼溶液？", "A": "morphine", "B": "tiagabine", "C": "codeine", "D": "phenytoin", "answer": "C", "questions": "下列中樞神經作用藥物，何者最難溶於強鹼溶液？", "choices": ["morphine", "tiagabine", "codeine", "phenytoin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中樞神經作用藥物，何者最難溶於強鹼溶液？\nA. morphine\nB. tiagabine\nC. codeine\nD. phenytoin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中樞神經作用藥物，何者最難溶於強鹼溶液？\nA. morphine\nB. tiagabine\nC. codeine\nD. phenytoin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中樞神經作用藥物，何者最難溶於強鹼溶液？\nA. morphine\nB. tiagabine\nC. codeine\nD. phenytoin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中樞神經作用藥物，何者最難溶於強鹼溶液？\nA. morphine\nB. tiagabine\nC. codeine\nD. phenytoin\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.875", "False"]], [["-1.2578125", "False"]], [["-2.875", "False"]], [["-0.5078125", "True"]]], "filtered_resps": [["-2.875", "False"], ["-1.2578125", "False"], ["-2.875", "False"], ["-0.5078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8f921e79dc5c127ca720e0ae58e85dcc94b988a7064e6bd3aac948d66bc5a043", "prompt_hash": "752197dc77048790ee9811cf29482410d27f8e0a93753932af3c7b95ee08230e", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 218, "doc": {"question": "下列有關重金屬解毒劑 dimercaprol 的敘述，何者錯誤？", "A": "為水溶性", "B": "可以作為急性汞中毒之解毒劑", "C": "會造成高血壓的副作用", "D": "使用時需肌肉注射給藥", "answer": "A", "questions": "下列有關重金屬解毒劑 dimercaprol 的敘述，何者錯誤？", "choices": ["為水溶性", "可以作為急性汞中毒之解毒劑", "會造成高血壓的副作用", "使用時需肌肉注射給藥"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關重金屬解毒劑 dimercaprol 的敘述，何者錯誤？\nA. 為水溶性\nB. 可以作為急性汞中毒之解毒劑\nC. 會造成高血壓的副作用\nD. 使用時需肌肉注射給藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關重金屬解毒劑 dimercaprol 的敘述，何者錯誤？\nA. 為水溶性\nB. 可以作為急性汞中毒之解毒劑\nC. 會造成高血壓的副作用\nD. 使用時需肌肉注射給藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關重金屬解毒劑 dimercaprol 的敘述，何者錯誤？\nA. 為水溶性\nB. 可以作為急性汞中毒之解毒劑\nC. 會造成高血壓的副作用\nD. 使用時需肌肉注射給藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關重金屬解毒劑 dimercaprol 的敘述，何者錯誤？\nA. 為水溶性\nB. 可以作為急性汞中毒之解毒劑\nC. 會造成高血壓的副作用\nD. 使用時需肌肉注射給藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0615234375", "True"]], [["-4.4375", "False"]], [["-3.8125", "False"]], [["-3.6875", "False"]]], "filtered_resps": [["-0.0615234375", "True"], ["-4.4375", "False"], ["-3.8125", "False"], ["-3.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b09e0249321c6f04cc0fa130040ea99248e49dcac8c9b7817d7e10402bb07d72", "prompt_hash": "31b9512857f35424178ed13cfe3d04b51aca2ddd6622421f185ab954c19455d7", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 219, "doc": {"question": "下列敘述何者正確？", "A": "ceftazidime不會受到β-lactamase水解", "B": "ceftriaxone與ceftazidime在腎功能不佳的病人都需調整劑量使用", "C": "ceftazidime可有效治療綠膿桿菌", "D": "cefoxitin比起ceftazidime對格蘭氏陰性菌更廣效", "answer": "C", "questions": "下列敘述何者正確？", "choices": ["ceftazidime不會受到β-lactamase水解", "ceftriaxone與ceftazidime在腎功能不佳的病人都需調整劑量使用", "ceftazidime可有效治療綠膿桿菌", "cefoxitin比起ceftazidime對格蘭氏陰性菌更廣效"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列敘述何者正確？\nA. ceftazidime不會受到β-lactamase水解\nB. ceftriaxone與ceftazidime在腎功能不佳的病人都需調整劑量使用\nC. ceftazidime可有效治療綠膿桿菌\nD. cefoxitin比起ceftazidime對格蘭氏陰性菌更廣效\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列敘述何者正確？\nA. ceftazidime不會受到β-lactamase水解\nB. ceftriaxone與ceftazidime在腎功能不佳的病人都需調整劑量使用\nC. ceftazidime可有效治療綠膿桿菌\nD. cefoxitin比起ceftazidime對格蘭氏陰性菌更廣效\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列敘述何者正確？\nA. ceftazidime不會受到β-lactamase水解\nB. ceftriaxone與ceftazidime在腎功能不佳的病人都需調整劑量使用\nC. ceftazidime可有效治療綠膿桿菌\nD. cefoxitin比起ceftazidime對格蘭氏陰性菌更廣效\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列敘述何者正確？\nA. ceftazidime不會受到β-lactamase水解\nB. ceftriaxone與ceftazidime在腎功能不佳的病人都需調整劑量使用\nC. ceftazidime可有效治療綠膿桿菌\nD. cefoxitin比起ceftazidime對格蘭氏陰性菌更廣效\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.375", "False"]], [["-2.875", "False"]], [["-0.380859375", "True"]], [["-1.5078125", "False"]]], "filtered_resps": [["-3.375", "False"], ["-2.875", "False"], ["-0.380859375", "True"], ["-1.5078125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3cc0715902baca4812f856ef3fa0803cf7c263e3a5ce62b449c0e7eecdec1074", "prompt_hash": "9ae72af0f37ee172c3ebec342747f88c2248640bfec21d99216fbb81e2fd3194", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 220, "doc": {"question": "下列ACE抑制劑的作用，何者不需經過bioactivation？", "A": "perindopril", "B": "lisinopril", "C": "enalapril", "D": "fosinopril", "answer": "B", "questions": "下列ACE抑制劑的作用，何者不需經過bioactivation？", "choices": ["perindopril", "lisinopril", "enalapril", "fosinopril"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列ACE抑制劑的作用，何者不需經過bioactivation？\nA. perindopril\nB. lisinopril\nC. enalapril\nD. fosinopril\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列ACE抑制劑的作用，何者不需經過bioactivation？\nA. perindopril\nB. lisinopril\nC. enalapril\nD. fosinopril\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列ACE抑制劑的作用，何者不需經過bioactivation？\nA. perindopril\nB. lisinopril\nC. enalapril\nD. fosinopril\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列ACE抑制劑的作用，何者不需經過bioactivation？\nA. perindopril\nB. lisinopril\nC. enalapril\nD. fosinopril\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.75", "False"]], [["-0.007080078125", "True"]], [["-6.875", "False"]], [["-5.625", "False"]]], "filtered_resps": [["-7.75", "False"], ["-0.007080078125", "True"], ["-6.875", "False"], ["-5.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fbde0a1da9b9d01ff11864bc4683951ebf3d8295f440137df80b9d5377076ccc", "prompt_hash": "76199fa064c518ba034daa6c95f016cbfc304bdb0a158890b9a9aeb0281a28f7", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 221, "doc": {"question": "第一個用於治療病毒性感染的反義（antisense）藥物fomivirsen是由幾個核苷酸（nucleotide）組成？", "A": "18", "B": "15", "C": "12", "D": "21", "answer": "D", "questions": "第一個用於治療病毒性感染的反義（antisense）藥物fomivirsen是由幾個核苷酸（nucleotide）組成？", "choices": ["18", "15", "12", "21"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n第一個用於治療病毒性感染的反義（antisense）藥物fomivirsen是由幾個核苷酸（nucleotide）組成？\nA. 18\nB. 15\nC. 12\nD. 21\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n第一個用於治療病毒性感染的反義（antisense）藥物fomivirsen是由幾個核苷酸（nucleotide）組成？\nA. 18\nB. 15\nC. 12\nD. 21\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n第一個用於治療病毒性感染的反義（antisense）藥物fomivirsen是由幾個核苷酸（nucleotide）組成？\nA. 18\nB. 15\nC. 12\nD. 21\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n第一個用於治療病毒性感染的反義（antisense）藥物fomivirsen是由幾個核苷酸（nucleotide）組成？\nA. 18\nB. 15\nC. 12\nD. 21\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.0625", "False"]], [["-0.6875", "True"]], [["-1.3125", "False"]], [["-2.3125", "False"]]], "filtered_resps": [["-2.0625", "False"], ["-0.6875", "True"], ["-1.3125", "False"], ["-2.3125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "966f3359d67c13305c53c489d7e0be7d0ffc2f0569320d5fdbc39eee3f702291", "prompt_hash": "b53db1552f4119268641de4ad63e1fa45925a5342292bab4b1182bfd7d6f7707", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 222, "doc": {"question": "下列何者於外科手術時，可作為全身麻醉劑之輔助藥?", "A": "pancuronium", "B": "enflurane", "C": "propofol", "D": "etomidate", "answer": "A", "questions": "下列何者於外科手術時，可作為全身麻醉劑之輔助藥?", "choices": ["pancuronium", "enflurane", "propofol", "etomidate"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者於外科手術時，可作為全身麻醉劑之輔助藥?\nA. pancuronium\nB. enflurane\nC. propofol\nD. etomidate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者於外科手術時，可作為全身麻醉劑之輔助藥?\nA. pancuronium\nB. enflurane\nC. propofol\nD. etomidate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者於外科手術時，可作為全身麻醉劑之輔助藥?\nA. pancuronium\nB. enflurane\nC. propofol\nD. etomidate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者於外科手術時，可作為全身麻醉劑之輔助藥?\nA. pancuronium\nB. enflurane\nC. propofol\nD. etomidate\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.10205078125", "True"]], [["-3.859375", "False"]], [["-4.21875", "False"]], [["-2.859375", "False"]]], "filtered_resps": [["-0.10205078125", "True"], ["-3.859375", "False"], ["-4.21875", "False"], ["-2.859375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4972b6b6f3849f397999326bcaac18e7d4fb98196abcd8c0ae42403c2d8550a3", "prompt_hash": "93b634a85880fe67da0ff266f60d7df84a4b1a055f03893e3931cbd5ec2a1484", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 223, "doc": {"question": "下列有關降血脂藥物之敘述，何者錯誤？", "A": "atorvastatin會增加肝臟細胞中LDL受體", "B": "niacin除了降低VLDL的分泌，也會影響膽酸（bile acid）產量", "C": "ezetimibe會降低體內LDL，用於植物固醇血症（phytosterolemia）病人", "D": "fenofibrate會降低VLDL含量，用於高三酸甘油酯血症（hypertriglyceridemia）", "answer": "B", "questions": "下列有關降血脂藥物之敘述，何者錯誤？", "choices": ["atorvastatin會增加肝臟細胞中LDL受體", "niacin除了降低VLDL的分泌，也會影響膽酸（bile acid）產量", "ezetimibe會降低體內LDL，用於植物固醇血症（phytosterolemia）病人", "fenofibrate會降低VLDL含量，用於高三酸甘油酯血症（hypertriglyceridemia）"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血脂藥物之敘述，何者錯誤？\nA. atorvastatin會增加肝臟細胞中LDL受體\nB. niacin除了降低VLDL的分泌，也會影響膽酸（bile acid）產量\nC. ezetimibe會降低體內LDL，用於植物固醇血症（phytosterolemia）病人\nD. fenofibrate會降低VLDL含量，用於高三酸甘油酯血症（hypertriglyceridemia）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血脂藥物之敘述，何者錯誤？\nA. atorvastatin會增加肝臟細胞中LDL受體\nB. niacin除了降低VLDL的分泌，也會影響膽酸（bile acid）產量\nC. ezetimibe會降低體內LDL，用於植物固醇血症（phytosterolemia）病人\nD. fenofibrate會降低VLDL含量，用於高三酸甘油酯血症（hypertriglyceridemia）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血脂藥物之敘述，何者錯誤？\nA. atorvastatin會增加肝臟細胞中LDL受體\nB. niacin除了降低VLDL的分泌，也會影響膽酸（bile acid）產量\nC. ezetimibe會降低體內LDL，用於植物固醇血症（phytosterolemia）病人\nD. fenofibrate會降低VLDL含量，用於高三酸甘油酯血症（hypertriglyceridemia）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關降血脂藥物之敘述，何者錯誤？\nA. atorvastatin會增加肝臟細胞中LDL受體\nB. niacin除了降低VLDL的分泌，也會影響膽酸（bile acid）產量\nC. ezetimibe會降低體內LDL，用於植物固醇血症（phytosterolemia）病人\nD. fenofibrate會降低VLDL含量，用於高三酸甘油酯血症（hypertriglyceridemia）\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.84375", "False"]], [["-3.59375", "False"]], [["-0.0947265625", "True"]], [["-3.21875", "False"]]], "filtered_resps": [["-3.84375", "False"], ["-3.59375", "False"], ["-0.0947265625", "True"], ["-3.21875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "68f8da4b438bf8627d7f4360325d6ce1e737aae6806d34f1d4a0efd89626ddf9", "prompt_hash": "00708d503a124e10d6f4350373c49e2528effbe200a838abbaca534f36fc0b5a", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 224, "doc": {"question": "下列何者為5-HT1A agonist，可治療Parkinson disease？", "A": "buspirone", "B": "sarizotan", "C": "ipsapirone", "D": "gepirone", "answer": "B", "questions": "下列何者為5-HT1A agonist，可治療Parkinson disease？", "choices": ["buspirone", "sarizotan", "ipsapirone", "gepirone"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為5-HT1A agonist，可治療Parkinson disease？\nA. buspirone\nB. sarizotan\nC. ipsapirone\nD. gepirone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為5-HT1A agonist，可治療Parkinson disease？\nA. buspirone\nB. sarizotan\nC. ipsapirone\nD. gepirone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為5-HT1A agonist，可治療Parkinson disease？\nA. buspirone\nB. sarizotan\nC. ipsapirone\nD. gepirone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為5-HT1A agonist，可治療Parkinson disease？\nA. buspirone\nB. sarizotan\nC. ipsapirone\nD. gepirone\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.875", "False"]], [["-0.004547119140625", "True"]], [["-6.875", "False"]], [["-6.375", "False"]]], "filtered_resps": [["-6.875", "False"], ["-0.004547119140625", "True"], ["-6.875", "False"], ["-6.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8fa979d241ff7dcf5586ea342a652eaf2a68b0c0e86edb3b7762fb7f8b2e2045", "prompt_hash": "e5ad7434fe232fd07cf09833e71eb80801ee75b4e65bed8d5465cddc475e5f39", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 225, "doc": {"question": "下列何者是第二代抗精神病藥物作用之主要標的？", "A": "5-HT2A", "B": "D1", "C": "D2", "D": "sodium channel", "answer": "A", "questions": "下列何者是第二代抗精神病藥物作用之主要標的？", "choices": ["5-HT2A", "D1", "D2", "sodium channel"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是第二代抗精神病藥物作用之主要標的？\nA. 5-HT2A\nB. D1\nC. D2\nD. sodium channel\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是第二代抗精神病藥物作用之主要標的？\nA. 5-HT2A\nB. D1\nC. D2\nD. sodium channel\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是第二代抗精神病藥物作用之主要標的？\nA. 5-HT2A\nB. D1\nC. D2\nD. sodium channel\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是第二代抗精神病藥物作用之主要標的？\nA. 5-HT2A\nB. D1\nC. D2\nD. sodium channel\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0478515625", "True"]], [["-3.921875", "False"]], [["-5.0625", "False"]], [["-3.921875", "False"]]], "filtered_resps": [["-0.0478515625", "True"], ["-3.921875", "False"], ["-5.0625", "False"], ["-3.921875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2f3704c3863d21f52d3846f326bd1284270f9d0dd1aebc2bab91f3b48a03a32e", "prompt_hash": "3c4cd059ca3674d275332d94a62f4d6e136fa741ee72c9126e69019ff867c24f", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 226, "doc": {"question": "下列黃體素（progestins）之結構中，何者不具17α-ethynyl基團？", "A": "norethindrone", "B": "norethynodrel", "C": "desogestrel", "D": "dienogest", "answer": "D", "questions": "下列黃體素（progestins）之結構中，何者不具17α-ethynyl基團？", "choices": ["norethindrone", "norethynodrel", "desogestrel", "dienogest"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列黃體素（progestins）之結構中，何者不具17α-ethynyl基團？\nA. norethindrone\nB. norethynodrel\nC. desogestrel\nD. dienogest\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列黃體素（progestins）之結構中，何者不具17α-ethynyl基團？\nA. norethindrone\nB. norethynodrel\nC. desogestrel\nD. dienogest\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列黃體素（progestins）之結構中，何者不具17α-ethynyl基團？\nA. norethindrone\nB. norethynodrel\nC. desogestrel\nD. dienogest\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列黃體素（progestins）之結構中，何者不具17α-ethynyl基團？\nA. norethindrone\nB. norethynodrel\nC. desogestrel\nD. dienogest\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.75", "False"]], [["-5.625", "False"]], [["-7.375", "False"]], [["-0.00537109375", "True"]]], "filtered_resps": [["-7.75", "False"], ["-5.625", "False"], ["-7.375", "False"], ["-0.00537109375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "04aad4ac3ef96d3017b917400149fd5d7c600f5f3d6d8024ec2f3dc8c7e94990", "prompt_hash": "a481af8483475621015b63053e269138312a87eba3c4b1126b1ef2d7f8030f03", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 227, "doc": {"question": "胰臟中每一胰島素六聚體（hexamer），通常與幾個鋅離子形成配位？", "A": "6", "B": "2", "C": "4", "D": "1", "answer": "B", "questions": "胰臟中每一胰島素六聚體（hexamer），通常與幾個鋅離子形成配位？", "choices": ["6", "2", "4", "1"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n胰臟中每一胰島素六聚體（hexamer），通常與幾個鋅離子形成配位？\nA. 6\nB. 2\nC. 4\nD. 1\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n胰臟中每一胰島素六聚體（hexamer），通常與幾個鋅離子形成配位？\nA. 6\nB. 2\nC. 4\nD. 1\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n胰臟中每一胰島素六聚體（hexamer），通常與幾個鋅離子形成配位？\nA. 6\nB. 2\nC. 4\nD. 1\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n胰臟中每一胰島素六聚體（hexamer），通常與幾個鋅離子形成配位？\nA. 6\nB. 2\nC. 4\nD. 1\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.71875", "False"]], [["-1.2265625", "False"]], [["-1.8515625", "False"]], [["-0.7265625", "True"]]], "filtered_resps": [["-2.71875", "False"], ["-1.2265625", "False"], ["-1.8515625", "False"], ["-0.7265625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "37044c6eeb5631b25369690448d9caded9c9fa72d1e44da1d18239de75dfb1fb", "prompt_hash": "fa030975499733f355504524c0a7e5aff8f638bacc0cf11117a8580aec15b87a", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 228, "doc": {"question": "下列有關胰島素製劑之敘述，何者正確？", "A": "以 crystalline zinc insulin 治療糖尿病酮酸中毒（diabetic ketoacidosis）效果最好", "B": "insulin glulisine 是長效型製劑，主要是維持血中低量而持續性的胰島素濃度", "C": "NPH insulin 內含 protamine 可以加速吸收效果", "D": "可以結合至 insulin receptor 進而活化胰臟β細胞之 adenylyl cyclase", "answer": "A", "questions": "下列有關胰島素製劑之敘述，何者正確？", "choices": ["以 crystalline zinc insulin 治療糖尿病酮酸中毒（diabetic ketoacidosis）效果最好", "insulin glulisine 是長效型製劑，主要是維持血中低量而持續性的胰島素濃度", "NPH insulin 內含 protamine 可以加速吸收效果", "可以結合至 insulin receptor 進而活化胰臟β細胞之 adenylyl cyclase"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關胰島素製劑之敘述，何者正確？\nA. 以 crystalline zinc insulin 治療糖尿病酮酸中毒（diabetic ketoacidosis）效果最好\nB. insulin glulisine 是長效型製劑，主要是維持血中低量而持續性的胰島素濃度\nC. NPH insulin 內含 protamine 可以加速吸收效果\nD. 可以結合至 insulin receptor 進而活化胰臟β細胞之 adenylyl cyclase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關胰島素製劑之敘述，何者正確？\nA. 以 crystalline zinc insulin 治療糖尿病酮酸中毒（diabetic ketoacidosis）效果最好\nB. insulin glulisine 是長效型製劑，主要是維持血中低量而持續性的胰島素濃度\nC. NPH insulin 內含 protamine 可以加速吸收效果\nD. 可以結合至 insulin receptor 進而活化胰臟β細胞之 adenylyl cyclase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關胰島素製劑之敘述，何者正確？\nA. 以 crystalline zinc insulin 治療糖尿病酮酸中毒（diabetic ketoacidosis）效果最好\nB. insulin glulisine 是長效型製劑，主要是維持血中低量而持續性的胰島素濃度\nC. NPH insulin 內含 protamine 可以加速吸收效果\nD. 可以結合至 insulin receptor 進而活化胰臟β細胞之 adenylyl cyclase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關胰島素製劑之敘述，何者正確？\nA. 以 crystalline zinc insulin 治療糖尿病酮酸中毒（diabetic ketoacidosis）效果最好\nB. insulin glulisine 是長效型製劑，主要是維持血中低量而持續性的胰島素濃度\nC. NPH insulin 內含 protamine 可以加速吸收效果\nD. 可以結合至 insulin receptor 進而活化胰臟β細胞之 adenylyl cyclase\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.55859375", "True"]], [["-2.5625", "False"]], [["-3.1875", "False"]], [["-1.1796875", "False"]]], "filtered_resps": [["-0.55859375", "True"], ["-2.5625", "False"], ["-3.1875", "False"], ["-1.1796875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "410f7a5ed9143048e55578c7aaff2325f898ddcbf63117ebcb1d007348d1b7d9", "prompt_hash": "92f2985e9c788c60ba580d09ddfab731fa23d43a9092cc842348074bfd6cd6fe", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 229, "doc": {"question": "下列何者並非副交感神經系統的特點？", "A": "副交感神經系統以乙醯膽鹼作為神經傳遞物質", "B": "活化副交感神經系統可抑制心跳", "C": "副交感神經系統之節後神經纖維比交感神經系統之節後神經纖維長", "D": "抑制副交感神經系統會導致口乾", "answer": "C", "questions": "下列何者並非副交感神經系統的特點？", "choices": ["副交感神經系統以乙醯膽鹼作為神經傳遞物質", "活化副交感神經系統可抑制心跳", "副交感神經系統之節後神經纖維比交感神經系統之節後神經纖維長", "抑制副交感神經系統會導致口乾"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非副交感神經系統的特點？\nA. 副交感神經系統以乙醯膽鹼作為神經傳遞物質\nB. 活化副交感神經系統可抑制心跳\nC. 副交感神經系統之節後神經纖維比交感神經系統之節後神經纖維長\nD. 抑制副交感神經系統會導致口乾\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非副交感神經系統的特點？\nA. 副交感神經系統以乙醯膽鹼作為神經傳遞物質\nB. 活化副交感神經系統可抑制心跳\nC. 副交感神經系統之節後神經纖維比交感神經系統之節後神經纖維長\nD. 抑制副交感神經系統會導致口乾\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非副交感神經系統的特點？\nA. 副交感神經系統以乙醯膽鹼作為神經傳遞物質\nB. 活化副交感神經系統可抑制心跳\nC. 副交感神經系統之節後神經纖維比交感神經系統之節後神經纖維長\nD. 抑制副交感神經系統會導致口乾\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非副交感神經系統的特點？\nA. 副交感神經系統以乙醯膽鹼作為神經傳遞物質\nB. 活化副交感神經系統可抑制心跳\nC. 副交感神經系統之節後神經纖維比交感神經系統之節後神經纖維長\nD. 抑制副交感神經系統會導致口乾\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.71875", "False"]], [["-2.59375", "False"]], [["-0.34375", "True"]], [["-3.34375", "False"]]], "filtered_resps": [["-1.71875", "False"], ["-2.59375", "False"], ["-0.34375", "True"], ["-3.34375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8bb72998eb5b08cf74a51ab35996dc899c73943db9299844951bfd08a6066498", "prompt_hash": "079b3433aaa053e36d189b322a37ccd3740daae704ecee0237ffd2776bcc0ec8", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 230, "doc": {"question": "下列何種藥物與生理食鹽水併用，是治療嚴重血中鈣濃度過高之最佳選擇？", "A": "amiloride", "B": "furosemide", "C": "spironolactone", "D": "hydrochlorothiazide", "answer": "B", "questions": "下列何種藥物與生理食鹽水併用，是治療嚴重血中鈣濃度過高之最佳選擇？", "choices": ["amiloride", "furosemide", "spironolactone", "hydrochlorothiazide"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物與生理食鹽水併用，是治療嚴重血中鈣濃度過高之最佳選擇？\nA. amiloride\nB. furosemide\nC. spironolactone\nD. hydrochlorothiazide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物與生理食鹽水併用，是治療嚴重血中鈣濃度過高之最佳選擇？\nA. amiloride\nB. furosemide\nC. spironolactone\nD. hydrochlorothiazide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物與生理食鹽水併用，是治療嚴重血中鈣濃度過高之最佳選擇？\nA. amiloride\nB. furosemide\nC. spironolactone\nD. hydrochlorothiazide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物與生理食鹽水併用，是治療嚴重血中鈣濃度過高之最佳選擇？\nA. amiloride\nB. furosemide\nC. spironolactone\nD. hydrochlorothiazide\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.28125", "False"]], [["-0.0205078125", "True"]], [["-5.78125", "False"]], [["-4.53125", "False"]]], "filtered_resps": [["-5.28125", "False"], ["-0.0205078125", "True"], ["-5.78125", "False"], ["-4.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ba08e5e1fa2c2d526e61f8150fda0d3cb5dcaeca354e980500017e775c257914", "prompt_hash": "bbf3f4fdf795c1b0beb58682676056c1a7f25e1a8d535d7ab467ba95f6441317", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 231, "doc": {"question": "下列血管收縮素拮抗劑（angiotensin II receptor antagonists）中，何者之結構有二個benzimidazole環，故脂溶性最高，藥效最長？", "A": "candesartan", "B": "irbesartan", "C": "telmisartan", "D": "valsartan", "answer": "C", "questions": "下列血管收縮素拮抗劑（angiotensin II receptor antagonists）中，何者之結構有二個benzimidazole環，故脂溶性最高，藥效最長？", "choices": ["candesartan", "irbesartan", "telmisartan", "valsartan"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列血管收縮素拮抗劑（angiotensin II receptor antagonists）中，何者之結構有二個benzimidazole環，故脂溶性最高，藥效最長？\nA. candesartan\nB. irbesartan\nC. telmisartan\nD. valsartan\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列血管收縮素拮抗劑（angiotensin II receptor antagonists）中，何者之結構有二個benzimidazole環，故脂溶性最高，藥效最長？\nA. candesartan\nB. irbesartan\nC. telmisartan\nD. valsartan\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列血管收縮素拮抗劑（angiotensin II receptor antagonists）中，何者之結構有二個benzimidazole環，故脂溶性最高，藥效最長？\nA. candesartan\nB. irbesartan\nC. telmisartan\nD. valsartan\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列血管收縮素拮抗劑（angiotensin II receptor antagonists）中，何者之結構有二個benzimidazole環，故脂溶性最高，藥效最長？\nA. candesartan\nB. irbesartan\nC. telmisartan\nD. valsartan\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.65625", "False"]], [["-5.40625", "False"]], [["-0.017822265625", "True"]], [["-5.03125", "False"]]], "filtered_resps": [["-5.65625", "False"], ["-5.40625", "False"], ["-0.017822265625", "True"], ["-5.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bda114f39c988024c311cbf69f95888f9c91c0962d6b0f2ca0ed9e7fee5f5b0c", "prompt_hash": "b18629f46f7e1be6e35100f1efd1d266c5e92c0f38e29f29212f790e65c96c10", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 232, "doc": {"question": "利尿劑bumetanide的N-butyl修飾成pyrrolidinyl取代基時，即成為下列何種藥物？", "A": "torsemide", "B": "tripamide", "C": "azosemide", "D": "piretanide", "answer": "D", "questions": "利尿劑bumetanide的N-butyl修飾成pyrrolidinyl取代基時，即成為下列何種藥物？", "choices": ["torsemide", "tripamide", "azosemide", "piretanide"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑bumetanide的N-butyl修飾成pyrrolidinyl取代基時，即成為下列何種藥物？\nA. torsemide\nB. tripamide\nC. azosemide\nD. piretanide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑bumetanide的N-butyl修飾成pyrrolidinyl取代基時，即成為下列何種藥物？\nA. torsemide\nB. tripamide\nC. azosemide\nD. piretanide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑bumetanide的N-butyl修飾成pyrrolidinyl取代基時，即成為下列何種藥物？\nA. torsemide\nB. tripamide\nC. azosemide\nD. piretanide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑bumetanide的N-butyl修飾成pyrrolidinyl取代基時，即成為下列何種藥物？\nA. torsemide\nB. tripamide\nC. azosemide\nD. piretanide\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.875", "False"]], [["-6.125", "False"]], [["-6.875", "False"]], [["-0.00921630859375", "True"]]], "filtered_resps": [["-6.875", "False"], ["-6.125", "False"], ["-6.875", "False"], ["-0.00921630859375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "efa47d7a4f171fa65895793b65776c07be713d673fe95b46e115221255999176", "prompt_hash": "f5f74c86f79811afdc59b82988f360187e3688bb8a8de113dbda47fd5c821f6a", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 233, "doc": {"question": "Baclofen臨床上可用於肌肉痙攣（spasm）的治療是基於何種作用機轉？", "A": "GABAB receptor agonist", "B": "GABAA receptor agonist", "C": "GABAA receptor antagonist", "D": "GABAB receptor antagonist", "answer": "A", "questions": "Baclofen臨床上可用於肌肉痙攣（spasm）的治療是基於何種作用機轉？", "choices": ["GABAB receptor agonist", "GABAA receptor agonist", "GABAA receptor antagonist", "GABAB receptor antagonist"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBaclofen臨床上可用於肌肉痙攣（spasm）的治療是基於何種作用機轉？\nA. GABAB receptor agonist\nB. GABAA receptor agonist\nC. GABAA receptor antagonist\nD. GABAB receptor antagonist\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBaclofen臨床上可用於肌肉痙攣（spasm）的治療是基於何種作用機轉？\nA. GABAB receptor agonist\nB. GABAA receptor agonist\nC. GABAA receptor antagonist\nD. GABAB receptor antagonist\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBaclofen臨床上可用於肌肉痙攣（spasm）的治療是基於何種作用機轉？\nA. GABAB receptor agonist\nB. GABAA receptor agonist\nC. GABAA receptor antagonist\nD. GABAB receptor antagonist\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBaclofen臨床上可用於肌肉痙攣（spasm）的治療是基於何種作用機轉？\nA. GABAB receptor agonist\nB. GABAA receptor agonist\nC. GABAA receptor antagonist\nD. GABAB receptor antagonist\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0322265625", "True"]], [["-5.40625", "False"]], [["-5.90625", "False"]], [["-3.90625", "False"]]], "filtered_resps": [["-0.0322265625", "True"], ["-5.40625", "False"], ["-5.90625", "False"], ["-3.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6ce1cdc43dfee42dc892cab969f4868f3adca3da50b71b4f8745bf19cdaaa1c5", "prompt_hash": "46b2770d088c4ffb6e6b8af1e451eaff3d9f06483acfa7692306410c1467a036", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 234, "doc": {"question": "有關治療妥瑞氏症（Tourette syndrome）藥物及其作用機制，何者錯誤？", "A": "botulinum toxin A－神經肌肉阻斷", "B": "haloperidol－dopamine receptor antagonist", "C": "guanfacine－β2 agonist", "D": "pimozide－dopamine receptor antagonist", "answer": "C", "questions": "有關治療妥瑞氏症（Tourette syndrome）藥物及其作用機制，何者錯誤？", "choices": ["botulinum toxin A－神經肌肉阻斷", "haloperidol－dopamine receptor antagonist", "guanfacine－β2 agonist", "pimozide－dopamine receptor antagonist"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關治療妥瑞氏症（Tourette syndrome）藥物及其作用機制，何者錯誤？\nA. botulinum toxin A－神經肌肉阻斷\nB. haloperidol－dopamine receptor antagonist\nC. guanfacine－β2 agonist\nD. pimozide－dopamine receptor antagonist\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關治療妥瑞氏症（Tourette syndrome）藥物及其作用機制，何者錯誤？\nA. botulinum toxin A－神經肌肉阻斷\nB. haloperidol－dopamine receptor antagonist\nC. guanfacine－β2 agonist\nD. pimozide－dopamine receptor antagonist\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關治療妥瑞氏症（Tourette syndrome）藥物及其作用機制，何者錯誤？\nA. botulinum toxin A－神經肌肉阻斷\nB. haloperidol－dopamine receptor antagonist\nC. guanfacine－β2 agonist\nD. pimozide－dopamine receptor antagonist\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關治療妥瑞氏症（Tourette syndrome）藥物及其作用機制，何者錯誤？\nA. botulinum toxin A－神經肌肉阻斷\nB. haloperidol－dopamine receptor antagonist\nC. guanfacine－β2 agonist\nD. pimozide－dopamine receptor antagonist\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.53125", "False"]], [["-6.28125", "False"]], [["-0.02587890625", "True"]], [["-6.59375", "False"]]], "filtered_resps": [["-5.53125", "False"], ["-6.28125", "False"], ["-0.02587890625", "True"], ["-6.59375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bcda1ccad87c971c96323e94ab2824e393a3a782eeb84d6719e861f292bea324", "prompt_hash": "baa932eb295652900fbe2f7fcf005dc6fd86d4d33c48f5b17b0fef62156fed8b", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 235, "doc": {"question": "Methimazole可抑制下列何種機制，而達到抗甲狀腺功能亢進之作用？", "A": "thyroid peroxidase", "B": "Na+ / Isymporter", "C": "5'-deiodinase", "D": "5α-reductase", "answer": "A", "questions": "Methimazole可抑制下列何種機制，而達到抗甲狀腺功能亢進之作用？", "choices": ["thyroid peroxidase", "Na+ / Isymporter", "5'-deiodinase", "5α-reductase"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethimazole可抑制下列何種機制，而達到抗甲狀腺功能亢進之作用？\nA. thyroid peroxidase\nB. Na+ / Isymporter\nC. 5'-deiodinase\nD. 5α-reductase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethimazole可抑制下列何種機制，而達到抗甲狀腺功能亢進之作用？\nA. thyroid peroxidase\nB. Na+ / Isymporter\nC. 5'-deiodinase\nD. 5α-reductase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethimazole可抑制下列何種機制，而達到抗甲狀腺功能亢進之作用？\nA. thyroid peroxidase\nB. Na+ / Isymporter\nC. 5'-deiodinase\nD. 5α-reductase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethimazole可抑制下列何種機制，而達到抗甲狀腺功能亢進之作用？\nA. thyroid peroxidase\nB. Na+ / Isymporter\nC. 5'-deiodinase\nD. 5α-reductase\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.047119140625", "True"]], [["-4.1875", "False"]], [["-5.0625", "False"]], [["-4.0625", "False"]]], "filtered_resps": [["-0.047119140625", "True"], ["-4.1875", "False"], ["-5.0625", "False"], ["-4.0625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "cc2aecb14d337f398b47fb80848fd0e7e9f0c213f0c442ce519d069d4cf433e2", "prompt_hash": "05ff5f7e3fa07eb6477275685b1186c1282d143d5bad8486cb76ed84920a4614", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 236, "doc": {"question": "下列何者為PGE2同類物，可作為墮胎藥物？", "A": "alprostadil", "B": "dinoprostone", "C": "carboprost", "D": "misoprostol", "answer": "B", "questions": "下列何者為PGE2同類物，可作為墮胎藥物？", "choices": ["alprostadil", "dinoprostone", "carboprost", "misoprostol"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為PGE2同類物，可作為墮胎藥物？\nA. alprostadil\nB. dinoprostone\nC. carboprost\nD. misoprostol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為PGE2同類物，可作為墮胎藥物？\nA. alprostadil\nB. dinoprostone\nC. carboprost\nD. misoprostol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為PGE2同類物，可作為墮胎藥物？\nA. alprostadil\nB. dinoprostone\nC. carboprost\nD. misoprostol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為PGE2同類物，可作為墮胎藥物？\nA. alprostadil\nB. dinoprostone\nC. carboprost\nD. misoprostol\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.5", "False"]], [["-0.008544921875", "True"]], [["-6.5", "False"]], [["-6.0", "False"]]], "filtered_resps": [["-6.5", "False"], ["-0.008544921875", "True"], ["-6.5", "False"], ["-6.0", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "202ceda9b6aabd8bf0f3bc586e0c252a063c8f4f3ec86375c4de8588096cb97f", "prompt_hash": "63aae0b3e57cecfd4ed26a79ba70e37493330d3dd95a85fd27b82f9bd95c771e", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 237, "doc": {"question": "有關抗病毒藥物之敘述，下列何者錯誤？", "A": "抗病毒藥物一般可作用在病毒的複製及潛伏期而達到效用", "B": "抗流感的神經氨酸酶抑制劑（neuraminidase inhibitor）主要是抑制病毒從宿主細胞中釋放", "C": "抗病毒藥物對人體的毒性有部分是來自同時抑制了宿主細胞DNA合成", "D": "抗疱疹病毒的藥可預先投與進行器官移植的病人，當做單純疱疹病毒（HSV）或水痘帶狀疱疹病毒（VZV）感染風險的預防", "answer": "A", "questions": "有關抗病毒藥物之敘述，下列何者錯誤？", "choices": ["抗病毒藥物一般可作用在病毒的複製及潛伏期而達到效用", "抗流感的神經氨酸酶抑制劑（neuraminidase inhibitor）主要是抑制病毒從宿主細胞中釋放", "抗病毒藥物對人體的毒性有部分是來自同時抑制了宿主細胞DNA合成", "抗疱疹病毒的藥可預先投與進行器官移植的病人，當做單純疱疹病毒（HSV）或水痘帶狀疱疹病毒（VZV）感染風險的預防"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗病毒藥物之敘述，下列何者錯誤？\nA. 抗病毒藥物一般可作用在病毒的複製及潛伏期而達到效用\nB. 抗流感的神經氨酸酶抑制劑（neuraminidase inhibitor）主要是抑制病毒從宿主細胞中釋放\nC. 抗病毒藥物對人體的毒性有部分是來自同時抑制了宿主細胞DNA合成\nD. 抗疱疹病毒的藥可預先投與進行器官移植的病人，當做單純疱疹病毒（HSV）或水痘帶狀疱疹病毒（VZV）感染風險的預防\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗病毒藥物之敘述，下列何者錯誤？\nA. 抗病毒藥物一般可作用在病毒的複製及潛伏期而達到效用\nB. 抗流感的神經氨酸酶抑制劑（neuraminidase inhibitor）主要是抑制病毒從宿主細胞中釋放\nC. 抗病毒藥物對人體的毒性有部分是來自同時抑制了宿主細胞DNA合成\nD. 抗疱疹病毒的藥可預先投與進行器官移植的病人，當做單純疱疹病毒（HSV）或水痘帶狀疱疹病毒（VZV）感染風險的預防\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗病毒藥物之敘述，下列何者錯誤？\nA. 抗病毒藥物一般可作用在病毒的複製及潛伏期而達到效用\nB. 抗流感的神經氨酸酶抑制劑（neuraminidase inhibitor）主要是抑制病毒從宿主細胞中釋放\nC. 抗病毒藥物對人體的毒性有部分是來自同時抑制了宿主細胞DNA合成\nD. 抗疱疹病毒的藥可預先投與進行器官移植的病人，當做單純疱疹病毒（HSV）或水痘帶狀疱疹病毒（VZV）感染風險的預防\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗病毒藥物之敘述，下列何者錯誤？\nA. 抗病毒藥物一般可作用在病毒的複製及潛伏期而達到效用\nB. 抗流感的神經氨酸酶抑制劑（neuraminidase inhibitor）主要是抑制病毒從宿主細胞中釋放\nC. 抗病毒藥物對人體的毒性有部分是來自同時抑制了宿主細胞DNA合成\nD. 抗疱疹病毒的藥可預先投與進行器官移植的病人，當做單純疱疹病毒（HSV）或水痘帶狀疱疹病毒（VZV）感染風險的預防\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1630859375", "True"]], [["-2.78125", "False"]], [["-2.78125", "False"]], [["-3.65625", "False"]]], "filtered_resps": [["-0.1630859375", "True"], ["-2.78125", "False"], ["-2.78125", "False"], ["-3.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "dae01027dc32f9c82de4fb307bf6b38c00874277a3df358537923d1059459f49", "prompt_hash": "e08232a78a804052934e11c27a4452b37bbf5e60014e9695b737be350bcf1c72", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 238, "doc": {"question": "抗結核藥capreomycin是由幾個cyclic polypeptide組成的混合物？", "A": "4", "B": "3", "C": "2", "D": "5", "answer": "A", "questions": "抗結核藥capreomycin是由幾個cyclic polypeptide組成的混合物？", "choices": ["4", "3", "2", "5"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗結核藥capreomycin是由幾個cyclic polypeptide組成的混合物？\nA. 4\nB. 3\nC. 2\nD. 5\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗結核藥capreomycin是由幾個cyclic polypeptide組成的混合物？\nA. 4\nB. 3\nC. 2\nD. 5\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗結核藥capreomycin是由幾個cyclic polypeptide組成的混合物？\nA. 4\nB. 3\nC. 2\nD. 5\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗結核藥capreomycin是由幾個cyclic polypeptide組成的混合物？\nA. 4\nB. 3\nC. 2\nD. 5\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.8515625", "True"]], [["-0.9765625", "False"]], [["-2.859375", "False"]], [["-1.9765625", "False"]]], "filtered_resps": [["-0.8515625", "True"], ["-0.9765625", "False"], ["-2.859375", "False"], ["-1.9765625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6e1bfc1980d19dd4456f8770741ab86d24324c9594437f1d90df66d4ca4fb53d", "prompt_hash": "a09a6be03db546a42288c943fc2aaddc8b5704e7c3219bd14f1af8cee8287ee5", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 239, "doc": {"question": "下列關於肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？", "A": "是一種蛋白質水解酵素", "B": "可以治療膀胱過度活性之尿失禁（incontinence due to overactive bladder）", "C": "可能的副作用為肌肉無力、疼痛", "D": "局部注射可以治療腦性麻痺（cerebral palsy），急性偏頭痛（acute migraine）", "answer": "D", "questions": "下列關於肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？", "choices": ["是一種蛋白質水解酵素", "可以治療膀胱過度活性之尿失禁（incontinence due to overactive bladder）", "可能的副作用為肌肉無力、疼痛", "局部注射可以治療腦性麻痺（cerebral palsy），急性偏頭痛（acute migraine）"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？\nA. 是一種蛋白質水解酵素\nB. 可以治療膀胱過度活性之尿失禁（incontinence due to overactive bladder）\nC. 可能的副作用為肌肉無力、疼痛\nD. 局部注射可以治療腦性麻痺（cerebral palsy），急性偏頭痛（acute migraine）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？\nA. 是一種蛋白質水解酵素\nB. 可以治療膀胱過度活性之尿失禁（incontinence due to overactive bladder）\nC. 可能的副作用為肌肉無力、疼痛\nD. 局部注射可以治療腦性麻痺（cerebral palsy），急性偏頭痛（acute migraine）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？\nA. 是一種蛋白質水解酵素\nB. 可以治療膀胱過度活性之尿失禁（incontinence due to overactive bladder）\nC. 可能的副作用為肌肉無力、疼痛\nD. 局部注射可以治療腦性麻痺（cerebral palsy），急性偏頭痛（acute migraine）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？\nA. 是一種蛋白質水解酵素\nB. 可以治療膀胱過度活性之尿失禁（incontinence due to overactive bladder）\nC. 可能的副作用為肌肉無力、疼痛\nD. 局部注射可以治療腦性麻痺（cerebral palsy），急性偏頭痛（acute migraine）\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.27734375", "True"]], [["-2.03125", "False"]], [["-2.78125", "False"]], [["-3.03125", "False"]]], "filtered_resps": [["-0.27734375", "True"], ["-2.03125", "False"], ["-2.78125", "False"], ["-3.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "722c8ee2d38b1edae6358c3995792a324fe3f3b4370bccecaacd6707730dd936", "prompt_hash": "79c2c11f49b45bf5e5a4d150c085b52aaed27c97ee639d2f5f2a77ec343f0efb", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 240, "doc": {"question": "下列關於眼睛用藥之敘述，何者錯誤？", "A": "timolol減少眼房水產生，減少眼內壓", "B": "phenylephrine可活化眼睛虹膜輻射狀肌alpha受體，產生散瞳", "C": "organophosphates可抑制眼睛虹膜輻射狀肌alpha受體，產生縮瞳", "D": "pilocarpine增加眼房水外流，減少眼內壓", "answer": "C", "questions": "下列關於眼睛用藥之敘述，何者錯誤？", "choices": ["timolol減少眼房水產生，減少眼內壓", "phenylephrine可活化眼睛虹膜輻射狀肌alpha受體，產生散瞳", "organophosphates可抑制眼睛虹膜輻射狀肌alpha受體，產生縮瞳", "pilocarpine增加眼房水外流，減少眼內壓"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於眼睛用藥之敘述，何者錯誤？\nA. timolol減少眼房水產生，減少眼內壓\nB. phenylephrine可活化眼睛虹膜輻射狀肌alpha受體，產生散瞳\nC. organophosphates可抑制眼睛虹膜輻射狀肌alpha受體，產生縮瞳\nD. pilocarpine增加眼房水外流，減少眼內壓\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於眼睛用藥之敘述，何者錯誤？\nA. timolol減少眼房水產生，減少眼內壓\nB. phenylephrine可活化眼睛虹膜輻射狀肌alpha受體，產生散瞳\nC. organophosphates可抑制眼睛虹膜輻射狀肌alpha受體，產生縮瞳\nD. pilocarpine增加眼房水外流，減少眼內壓\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於眼睛用藥之敘述，何者錯誤？\nA. timolol減少眼房水產生，減少眼內壓\nB. phenylephrine可活化眼睛虹膜輻射狀肌alpha受體，產生散瞳\nC. organophosphates可抑制眼睛虹膜輻射狀肌alpha受體，產生縮瞳\nD. pilocarpine增加眼房水外流，減少眼內壓\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於眼睛用藥之敘述，何者錯誤？\nA. timolol減少眼房水產生，減少眼內壓\nB. phenylephrine可活化眼睛虹膜輻射狀肌alpha受體，產生散瞳\nC. organophosphates可抑制眼睛虹膜輻射狀肌alpha受體，產生縮瞳\nD. pilocarpine增加眼房水外流，減少眼內壓\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.9375", "False"]], [["-3.921875", "False"]], [["-0.054443359375", "True"]], [["-3.796875", "False"]]], "filtered_resps": [["-4.9375", "False"], ["-3.921875", "False"], ["-0.054443359375", "True"], ["-3.796875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "024ad6c0770df3a0dd9daf250d17cff6dbfbc5cde8758025025a49241697eb5d", "prompt_hash": "24145fcb38643020bb6283fe44bfc7ad2c5dc6da49e0064cfc1ed8ef1a810108", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 241, "doc": {"question": "下列有關HMG-CoA還原酶抑制劑降低血中膽固醇之敘述，何者錯誤？", "A": "抑制膽固醇生合成", "B": "減少VLDL生成", "C": "增加膽固醇代謝", "D": "增加受體對LDL攝入肝細胞", "answer": "C", "questions": "下列有關HMG-CoA還原酶抑制劑降低血中膽固醇之敘述，何者錯誤？", "choices": ["抑制膽固醇生合成", "減少VLDL生成", "增加膽固醇代謝", "增加受體對LDL攝入肝細胞"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關HMG-CoA還原酶抑制劑降低血中膽固醇之敘述，何者錯誤？\nA. 抑制膽固醇生合成\nB. 減少VLDL生成\nC. 增加膽固醇代謝\nD. 增加受體對LDL攝入肝細胞\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關HMG-CoA還原酶抑制劑降低血中膽固醇之敘述，何者錯誤？\nA. 抑制膽固醇生合成\nB. 減少VLDL生成\nC. 增加膽固醇代謝\nD. 增加受體對LDL攝入肝細胞\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關HMG-CoA還原酶抑制劑降低血中膽固醇之敘述，何者錯誤？\nA. 抑制膽固醇生合成\nB. 減少VLDL生成\nC. 增加膽固醇代謝\nD. 增加受體對LDL攝入肝細胞\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關HMG-CoA還原酶抑制劑降低血中膽固醇之敘述，何者錯誤？\nA. 抑制膽固醇生合成\nB. 減少VLDL生成\nC. 增加膽固醇代謝\nD. 增加受體對LDL攝入肝細胞\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.9375", "False"]], [["-4.6875", "False"]], [["-0.0625", "True"]], [["-3.1875", "False"]]], "filtered_resps": [["-4.9375", "False"], ["-4.6875", "False"], ["-0.0625", "True"], ["-3.1875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b49cb698373e21ecfe19a5f473db28f61a0c3526462409a25dbcdc5e0e517964", "prompt_hash": "0becc8499c0606f6ed4e617845995d7c861f9d6a6ea209c1bed4328985ad86e2", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 242, "doc": {"question": "下列藥物何者不是經由影響細菌細胞壁而產生作用？", "A": "daptomycin", "B": "penicillin", "C": "vancomycin", "D": "erythromycin", "answer": "D", "questions": "下列藥物何者不是經由影響細菌細胞壁而產生作用？", "choices": ["daptomycin", "penicillin", "vancomycin", "erythromycin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不是經由影響細菌細胞壁而產生作用？\nA. daptomycin\nB. penicillin\nC. vancomycin\nD. erythromycin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不是經由影響細菌細胞壁而產生作用？\nA. daptomycin\nB. penicillin\nC. vancomycin\nD. erythromycin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不是經由影響細菌細胞壁而產生作用？\nA. daptomycin\nB. penicillin\nC. vancomycin\nD. erythromycin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不是經由影響細菌細胞壁而產生作用？\nA. daptomycin\nB. penicillin\nC. vancomycin\nD. erythromycin\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.296875", "False"]], [["-6.28125", "False"]], [["-7.03125", "False"]], [["-0.0439453125", "True"]]], "filtered_resps": [["-3.296875", "False"], ["-6.28125", "False"], ["-7.03125", "False"], ["-0.0439453125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "da968f3befdbd323a5f8d198d2714525d1aa861ab47377bd19d3816f0dee8fca", "prompt_hash": "c3f0256fec86ff3d66311cabf375dc53eae602a57d2373cb1841c8378de01d10", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 243, "doc": {"question": "β1選擇性致效劑較非選擇性β致效劑不易產生反射性心跳過速，原因為何？", "A": "非選擇性β致效劑能直接收縮血管", "B": "β1選擇性致效劑不作用在心肌", "C": "β1選擇性致效劑不活化舒張血管的β2受體", "D": "非選擇性β致效劑能抑制迷走神經的傳導", "answer": "C", "questions": "β1選擇性致效劑較非選擇性β致效劑不易產生反射性心跳過速，原因為何？", "choices": ["非選擇性β致效劑能直接收縮血管", "β1選擇性致效劑不作用在心肌", "β1選擇性致效劑不活化舒張血管的β2受體", "非選擇性β致效劑能抑制迷走神經的傳導"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nβ1選擇性致效劑較非選擇性β致效劑不易產生反射性心跳過速，原因為何？\nA. 非選擇性β致效劑能直接收縮血管\nB. β1選擇性致效劑不作用在心肌\nC. β1選擇性致效劑不活化舒張血管的β2受體\nD. 非選擇性β致效劑能抑制迷走神經的傳導\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nβ1選擇性致效劑較非選擇性β致效劑不易產生反射性心跳過速，原因為何？\nA. 非選擇性β致效劑能直接收縮血管\nB. β1選擇性致效劑不作用在心肌\nC. β1選擇性致效劑不活化舒張血管的β2受體\nD. 非選擇性β致效劑能抑制迷走神經的傳導\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nβ1選擇性致效劑較非選擇性β致效劑不易產生反射性心跳過速，原因為何？\nA. 非選擇性β致效劑能直接收縮血管\nB. β1選擇性致效劑不作用在心肌\nC. β1選擇性致效劑不活化舒張血管的β2受體\nD. 非選擇性β致效劑能抑制迷走神經的傳導\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nβ1選擇性致效劑較非選擇性β致效劑不易產生反射性心跳過速，原因為何？\nA. 非選擇性β致效劑能直接收縮血管\nB. β1選擇性致效劑不作用在心肌\nC. β1選擇性致效劑不活化舒張血管的β2受體\nD. 非選擇性β致效劑能抑制迷走神經的傳導\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.875", "False"]], [["-3.5", "False"]], [["-0.130859375", "True"]], [["-2.625", "False"]]], "filtered_resps": [["-3.875", "False"], ["-3.5", "False"], ["-0.130859375", "True"], ["-2.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "eb4feb6d1c5eb24539b09eec526765150c6f29aeae51238e57a4b9fc78dddab0", "prompt_hash": "fdf76b52983e1167488246780c93141375100a4fda681941074e07708f9bfefe", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 244, "doc": {"question": "下列藥品何者的pKa值最大？", "A": "valsartan", "B": "montelukast", "C": "temazepam", "D": "ibuprofen", "answer": "C", "questions": "下列藥品何者的pKa值最大？", "choices": ["valsartan", "montelukast", "temazepam", "ibuprofen"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品何者的pKa值最大？\nA. valsartan\nB. montelukast\nC. temazepam\nD. ibuprofen\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品何者的pKa值最大？\nA. valsartan\nB. montelukast\nC. temazepam\nD. ibuprofen\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品何者的pKa值最大？\nA. valsartan\nB. montelukast\nC. temazepam\nD. ibuprofen\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品何者的pKa值最大？\nA. valsartan\nB. montelukast\nC. temazepam\nD. ibuprofen\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.4375", "False"]], [["-5.0625", "False"]], [["-0.068359375", "True"]], [["-3.0625", "False"]]], "filtered_resps": [["-4.4375", "False"], ["-5.0625", "False"], ["-0.068359375", "True"], ["-3.0625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8bd9f1244c8769d33fcb4d615b52ae01264b1d95da7b2af5ca4b216ca81d56e9", "prompt_hash": "7f9f59a2e2488c2c1dcf6f99618bbdbfb955e89965d7daa695b4327509e89dfc", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 245, "doc": {"question": "下列關於ezetimibe的敘述，何者正確？", "A": "含azetidinone結構", "B": "作用標的為HMG-CoA還原酶", "C": "與statin類藥物併用時，會增加橫紋肌溶解症之風險", "D": "可與制酸劑一起服用", "answer": "A", "questions": "下列關於ezetimibe的敘述，何者正確？", "choices": ["含azetidinone結構", "作用標的為HMG-CoA還原酶", "與statin類藥物併用時，會增加橫紋肌溶解症之風險", "可與制酸劑一起服用"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於ezetimibe的敘述，何者正確？\nA. 含azetidinone結構\nB. 作用標的為HMG-CoA還原酶\nC. 與statin類藥物併用時，會增加橫紋肌溶解症之風險\nD. 可與制酸劑一起服用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於ezetimibe的敘述，何者正確？\nA. 含azetidinone結構\nB. 作用標的為HMG-CoA還原酶\nC. 與statin類藥物併用時，會增加橫紋肌溶解症之風險\nD. 可與制酸劑一起服用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於ezetimibe的敘述，何者正確？\nA. 含azetidinone結構\nB. 作用標的為HMG-CoA還原酶\nC. 與statin類藥物併用時，會增加橫紋肌溶解症之風險\nD. 可與制酸劑一起服用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於ezetimibe的敘述，何者正確？\nA. 含azetidinone結構\nB. 作用標的為HMG-CoA還原酶\nC. 與statin類藥物併用時，會增加橫紋肌溶解症之風險\nD. 可與制酸劑一起服用\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1083984375", "True"]], [["-3.484375", "False"]], [["-3.859375", "False"]], [["-2.984375", "False"]]], "filtered_resps": [["-0.1083984375", "True"], ["-3.484375", "False"], ["-3.859375", "False"], ["-2.984375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6e29a77e85152c364eee8907bdc36a3323e70cd94ac6f2ea156920f7f7326e31", "prompt_hash": "c0e27a5535853e9311e9cd9ed85789868956296e9fc1dc541a5fde2857df760e", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 246, "doc": {"question": "有關aminoglycosides類抗生素抗藥性敘述，下列何者正確？", "A": "對streptomycin已產生抗藥性的結核分枝桿菌通常也對amikacin有交互抗藥性", "B": "gentamicin對鏈球菌及腸球菌效用較差主要是因為對細菌核糖體作用差", "C": "vancomycin可以促進gentamicin效用是因為增進gentamicin在細菌中的藥物攝取量", "D": "若產生kanamycin與neomycin交互抗藥性，並不會進一步導致對amikacin的抗藥性產生", "answer": "C", "questions": "有關aminoglycosides類抗生素抗藥性敘述，下列何者正確？", "choices": ["對streptomycin已產生抗藥性的結核分枝桿菌通常也對amikacin有交互抗藥性", "gentamicin對鏈球菌及腸球菌效用較差主要是因為對細菌核糖體作用差", "vancomycin可以促進gentamicin效用是因為增進gentamicin在細菌中的藥物攝取量", "若產生kanamycin與neomycin交互抗藥性，並不會進一步導致對amikacin的抗藥性產生"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關aminoglycosides類抗生素抗藥性敘述，下列何者正確？\nA. 對streptomycin已產生抗藥性的結核分枝桿菌通常也對amikacin有交互抗藥性\nB. gentamicin對鏈球菌及腸球菌效用較差主要是因為對細菌核糖體作用差\nC. vancomycin可以促進gentamicin效用是因為增進gentamicin在細菌中的藥物攝取量\nD. 若產生kanamycin與neomycin交互抗藥性，並不會進一步導致對amikacin的抗藥性產生\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關aminoglycosides類抗生素抗藥性敘述，下列何者正確？\nA. 對streptomycin已產生抗藥性的結核分枝桿菌通常也對amikacin有交互抗藥性\nB. gentamicin對鏈球菌及腸球菌效用較差主要是因為對細菌核糖體作用差\nC. vancomycin可以促進gentamicin效用是因為增進gentamicin在細菌中的藥物攝取量\nD. 若產生kanamycin與neomycin交互抗藥性，並不會進一步導致對amikacin的抗藥性產生\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關aminoglycosides類抗生素抗藥性敘述，下列何者正確？\nA. 對streptomycin已產生抗藥性的結核分枝桿菌通常也對amikacin有交互抗藥性\nB. gentamicin對鏈球菌及腸球菌效用較差主要是因為對細菌核糖體作用差\nC. vancomycin可以促進gentamicin效用是因為增進gentamicin在細菌中的藥物攝取量\nD. 若產生kanamycin與neomycin交互抗藥性，並不會進一步導致對amikacin的抗藥性產生\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關aminoglycosides類抗生素抗藥性敘述，下列何者正確？\nA. 對streptomycin已產生抗藥性的結核分枝桿菌通常也對amikacin有交互抗藥性\nB. gentamicin對鏈球菌及腸球菌效用較差主要是因為對細菌核糖體作用差\nC. vancomycin可以促進gentamicin效用是因為增進gentamicin在細菌中的藥物攝取量\nD. 若產生kanamycin與neomycin交互抗藥性，並不會進一步導致對amikacin的抗藥性產生\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.546875", "True"]], [["-1.671875", "False"]], [["-2.296875", "False"]], [["-2.046875", "False"]]], "filtered_resps": [["-0.546875", "True"], ["-1.671875", "False"], ["-2.296875", "False"], ["-2.046875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0d4c16993cbfc92c7c43e16df99f7d5ae18049fa31aae9c5376adbcc89f1f892", "prompt_hash": "80f890f2126ec7f2cb2587523d5a043c07636295a9cc2e8aa6d50c14c1fd306c", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 247, "doc": {"question": "下列何者是zidovudine結構中的鹼基？", "A": "cytosine", "B": "adenine", "C": "guanine", "D": "thymine", "answer": "D", "questions": "下列何者是zidovudine結構中的鹼基？", "choices": ["cytosine", "adenine", "guanine", "thymine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是zidovudine結構中的鹼基？\nA. cytosine\nB. adenine\nC. guanine\nD. thymine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是zidovudine結構中的鹼基？\nA. cytosine\nB. adenine\nC. guanine\nD. thymine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是zidovudine結構中的鹼基？\nA. cytosine\nB. adenine\nC. guanine\nD. thymine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是zidovudine結構中的鹼基？\nA. cytosine\nB. adenine\nC. guanine\nD. thymine\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.09375", "False"]], [["-0.71484375", "True"]], [["-2.96875", "False"]], [["-2.09375", "False"]]], "filtered_resps": [["-1.09375", "False"], ["-0.71484375", "True"], ["-2.96875", "False"], ["-2.09375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "253cb7bde3039ed633f968e82ec0e601e59a6c5239986da404ed2c778bc69f18", "prompt_hash": "6069da6d88218bd99c43bf7bf5b03fdbf42e502fbb60b6afbb1248a4a3756407", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 248, "doc": {"question": "下列H2 -receptor antagonist中，何者會抑制雄激素受體而產生性無能？", "A": "cimetidine", "B": "nizatidine", "C": "famotidine", "D": "ranitidine", "answer": "A", "questions": "下列H2 -receptor antagonist中，何者會抑制雄激素受體而產生性無能？", "choices": ["cimetidine", "nizatidine", "famotidine", "ranitidine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列H2 -receptor antagonist中，何者會抑制雄激素受體而產生性無能？\nA. cimetidine\nB. nizatidine\nC. famotidine\nD. ranitidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列H2 -receptor antagonist中，何者會抑制雄激素受體而產生性無能？\nA. cimetidine\nB. nizatidine\nC. famotidine\nD. ranitidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列H2 -receptor antagonist中，何者會抑制雄激素受體而產生性無能？\nA. cimetidine\nB. nizatidine\nC. famotidine\nD. ranitidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列H2 -receptor antagonist中，何者會抑制雄激素受體而產生性無能？\nA. cimetidine\nB. nizatidine\nC. famotidine\nD. ranitidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1123046875", "True"]], [["-3.984375", "False"]], [["-4.875", "False"]], [["-2.609375", "False"]]], "filtered_resps": [["-0.1123046875", "True"], ["-3.984375", "False"], ["-4.875", "False"], ["-2.609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "30fee6658bf0e4412b6a5bf880bfb8e16dbd9afdafbaafee41d95c34c05d2270", "prompt_hash": "02ed8269d8d4f160f2ff5942ab691ad60fc80f2341ecc3dff15f3d7b07ee2b3d", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 249, "doc": {"question": "下列何種DPP-IV抑制劑，具有最高的口服生體可用率？", "A": "sitagliptin", "B": "linagliptin", "C": "alogliptin", "D": "saxagliptin", "answer": "A", "questions": "下列何種DPP-IV抑制劑，具有最高的口服生體可用率？", "choices": ["sitagliptin", "linagliptin", "alogliptin", "saxagliptin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種DPP-IV抑制劑，具有最高的口服生體可用率？\nA. sitagliptin\nB. linagliptin\nC. alogliptin\nD. saxagliptin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種DPP-IV抑制劑，具有最高的口服生體可用率？\nA. sitagliptin\nB. linagliptin\nC. alogliptin\nD. saxagliptin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種DPP-IV抑制劑，具有最高的口服生體可用率？\nA. sitagliptin\nB. linagliptin\nC. alogliptin\nD. saxagliptin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種DPP-IV抑制劑，具有最高的口服生體可用率？\nA. sitagliptin\nB. linagliptin\nC. alogliptin\nD. saxagliptin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.04833984375", "True"]], [["-4.3125", "False"]], [["-4.9375", "False"]], [["-3.671875", "False"]]], "filtered_resps": [["-0.04833984375", "True"], ["-4.3125", "False"], ["-4.9375", "False"], ["-3.671875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "49f1e1627ae1d4359e6adcd435292883da6ccc0d5a9bf037add128c606e61662", "prompt_hash": "40d31f8e315858ba849bcf789f067d5bd70a4d0fed33c5ad8774ff0bb1482c9e", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 250, "doc": {"question": "下列何者需肌肉給藥，用於治療汞、鉛及砷中毒？", "A": "dimercaprol", "B": "deferoxamine", "C": "succimer", "D": "penicillamine", "answer": "A", "questions": "下列何者需肌肉給藥，用於治療汞、鉛及砷中毒？", "choices": ["dimercaprol", "deferoxamine", "succimer", "penicillamine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者需肌肉給藥，用於治療汞、鉛及砷中毒？\nA. dimercaprol\nB. deferoxamine\nC. succimer\nD. penicillamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者需肌肉給藥，用於治療汞、鉛及砷中毒？\nA. dimercaprol\nB. deferoxamine\nC. succimer\nD. penicillamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者需肌肉給藥，用於治療汞、鉛及砷中毒？\nA. dimercaprol\nB. deferoxamine\nC. succimer\nD. penicillamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者需肌肉給藥，用於治療汞、鉛及砷中毒？\nA. dimercaprol\nB. deferoxamine\nC. succimer\nD. penicillamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0174560546875", "True"]], [["-6.78125", "False"]], [["-5.78125", "False"]], [["-4.90625", "False"]]], "filtered_resps": [["-0.0174560546875", "True"], ["-6.78125", "False"], ["-5.78125", "False"], ["-4.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6237cfd1d5db89809d15c837aa99c6d8d22d5240afb2c272df50a92fd6bcd7b7", "prompt_hash": "cc9dec8559edc6d9c850935e6c7923815d368bafdc1b441173394627bea30340", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 251, "doc": {"question": "當心臟衰竭又相伴發生水腫，除了使用亨利氏環之利尿劑（loop diuretics），可併用下列何種藥物以增加療效？", "A": "acetazolamide", "B": "spironolactone", "C": "triamterene", "D": "hydrochlorothiazide", "answer": "D", "questions": "當心臟衰竭又相伴發生水腫，除了使用亨利氏環之利尿劑（loop diuretics），可併用下列何種藥物以增加療效？", "choices": ["acetazolamide", "spironolactone", "triamterene", "hydrochlorothiazide"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當心臟衰竭又相伴發生水腫，除了使用亨利氏環之利尿劑（loop diuretics），可併用下列何種藥物以增加療效？\nA. acetazolamide\nB. spironolactone\nC. triamterene\nD. hydrochlorothiazide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當心臟衰竭又相伴發生水腫，除了使用亨利氏環之利尿劑（loop diuretics），可併用下列何種藥物以增加療效？\nA. acetazolamide\nB. spironolactone\nC. triamterene\nD. hydrochlorothiazide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當心臟衰竭又相伴發生水腫，除了使用亨利氏環之利尿劑（loop diuretics），可併用下列何種藥物以增加療效？\nA. acetazolamide\nB. spironolactone\nC. triamterene\nD. hydrochlorothiazide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當心臟衰竭又相伴發生水腫，除了使用亨利氏環之利尿劑（loop diuretics），可併用下列何種藥物以增加療效？\nA. acetazolamide\nB. spironolactone\nC. triamterene\nD. hydrochlorothiazide\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.7265625", "False"]], [["-0.84765625", "True"]], [["-4.21875", "False"]], [["-0.97265625", "False"]]], "filtered_resps": [["-1.7265625", "False"], ["-0.84765625", "True"], ["-4.21875", "False"], ["-0.97265625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9bf6e7f2bad7e02e2654fed7f6f6564efcb7cd2949dc118d996be025c67180da", "prompt_hash": "c07c1d48ffa91f19db4c14679cf3991a4bd52afa2d10042c055fc752ded5c9c1", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 252, "doc": {"question": "Leu-enkephalin是由幾種不同胺基酸組成？", "A": "5", "B": "4", "C": "6", "D": "8", "answer": "B", "questions": "Leu-enkephalin是由幾種不同胺基酸組成？", "choices": ["5", "4", "6", "8"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLeu-enkephalin是由幾種不同胺基酸組成？\nA. 5\nB. 4\nC. 6\nD. 8\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLeu-enkephalin是由幾種不同胺基酸組成？\nA. 5\nB. 4\nC. 6\nD. 8\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLeu-enkephalin是由幾種不同胺基酸組成？\nA. 5\nB. 4\nC. 6\nD. 8\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLeu-enkephalin是由幾種不同胺基酸組成？\nA. 5\nB. 4\nC. 6\nD. 8\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.3125", "False"]], [["-0.19140625", "True"]], [["-3.5625", "False"]], [["-3.0625", "False"]]], "filtered_resps": [["-2.3125", "False"], ["-0.19140625", "True"], ["-3.5625", "False"], ["-3.0625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8cc0035d962d8ad85ee3a80d4d220957176d32eb3446a2759908d7b10eefc610", "prompt_hash": "c1b21341a55c042f68a8872fdf06374dd309a7718469b5b04c09af769f7f61c9", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 253, "doc": {"question": "Cosyntropin與human ACTH結構中那一段胺基酸序列相同？", "A": "25～39", "B": "16～33", "C": "5～27", "D": "1～24", "answer": "D", "questions": "Cosyntropin與human ACTH結構中那一段胺基酸序列相同？", "choices": ["25～39", "16～33", "5～27", "1～24"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCosyntropin與human ACTH結構中那一段胺基酸序列相同？\nA. 25～39\nB. 16～33\nC. 5～27\nD. 1～24\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCosyntropin與human ACTH結構中那一段胺基酸序列相同？\nA. 25～39\nB. 16～33\nC. 5～27\nD. 1～24\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCosyntropin與human ACTH結構中那一段胺基酸序列相同？\nA. 25～39\nB. 16～33\nC. 5～27\nD. 1～24\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCosyntropin與human ACTH結構中那一段胺基酸序列相同？\nA. 25～39\nB. 16～33\nC. 5～27\nD. 1～24\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.90625", "False"]], [["-1.90625", "False"]], [["-3.15625", "False"]], [["-0.283203125", "True"]]], "filtered_resps": [["-2.90625", "False"], ["-1.90625", "False"], ["-3.15625", "False"], ["-0.283203125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2b5d0a9da848f85c428a8fa00f7c012ac215f894c3bc725f7df49fcc1a5f9377", "prompt_hash": "a73a7f91e8fee13f9eb07129616659db0d29ccb6af49f1df23ecee64c32bf4b0", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 254, "doc": {"question": "在hydrocortisone之結構式中，導入下列何者取代基，會增加其鈉離子滯留效果？", "A": "16α-methyl", "B": "9α-fluoro", "C": "17α-hydroxy", "D": "16β-methyl", "answer": "B", "questions": "在hydrocortisone之結構式中，導入下列何者取代基，會增加其鈉離子滯留效果？", "choices": ["16α-methyl", "9α-fluoro", "17α-hydroxy", "16β-methyl"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在hydrocortisone之結構式中，導入下列何者取代基，會增加其鈉離子滯留效果？\nA. 16α-methyl\nB. 9α-fluoro\nC. 17α-hydroxy\nD. 16β-methyl\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在hydrocortisone之結構式中，導入下列何者取代基，會增加其鈉離子滯留效果？\nA. 16α-methyl\nB. 9α-fluoro\nC. 17α-hydroxy\nD. 16β-methyl\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在hydrocortisone之結構式中，導入下列何者取代基，會增加其鈉離子滯留效果？\nA. 16α-methyl\nB. 9α-fluoro\nC. 17α-hydroxy\nD. 16β-methyl\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在hydrocortisone之結構式中，導入下列何者取代基，會增加其鈉離子滯留效果？\nA. 16α-methyl\nB. 9α-fluoro\nC. 17α-hydroxy\nD. 16β-methyl\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.515625", "False"]], [["-0.26953125", "True"]], [["-3.265625", "False"]], [["-2.140625", "False"]]], "filtered_resps": [["-2.515625", "False"], ["-0.26953125", "True"], ["-3.265625", "False"], ["-2.140625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "675bcd4c2d8e05066e9a6533fde3907e7d8ee3ebb1a11a95014fe417dd5e8aaf", "prompt_hash": "10d418b4fffd44ef76c2eccff49b213c24fac3587b992c99377a29d494ee2ef8", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 255, "doc": {"question": "Flecainide 能有效地抑制心室期外收縮（premature ventricular contraction），下列敘述其藥物作用特質何者正確？", "A": "抑制鈉離子管道及鉀離子管道，半衰期短、大約 2 小時", "B": "代謝物能抑制乙型腎上腺受體（beta-adenoceptor），半衰期長達 20 小時", "C": "抑制鈉離子管道及鉀離子管道，會延長動作電位期間", "D": "抑制鈉離子管道效價強、作用具 slow unblocking kinetics", "answer": "D", "questions": "Flecainide 能有效地抑制心室期外收縮（premature ventricular contraction），下列敘述其藥物作用特質何者正確？", "choices": ["抑制鈉離子管道及鉀離子管道，半衰期短、大約 2 小時", "代謝物能抑制乙型腎上腺受體（beta-adenoceptor），半衰期長達 20 小時", "抑制鈉離子管道及鉀離子管道，會延長動作電位期間", "抑制鈉離子管道效價強、作用具 slow unblocking kinetics"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFlecainide 能有效地抑制心室期外收縮（premature ventricular contraction），下列敘述其藥物作用特質何者正確？\nA. 抑制鈉離子管道及鉀離子管道，半衰期短、大約 2 小時\nB. 代謝物能抑制乙型腎上腺受體（beta-adenoceptor），半衰期長達 20 小時\nC. 抑制鈉離子管道及鉀離子管道，會延長動作電位期間\nD. 抑制鈉離子管道效價強、作用具 slow unblocking kinetics\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFlecainide 能有效地抑制心室期外收縮（premature ventricular contraction），下列敘述其藥物作用特質何者正確？\nA. 抑制鈉離子管道及鉀離子管道，半衰期短、大約 2 小時\nB. 代謝物能抑制乙型腎上腺受體（beta-adenoceptor），半衰期長達 20 小時\nC. 抑制鈉離子管道及鉀離子管道，會延長動作電位期間\nD. 抑制鈉離子管道效價強、作用具 slow unblocking kinetics\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFlecainide 能有效地抑制心室期外收縮（premature ventricular contraction），下列敘述其藥物作用特質何者正確？\nA. 抑制鈉離子管道及鉀離子管道，半衰期短、大約 2 小時\nB. 代謝物能抑制乙型腎上腺受體（beta-adenoceptor），半衰期長達 20 小時\nC. 抑制鈉離子管道及鉀離子管道，會延長動作電位期間\nD. 抑制鈉離子管道效價強、作用具 slow unblocking kinetics\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFlecainide 能有效地抑制心室期外收縮（premature ventricular contraction），下列敘述其藥物作用特質何者正確？\nA. 抑制鈉離子管道及鉀離子管道，半衰期短、大約 2 小時\nB. 代謝物能抑制乙型腎上腺受體（beta-adenoceptor），半衰期長達 20 小時\nC. 抑制鈉離子管道及鉀離子管道，會延長動作電位期間\nD. 抑制鈉離子管道效價強、作用具 slow unblocking kinetics\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.125", "False"]], [["-3.609375", "False"]], [["-0.7421875", "True"]], [["-0.7421875", "False"]]], "filtered_resps": [["-4.125", "False"], ["-3.609375", "False"], ["-0.7421875", "True"], ["-0.7421875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "da3568a8221e83ec464651c9f48097b9e69ed764a751321275ce0bceb4edbd58", "prompt_hash": "c3ded11a3457d1cf115fe66b8d47c911d3da21176b50b9eb9d9e9cfb5442754b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 256, "doc": {"question": "下列關於prodrug之敘述，何者最適當？", "A": "代謝物易由腎臟排出，半衰期短", "B": "在血中與白蛋白（albumin）結合度高", "C": "在體內之代謝產物具有生物活性", "D": "因有first-pass effect，口服吸收效果差", "answer": "C", "questions": "下列關於prodrug之敘述，何者最適當？", "choices": ["代謝物易由腎臟排出，半衰期短", "在血中與白蛋白（albumin）結合度高", "在體內之代謝產物具有生物活性", "因有first-pass effect，口服吸收效果差"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於prodrug之敘述，何者最適當？\nA. 代謝物易由腎臟排出，半衰期短\nB. 在血中與白蛋白（albumin）結合度高\nC. 在體內之代謝產物具有生物活性\nD. 因有first-pass effect，口服吸收效果差\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於prodrug之敘述，何者最適當？\nA. 代謝物易由腎臟排出，半衰期短\nB. 在血中與白蛋白（albumin）結合度高\nC. 在體內之代謝產物具有生物活性\nD. 因有first-pass effect，口服吸收效果差\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於prodrug之敘述，何者最適當？\nA. 代謝物易由腎臟排出，半衰期短\nB. 在血中與白蛋白（albumin）結合度高\nC. 在體內之代謝產物具有生物活性\nD. 因有first-pass effect，口服吸收效果差\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於prodrug之敘述，何者最適當？\nA. 代謝物易由腎臟排出，半衰期短\nB. 在血中與白蛋白（albumin）結合度高\nC. 在體內之代謝產物具有生物活性\nD. 因有first-pass effect，口服吸收效果差\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.796875", "False"]], [["-5.0625", "False"]], [["-0.177734375", "True"]], [["-2.046875", "False"]]], "filtered_resps": [["-3.796875", "False"], ["-5.0625", "False"], ["-0.177734375", "True"], ["-2.046875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fdcf76a0c3837773cce4af7b2c668fe6c429de8c0460031ae1a189deb5b5c0f1", "prompt_hash": "788f5b7c75e80d3346a48c925c34713be7977070dfea1a44d4962173f2ae03d1", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 257, "doc": {"question": "Minoxidil在體內可產生何種活性代謝物？", "A": "NH-sulfate", "B": "NH-glucuronide", "C": "N-O-sulfate", "D": "N-O-glucuronide", "answer": "C", "questions": "Minoxidil在體內可產生何種活性代謝物？", "choices": ["NH-sulfate", "NH-glucuronide", "N-O-sulfate", "N-O-glucuronide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMinoxidil在體內可產生何種活性代謝物？\nA. NH-sulfate\nB. NH-glucuronide\nC. N-O-sulfate\nD. N-O-glucuronide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMinoxidil在體內可產生何種活性代謝物？\nA. NH-sulfate\nB. NH-glucuronide\nC. N-O-sulfate\nD. N-O-glucuronide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMinoxidil在體內可產生何種活性代謝物？\nA. NH-sulfate\nB. NH-glucuronide\nC. N-O-sulfate\nD. N-O-glucuronide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMinoxidil在體內可產生何種活性代謝物？\nA. NH-sulfate\nB. NH-glucuronide\nC. N-O-sulfate\nD. N-O-glucuronide\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.28125", "False"]], [["-2.90625", "False"]], [["-0.53515625", "True"]], [["-2.53125", "False"]]], "filtered_resps": [["-1.28125", "False"], ["-2.90625", "False"], ["-0.53515625", "True"], ["-2.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e5ea3dd2b10cf08e37b18c1b5d4ef7536a7ae9ebb4cf68aca23c65d2f3d50a0d", "prompt_hash": "aa2b47b1e4afd66aa31a995946908e3430df9cc393f6f4cac0bb98f685d2145b", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 258, "doc": {"question": "葡萄糖六磷酸鹽脫氫酶缺陷（glucose-6-phosphate dehydrogenase-deficient）的病人使用下列何種藥物並不會引起溶血性貧血（hemolytic anemia）之副作用？", "A": "ampicillin", "B": "chloramphenicol", "C": "primaquine", "D": "p-aminosalicylic acid", "answer": "A", "questions": "葡萄糖六磷酸鹽脫氫酶缺陷（glucose-6-phosphate dehydrogenase-deficient）的病人使用下列何種藥物並不會引起溶血性貧血（hemolytic anemia）之副作用？", "choices": ["ampicillin", "chloramphenicol", "primaquine", "p-aminosalicylic acid"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n葡萄糖六磷酸鹽脫氫酶缺陷（glucose-6-phosphate dehydrogenase-deficient）的病人使用下列何種藥物並不會引起溶血性貧血（hemolytic anemia）之副作用？\nA. ampicillin\nB. chloramphenicol\nC. primaquine\nD. p-aminosalicylic acid\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n葡萄糖六磷酸鹽脫氫酶缺陷（glucose-6-phosphate dehydrogenase-deficient）的病人使用下列何種藥物並不會引起溶血性貧血（hemolytic anemia）之副作用？\nA. ampicillin\nB. chloramphenicol\nC. primaquine\nD. p-aminosalicylic acid\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n葡萄糖六磷酸鹽脫氫酶缺陷（glucose-6-phosphate dehydrogenase-deficient）的病人使用下列何種藥物並不會引起溶血性貧血（hemolytic anemia）之副作用？\nA. ampicillin\nB. chloramphenicol\nC. primaquine\nD. p-aminosalicylic acid\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n葡萄糖六磷酸鹽脫氫酶缺陷（glucose-6-phosphate dehydrogenase-deficient）的病人使用下列何種藥物並不會引起溶血性貧血（hemolytic anemia）之副作用？\nA. ampicillin\nB. chloramphenicol\nC. primaquine\nD. p-aminosalicylic acid\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.08203125", "True"]], [["-3.078125", "False"]], [["-6.09375", "False"]], [["-3.578125", "False"]]], "filtered_resps": [["-0.08203125", "True"], ["-3.078125", "False"], ["-6.09375", "False"], ["-3.578125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8520dd36ed36dd91638bba2ae973b67e2c52246f9f9c8af032dbbe24a0d25223", "prompt_hash": "ffc9ce68651dc581bf5a830922ac81b06a4175b051963a25dd363fc50c932797", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 259, "doc": {"question": "下列有關benzodiazepine之敘述，何者正確？", "A": "flurazepam是benzodiazepine受體拮抗劑，能快速地反轉benzodiazepine藥物的作用", "B": "半衰期較短的benzodiazepine較不易產生藥物依賴性", "C": "增加GABAA接受器氯離子通道開啟的時間（duration）", "D": "長期使用會造成耐藥性（tolerance），與benzodiazepine受體數量降低（down regulation）有關", "answer": "D", "questions": "下列有關benzodiazepine之敘述，何者正確？", "choices": ["flurazepam是benzodiazepine受體拮抗劑，能快速地反轉benzodiazepine藥物的作用", "半衰期較短的benzodiazepine較不易產生藥物依賴性", "增加GABAA接受器氯離子通道開啟的時間（duration）", "長期使用會造成耐藥性（tolerance），與benzodiazepine受體數量降低（down regulation）有關"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關benzodiazepine之敘述，何者正確？\nA. flurazepam是benzodiazepine受體拮抗劑，能快速地反轉benzodiazepine藥物的作用\nB. 半衰期較短的benzodiazepine較不易產生藥物依賴性\nC. 增加GABAA接受器氯離子通道開啟的時間（duration）\nD. 長期使用會造成耐藥性（tolerance），與benzodiazepine受體數量降低（down regulation）有關\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關benzodiazepine之敘述，何者正確？\nA. flurazepam是benzodiazepine受體拮抗劑，能快速地反轉benzodiazepine藥物的作用\nB. 半衰期較短的benzodiazepine較不易產生藥物依賴性\nC. 增加GABAA接受器氯離子通道開啟的時間（duration）\nD. 長期使用會造成耐藥性（tolerance），與benzodiazepine受體數量降低（down regulation）有關\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關benzodiazepine之敘述，何者正確？\nA. flurazepam是benzodiazepine受體拮抗劑，能快速地反轉benzodiazepine藥物的作用\nB. 半衰期較短的benzodiazepine較不易產生藥物依賴性\nC. 增加GABAA接受器氯離子通道開啟的時間（duration）\nD. 長期使用會造成耐藥性（tolerance），與benzodiazepine受體數量降低（down regulation）有關\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關benzodiazepine之敘述，何者正確？\nA. flurazepam是benzodiazepine受體拮抗劑，能快速地反轉benzodiazepine藥物的作用\nB. 半衰期較短的benzodiazepine較不易產生藥物依賴性\nC. 增加GABAA接受器氯離子通道開啟的時間（duration）\nD. 長期使用會造成耐藥性（tolerance），與benzodiazepine受體數量降低（down regulation）有關\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.109375", "False"]], [["-2.359375", "False"]], [["-0.353515625", "True"]], [["-1.8515625", "False"]]], "filtered_resps": [["-3.109375", "False"], ["-2.359375", "False"], ["-0.353515625", "True"], ["-1.8515625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1d653df4df2072810a6199c91e795eba943df8df5bb93273529d7a985a882936", "prompt_hash": "502920768b91c07d16b5e9ec6d6f958a9b266a0d644ae469211242f21ac0bbc5", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 260, "doc": {"question": "下列有關buspirone之敘述，何者錯誤？", "A": "不具有鎮靜及肌肉放鬆之作用", "B": "為抗焦慮藥物，可用於長期治療慢性焦慮之易怒與敵意症狀", "C": "藥物成癮性較低", "D": "屬於速效的作用，可用於恐慌症", "answer": "D", "questions": "下列有關buspirone之敘述，何者錯誤？", "choices": ["不具有鎮靜及肌肉放鬆之作用", "為抗焦慮藥物，可用於長期治療慢性焦慮之易怒與敵意症狀", "藥物成癮性較低", "屬於速效的作用，可用於恐慌症"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關buspirone之敘述，何者錯誤？\nA. 不具有鎮靜及肌肉放鬆之作用\nB. 為抗焦慮藥物，可用於長期治療慢性焦慮之易怒與敵意症狀\nC. 藥物成癮性較低\nD. 屬於速效的作用，可用於恐慌症\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關buspirone之敘述，何者錯誤？\nA. 不具有鎮靜及肌肉放鬆之作用\nB. 為抗焦慮藥物，可用於長期治療慢性焦慮之易怒與敵意症狀\nC. 藥物成癮性較低\nD. 屬於速效的作用，可用於恐慌症\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關buspirone之敘述，何者錯誤？\nA. 不具有鎮靜及肌肉放鬆之作用\nB. 為抗焦慮藥物，可用於長期治療慢性焦慮之易怒與敵意症狀\nC. 藥物成癮性較低\nD. 屬於速效的作用，可用於恐慌症\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關buspirone之敘述，何者錯誤？\nA. 不具有鎮靜及肌肉放鬆之作用\nB. 為抗焦慮藥物，可用於長期治療慢性焦慮之易怒與敵意症狀\nC. 藥物成癮性較低\nD. 屬於速效的作用，可用於恐慌症\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.25", "False"]], [["-6.5", "False"]], [["-8.5", "False"]], [["-0.008544921875", "True"]]], "filtered_resps": [["-5.25", "False"], ["-6.5", "False"], ["-8.5", "False"], ["-0.008544921875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "12a41d6b8007a23af0ea0064a4c5364823134697ce56980dd64dd130228295eb", "prompt_hash": "1cf99ad77f70ea8b2b380aab4ed0e46fa98d895939a19496965380c336a0c277", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 261, "doc": {"question": "有關降血脂藥物niacin之作用機制與副作用，下列敘述何者錯誤？", "A": "可能會增加血中尿酸濃度", "B": "能促進HDL分解代謝", "C": "能降低三酸甘油脂（triglycerides）、LDL及Lp(a)", "D": "能抑制肝臟分泌VLDL，進而減少LDL產生", "answer": "B", "questions": "有關降血脂藥物niacin之作用機制與副作用，下列敘述何者錯誤？", "choices": ["可能會增加血中尿酸濃度", "能促進HDL分解代謝", "能降低三酸甘油脂（triglycerides）、LDL及Lp(a)", "能抑制肝臟分泌VLDL，進而減少LDL產生"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關降血脂藥物niacin之作用機制與副作用，下列敘述何者錯誤？\nA. 可能會增加血中尿酸濃度\nB. 能促進HDL分解代謝\nC. 能降低三酸甘油脂（triglycerides）、LDL及Lp(a)\nD. 能抑制肝臟分泌VLDL，進而減少LDL產生\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關降血脂藥物niacin之作用機制與副作用，下列敘述何者錯誤？\nA. 可能會增加血中尿酸濃度\nB. 能促進HDL分解代謝\nC. 能降低三酸甘油脂（triglycerides）、LDL及Lp(a)\nD. 能抑制肝臟分泌VLDL，進而減少LDL產生\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關降血脂藥物niacin之作用機制與副作用，下列敘述何者錯誤？\nA. 可能會增加血中尿酸濃度\nB. 能促進HDL分解代謝\nC. 能降低三酸甘油脂（triglycerides）、LDL及Lp(a)\nD. 能抑制肝臟分泌VLDL，進而減少LDL產生\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關降血脂藥物niacin之作用機制與副作用，下列敘述何者錯誤？\nA. 可能會增加血中尿酸濃度\nB. 能促進HDL分解代謝\nC. 能降低三酸甘油脂（triglycerides）、LDL及Lp(a)\nD. 能抑制肝臟分泌VLDL，進而減少LDL產生\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.09375", "False"]], [["-0.0947265625", "True"]], [["-2.59375", "False"]], [["-4.34375", "False"]]], "filtered_resps": [["-6.09375", "False"], ["-0.0947265625", "True"], ["-2.59375", "False"], ["-4.34375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "53a942739e12301f12c2f0023079cc1d7e040c185c21a286ef9907f12e6fd657", "prompt_hash": "95f624e977e803e7d5796e9b99cbf5921285af24daf13504bc362d84cf2ef62f", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 262, "doc": {"question": "下列何種藥物最適合用於癲癇重積症（status epileptics）？", "A": "Lorazepam", "B": "Lamotrigine", "C": "Carbamazepine", "D": "Zopidem", "answer": "A", "questions": "下列何種藥物最適合用於癲癇重積症（status epileptics）？", "choices": ["Lorazepam", "Lamotrigine", "Carbamazepine", "Zopidem"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物最適合用於癲癇重積症（status epileptics）？\nA. Lorazepam\nB. Lamotrigine\nC. Carbamazepine\nD. Zopidem\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物最適合用於癲癇重積症（status epileptics）？\nA. Lorazepam\nB. Lamotrigine\nC. Carbamazepine\nD. Zopidem\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物最適合用於癲癇重積症（status epileptics）？\nA. Lorazepam\nB. Lamotrigine\nC. Carbamazepine\nD. Zopidem\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物最適合用於癲癇重積症（status epileptics）？\nA. Lorazepam\nB. Lamotrigine\nC. Carbamazepine\nD. Zopidem\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.041748046875", "True"]], [["-4.65625", "False"]], [["-5.53125", "False"]], [["-4.03125", "False"]]], "filtered_resps": [["-0.041748046875", "True"], ["-4.65625", "False"], ["-5.53125", "False"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d3df4ffd0d81ab35dd8c610e2045cb6270afc6d785244fb0b9dc4bb421731089", "prompt_hash": "81ca55f482b9dc2a7aa37cc9d3c00468324f104ef76970ad49961bbd30ca7872", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 263, "doc": {"question": "下列何種血中離子減少會增強Digoxin的毒性副作用？", "A": "鈉離子", "B": "氯離子", "C": "鈣離子", "D": "鉀離子", "answer": "D", "questions": "下列何種血中離子減少會增強Digoxin的毒性副作用？", "choices": ["鈉離子", "氯離子", "鈣離子", "鉀離子"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種血中離子減少會增強Digoxin的毒性副作用？\nA. 鈉離子\nB. 氯離子\nC. 鈣離子\nD. 鉀離子\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種血中離子減少會增強Digoxin的毒性副作用？\nA. 鈉離子\nB. 氯離子\nC. 鈣離子\nD. 鉀離子\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種血中離子減少會增強Digoxin的毒性副作用？\nA. 鈉離子\nB. 氯離子\nC. 鈣離子\nD. 鉀離子\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種血中離子減少會增強Digoxin的毒性副作用？\nA. 鈉離子\nB. 氯離子\nC. 鈣離子\nD. 鉀離子\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.15625", "False"]], [["-4.53125", "False"]], [["-4.78125", "False"]], [["-0.027099609375", "True"]]], "filtered_resps": [["-5.15625", "False"], ["-4.53125", "False"], ["-4.78125", "False"], ["-0.027099609375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "97a44e86aaca572d62be9ac8bcf5dc50edcab4b6d38ceee575bca65a877f10d6", "prompt_hash": "c5f16030cc64d44cc33a578fee3f9820fa19dfda766247241fcc9efc287f2613", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 264, "doc": {"question": "Flavin monooxygenase不會產生下列何種代謝反應？", "A": "S-oxidation", "B": "epoxidation", "C": "benzylic hydroxylation", "D": "N-oxidation", "answer": "B", "questions": "Flavin monooxygenase不會產生下列何種代謝反應？", "choices": ["S-oxidation", "epoxidation", "benzylic hydroxylation", "N-oxidation"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFlavin monooxygenase不會產生下列何種代謝反應？\nA. S-oxidation\nB. epoxidation\nC. benzylic hydroxylation\nD. N-oxidation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFlavin monooxygenase不會產生下列何種代謝反應？\nA. S-oxidation\nB. epoxidation\nC. benzylic hydroxylation\nD. N-oxidation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFlavin monooxygenase不會產生下列何種代謝反應？\nA. S-oxidation\nB. epoxidation\nC. benzylic hydroxylation\nD. N-oxidation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFlavin monooxygenase不會產生下列何種代謝反應？\nA. S-oxidation\nB. epoxidation\nC. benzylic hydroxylation\nD. N-oxidation\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.263671875", "True"]], [["-2.265625", "False"]], [["-3.390625", "False"]], [["-2.390625", "False"]]], "filtered_resps": [["-0.263671875", "True"], ["-2.265625", "False"], ["-3.390625", "False"], ["-2.390625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3cc87cc3a759b91fad7b101ed50bca1c3f2f4f558871d25b8782f765e319885b", "prompt_hash": "aa864480b4587db916d67d33d5f541227ab2eba4b93c3eb7c6bc48a218cce6fa", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 265, "doc": {"question": "下列何種藥物會加入PEG以降低抗體免疫反應？", "A": "certolizumab", "B": "etanercept", "C": "golimumab", "D": "rituximab", "answer": "A", "questions": "下列何種藥物會加入PEG以降低抗體免疫反應？", "choices": ["certolizumab", "etanercept", "golimumab", "rituximab"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物會加入PEG以降低抗體免疫反應？\nA. certolizumab\nB. etanercept\nC. golimumab\nD. rituximab\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物會加入PEG以降低抗體免疫反應？\nA. certolizumab\nB. etanercept\nC. golimumab\nD. rituximab\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物會加入PEG以降低抗體免疫反應？\nA. certolizumab\nB. etanercept\nC. golimumab\nD. rituximab\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物會加入PEG以降低抗體免疫反應？\nA. certolizumab\nB. etanercept\nC. golimumab\nD. rituximab\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.12353515625", "True"]], [["-4.125", "False"]], [["-4.125", "False"]], [["-2.5", "False"]]], "filtered_resps": [["-0.12353515625", "True"], ["-4.125", "False"], ["-4.125", "False"], ["-2.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9c3270081f9bb90aa8d999f0027a4620fb26b81e9109af9fecbeaf3380253bcc", "prompt_hash": "9bd9f5d77930e70c2b8c1c70d7922e162cf0bb89429112be513cb0f64d669a1a", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 266, "doc": {"question": "陳先生腦下垂體長腺瘤（adenoma），且發現血中含大量之生長激素（growth hormone），經進行手術切除腺瘤後，仍發現血中生長激素濃度過高，此時給與下列何種藥物應可降低生長激素過度分泌的問題？", "A": "leuprolide", "B": "conivaptan", "C": "atosiban", "D": "octreotide", "answer": "D", "questions": "陳先生腦下垂體長腺瘤（adenoma），且發現血中含大量之生長激素（growth hormone），經進行手術切除腺瘤後，仍發現血中生長激素濃度過高，此時給與下列何種藥物應可降低生長激素過度分泌的問題？", "choices": ["leuprolide", "conivaptan", "atosiban", "octreotide"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n陳先生腦下垂體長腺瘤（adenoma），且發現血中含大量之生長激素（growth hormone），經進行手術切除腺瘤後，仍發現血中生長激素濃度過高，此時給與下列何種藥物應可降低生長激素過度分泌的問題？\nA. leuprolide\nB. conivaptan\nC. atosiban\nD. octreotide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n陳先生腦下垂體長腺瘤（adenoma），且發現血中含大量之生長激素（growth hormone），經進行手術切除腺瘤後，仍發現血中生長激素濃度過高，此時給與下列何種藥物應可降低生長激素過度分泌的問題？\nA. leuprolide\nB. conivaptan\nC. atosiban\nD. octreotide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n陳先生腦下垂體長腺瘤（adenoma），且發現血中含大量之生長激素（growth hormone），經進行手術切除腺瘤後，仍發現血中生長激素濃度過高，此時給與下列何種藥物應可降低生長激素過度分泌的問題？\nA. leuprolide\nB. conivaptan\nC. atosiban\nD. octreotide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n陳先生腦下垂體長腺瘤（adenoma），且發現血中含大量之生長激素（growth hormone），經進行手術切除腺瘤後，仍發現血中生長激素濃度過高，此時給與下列何種藥物應可降低生長激素過度分泌的問題？\nA. leuprolide\nB. conivaptan\nC. atosiban\nD. octreotide\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.5", "False"]], [["-7.125", "False"]], [["-8.25", "False"]], [["-0.00592041015625", "True"]]], "filtered_resps": [["-5.5", "False"], ["-7.125", "False"], ["-8.25", "False"], ["-0.00592041015625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "53d3a91af5fcd370f426d56355f0fee435fdff98efdda8d44455a26344fba08c", "prompt_hash": "1250c4e4a6caf5901eb9cd0ff36cff237a0cfbf21fc3d822c039372e829bcbf7", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 267, "doc": {"question": "下列選擇性雌激素受體調節劑（SERMs），何者不具有triphenylethylene之結構？", "A": "tamoxifen", "B": "raloxifene", "C": "clomiphene", "D": "toremifene", "answer": "B", "questions": "下列選擇性雌激素受體調節劑（SERMs），何者不具有triphenylethylene之結構？", "choices": ["tamoxifen", "raloxifene", "clomiphene", "toremifene"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列選擇性雌激素受體調節劑（SERMs），何者不具有triphenylethylene之結構？\nA. tamoxifen\nB. raloxifene\nC. clomiphene\nD. toremifene\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列選擇性雌激素受體調節劑（SERMs），何者不具有triphenylethylene之結構？\nA. tamoxifen\nB. raloxifene\nC. clomiphene\nD. toremifene\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列選擇性雌激素受體調節劑（SERMs），何者不具有triphenylethylene之結構？\nA. tamoxifen\nB. raloxifene\nC. clomiphene\nD. toremifene\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列選擇性雌激素受體調節劑（SERMs），何者不具有triphenylethylene之結構？\nA. tamoxifen\nB. raloxifene\nC. clomiphene\nD. toremifene\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.125", "False"]], [["-2.515625", "False"]], [["-0.140625", "True"]], [["-3.515625", "False"]]], "filtered_resps": [["-4.125", "False"], ["-2.515625", "False"], ["-0.140625", "True"], ["-3.515625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c6f73936ebafeba334f41e4a9acf7cb942c7e28139bdb623d0e61d8ade24fa24", "prompt_hash": "13d51c3f41e841b9577b6a3e824fc3b448bc50d7d73b0e6f78eed1f27feff3be", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 268, "doc": {"question": "下列ACE抑制劑中，何者因結構含-SH基團使藥效最短？", "A": "captopril", "B": "fosinopril", "C": "lisinopril", "D": "enalapril", "answer": "A", "questions": "下列ACE抑制劑中，何者因結構含-SH基團使藥效最短？", "choices": ["captopril", "fosinopril", "lisinopril", "enalapril"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列ACE抑制劑中，何者因結構含-SH基團使藥效最短？\nA. captopril\nB. fosinopril\nC. lisinopril\nD. enalapril\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列ACE抑制劑中，何者因結構含-SH基團使藥效最短？\nA. captopril\nB. fosinopril\nC. lisinopril\nD. enalapril\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列ACE抑制劑中，何者因結構含-SH基團使藥效最短？\nA. captopril\nB. fosinopril\nC. lisinopril\nD. enalapril\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列ACE抑制劑中，何者因結構含-SH基團使藥效最短？\nA. captopril\nB. fosinopril\nC. lisinopril\nD. enalapril\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.3125", "False"]], [["-5.4375", "False"]], [["-0.053466796875", "True"]], [["-3.421875", "False"]]], "filtered_resps": [["-4.3125", "False"], ["-5.4375", "False"], ["-0.053466796875", "True"], ["-3.421875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4a94bf84f90acfeea973bfba691d72d2d5a81b28bb79d442b06b61fe36775c52", "prompt_hash": "7988277ef7ee2494228a67e20ebee9e076d9141a89e9b129ed788410042bd251", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 269, "doc": {"question": "下列那一種降壓藥在高血壓又有心絞痛病人使用時，會增加交感神經刺激，增加引發心肌梗塞的危險？", "A": "labetalol", "B": "hydralazine", "C": "losartan", "D": "carvedilol", "answer": "B", "questions": "下列那一種降壓藥在高血壓又有心絞痛病人使用時，會增加交感神經刺激，增加引發心肌梗塞的危險？", "choices": ["labetalol", "hydralazine", "losartan", "carvedilol"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種降壓藥在高血壓又有心絞痛病人使用時，會增加交感神經刺激，增加引發心肌梗塞的危險？\nA. labetalol\nB. hydralazine\nC. losartan\nD. carvedilol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種降壓藥在高血壓又有心絞痛病人使用時，會增加交感神經刺激，增加引發心肌梗塞的危險？\nA. labetalol\nB. hydralazine\nC. losartan\nD. carvedilol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種降壓藥在高血壓又有心絞痛病人使用時，會增加交感神經刺激，增加引發心肌梗塞的危險？\nA. labetalol\nB. hydralazine\nC. losartan\nD. carvedilol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種降壓藥在高血壓又有心絞痛病人使用時，會增加交感神經刺激，增加引發心肌梗塞的危險？\nA. labetalol\nB. hydralazine\nC. losartan\nD. carvedilol\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.203125", "False"]], [["-0.08056640625", "True"]], [["-4.46875", "False"]], [["-3.703125", "False"]]], "filtered_resps": [["-3.203125", "False"], ["-0.08056640625", "True"], ["-4.46875", "False"], ["-3.703125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "84b9145e23c300838d7fe4a208ff68b93c8ebf1f6cf92d3be3705c0b8274bd85", "prompt_hash": "8ee757ae4ede1bc3c87d849bfe06d590d96326124832846387bf38ac0bfb4208", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 270, "doc": {"question": "下列消化性潰瘍治療藥物，何者長期服用會造成男性勃起功能障礙？", "A": "Sucralfate", "B": "Ranitidine", "C": "Omeprazole", "D": "Cimetidine", "answer": "D", "questions": "下列消化性潰瘍治療藥物，何者長期服用會造成男性勃起功能障礙？", "choices": ["Sucralfate", "Ranitidine", "Omeprazole", "Cimetidine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列消化性潰瘍治療藥物，何者長期服用會造成男性勃起功能障礙？\nA. Sucralfate\nB. Ranitidine\nC. Omeprazole\nD. Cimetidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列消化性潰瘍治療藥物，何者長期服用會造成男性勃起功能障礙？\nA. Sucralfate\nB. Ranitidine\nC. Omeprazole\nD. Cimetidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列消化性潰瘍治療藥物，何者長期服用會造成男性勃起功能障礙？\nA. Sucralfate\nB. Ranitidine\nC. Omeprazole\nD. Cimetidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列消化性潰瘍治療藥物，何者長期服用會造成男性勃起功能障礙？\nA. Sucralfate\nB. Ranitidine\nC. Omeprazole\nD. Cimetidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.75", "False"]], [["-5.5", "False"]], [["-7.75", "False"]], [["-0.009033203125", "True"]]], "filtered_resps": [["-7.75", "False"], ["-5.5", "False"], ["-7.75", "False"], ["-0.009033203125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "02483770819347582ecd5389e221f5338b8223c9803cbe969ce2c9128f1edd8a", "prompt_hash": "82188e0908485e518a666f7219b3deccc02fc1aecb8149db969eb9511c62291f", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 271, "doc": {"question": "下列有關raltegravir的敘述，何者錯誤？", "A": "結構中含有furan ring", "B": "為HIV整合酶抑制劑（integrase inhibitor）", "C": "食物不會影響吸收速率", "D": "口服易吸收", "answer": "A", "questions": "下列有關raltegravir的敘述，何者錯誤？", "choices": ["結構中含有furan ring", "為HIV整合酶抑制劑（integrase inhibitor）", "食物不會影響吸收速率", "口服易吸收"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關raltegravir的敘述，何者錯誤？\nA. 結構中含有furan ring\nB. 為HIV整合酶抑制劑（integrase inhibitor）\nC. 食物不會影響吸收速率\nD. 口服易吸收\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關raltegravir的敘述，何者錯誤？\nA. 結構中含有furan ring\nB. 為HIV整合酶抑制劑（integrase inhibitor）\nC. 食物不會影響吸收速率\nD. 口服易吸收\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關raltegravir的敘述，何者錯誤？\nA. 結構中含有furan ring\nB. 為HIV整合酶抑制劑（integrase inhibitor）\nC. 食物不會影響吸收速率\nD. 口服易吸收\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關raltegravir的敘述，何者錯誤？\nA. 結構中含有furan ring\nB. 為HIV整合酶抑制劑（integrase inhibitor）\nC. 食物不會影響吸收速率\nD. 口服易吸收\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.4375", "False"]], [["-3.5625", "False"]], [["-0.314453125", "True"]], [["-5.6875", "False"]]], "filtered_resps": [["-1.4375", "False"], ["-3.5625", "False"], ["-0.314453125", "True"], ["-5.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "30c9d5638633a8078879d6181624f55fccba29ccc8f2ebb52bfc775262bcaba9", "prompt_hash": "437474da90d5f6fb30562eb627e65e3e7863d7b513a839064d5dc74a27b01ca4", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 272, "doc": {"question": "有關抗癲癇藥物副作用之敘述，下列何者錯誤？", "A": "topiramate可能造成感覺異常", "B": "valproate可能造成體重減輕", "C": "phenytoin可能造成牙齦增生（gingival hyperplasia）", "D": "carbamazepine可能造成白血球降低（leukopenia）", "answer": "B", "questions": "有關抗癲癇藥物副作用之敘述，下列何者錯誤？", "choices": ["topiramate可能造成感覺異常", "valproate可能造成體重減輕", "phenytoin可能造成牙齦增生（gingival hyperplasia）", "carbamazepine可能造成白血球降低（leukopenia）"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗癲癇藥物副作用之敘述，下列何者錯誤？\nA. topiramate可能造成感覺異常\nB. valproate可能造成體重減輕\nC. phenytoin可能造成牙齦增生（gingival hyperplasia）\nD. carbamazepine可能造成白血球降低（leukopenia）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗癲癇藥物副作用之敘述，下列何者錯誤？\nA. topiramate可能造成感覺異常\nB. valproate可能造成體重減輕\nC. phenytoin可能造成牙齦增生（gingival hyperplasia）\nD. carbamazepine可能造成白血球降低（leukopenia）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗癲癇藥物副作用之敘述，下列何者錯誤？\nA. topiramate可能造成感覺異常\nB. valproate可能造成體重減輕\nC. phenytoin可能造成牙齦增生（gingival hyperplasia）\nD. carbamazepine可能造成白血球降低（leukopenia）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗癲癇藥物副作用之敘述，下列何者錯誤？\nA. topiramate可能造成感覺異常\nB. valproate可能造成體重減輕\nC. phenytoin可能造成牙齦增生（gingival hyperplasia）\nD. carbamazepine可能造成白血球降低（leukopenia）\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.375", "False"]], [["-0.005645751953125", "True"]], [["-6.625", "False"]], [["-6.0", "False"]]], "filtered_resps": [["-6.375", "False"], ["-0.005645751953125", "True"], ["-6.625", "False"], ["-6.0", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "314e3e74e69be39886167379e93a95a2ce121f091746f09019e6ba8328249bd7", "prompt_hash": "aa185eab938d8231019a26c5411d38156d67559165e42fa8825560d569fed638", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 273, "doc": {"question": "下列有關 carvedilol 之敘述，何者錯誤?", "A": "屬於混合型α/β受體阻斷劑", "B": "去甲基代謝物不具作用活性", "C": "可治療心衰竭", "D": "S(-)-異構物主要具β-受體拮抗作用", "answer": "B", "questions": "下列有關 carvedilol 之敘述，何者錯誤?", "choices": ["屬於混合型α/β受體阻斷劑", "去甲基代謝物不具作用活性", "可治療心衰竭", "S(-)-異構物主要具β-受體拮抗作用"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 carvedilol 之敘述，何者錯誤?\nA. 屬於混合型α/β受體阻斷劑\nB. 去甲基代謝物不具作用活性\nC. 可治療心衰竭\nD. S(-)-異構物主要具β-受體拮抗作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 carvedilol 之敘述，何者錯誤?\nA. 屬於混合型α/β受體阻斷劑\nB. 去甲基代謝物不具作用活性\nC. 可治療心衰竭\nD. S(-)-異構物主要具β-受體拮抗作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 carvedilol 之敘述，何者錯誤?\nA. 屬於混合型α/β受體阻斷劑\nB. 去甲基代謝物不具作用活性\nC. 可治療心衰竭\nD. S(-)-異構物主要具β-受體拮抗作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 carvedilol 之敘述，何者錯誤?\nA. 屬於混合型α/β受體阻斷劑\nB. 去甲基代謝物不具作用活性\nC. 可治療心衰竭\nD. S(-)-異構物主要具β-受體拮抗作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.78125", "False"]], [["-0.042724609375", "True"]], [["-4.90625", "False"]], [["-3.671875", "False"]]], "filtered_resps": [["-4.78125", "False"], ["-0.042724609375", "True"], ["-4.90625", "False"], ["-3.671875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3011b2155860668d7ccd192de347560ca793ff7ede9af407e3aa5022c310d88d", "prompt_hash": "3f0f634725269ec3d2d6ce7c01e3e7d34f600beee29fdcd456df29d07c70f0a5", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 274, "doc": {"question": "下列那一組抗生素併用時，(a)藥物可以增加(b)藥物進入細菌細胞內的濃度，因而產生抑菌協同作用：", "A": "(a)sulbactam；(b)ampicillin", "B": "(a)imipenem；(b)cilastatin", "C": "(a)sulfamethoxazole；(b)trimethoprim", "D": "(a)ticarcillin；(b)kanamycin", "answer": "D", "questions": "下列那一組抗生素併用時，(a)藥物可以增加(b)藥物進入細菌細胞內的濃度，因而產生抑菌協同作用：", "choices": ["(a)sulbactam；(b)ampicillin", "(a)imipenem；(b)cilastatin", "(a)sulfamethoxazole；(b)trimethoprim", "(a)ticarcillin；(b)kanamycin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一組抗生素併用時，(a)藥物可以增加(b)藥物進入細菌細胞內的濃度，因而產生抑菌協同作用：\nA. (a)sulbactam；(b)ampicillin\nB. (a)imipenem；(b)cilastatin\nC. (a)sulfamethoxazole；(b)trimethoprim\nD. (a)ticarcillin；(b)kanamycin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一組抗生素併用時，(a)藥物可以增加(b)藥物進入細菌細胞內的濃度，因而產生抑菌協同作用：\nA. (a)sulbactam；(b)ampicillin\nB. (a)imipenem；(b)cilastatin\nC. (a)sulfamethoxazole；(b)trimethoprim\nD. (a)ticarcillin；(b)kanamycin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一組抗生素併用時，(a)藥物可以增加(b)藥物進入細菌細胞內的濃度，因而產生抑菌協同作用：\nA. (a)sulbactam；(b)ampicillin\nB. (a)imipenem；(b)cilastatin\nC. (a)sulfamethoxazole；(b)trimethoprim\nD. (a)ticarcillin；(b)kanamycin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一組抗生素併用時，(a)藥物可以增加(b)藥物進入細菌細胞內的濃度，因而產生抑菌協同作用：\nA. (a)sulbactam；(b)ampicillin\nB. (a)imipenem；(b)cilastatin\nC. (a)sulfamethoxazole；(b)trimethoprim\nD. (a)ticarcillin；(b)kanamycin\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.4375", "False"]], [["-3.8125", "False"]], [["-5.6875", "False"]], [["-0.060791015625", "True"]]], "filtered_resps": [["-3.4375", "False"], ["-3.8125", "False"], ["-5.6875", "False"], ["-0.060791015625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d5548bc1c7b850b5f35fb360e596a834b308581a790bcaa0238179fa9dd2ab5d", "prompt_hash": "48c6dc28df8808ddd3ccfe41ca8b8be3dd501443c9644128fe31bfd946031ee9", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 275, "doc": {"question": "下列何者為acetaminophen急性中毒之解毒劑？", "A": "N-acetylcysteine", "B": "heparin", "C": "pralidoxime chloride", "D": "vitamin K", "answer": "A", "questions": "下列何者為acetaminophen急性中毒之解毒劑？", "choices": ["N-acetylcysteine", "heparin", "pralidoxime chloride", "vitamin K"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為acetaminophen急性中毒之解毒劑？\nA. N-acetylcysteine\nB. heparin\nC. pralidoxime chloride\nD. vitamin K\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為acetaminophen急性中毒之解毒劑？\nA. N-acetylcysteine\nB. heparin\nC. pralidoxime chloride\nD. vitamin K\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為acetaminophen急性中毒之解毒劑？\nA. N-acetylcysteine\nB. heparin\nC. pralidoxime chloride\nD. vitamin K\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為acetaminophen急性中毒之解毒劑？\nA. N-acetylcysteine\nB. heparin\nC. pralidoxime chloride\nD. vitamin K\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.00933837890625", "True"]], [["-6.375", "False"]], [["-6.0", "False"]], [["-5.75", "False"]]], "filtered_resps": [["-0.00933837890625", "True"], ["-6.375", "False"], ["-6.0", "False"], ["-5.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "70d08af346596a5d58aa3da225e23b73b936e7a55e2b6a4f81512a09c0778593", "prompt_hash": "b5bee9e214f4559988b5ad40e08ad9cd57e7109cfbcfbaf9debbac1dd32146a7", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 276, "doc": {"question": "下列何者為口服propranolol的禁忌？", "A": "青光眼", "B": "氣喘", "C": "震顫", "D": "高血壓", "answer": "B", "questions": "下列何者為口服propranolol的禁忌？", "choices": ["青光眼", "氣喘", "震顫", "高血壓"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為口服propranolol的禁忌？\nA. 青光眼\nB. 氣喘\nC. 震顫\nD. 高血壓\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為口服propranolol的禁忌？\nA. 青光眼\nB. 氣喘\nC. 震顫\nD. 高血壓\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為口服propranolol的禁忌？\nA. 青光眼\nB. 氣喘\nC. 震顫\nD. 高血壓\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為口服propranolol的禁忌？\nA. 青光眼\nB. 氣喘\nC. 震顫\nD. 高血壓\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.625", "False"]], [["-0.00396728515625", "True"]], [["-6.125", "False"]], [["-7.375", "False"]]], "filtered_resps": [["-7.625", "False"], ["-0.00396728515625", "True"], ["-6.125", "False"], ["-7.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4dd9ea7029779bf6063f44aa453665c9cb9ebc6769c0942e5ad57df84e5fec80", "prompt_hash": "5c7456ce035487a80212417c5802d47ceca8eb50ee51a7eb05c4865165fd1ce3", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 277, "doc": {"question": "為篩檢人體內代謝酵素CYP3A4之活性，選用下列何種藥物當作指標最適當？", "A": "caffeine", "B": "erythromycin", "C": "dextromethorphan", "D": "tolbutamide", "answer": "B", "questions": "為篩檢人體內代謝酵素CYP3A4之活性，選用下列何種藥物當作指標最適當？", "choices": ["caffeine", "erythromycin", "dextromethorphan", "tolbutamide"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n為篩檢人體內代謝酵素CYP3A4之活性，選用下列何種藥物當作指標最適當？\nA. caffeine\nB. erythromycin\nC. dextromethorphan\nD. tolbutamide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n為篩檢人體內代謝酵素CYP3A4之活性，選用下列何種藥物當作指標最適當？\nA. caffeine\nB. erythromycin\nC. dextromethorphan\nD. tolbutamide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n為篩檢人體內代謝酵素CYP3A4之活性，選用下列何種藥物當作指標最適當？\nA. caffeine\nB. erythromycin\nC. dextromethorphan\nD. tolbutamide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n為篩檢人體內代謝酵素CYP3A4之活性，選用下列何種藥物當作指標最適當？\nA. caffeine\nB. erythromycin\nC. dextromethorphan\nD. tolbutamide\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.625", "False"]], [["-0.01513671875", "True"]], [["-4.875", "False"]], [["-5.875", "False"]]], "filtered_resps": [["-5.625", "False"], ["-0.01513671875", "True"], ["-4.875", "False"], ["-5.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "41776a34f98744ac0d8bbaab66728cba428c784e7ef8e76d1c8e0a42a19f81a0", "prompt_hash": "57033bc32722821a7b4f4cd2317d8fb9b7ba0bae405cc804871353d607400515", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 278, "doc": {"question": "下列何者為前驅藥轉換為原型藥過程中，最常見參與反應的官能基團？", "A": "ester", "B": "carbamate", "C": "urea", "D": "amide", "answer": "A", "questions": "下列何者為前驅藥轉換為原型藥過程中，最常見參與反應的官能基團？", "choices": ["ester", "carbamate", "urea", "amide"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為前驅藥轉換為原型藥過程中，最常見參與反應的官能基團？\nA. ester\nB. carbamate\nC. urea\nD. amide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為前驅藥轉換為原型藥過程中，最常見參與反應的官能基團？\nA. ester\nB. carbamate\nC. urea\nD. amide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為前驅藥轉換為原型藥過程中，最常見參與反應的官能基團？\nA. ester\nB. carbamate\nC. urea\nD. amide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為前驅藥轉換為原型藥過程中，最常見參與反應的官能基團？\nA. ester\nB. carbamate\nC. urea\nD. amide\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1728515625", "True"]], [["-3.171875", "False"]], [["-4.1875", "False"]], [["-2.296875", "False"]]], "filtered_resps": [["-0.1728515625", "True"], ["-3.171875", "False"], ["-4.1875", "False"], ["-2.296875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "df4b07324d53131af60b06c427aa6d19c9f40dff695f198c34dcdeb2ec3f74e3", "prompt_hash": "fb2c9f736679f631b791e0e8ba18f1908f5e642b33392b26f385149fbe8c9d35", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 279, "doc": {"question": "以下何者為deoxyribose nucleoside之抗病毒劑？", "A": "5-fluorouracil", "B": "idoxuridine", "C": "acyclovir", "D": "vidarabine", "answer": "B", "questions": "以下何者為deoxyribose nucleoside之抗病毒劑？", "choices": ["5-fluorouracil", "idoxuridine", "acyclovir", "vidarabine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n以下何者為deoxyribose nucleoside之抗病毒劑？\nA. 5-fluorouracil\nB. idoxuridine\nC. acyclovir\nD. vidarabine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n以下何者為deoxyribose nucleoside之抗病毒劑？\nA. 5-fluorouracil\nB. idoxuridine\nC. acyclovir\nD. vidarabine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n以下何者為deoxyribose nucleoside之抗病毒劑？\nA. 5-fluorouracil\nB. idoxuridine\nC. acyclovir\nD. vidarabine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n以下何者為deoxyribose nucleoside之抗病毒劑？\nA. 5-fluorouracil\nB. idoxuridine\nC. acyclovir\nD. vidarabine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.15625", "False"]], [["-0.15625", "True"]], [["-3.90625", "False"]], [["-2.15625", "False"]]], "filtered_resps": [["-5.15625", "False"], ["-0.15625", "True"], ["-3.90625", "False"], ["-2.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "46ce2550a60b769b787918c1fb3055a92e746bb2c280dd69ffb7d78e7b975248", "prompt_hash": "b4cae869fde5f6e50cc443853606e4236cb9dc58988e532220ca8ba6985c8213", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 280, "doc": {"question": "下列何者是terbutaline治療氣喘時的主要副作用？", "A": "便秘", "B": "嗜睡", "C": "心跳加快", "D": "肌肉顫抖", "answer": "D", "questions": "下列何者是terbutaline治療氣喘時的主要副作用？", "choices": ["便秘", "嗜睡", "心跳加快", "肌肉顫抖"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是terbutaline治療氣喘時的主要副作用？\nA. 便秘\nB. 嗜睡\nC. 心跳加快\nD. 肌肉顫抖\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是terbutaline治療氣喘時的主要副作用？\nA. 便秘\nB. 嗜睡\nC. 心跳加快\nD. 肌肉顫抖\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是terbutaline治療氣喘時的主要副作用？\nA. 便秘\nB. 嗜睡\nC. 心跳加快\nD. 肌肉顫抖\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是terbutaline治療氣喘時的主要副作用？\nA. 便秘\nB. 嗜睡\nC. 心跳加快\nD. 肌肉顫抖\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.10693359375", "True"]], [["-3.984375", "False"]], [["-3.484375", "False"]], [["-2.984375", "False"]]], "filtered_resps": [["-0.10693359375", "True"], ["-3.984375", "False"], ["-3.484375", "False"], ["-2.984375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3c8210c1a92415d2758a8ed19147d60fcbf2c5f1324c9a93f85a8bc5c824aa8e", "prompt_hash": "d15aaa43c95632ca39fd3eb02486743e30c0ccd67b746da5b49ba5f2b07d8d9d", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 281, "doc": {"question": "羅伯是一位1歲2個月的新生兒，患有癲癇，醫生處方為何？若吃過量的藥物，要如何處理以幫助藥物排泄（elimination）？", "A": "phenobarbital；酸化尿液", "B": "pentobarbital；酸化尿液", "C": "phenobarbital；鹼化尿液", "D": "pentobarbital；鹼化尿液", "answer": "C", "questions": "羅伯是一位1歲2個月的新生兒，患有癲癇，醫生處方為何？若吃過量的藥物，要如何處理以幫助藥物排泄（elimination）？", "choices": ["phenobarbital；酸化尿液", "pentobarbital；酸化尿液", "phenobarbital；鹼化尿液", "pentobarbital；鹼化尿液"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n羅伯是一位1歲2個月的新生兒，患有癲癇，醫生處方為何？若吃過量的藥物，要如何處理以幫助藥物排泄（elimination）？\nA. phenobarbital；酸化尿液\nB. pentobarbital；酸化尿液\nC. phenobarbital；鹼化尿液\nD. pentobarbital；鹼化尿液\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n羅伯是一位1歲2個月的新生兒，患有癲癇，醫生處方為何？若吃過量的藥物，要如何處理以幫助藥物排泄（elimination）？\nA. phenobarbital；酸化尿液\nB. pentobarbital；酸化尿液\nC. phenobarbital；鹼化尿液\nD. pentobarbital；鹼化尿液\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n羅伯是一位1歲2個月的新生兒，患有癲癇，醫生處方為何？若吃過量的藥物，要如何處理以幫助藥物排泄（elimination）？\nA. phenobarbital；酸化尿液\nB. pentobarbital；酸化尿液\nC. phenobarbital；鹼化尿液\nD. pentobarbital；鹼化尿液\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n羅伯是一位1歲2個月的新生兒，患有癲癇，醫生處方為何？若吃過量的藥物，要如何處理以幫助藥物排泄（elimination）？\nA. phenobarbital；酸化尿液\nB. pentobarbital；酸化尿液\nC. phenobarbital；鹼化尿液\nD. pentobarbital；鹼化尿液\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.25", "False"]], [["-3.0", "False"]], [["-0.251953125", "True"]], [["-2.75", "False"]]], "filtered_resps": [["-2.25", "False"], ["-3.0", "False"], ["-0.251953125", "True"], ["-2.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "664bdd0543b65030457d24f1deb9cc6c5fa85e9f936d803e3881707e145d3079", "prompt_hash": "3416bd7db62b2c0104eb6a946a387e190996ae6b50493569b8ec5616b7de0aed", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 282, "doc": {"question": "下列何種局部麻醉劑是由天然物isogramine經生物等價（bioisostere）之原理設計合成？", "A": "benzocaine", "B": "ropivacaine", "C": "proparacaine", "D": "lidocaine", "answer": "D", "questions": "下列何種局部麻醉劑是由天然物isogramine經生物等價（bioisostere）之原理設計合成？", "choices": ["benzocaine", "ropivacaine", "proparacaine", "lidocaine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種局部麻醉劑是由天然物isogramine經生物等價（bioisostere）之原理設計合成？\nA. benzocaine\nB. ropivacaine\nC. proparacaine\nD. lidocaine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種局部麻醉劑是由天然物isogramine經生物等價（bioisostere）之原理設計合成？\nA. benzocaine\nB. ropivacaine\nC. proparacaine\nD. lidocaine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種局部麻醉劑是由天然物isogramine經生物等價（bioisostere）之原理設計合成？\nA. benzocaine\nB. ropivacaine\nC. proparacaine\nD. lidocaine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種局部麻醉劑是由天然物isogramine經生物等價（bioisostere）之原理設計合成？\nA. benzocaine\nB. ropivacaine\nC. proparacaine\nD. lidocaine\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.90625", "False"]], [["-4.40625", "False"]], [["-5.28125", "False"]], [["-0.0294189453125", "True"]]], "filtered_resps": [["-4.90625", "False"], ["-4.40625", "False"], ["-5.28125", "False"], ["-0.0294189453125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "46be744fca188dc339f6601cf1c40779a75490cb0daa77dc84083f5e697c0b96", "prompt_hash": "c6342c0a719514fef7eeda50631ebf96bee001c3d5f734899683bb60fbd08400", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 283, "doc": {"question": "下列何者不是長期使用amiodarone可能產生之副作用？", "A": "心搏過速", "B": "甲狀腺功能低下", "C": "肝功能異常", "D": "肺部纖維化", "answer": "A", "questions": "下列何者不是長期使用amiodarone可能產生之副作用？", "choices": ["心搏過速", "甲狀腺功能低下", "肝功能異常", "肺部纖維化"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是長期使用amiodarone可能產生之副作用？\nA. 心搏過速\nB. 甲狀腺功能低下\nC. 肝功能異常\nD. 肺部纖維化\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是長期使用amiodarone可能產生之副作用？\nA. 心搏過速\nB. 甲狀腺功能低下\nC. 肝功能異常\nD. 肺部纖維化\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是長期使用amiodarone可能產生之副作用？\nA. 心搏過速\nB. 甲狀腺功能低下\nC. 肝功能異常\nD. 肺部纖維化\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是長期使用amiodarone可能產生之副作用？\nA. 心搏過速\nB. 甲狀腺功能低下\nC. 肝功能異常\nD. 肺部纖維化\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.036865234375", "True"]], [["-5.28125", "False"]], [["-4.90625", "False"]], [["-3.78125", "False"]]], "filtered_resps": [["-0.036865234375", "True"], ["-5.28125", "False"], ["-4.90625", "False"], ["-3.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "21ce8db60aaa3dbe9c98a14983fcad28036f44e559755a333a9478a5baac08c2", "prompt_hash": "5c49cb9776edf42de1f8931a9cea619c0c078f05d02b169624bcea1b900e5f2c", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 284, "doc": {"question": "下列何者無法產生氣管平滑肌鬆弛作用？", "A": "muscarinic antagonist", "B": "adenosine receptor agonist", "C": "phosphodiesterase inhibitor", "D": "beta adrenoceptor agonist", "answer": "B", "questions": "下列何者無法產生氣管平滑肌鬆弛作用？", "choices": ["muscarinic antagonist", "adenosine receptor agonist", "phosphodiesterase inhibitor", "beta adrenoceptor agonist"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者無法產生氣管平滑肌鬆弛作用？\nA. muscarinic antagonist\nB. adenosine receptor agonist\nC. phosphodiesterase inhibitor\nD. beta adrenoceptor agonist\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者無法產生氣管平滑肌鬆弛作用？\nA. muscarinic antagonist\nB. adenosine receptor agonist\nC. phosphodiesterase inhibitor\nD. beta adrenoceptor agonist\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者無法產生氣管平滑肌鬆弛作用？\nA. muscarinic antagonist\nB. adenosine receptor agonist\nC. phosphodiesterase inhibitor\nD. beta adrenoceptor agonist\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者無法產生氣管平滑肌鬆弛作用？\nA. muscarinic antagonist\nB. adenosine receptor agonist\nC. phosphodiesterase inhibitor\nD. beta adrenoceptor agonist\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.78125", "False"]], [["-0.0225830078125", "True"]], [["-4.53125", "False"]], [["-4.65625", "False"]]], "filtered_resps": [["-6.78125", "False"], ["-0.0225830078125", "True"], ["-4.53125", "False"], ["-4.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "696793533b93511fceaa60ec424e09cdcf382c0d89a65ec8128fb3ae60e94399", "prompt_hash": "3fbac4aaf5188c61a3ad98bde8d1fa526be969dab14ee978c65dc2bd3769446b", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 285, "doc": {"question": "下列有關神經傳遞物質之敘述，何者錯誤？", "A": "acetylcholine之代謝酵素為choline acetyltransferase", "B": "norepinephrine之代謝酵素為catechol-O-methyltransferase", "C": "dopamine之代謝酵素為monoamine oxidase-B", "D": "serotonin之代謝酵素為monoamine oxidase-A", "answer": "A", "questions": "下列有關神經傳遞物質之敘述，何者錯誤？", "choices": ["acetylcholine之代謝酵素為choline acetyltransferase", "norepinephrine之代謝酵素為catechol-O-methyltransferase", "dopamine之代謝酵素為monoamine oxidase-B", "serotonin之代謝酵素為monoamine oxidase-A"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關神經傳遞物質之敘述，何者錯誤？\nA. acetylcholine之代謝酵素為choline acetyltransferase\nB. norepinephrine之代謝酵素為catechol-O-methyltransferase\nC. dopamine之代謝酵素為monoamine oxidase-B\nD. serotonin之代謝酵素為monoamine oxidase-A\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關神經傳遞物質之敘述，何者錯誤？\nA. acetylcholine之代謝酵素為choline acetyltransferase\nB. norepinephrine之代謝酵素為catechol-O-methyltransferase\nC. dopamine之代謝酵素為monoamine oxidase-B\nD. serotonin之代謝酵素為monoamine oxidase-A\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關神經傳遞物質之敘述，何者錯誤？\nA. acetylcholine之代謝酵素為choline acetyltransferase\nB. norepinephrine之代謝酵素為catechol-O-methyltransferase\nC. dopamine之代謝酵素為monoamine oxidase-B\nD. serotonin之代謝酵素為monoamine oxidase-A\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關神經傳遞物質之敘述，何者錯誤？\nA. acetylcholine之代謝酵素為choline acetyltransferase\nB. norepinephrine之代謝酵素為catechol-O-methyltransferase\nC. dopamine之代謝酵素為monoamine oxidase-B\nD. serotonin之代謝酵素為monoamine oxidase-A\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.042724609375", "True"]], [["-4.78125", "False"]], [["-4.28125", "False"]], [["-4.03125", "False"]]], "filtered_resps": [["-0.042724609375", "True"], ["-4.78125", "False"], ["-4.28125", "False"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0a0044938da80a1a891f381848088fe510adb6e6a99ae03562313c7e9be1c025", "prompt_hash": "3b1670c089eec5bf3d4f203618c427216662114fe24551d4bb678694127cb48c", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 286, "doc": {"question": "下列非固醇抗炎藥，何者有明顯的首渡效應？", "A": "naproxen", "B": "indomethacin", "C": "diclofenac", "D": "piroxicam", "answer": "C", "questions": "下列非固醇抗炎藥，何者有明顯的首渡效應？", "choices": ["naproxen", "indomethacin", "diclofenac", "piroxicam"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列非固醇抗炎藥，何者有明顯的首渡效應？\nA. naproxen\nB. indomethacin\nC. diclofenac\nD. piroxicam\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列非固醇抗炎藥，何者有明顯的首渡效應？\nA. naproxen\nB. indomethacin\nC. diclofenac\nD. piroxicam\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列非固醇抗炎藥，何者有明顯的首渡效應？\nA. naproxen\nB. indomethacin\nC. diclofenac\nD. piroxicam\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列非固醇抗炎藥，何者有明顯的首渡效應？\nA. naproxen\nB. indomethacin\nC. diclofenac\nD. piroxicam\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.640625", "True"]], [["-1.765625", "False"]], [["-1.515625", "False"]], [["-2.515625", "False"]]], "filtered_resps": [["-0.640625", "True"], ["-1.765625", "False"], ["-1.515625", "False"], ["-2.515625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "684827ebae55561d15e40f6b69d7d294834950f745bb1f746edb23adbd3f430f", "prompt_hash": "0dc8d7535113a0ce89900e446a4b66934587fd3df5b603d45b51c3ee2ca5eb94", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 287, "doc": {"question": "下列何者為linezolid與其它抗生素比較不會有交互抗藥性的原因？", "A": "因為其可以結合到50S核糖體RNA上的23S核糖小體", "B": "可以抑制粒線體蛋白質生成", "C": "可以特異性阻斷細菌蛋白質的生成", "D": "不受細胞色素P450酵素活性影響", "answer": "A", "questions": "下列何者為linezolid與其它抗生素比較不會有交互抗藥性的原因？", "choices": ["因為其可以結合到50S核糖體RNA上的23S核糖小體", "可以抑制粒線體蛋白質生成", "可以特異性阻斷細菌蛋白質的生成", "不受細胞色素P450酵素活性影響"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為linezolid與其它抗生素比較不會有交互抗藥性的原因？\nA. 因為其可以結合到50S核糖體RNA上的23S核糖小體\nB. 可以抑制粒線體蛋白質生成\nC. 可以特異性阻斷細菌蛋白質的生成\nD. 不受細胞色素P450酵素活性影響\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為linezolid與其它抗生素比較不會有交互抗藥性的原因？\nA. 因為其可以結合到50S核糖體RNA上的23S核糖小體\nB. 可以抑制粒線體蛋白質生成\nC. 可以特異性阻斷細菌蛋白質的生成\nD. 不受細胞色素P450酵素活性影響\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為linezolid與其它抗生素比較不會有交互抗藥性的原因？\nA. 因為其可以結合到50S核糖體RNA上的23S核糖小體\nB. 可以抑制粒線體蛋白質生成\nC. 可以特異性阻斷細菌蛋白質的生成\nD. 不受細胞色素P450酵素活性影響\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為linezolid與其它抗生素比較不會有交互抗藥性的原因？\nA. 因為其可以結合到50S核糖體RNA上的23S核糖小體\nB. 可以抑制粒線體蛋白質生成\nC. 可以特異性阻斷細菌蛋白質的生成\nD. 不受細胞色素P450酵素活性影響\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.796875", "False"]], [["-0.171875", "True"]], [["-3.171875", "False"]], [["-2.921875", "False"]]], "filtered_resps": [["-2.796875", "False"], ["-0.171875", "True"], ["-3.171875", "False"], ["-2.921875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c02013b352744a9eda21c5ccbb9a3156d5315c56d0bd70beee071f82f8809ec2", "prompt_hash": "b5ddd1c2fd51693e261f0389cf8eba5d19e886e7f8aad2d054507d4840ce210c", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 288, "doc": {"question": "NH4 Cl可以加速下列各藥物之腎臟清除率，惟何者除外？", "A": "Quinine", "B": "Mecamylamine", "C": "Phenobarbital", "D": "Amphetamine", "answer": "C", "questions": "NH4 Cl可以加速下列各藥物之腎臟清除率，惟何者除外？", "choices": ["Quinine", "Mecamylamine", "Phenobarbital", "Amphetamine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNH4 Cl可以加速下列各藥物之腎臟清除率，惟何者除外？\nA. Quinine\nB. Mecamylamine\nC. Phenobarbital\nD. Amphetamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNH4 Cl可以加速下列各藥物之腎臟清除率，惟何者除外？\nA. Quinine\nB. Mecamylamine\nC. Phenobarbital\nD. Amphetamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNH4 Cl可以加速下列各藥物之腎臟清除率，惟何者除外？\nA. Quinine\nB. Mecamylamine\nC. Phenobarbital\nD. Amphetamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNH4 Cl可以加速下列各藥物之腎臟清除率，惟何者除外？\nA. Quinine\nB. Mecamylamine\nC. Phenobarbital\nD. Amphetamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.53125", "False"]], [["-5.03125", "False"]], [["-0.0322265625", "True"]], [["-4.65625", "False"]]], "filtered_resps": [["-5.53125", "False"], ["-5.03125", "False"], ["-0.0322265625", "True"], ["-4.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ccb9ce2581748c3a82d04318e0f78ae673086cb846042aa7bfb8640d4a0d674e", "prompt_hash": "d013d13724ba5c413c903d394d0c5b4c91140c8ce56604a34dd12220090454ee", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 289, "doc": {"question": "Evolocumab可用於治療高膽固醇血症、異合子及同合子家族性高膽固醇血症，其藥理機制為何？", "A": "antibody against CETP", "B": "AMP kinase activator", "C": "antibody against PCSK9", "D": "antisense oligonucleotide against apo B-100 synthesis", "answer": "C", "questions": "Evolocumab可用於治療高膽固醇血症、異合子及同合子家族性高膽固醇血症，其藥理機制為何？", "choices": ["antibody against CETP", "AMP kinase activator", "antibody against PCSK9", "antisense oligonucleotide against apo B-100 synthesis"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nEvolocumab可用於治療高膽固醇血症、異合子及同合子家族性高膽固醇血症，其藥理機制為何？\nA. antibody against CETP\nB. AMP kinase activator\nC. antibody against PCSK9\nD. antisense oligonucleotide against apo B-100 synthesis\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nEvolocumab可用於治療高膽固醇血症、異合子及同合子家族性高膽固醇血症，其藥理機制為何？\nA. antibody against CETP\nB. AMP kinase activator\nC. antibody against PCSK9\nD. antisense oligonucleotide against apo B-100 synthesis\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nEvolocumab可用於治療高膽固醇血症、異合子及同合子家族性高膽固醇血症，其藥理機制為何？\nA. antibody against CETP\nB. AMP kinase activator\nC. antibody against PCSK9\nD. antisense oligonucleotide against apo B-100 synthesis\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nEvolocumab可用於治療高膽固醇血症、異合子及同合子家族性高膽固醇血症，其藥理機制為何？\nA. antibody against CETP\nB. AMP kinase activator\nC. antibody against PCSK9\nD. antisense oligonucleotide against apo B-100 synthesis\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.875", "False"]], [["-8.3125", "False"]], [["-0.01080322265625", "True"]], [["-6.25", "False"]]], "filtered_resps": [["-6.875", "False"], ["-8.3125", "False"], ["-0.01080322265625", "True"], ["-6.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8cfc258b24844b83aa0d0582bce1ea93402a75bfced37fd1427e7f5c8e21e56f", "prompt_hash": "37614ba57be066a2cceabd680e716da1e4a4cf917b14056780147e9c461609bb", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 290, "doc": {"question": "下列那些非固醇抗炎藥物屬於前驅藥？①diclofenac ②sulindac ③nabumetone ④fenoprofen", "A": "②③", "B": "②④", "C": "①④", "D": "①③", "answer": "A", "questions": "下列那些非固醇抗炎藥物屬於前驅藥？①diclofenac ②sulindac ③nabumetone ④fenoprofen", "choices": ["②③", "②④", "①④", "①③"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那些非固醇抗炎藥物屬於前驅藥？①diclofenac ②sulindac ③nabumetone ④fenoprofen\nA. ②③\nB. ②④\nC. ①④\nD. ①③\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那些非固醇抗炎藥物屬於前驅藥？①diclofenac ②sulindac ③nabumetone ④fenoprofen\nA. ②③\nB. ②④\nC. ①④\nD. ①③\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那些非固醇抗炎藥物屬於前驅藥？①diclofenac ②sulindac ③nabumetone ④fenoprofen\nA. ②③\nB. ②④\nC. ①④\nD. ①③\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那些非固醇抗炎藥物屬於前驅藥？①diclofenac ②sulindac ③nabumetone ④fenoprofen\nA. ②③\nB. ②④\nC. ①④\nD. ①③\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.6953125", "False"]], [["-1.4453125", "False"]], [["-1.9453125", "False"]], [["-0.82421875", "True"]]], "filtered_resps": [["-1.6953125", "False"], ["-1.4453125", "False"], ["-1.9453125", "False"], ["-0.82421875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "46b13590f418f12099d4fa6ede0bb2acc34c42934009c2520f48d38c6075240e", "prompt_hash": "2503186444804018d052f55409ee65574b29b6c6111017801bc8ffa625a5682d", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 291, "doc": {"question": "關於erlotinib敘述，下列何者正確？", "A": "適用於EGFR T790M變異之肺癌", "B": "可用於對crizotinib產生抗藥性之治療", "C": "與cetuximab相同都能抑制EGFR來達到治療效果", "D": "主要作用機轉為同時抑制EGFR, HER2及HER4", "answer": "C", "questions": "關於erlotinib敘述，下列何者正確？", "choices": ["適用於EGFR T790M變異之肺癌", "可用於對crizotinib產生抗藥性之治療", "與cetuximab相同都能抑制EGFR來達到治療效果", "主要作用機轉為同時抑制EGFR, HER2及HER4"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於erlotinib敘述，下列何者正確？\nA. 適用於EGFR T790M變異之肺癌\nB. 可用於對crizotinib產生抗藥性之治療\nC. 與cetuximab相同都能抑制EGFR來達到治療效果\nD. 主要作用機轉為同時抑制EGFR, HER2及HER4\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於erlotinib敘述，下列何者正確？\nA. 適用於EGFR T790M變異之肺癌\nB. 可用於對crizotinib產生抗藥性之治療\nC. 與cetuximab相同都能抑制EGFR來達到治療效果\nD. 主要作用機轉為同時抑制EGFR, HER2及HER4\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於erlotinib敘述，下列何者正確？\nA. 適用於EGFR T790M變異之肺癌\nB. 可用於對crizotinib產生抗藥性之治療\nC. 與cetuximab相同都能抑制EGFR來達到治療效果\nD. 主要作用機轉為同時抑制EGFR, HER2及HER4\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於erlotinib敘述，下列何者正確？\nA. 適用於EGFR T790M變異之肺癌\nB. 可用於對crizotinib產生抗藥性之治療\nC. 與cetuximab相同都能抑制EGFR來達到治療效果\nD. 主要作用機轉為同時抑制EGFR, HER2及HER4\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.703125", "False"]], [["-6.09375", "False"]], [["-0.07861328125", "True"]], [["-5.34375", "False"]]], "filtered_resps": [["-2.703125", "False"], ["-6.09375", "False"], ["-0.07861328125", "True"], ["-5.34375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c1300fc004a83535cd377f84bd901527ae8b535b9f0f86804f4c60e181e14f2e", "prompt_hash": "6c86386d264bf985b902d4908a359404da96501120bc587cc184235513c9bc68", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 292, "doc": {"question": "下化合物: C8H10N4O2 在健康人的空腹胃中，最主要的電荷態為：", "A": "0", "B": "-2", "C": "+1", "D": "-1", "answer": "C", "questions": "下化合物: C8H10N4O2 在健康人的空腹胃中，最主要的電荷態為：", "choices": ["0", "-2", "+1", "-1"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下化合物: C8H10N4O2 在健康人的空腹胃中，最主要的電荷態為：\nA. 0\nB. -2\nC. +1\nD. -1\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下化合物: C8H10N4O2 在健康人的空腹胃中，最主要的電荷態為：\nA. 0\nB. -2\nC. +1\nD. -1\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下化合物: C8H10N4O2 在健康人的空腹胃中，最主要的電荷態為：\nA. 0\nB. -2\nC. +1\nD. -1\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下化合物: C8H10N4O2 在健康人的空腹胃中，最主要的電荷態為：\nA. 0\nB. -2\nC. +1\nD. -1\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.1640625", "False"]], [["-1.4140625", "False"]], [["-2.40625", "False"]], [["-1.0390625", "True"]]], "filtered_resps": [["-1.1640625", "False"], ["-1.4140625", "False"], ["-2.40625", "False"], ["-1.0390625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b4c2368072fc8e1061a6a5a35a217eb4494e71c345ac49f578ce531f93250c9c", "prompt_hash": "ec5db116bfa86fa61e0c68fa0905a4604530abd410958ac6e480dacd0937a435", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 293, "doc": {"question": "下列何種酵素可催化purine nucleotides生合成？", "A": "hypoxanthine guanine phosphoribosyl transferase（HGPRT）", "B": "thymidylate synthetase", "C": "amidophosphoribosyl transferase", "D": "xanthine oxidase", "answer": "C", "questions": "下列何種酵素可催化purine nucleotides生合成？", "choices": ["hypoxanthine guanine phosphoribosyl transferase（HGPRT）", "thymidylate synthetase", "amidophosphoribosyl transferase", "xanthine oxidase"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種酵素可催化purine nucleotides生合成？\nA. hypoxanthine guanine phosphoribosyl transferase（HGPRT）\nB. thymidylate synthetase\nC. amidophosphoribosyl transferase\nD. xanthine oxidase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種酵素可催化purine nucleotides生合成？\nA. hypoxanthine guanine phosphoribosyl transferase（HGPRT）\nB. thymidylate synthetase\nC. amidophosphoribosyl transferase\nD. xanthine oxidase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種酵素可催化purine nucleotides生合成？\nA. hypoxanthine guanine phosphoribosyl transferase（HGPRT）\nB. thymidylate synthetase\nC. amidophosphoribosyl transferase\nD. xanthine oxidase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種酵素可催化purine nucleotides生合成？\nA. hypoxanthine guanine phosphoribosyl transferase（HGPRT）\nB. thymidylate synthetase\nC. amidophosphoribosyl transferase\nD. xanthine oxidase\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.4296875", "False"]], [["-5.5625", "False"]], [["-0.30078125", "True"]], [["-4.3125", "False"]]], "filtered_resps": [["-1.4296875", "False"], ["-5.5625", "False"], ["-0.30078125", "True"], ["-4.3125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "150795b3fc6dc6675ac436912db94d5739f2f52832721f16b376c1eaaa06757c", "prompt_hash": "c1a3fa22f889b27c6cffb4593afb7d2277246292a506fd6212817c24e27ad338", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 294, "doc": {"question": "下列何者可作為theophylline及caffeine中毒之解毒劑？", "A": "bicarbonate", "B": "fomepizole", "C": "flumazenil", "D": "esmolol", "answer": "D", "questions": "下列何者可作為theophylline及caffeine中毒之解毒劑？", "choices": ["bicarbonate", "fomepizole", "flumazenil", "esmolol"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可作為theophylline及caffeine中毒之解毒劑？\nA. bicarbonate\nB. fomepizole\nC. flumazenil\nD. esmolol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可作為theophylline及caffeine中毒之解毒劑？\nA. bicarbonate\nB. fomepizole\nC. flumazenil\nD. esmolol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可作為theophylline及caffeine中毒之解毒劑？\nA. bicarbonate\nB. fomepizole\nC. flumazenil\nD. esmolol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可作為theophylline及caffeine中毒之解毒劑？\nA. bicarbonate\nB. fomepizole\nC. flumazenil\nD. esmolol\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.828125", "False"]], [["-4.09375", "False"]], [["-4.59375", "False"]], [["-0.0791015625", "True"]]], "filtered_resps": [["-3.828125", "False"], ["-4.09375", "False"], ["-4.59375", "False"], ["-0.0791015625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "922a83a93f2bc4bcc877b3ede6d2a6923d9ea34c1a3ecdf61d4092e9aeb79ac6", "prompt_hash": "20d2fbbeb11d3127ca6f4d0d7458d83bfc089a191a7182dc25fa5872de5854bb", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 295, "doc": {"question": "下列何種利尿劑不具sulfonamide結構？", "A": "torsemide", "B": "ethacrynic acid", "C": "metolazone", "D": "indapamide", "answer": "B", "questions": "下列何種利尿劑不具sulfonamide結構？", "choices": ["torsemide", "ethacrynic acid", "metolazone", "indapamide"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑不具sulfonamide結構？\nA. torsemide\nB. ethacrynic acid\nC. metolazone\nD. indapamide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑不具sulfonamide結構？\nA. torsemide\nB. ethacrynic acid\nC. metolazone\nD. indapamide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑不具sulfonamide結構？\nA. torsemide\nB. ethacrynic acid\nC. metolazone\nD. indapamide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑不具sulfonamide結構？\nA. torsemide\nB. ethacrynic acid\nC. metolazone\nD. indapamide\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.03125", "False"]], [["-0.041259765625", "True"]], [["-6.03125", "False"]], [["-3.921875", "False"]]], "filtered_resps": [["-4.03125", "False"], ["-0.041259765625", "True"], ["-6.03125", "False"], ["-3.921875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4a4e521cc0842673dcfebbfa6831c76454873e51c7732f6244023c7bd0c42259", "prompt_hash": "7c8eaa3cf9e44bb0d21ed6e41dbb24b2287a5bdc15ad21b1c55604ff23e25a27", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 296, "doc": {"question": "下列何者用於緊急性高血壓（Hypertensive emergencies）及手術後高血壓（postoperative hypertension）之藥物為 dopamine D1受體致效劑？", "A": "minoxidil", "B": "diazoxide", "C": "nitroprusside", "D": "fenoldopam", "answer": "D", "questions": "下列何者用於緊急性高血壓（Hypertensive emergencies）及手術後高血壓（postoperative hypertension）之藥物為 dopamine D1受體致效劑？", "choices": ["minoxidil", "diazoxide", "nitroprusside", "fenoldopam"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者用於緊急性高血壓（Hypertensive emergencies）及手術後高血壓（postoperative hypertension）之藥物為 dopamine D1受體致效劑？\nA. minoxidil\nB. diazoxide\nC. nitroprusside\nD. fenoldopam\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者用於緊急性高血壓（Hypertensive emergencies）及手術後高血壓（postoperative hypertension）之藥物為 dopamine D1受體致效劑？\nA. minoxidil\nB. diazoxide\nC. nitroprusside\nD. fenoldopam\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者用於緊急性高血壓（Hypertensive emergencies）及手術後高血壓（postoperative hypertension）之藥物為 dopamine D1受體致效劑？\nA. minoxidil\nB. diazoxide\nC. nitroprusside\nD. fenoldopam\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者用於緊急性高血壓（Hypertensive emergencies）及手術後高血壓（postoperative hypertension）之藥物為 dopamine D1受體致效劑？\nA. minoxidil\nB. diazoxide\nC. nitroprusside\nD. fenoldopam\nAnswer:", "arg_1": " D"}}, "resps": [[["-8.375", "False"]], [["-6.875", "False"]], [["-7.75", "False"]], [["-0.0029144287109375", "True"]]], "filtered_resps": [["-8.375", "False"], ["-6.875", "False"], ["-7.75", "False"], ["-0.0029144287109375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "26d1923c9b062ab739aa7011cf64e6d598272e6e295f775fa35fc857f91054dd", "prompt_hash": "3b01b8d49098f304bbd4042610f8eed5bc067ea553e9ec07de8b97a9ca8013a1", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 297, "doc": {"question": "有關digoxin和digitoxin的比較，下列何者錯誤？", "A": "digoxin比digitoxin多了C12-OH，所以極性較大", "B": "digoxin的口服劑量是digitoxin的二倍", "C": "digoxin不被肝臟代謝，而digitoxin經肝臟代謝", "D": "digoxin與血清蛋白的結合力比digitoxin低", "answer": "B", "questions": "有關digoxin和digitoxin的比較，下列何者錯誤？", "choices": ["digoxin比digitoxin多了C12-OH，所以極性較大", "digoxin的口服劑量是digitoxin的二倍", "digoxin不被肝臟代謝，而digitoxin經肝臟代謝", "digoxin與血清蛋白的結合力比digitoxin低"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關digoxin和digitoxin的比較，下列何者錯誤？\nA. digoxin比digitoxin多了C12-OH，所以極性較大\nB. digoxin的口服劑量是digitoxin的二倍\nC. digoxin不被肝臟代謝，而digitoxin經肝臟代謝\nD. digoxin與血清蛋白的結合力比digitoxin低\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關digoxin和digitoxin的比較，下列何者錯誤？\nA. digoxin比digitoxin多了C12-OH，所以極性較大\nB. digoxin的口服劑量是digitoxin的二倍\nC. digoxin不被肝臟代謝，而digitoxin經肝臟代謝\nD. digoxin與血清蛋白的結合力比digitoxin低\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關digoxin和digitoxin的比較，下列何者錯誤？\nA. digoxin比digitoxin多了C12-OH，所以極性較大\nB. digoxin的口服劑量是digitoxin的二倍\nC. digoxin不被肝臟代謝，而digitoxin經肝臟代謝\nD. digoxin與血清蛋白的結合力比digitoxin低\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關digoxin和digitoxin的比較，下列何者錯誤？\nA. digoxin比digitoxin多了C12-OH，所以極性較大\nB. digoxin的口服劑量是digitoxin的二倍\nC. digoxin不被肝臟代謝，而digitoxin經肝臟代謝\nD. digoxin與血清蛋白的結合力比digitoxin低\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.375", "False"]], [["-1.1171875", "False"]], [["-1.3671875", "False"]], [["-1.1171875", "True"]]], "filtered_resps": [["-2.375", "False"], ["-1.1171875", "False"], ["-1.3671875", "False"], ["-1.1171875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "41a26d44b9e90d52d1c9ca14f7229c5683992965080cf3c1aa273ea10062feba", "prompt_hash": "6ce34decd61a0ca575674a2c9c038af4f4f86faaf1235602a5d804e42a585455", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 298, "doc": {"question": "Risedronate 結構中，含有下列何種雜環?", "A": "pyrrole", "B": "pyrazole", "C": "pyrimidine", "D": "pyridine", "answer": "D", "questions": "Risedronate 結構中，含有下列何種雜環?", "choices": ["pyrrole", "pyrazole", "pyrimidine", "pyridine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRisedronate 結構中，含有下列何種雜環?\nA. pyrrole\nB. pyrazole\nC. pyrimidine\nD. pyridine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRisedronate 結構中，含有下列何種雜環?\nA. pyrrole\nB. pyrazole\nC. pyrimidine\nD. pyridine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRisedronate 結構中，含有下列何種雜環?\nA. pyrrole\nB. pyrazole\nC. pyrimidine\nD. pyridine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRisedronate 結構中，含有下列何種雜環?\nA. pyrrole\nB. pyrazole\nC. pyrimidine\nD. pyridine\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.78125", "False"]], [["-4.40625", "False"]], [["-5.40625", "False"]], [["-0.027099609375", "True"]]], "filtered_resps": [["-4.78125", "False"], ["-4.40625", "False"], ["-5.40625", "False"], ["-0.027099609375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "20307e13a32eb16c272ca7c5d637b6871d5d48970633c816780e02b865067e57", "prompt_hash": "10e4e50be92f022ab2d2763c05ac32b3115036517d5a627f65a9bf76c4c261d9", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 299, "doc": {"question": "免疫抑制劑cyclosporin A運用於器官移植，以防止排斥作用。下列敘述何者錯誤？", "A": "可運用於自體免疫疾病（autoimmune disorders）", "B": "降低NF-AT轉錄因子之活性", "C": "增加IFN-γ之產生", "D": "在T細胞內與cyclophilin結合成複合體，以抑制calcineurin作用", "answer": "C", "questions": "免疫抑制劑cyclosporin A運用於器官移植，以防止排斥作用。下列敘述何者錯誤？", "choices": ["可運用於自體免疫疾病（autoimmune disorders）", "降低NF-AT轉錄因子之活性", "增加IFN-γ之產生", "在T細胞內與cyclophilin結合成複合體，以抑制calcineurin作用"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n免疫抑制劑cyclosporin A運用於器官移植，以防止排斥作用。下列敘述何者錯誤？\nA. 可運用於自體免疫疾病（autoimmune disorders）\nB. 降低NF-AT轉錄因子之活性\nC. 增加IFN-γ之產生\nD. 在T細胞內與cyclophilin結合成複合體，以抑制calcineurin作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n免疫抑制劑cyclosporin A運用於器官移植，以防止排斥作用。下列敘述何者錯誤？\nA. 可運用於自體免疫疾病（autoimmune disorders）\nB. 降低NF-AT轉錄因子之活性\nC. 增加IFN-γ之產生\nD. 在T細胞內與cyclophilin結合成複合體，以抑制calcineurin作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n免疫抑制劑cyclosporin A運用於器官移植，以防止排斥作用。下列敘述何者錯誤？\nA. 可運用於自體免疫疾病（autoimmune disorders）\nB. 降低NF-AT轉錄因子之活性\nC. 增加IFN-γ之產生\nD. 在T細胞內與cyclophilin結合成複合體，以抑制calcineurin作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n免疫抑制劑cyclosporin A運用於器官移植，以防止排斥作用。下列敘述何者錯誤？\nA. 可運用於自體免疫疾病（autoimmune disorders）\nB. 降低NF-AT轉錄因子之活性\nC. 增加IFN-γ之產生\nD. 在T細胞內與cyclophilin結合成複合體，以抑制calcineurin作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-6.53125", "False"]], [["-0.0203857421875", "True"]], [["-5.03125", "False"]]], "filtered_resps": [["-5.78125", "False"], ["-6.53125", "False"], ["-0.0203857421875", "True"], ["-5.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "664e7db4c4bcb766d9add705c4b4d6598bb363fcb09812a67b4c3496855aa63c", "prompt_hash": "3e693170d8e64deb4a72466a18a2b3e0ebe3581118e6a9d122080bc97c79a238", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 300, "doc": {"question": "下列有關fondaparinux的敘述，何者錯誤？", "A": "為選擇性凝血因子Xa抑制劑", "B": "具有sulfonated hexa-saccharide結構", "C": "與antithrombin III具有高度結合力", "D": "投藥途徑為皮下注射", "answer": "B", "questions": "下列有關fondaparinux的敘述，何者錯誤？", "choices": ["為選擇性凝血因子Xa抑制劑", "具有sulfonated hexa-saccharide結構", "與antithrombin III具有高度結合力", "投藥途徑為皮下注射"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fondaparinux的敘述，何者錯誤？\nA. 為選擇性凝血因子Xa抑制劑\nB. 具有sulfonated hexa-saccharide結構\nC. 與antithrombin III具有高度結合力\nD. 投藥途徑為皮下注射\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fondaparinux的敘述，何者錯誤？\nA. 為選擇性凝血因子Xa抑制劑\nB. 具有sulfonated hexa-saccharide結構\nC. 與antithrombin III具有高度結合力\nD. 投藥途徑為皮下注射\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fondaparinux的敘述，何者錯誤？\nA. 為選擇性凝血因子Xa抑制劑\nB. 具有sulfonated hexa-saccharide結構\nC. 與antithrombin III具有高度結合力\nD. 投藥途徑為皮下注射\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關fondaparinux的敘述，何者錯誤？\nA. 為選擇性凝血因子Xa抑制劑\nB. 具有sulfonated hexa-saccharide結構\nC. 與antithrombin III具有高度結合力\nD. 投藥途徑為皮下注射\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-0.01239013671875", "True"]], [["-6.25", "False"]], [["-5.0", "False"]]], "filtered_resps": [["-5.875", "False"], ["-0.01239013671875", "True"], ["-6.25", "False"], ["-5.0", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9a29f50eed89862532d95e9a4a5c1186d8b266977cc313fcc70f617ee9edfde4", "prompt_hash": "693c26fcfcc87e2123462399634720ac408fcb6d613c3fe83d68bd7740523c13", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 301, "doc": {"question": "下列抗癌藥物何者會進入細胞內，抑制EGFR tyrosine kinase的活性？", "A": "dasatinib", "B": "imatinib", "C": "trastuzumab", "D": "erlotinib", "answer": "D", "questions": "下列抗癌藥物何者會進入細胞內，抑制EGFR tyrosine kinase的活性？", "choices": ["dasatinib", "imatinib", "trastuzumab", "erlotinib"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌藥物何者會進入細胞內，抑制EGFR tyrosine kinase的活性？\nA. dasatinib\nB. imatinib\nC. trastuzumab\nD. erlotinib\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌藥物何者會進入細胞內，抑制EGFR tyrosine kinase的活性？\nA. dasatinib\nB. imatinib\nC. trastuzumab\nD. erlotinib\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌藥物何者會進入細胞內，抑制EGFR tyrosine kinase的活性？\nA. dasatinib\nB. imatinib\nC. trastuzumab\nD. erlotinib\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌藥物何者會進入細胞內，抑制EGFR tyrosine kinase的活性？\nA. dasatinib\nB. imatinib\nC. trastuzumab\nD. erlotinib\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.03125", "False"]], [["-5.28125", "False"]], [["-5.65625", "False"]], [["-0.0184326171875", "True"]]], "filtered_resps": [["-5.03125", "False"], ["-5.28125", "False"], ["-5.65625", "False"], ["-0.0184326171875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "87218224f4f8c3d5c4f505ad5fb6208abeb4515785cfd9f3cbee45f71e8a2755", "prompt_hash": "a73f72cfe6af10c9bf6fc38ff24d48a2402db0721fed6452cfd20c690e00ee0b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 302, "doc": {"question": "下列有關enalapril之敘述，何者錯誤？", "A": "於體內受酯酶活化", "B": "代謝為活性物enalaprilat後，logP值上升", "C": "口服生體可用率約60%", "D": "具有乙酯結構", "answer": "B", "questions": "下列有關enalapril之敘述，何者錯誤？", "choices": ["於體內受酯酶活化", "代謝為活性物enalaprilat後，logP值上升", "口服生體可用率約60%", "具有乙酯結構"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關enalapril之敘述，何者錯誤？\nA. 於體內受酯酶活化\nB. 代謝為活性物enalaprilat後，logP值上升\nC. 口服生體可用率約60%\nD. 具有乙酯結構\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關enalapril之敘述，何者錯誤？\nA. 於體內受酯酶活化\nB. 代謝為活性物enalaprilat後，logP值上升\nC. 口服生體可用率約60%\nD. 具有乙酯結構\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關enalapril之敘述，何者錯誤？\nA. 於體內受酯酶活化\nB. 代謝為活性物enalaprilat後，logP值上升\nC. 口服生體可用率約60%\nD. 具有乙酯結構\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關enalapril之敘述，何者錯誤？\nA. 於體內受酯酶活化\nB. 代謝為活性物enalaprilat後，logP值上升\nC. 口服生體可用率約60%\nD. 具有乙酯結構\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.71875", "False"]], [["-0.474609375", "True"]], [["-1.1015625", "False"]], [["-3.84375", "False"]]], "filtered_resps": [["-3.71875", "False"], ["-0.474609375", "True"], ["-1.1015625", "False"], ["-3.84375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2279869c9f6cb8486d4c79037c466f9b74edf614b4cd1d4cfd8895a7eb4f7ac4", "prompt_hash": "6c13505db103fa9953f98423f2f0193df214e8a62f686c529e60acffc0ac7157", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 303, "doc": {"question": "下列抗癌抗生素中，屬於配醣體者為：", "A": "mitomycin", "B": "dactinomycin", "C": "mitoxantrone", "D": "daunorubicin", "answer": "D", "questions": "下列抗癌抗生素中，屬於配醣體者為：", "choices": ["mitomycin", "dactinomycin", "mitoxantrone", "daunorubicin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌抗生素中，屬於配醣體者為：\nA. mitomycin\nB. dactinomycin\nC. mitoxantrone\nD. daunorubicin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌抗生素中，屬於配醣體者為：\nA. mitomycin\nB. dactinomycin\nC. mitoxantrone\nD. daunorubicin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌抗生素中，屬於配醣體者為：\nA. mitomycin\nB. dactinomycin\nC. mitoxantrone\nD. daunorubicin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌抗生素中，屬於配醣體者為：\nA. mitomycin\nB. dactinomycin\nC. mitoxantrone\nD. daunorubicin\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.1875", "False"]], [["-3.796875", "False"]], [["-4.6875", "False"]], [["-0.050048828125", "True"]]], "filtered_resps": [["-4.1875", "False"], ["-3.796875", "False"], ["-4.6875", "False"], ["-0.050048828125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9b539709cd5fd89b7294c536f03a9fa436d8728f49ac766202e1c80e101bb8d3", "prompt_hash": "235cfc6fcd3aa605a388aad719eadcd003f4b9a4ea63fb62c329a17fc7127630", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 304, "doc": {"question": "在慢性腎衰竭的老年人，digoxin的腎清除率會明顯降低，但藥物半衰期卻改變不大，此情況的主要原因為何？", "A": "藥物的Vd值變大所致", "B": "藥物與血中蛋白的結合量增加", "C": "病人的骨骼肌重量減少所致", "D": "藥物在腎臟的結合量增加", "answer": "C", "questions": "在慢性腎衰竭的老年人，digoxin的腎清除率會明顯降低，但藥物半衰期卻改變不大，此情況的主要原因為何？", "choices": ["藥物的Vd值變大所致", "藥物與血中蛋白的結合量增加", "病人的骨骼肌重量減少所致", "藥物在腎臟的結合量增加"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在慢性腎衰竭的老年人，digoxin的腎清除率會明顯降低，但藥物半衰期卻改變不大，此情況的主要原因為何？\nA. 藥物的Vd值變大所致\nB. 藥物與血中蛋白的結合量增加\nC. 病人的骨骼肌重量減少所致\nD. 藥物在腎臟的結合量增加\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在慢性腎衰竭的老年人，digoxin的腎清除率會明顯降低，但藥物半衰期卻改變不大，此情況的主要原因為何？\nA. 藥物的Vd值變大所致\nB. 藥物與血中蛋白的結合量增加\nC. 病人的骨骼肌重量減少所致\nD. 藥物在腎臟的結合量增加\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在慢性腎衰竭的老年人，digoxin的腎清除率會明顯降低，但藥物半衰期卻改變不大，此情況的主要原因為何？\nA. 藥物的Vd值變大所致\nB. 藥物與血中蛋白的結合量增加\nC. 病人的骨骼肌重量減少所致\nD. 藥物在腎臟的結合量增加\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在慢性腎衰竭的老年人，digoxin的腎清除率會明顯降低，但藥物半衰期卻改變不大，此情況的主要原因為何？\nA. 藥物的Vd值變大所致\nB. 藥物與血中蛋白的結合量增加\nC. 病人的骨骼肌重量減少所致\nD. 藥物在腎臟的結合量增加\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.478515625", "True"]], [["-2.359375", "False"]], [["-1.6015625", "False"]], [["-2.484375", "False"]]], "filtered_resps": [["-0.478515625", "True"], ["-2.359375", "False"], ["-1.6015625", "False"], ["-2.484375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "94926b222fdae5256fc5e5c5f15fb3af6038a4f7a15f3e43d477077969fb7333", "prompt_hash": "f7302c6d9d21311ab9b50fc141feb305dc2a86b0b8aab487d0e0f3fad80da59a", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 305, "doc": {"question": "下列何者不是aspirin可能產生之作用？", "A": "促進血小板凝集", "B": "腎毒性", "C": "抗發炎", "D": "止痛", "answer": "A", "questions": "下列何者不是aspirin可能產生之作用？", "choices": ["促進血小板凝集", "腎毒性", "抗發炎", "止痛"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是aspirin可能產生之作用？\nA. 促進血小板凝集\nB. 腎毒性\nC. 抗發炎\nD. 止痛\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是aspirin可能產生之作用？\nA. 促進血小板凝集\nB. 腎毒性\nC. 抗發炎\nD. 止痛\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是aspirin可能產生之作用？\nA. 促進血小板凝集\nB. 腎毒性\nC. 抗發炎\nD. 止痛\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是aspirin可能產生之作用？\nA. 促進血小板凝集\nB. 腎毒性\nC. 抗發炎\nD. 止痛\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.546875", "False"]], [["-0.040283203125", "True"]], [["-4.90625", "False"]], [["-6.03125", "False"]]], "filtered_resps": [["-3.546875", "False"], ["-0.040283203125", "True"], ["-4.90625", "False"], ["-6.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b4b62b30ef00f0ab139b49b1fdedf5e120bdf91c964433b658ed33fdaa7dca5a", "prompt_hash": "a457bfed7389776ee2b7b0e48033ae5aebd9b629c765c270526d17a85689c0e3", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 306, "doc": {"question": "下列有關抗寄生蟲藥tafenoquine的敘述，何者錯誤？", "A": "屬4-aminoquinoline結構", "B": "可經CYP2D6代謝", "C": "作用於肝臟休眠期寄生蟲", "D": "為前驅藥物", "answer": "A", "questions": "下列有關抗寄生蟲藥tafenoquine的敘述，何者錯誤？", "choices": ["屬4-aminoquinoline結構", "可經CYP2D6代謝", "作用於肝臟休眠期寄生蟲", "為前驅藥物"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗寄生蟲藥tafenoquine的敘述，何者錯誤？\nA. 屬4-aminoquinoline結構\nB. 可經CYP2D6代謝\nC. 作用於肝臟休眠期寄生蟲\nD. 為前驅藥物\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗寄生蟲藥tafenoquine的敘述，何者錯誤？\nA. 屬4-aminoquinoline結構\nB. 可經CYP2D6代謝\nC. 作用於肝臟休眠期寄生蟲\nD. 為前驅藥物\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗寄生蟲藥tafenoquine的敘述，何者錯誤？\nA. 屬4-aminoquinoline結構\nB. 可經CYP2D6代謝\nC. 作用於肝臟休眠期寄生蟲\nD. 為前驅藥物\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗寄生蟲藥tafenoquine的敘述，何者錯誤？\nA. 屬4-aminoquinoline結構\nB. 可經CYP2D6代謝\nC. 作用於肝臟休眠期寄生蟲\nD. 為前驅藥物\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.125", "False"]], [["-1.875", "False"]], [["-0.25", "True"]], [["-3.75", "False"]]], "filtered_resps": [["-3.125", "False"], ["-1.875", "False"], ["-0.25", "True"], ["-3.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "443937fafeb540f3640da1b001a99d4a28734f3d23fd9da28f3f1ca2aa976427", "prompt_hash": "83099543092c01d3ba6b1ddbbfa4bb63d17b5d5b8d98efe96dba57f76a36a0a5", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 307, "doc": {"question": "CYP代謝酵素分子內含下列何種金屬離子參與氧化反應？", "A": "copper", "B": "zinc", "C": "magnesium", "D": "iron", "answer": "D", "questions": "CYP代謝酵素分子內含下列何種金屬離子參與氧化反應？", "choices": ["copper", "zinc", "magnesium", "iron"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCYP代謝酵素分子內含下列何種金屬離子參與氧化反應？\nA. copper\nB. zinc\nC. magnesium\nD. iron\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCYP代謝酵素分子內含下列何種金屬離子參與氧化反應？\nA. copper\nB. zinc\nC. magnesium\nD. iron\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCYP代謝酵素分子內含下列何種金屬離子參與氧化反應？\nA. copper\nB. zinc\nC. magnesium\nD. iron\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCYP代謝酵素分子內含下列何種金屬離子參與氧化反應？\nA. copper\nB. zinc\nC. magnesium\nD. iron\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.03125", "False"]], [["-4.65625", "False"]], [["-5.28125", "False"]], [["-0.034912109375", "True"]]], "filtered_resps": [["-4.03125", "False"], ["-4.65625", "False"], ["-5.28125", "False"], ["-0.034912109375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b223191067c6090e4e20bfb5c0d28d2e8d9e7c04f699730ad2299be6db1cb1e2", "prompt_hash": "2a3f9e76e8ecdf59211aa6837cabf67eb3fb1a8d9b13e3ece7b5c53a7925e543", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 308, "doc": {"question": "下列何者之抗癌作用與金屬螯合（chelation）有關？", "A": "mitomycin", "B": "dactinomycin", "C": "mitoxantrone", "D": "doxorubicin", "answer": "D", "questions": "下列何者之抗癌作用與金屬螯合（chelation）有關？", "choices": ["mitomycin", "dactinomycin", "mitoxantrone", "doxorubicin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者之抗癌作用與金屬螯合（chelation）有關？\nA. mitomycin\nB. dactinomycin\nC. mitoxantrone\nD. doxorubicin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者之抗癌作用與金屬螯合（chelation）有關？\nA. mitomycin\nB. dactinomycin\nC. mitoxantrone\nD. doxorubicin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者之抗癌作用與金屬螯合（chelation）有關？\nA. mitomycin\nB. dactinomycin\nC. mitoxantrone\nD. doxorubicin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者之抗癌作用與金屬螯合（chelation）有關？\nA. mitomycin\nB. dactinomycin\nC. mitoxantrone\nD. doxorubicin\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.703125", "False"]], [["-1.703125", "False"]], [["-2.203125", "False"]], [["-0.453125", "True"]]], "filtered_resps": [["-2.703125", "False"], ["-1.703125", "False"], ["-2.203125", "False"], ["-0.453125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "84df913052d3dae2231d01e549054c26f8fd7ec9364385a8750d3fd374c01ce9", "prompt_hash": "37f08337384e0d9e35ba5133e5085c631f42996a1fa27cc9937b19059e70cc9d", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 309, "doc": {"question": "下列何種利尿劑為肝硬化（cirrhosis）之禁用藥物，可能導致尿液鹼化而減少尿NH4+排出，而造成高血氨（hyperammonemia）及肝腦病變（hepatic encephalopathy）併發症？", "A": "acetazolamide", "B": "furosemide", "C": "triamterene", "D": "thiazide", "answer": "A", "questions": "下列何種利尿劑為肝硬化（cirrhosis）之禁用藥物，可能導致尿液鹼化而減少尿NH4+排出，而造成高血氨（hyperammonemia）及肝腦病變（hepatic encephalopathy）併發症？", "choices": ["acetazolamide", "furosemide", "triamterene", "thiazide"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑為肝硬化（cirrhosis）之禁用藥物，可能導致尿液鹼化而減少尿NH4+排出，而造成高血氨（hyperammonemia）及肝腦病變（hepatic encephalopathy）併發症？\nA. acetazolamide\nB. furosemide\nC. triamterene\nD. thiazide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑為肝硬化（cirrhosis）之禁用藥物，可能導致尿液鹼化而減少尿NH4+排出，而造成高血氨（hyperammonemia）及肝腦病變（hepatic encephalopathy）併發症？\nA. acetazolamide\nB. furosemide\nC. triamterene\nD. thiazide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑為肝硬化（cirrhosis）之禁用藥物，可能導致尿液鹼化而減少尿NH4+排出，而造成高血氨（hyperammonemia）及肝腦病變（hepatic encephalopathy）併發症？\nA. acetazolamide\nB. furosemide\nC. triamterene\nD. thiazide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑為肝硬化（cirrhosis）之禁用藥物，可能導致尿液鹼化而減少尿NH4+排出，而造成高血氨（hyperammonemia）及肝腦病變（hepatic encephalopathy）併發症？\nA. acetazolamide\nB. furosemide\nC. triamterene\nD. thiazide\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.08544921875", "True"]], [["-3.828125", "False"]], [["-4.34375", "False"]], [["-3.078125", "False"]]], "filtered_resps": [["-0.08544921875", "True"], ["-3.828125", "False"], ["-4.34375", "False"], ["-3.078125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7d9b1d88961e8670bb35da3f63994b6e8fbf0e2f7ff1b9b045126f7047d66cd9", "prompt_hash": "36f23e1c9182e5793ccadadc15e0d746fc1f1cca81df2ba5a3d0aa59054b4838", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 310, "doc": {"question": "下列藥品何者的pKa值最小？", "A": "morphine", "B": "acetaminophen", "C": "diclofenac", "D": "lorazepam", "answer": "C", "questions": "下列藥品何者的pKa值最小？", "choices": ["morphine", "acetaminophen", "diclofenac", "lorazepam"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品何者的pKa值最小？\nA. morphine\nB. acetaminophen\nC. diclofenac\nD. lorazepam\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品何者的pKa值最小？\nA. morphine\nB. acetaminophen\nC. diclofenac\nD. lorazepam\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品何者的pKa值最小？\nA. morphine\nB. acetaminophen\nC. diclofenac\nD. lorazepam\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品何者的pKa值最小？\nA. morphine\nB. acetaminophen\nC. diclofenac\nD. lorazepam\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.90625", "False"]], [["-1.03125", "True"]], [["-1.40625", "False"]], [["-1.40625", "False"]]], "filtered_resps": [["-1.90625", "False"], ["-1.03125", "True"], ["-1.40625", "False"], ["-1.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0382bad22038c5b67e21eb36ed57d9a623f732f3f8e710452093f35f67cc8d08", "prompt_hash": "d570412c328989a814b6213613f1e6c8766e31642c5776e969224adeb013cbab", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 311, "doc": {"question": "Risedronate 結構中，含有下列何種雜環含有下列何種雜環？", "A": "pyrazole", "B": "pyrimidine", "C": "pyridine", "D": "pyrrole", "answer": "C", "questions": "Risedronate 結構中，含有下列何種雜環含有下列何種雜環？", "choices": ["pyrazole", "pyrimidine", "pyridine", "pyrrole"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRisedronate 結構中，含有下列何種雜環含有下列何種雜環？\nA. pyrazole\nB. pyrimidine\nC. pyridine\nD. pyrrole\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRisedronate 結構中，含有下列何種雜環含有下列何種雜環？\nA. pyrazole\nB. pyrimidine\nC. pyridine\nD. pyrrole\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRisedronate 結構中，含有下列何種雜環含有下列何種雜環？\nA. pyrazole\nB. pyrimidine\nC. pyridine\nD. pyrrole\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRisedronate 結構中，含有下列何種雜環含有下列何種雜環？\nA. pyrazole\nB. pyrimidine\nC. pyridine\nD. pyrrole\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.640625", "False"]], [["-4.0", "False"]], [["-0.1337890625", "True"]], [["-2.765625", "False"]]], "filtered_resps": [["-3.640625", "False"], ["-4.0", "False"], ["-0.1337890625", "True"], ["-2.765625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3869e25e6d476f674e7f565e25b105c820c86794f2a8e4f5b00824b9b6487bc1", "prompt_hash": "b518dfe52dfb44a0a718386e54e83ba57520577e809ba70e65b7dfce827ed445", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 312, "doc": {"question": "下列那個非固醇類抗發炎藥物對COX-2之選擇性最高？", "A": "rofecoxib", "B": "meloxicam", "C": "diclofenac", "D": "celecoxib", "answer": "A", "questions": "下列那個非固醇類抗發炎藥物對COX-2之選擇性最高？", "choices": ["rofecoxib", "meloxicam", "diclofenac", "celecoxib"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那個非固醇類抗發炎藥物對COX-2之選擇性最高？\nA. rofecoxib\nB. meloxicam\nC. diclofenac\nD. celecoxib\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那個非固醇類抗發炎藥物對COX-2之選擇性最高？\nA. rofecoxib\nB. meloxicam\nC. diclofenac\nD. celecoxib\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那個非固醇類抗發炎藥物對COX-2之選擇性最高？\nA. rofecoxib\nB. meloxicam\nC. diclofenac\nD. celecoxib\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那個非固醇類抗發炎藥物對COX-2之選擇性最高？\nA. rofecoxib\nB. meloxicam\nC. diclofenac\nD. celecoxib\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0269775390625", "True"]], [["-5.28125", "False"]], [["-5.90625", "False"]], [["-4.03125", "False"]]], "filtered_resps": [["-0.0269775390625", "True"], ["-5.28125", "False"], ["-5.90625", "False"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "07fadda47a9087698885926880c8758de027e04cc2dfe39a9e92a0a9e3056a56", "prompt_hash": "6bdb810332346a09bbea597e6f67f7f8e2e4a06b1dde16ee84e47e4227cc08ec", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 313, "doc": {"question": "下列何者為penciclovir之前驅藥？", "A": "ganciclovir", "B": "famciclovir", "C": "valacyclovir", "D": "acyclovir", "answer": "B", "questions": "下列何者為penciclovir之前驅藥？", "choices": ["ganciclovir", "famciclovir", "valacyclovir", "acyclovir"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為penciclovir之前驅藥？\nA. ganciclovir\nB. famciclovir\nC. valacyclovir\nD. acyclovir\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為penciclovir之前驅藥？\nA. ganciclovir\nB. famciclovir\nC. valacyclovir\nD. acyclovir\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為penciclovir之前驅藥？\nA. ganciclovir\nB. famciclovir\nC. valacyclovir\nD. acyclovir\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為penciclovir之前驅藥？\nA. ganciclovir\nB. famciclovir\nC. valacyclovir\nD. acyclovir\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.03125", "False"]], [["-0.026611328125", "True"]], [["-5.65625", "False"]], [["-4.03125", "False"]]], "filtered_resps": [["-6.03125", "False"], ["-0.026611328125", "True"], ["-5.65625", "False"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a5da29f527041229556ee5b47b0601cf5718114d946ad59503ee056fef9c7d86", "prompt_hash": "15aa0615a5727ab8e0dbc539356894cd990ed2a52e08d328b05d848ee84b6ac8", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 314, "doc": {"question": "擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？", "A": "phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失", "B": "phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣", "C": "phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失", "D": "phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣", "answer": "C", "questions": "擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？", "choices": ["phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失", "phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣", "phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失", "phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？\nA. phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失\nB. phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣\nC. phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失\nD. phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？\nA. phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失\nB. phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣\nC. phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失\nD. phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？\nA. phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失\nB. phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣\nC. phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失\nD. phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？\nA. phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失\nB. phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣\nC. phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失\nD. phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.625", "False"]], [["-3.125", "False"]], [["-0.50390625", "True"]], [["-1.875", "False"]]], "filtered_resps": [["-1.625", "False"], ["-3.125", "False"], ["-0.50390625", "True"], ["-1.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c3cc7093269a35b631fc4c30f66a9d8276454a4df0a2064de4748ac529c414f0", "prompt_hash": "4b997e66ea51c910bd042203163542d4c1c4e16acf427d2dda88ed1c0936aa22", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 315, "doc": {"question": "用於治療高血壓之藥物Aliskiren是屬於下列何類作用之藥物？", "A": "vasopeptidase inhibitor", "B": "natriuretic peptide", "C": "renin inhibitor", "D": "angiotensin receptor blocker", "answer": "C", "questions": "用於治療高血壓之藥物Aliskiren是屬於下列何類作用之藥物？", "choices": ["vasopeptidase inhibitor", "natriuretic peptide", "renin inhibitor", "angiotensin receptor blocker"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n用於治療高血壓之藥物Aliskiren是屬於下列何類作用之藥物？\nA. vasopeptidase inhibitor\nB. natriuretic peptide\nC. renin inhibitor\nD. angiotensin receptor blocker\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n用於治療高血壓之藥物Aliskiren是屬於下列何類作用之藥物？\nA. vasopeptidase inhibitor\nB. natriuretic peptide\nC. renin inhibitor\nD. angiotensin receptor blocker\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n用於治療高血壓之藥物Aliskiren是屬於下列何類作用之藥物？\nA. vasopeptidase inhibitor\nB. natriuretic peptide\nC. renin inhibitor\nD. angiotensin receptor blocker\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n用於治療高血壓之藥物Aliskiren是屬於下列何類作用之藥物？\nA. vasopeptidase inhibitor\nB. natriuretic peptide\nC. renin inhibitor\nD. angiotensin receptor blocker\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.375", "False"]], [["-9.5", "False"]], [["-0.007354736328125", "True"]], [["-5.375", "False"]]], "filtered_resps": [["-6.375", "False"], ["-9.5", "False"], ["-0.007354736328125", "True"], ["-5.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "48917ed5bdf319084846f185ce7d1f8ad9348902d59d5e593bf2fbfd7c986585", "prompt_hash": "d2eaa2459696493cae9d503cc9a49c088d9341cc5fcf5c7e8919230cfda3cc87", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 316, "doc": {"question": "下列何者屬於benzomorphan結構之鎮痛劑：", "A": "methadone", "B": "pentazocine", "C": "meperidine", "D": "fentanyl", "answer": "B", "questions": "下列何者屬於benzomorphan結構之鎮痛劑：", "choices": ["methadone", "pentazocine", "meperidine", "fentanyl"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者屬於benzomorphan結構之鎮痛劑：\nA. methadone\nB. pentazocine\nC. meperidine\nD. fentanyl\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者屬於benzomorphan結構之鎮痛劑：\nA. methadone\nB. pentazocine\nC. meperidine\nD. fentanyl\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者屬於benzomorphan結構之鎮痛劑：\nA. methadone\nB. pentazocine\nC. meperidine\nD. fentanyl\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者屬於benzomorphan結構之鎮痛劑：\nA. methadone\nB. pentazocine\nC. meperidine\nD. fentanyl\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.75", "False"]], [["-0.0048828125", "True"]], [["-7.0", "False"]], [["-6.875", "False"]]], "filtered_resps": [["-7.75", "False"], ["-0.0048828125", "True"], ["-7.0", "False"], ["-6.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b4aa77e9384281e91199e558a028c154a8be2563b109fcafca0f41a53b77da15", "prompt_hash": "4be0c755e85708fdcfaa3f14cf56223d65b9634f5042073f8544bad1f6808066", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 317, "doc": {"question": "下列何者為pentostatin用以預防同種異體移植排斥（allograft rejection）的藥理機制？", "A": "抑制JAK enzymes", "B": "抑制dihydroorotate dehydrogenase", "C": "抑制adenosine deaminase", "D": "抑制sphingosine-1-phosphate (S1P) receptor", "answer": "C", "questions": "下列何者為pentostatin用以預防同種異體移植排斥（allograft rejection）的藥理機制？", "choices": ["抑制JAK enzymes", "抑制dihydroorotate dehydrogenase", "抑制adenosine deaminase", "抑制sphingosine-1-phosphate (S1P) receptor"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pentostatin用以預防同種異體移植排斥（allograft rejection）的藥理機制？\nA. 抑制JAK enzymes\nB. 抑制dihydroorotate dehydrogenase\nC. 抑制adenosine deaminase\nD. 抑制sphingosine-1-phosphate (S1P) receptor\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pentostatin用以預防同種異體移植排斥（allograft rejection）的藥理機制？\nA. 抑制JAK enzymes\nB. 抑制dihydroorotate dehydrogenase\nC. 抑制adenosine deaminase\nD. 抑制sphingosine-1-phosphate (S1P) receptor\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pentostatin用以預防同種異體移植排斥（allograft rejection）的藥理機制？\nA. 抑制JAK enzymes\nB. 抑制dihydroorotate dehydrogenase\nC. 抑制adenosine deaminase\nD. 抑制sphingosine-1-phosphate (S1P) receptor\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為pentostatin用以預防同種異體移植排斥（allograft rejection）的藥理機制？\nA. 抑制JAK enzymes\nB. 抑制dihydroorotate dehydrogenase\nC. 抑制adenosine deaminase\nD. 抑制sphingosine-1-phosphate (S1P) receptor\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.6875", "False"]], [["-4.6875", "False"]], [["-0.05126953125", "True"]], [["-3.796875", "False"]]], "filtered_resps": [["-4.6875", "False"], ["-4.6875", "False"], ["-0.05126953125", "True"], ["-3.796875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "052438ce49c602d4209aae54b9d88baca7e3d019deddf83723a2d519391d6859", "prompt_hash": "a63c4e873c046f321f190691ce0db9f59d7d3ab0742ebb52af555b4ca2ca2e10", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 318, "doc": {"question": "下列何者是quinidine之不純物，具有顯著毒性？", "A": "quinoline", "B": "O-demethylquinidine", "C": "oxydihydroquinidine", "D": "dihydroquinidine", "answer": "D", "questions": "下列何者是quinidine之不純物，具有顯著毒性？", "choices": ["quinoline", "O-demethylquinidine", "oxydihydroquinidine", "dihydroquinidine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是quinidine之不純物，具有顯著毒性？\nA. quinoline\nB. O-demethylquinidine\nC. oxydihydroquinidine\nD. dihydroquinidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是quinidine之不純物，具有顯著毒性？\nA. quinoline\nB. O-demethylquinidine\nC. oxydihydroquinidine\nD. dihydroquinidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是quinidine之不純物，具有顯著毒性？\nA. quinoline\nB. O-demethylquinidine\nC. oxydihydroquinidine\nD. dihydroquinidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是quinidine之不純物，具有顯著毒性？\nA. quinoline\nB. O-demethylquinidine\nC. oxydihydroquinidine\nD. dihydroquinidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.7265625", "False"]], [["-2.84375", "False"]], [["-1.9765625", "False"]], [["-0.474609375", "True"]]], "filtered_resps": [["-1.7265625", "False"], ["-2.84375", "False"], ["-1.9765625", "False"], ["-0.474609375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a17824372054893d1fffb8d10403e6ccf96bdf8eca9bcd6847dbaabc388c442e", "prompt_hash": "cc510eb164886d600c78a7a2d7d8b3763deca270d2b42d872d94692aa8d36609", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 319, "doc": {"question": "有關保鉀型利尿劑amiloride於腎小管中之作用機制，下列敘述何者正確？", "A": "抑制近曲小管（proximal convoluted tubule）中aldosterone receptor", "B": "抑制遠曲小管（distal convoluted tubule）中Na+/Cl- cotransporter", "C": "抑制亨利氏環（loop of Henle）中Na+/K+/2Cl- cotransporter", "D": "抑制集尿管（collecting duct）中Na+ channel", "answer": "D", "questions": "有關保鉀型利尿劑amiloride於腎小管中之作用機制，下列敘述何者正確？", "choices": ["抑制近曲小管（proximal convoluted tubule）中aldosterone receptor", "抑制遠曲小管（distal convoluted tubule）中Na+/Cl- cotransporter", "抑制亨利氏環（loop of Henle）中Na+/K+/2Cl- cotransporter", "抑制集尿管（collecting duct）中Na+ channel"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關保鉀型利尿劑amiloride於腎小管中之作用機制，下列敘述何者正確？\nA. 抑制近曲小管（proximal convoluted tubule）中aldosterone receptor\nB. 抑制遠曲小管（distal convoluted tubule）中Na+/Cl- cotransporter\nC. 抑制亨利氏環（loop of Henle）中Na+/K+/2Cl- cotransporter\nD. 抑制集尿管（collecting duct）中Na+ channel\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關保鉀型利尿劑amiloride於腎小管中之作用機制，下列敘述何者正確？\nA. 抑制近曲小管（proximal convoluted tubule）中aldosterone receptor\nB. 抑制遠曲小管（distal convoluted tubule）中Na+/Cl- cotransporter\nC. 抑制亨利氏環（loop of Henle）中Na+/K+/2Cl- cotransporter\nD. 抑制集尿管（collecting duct）中Na+ channel\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關保鉀型利尿劑amiloride於腎小管中之作用機制，下列敘述何者正確？\nA. 抑制近曲小管（proximal convoluted tubule）中aldosterone receptor\nB. 抑制遠曲小管（distal convoluted tubule）中Na+/Cl- cotransporter\nC. 抑制亨利氏環（loop of Henle）中Na+/K+/2Cl- cotransporter\nD. 抑制集尿管（collecting duct）中Na+ channel\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關保鉀型利尿劑amiloride於腎小管中之作用機制，下列敘述何者正確？\nA. 抑制近曲小管（proximal convoluted tubule）中aldosterone receptor\nB. 抑制遠曲小管（distal convoluted tubule）中Na+/Cl- cotransporter\nC. 抑制亨利氏環（loop of Henle）中Na+/K+/2Cl- cotransporter\nD. 抑制集尿管（collecting duct）中Na+ channel\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-5.25", "False"]], [["-6.5", "False"]], [["-0.01007080078125", "True"]]], "filtered_resps": [["-5.875", "False"], ["-5.25", "False"], ["-6.5", "False"], ["-0.01007080078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7cebea9580d25d1994c40f0a69374b044ac96a55e852035b6da4d3b343d74474", "prompt_hash": "b8b8a20de302d8321254a72e618d45aaab73318d385503c2cbe7db13a296155a", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 320, "doc": {"question": "下列有關 PDE5 抑制劑之敘述，何者正確何者正確？", "A": "tadalafil 具活性代謝物", "B": "活性依序為 vardenafil＞sildenafil＞tadalafil tadalafil", "C": "藥效最長者為 sildenafil", "D": "sildenafil 與 vardenafil 均具 pyrazolopyrimidinone 結構", "answer": "B", "questions": "下列有關 PDE5 抑制劑之敘述，何者正確何者正確？", "choices": ["tadalafil 具活性代謝物", "活性依序為 vardenafil＞sildenafil＞tadalafil tadalafil", "藥效最長者為 sildenafil", "sildenafil 與 vardenafil 均具 pyrazolopyrimidinone 結構"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 PDE5 抑制劑之敘述，何者正確何者正確？\nA. tadalafil 具活性代謝物\nB. 活性依序為 vardenafil＞sildenafil＞tadalafil tadalafil\nC. 藥效最長者為 sildenafil\nD. sildenafil 與 vardenafil 均具 pyrazolopyrimidinone 結構\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 PDE5 抑制劑之敘述，何者正確何者正確？\nA. tadalafil 具活性代謝物\nB. 活性依序為 vardenafil＞sildenafil＞tadalafil tadalafil\nC. 藥效最長者為 sildenafil\nD. sildenafil 與 vardenafil 均具 pyrazolopyrimidinone 結構\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 PDE5 抑制劑之敘述，何者正確何者正確？\nA. tadalafil 具活性代謝物\nB. 活性依序為 vardenafil＞sildenafil＞tadalafil tadalafil\nC. 藥效最長者為 sildenafil\nD. sildenafil 與 vardenafil 均具 pyrazolopyrimidinone 結構\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 PDE5 抑制劑之敘述，何者正確何者正確？\nA. tadalafil 具活性代謝物\nB. 活性依序為 vardenafil＞sildenafil＞tadalafil tadalafil\nC. 藥效最長者為 sildenafil\nD. sildenafil 與 vardenafil 均具 pyrazolopyrimidinone 結構\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.71875", "False"]], [["-0.83984375", "True"]], [["-2.96875", "False"]], [["-1.09375", "False"]]], "filtered_resps": [["-1.71875", "False"], ["-0.83984375", "True"], ["-2.96875", "False"], ["-1.09375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3a7084d16e68dcfce663e6e795920f6be093dc6c1da180af3fc2072ca257d8c8", "prompt_hash": "eb6fcae24b4636d1aec4062e431a8bae286020b8082e680962c98d84b0bac9c2", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 321, "doc": {"question": "造血生長因子interleukin（IL）-11及藥物romiplostim為調節何種血球生成為主？", "A": "血小板platelet", "B": "紅血球RBC", "C": "網狀球reticulocyte", "D": "單核球monocyte", "answer": "A", "questions": "造血生長因子interleukin（IL）-11及藥物romiplostim為調節何種血球生成為主？", "choices": ["血小板platelet", "紅血球RBC", "網狀球reticulocyte", "單核球monocyte"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n造血生長因子interleukin（IL）-11及藥物romiplostim為調節何種血球生成為主？\nA. 血小板platelet\nB. 紅血球RBC\nC. 網狀球reticulocyte\nD. 單核球monocyte\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n造血生長因子interleukin（IL）-11及藥物romiplostim為調節何種血球生成為主？\nA. 血小板platelet\nB. 紅血球RBC\nC. 網狀球reticulocyte\nD. 單核球monocyte\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n造血生長因子interleukin（IL）-11及藥物romiplostim為調節何種血球生成為主？\nA. 血小板platelet\nB. 紅血球RBC\nC. 網狀球reticulocyte\nD. 單核球monocyte\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n造血生長因子interleukin（IL）-11及藥物romiplostim為調節何種血球生成為主？\nA. 血小板platelet\nB. 紅血球RBC\nC. 網狀球reticulocyte\nD. 單核球monocyte\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.01214599609375", "True"]], [["-6.125", "False"]], [["-5.75", "False"]], [["-5.25", "False"]]], "filtered_resps": [["-0.01214599609375", "True"], ["-6.125", "False"], ["-5.75", "False"], ["-5.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6acf2367ff727ff0f91f2e403cf542e719af8c17c4e01ff43fbad88a19f2c73b", "prompt_hash": "06aab73599d45ebacb6ca0da37988eb31f5f080a13a27100f6447fd5952b90ac", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 322, "doc": {"question": "下列有關ciclesonide的敘述，何者錯誤？", "A": "其代謝物為desisopropylciclesonide", "B": "R-異構物活性大於S-異構物", "C": "是一個前驅藥", "D": "用於治療氣喘與鼻炎", "answer": "A", "questions": "下列有關ciclesonide的敘述，何者錯誤？", "choices": ["其代謝物為desisopropylciclesonide", "R-異構物活性大於S-異構物", "是一個前驅藥", "用於治療氣喘與鼻炎"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ciclesonide的敘述，何者錯誤？\nA. 其代謝物為desisopropylciclesonide\nB. R-異構物活性大於S-異構物\nC. 是一個前驅藥\nD. 用於治療氣喘與鼻炎\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ciclesonide的敘述，何者錯誤？\nA. 其代謝物為desisopropylciclesonide\nB. R-異構物活性大於S-異構物\nC. 是一個前驅藥\nD. 用於治療氣喘與鼻炎\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ciclesonide的敘述，何者錯誤？\nA. 其代謝物為desisopropylciclesonide\nB. R-異構物活性大於S-異構物\nC. 是一個前驅藥\nD. 用於治療氣喘與鼻炎\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ciclesonide的敘述，何者錯誤？\nA. 其代謝物為desisopropylciclesonide\nB. R-異構物活性大於S-異構物\nC. 是一個前驅藥\nD. 用於治療氣喘與鼻炎\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.6640625", "True"]], [["-1.0390625", "False"]], [["-2.046875", "False"]], [["-6.03125", "False"]]], "filtered_resps": [["-0.6640625", "True"], ["-1.0390625", "False"], ["-2.046875", "False"], ["-6.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f2733c1d8667d278cf0b817fdf4932e3b065967f2fedd3ef81ccde7820c39dfb", "prompt_hash": "611339dd292d8711069f26cf78e18d12ede0ced7d7754396dad88571feb518d7", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 323, "doc": {"question": "下列何種痛風治療藥物具有促進尿酸排除作用？", "A": "sulfinpyrazone", "B": "colchicine", "C": "allopurinol", "D": "indomethacin", "answer": "A", "questions": "下列何種痛風治療藥物具有促進尿酸排除作用？", "choices": ["sulfinpyrazone", "colchicine", "allopurinol", "indomethacin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種痛風治療藥物具有促進尿酸排除作用？\nA. sulfinpyrazone\nB. colchicine\nC. allopurinol\nD. indomethacin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種痛風治療藥物具有促進尿酸排除作用？\nA. sulfinpyrazone\nB. colchicine\nC. allopurinol\nD. indomethacin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種痛風治療藥物具有促進尿酸排除作用？\nA. sulfinpyrazone\nB. colchicine\nC. allopurinol\nD. indomethacin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種痛風治療藥物具有促進尿酸排除作用？\nA. sulfinpyrazone\nB. colchicine\nC. allopurinol\nD. indomethacin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.01226806640625", "True"]], [["-5.5", "False"]], [["-6.25", "False"]], [["-5.25", "False"]]], "filtered_resps": [["-0.01226806640625", "True"], ["-5.5", "False"], ["-6.25", "False"], ["-5.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "82fd70db3328093b09e532fef84bbe60bda0bb70e56a4c9504817b569e22d862", "prompt_hash": "b61a87009a4aa2da03f581ba1ea83eb251b9b622999b17c6ddc34073504f2432", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 324, "doc": {"question": "下列有關pertechnetate（99mTcO4−）之敘述，何者錯誤？", "A": "主要經由肝臟代謝", "B": "由molybdenum-99製備而來", "C": "半衰期為6小時", "D": "主要用於甲狀腺之診斷", "answer": "A", "questions": "下列有關pertechnetate（99mTcO4−）之敘述，何者錯誤？", "choices": ["主要經由肝臟代謝", "由molybdenum-99製備而來", "半衰期為6小時", "主要用於甲狀腺之診斷"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關pertechnetate（99mTcO4−）之敘述，何者錯誤？\nA. 主要經由肝臟代謝\nB. 由molybdenum-99製備而來\nC. 半衰期為6小時\nD. 主要用於甲狀腺之診斷\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關pertechnetate（99mTcO4−）之敘述，何者錯誤？\nA. 主要經由肝臟代謝\nB. 由molybdenum-99製備而來\nC. 半衰期為6小時\nD. 主要用於甲狀腺之診斷\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關pertechnetate（99mTcO4−）之敘述，何者錯誤？\nA. 主要經由肝臟代謝\nB. 由molybdenum-99製備而來\nC. 半衰期為6小時\nD. 主要用於甲狀腺之診斷\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關pertechnetate（99mTcO4−）之敘述，何者錯誤？\nA. 主要經由肝臟代謝\nB. 由molybdenum-99製備而來\nC. 半衰期為6小時\nD. 主要用於甲狀腺之診斷\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.97265625", "False"]], [["-3.34375", "False"]], [["-0.59765625", "True"]], [["-3.34375", "False"]]], "filtered_resps": [["-0.97265625", "False"], ["-3.34375", "False"], ["-0.59765625", "True"], ["-3.34375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bf52f3bfa68854f88747f1c361182d1a76309bff29af9481e8a13af3d0ff9fff", "prompt_hash": "1f7b98284f0cf93529e20d68af7d5eac4f6ff338d1c7dc45dc3b96d7cec23ca2", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 325, "doc": {"question": "下列何種化療組合較不適當？", "A": "procarbazine, lomustine, vincristine", "B": "vincristine, doxorubicin, eribulin", "C": "mechlorethamine, vincristine, procarbazine, prednisone", "D": "5-fluorouracil, leucovorin, oxaliplatin", "answer": "B", "questions": "下列何種化療組合較不適當？", "choices": ["procarbazine, lomustine, vincristine", "vincristine, doxorubicin, eribulin", "mechlorethamine, vincristine, procarbazine, prednisone", "5-fluorouracil, leucovorin, oxaliplatin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種化療組合較不適當？\nA. procarbazine, lomustine, vincristine\nB. vincristine, doxorubicin, eribulin\nC. mechlorethamine, vincristine, procarbazine, prednisone\nD. 5-fluorouracil, leucovorin, oxaliplatin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種化療組合較不適當？\nA. procarbazine, lomustine, vincristine\nB. vincristine, doxorubicin, eribulin\nC. mechlorethamine, vincristine, procarbazine, prednisone\nD. 5-fluorouracil, leucovorin, oxaliplatin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種化療組合較不適當？\nA. procarbazine, lomustine, vincristine\nB. vincristine, doxorubicin, eribulin\nC. mechlorethamine, vincristine, procarbazine, prednisone\nD. 5-fluorouracil, leucovorin, oxaliplatin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種化療組合較不適當？\nA. procarbazine, lomustine, vincristine\nB. vincristine, doxorubicin, eribulin\nC. mechlorethamine, vincristine, procarbazine, prednisone\nD. 5-fluorouracil, leucovorin, oxaliplatin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.828125", "False"]], [["-0.703125", "True"]], [["-4.8125", "False"]], [["-2.953125", "False"]]], "filtered_resps": [["-0.828125", "False"], ["-0.703125", "True"], ["-4.8125", "False"], ["-2.953125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4c79146721074513fa65c0fa9e8cf91afd122cbb39c04a7c8e9c32391cb67974", "prompt_hash": "74543f82ac089f844168b1c32dcc440d2bcd7da46de79d42776971afeacd45ac", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 326, "doc": {"question": "使用利尿劑hydrochlorothiazide時可能導致之副作用，下列何者錯誤？", "A": "低血鈉症（hyponatremia）", "B": "代謝性鹼中毒（metabolic alkalosis）", "C": "低血脂症（hypolipidemia）", "D": "痛風（gout）", "answer": "C", "questions": "使用利尿劑hydrochlorothiazide時可能導致之副作用，下列何者錯誤？", "choices": ["低血鈉症（hyponatremia）", "代謝性鹼中毒（metabolic alkalosis）", "低血脂症（hypolipidemia）", "痛風（gout）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用利尿劑hydrochlorothiazide時可能導致之副作用，下列何者錯誤？\nA. 低血鈉症（hyponatremia）\nB. 代謝性鹼中毒（metabolic alkalosis）\nC. 低血脂症（hypolipidemia）\nD. 痛風（gout）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用利尿劑hydrochlorothiazide時可能導致之副作用，下列何者錯誤？\nA. 低血鈉症（hyponatremia）\nB. 代謝性鹼中毒（metabolic alkalosis）\nC. 低血脂症（hypolipidemia）\nD. 痛風（gout）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用利尿劑hydrochlorothiazide時可能導致之副作用，下列何者錯誤？\nA. 低血鈉症（hyponatremia）\nB. 代謝性鹼中毒（metabolic alkalosis）\nC. 低血脂症（hypolipidemia）\nD. 痛風（gout）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用利尿劑hydrochlorothiazide時可能導致之副作用，下列何者錯誤？\nA. 低血鈉症（hyponatremia）\nB. 代謝性鹼中毒（metabolic alkalosis）\nC. 低血脂症（hypolipidemia）\nD. 痛風（gout）\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.375", "False"]], [["-6.25", "False"]], [["-0.011474609375", "True"]], [["-5.5", "False"]]], "filtered_resps": [["-7.375", "False"], ["-6.25", "False"], ["-0.011474609375", "True"], ["-5.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "be1b627bf11a5550e7a8b2fc3f9bba09f07844aa2f1e61c041e112e12c888733", "prompt_hash": "8d4b6dac4af33b630545b06741c44ac44b5b71cd14a8b19c947d3560812ef2a3", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 327, "doc": {"question": "Ixabepilone不具有下列何種結構？", "A": "thiazole", "B": "lactone", "C": "lactam", "D": "epoxide", "answer": "B", "questions": "Ixabepilone不具有下列何種結構？", "choices": ["thiazole", "lactone", "lactam", "epoxide"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nIxabepilone不具有下列何種結構？\nA. thiazole\nB. lactone\nC. lactam\nD. epoxide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nIxabepilone不具有下列何種結構？\nA. thiazole\nB. lactone\nC. lactam\nD. epoxide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nIxabepilone不具有下列何種結構？\nA. thiazole\nB. lactone\nC. lactam\nD. epoxide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nIxabepilone不具有下列何種結構？\nA. thiazole\nB. lactone\nC. lactam\nD. epoxide\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.1953125", "False"]], [["-1.9453125", "False"]], [["-0.8203125", "True"]], [["-2.1875", "False"]]], "filtered_resps": [["-1.1953125", "False"], ["-1.9453125", "False"], ["-0.8203125", "True"], ["-2.1875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "199d0d6ff4d32aec640ad1d9e09b30a8c6c2c99cc0d225ff3f2a465f8c6a54a0", "prompt_hash": "1e31289e76aee15a4af1eb8fb86dda56434c00bd066cbc3e55c5c3e9b630e96c", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 328, "doc": {"question": "下列藥物中，何者最可能會抑制代謝該藥物本身的肝臟酵素，長期服用需注意調整劑量？", "A": "rifampin", "B": "clopidogrel", "C": "phenytoin", "D": "carbamazepine", "answer": "B", "questions": "下列藥物中，何者最可能會抑制代謝該藥物本身的肝臟酵素，長期服用需注意調整劑量？", "choices": ["rifampin", "clopidogrel", "phenytoin", "carbamazepine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者最可能會抑制代謝該藥物本身的肝臟酵素，長期服用需注意調整劑量？\nA. rifampin\nB. clopidogrel\nC. phenytoin\nD. carbamazepine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者最可能會抑制代謝該藥物本身的肝臟酵素，長期服用需注意調整劑量？\nA. rifampin\nB. clopidogrel\nC. phenytoin\nD. carbamazepine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者最可能會抑制代謝該藥物本身的肝臟酵素，長期服用需注意調整劑量？\nA. rifampin\nB. clopidogrel\nC. phenytoin\nD. carbamazepine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者最可能會抑制代謝該藥物本身的肝臟酵素，長期服用需注意調整劑量？\nA. rifampin\nB. clopidogrel\nC. phenytoin\nD. carbamazepine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.90625", "False"]], [["-0.025634765625", "True"]], [["-4.78125", "False"]], [["-4.28125", "False"]]], "filtered_resps": [["-5.90625", "False"], ["-0.025634765625", "True"], ["-4.78125", "False"], ["-4.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8f1bcdca30b0f9acb195bdc140a7ea52e1d2920906b5c464aa1c72f744a2bd4d", "prompt_hash": "d812fc3e61aab64a8b7925dc9cbc43bb19bc86190677ce5dcca21d07bc70545b", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 329, "doc": {"question": "下列中樞神經性疾病和治療藥物之配對，何者錯誤？", "A": "benztropine因拮抗muscarinic受體，可以治療帕金森氏症（Parkinson disease）", "B": "donepezil抑制cholinesterase，可以治療阿茲海默症（Alzheimer disease）", "C": "metoprolol是β1 adrenergic antagonist，可以治療顫抖（tremor）", "D": "tetrabenazine因減少dopamine濃度，可以治療亨汀頓氏舞蹈症（Huntington disease）", "answer": "C", "questions": "下列中樞神經性疾病和治療藥物之配對，何者錯誤？", "choices": ["benztropine因拮抗muscarinic受體，可以治療帕金森氏症（Parkinson disease）", "donepezil抑制cholinesterase，可以治療阿茲海默症（Alzheimer disease）", "metoprolol是β1 adrenergic antagonist，可以治療顫抖（tremor）", "tetrabenazine因減少dopamine濃度，可以治療亨汀頓氏舞蹈症（Huntington disease）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中樞神經性疾病和治療藥物之配對，何者錯誤？\nA. benztropine因拮抗muscarinic受體，可以治療帕金森氏症（Parkinson disease）\nB. donepezil抑制cholinesterase，可以治療阿茲海默症（Alzheimer disease）\nC. metoprolol是β1 adrenergic antagonist，可以治療顫抖（tremor）\nD. tetrabenazine因減少dopamine濃度，可以治療亨汀頓氏舞蹈症（Huntington disease）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中樞神經性疾病和治療藥物之配對，何者錯誤？\nA. benztropine因拮抗muscarinic受體，可以治療帕金森氏症（Parkinson disease）\nB. donepezil抑制cholinesterase，可以治療阿茲海默症（Alzheimer disease）\nC. metoprolol是β1 adrenergic antagonist，可以治療顫抖（tremor）\nD. tetrabenazine因減少dopamine濃度，可以治療亨汀頓氏舞蹈症（Huntington disease）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中樞神經性疾病和治療藥物之配對，何者錯誤？\nA. benztropine因拮抗muscarinic受體，可以治療帕金森氏症（Parkinson disease）\nB. donepezil抑制cholinesterase，可以治療阿茲海默症（Alzheimer disease）\nC. metoprolol是β1 adrenergic antagonist，可以治療顫抖（tremor）\nD. tetrabenazine因減少dopamine濃度，可以治療亨汀頓氏舞蹈症（Huntington disease）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中樞神經性疾病和治療藥物之配對，何者錯誤？\nA. benztropine因拮抗muscarinic受體，可以治療帕金森氏症（Parkinson disease）\nB. donepezil抑制cholinesterase，可以治療阿茲海默症（Alzheimer disease）\nC. metoprolol是β1 adrenergic antagonist，可以治療顫抖（tremor）\nD. tetrabenazine因減少dopamine濃度，可以治療亨汀頓氏舞蹈症（Huntington disease）\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.65625", "False"]], [["-5.78125", "False"]], [["-0.0277099609375", "True"]], [["-4.40625", "False"]]], "filtered_resps": [["-4.65625", "False"], ["-5.78125", "False"], ["-0.0277099609375", "True"], ["-4.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d98287dbbdd9fbe567a2a4a0da925135b8d51d6388f1f5058768f725ef10bb58", "prompt_hash": "5fb5d24c7770041513879fd506e9779b843e1dc1794208ce5acf6cfa32c86205", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 330, "doc": {"question": "那一種降壓藥物投與後會引起鎮靜或嗜睡之副作用？", "A": "Clonidine", "B": "Prazosin", "C": "Verapamil", "D": "Guanethidine", "answer": "A", "questions": "那一種降壓藥物投與後會引起鎮靜或嗜睡之副作用？", "choices": ["Clonidine", "Prazosin", "Verapamil", "Guanethidine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種降壓藥物投與後會引起鎮靜或嗜睡之副作用？\nA. Clonidine\nB. Prazosin\nC. Verapamil\nD. Guanethidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種降壓藥物投與後會引起鎮靜或嗜睡之副作用？\nA. Clonidine\nB. Prazosin\nC. Verapamil\nD. Guanethidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種降壓藥物投與後會引起鎮靜或嗜睡之副作用？\nA. Clonidine\nB. Prazosin\nC. Verapamil\nD. Guanethidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種降壓藥物投與後會引起鎮靜或嗜睡之副作用？\nA. Clonidine\nB. Prazosin\nC. Verapamil\nD. Guanethidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.040771484375", "True"]], [["-4.90625", "False"]], [["-4.15625", "False"]], [["-5.03125", "False"]]], "filtered_resps": [["-0.040771484375", "True"], ["-4.90625", "False"], ["-4.15625", "False"], ["-5.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c213ff7a5f144d28e93ac1638e6f977075ea54ee228af288b07a518db93556d7", "prompt_hash": "d4682bf0da29702bebe8f51c4e0845dab01fd317b4c855d824f7e0616291da64", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 331, "doc": {"question": "同時患有糖尿病及高血壓的病人，服用下列何種抗高血壓藥物最易造成咳嗽之副作用？", "A": "Verapamil", "B": "Propranolol", "C": "Captopril", "D": "Losartan", "answer": "C", "questions": "同時患有糖尿病及高血壓的病人，服用下列何種抗高血壓藥物最易造成咳嗽之副作用？", "choices": ["Verapamil", "Propranolol", "Captopril", "Losartan"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n同時患有糖尿病及高血壓的病人，服用下列何種抗高血壓藥物最易造成咳嗽之副作用？\nA. Verapamil\nB. Propranolol\nC. Captopril\nD. Losartan\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n同時患有糖尿病及高血壓的病人，服用下列何種抗高血壓藥物最易造成咳嗽之副作用？\nA. Verapamil\nB. Propranolol\nC. Captopril\nD. Losartan\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n同時患有糖尿病及高血壓的病人，服用下列何種抗高血壓藥物最易造成咳嗽之副作用？\nA. Verapamil\nB. Propranolol\nC. Captopril\nD. Losartan\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n同時患有糖尿病及高血壓的病人，服用下列何種抗高血壓藥物最易造成咳嗽之副作用？\nA. Verapamil\nB. Propranolol\nC. Captopril\nD. Losartan\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.625", "False"]], [["-7.25", "False"]], [["-0.00970458984375", "True"]], [["-6.125", "False"]]], "filtered_resps": [["-7.625", "False"], ["-7.25", "False"], ["-0.00970458984375", "True"], ["-6.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "58cfac26b57773379377f9ee192ed837fe868e7683d8c3b3e63ff883ef881229", "prompt_hash": "cf56078e1c2e3add6419b2a57b52bcb27b7eba57c5a88989c2f146faec60d58c", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 332, "doc": {"question": "有關infliximab之敘述，下列何者錯誤？", "A": "半衰期為9〜12天", "B": "類風濕性關節炎治療用藥", "C": "主要作用在TNF-α", "D": "為IgE單株抗體", "answer": "D", "questions": "有關infliximab之敘述，下列何者錯誤？", "choices": ["半衰期為9〜12天", "類風濕性關節炎治療用藥", "主要作用在TNF-α", "為IgE單株抗體"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關infliximab之敘述，下列何者錯誤？\nA. 半衰期為9〜12天\nB. 類風濕性關節炎治療用藥\nC. 主要作用在TNF-α\nD. 為IgE單株抗體\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關infliximab之敘述，下列何者錯誤？\nA. 半衰期為9〜12天\nB. 類風濕性關節炎治療用藥\nC. 主要作用在TNF-α\nD. 為IgE單株抗體\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關infliximab之敘述，下列何者錯誤？\nA. 半衰期為9〜12天\nB. 類風濕性關節炎治療用藥\nC. 主要作用在TNF-α\nD. 為IgE單株抗體\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關infliximab之敘述，下列何者錯誤？\nA. 半衰期為9〜12天\nB. 類風濕性關節炎治療用藥\nC. 主要作用在TNF-α\nD. 為IgE單株抗體\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.125", "False"]], [["-9.125", "False"]], [["-7.375", "False"]], [["-0.0031890869140625", "True"]]], "filtered_resps": [["-6.125", "False"], ["-9.125", "False"], ["-7.375", "False"], ["-0.0031890869140625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e3b7fc93517a80a49c8f374e00e75c4b482a037f7d3c4ca6a277304dfa20d268", "prompt_hash": "067a73fb5ce2bfb6f555cd7761b8a2425155a62df3c07223d45866c0984f24d1", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 333, "doc": {"question": "Organic nitrates用於治療心絞痛主要的藥理機制為何？", "A": "抑制血小板凝集，避免粥狀硬化區更加狹窄", "B": "擴張動脈血管，減少心臟後負荷，降低心臟壓力", "C": "經由抑制平滑肌細胞內cGMP代謝，擴張冠狀動脈以增加血流量", "D": "經由減少心臟前負荷，降低心輸出量，使心肌需氧量降低", "answer": "D", "questions": "Organic nitrates用於治療心絞痛主要的藥理機制為何？", "choices": ["抑制血小板凝集，避免粥狀硬化區更加狹窄", "擴張動脈血管，減少心臟後負荷，降低心臟壓力", "經由抑制平滑肌細胞內cGMP代謝，擴張冠狀動脈以增加血流量", "經由減少心臟前負荷，降低心輸出量，使心肌需氧量降低"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nOrganic nitrates用於治療心絞痛主要的藥理機制為何？\nA. 抑制血小板凝集，避免粥狀硬化區更加狹窄\nB. 擴張動脈血管，減少心臟後負荷，降低心臟壓力\nC. 經由抑制平滑肌細胞內cGMP代謝，擴張冠狀動脈以增加血流量\nD. 經由減少心臟前負荷，降低心輸出量，使心肌需氧量降低\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nOrganic nitrates用於治療心絞痛主要的藥理機制為何？\nA. 抑制血小板凝集，避免粥狀硬化區更加狹窄\nB. 擴張動脈血管，減少心臟後負荷，降低心臟壓力\nC. 經由抑制平滑肌細胞內cGMP代謝，擴張冠狀動脈以增加血流量\nD. 經由減少心臟前負荷，降低心輸出量，使心肌需氧量降低\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nOrganic nitrates用於治療心絞痛主要的藥理機制為何？\nA. 抑制血小板凝集，避免粥狀硬化區更加狹窄\nB. 擴張動脈血管，減少心臟後負荷，降低心臟壓力\nC. 經由抑制平滑肌細胞內cGMP代謝，擴張冠狀動脈以增加血流量\nD. 經由減少心臟前負荷，降低心輸出量，使心肌需氧量降低\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nOrganic nitrates用於治療心絞痛主要的藥理機制為何？\nA. 抑制血小板凝集，避免粥狀硬化區更加狹窄\nB. 擴張動脈血管，減少心臟後負荷，降低心臟壓力\nC. 經由抑制平滑肌細胞內cGMP代謝，擴張冠狀動脈以增加血流量\nD. 經由減少心臟前負荷，降低心輸出量，使心肌需氧量降低\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.3125", "False"]], [["-0.1787109375", "True"]], [["-2.046875", "False"]], [["-3.921875", "False"]]], "filtered_resps": [["-5.3125", "False"], ["-0.1787109375", "True"], ["-2.046875", "False"], ["-3.921875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "34f2be9886b53a54965d915f3fa5f90b1d9aa0db09b4a8fdbd8f647d58bba80c", "prompt_hash": "1bd70235e682fbf56f1a19e1068623b2cf32d12a48cebd3780b4ee475603efaa", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 334, "doc": {"question": "下列何者最適合作為phenyl的等效異構基團？", "A": "hexyl", "B": "pyridinyl", "C": "benzyl", "D": "cyclohexyl", "answer": "B", "questions": "下列何者最適合作為phenyl的等效異構基團？", "choices": ["hexyl", "pyridinyl", "benzyl", "cyclohexyl"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者最適合作為phenyl的等效異構基團？\nA. hexyl\nB. pyridinyl\nC. benzyl\nD. cyclohexyl\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者最適合作為phenyl的等效異構基團？\nA. hexyl\nB. pyridinyl\nC. benzyl\nD. cyclohexyl\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者最適合作為phenyl的等效異構基團？\nA. hexyl\nB. pyridinyl\nC. benzyl\nD. cyclohexyl\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者最適合作為phenyl的等效異構基團？\nA. hexyl\nB. pyridinyl\nC. benzyl\nD. cyclohexyl\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.1875", "False"]], [["-3.5625", "False"]], [["-0.06494140625", "True"]], [["-3.6875", "False"]]], "filtered_resps": [["-5.1875", "False"], ["-3.5625", "False"], ["-0.06494140625", "True"], ["-3.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6839b4ab336d14635e18ed9fef937a0e518e2065dbc6b6d7027a5e965fffd2ef", "prompt_hash": "a4bb2a02150f4425a50a2e76059f682087bac37ee2f4b501508f3aac79896085", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 335, "doc": {"question": "手術快結束時要停止連續輸注麻醉劑，下列關於藥物的排除（elimination）速率之敘述，何者正確？", "A": "藥物排除速率順序（快到慢）：thiopental＞midazolam＞propofol", "B": "context-sensitive half-time數字越大，藥物移除速率越快", "C": "藥物排除速率順序（快到慢）：propofol＞midazolam＞thiopental", "D": "藥物排除速率順序（快到慢）：thiopental＞propofol＞midazolam", "answer": "C", "questions": "手術快結束時要停止連續輸注麻醉劑，下列關於藥物的排除（elimination）速率之敘述，何者正確？", "choices": ["藥物排除速率順序（快到慢）：thiopental＞midazolam＞propofol", "context-sensitive half-time數字越大，藥物移除速率越快", "藥物排除速率順序（快到慢）：propofol＞midazolam＞thiopental", "藥物排除速率順序（快到慢）：thiopental＞propofol＞midazolam"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n手術快結束時要停止連續輸注麻醉劑，下列關於藥物的排除（elimination）速率之敘述，何者正確？\nA. 藥物排除速率順序（快到慢）：thiopental＞midazolam＞propofol\nB. context-sensitive half-time數字越大，藥物移除速率越快\nC. 藥物排除速率順序（快到慢）：propofol＞midazolam＞thiopental\nD. 藥物排除速率順序（快到慢）：thiopental＞propofol＞midazolam\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n手術快結束時要停止連續輸注麻醉劑，下列關於藥物的排除（elimination）速率之敘述，何者正確？\nA. 藥物排除速率順序（快到慢）：thiopental＞midazolam＞propofol\nB. context-sensitive half-time數字越大，藥物移除速率越快\nC. 藥物排除速率順序（快到慢）：propofol＞midazolam＞thiopental\nD. 藥物排除速率順序（快到慢）：thiopental＞propofol＞midazolam\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n手術快結束時要停止連續輸注麻醉劑，下列關於藥物的排除（elimination）速率之敘述，何者正確？\nA. 藥物排除速率順序（快到慢）：thiopental＞midazolam＞propofol\nB. context-sensitive half-time數字越大，藥物移除速率越快\nC. 藥物排除速率順序（快到慢）：propofol＞midazolam＞thiopental\nD. 藥物排除速率順序（快到慢）：thiopental＞propofol＞midazolam\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n手術快結束時要停止連續輸注麻醉劑，下列關於藥物的排除（elimination）速率之敘述，何者正確？\nA. 藥物排除速率順序（快到慢）：thiopental＞midazolam＞propofol\nB. context-sensitive half-time數字越大，藥物移除速率越快\nC. 藥物排除速率順序（快到慢）：propofol＞midazolam＞thiopental\nD. 藥物排除速率順序（快到慢）：thiopental＞propofol＞midazolam\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.734375", "False"]], [["-2.984375", "False"]], [["-1.484375", "False"]], [["-0.60546875", "True"]]], "filtered_resps": [["-1.734375", "False"], ["-2.984375", "False"], ["-1.484375", "False"], ["-0.60546875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "27d94bbc157fce9825b9f335432967e56141c6eec62cae646ba1d796c7f83d48", "prompt_hash": "5b217653fd1c557ea47c3c3bb3e6aafbdc9f1f7a41f5c58a18647ee72211d54f", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 336, "doc": {"question": "下列何者為最主要影響thiopental快速產生藥效（onset）的因素？", "A": "肝臟的代謝速率", "B": "藥物的脂溶性", "C": "腎臟的排泄速率", "D": "和GABAA受體（receptor）的結合率", "answer": "B", "questions": "下列何者為最主要影響thiopental快速產生藥效（onset）的因素？", "choices": ["肝臟的代謝速率", "藥物的脂溶性", "腎臟的排泄速率", "和GABAA受體（receptor）的結合率"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為最主要影響thiopental快速產生藥效（onset）的因素？\nA. 肝臟的代謝速率\nB. 藥物的脂溶性\nC. 腎臟的排泄速率\nD. 和GABAA受體（receptor）的結合率\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為最主要影響thiopental快速產生藥效（onset）的因素？\nA. 肝臟的代謝速率\nB. 藥物的脂溶性\nC. 腎臟的排泄速率\nD. 和GABAA受體（receptor）的結合率\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為最主要影響thiopental快速產生藥效（onset）的因素？\nA. 肝臟的代謝速率\nB. 藥物的脂溶性\nC. 腎臟的排泄速率\nD. 和GABAA受體（receptor）的結合率\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為最主要影響thiopental快速產生藥效（onset）的因素？\nA. 肝臟的代謝速率\nB. 藥物的脂溶性\nC. 腎臟的排泄速率\nD. 和GABAA受體（receptor）的結合率\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.5625", "False"]], [["-0.061279296875", "True"]], [["-6.5625", "False"]], [["-2.9375", "False"]]], "filtered_resps": [["-5.5625", "False"], ["-0.061279296875", "True"], ["-6.5625", "False"], ["-2.9375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b5697268c7a92db34039c9f9feb6eeebc03b4242cab58c3b5724f4971b427b7a", "prompt_hash": "d4859ba3b262a74a51c6637292db9777f6e6ad4caac6c48f2aacd376c48adb2b", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 337, "doc": {"question": "下列抗生素中，何者抗菌機轉不是抑制細菌之蛋白質合成，以達到bacteriostatic或bactericidal effects？", "A": "quinupristin-dalfopristin", "B": "tedizolid", "C": "tigecycline", "D": "fosfomycin", "answer": "D", "questions": "下列抗生素中，何者抗菌機轉不是抑制細菌之蛋白質合成，以達到bacteriostatic或bactericidal effects？", "choices": ["quinupristin-dalfopristin", "tedizolid", "tigecycline", "fosfomycin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者抗菌機轉不是抑制細菌之蛋白質合成，以達到bacteriostatic或bactericidal effects？\nA. quinupristin-dalfopristin\nB. tedizolid\nC. tigecycline\nD. fosfomycin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者抗菌機轉不是抑制細菌之蛋白質合成，以達到bacteriostatic或bactericidal effects？\nA. quinupristin-dalfopristin\nB. tedizolid\nC. tigecycline\nD. fosfomycin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者抗菌機轉不是抑制細菌之蛋白質合成，以達到bacteriostatic或bactericidal effects？\nA. quinupristin-dalfopristin\nB. tedizolid\nC. tigecycline\nD. fosfomycin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者抗菌機轉不是抑制細菌之蛋白質合成，以達到bacteriostatic或bactericidal effects？\nA. quinupristin-dalfopristin\nB. tedizolid\nC. tigecycline\nD. fosfomycin\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.5", "False"]], [["-6.125", "False"]], [["-6.5", "False"]], [["-0.00634765625", "True"]]], "filtered_resps": [["-6.5", "False"], ["-6.125", "False"], ["-6.5", "False"], ["-0.00634765625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6d5ee091e56455307a46a43ca12f94a873fe3d9ec3102be730f8cc03c197f87e", "prompt_hash": "68f8850dc347574b3fba1f296eae8a2441e6895de4042a990b3519f50ed8da3b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 338, "doc": {"question": "Abciximab可用於治療及預防不穩定型心絞痛發生，並可有效減少非致死性心肌梗塞後病人的死亡率，其作用 機制為何？", "A": "thrombin inhibitor", "B": "ADP P2Y12 receptor blocker", "C": "antibody against factor Xa", "D": "glycoprotein IIb/IIIa receptor blocker", "answer": "D", "questions": "Abciximab可用於治療及預防不穩定型心絞痛發生，並可有效減少非致死性心肌梗塞後病人的死亡率，其作用 機制為何？", "choices": ["thrombin inhibitor", "ADP P2Y12 receptor blocker", "antibody against factor Xa", "glycoprotein IIb/IIIa receptor blocker"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAbciximab可用於治療及預防不穩定型心絞痛發生，並可有效減少非致死性心肌梗塞後病人的死亡率，其作用 機制為何？\nA. thrombin inhibitor\nB. ADP P2Y12 receptor blocker\nC. antibody against factor Xa\nD. glycoprotein IIb/IIIa receptor blocker\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAbciximab可用於治療及預防不穩定型心絞痛發生，並可有效減少非致死性心肌梗塞後病人的死亡率，其作用 機制為何？\nA. thrombin inhibitor\nB. ADP P2Y12 receptor blocker\nC. antibody against factor Xa\nD. glycoprotein IIb/IIIa receptor blocker\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAbciximab可用於治療及預防不穩定型心絞痛發生，並可有效減少非致死性心肌梗塞後病人的死亡率，其作用 機制為何？\nA. thrombin inhibitor\nB. ADP P2Y12 receptor blocker\nC. antibody against factor Xa\nD. glycoprotein IIb/IIIa receptor blocker\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAbciximab可用於治療及預防不穩定型心絞痛發生，並可有效減少非致死性心肌梗塞後病人的死亡率，其作用 機制為何？\nA. thrombin inhibitor\nB. ADP P2Y12 receptor blocker\nC. antibody against factor Xa\nD. glycoprotein IIb/IIIa receptor blocker\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.75", "False"]], [["-6.125", "False"]], [["-8.625", "False"]], [["-0.005645751953125", "True"]]], "filtered_resps": [["-6.75", "False"], ["-6.125", "False"], ["-8.625", "False"], ["-0.005645751953125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5992427fd1124628de15422cbe1e1693945651b4be3416808dde34fd0028a02b", "prompt_hash": "3b768e2727b00670595c39bd3489a986cf4621b10373a8641912ef8f62983fd9", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 339, "doc": {"question": "口服藥物時，鹼性藥物較酸性藥物易留在胃中，此現象的主要原因為何？", "A": "鹼性藥物易與脂溶性食物結合", "B": "鹼性藥物會抑制胃分解酶的分泌", "C": "鹼性藥物較耐酸性，不易分解", "D": "鹼性藥物在胃中帶正電荷不易吸收", "answer": "D", "questions": "口服藥物時，鹼性藥物較酸性藥物易留在胃中，此現象的主要原因為何？", "choices": ["鹼性藥物易與脂溶性食物結合", "鹼性藥物會抑制胃分解酶的分泌", "鹼性藥物較耐酸性，不易分解", "鹼性藥物在胃中帶正電荷不易吸收"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n口服藥物時，鹼性藥物較酸性藥物易留在胃中，此現象的主要原因為何？\nA. 鹼性藥物易與脂溶性食物結合\nB. 鹼性藥物會抑制胃分解酶的分泌\nC. 鹼性藥物較耐酸性，不易分解\nD. 鹼性藥物在胃中帶正電荷不易吸收\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n口服藥物時，鹼性藥物較酸性藥物易留在胃中，此現象的主要原因為何？\nA. 鹼性藥物易與脂溶性食物結合\nB. 鹼性藥物會抑制胃分解酶的分泌\nC. 鹼性藥物較耐酸性，不易分解\nD. 鹼性藥物在胃中帶正電荷不易吸收\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n口服藥物時，鹼性藥物較酸性藥物易留在胃中，此現象的主要原因為何？\nA. 鹼性藥物易與脂溶性食物結合\nB. 鹼性藥物會抑制胃分解酶的分泌\nC. 鹼性藥物較耐酸性，不易分解\nD. 鹼性藥物在胃中帶正電荷不易吸收\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n口服藥物時，鹼性藥物較酸性藥物易留在胃中，此現象的主要原因為何？\nA. 鹼性藥物易與脂溶性食物結合\nB. 鹼性藥物會抑制胃分解酶的分泌\nC. 鹼性藥物較耐酸性，不易分解\nD. 鹼性藥物在胃中帶正電荷不易吸收\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.625", "False"]], [["-3.25", "False"]], [["-0.75", "True"]], [["-0.875", "False"]]], "filtered_resps": [["-2.625", "False"], ["-3.25", "False"], ["-0.75", "True"], ["-0.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1f0abfd69b8b8591f11f8e24ab9656cab3001bee50842845348bb44fe9766e1b", "prompt_hash": "98ae7efcf18d8b9eb32bf3b423aa68add3c2e1713cb8bbe6228ae926468e27b9", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 340, "doc": {"question": "下列止痛劑中，何者不具4-phenylpiperidine骨架？", "A": "fentanyl", "B": "hydromorphone", "C": "meperidine", "D": "butorphanol", "answer": "A", "questions": "下列止痛劑中，何者不具4-phenylpiperidine骨架？", "choices": ["fentanyl", "hydromorphone", "meperidine", "butorphanol"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列止痛劑中，何者不具4-phenylpiperidine骨架？\nA. fentanyl\nB. hydromorphone\nC. meperidine\nD. butorphanol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列止痛劑中，何者不具4-phenylpiperidine骨架？\nA. fentanyl\nB. hydromorphone\nC. meperidine\nD. butorphanol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列止痛劑中，何者不具4-phenylpiperidine骨架？\nA. fentanyl\nB. hydromorphone\nC. meperidine\nD. butorphanol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列止痛劑中，何者不具4-phenylpiperidine骨架？\nA. fentanyl\nB. hydromorphone\nC. meperidine\nD. butorphanol\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.015625", "False"]], [["-0.26171875", "True"]], [["-4.375", "False"]], [["-2.515625", "False"]]], "filtered_resps": [["-2.015625", "False"], ["-0.26171875", "True"], ["-4.375", "False"], ["-2.515625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f511afd6925e7e39238e80377696b227e2a89e7ed18fea15c26778843e5401b2", "prompt_hash": "e69fccae24717ab5632e33374a96ffc500f5dd233ac6899eb1652ca8cf35943e", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 341, "doc": {"question": "下列何種利尿劑之主要作用部位在遠端彎曲的腎小管？", "A": "amiloride", "B": "metolazone", "C": "acetazolamide", "D": "ethacrynic acid", "answer": "B", "questions": "下列何種利尿劑之主要作用部位在遠端彎曲的腎小管？", "choices": ["amiloride", "metolazone", "acetazolamide", "ethacrynic acid"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑之主要作用部位在遠端彎曲的腎小管？\nA. amiloride\nB. metolazone\nC. acetazolamide\nD. ethacrynic acid\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑之主要作用部位在遠端彎曲的腎小管？\nA. amiloride\nB. metolazone\nC. acetazolamide\nD. ethacrynic acid\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑之主要作用部位在遠端彎曲的腎小管？\nA. amiloride\nB. metolazone\nC. acetazolamide\nD. ethacrynic acid\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種利尿劑之主要作用部位在遠端彎曲的腎小管？\nA. amiloride\nB. metolazone\nC. acetazolamide\nD. ethacrynic acid\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-3.65625", "False"]], [["-5.90625", "False"]], [["-0.033203125", "True"]]], "filtered_resps": [["-5.78125", "False"], ["-3.65625", "False"], ["-5.90625", "False"], ["-0.033203125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c314c7e3e950fcd7709c0d33a4bf9bfaa03ccfc412976a19c10a667203c82b6b", "prompt_hash": "0d1ae1c0cdeaea7cb621239888c2563b0dd9c0213ff261e68034440b2c5b4d63", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 342, "doc": {"question": "下列全身麻醉劑中，何者在37℃的blood/gas分配係數值最大？", "A": "isoflurane", "B": "enflurane", "C": "sevoflurane", "D": "nitrous oxide", "answer": "B", "questions": "下列全身麻醉劑中，何者在37℃的blood/gas分配係數值最大？", "choices": ["isoflurane", "enflurane", "sevoflurane", "nitrous oxide"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者在37℃的blood/gas分配係數值最大？\nA. isoflurane\nB. enflurane\nC. sevoflurane\nD. nitrous oxide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者在37℃的blood/gas分配係數值最大？\nA. isoflurane\nB. enflurane\nC. sevoflurane\nD. nitrous oxide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者在37℃的blood/gas分配係數值最大？\nA. isoflurane\nB. enflurane\nC. sevoflurane\nD. nitrous oxide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者在37℃的blood/gas分配係數值最大？\nA. isoflurane\nB. enflurane\nC. sevoflurane\nD. nitrous oxide\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.125", "False"]], [["-2.625", "False"]], [["-1.6171875", "False"]], [["-0.49609375", "True"]]], "filtered_resps": [["-2.125", "False"], ["-2.625", "False"], ["-1.6171875", "False"], ["-0.49609375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f550cbb7b58936b0aabdf5afffd023e9f40c32e7f0e4783749f74d26e6c0d3d9", "prompt_hash": "7613e13e0fdd0d97f2974674da792068866483212240735465419e3cb7ee7585", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 343, "doc": {"question": "下列比較鎮靜安眠劑ramelteon和suvorexant之敘述，何者正確？", "A": "melatonin脂溶性高；suvorexant脂溶性低", "B": "兩者皆是針對治療「入睡困難」的疾病", "C": "melatonin作用在腦下垂體（pituitary gland）；suvorexant作用在下視丘（hypothalamus）", "D": "melatonin receptor antagonist；orexin receptor antagonist", "answer": "B", "questions": "下列比較鎮靜安眠劑ramelteon和suvorexant之敘述，何者正確？", "choices": ["melatonin脂溶性高；suvorexant脂溶性低", "兩者皆是針對治療「入睡困難」的疾病", "melatonin作用在腦下垂體（pituitary gland）；suvorexant作用在下視丘（hypothalamus）", "melatonin receptor antagonist；orexin receptor antagonist"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列比較鎮靜安眠劑ramelteon和suvorexant之敘述，何者正確？\nA. melatonin脂溶性高；suvorexant脂溶性低\nB. 兩者皆是針對治療「入睡困難」的疾病\nC. melatonin作用在腦下垂體（pituitary gland）；suvorexant作用在下視丘（hypothalamus）\nD. melatonin receptor antagonist；orexin receptor antagonist\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列比較鎮靜安眠劑ramelteon和suvorexant之敘述，何者正確？\nA. melatonin脂溶性高；suvorexant脂溶性低\nB. 兩者皆是針對治療「入睡困難」的疾病\nC. melatonin作用在腦下垂體（pituitary gland）；suvorexant作用在下視丘（hypothalamus）\nD. melatonin receptor antagonist；orexin receptor antagonist\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列比較鎮靜安眠劑ramelteon和suvorexant之敘述，何者正確？\nA. melatonin脂溶性高；suvorexant脂溶性低\nB. 兩者皆是針對治療「入睡困難」的疾病\nC. melatonin作用在腦下垂體（pituitary gland）；suvorexant作用在下視丘（hypothalamus）\nD. melatonin receptor antagonist；orexin receptor antagonist\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列比較鎮靜安眠劑ramelteon和suvorexant之敘述，何者正確？\nA. melatonin脂溶性高；suvorexant脂溶性低\nB. 兩者皆是針對治療「入睡困難」的疾病\nC. melatonin作用在腦下垂體（pituitary gland）；suvorexant作用在下視丘（hypothalamus）\nD. melatonin receptor antagonist；orexin receptor antagonist\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.5234375", "False"]], [["-0.89453125", "True"]], [["-2.390625", "False"]], [["-1.2734375", "False"]]], "filtered_resps": [["-1.5234375", "False"], ["-0.89453125", "True"], ["-2.390625", "False"], ["-1.2734375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6a7cd272a5affaddbf9f37eb5cb74301cc9e2e1d6c04b4baed7a2e8c3a7dcea6", "prompt_hash": "47b43c75e7627a3353c48cf7016b39fb5116383a89100836e07cf3b1a82071f5", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 344, "doc": {"question": "下列何種藥物在血液中的protein binding程度最低？", "A": "valproic acid", "B": "tiagabine", "C": "clonazepam", "D": "topiramate", "answer": "D", "questions": "下列何種藥物在血液中的protein binding程度最低？", "choices": ["valproic acid", "tiagabine", "clonazepam", "topiramate"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物在血液中的protein binding程度最低？\nA. valproic acid\nB. tiagabine\nC. clonazepam\nD. topiramate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物在血液中的protein binding程度最低？\nA. valproic acid\nB. tiagabine\nC. clonazepam\nD. topiramate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物在血液中的protein binding程度最低？\nA. valproic acid\nB. tiagabine\nC. clonazepam\nD. topiramate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物在血液中的protein binding程度最低？\nA. valproic acid\nB. tiagabine\nC. clonazepam\nD. topiramate\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.80078125", "True"]], [["-1.6796875", "False"]], [["-4.3125", "False"]], [["-1.0546875", "False"]]], "filtered_resps": [["-0.80078125", "True"], ["-1.6796875", "False"], ["-4.3125", "False"], ["-1.0546875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8835b3e46dc2ba48a941d45403183cdcb096535861f4e479fdbe4d7b2d28e68c", "prompt_hash": "9792d05363f28d1f0e72478bf946f1ef42bdd01d9c8a7a2754d25da462e299d8", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 345, "doc": {"question": "下列有關EMLA（Eutectic Mixture of a Local Anesthetic）軟膏之敘述，何者錯誤？", "A": "可能產生變性血紅蛋白血症（methemoglobinemia）之毒性", "B": "適用於表皮", "C": "適用於黏膜", "D": "含2.5% lidocaine及2.5% prilocaine", "answer": "C", "questions": "下列有關EMLA（Eutectic Mixture of a Local Anesthetic）軟膏之敘述，何者錯誤？", "choices": ["可能產生變性血紅蛋白血症（methemoglobinemia）之毒性", "適用於表皮", "適用於黏膜", "含2.5% lidocaine及2.5% prilocaine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關EMLA（Eutectic Mixture of a Local Anesthetic）軟膏之敘述，何者錯誤？\nA. 可能產生變性血紅蛋白血症（methemoglobinemia）之毒性\nB. 適用於表皮\nC. 適用於黏膜\nD. 含2.5% lidocaine及2.5% prilocaine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關EMLA（Eutectic Mixture of a Local Anesthetic）軟膏之敘述，何者錯誤？\nA. 可能產生變性血紅蛋白血症（methemoglobinemia）之毒性\nB. 適用於表皮\nC. 適用於黏膜\nD. 含2.5% lidocaine及2.5% prilocaine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關EMLA（Eutectic Mixture of a Local Anesthetic）軟膏之敘述，何者錯誤？\nA. 可能產生變性血紅蛋白血症（methemoglobinemia）之毒性\nB. 適用於表皮\nC. 適用於黏膜\nD. 含2.5% lidocaine及2.5% prilocaine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關EMLA（Eutectic Mixture of a Local Anesthetic）軟膏之敘述，何者錯誤？\nA. 可能產生變性血紅蛋白血症（methemoglobinemia）之毒性\nB. 適用於表皮\nC. 適用於黏膜\nD. 含2.5% lidocaine及2.5% prilocaine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.5", "False"]], [["-4.0", "False"]], [["-0.1240234375", "True"]], [["-3.625", "False"]]], "filtered_resps": [["-5.5", "False"], ["-4.0", "False"], ["-0.1240234375", "True"], ["-3.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "aeb7f8319055e32d658433f4f09ca410c9491dd36a16cdf262a7e2b1592e3a7e", "prompt_hash": "2826cd6562e2fb8c686e03886a810c0e30046b7354e12953fcf2cf42bacfcedf", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 346, "doc": {"question": "下列藥物中，何者同時具有quinuclidine與quinoline之結構？", "A": "quinapril", "B": "quinupristin", "C": "quinacrine", "D": "quinidine", "answer": "D", "questions": "下列藥物中，何者同時具有quinuclidine與quinoline之結構？", "choices": ["quinapril", "quinupristin", "quinacrine", "quinidine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者同時具有quinuclidine與quinoline之結構？\nA. quinapril\nB. quinupristin\nC. quinacrine\nD. quinidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者同時具有quinuclidine與quinoline之結構？\nA. quinapril\nB. quinupristin\nC. quinacrine\nD. quinidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者同時具有quinuclidine與quinoline之結構？\nA. quinapril\nB. quinupristin\nC. quinacrine\nD. quinidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者同時具有quinuclidine與quinoline之結構？\nA. quinapril\nB. quinupristin\nC. quinacrine\nD. quinidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.75", "False"]], [["-4.0", "False"]], [["-2.375", "False"]], [["-0.1328125", "True"]]], "filtered_resps": [["-5.75", "False"], ["-4.0", "False"], ["-2.375", "False"], ["-0.1328125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6401c7714159338a27d41b6eb0222cc9d3ffa1ebb5fa6ff55b0d44adff229613", "prompt_hash": "574ccb7a7fb97fe27c440d40c11a40c56c221ce1be690db41c411eac47a49cac", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 347, "doc": {"question": "下列有關藥物代謝的敘述，何者正確？①CYP酵素進行的催化反應，喜在缺電子的位置進行氧化 ②CYP酵素進行的催化反應，喜在多電子的位置進行氧化 ③CYP酵素多含有鎂離子 ④Phase I代謝通常造成藥物極性變大", "A": "②③", "B": "①④", "C": "①③", "D": "②④", "answer": "D", "questions": "下列有關藥物代謝的敘述，何者正確？①CYP酵素進行的催化反應，喜在缺電子的位置進行氧化 ②CYP酵素進行的催化反應，喜在多電子的位置進行氧化 ③CYP酵素多含有鎂離子 ④Phase I代謝通常造成藥物極性變大", "choices": ["②③", "①④", "①③", "②④"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關藥物代謝的敘述，何者正確？①CYP酵素進行的催化反應，喜在缺電子的位置進行氧化 ②CYP酵素進行的催化反應，喜在多電子的位置進行氧化 ③CYP酵素多含有鎂離子 ④Phase I代謝通常造成藥物極性變大\nA. ②③\nB. ①④\nC. ①③\nD. ②④\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關藥物代謝的敘述，何者正確？①CYP酵素進行的催化反應，喜在缺電子的位置進行氧化 ②CYP酵素進行的催化反應，喜在多電子的位置進行氧化 ③CYP酵素多含有鎂離子 ④Phase I代謝通常造成藥物極性變大\nA. ②③\nB. ①④\nC. ①③\nD. ②④\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關藥物代謝的敘述，何者正確？①CYP酵素進行的催化反應，喜在缺電子的位置進行氧化 ②CYP酵素進行的催化反應，喜在多電子的位置進行氧化 ③CYP酵素多含有鎂離子 ④Phase I代謝通常造成藥物極性變大\nA. ②③\nB. ①④\nC. ①③\nD. ②④\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關藥物代謝的敘述，何者正確？①CYP酵素進行的催化反應，喜在缺電子的位置進行氧化 ②CYP酵素進行的催化反應，喜在多電子的位置進行氧化 ③CYP酵素多含有鎂離子 ④Phase I代謝通常造成藥物極性變大\nA. ②③\nB. ①④\nC. ①③\nD. ②④\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.1875", "False"]], [["-1.0625", "False"]], [["-3.1875", "False"]], [["-0.55859375", "True"]]], "filtered_resps": [["-3.1875", "False"], ["-1.0625", "False"], ["-3.1875", "False"], ["-0.55859375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6ee19f903469702d5715ad857ed5b856f02ec4319bf28aa6e742bc48a824f31f", "prompt_hash": "41afbd13106c8bab398ef66bcb5afa8bffbf67feaf4bbc25a6934315ec9b0b20", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 348, "doc": {"question": "下列有關salmeterol之敘述，何者錯誤？", "A": "不易受COMT代謝", "B": "具catechol之結構", "C": "可用於治療氣喘", "D": "比formoterol起效慢", "answer": "B", "questions": "下列有關salmeterol之敘述，何者錯誤？", "choices": ["不易受COMT代謝", "具catechol之結構", "可用於治療氣喘", "比formoterol起效慢"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關salmeterol之敘述，何者錯誤？\nA. 不易受COMT代謝\nB. 具catechol之結構\nC. 可用於治療氣喘\nD. 比formoterol起效慢\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關salmeterol之敘述，何者錯誤？\nA. 不易受COMT代謝\nB. 具catechol之結構\nC. 可用於治療氣喘\nD. 比formoterol起效慢\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關salmeterol之敘述，何者錯誤？\nA. 不易受COMT代謝\nB. 具catechol之結構\nC. 可用於治療氣喘\nD. 比formoterol起效慢\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關salmeterol之敘述，何者錯誤？\nA. 不易受COMT代謝\nB. 具catechol之結構\nC. 可用於治療氣喘\nD. 比formoterol起效慢\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.859375", "False"]], [["-1.1171875", "False"]], [["-5.75", "False"]], [["-0.490234375", "True"]]], "filtered_resps": [["-2.859375", "False"], ["-1.1171875", "False"], ["-5.75", "False"], ["-0.490234375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "93b3e328114630aa0fa172e7e34c47c3076dfeef880a45b1ccef25618dd7c9c5", "prompt_hash": "fa34043f699f44a44b892a98b23e3844e903304061f0167ed43ed84adea018b2", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 349, "doc": {"question": "下列有關prazosin結構的描述，何者錯誤？", "A": "piperazine以酮基連接furan", "B": "以tetrahydrofuran取代furan時，則為doxazosin", "C": "quinazoline直接與piperazine連接", "D": "含有4-amino-6,7-dimethoxyquinazoline", "answer": "B", "questions": "下列有關prazosin結構的描述，何者錯誤？", "choices": ["piperazine以酮基連接furan", "以tetrahydrofuran取代furan時，則為doxazosin", "quinazoline直接與piperazine連接", "含有4-amino-6,7-dimethoxyquinazoline"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關prazosin結構的描述，何者錯誤？\nA. piperazine以酮基連接furan\nB. 以tetrahydrofuran取代furan時，則為doxazosin\nC. quinazoline直接與piperazine連接\nD. 含有4-amino-6,7-dimethoxyquinazoline\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關prazosin結構的描述，何者錯誤？\nA. piperazine以酮基連接furan\nB. 以tetrahydrofuran取代furan時，則為doxazosin\nC. quinazoline直接與piperazine連接\nD. 含有4-amino-6,7-dimethoxyquinazoline\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關prazosin結構的描述，何者錯誤？\nA. piperazine以酮基連接furan\nB. 以tetrahydrofuran取代furan時，則為doxazosin\nC. quinazoline直接與piperazine連接\nD. 含有4-amino-6,7-dimethoxyquinazoline\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關prazosin結構的描述，何者錯誤？\nA. piperazine以酮基連接furan\nB. 以tetrahydrofuran取代furan時，則為doxazosin\nC. quinazoline直接與piperazine連接\nD. 含有4-amino-6,7-dimethoxyquinazoline\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.4140625", "False"]], [["-1.2890625", "False"]], [["-0.9140625", "True"]], [["-2.546875", "False"]]], "filtered_resps": [["-1.4140625", "False"], ["-1.2890625", "False"], ["-0.9140625", "True"], ["-2.546875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4ff6a43e450a65fb441e03546f092f00695d50bdcdd7c250ef39454daaabcaa8", "prompt_hash": "7b85ee0299f8c5d43dcef4530459eff89f5e16805e1627e9010276e168e74d89", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 350, "doc": {"question": "下列那一種鎮靜－安眠（sedative-hypnotic）藥物可以用來治療大發作（grand mal），其在長期使用時會導致 增加warfarin及digitalis類藥物的代謝速率？", "A": "buspirone", "B": "phenobarbital", "C": "secobarbital", "D": "alprazolam", "answer": "B", "questions": "下列那一種鎮靜－安眠（sedative-hypnotic）藥物可以用來治療大發作（grand mal），其在長期使用時會導致 增加warfarin及digitalis類藥物的代謝速率？", "choices": ["buspirone", "phenobarbital", "secobarbital", "alprazolam"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種鎮靜－安眠（sedative-hypnotic）藥物可以用來治療大發作（grand mal），其在長期使用時會導致 增加warfarin及digitalis類藥物的代謝速率？\nA. buspirone\nB. phenobarbital\nC. secobarbital\nD. alprazolam\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種鎮靜－安眠（sedative-hypnotic）藥物可以用來治療大發作（grand mal），其在長期使用時會導致 增加warfarin及digitalis類藥物的代謝速率？\nA. buspirone\nB. phenobarbital\nC. secobarbital\nD. alprazolam\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種鎮靜－安眠（sedative-hypnotic）藥物可以用來治療大發作（grand mal），其在長期使用時會導致 增加warfarin及digitalis類藥物的代謝速率？\nA. buspirone\nB. phenobarbital\nC. secobarbital\nD. alprazolam\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種鎮靜－安眠（sedative-hypnotic）藥物可以用來治療大發作（grand mal），其在長期使用時會導致 增加warfarin及digitalis類藥物的代謝速率？\nA. buspirone\nB. phenobarbital\nC. secobarbital\nD. alprazolam\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.375", "False"]], [["-0.007049560546875", "True"]], [["-6.375", "False"]], [["-6.375", "False"]]], "filtered_resps": [["-6.375", "False"], ["-0.007049560546875", "True"], ["-6.375", "False"], ["-6.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d145b06fa74f8cae08a307bdcfe1ffda73689bad60ccf5066900b0827c1308f2", "prompt_hash": "c2123c42f7f06271b6a360add10e2825561dce8c21c25f276102e9694957f3b0", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 351, "doc": {"question": "下列有關Thiazide利尿劑與其他藥物交互作用之敘述，何者錯誤？", "A": "可增加鋰（Li+）之排出而減少鋰鹽之毒性", "B": "會增加Digoxin毒性", "C": "與Quinidine併用有增加Torsade de Pointes等心室心律過快之危險", "D": "與Corticosteroid併用使血鉀降低作用增強", "answer": "A", "questions": "下列有關Thiazide利尿劑與其他藥物交互作用之敘述，何者錯誤？", "choices": ["可增加鋰（Li+）之排出而減少鋰鹽之毒性", "會增加Digoxin毒性", "與Quinidine併用有增加Torsade de Pointes等心室心律過快之危險", "與Corticosteroid併用使血鉀降低作用增強"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Thiazide利尿劑與其他藥物交互作用之敘述，何者錯誤？\nA. 可增加鋰（Li+）之排出而減少鋰鹽之毒性\nB. 會增加Digoxin毒性\nC. 與Quinidine併用有增加Torsade de Pointes等心室心律過快之危險\nD. 與Corticosteroid併用使血鉀降低作用增強\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Thiazide利尿劑與其他藥物交互作用之敘述，何者錯誤？\nA. 可增加鋰（Li+）之排出而減少鋰鹽之毒性\nB. 會增加Digoxin毒性\nC. 與Quinidine併用有增加Torsade de Pointes等心室心律過快之危險\nD. 與Corticosteroid併用使血鉀降低作用增強\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Thiazide利尿劑與其他藥物交互作用之敘述，何者錯誤？\nA. 可增加鋰（Li+）之排出而減少鋰鹽之毒性\nB. 會增加Digoxin毒性\nC. 與Quinidine併用有增加Torsade de Pointes等心室心律過快之危險\nD. 與Corticosteroid併用使血鉀降低作用增強\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Thiazide利尿劑與其他藥物交互作用之敘述，何者錯誤？\nA. 可增加鋰（Li+）之排出而減少鋰鹽之毒性\nB. 會增加Digoxin毒性\nC. 與Quinidine併用有增加Torsade de Pointes等心室心律過快之危險\nD. 與Corticosteroid併用使血鉀降低作用增強\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.97265625", "False"]], [["-2.96875", "False"]], [["-2.46875", "False"]], [["-0.72265625", "True"]]], "filtered_resps": [["-0.97265625", "False"], ["-2.96875", "False"], ["-2.46875", "False"], ["-0.72265625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8b9c367bebf4f4895d1bf2d3e58f102433b97d22b9989e999f8913af919ab60f", "prompt_hash": "7db06061924e68068fcd711cedc8fa34df06c9050712184c075942aa8dcaa97d", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 352, "doc": {"question": "下列治療類風濕關節炎的藥物中，何者為prodrug？", "A": "hydroxychloroquine", "B": "auranofin", "C": "leflunomide", "D": "methotrexate", "answer": "C", "questions": "下列治療類風濕關節炎的藥物中，何者為prodrug？", "choices": ["hydroxychloroquine", "auranofin", "leflunomide", "methotrexate"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療類風濕關節炎的藥物中，何者為prodrug？\nA. hydroxychloroquine\nB. auranofin\nC. leflunomide\nD. methotrexate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療類風濕關節炎的藥物中，何者為prodrug？\nA. hydroxychloroquine\nB. auranofin\nC. leflunomide\nD. methotrexate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療類風濕關節炎的藥物中，何者為prodrug？\nA. hydroxychloroquine\nB. auranofin\nC. leflunomide\nD. methotrexate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療類風濕關節炎的藥物中，何者為prodrug？\nA. hydroxychloroquine\nB. auranofin\nC. leflunomide\nD. methotrexate\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.6875", "False"]], [["-5.3125", "False"]], [["-0.064453125", "True"]], [["-2.9375", "False"]]], "filtered_resps": [["-5.6875", "False"], ["-5.3125", "False"], ["-0.064453125", "True"], ["-2.9375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e11065efdf3a9459d891eee7e1ec2f1f6146e517ebcb11746733087d7506cf6c", "prompt_hash": "a95c6cb222a166c9a88d64923552c9e7ad5218fe74e7b33d710f6b960c89f4e8", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 353, "doc": {"question": "下列癌症化學治療藥物，何者不屬於抗代謝類（antimetabolites）？", "A": "Dacarbazine", "B": "Pemetrexed", "C": "5-Fluorouracil", "D": "6-Mercaptopurine", "answer": "A", "questions": "下列癌症化學治療藥物，何者不屬於抗代謝類（antimetabolites）？", "choices": ["Dacarbazine", "Pemetrexed", "5-Fluorouracil", "6-Mercaptopurine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列癌症化學治療藥物，何者不屬於抗代謝類（antimetabolites）？\nA. Dacarbazine\nB. Pemetrexed\nC. 5-Fluorouracil\nD. 6-Mercaptopurine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列癌症化學治療藥物，何者不屬於抗代謝類（antimetabolites）？\nA. Dacarbazine\nB. Pemetrexed\nC. 5-Fluorouracil\nD. 6-Mercaptopurine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列癌症化學治療藥物，何者不屬於抗代謝類（antimetabolites）？\nA. Dacarbazine\nB. Pemetrexed\nC. 5-Fluorouracil\nD. 6-Mercaptopurine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列癌症化學治療藥物，何者不屬於抗代謝類（antimetabolites）？\nA. Dacarbazine\nB. Pemetrexed\nC. 5-Fluorouracil\nD. 6-Mercaptopurine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.10498046875", "True"]], [["-2.734375", "False"]], [["-6.46875", "False"]], [["-3.609375", "False"]]], "filtered_resps": [["-0.10498046875", "True"], ["-2.734375", "False"], ["-6.46875", "False"], ["-3.609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b647079e753d1d9fbcef84b4563eca866db259f09aac09615fab5096f5fe6c03", "prompt_hash": "d67341c873a11fe0889ffaf2ba29deee096177e9416fbbfb6719c0c19fe24f5c", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 354, "doc": {"question": "下列何種藥物之類固醇結構骨架中，不具 9α-氟取代基？", "A": "triamcinolone", "B": "methylprednisolone", "C": "dexamethasone", "D": "betamethasone", "answer": "B", "questions": "下列何種藥物之類固醇結構骨架中，不具 9α-氟取代基？", "choices": ["triamcinolone", "methylprednisolone", "dexamethasone", "betamethasone"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之類固醇結構骨架中，不具 9α-氟取代基？\nA. triamcinolone\nB. methylprednisolone\nC. dexamethasone\nD. betamethasone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之類固醇結構骨架中，不具 9α-氟取代基？\nA. triamcinolone\nB. methylprednisolone\nC. dexamethasone\nD. betamethasone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之類固醇結構骨架中，不具 9α-氟取代基？\nA. triamcinolone\nB. methylprednisolone\nC. dexamethasone\nD. betamethasone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之類固醇結構骨架中，不具 9α-氟取代基？\nA. triamcinolone\nB. methylprednisolone\nC. dexamethasone\nD. betamethasone\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.28125", "False"]], [["-0.037109375", "True"]], [["-3.65625", "False"]], [["-5.28125", "False"]]], "filtered_resps": [["-5.28125", "False"], ["-0.037109375", "True"], ["-3.65625", "False"], ["-5.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9675c475b71c6e3ed30cebf9038c6845e2e0b2892f5718e8d4cddb3021583d06", "prompt_hash": "c1396388c22338095bc0a08bdd48ed6921a6700df632bb5f446a91c7313b16de", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 355, "doc": {"question": "Phenobarbital在下列何種pH值之水溶解度最大？", "A": "9.1", "B": "7.4", "C": "4", "D": "5.7", "answer": "A", "questions": "Phenobarbital在下列何種pH值之水溶解度最大？", "choices": ["9.1", "7.4", "4", "5.7"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPhenobarbital在下列何種pH值之水溶解度最大？\nA. 9.1\nB. 7.4\nC. 4\nD. 5.7\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPhenobarbital在下列何種pH值之水溶解度最大？\nA. 9.1\nB. 7.4\nC. 4\nD. 5.7\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPhenobarbital在下列何種pH值之水溶解度最大？\nA. 9.1\nB. 7.4\nC. 4\nD. 5.7\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPhenobarbital在下列何種pH值之水溶解度最大？\nA. 9.1\nB. 7.4\nC. 4\nD. 5.7\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.15625", "False"]], [["-2.03125", "False"]], [["-1.90625", "False"]], [["-0.90625", "True"]]], "filtered_resps": [["-1.15625", "False"], ["-2.03125", "False"], ["-1.90625", "False"], ["-0.90625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9aba99b9661394ee97fbad6c1969bde1fc49783c646e0001b29ce4ce09a394a4", "prompt_hash": "6230d0eeacf531e3d6dac499abde4204effc4e4452794f45fd275c0f5b08f4f9", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 356, "doc": {"question": "下列膽鹼受體阻斷劑作用之敘述，何者錯誤？", "A": "給與吸入性麻醉劑前，先給與膽鹼受體阻斷劑可以減少氣管分泌與喉頭痙攣", "B": "膽鹼受體阻斷劑造成心跳減慢是因為阻斷受迷走神經支配的心室細胞", "C": "選擇性M3受體之膽鹼受體阻斷劑可促使支氣管舒張，緩解氣喘和慢性呼吸道阻塞病患症狀", "D": "膽鹼受體阻斷劑可暫時緩解腹瀉", "answer": "B", "questions": "下列膽鹼受體阻斷劑作用之敘述，何者錯誤？", "choices": ["給與吸入性麻醉劑前，先給與膽鹼受體阻斷劑可以減少氣管分泌與喉頭痙攣", "膽鹼受體阻斷劑造成心跳減慢是因為阻斷受迷走神經支配的心室細胞", "選擇性M3受體之膽鹼受體阻斷劑可促使支氣管舒張，緩解氣喘和慢性呼吸道阻塞病患症狀", "膽鹼受體阻斷劑可暫時緩解腹瀉"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列膽鹼受體阻斷劑作用之敘述，何者錯誤？\nA. 給與吸入性麻醉劑前，先給與膽鹼受體阻斷劑可以減少氣管分泌與喉頭痙攣\nB. 膽鹼受體阻斷劑造成心跳減慢是因為阻斷受迷走神經支配的心室細胞\nC. 選擇性M3受體之膽鹼受體阻斷劑可促使支氣管舒張，緩解氣喘和慢性呼吸道阻塞病患症狀\nD. 膽鹼受體阻斷劑可暫時緩解腹瀉\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列膽鹼受體阻斷劑作用之敘述，何者錯誤？\nA. 給與吸入性麻醉劑前，先給與膽鹼受體阻斷劑可以減少氣管分泌與喉頭痙攣\nB. 膽鹼受體阻斷劑造成心跳減慢是因為阻斷受迷走神經支配的心室細胞\nC. 選擇性M3受體之膽鹼受體阻斷劑可促使支氣管舒張，緩解氣喘和慢性呼吸道阻塞病患症狀\nD. 膽鹼受體阻斷劑可暫時緩解腹瀉\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列膽鹼受體阻斷劑作用之敘述，何者錯誤？\nA. 給與吸入性麻醉劑前，先給與膽鹼受體阻斷劑可以減少氣管分泌與喉頭痙攣\nB. 膽鹼受體阻斷劑造成心跳減慢是因為阻斷受迷走神經支配的心室細胞\nC. 選擇性M3受體之膽鹼受體阻斷劑可促使支氣管舒張，緩解氣喘和慢性呼吸道阻塞病患症狀\nD. 膽鹼受體阻斷劑可暫時緩解腹瀉\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列膽鹼受體阻斷劑作用之敘述，何者錯誤？\nA. 給與吸入性麻醉劑前，先給與膽鹼受體阻斷劑可以減少氣管分泌與喉頭痙攣\nB. 膽鹼受體阻斷劑造成心跳減慢是因為阻斷受迷走神經支配的心室細胞\nC. 選擇性M3受體之膽鹼受體阻斷劑可促使支氣管舒張，緩解氣喘和慢性呼吸道阻塞病患症狀\nD. 膽鹼受體阻斷劑可暫時緩解腹瀉\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.8125", "False"]], [["-0.3125", "True"]], [["-1.4375", "False"]], [["-3.8125", "False"]]], "filtered_resps": [["-4.8125", "False"], ["-0.3125", "True"], ["-1.4375", "False"], ["-3.8125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b223557f7ed2a29b97a592b96c698fb414975eec0a32914b3a5ca08184c47e6b", "prompt_hash": "e547b609e3d66a98db1324a3219ec2635f7ae971ad3cb1d41eff4dd10dae792e", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 357, "doc": {"question": "下列何者不適合使用在因抗凝血藥物warfarin造成出血（bleeding）的情況？", "A": "heparin", "B": "fresh-frozen plasma", "C": "recombinant factor VIIa", "D": "vitamin K1", "answer": "A", "questions": "下列何者不適合使用在因抗凝血藥物warfarin造成出血（bleeding）的情況？", "choices": ["heparin", "fresh-frozen plasma", "recombinant factor VIIa", "vitamin K1"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不適合使用在因抗凝血藥物warfarin造成出血（bleeding）的情況？\nA. heparin\nB. fresh-frozen plasma\nC. recombinant factor VIIa\nD. vitamin K1\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不適合使用在因抗凝血藥物warfarin造成出血（bleeding）的情況？\nA. heparin\nB. fresh-frozen plasma\nC. recombinant factor VIIa\nD. vitamin K1\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不適合使用在因抗凝血藥物warfarin造成出血（bleeding）的情況？\nA. heparin\nB. fresh-frozen plasma\nC. recombinant factor VIIa\nD. vitamin K1\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不適合使用在因抗凝血藥物warfarin造成出血（bleeding）的情況？\nA. heparin\nB. fresh-frozen plasma\nC. recombinant factor VIIa\nD. vitamin K1\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.765625", "False"]], [["-4.15625", "False"]], [["-0.265625", "True"]], [["-1.640625", "False"]]], "filtered_resps": [["-3.765625", "False"], ["-4.15625", "False"], ["-0.265625", "True"], ["-1.640625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c7d8e96fb182290a2a211ecbdcf7be1d064ad93a89a751f9b4c094e889e8a1c6", "prompt_hash": "4df06c481fde76a65a9013436b1a202dac255ee77961bb73afc042a7d5bfabea", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 358, "doc": {"question": "強心苷結構中有幾個糖分子時，具最佳強心活性？", "A": "3", "B": "2", "C": "1", "D": "4", "answer": "A", "questions": "強心苷結構中有幾個糖分子時，具最佳強心活性？", "choices": ["3", "2", "1", "4"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n強心苷結構中有幾個糖分子時，具最佳強心活性？\nA. 3\nB. 2\nC. 1\nD. 4\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n強心苷結構中有幾個糖分子時，具最佳強心活性？\nA. 3\nB. 2\nC. 1\nD. 4\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n強心苷結構中有幾個糖分子時，具最佳強心活性？\nA. 3\nB. 2\nC. 1\nD. 4\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n強心苷結構中有幾個糖分子時，具最佳強心活性？\nA. 3\nB. 2\nC. 1\nD. 4\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.94140625", "True"]], [["-1.1953125", "False"]], [["-1.5703125", "False"]], [["-2.3125", "False"]]], "filtered_resps": [["-0.94140625", "True"], ["-1.1953125", "False"], ["-1.5703125", "False"], ["-2.3125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "29497038974537de3ef82982eaf29d8e141150500c97e10d2661f0b25a1e4494", "prompt_hash": "1ef55bc97ce2c0726a2320e385e9a4093ee1d73fd16044a16ef65097196939c5", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 359, "doc": {"question": "下列肥大細胞脫粒抑制劑（mast cell degranulation inhibitors），何者具有tetrazole之結構？", "A": "nedocromil", "B": "pemirolast", "C": "lodoxamide", "D": "cromolyn", "answer": "B", "questions": "下列肥大細胞脫粒抑制劑（mast cell degranulation inhibitors），何者具有tetrazole之結構？", "choices": ["nedocromil", "pemirolast", "lodoxamide", "cromolyn"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列肥大細胞脫粒抑制劑（mast cell degranulation inhibitors），何者具有tetrazole之結構？\nA. nedocromil\nB. pemirolast\nC. lodoxamide\nD. cromolyn\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列肥大細胞脫粒抑制劑（mast cell degranulation inhibitors），何者具有tetrazole之結構？\nA. nedocromil\nB. pemirolast\nC. lodoxamide\nD. cromolyn\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列肥大細胞脫粒抑制劑（mast cell degranulation inhibitors），何者具有tetrazole之結構？\nA. nedocromil\nB. pemirolast\nC. lodoxamide\nD. cromolyn\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列肥大細胞脫粒抑制劑（mast cell degranulation inhibitors），何者具有tetrazole之結構？\nA. nedocromil\nB. pemirolast\nC. lodoxamide\nD. cromolyn\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.53125", "False"]], [["-1.6640625", "False"]], [["-0.2890625", "True"]], [["-3.53125", "False"]]], "filtered_resps": [["-3.53125", "False"], ["-1.6640625", "False"], ["-0.2890625", "True"], ["-3.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "50a4ab47a573b6d7b3f3a6f611c5a6951962f74d0a94ca59164c687fadebed26", "prompt_hash": "8832bbc3bb6128f1e91b8b394617e8fd15ebaa64d846936f4218c9548c0da673", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 360, "doc": {"question": "下列有關前驅藥與原型藥的敘述，何者最不可能發生？", "A": "前驅藥與生物標的結合力小於原型藥", "B": "前驅藥與生物標的結合力大於原型藥", "C": "前驅藥分子量小於原型藥分子量", "D": "前驅藥分子量大於原型藥分子量", "answer": "B", "questions": "下列有關前驅藥與原型藥的敘述，何者最不可能發生？", "choices": ["前驅藥與生物標的結合力小於原型藥", "前驅藥與生物標的結合力大於原型藥", "前驅藥分子量小於原型藥分子量", "前驅藥分子量大於原型藥分子量"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關前驅藥與原型藥的敘述，何者最不可能發生？\nA. 前驅藥與生物標的結合力小於原型藥\nB. 前驅藥與生物標的結合力大於原型藥\nC. 前驅藥分子量小於原型藥分子量\nD. 前驅藥分子量大於原型藥分子量\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關前驅藥與原型藥的敘述，何者最不可能發生？\nA. 前驅藥與生物標的結合力小於原型藥\nB. 前驅藥與生物標的結合力大於原型藥\nC. 前驅藥分子量小於原型藥分子量\nD. 前驅藥分子量大於原型藥分子量\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關前驅藥與原型藥的敘述，何者最不可能發生？\nA. 前驅藥與生物標的結合力小於原型藥\nB. 前驅藥與生物標的結合力大於原型藥\nC. 前驅藥分子量小於原型藥分子量\nD. 前驅藥分子量大於原型藥分子量\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關前驅藥與原型藥的敘述，何者最不可能發生？\nA. 前驅藥與生物標的結合力小於原型藥\nB. 前驅藥與生物標的結合力大於原型藥\nC. 前驅藥分子量小於原型藥分子量\nD. 前驅藥分子量大於原型藥分子量\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.1328125", "False"]], [["-0.5078125", "True"]], [["-5.75", "False"]], [["-2.625", "False"]]], "filtered_resps": [["-1.1328125", "False"], ["-0.5078125", "True"], ["-5.75", "False"], ["-2.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "64a873ce4352f3cba5e6223b2c40bd44f9bb57c7655936e0ed2f844c511e7939", "prompt_hash": "ee5fb05959bff0819d56c3bef9b327462b07c2799eb1ca38def4bb5616d40d16", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 361, "doc": {"question": "下列有關Guanfacine藥理作用的敘述，何者錯誤？", "A": "降壓作用受Imipramine抑制", "B": "會活化Imidazoline receptor", "C": "會使心跳減慢，減少心輸出量", "D": "可減輕憂鬱症病人之病情", "answer": "D", "questions": "下列有關Guanfacine藥理作用的敘述，何者錯誤？", "choices": ["降壓作用受Imipramine抑制", "會活化Imidazoline receptor", "會使心跳減慢，減少心輸出量", "可減輕憂鬱症病人之病情"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Guanfacine藥理作用的敘述，何者錯誤？\nA. 降壓作用受Imipramine抑制\nB. 會活化Imidazoline receptor\nC. 會使心跳減慢，減少心輸出量\nD. 可減輕憂鬱症病人之病情\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Guanfacine藥理作用的敘述，何者錯誤？\nA. 降壓作用受Imipramine抑制\nB. 會活化Imidazoline receptor\nC. 會使心跳減慢，減少心輸出量\nD. 可減輕憂鬱症病人之病情\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Guanfacine藥理作用的敘述，何者錯誤？\nA. 降壓作用受Imipramine抑制\nB. 會活化Imidazoline receptor\nC. 會使心跳減慢，減少心輸出量\nD. 可減輕憂鬱症病人之病情\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Guanfacine藥理作用的敘述，何者錯誤？\nA. 降壓作用受Imipramine抑制\nB. 會活化Imidazoline receptor\nC. 會使心跳減慢，減少心輸出量\nD. 可減輕憂鬱症病人之病情\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.0", "False"]], [["-5.875", "False"]], [["-6.875", "False"]], [["-0.0113525390625", "True"]]], "filtered_resps": [["-5.0", "False"], ["-5.875", "False"], ["-6.875", "False"], ["-0.0113525390625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9dba146e027c21bd92a3d4f6e7d5795d3cf64ede089b2cc1c003ec0d8cc55bbf", "prompt_hash": "e8626d95efca16494e2c61679ca2d4e4a2fb6051e4e8099cea81bb8ccc3badf8", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 362, "doc": {"question": "下列何種偏頭痛用藥，不經MAO-A代謝？", "A": "zolmitriptan", "B": "rizatriptan", "C": "sumatriptan", "D": "frovatriptan", "answer": "D", "questions": "下列何種偏頭痛用藥，不經MAO-A代謝？", "choices": ["zolmitriptan", "rizatriptan", "sumatriptan", "frovatriptan"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種偏頭痛用藥，不經MAO-A代謝？\nA. zolmitriptan\nB. rizatriptan\nC. sumatriptan\nD. frovatriptan\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種偏頭痛用藥，不經MAO-A代謝？\nA. zolmitriptan\nB. rizatriptan\nC. sumatriptan\nD. frovatriptan\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種偏頭痛用藥，不經MAO-A代謝？\nA. zolmitriptan\nB. rizatriptan\nC. sumatriptan\nD. frovatriptan\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種偏頭痛用藥，不經MAO-A代謝？\nA. zolmitriptan\nB. rizatriptan\nC. sumatriptan\nD. frovatriptan\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.75", "False"]], [["-6.25", "False"]], [["-5.875", "False"]], [["-0.0101318359375", "True"]]], "filtered_resps": [["-5.75", "False"], ["-6.25", "False"], ["-5.875", "False"], ["-0.0101318359375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8578a5c8fe63ed46710becc0e3ce0b1ef52cf5df634a990cc30b932223c8ac76", "prompt_hash": "5da1a175cee3d1c2e8f3d799a488015c3de8b87876a77a74bed45a4e6a58f77e", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 363, "doc": {"question": "下列有關(-)-ephedrine與(+)-pseudoephedrine相互關係的敘述，何者最正確？", "A": "isosteric isomers", "B": "conformational isomers", "C": "diastereomers", "D": "enantiomers", "answer": "C", "questions": "下列有關(-)-ephedrine與(+)-pseudoephedrine相互關係的敘述，何者最正確？", "choices": ["isosteric isomers", "conformational isomers", "diastereomers", "enantiomers"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關(-)-ephedrine與(+)-pseudoephedrine相互關係的敘述，何者最正確？\nA. isosteric isomers\nB. conformational isomers\nC. diastereomers\nD. enantiomers\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關(-)-ephedrine與(+)-pseudoephedrine相互關係的敘述，何者最正確？\nA. isosteric isomers\nB. conformational isomers\nC. diastereomers\nD. enantiomers\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關(-)-ephedrine與(+)-pseudoephedrine相互關係的敘述，何者最正確？\nA. isosteric isomers\nB. conformational isomers\nC. diastereomers\nD. enantiomers\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關(-)-ephedrine與(+)-pseudoephedrine相互關係的敘述，何者最正確？\nA. isosteric isomers\nB. conformational isomers\nC. diastereomers\nD. enantiomers\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.53125", "False"]], [["-7.90625", "False"]], [["-0.0184326171875", "True"]], [["-4.78125", "False"]]], "filtered_resps": [["-5.53125", "False"], ["-7.90625", "False"], ["-0.0184326171875", "True"], ["-4.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3f51ee32241a49fa374792c3fb0bc1310eba08a1aa3865071ec7940c55183de3", "prompt_hash": "5501360b0ece6f2ed1107f5aaebe05cab5fb7fbbaaa8e69b9c3fd7d6071ac21d", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 364, "doc": {"question": "下列Azoles類抗黴菌藥物中，何者的吸收良好且主要由腎臟排泄？", "A": "Voriconazole", "B": "Fluconazole", "C": "Itraconazole", "D": "Ketoconazole", "answer": "B", "questions": "下列Azoles類抗黴菌藥物中，何者的吸收良好且主要由腎臟排泄？", "choices": ["Voriconazole", "Fluconazole", "Itraconazole", "Ketoconazole"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列Azoles類抗黴菌藥物中，何者的吸收良好且主要由腎臟排泄？\nA. Voriconazole\nB. Fluconazole\nC. Itraconazole\nD. Ketoconazole\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列Azoles類抗黴菌藥物中，何者的吸收良好且主要由腎臟排泄？\nA. Voriconazole\nB. Fluconazole\nC. Itraconazole\nD. Ketoconazole\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列Azoles類抗黴菌藥物中，何者的吸收良好且主要由腎臟排泄？\nA. Voriconazole\nB. Fluconazole\nC. Itraconazole\nD. Ketoconazole\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列Azoles類抗黴菌藥物中，何者的吸收良好且主要由腎臟排泄？\nA. Voriconazole\nB. Fluconazole\nC. Itraconazole\nD. Ketoconazole\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.875", "False"]], [["-0.0037689208984375", "True"]], [["-7.375", "False"]], [["-7.25", "False"]]], "filtered_resps": [["-7.875", "False"], ["-0.0037689208984375", "True"], ["-7.375", "False"], ["-7.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "549141acec711aea7a1d20558dc13a194154c2e2d7ab241823754869638a86e3", "prompt_hash": "978a9f243a6b452c8ccc44a52b8bb0b38ec4577d45d5bfcf7f273283ab27cefb", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 365, "doc": {"question": "下列有關baclofen之藥理作用，何者正確？", "A": "肌肉鬆弛劑，藥理作用標的是GABAA受體", "B": "肌肉鬆弛劑，藥理作用標的是GABAB受體", "C": "鎮靜安眠藥物，藥理作用標的是GABAA受體", "D": "鎮靜安眠藥物，藥理作用標的是GABAB受體", "answer": "B", "questions": "下列有關baclofen之藥理作用，何者正確？", "choices": ["肌肉鬆弛劑，藥理作用標的是GABAA受體", "肌肉鬆弛劑，藥理作用標的是GABAB受體", "鎮靜安眠藥物，藥理作用標的是GABAA受體", "鎮靜安眠藥物，藥理作用標的是GABAB受體"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關baclofen之藥理作用，何者正確？\nA. 肌肉鬆弛劑，藥理作用標的是GABAA受體\nB. 肌肉鬆弛劑，藥理作用標的是GABAB受體\nC. 鎮靜安眠藥物，藥理作用標的是GABAA受體\nD. 鎮靜安眠藥物，藥理作用標的是GABAB受體\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關baclofen之藥理作用，何者正確？\nA. 肌肉鬆弛劑，藥理作用標的是GABAA受體\nB. 肌肉鬆弛劑，藥理作用標的是GABAB受體\nC. 鎮靜安眠藥物，藥理作用標的是GABAA受體\nD. 鎮靜安眠藥物，藥理作用標的是GABAB受體\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關baclofen之藥理作用，何者正確？\nA. 肌肉鬆弛劑，藥理作用標的是GABAA受體\nB. 肌肉鬆弛劑，藥理作用標的是GABAB受體\nC. 鎮靜安眠藥物，藥理作用標的是GABAA受體\nD. 鎮靜安眠藥物，藥理作用標的是GABAB受體\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關baclofen之藥理作用，何者正確？\nA. 肌肉鬆弛劑，藥理作用標的是GABAA受體\nB. 肌肉鬆弛劑，藥理作用標的是GABAB受體\nC. 鎮靜安眠藥物，藥理作用標的是GABAA受體\nD. 鎮靜安眠藥物，藥理作用標的是GABAB受體\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.125", "False"]], [["-0.01190185546875", "True"]], [["-5.75", "False"]], [["-5.0", "False"]]], "filtered_resps": [["-7.125", "False"], ["-0.01190185546875", "True"], ["-5.75", "False"], ["-5.0", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "100d64cf3aeac4ad5ce1d962e4d15459485fcfb339787234f124171f12ae6998", "prompt_hash": "f16fb205a318618891010f9cc648fa59b1620578bd7e817248dc11a307a530d1", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 366, "doc": {"question": "有關ziprasidone之敘述，下列何者錯誤？", "A": "具有dihydroindolone環", "B": "具benzisothiazole環", "C": "具piperazinyl基", "D": "主要代謝反應為N-oxidation", "answer": "D", "questions": "有關ziprasidone之敘述，下列何者錯誤？", "choices": ["具有dihydroindolone環", "具benzisothiazole環", "具piperazinyl基", "主要代謝反應為N-oxidation"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關ziprasidone之敘述，下列何者錯誤？\nA. 具有dihydroindolone環\nB. 具benzisothiazole環\nC. 具piperazinyl基\nD. 主要代謝反應為N-oxidation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關ziprasidone之敘述，下列何者錯誤？\nA. 具有dihydroindolone環\nB. 具benzisothiazole環\nC. 具piperazinyl基\nD. 主要代謝反應為N-oxidation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關ziprasidone之敘述，下列何者錯誤？\nA. 具有dihydroindolone環\nB. 具benzisothiazole環\nC. 具piperazinyl基\nD. 主要代謝反應為N-oxidation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關ziprasidone之敘述，下列何者錯誤？\nA. 具有dihydroindolone環\nB. 具benzisothiazole環\nC. 具piperazinyl基\nD. 主要代謝反應為N-oxidation\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.96875", "False"]], [["-3.59375", "False"]], [["-4.09375", "False"]], [["-0.1005859375", "True"]]], "filtered_resps": [["-2.96875", "False"], ["-3.59375", "False"], ["-4.09375", "False"], ["-0.1005859375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "96c00cc7fdb35635869ea4f4a873fcb2865bb436f7867c16c91d0390b1f42cc0", "prompt_hash": "fe9b9bd0dd26bd90499af2d9a63b299923f6e3eae4de0a62c358a159fcc84961", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 367, "doc": {"question": "腎上腺素性受體可有alpha及beta兩種亞型，下列擬交感神經作用劑在有藥理作用劑量時，何者對於腎上腺素性beta亞型受體親和力較大？", "A": "dobutamine", "B": "clonidine", "C": "phenylephrine", "D": "methoxamine", "answer": "A", "questions": "腎上腺素性受體可有alpha及beta兩種亞型，下列擬交感神經作用劑在有藥理作用劑量時，何者對於腎上腺素性beta亞型受體親和力較大？", "choices": ["dobutamine", "clonidine", "phenylephrine", "methoxamine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎上腺素性受體可有alpha及beta兩種亞型，下列擬交感神經作用劑在有藥理作用劑量時，何者對於腎上腺素性beta亞型受體親和力較大？\nA. dobutamine\nB. clonidine\nC. phenylephrine\nD. methoxamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎上腺素性受體可有alpha及beta兩種亞型，下列擬交感神經作用劑在有藥理作用劑量時，何者對於腎上腺素性beta亞型受體親和力較大？\nA. dobutamine\nB. clonidine\nC. phenylephrine\nD. methoxamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎上腺素性受體可有alpha及beta兩種亞型，下列擬交感神經作用劑在有藥理作用劑量時，何者對於腎上腺素性beta亞型受體親和力較大？\nA. dobutamine\nB. clonidine\nC. phenylephrine\nD. methoxamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎上腺素性受體可有alpha及beta兩種亞型，下列擬交感神經作用劑在有藥理作用劑量時，何者對於腎上腺素性beta亞型受體親和力較大？\nA. dobutamine\nB. clonidine\nC. phenylephrine\nD. methoxamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.017822265625", "True"]], [["-5.28125", "False"]], [["-5.90625", "False"]], [["-4.78125", "False"]]], "filtered_resps": [["-0.017822265625", "True"], ["-5.28125", "False"], ["-5.90625", "False"], ["-4.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "521dc4e47993e379c00a642694b533ade65d2cf94fdc6e1c79dd448ddba63c51", "prompt_hash": "37cf35f06998e5c098c1d08bd40b2093c6d96df81fe6f7d483c728ae37023b6d", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 368, "doc": {"question": "關於抗憂鬱藥物venlafaxine的藥理機制敘述，下列何者正確？", "A": "選擇性多巴胺再回收抑制劑", "B": "選擇性正腎上腺素致效劑", "C": "選擇性乙醯膽鹼再回收抑制劑", "D": "選擇性正腎上腺素及血清素再回收抑制劑", "answer": "D", "questions": "關於抗憂鬱藥物venlafaxine的藥理機制敘述，下列何者正確？", "choices": ["選擇性多巴胺再回收抑制劑", "選擇性正腎上腺素致效劑", "選擇性乙醯膽鹼再回收抑制劑", "選擇性正腎上腺素及血清素再回收抑制劑"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於抗憂鬱藥物venlafaxine的藥理機制敘述，下列何者正確？\nA. 選擇性多巴胺再回收抑制劑\nB. 選擇性正腎上腺素致效劑\nC. 選擇性乙醯膽鹼再回收抑制劑\nD. 選擇性正腎上腺素及血清素再回收抑制劑\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於抗憂鬱藥物venlafaxine的藥理機制敘述，下列何者正確？\nA. 選擇性多巴胺再回收抑制劑\nB. 選擇性正腎上腺素致效劑\nC. 選擇性乙醯膽鹼再回收抑制劑\nD. 選擇性正腎上腺素及血清素再回收抑制劑\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於抗憂鬱藥物venlafaxine的藥理機制敘述，下列何者正確？\nA. 選擇性多巴胺再回收抑制劑\nB. 選擇性正腎上腺素致效劑\nC. 選擇性乙醯膽鹼再回收抑制劑\nD. 選擇性正腎上腺素及血清素再回收抑制劑\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於抗憂鬱藥物venlafaxine的藥理機制敘述，下列何者正確？\nA. 選擇性多巴胺再回收抑制劑\nB. 選擇性正腎上腺素致效劑\nC. 選擇性乙醯膽鹼再回收抑制劑\nD. 選擇性正腎上腺素及血清素再回收抑制劑\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.625", "False"]], [["-6.375", "False"]], [["-7.25", "False"]], [["-0.0047607421875", "True"]]], "filtered_resps": [["-6.625", "False"], ["-6.375", "False"], ["-7.25", "False"], ["-0.0047607421875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "54bab6bc0b119ae9eb14b29d58b70aa2b008900705363a03d71271d7e6176db3", "prompt_hash": "f54bac49f51bd7946291546456f2829e2040b0fa4e95d40e631292f2f83c73c9", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 369, "doc": {"question": "有關降血脂藥物之敘述，下列何者正確？", "A": "Niacin：抑制HMG-CoA reductase", "B": "Ezetimibe：離子交換樹脂，與腸胃道內之膽酸結合降低其吸收", "C": "Fenofibrate：過氧化體增生活化受體-alpha（PPAR-α）作用劑", "D": "Cholestyramine：降低肝臟分泌VLDL", "answer": "C", "questions": "有關降血脂藥物之敘述，下列何者正確？", "choices": ["Niacin：抑制HMG-CoA reductase", "Ezetimibe：離子交換樹脂，與腸胃道內之膽酸結合降低其吸收", "Fenofibrate：過氧化體增生活化受體-alpha（PPAR-α）作用劑", "Cholestyramine：降低肝臟分泌VLDL"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關降血脂藥物之敘述，下列何者正確？\nA. Niacin：抑制HMG-CoA reductase\nB. Ezetimibe：離子交換樹脂，與腸胃道內之膽酸結合降低其吸收\nC. Fenofibrate：過氧化體增生活化受體-alpha（PPAR-α）作用劑\nD. Cholestyramine：降低肝臟分泌VLDL\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關降血脂藥物之敘述，下列何者正確？\nA. Niacin：抑制HMG-CoA reductase\nB. Ezetimibe：離子交換樹脂，與腸胃道內之膽酸結合降低其吸收\nC. Fenofibrate：過氧化體增生活化受體-alpha（PPAR-α）作用劑\nD. Cholestyramine：降低肝臟分泌VLDL\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關降血脂藥物之敘述，下列何者正確？\nA. Niacin：抑制HMG-CoA reductase\nB. Ezetimibe：離子交換樹脂，與腸胃道內之膽酸結合降低其吸收\nC. Fenofibrate：過氧化體增生活化受體-alpha（PPAR-α）作用劑\nD. Cholestyramine：降低肝臟分泌VLDL\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關降血脂藥物之敘述，下列何者正確？\nA. Niacin：抑制HMG-CoA reductase\nB. Ezetimibe：離子交換樹脂，與腸胃道內之膽酸結合降低其吸收\nC. Fenofibrate：過氧化體增生活化受體-alpha（PPAR-α）作用劑\nD. Cholestyramine：降低肝臟分泌VLDL\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.84375", "False"]], [["-2.859375", "False"]], [["-0.2314453125", "True"]], [["-1.984375", "False"]]], "filtered_resps": [["-4.84375", "False"], ["-2.859375", "False"], ["-0.2314453125", "True"], ["-1.984375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1913abe1169e7ff06f688e449d6e362b0c8c93404cda9104347d2fcf545073ef", "prompt_hash": "399872197192ecc8f8c71c745e2e2122f776777f8897042b8c903693ffb38800", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 370, "doc": {"question": "下列何種四環素不含 C-6-OH，所以不進行脫水反應？", "A": "oxytetracycline", "B": "minocycline", "C": "demeclocycline", "D": "chlortetracycline", "answer": "B", "questions": "下列何種四環素不含 C-6-OH，所以不進行脫水反應？", "choices": ["oxytetracycline", "minocycline", "demeclocycline", "chlortetracycline"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種四環素不含 C-6-OH，所以不進行脫水反應？\nA. oxytetracycline\nB. minocycline\nC. demeclocycline\nD. chlortetracycline\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種四環素不含 C-6-OH，所以不進行脫水反應？\nA. oxytetracycline\nB. minocycline\nC. demeclocycline\nD. chlortetracycline\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種四環素不含 C-6-OH，所以不進行脫水反應？\nA. oxytetracycline\nB. minocycline\nC. demeclocycline\nD. chlortetracycline\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種四環素不含 C-6-OH，所以不進行脫水反應？\nA. oxytetracycline\nB. minocycline\nC. demeclocycline\nD. chlortetracycline\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.109375", "False"]], [["-1.109375", "False"]], [["-0.984375", "True"]], [["-1.734375", "False"]]], "filtered_resps": [["-2.109375", "False"], ["-1.109375", "False"], ["-0.984375", "True"], ["-1.734375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "048673478f07f87a81f76768ffd709a2b960bc64a9f4cdebae03f4aceb92feaa", "prompt_hash": "ea14725b29755e0f1e49a8f63a4ea513e182328e1d327d162503b12a5a695df9", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 371, "doc": {"question": "下列藥品在健康人的血液中，何者解離態與未解離態的比例最接近於1？", "A": "ethanol", "B": "phenytoin", "C": "aspirin", "D": "sildenafil", "answer": "D", "questions": "下列藥品在健康人的血液中，何者解離態與未解離態的比例最接近於1？", "choices": ["ethanol", "phenytoin", "aspirin", "sildenafil"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品在健康人的血液中，何者解離態與未解離態的比例最接近於1？\nA. ethanol\nB. phenytoin\nC. aspirin\nD. sildenafil\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品在健康人的血液中，何者解離態與未解離態的比例最接近於1？\nA. ethanol\nB. phenytoin\nC. aspirin\nD. sildenafil\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品在健康人的血液中，何者解離態與未解離態的比例最接近於1？\nA. ethanol\nB. phenytoin\nC. aspirin\nD. sildenafil\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥品在健康人的血液中，何者解離態與未解離態的比例最接近於1？\nA. ethanol\nB. phenytoin\nC. aspirin\nD. sildenafil\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.4921875", "False"]], [["-1.1171875", "True"]], [["-1.4921875", "False"]], [["-1.4921875", "False"]]], "filtered_resps": [["-1.4921875", "False"], ["-1.1171875", "True"], ["-1.4921875", "False"], ["-1.4921875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8a018aee157a4b372c94d3a7367d3c7c8672a875dbde827ba70775aa6bd1fe6d", "prompt_hash": "57688fb9ca1db118f22b76d241e358d621b639f59afa2f05b26beb4b0c41b166", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 372, "doc": {"question": "下列藥物何者最易引起metabolic alkalosis？", "A": "Sorbitol", "B": "Magnesium hydroxide", "C": "Misoprostol", "D": "Sodium bicarbonate", "answer": "D", "questions": "下列藥物何者最易引起metabolic alkalosis？", "choices": ["Sorbitol", "Magnesium hydroxide", "Misoprostol", "Sodium bicarbonate"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者最易引起metabolic alkalosis？\nA. Sorbitol\nB. Magnesium hydroxide\nC. Misoprostol\nD. Sodium bicarbonate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者最易引起metabolic alkalosis？\nA. Sorbitol\nB. Magnesium hydroxide\nC. Misoprostol\nD. Sodium bicarbonate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者最易引起metabolic alkalosis？\nA. Sorbitol\nB. Magnesium hydroxide\nC. Misoprostol\nD. Sodium bicarbonate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者最易引起metabolic alkalosis？\nA. Sorbitol\nB. Magnesium hydroxide\nC. Misoprostol\nD. Sodium bicarbonate\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.875", "False"]], [["-5.625", "False"]], [["-6.625", "False"]], [["-0.00921630859375", "True"]]], "filtered_resps": [["-6.875", "False"], ["-5.625", "False"], ["-6.625", "False"], ["-0.00921630859375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e0d503900fbc69ee6537905d5a3acb9716af0e9e853c524fc8aed9d0b6a97bd4", "prompt_hash": "0625c71bf9240b8ead781b7a1e8c007d4e7cceb7e0e345a945428c73093387b8", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 373, "doc": {"question": "Indomethacin之indole環上第幾位氫原子，會造成藥物結構中的兩芳香環不共平面？", "A": "7", "B": "2", "C": "5", "D": "6", "answer": "A", "questions": "Indomethacin之indole環上第幾位氫原子，會造成藥物結構中的兩芳香環不共平面？", "choices": ["7", "2", "5", "6"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nIndomethacin之indole環上第幾位氫原子，會造成藥物結構中的兩芳香環不共平面？\nA. 7\nB. 2\nC. 5\nD. 6\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nIndomethacin之indole環上第幾位氫原子，會造成藥物結構中的兩芳香環不共平面？\nA. 7\nB. 2\nC. 5\nD. 6\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nIndomethacin之indole環上第幾位氫原子，會造成藥物結構中的兩芳香環不共平面？\nA. 7\nB. 2\nC. 5\nD. 6\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nIndomethacin之indole環上第幾位氫原子，會造成藥物結構中的兩芳香環不共平面？\nA. 7\nB. 2\nC. 5\nD. 6\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.0390625", "True"]], [["-1.1640625", "False"]], [["-1.7890625", "False"]], [["-1.7890625", "False"]]], "filtered_resps": [["-1.0390625", "True"], ["-1.1640625", "False"], ["-1.7890625", "False"], ["-1.7890625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2c970b6df6b4c7017d8308cdb4cfd2c669158653128ce22d8f14a28191b25e71", "prompt_hash": "1174ea4ec9e87eb2e8bbeac7bc4838ca437bc43da371717d308f1430c0dfb395", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 374, "doc": {"question": "使用 doxorubicin 對下列何種組織的功能影響較小?", "A": "生殖系統", "B": "胃腸道", "C": "骨骼肌", "D": "骨髓造血系統", "answer": "C", "questions": "使用 doxorubicin 對下列何種組織的功能影響較小?", "choices": ["生殖系統", "胃腸道", "骨骼肌", "骨髓造血系統"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用 doxorubicin 對下列何種組織的功能影響較小?\nA. 生殖系統\nB. 胃腸道\nC. 骨骼肌\nD. 骨髓造血系統\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用 doxorubicin 對下列何種組織的功能影響較小?\nA. 生殖系統\nB. 胃腸道\nC. 骨骼肌\nD. 骨髓造血系統\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用 doxorubicin 對下列何種組織的功能影響較小?\nA. 生殖系統\nB. 胃腸道\nC. 骨骼肌\nD. 骨髓造血系統\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n使用 doxorubicin 對下列何種組織的功能影響較小?\nA. 生殖系統\nB. 胃腸道\nC. 骨骼肌\nD. 骨髓造血系統\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.9375", "False"]], [["-2.5625", "False"]], [["-0.181640625", "True"]], [["-3.6875", "False"]]], "filtered_resps": [["-2.9375", "False"], ["-2.5625", "False"], ["-0.181640625", "True"], ["-3.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "89a82e08e27516928abdd479949b77991b794bc6dc902b9d68f85f056e00e3e8", "prompt_hash": "031540a041fcb34095f3ca0c1996385ae21dc03fc3eb95763e57b106c51e9cbd", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 375, "doc": {"question": "下列有關bevacizumab（Avastin）的敘述，何者錯誤？", "A": "可活化與腫瘤血管新生相關的VEGF-A", "B": "可抑制腫瘤血管新生，為一種angiogenesis inhibitor", "C": "與fluorouracil類藥物併用，可治療轉移性大腸直腸癌", "D": "是一種recombinant humanized monoclonal antibody", "answer": "A", "questions": "下列有關bevacizumab（Avastin）的敘述，何者錯誤？", "choices": ["可活化與腫瘤血管新生相關的VEGF-A", "可抑制腫瘤血管新生，為一種angiogenesis inhibitor", "與fluorouracil類藥物併用，可治療轉移性大腸直腸癌", "是一種recombinant humanized monoclonal antibody"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關bevacizumab（Avastin）的敘述，何者錯誤？\nA. 可活化與腫瘤血管新生相關的VEGF-A\nB. 可抑制腫瘤血管新生，為一種angiogenesis inhibitor\nC. 與fluorouracil類藥物併用，可治療轉移性大腸直腸癌\nD. 是一種recombinant humanized monoclonal antibody\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關bevacizumab（Avastin）的敘述，何者錯誤？\nA. 可活化與腫瘤血管新生相關的VEGF-A\nB. 可抑制腫瘤血管新生，為一種angiogenesis inhibitor\nC. 與fluorouracil類藥物併用，可治療轉移性大腸直腸癌\nD. 是一種recombinant humanized monoclonal antibody\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關bevacizumab（Avastin）的敘述，何者錯誤？\nA. 可活化與腫瘤血管新生相關的VEGF-A\nB. 可抑制腫瘤血管新生，為一種angiogenesis inhibitor\nC. 與fluorouracil類藥物併用，可治療轉移性大腸直腸癌\nD. 是一種recombinant humanized monoclonal antibody\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關bevacizumab（Avastin）的敘述，何者錯誤？\nA. 可活化與腫瘤血管新生相關的VEGF-A\nB. 可抑制腫瘤血管新生，為一種angiogenesis inhibitor\nC. 與fluorouracil類藥物併用，可治療轉移性大腸直腸癌\nD. 是一種recombinant humanized monoclonal antibody\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0615234375", "True"]], [["-4.0625", "False"]], [["-3.6875", "False"]], [["-4.3125", "False"]]], "filtered_resps": [["-0.0615234375", "True"], ["-4.0625", "False"], ["-3.6875", "False"], ["-4.3125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ffd736da70aa04ed5a093b6f62b1c973f05bf6a17e8d1f5c9eb64faa5531a0f4", "prompt_hash": "8d46b8844211b8c5089e1b5a804194670b75aab404862bca5cacec7259d77318", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 376, "doc": {"question": "下列有關idarubicin之敘述，何者錯誤？", "A": "為daunorubicin之4-desmethoxy類似物", "B": "代謝產物idarubicinol之抗癌活性與原藥相當", "C": "結構中anthracyclinone部分可嵌入DNA中", "D": "在體內會進行O-dealkylation", "answer": "D", "questions": "下列有關idarubicin之敘述，何者錯誤？", "choices": ["為daunorubicin之4-desmethoxy類似物", "代謝產物idarubicinol之抗癌活性與原藥相當", "結構中anthracyclinone部分可嵌入DNA中", "在體內會進行O-dealkylation"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關idarubicin之敘述，何者錯誤？\nA. 為daunorubicin之4-desmethoxy類似物\nB. 代謝產物idarubicinol之抗癌活性與原藥相當\nC. 結構中anthracyclinone部分可嵌入DNA中\nD. 在體內會進行O-dealkylation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關idarubicin之敘述，何者錯誤？\nA. 為daunorubicin之4-desmethoxy類似物\nB. 代謝產物idarubicinol之抗癌活性與原藥相當\nC. 結構中anthracyclinone部分可嵌入DNA中\nD. 在體內會進行O-dealkylation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關idarubicin之敘述，何者錯誤？\nA. 為daunorubicin之4-desmethoxy類似物\nB. 代謝產物idarubicinol之抗癌活性與原藥相當\nC. 結構中anthracyclinone部分可嵌入DNA中\nD. 在體內會進行O-dealkylation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關idarubicin之敘述，何者錯誤？\nA. 為daunorubicin之4-desmethoxy類似物\nB. 代謝產物idarubicinol之抗癌活性與原藥相當\nC. 結構中anthracyclinone部分可嵌入DNA中\nD. 在體內會進行O-dealkylation\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.734375", "False"]], [["-0.98828125", "False"]], [["-3.859375", "False"]], [["-0.61328125", "True"]]], "filtered_resps": [["-2.734375", "False"], ["-0.98828125", "False"], ["-3.859375", "False"], ["-0.61328125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a3b6ac028b02c755e3285a6d23e54a19fbcd9752e0924ca5a0bae1d05c87b104", "prompt_hash": "81976c53f718483a9e1967af0d038c8fb50c05cefe126f3ef679e4aaa55b04f7", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 377, "doc": {"question": "下列有關methoxamine之敘述，何者錯誤？", "A": "代謝為5'-phenolic活性代謝物", "B": "結構中含4',5'-dimethoxylphenyl 基團", "C": "作用於α1受體", "D": "高劑量具有β-blocking活性", "answer": "B", "questions": "下列有關methoxamine之敘述，何者錯誤？", "choices": ["代謝為5'-phenolic活性代謝物", "結構中含4',5'-dimethoxylphenyl 基團", "作用於α1受體", "高劑量具有β-blocking活性"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關methoxamine之敘述，何者錯誤？\nA. 代謝為5'-phenolic活性代謝物\nB. 結構中含4',5'-dimethoxylphenyl 基團\nC. 作用於α1受體\nD. 高劑量具有β-blocking活性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關methoxamine之敘述，何者錯誤？\nA. 代謝為5'-phenolic活性代謝物\nB. 結構中含4',5'-dimethoxylphenyl 基團\nC. 作用於α1受體\nD. 高劑量具有β-blocking活性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關methoxamine之敘述，何者錯誤？\nA. 代謝為5'-phenolic活性代謝物\nB. 結構中含4',5'-dimethoxylphenyl 基團\nC. 作用於α1受體\nD. 高劑量具有β-blocking活性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關methoxamine之敘述，何者錯誤？\nA. 代謝為5'-phenolic活性代謝物\nB. 結構中含4',5'-dimethoxylphenyl 基團\nC. 作用於α1受體\nD. 高劑量具有β-blocking活性\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.859375", "False"]], [["-1.234375", "False"]], [["-1.109375", "True"]], [["-1.484375", "False"]]], "filtered_resps": [["-1.859375", "False"], ["-1.234375", "False"], ["-1.109375", "True"], ["-1.484375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "00e12f603c9b99c6bfbf2f8ccdd7b9096e11abdad817cca29a69d6120897783c", "prompt_hash": "2fd4e4f1cacd26fd7c3fc8487e79d8e6d9fb72f2514cadd0abb2974776324a4d", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 378, "doc": {"question": "下列何者是Gs-coupled受體？", "A": "V2 receptor", "B": "5-HT3 receptor", "C": "histamine H1 receptor", "D": "rhodopsin", "answer": "A", "questions": "下列何者是Gs-coupled受體？", "choices": ["V2 receptor", "5-HT3 receptor", "histamine H1 receptor", "rhodopsin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是Gs-coupled受體？\nA. V2 receptor\nB. 5-HT3 receptor\nC. histamine H1 receptor\nD. rhodopsin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是Gs-coupled受體？\nA. V2 receptor\nB. 5-HT3 receptor\nC. histamine H1 receptor\nD. rhodopsin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是Gs-coupled受體？\nA. V2 receptor\nB. 5-HT3 receptor\nC. histamine H1 receptor\nD. rhodopsin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是Gs-coupled受體？\nA. V2 receptor\nB. 5-HT3 receptor\nC. histamine H1 receptor\nD. rhodopsin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0732421875", "True"]], [["-4.4375", "False"]], [["-4.0625", "False"]], [["-3.328125", "False"]]], "filtered_resps": [["-0.0732421875", "True"], ["-4.4375", "False"], ["-4.0625", "False"], ["-3.328125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "440fef705c516cb8d97247912812d5fe65756de564ed0799da1a685c7ccbef94", "prompt_hash": "d686b03b6113e0a2814b6b86048cc43840e82e601601f47b65b6d51cb8bb7845", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 379, "doc": {"question": "下列皮質類固醇藥中，何者具9α-Cl基？", "A": "alclometasone", "B": "halcinonide", "C": "triamcinolone", "D": "mometasone", "answer": "D", "questions": "下列皮質類固醇藥中，何者具9α-Cl基？", "choices": ["alclometasone", "halcinonide", "triamcinolone", "mometasone"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列皮質類固醇藥中，何者具9α-Cl基？\nA. alclometasone\nB. halcinonide\nC. triamcinolone\nD. mometasone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列皮質類固醇藥中，何者具9α-Cl基？\nA. alclometasone\nB. halcinonide\nC. triamcinolone\nD. mometasone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列皮質類固醇藥中，何者具9α-Cl基？\nA. alclometasone\nB. halcinonide\nC. triamcinolone\nD. mometasone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列皮質類固醇藥中，何者具9α-Cl基？\nA. alclometasone\nB. halcinonide\nC. triamcinolone\nD. mometasone\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.828125", "False"]], [["-1.578125", "False"]], [["-0.83203125", "True"]], [["-1.203125", "False"]]], "filtered_resps": [["-2.828125", "False"], ["-1.578125", "False"], ["-0.83203125", "True"], ["-1.203125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e4fb48ae90b652cbbc45496e416cac2e5d6f5e681722a192ab481aa2ee1b2c6a", "prompt_hash": "1499b9a7f2b2dcfa656b3017b6d922c904d6ed0c35b7f19c0cbb775771365bae", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 380, "doc": {"question": "下列給藥方式，何者最可能產生first-pass effect？", "A": "靜脈注射給藥", "B": "經皮（transdermal）給藥", "C": "口服（oral）給藥", "D": "舌下（sublingual）給藥", "answer": "C", "questions": "下列給藥方式，何者最可能產生first-pass effect？", "choices": ["靜脈注射給藥", "經皮（transdermal）給藥", "口服（oral）給藥", "舌下（sublingual）給藥"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式，何者最可能產生first-pass effect？\nA. 靜脈注射給藥\nB. 經皮（transdermal）給藥\nC. 口服（oral）給藥\nD. 舌下（sublingual）給藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式，何者最可能產生first-pass effect？\nA. 靜脈注射給藥\nB. 經皮（transdermal）給藥\nC. 口服（oral）給藥\nD. 舌下（sublingual）給藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式，何者最可能產生first-pass effect？\nA. 靜脈注射給藥\nB. 經皮（transdermal）給藥\nC. 口服（oral）給藥\nD. 舌下（sublingual）給藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列給藥方式，何者最可能產生first-pass effect？\nA. 靜脈注射給藥\nB. 經皮（transdermal）給藥\nC. 口服（oral）給藥\nD. 舌下（sublingual）給藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.375", "False"]], [["-7.375", "False"]], [["-0.0089111328125", "True"]], [["-6.125", "False"]]], "filtered_resps": [["-6.375", "False"], ["-7.375", "False"], ["-0.0089111328125", "True"], ["-6.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1508f94fd67854874b0bee1504229c6c0218a7ca7d53c2cfb62978e849ee0c44", "prompt_hash": "3e2bb4d599a7a4717d8b6be7ee97b96ccb4b52bab4c72505417ce98808e3e02b", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 381, "doc": {"question": "下列何者是minoxidil開啟鉀離子通道的活性代謝物？", "A": "minoxidil N-oxide", "B": "minoxidil N-O-glucuronide", "C": "minoxidil N-O-sulfate", "D": "minoxidil N-O-phosphate", "answer": "C", "questions": "下列何者是minoxidil開啟鉀離子通道的活性代謝物？", "choices": ["minoxidil N-oxide", "minoxidil N-O-glucuronide", "minoxidil N-O-sulfate", "minoxidil N-O-phosphate"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是minoxidil開啟鉀離子通道的活性代謝物？\nA. minoxidil N-oxide\nB. minoxidil N-O-glucuronide\nC. minoxidil N-O-sulfate\nD. minoxidil N-O-phosphate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是minoxidil開啟鉀離子通道的活性代謝物？\nA. minoxidil N-oxide\nB. minoxidil N-O-glucuronide\nC. minoxidil N-O-sulfate\nD. minoxidil N-O-phosphate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是minoxidil開啟鉀離子通道的活性代謝物？\nA. minoxidil N-oxide\nB. minoxidil N-O-glucuronide\nC. minoxidil N-O-sulfate\nD. minoxidil N-O-phosphate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是minoxidil開啟鉀離子通道的活性代謝物？\nA. minoxidil N-oxide\nB. minoxidil N-O-glucuronide\nC. minoxidil N-O-sulfate\nD. minoxidil N-O-phosphate\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.90625", "False"]], [["-1.15625", "False"]], [["-0.78125", "True"]], [["-2.53125", "False"]]], "filtered_resps": [["-1.90625", "False"], ["-1.15625", "False"], ["-0.78125", "True"], ["-2.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "28ffe704afccd314619ef1c1ffcfa0cda3c0207f285545d6bec712af7490362b", "prompt_hash": "3cb4496de2fe2c3e2ab4919184c90c6c06150cbc8b44456922a881fa05bf59b3", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 382, "doc": {"question": "下列降壓藥物中，何者會有血脂肪降低效果？", "A": "Terazosin", "B": "Nadolol", "C": "Carteolol", "D": "Verapamil", "answer": "A", "questions": "下列降壓藥物中，何者會有血脂肪降低效果？", "choices": ["Terazosin", "Nadolol", "Carteolol", "Verapamil"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列降壓藥物中，何者會有血脂肪降低效果？\nA. Terazosin\nB. Nadolol\nC. Carteolol\nD. Verapamil\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列降壓藥物中，何者會有血脂肪降低效果？\nA. Terazosin\nB. Nadolol\nC. Carteolol\nD. Verapamil\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列降壓藥物中，何者會有血脂肪降低效果？\nA. Terazosin\nB. Nadolol\nC. Carteolol\nD. Verapamil\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列降壓藥物中，何者會有血脂肪降低效果？\nA. Terazosin\nB. Nadolol\nC. Carteolol\nD. Verapamil\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.73046875", "True"]], [["-1.734375", "False"]], [["-1.984375", "False"]], [["-1.609375", "False"]]], "filtered_resps": [["-0.73046875", "True"], ["-1.734375", "False"], ["-1.984375", "False"], ["-1.609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "457392dac4f8c3aaa4cf3f2cedc216046ded23100e11d7dfa737b83731b5085c", "prompt_hash": "3f0d000b4aa794467465a07a22746218f2cdb92b4066e44077921a10bf53ac4d", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 383, "doc": {"question": "阿斯匹靈（aspirin）可抑制血小板的活化，其作用機制為何？", "A": "甲基化 prostaglandin synthase-1，產生不可逆抑制", "B": "乙醯化 cyclooxygenase，產生不可逆抑制", "C": "乙醯化 thromboxane-A2 receptor，產生不可逆抑制", "D": "甲基化 cyclooxygenases，產生不可逆抑制", "answer": "B", "questions": "阿斯匹靈（aspirin）可抑制血小板的活化，其作用機制為何？", "choices": ["甲基化 prostaglandin synthase-1，產生不可逆抑制", "乙醯化 cyclooxygenase，產生不可逆抑制", "乙醯化 thromboxane-A2 receptor，產生不可逆抑制", "甲基化 cyclooxygenases，產生不可逆抑制"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿斯匹靈（aspirin）可抑制血小板的活化，其作用機制為何？\nA. 甲基化 prostaglandin synthase-1，產生不可逆抑制\nB. 乙醯化 cyclooxygenase，產生不可逆抑制\nC. 乙醯化 thromboxane-A2 receptor，產生不可逆抑制\nD. 甲基化 cyclooxygenases，產生不可逆抑制\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿斯匹靈（aspirin）可抑制血小板的活化，其作用機制為何？\nA. 甲基化 prostaglandin synthase-1，產生不可逆抑制\nB. 乙醯化 cyclooxygenase，產生不可逆抑制\nC. 乙醯化 thromboxane-A2 receptor，產生不可逆抑制\nD. 甲基化 cyclooxygenases，產生不可逆抑制\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿斯匹靈（aspirin）可抑制血小板的活化，其作用機制為何？\nA. 甲基化 prostaglandin synthase-1，產生不可逆抑制\nB. 乙醯化 cyclooxygenase，產生不可逆抑制\nC. 乙醯化 thromboxane-A2 receptor，產生不可逆抑制\nD. 甲基化 cyclooxygenases，產生不可逆抑制\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿斯匹靈（aspirin）可抑制血小板的活化，其作用機制為何？\nA. 甲基化 prostaglandin synthase-1，產生不可逆抑制\nB. 乙醯化 cyclooxygenase，產生不可逆抑制\nC. 乙醯化 thromboxane-A2 receptor，產生不可逆抑制\nD. 甲基化 cyclooxygenases，產生不可逆抑制\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.3125", "False"]], [["-0.07373046875", "True"]], [["-6.1875", "False"]], [["-2.953125", "False"]]], "filtered_resps": [["-4.3125", "False"], ["-0.07373046875", "True"], ["-6.1875", "False"], ["-2.953125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3e12368855ec3bcd11806ae18cfab5a7893c438897161e688cf6a1053dbbb977", "prompt_hash": "9062baf1b2aee15b93f7d6b906d2170acdcf623813fd166ca2286d3e2b007dd5", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 384, "doc": {"question": "那一種用於Supraventricular arrhythmia治療藥物最有可能誘發Atrial fibrillation之副作用？", "A": "Sotalol", "B": "Adenosine", "C": "Propranolol", "D": "Verapamil", "answer": "B", "questions": "那一種用於Supraventricular arrhythmia治療藥物最有可能誘發Atrial fibrillation之副作用？", "choices": ["Sotalol", "Adenosine", "Propranolol", "Verapamil"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種用於Supraventricular arrhythmia治療藥物最有可能誘發Atrial fibrillation之副作用？\nA. Sotalol\nB. Adenosine\nC. Propranolol\nD. Verapamil\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種用於Supraventricular arrhythmia治療藥物最有可能誘發Atrial fibrillation之副作用？\nA. Sotalol\nB. Adenosine\nC. Propranolol\nD. Verapamil\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種用於Supraventricular arrhythmia治療藥物最有可能誘發Atrial fibrillation之副作用？\nA. Sotalol\nB. Adenosine\nC. Propranolol\nD. Verapamil\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n那一種用於Supraventricular arrhythmia治療藥物最有可能誘發Atrial fibrillation之副作用？\nA. Sotalol\nB. Adenosine\nC. Propranolol\nD. Verapamil\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.90625", "False"]], [["-0.0162353515625", "True"]], [["-6.28125", "False"]], [["-4.65625", "False"]]], "filtered_resps": [["-5.90625", "False"], ["-0.0162353515625", "True"], ["-6.28125", "False"], ["-4.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4a5216fc7f23721be43f95a15b20c9071ff24faf6569a33f1fdd1c8b6dcef085", "prompt_hash": "9908fdabd0ff1784918a96a73bd4ff5007118d2f47cf8557bf8e79e70ee80f9d", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 385, "doc": {"question": "Liddle's syndrome為一種顯性遺傳疾病，促進腎臟對鈉離子回收及鉀離子釋出，下列何種利尿劑最適合緩解此病症？", "A": "acetazolamide", "B": "spironolactone", "C": "amiloride", "D": "furosemide", "answer": "C", "questions": "Liddle's syndrome為一種顯性遺傳疾病，促進腎臟對鈉離子回收及鉀離子釋出，下列何種利尿劑最適合緩解此病症？", "choices": ["acetazolamide", "spironolactone", "amiloride", "furosemide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLiddle's syndrome為一種顯性遺傳疾病，促進腎臟對鈉離子回收及鉀離子釋出，下列何種利尿劑最適合緩解此病症？\nA. acetazolamide\nB. spironolactone\nC. amiloride\nD. furosemide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLiddle's syndrome為一種顯性遺傳疾病，促進腎臟對鈉離子回收及鉀離子釋出，下列何種利尿劑最適合緩解此病症？\nA. acetazolamide\nB. spironolactone\nC. amiloride\nD. furosemide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLiddle's syndrome為一種顯性遺傳疾病，促進腎臟對鈉離子回收及鉀離子釋出，下列何種利尿劑最適合緩解此病症？\nA. acetazolamide\nB. spironolactone\nC. amiloride\nD. furosemide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLiddle's syndrome為一種顯性遺傳疾病，促進腎臟對鈉離子回收及鉀離子釋出，下列何種利尿劑最適合緩解此病症？\nA. acetazolamide\nB. spironolactone\nC. amiloride\nD. furosemide\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.375", "False"]], [["-0.263671875", "True"]], [["-1.515625", "False"]], [["-4.875", "False"]]], "filtered_resps": [["-6.375", "False"], ["-0.263671875", "True"], ["-1.515625", "False"], ["-4.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a6a5872b7212b9502c88aabc2f35943acaf811f136ed0e8f4ba76095c25ad124", "prompt_hash": "777ef47d05d41e073e1586fb9c6696a17eb8b065486fb22048bd17fed2732884", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 386, "doc": {"question": "下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子?", "A": "tiludronate", "B": "pamidronate", "C": "risedronate", "D": "ibandronate", "answer": "A", "questions": "下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子?", "choices": ["tiludronate", "pamidronate", "risedronate", "ibandronate"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子?\nA. tiludronate\nB. pamidronate\nC. risedronate\nD. ibandronate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子?\nA. tiludronate\nB. pamidronate\nC. risedronate\nD. ibandronate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子?\nA. tiludronate\nB. pamidronate\nC. risedronate\nD. ibandronate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子?\nA. tiludronate\nB. pamidronate\nC. risedronate\nD. ibandronate\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.11962890625", "True"]], [["-3.75", "False"]], [["-3.625", "False"]], [["-2.875", "False"]]], "filtered_resps": [["-0.11962890625", "True"], ["-3.75", "False"], ["-3.625", "False"], ["-2.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "da331fd1ac7ed616f9e2fdb295d0513a20625b7aad46d6f1f05c6ade2c05cfb1", "prompt_hash": "f8bc2e400700c0a76d18f573429c56de65297beede855267c172aab416714d4a", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 387, "doc": {"question": "下列adrenergic agonists中，何者最易受COMT代謝？", "A": "formoterol", "B": "albuterol", "C": "isoetharine", "D": "terbutaline", "answer": "C", "questions": "下列adrenergic agonists中，何者最易受COMT代謝？", "choices": ["formoterol", "albuterol", "isoetharine", "terbutaline"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列adrenergic agonists中，何者最易受COMT代謝？\nA. formoterol\nB. albuterol\nC. isoetharine\nD. terbutaline\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列adrenergic agonists中，何者最易受COMT代謝？\nA. formoterol\nB. albuterol\nC. isoetharine\nD. terbutaline\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列adrenergic agonists中，何者最易受COMT代謝？\nA. formoterol\nB. albuterol\nC. isoetharine\nD. terbutaline\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列adrenergic agonists中，何者最易受COMT代謝？\nA. formoterol\nB. albuterol\nC. isoetharine\nD. terbutaline\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.25", "False"]], [["-3.5", "False"]], [["-0.12109375", "True"]], [["-3.125", "False"]]], "filtered_resps": [["-3.25", "False"], ["-3.5", "False"], ["-0.12109375", "True"], ["-3.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0b3b7b0c5b5dbf776190d152546bf32f96d4b96de8d98117e851e31a0701c055", "prompt_hash": "a8aae408557699fe7bcb489758c6608dfae7d4684c18fd097409b902fe0be616", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 388, "doc": {"question": "下列antimuscarinic drug之點眼劑，何者之散瞳作用時間最短？", "A": "homatropine", "B": "atropine", "C": "scopolamine", "D": "tropicamide", "answer": "D", "questions": "下列antimuscarinic drug之點眼劑，何者之散瞳作用時間最短？", "choices": ["homatropine", "atropine", "scopolamine", "tropicamide"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列antimuscarinic drug之點眼劑，何者之散瞳作用時間最短？\nA. homatropine\nB. atropine\nC. scopolamine\nD. tropicamide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列antimuscarinic drug之點眼劑，何者之散瞳作用時間最短？\nA. homatropine\nB. atropine\nC. scopolamine\nD. tropicamide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列antimuscarinic drug之點眼劑，何者之散瞳作用時間最短？\nA. homatropine\nB. atropine\nC. scopolamine\nD. tropicamide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列antimuscarinic drug之點眼劑，何者之散瞳作用時間最短？\nA. homatropine\nB. atropine\nC. scopolamine\nD. tropicamide\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.25", "False"]], [["-7.0", "False"]], [["-7.5", "False"]], [["-0.00445556640625", "True"]]], "filtered_resps": [["-6.25", "False"], ["-7.0", "False"], ["-7.5", "False"], ["-0.00445556640625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "68ec3325e178444b0794673a2f10a7adbb278df5aaf21a48ec1c558b4149dc75", "prompt_hash": "b68df9e309ca3d043304ca65c08209a100ee888d94f9d2dfe7f2c1bb2d4d17c3", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 389, "doc": {"question": "下列何種藥物可抑制黴菌之Squalene epoxidase，影響細胞膜麥角固醇生合成，而達到殺菌作用？", "A": "Amphotericin B", "B": "Micafungin", "C": "Terbinafine", "D": "Itraconazole", "answer": "C", "questions": "下列何種藥物可抑制黴菌之Squalene epoxidase，影響細胞膜麥角固醇生合成，而達到殺菌作用？", "choices": ["Amphotericin B", "Micafungin", "Terbinafine", "Itraconazole"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可抑制黴菌之Squalene epoxidase，影響細胞膜麥角固醇生合成，而達到殺菌作用？\nA. Amphotericin B\nB. Micafungin\nC. Terbinafine\nD. Itraconazole\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可抑制黴菌之Squalene epoxidase，影響細胞膜麥角固醇生合成，而達到殺菌作用？\nA. Amphotericin B\nB. Micafungin\nC. Terbinafine\nD. Itraconazole\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可抑制黴菌之Squalene epoxidase，影響細胞膜麥角固醇生合成，而達到殺菌作用？\nA. Amphotericin B\nB. Micafungin\nC. Terbinafine\nD. Itraconazole\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物可抑制黴菌之Squalene epoxidase，影響細胞膜麥角固醇生合成，而達到殺菌作用？\nA. Amphotericin B\nB. Micafungin\nC. Terbinafine\nD. Itraconazole\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.5", "False"]], [["-5.375", "False"]], [["-0.236328125", "True"]], [["-1.609375", "False"]]], "filtered_resps": [["-5.5", "False"], ["-5.375", "False"], ["-0.236328125", "True"], ["-1.609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a48eb977e1b36317dc38c4fb1a17db12aed90ab32567a993339a029e5ca2376f", "prompt_hash": "8ac41ba799677597521e12ea62f8997ff8397d3ae08b467b881520c02e327cde", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 390, "doc": {"question": "下列有關Aspirin之敘述，何者錯誤？", "A": "抑制cyclooxygenase主要來自其水解產物salicylate之作用", "B": "可用於預防心肌梗塞", "C": "抑制血小板凝集與抑制thromboxane A2之形成有關", "D": "不可逆地抑制血小板cyclooxygenase-1活性", "answer": "A", "questions": "下列有關Aspirin之敘述，何者錯誤？", "choices": ["抑制cyclooxygenase主要來自其水解產物salicylate之作用", "可用於預防心肌梗塞", "抑制血小板凝集與抑制thromboxane A2之形成有關", "不可逆地抑制血小板cyclooxygenase-1活性"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Aspirin之敘述，何者錯誤？\nA. 抑制cyclooxygenase主要來自其水解產物salicylate之作用\nB. 可用於預防心肌梗塞\nC. 抑制血小板凝集與抑制thromboxane A2之形成有關\nD. 不可逆地抑制血小板cyclooxygenase-1活性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Aspirin之敘述，何者錯誤？\nA. 抑制cyclooxygenase主要來自其水解產物salicylate之作用\nB. 可用於預防心肌梗塞\nC. 抑制血小板凝集與抑制thromboxane A2之形成有關\nD. 不可逆地抑制血小板cyclooxygenase-1活性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Aspirin之敘述，何者錯誤？\nA. 抑制cyclooxygenase主要來自其水解產物salicylate之作用\nB. 可用於預防心肌梗塞\nC. 抑制血小板凝集與抑制thromboxane A2之形成有關\nD. 不可逆地抑制血小板cyclooxygenase-1活性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Aspirin之敘述，何者錯誤？\nA. 抑制cyclooxygenase主要來自其水解產物salicylate之作用\nB. 可用於預防心肌梗塞\nC. 抑制血小板凝集與抑制thromboxane A2之形成有關\nD. 不可逆地抑制血小板cyclooxygenase-1活性\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.10888671875", "True"]], [["-3.484375", "False"]], [["-5.21875", "False"]], [["-2.734375", "False"]]], "filtered_resps": [["-0.10888671875", "True"], ["-3.484375", "False"], ["-5.21875", "False"], ["-2.734375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a2e50920c703c7613e1a3deb2fdcde35244d47195304dff8e4d7e85acd24dd66", "prompt_hash": "bdd01e36937ec10edddeeeb8464975c949168b85d425415d73b67d3fe7f6fe0b", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 391, "doc": {"question": "下列何種藥物最適用於心絞痛之急性發作（acute episode）？", "A": "nitroglycerin", "B": "nifedipine", "C": "diltiazem", "D": "propranolol", "answer": "A", "questions": "下列何種藥物最適用於心絞痛之急性發作（acute episode）？", "choices": ["nitroglycerin", "nifedipine", "diltiazem", "propranolol"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物最適用於心絞痛之急性發作（acute episode）？\nA. nitroglycerin\nB. nifedipine\nC. diltiazem\nD. propranolol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物最適用於心絞痛之急性發作（acute episode）？\nA. nitroglycerin\nB. nifedipine\nC. diltiazem\nD. propranolol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物最適用於心絞痛之急性發作（acute episode）？\nA. nitroglycerin\nB. nifedipine\nC. diltiazem\nD. propranolol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物最適用於心絞痛之急性發作（acute episode）？\nA. nitroglycerin\nB. nifedipine\nC. diltiazem\nD. propranolol\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0302734375", "True"]], [["-4.65625", "False"]], [["-5.53125", "False"]], [["-4.40625", "False"]]], "filtered_resps": [["-0.0302734375", "True"], ["-4.65625", "False"], ["-5.53125", "False"], ["-4.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bd8a85c4e797a75329ea15e319d7db2e07aaf3edab8898948c2e3f9895b2f448", "prompt_hash": "20b9c9e8784887a21c7a6dd1076b095e8e8858e476b2dd8181f888a472b08bcd", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 392, "doc": {"question": "下列何者不是經由cAMP之訊息傳遞途徑？", "A": "α-交感神經致效劑之血管收縮作用", "B": "副甲狀腺荷爾蒙調控鈣離子之平衡", "C": "β-交感神經致效劑調控心肌收縮", "D": "vasopressin在腎臟中保持水分", "answer": "A", "questions": "下列何者不是經由cAMP之訊息傳遞途徑？", "choices": ["α-交感神經致效劑之血管收縮作用", "副甲狀腺荷爾蒙調控鈣離子之平衡", "β-交感神經致效劑調控心肌收縮", "vasopressin在腎臟中保持水分"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是經由cAMP之訊息傳遞途徑？\nA. α-交感神經致效劑之血管收縮作用\nB. 副甲狀腺荷爾蒙調控鈣離子之平衡\nC. β-交感神經致效劑調控心肌收縮\nD. vasopressin在腎臟中保持水分\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是經由cAMP之訊息傳遞途徑？\nA. α-交感神經致效劑之血管收縮作用\nB. 副甲狀腺荷爾蒙調控鈣離子之平衡\nC. β-交感神經致效劑調控心肌收縮\nD. vasopressin在腎臟中保持水分\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是經由cAMP之訊息傳遞途徑？\nA. α-交感神經致效劑之血管收縮作用\nB. 副甲狀腺荷爾蒙調控鈣離子之平衡\nC. β-交感神經致效劑調控心肌收縮\nD. vasopressin在腎臟中保持水分\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是經由cAMP之訊息傳遞途徑？\nA. α-交感神經致效劑之血管收縮作用\nB. 副甲狀腺荷爾蒙調控鈣離子之平衡\nC. β-交感神經致效劑調控心肌收縮\nD. vasopressin在腎臟中保持水分\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.07470703125", "True"]], [["-4.1875", "False"]], [["-5.5625", "False"]], [["-2.953125", "False"]]], "filtered_resps": [["-0.07470703125", "True"], ["-4.1875", "False"], ["-5.5625", "False"], ["-2.953125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ce2860f57916b022b99b65de669b4f35d6cec29013d6efa604a4d9922e76dcf2", "prompt_hash": "b72742d64edbb87b4900c381a565cc203e025e27c0c67559484ba31cc7ca01ce", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 393, "doc": {"question": "下列何種抗心絞痛藥物最可能會使病人之心臟舒張期體積增加，並且使心臟血液射出之時間（ejection time）延長？", "A": "Atenolol", "B": "Nitroglycerin", "C": "Nifedipine", "D": "Amyl nitrite", "answer": "A", "questions": "下列何種抗心絞痛藥物最可能會使病人之心臟舒張期體積增加，並且使心臟血液射出之時間（ejection time）延長？", "choices": ["Atenolol", "Nitroglycerin", "Nifedipine", "Amyl nitrite"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗心絞痛藥物最可能會使病人之心臟舒張期體積增加，並且使心臟血液射出之時間（ejection time）延長？\nA. Atenolol\nB. Nitroglycerin\nC. Nifedipine\nD. Amyl nitrite\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗心絞痛藥物最可能會使病人之心臟舒張期體積增加，並且使心臟血液射出之時間（ejection time）延長？\nA. Atenolol\nB. Nitroglycerin\nC. Nifedipine\nD. Amyl nitrite\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗心絞痛藥物最可能會使病人之心臟舒張期體積增加，並且使心臟血液射出之時間（ejection time）延長？\nA. Atenolol\nB. Nitroglycerin\nC. Nifedipine\nD. Amyl nitrite\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗心絞痛藥物最可能會使病人之心臟舒張期體積增加，並且使心臟血液射出之時間（ejection time）延長？\nA. Atenolol\nB. Nitroglycerin\nC. Nifedipine\nD. Amyl nitrite\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.353515625", "True"]], [["-2.109375", "False"]], [["-2.359375", "False"]], [["-2.609375", "False"]]], "filtered_resps": [["-0.353515625", "True"], ["-2.109375", "False"], ["-2.359375", "False"], ["-2.609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d16290320384c573507557b6fd71653c4a0756e2185e35124feca900c33ec157", "prompt_hash": "95371cfdfb3dc78011c257de9e10310960004388de99f222dae52433258b1ea1", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 394, "doc": {"question": "下列有關類固醇型雄性激素（steroidal androgen）的結構與活性關係之敘述，何者錯誤？", "A": "修飾成5β-H後，仍具有雄性激素活性", "B": "修飾成3α-OH後，可增加雄性激素活性", "C": "修飾成17α-OH後，會失去雄性激素活性", "D": "第3位置ketone取代為非必要結構", "answer": "A", "questions": "下列有關類固醇型雄性激素（steroidal androgen）的結構與活性關係之敘述，何者錯誤？", "choices": ["修飾成5β-H後，仍具有雄性激素活性", "修飾成3α-OH後，可增加雄性激素活性", "修飾成17α-OH後，會失去雄性激素活性", "第3位置ketone取代為非必要結構"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關類固醇型雄性激素（steroidal androgen）的結構與活性關係之敘述，何者錯誤？\nA. 修飾成5β-H後，仍具有雄性激素活性\nB. 修飾成3α-OH後，可增加雄性激素活性\nC. 修飾成17α-OH後，會失去雄性激素活性\nD. 第3位置ketone取代為非必要結構\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關類固醇型雄性激素（steroidal androgen）的結構與活性關係之敘述，何者錯誤？\nA. 修飾成5β-H後，仍具有雄性激素活性\nB. 修飾成3α-OH後，可增加雄性激素活性\nC. 修飾成17α-OH後，會失去雄性激素活性\nD. 第3位置ketone取代為非必要結構\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關類固醇型雄性激素（steroidal androgen）的結構與活性關係之敘述，何者錯誤？\nA. 修飾成5β-H後，仍具有雄性激素活性\nB. 修飾成3α-OH後，可增加雄性激素活性\nC. 修飾成17α-OH後，會失去雄性激素活性\nD. 第3位置ketone取代為非必要結構\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關類固醇型雄性激素（steroidal androgen）的結構與活性關係之敘述，何者錯誤？\nA. 修飾成5β-H後，仍具有雄性激素活性\nB. 修飾成3α-OH後，可增加雄性激素活性\nC. 修飾成17α-OH後，會失去雄性激素活性\nD. 第3位置ketone取代為非必要結構\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.384765625", "True"]], [["-1.3828125", "False"]], [["-3.515625", "False"]], [["-3.265625", "False"]]], "filtered_resps": [["-0.384765625", "True"], ["-1.3828125", "False"], ["-3.515625", "False"], ["-3.265625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d60098600be31ca45f6d1ff4b29c927eca1badf62584f9e18695fac39b4d1263", "prompt_hash": "c31df83128b1e5ed6a5ce011e91fb1839c1eea73822041b89e496bbf69d9d7f3", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 395, "doc": {"question": "關於hydralazine應用於治療嚴重高血壓及妊娠高血壓之敘述，下列何者正確？", "A": "主要對小動脈（arterioles）而非對靜脈，產生血管舒張作用", "B": "對缺血性心臟病高血壓病人，不會產生心絞痛或心律不整", "C": "經由減少cGMP及cAMP代謝，產生血管舒張作用", "D": "不需經由肝臟代謝成有效成分，無首渡效應，高生物可用率", "answer": "A", "questions": "關於hydralazine應用於治療嚴重高血壓及妊娠高血壓之敘述，下列何者正確？", "choices": ["主要對小動脈（arterioles）而非對靜脈，產生血管舒張作用", "對缺血性心臟病高血壓病人，不會產生心絞痛或心律不整", "經由減少cGMP及cAMP代謝，產生血管舒張作用", "不需經由肝臟代謝成有效成分，無首渡效應，高生物可用率"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於hydralazine應用於治療嚴重高血壓及妊娠高血壓之敘述，下列何者正確？\nA. 主要對小動脈（arterioles）而非對靜脈，產生血管舒張作用\nB. 對缺血性心臟病高血壓病人，不會產生心絞痛或心律不整\nC. 經由減少cGMP及cAMP代謝，產生血管舒張作用\nD. 不需經由肝臟代謝成有效成分，無首渡效應，高生物可用率\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於hydralazine應用於治療嚴重高血壓及妊娠高血壓之敘述，下列何者正確？\nA. 主要對小動脈（arterioles）而非對靜脈，產生血管舒張作用\nB. 對缺血性心臟病高血壓病人，不會產生心絞痛或心律不整\nC. 經由減少cGMP及cAMP代謝，產生血管舒張作用\nD. 不需經由肝臟代謝成有效成分，無首渡效應，高生物可用率\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於hydralazine應用於治療嚴重高血壓及妊娠高血壓之敘述，下列何者正確？\nA. 主要對小動脈（arterioles）而非對靜脈，產生血管舒張作用\nB. 對缺血性心臟病高血壓病人，不會產生心絞痛或心律不整\nC. 經由減少cGMP及cAMP代謝，產生血管舒張作用\nD. 不需經由肝臟代謝成有效成分，無首渡效應，高生物可用率\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於hydralazine應用於治療嚴重高血壓及妊娠高血壓之敘述，下列何者正確？\nA. 主要對小動脈（arterioles）而非對靜脈，產生血管舒張作用\nB. 對缺血性心臟病高血壓病人，不會產生心絞痛或心律不整\nC. 經由減少cGMP及cAMP代謝，產生血管舒張作用\nD. 不需經由肝臟代謝成有效成分，無首渡效應，高生物可用率\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.279296875", "True"]], [["-2.78125", "False"]], [["-3.03125", "False"]], [["-2.03125", "False"]]], "filtered_resps": [["-0.279296875", "True"], ["-2.78125", "False"], ["-3.03125", "False"], ["-2.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9fa009e2be4b5d6642ad0ee2fcf668d57075ef53707e5c791e27bdcde315c58f", "prompt_hash": "0518e0672852c895e48eea87f79189aaa2f9745a9f12549ac465f5b385b4ecab", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 396, "doc": {"question": "下列藥物何者可與phenothiazine合用，加強止吐作用及減少副作用？", "A": "ondansetron", "B": "dronabinol", "C": "meclizine", "D": "metoclopramide", "answer": "B", "questions": "下列藥物何者可與phenothiazine合用，加強止吐作用及減少副作用？", "choices": ["ondansetron", "dronabinol", "meclizine", "metoclopramide"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者可與phenothiazine合用，加強止吐作用及減少副作用？\nA. ondansetron\nB. dronabinol\nC. meclizine\nD. metoclopramide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者可與phenothiazine合用，加強止吐作用及減少副作用？\nA. ondansetron\nB. dronabinol\nC. meclizine\nD. metoclopramide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者可與phenothiazine合用，加強止吐作用及減少副作用？\nA. ondansetron\nB. dronabinol\nC. meclizine\nD. metoclopramide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者可與phenothiazine合用，加強止吐作用及減少副作用？\nA. ondansetron\nB. dronabinol\nC. meclizine\nD. metoclopramide\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.1875", "False"]], [["-0.047119140625", "True"]], [["-3.796875", "False"]], [["-4.1875", "False"]]], "filtered_resps": [["-5.1875", "False"], ["-0.047119140625", "True"], ["-3.796875", "False"], ["-4.1875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7d61536e119fdf109098e3337cc299a4b7545cf946e95826da1690e810b9c5df", "prompt_hash": "ec3d5a3a23b96bf8ae5877ac6d7c1e7aa762074a3427ff32099dac708e9cfffb", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 397, "doc": {"question": "下列何種藥物是藉由調控T細胞活性來抑制腫瘤生長？", "A": "rituximab", "B": "trastuzumab", "C": "bevacizumab", "D": "nivolumab", "answer": "D", "questions": "下列何種藥物是藉由調控T細胞活性來抑制腫瘤生長？", "choices": ["rituximab", "trastuzumab", "bevacizumab", "nivolumab"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物是藉由調控T細胞活性來抑制腫瘤生長？\nA. rituximab\nB. trastuzumab\nC. bevacizumab\nD. nivolumab\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物是藉由調控T細胞活性來抑制腫瘤生長？\nA. rituximab\nB. trastuzumab\nC. bevacizumab\nD. nivolumab\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物是藉由調控T細胞活性來抑制腫瘤生長？\nA. rituximab\nB. trastuzumab\nC. bevacizumab\nD. nivolumab\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物是藉由調控T細胞活性來抑制腫瘤生長？\nA. rituximab\nB. trastuzumab\nC. bevacizumab\nD. nivolumab\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.875", "False"]], [["-6.375", "False"]], [["-6.75", "False"]], [["-0.01171875", "True"]]], "filtered_resps": [["-4.875", "False"], ["-6.375", "False"], ["-6.75", "False"], ["-0.01171875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b0a4ca9e5e1731aa412b2d83a1034e6ef85c0e3fe58432219dfd6ea38b6994fa", "prompt_hash": "86bf547166fe1d41cb711e0e2361e19676efd38bca2cc07aa449018ea5816f0f", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 398, "doc": {"question": "下列藥物何者不是直接進入癌細胞內產生毒殺作用？", "A": "cyclophosphamide", "B": "gemcitabine", "C": "atezolizumab", "D": "oxaliplatin", "answer": "C", "questions": "下列藥物何者不是直接進入癌細胞內產生毒殺作用？", "choices": ["cyclophosphamide", "gemcitabine", "atezolizumab", "oxaliplatin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不是直接進入癌細胞內產生毒殺作用？\nA. cyclophosphamide\nB. gemcitabine\nC. atezolizumab\nD. oxaliplatin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不是直接進入癌細胞內產生毒殺作用？\nA. cyclophosphamide\nB. gemcitabine\nC. atezolizumab\nD. oxaliplatin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不是直接進入癌細胞內產生毒殺作用？\nA. cyclophosphamide\nB. gemcitabine\nC. atezolizumab\nD. oxaliplatin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物何者不是直接進入癌細胞內產生毒殺作用？\nA. cyclophosphamide\nB. gemcitabine\nC. atezolizumab\nD. oxaliplatin\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.65625", "False"]], [["-6.03125", "False"]], [["-0.018310546875", "True"]], [["-4.90625", "False"]]], "filtered_resps": [["-6.65625", "False"], ["-6.03125", "False"], ["-0.018310546875", "True"], ["-4.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "784f3cda26fbfeaeb07e19ad6b5dbadad55139c8ac6164385a7ddc90a04fe025", "prompt_hash": "d8651b7fa82c67180150d0cca258bd23f322710e47134f308becde44b812ea33", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 399, "doc": {"question": "下列藥物，何者屬擬肽（peptidomimetic）物？", "A": "tirofiban", "B": "apixaban", "C": "argatroban", "D": "dabigatran", "answer": "C", "questions": "下列藥物，何者屬擬肽（peptidomimetic）物？", "choices": ["tirofiban", "apixaban", "argatroban", "dabigatran"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者屬擬肽（peptidomimetic）物？\nA. tirofiban\nB. apixaban\nC. argatroban\nD. dabigatran\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者屬擬肽（peptidomimetic）物？\nA. tirofiban\nB. apixaban\nC. argatroban\nD. dabigatran\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者屬擬肽（peptidomimetic）物？\nA. tirofiban\nB. apixaban\nC. argatroban\nD. dabigatran\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者屬擬肽（peptidomimetic）物？\nA. tirofiban\nB. apixaban\nC. argatroban\nD. dabigatran\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.78125", "False"]], [["-6.53125", "False"]], [["-0.01708984375", "True"]], [["-6.03125", "False"]]], "filtered_resps": [["-4.78125", "False"], ["-6.53125", "False"], ["-0.01708984375", "True"], ["-6.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c22645da0dc9ecfdd70d31e3e620bb960ec42b7b185e81a3dc71d6f4fdcebba1", "prompt_hash": "6c6f44d7a08493e04fbf10d4b031af91a28cfdf3808125cab8a0b9a585cc95f7", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 400, "doc": {"question": "下列關於服用nortriptyline所產生之副作用，何者錯誤？", "A": "視覺模糊（blurred vision）", "B": "血壓升高", "C": "便秘", "D": "心律不整", "answer": "B", "questions": "下列關於服用nortriptyline所產生之副作用，何者錯誤？", "choices": ["視覺模糊（blurred vision）", "血壓升高", "便秘", "心律不整"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於服用nortriptyline所產生之副作用，何者錯誤？\nA. 視覺模糊（blurred vision）\nB. 血壓升高\nC. 便秘\nD. 心律不整\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於服用nortriptyline所產生之副作用，何者錯誤？\nA. 視覺模糊（blurred vision）\nB. 血壓升高\nC. 便秘\nD. 心律不整\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於服用nortriptyline所產生之副作用，何者錯誤？\nA. 視覺模糊（blurred vision）\nB. 血壓升高\nC. 便秘\nD. 心律不整\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於服用nortriptyline所產生之副作用，何者錯誤？\nA. 視覺模糊（blurred vision）\nB. 血壓升高\nC. 便秘\nD. 心律不整\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.28125", "False"]], [["-0.0159912109375", "True"]], [["-5.90625", "False"]], [["-4.53125", "False"]]], "filtered_resps": [["-6.28125", "False"], ["-0.0159912109375", "True"], ["-5.90625", "False"], ["-4.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a087f4500b52aed5ee9282747e9913ce921de94328039656f4383c46039b7ec5", "prompt_hash": "4974e70c7812c0d689800f0e6620a3e3c0fc3b72c45e9f6dac02c4e698c3365d", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 401, "doc": {"question": "下列青黴素（penicillins）中，何者對penicillinase穩定且可口服？", "A": "carbenicillin", "B": "oxacillin", "C": "ampicillin", "D": "methicillin", "answer": "B", "questions": "下列青黴素（penicillins）中，何者對penicillinase穩定且可口服？", "choices": ["carbenicillin", "oxacillin", "ampicillin", "methicillin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列青黴素（penicillins）中，何者對penicillinase穩定且可口服？\nA. carbenicillin\nB. oxacillin\nC. ampicillin\nD. methicillin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列青黴素（penicillins）中，何者對penicillinase穩定且可口服？\nA. carbenicillin\nB. oxacillin\nC. ampicillin\nD. methicillin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列青黴素（penicillins）中，何者對penicillinase穩定且可口服？\nA. carbenicillin\nB. oxacillin\nC. ampicillin\nD. methicillin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列青黴素（penicillins）中，何者對penicillinase穩定且可口服？\nA. carbenicillin\nB. oxacillin\nC. ampicillin\nD. methicillin\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.828125", "False"]], [["-0.08154296875", "True"]], [["-5.34375", "False"]], [["-4.84375", "False"]]], "filtered_resps": [["-2.828125", "False"], ["-0.08154296875", "True"], ["-5.34375", "False"], ["-4.84375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "04ea9d9548d0825bea858cdd4958169307db1a4b2a6b0e6027b661e314af26ba", "prompt_hash": "ce4b82624f257891998bd4fcbaa29789a1cbfe2dab78a0b422f840aafcfbeec3", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 402, "doc": {"question": "擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1 受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？", "A": "phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失", "B": "phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失", "C": "phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣", "D": "phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣", "answer": "A", "questions": "擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1 受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？", "choices": ["phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失", "phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失", "phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣", "phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1 受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？\nA. phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失\nB. phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失\nC. phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣\nD. phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1 受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？\nA. phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失\nB. phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失\nC. phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣\nD. phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1 受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？\nA. phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失\nB. phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失\nC. phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣\nD. phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬交感神經作用劑 phenylephrine 投與後，可因為活化血管壁上 alpha1 受體誘發血壓上升和接續之反射性心跳下降現象，前述現象會因為前處理神經節拮抗劑 trimethaphan 而有何變化？\nA. phenylephrine 誘發之血壓上升顯著加劇，但反射性心跳下降消失\nB. phenylephrine 誘發之血壓上升消失，反射性心跳下降也消失\nC. phenylephrine 誘發之血壓上升程度一樣，反射性心跳下降程度一樣\nD. phenylephrine 誘發之血壓上升消失，但反射性心跳下降程度一樣\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.380859375", "True"]], [["-1.7578125", "False"]], [["-3.375", "False"]], [["-2.25", "False"]]], "filtered_resps": [["-0.380859375", "True"], ["-1.7578125", "False"], ["-3.375", "False"], ["-2.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8ee191b6178c972815a893bb0f687381ffc267557d975418a9c7c64daa008e4f", "prompt_hash": "7c137f66c813277dd4ee3c7a69b24bf7e775c603c7da20d2a37fb56d08bd1b30", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 403, "doc": {"question": "臨床上lopinavir常併用ritonavir，最主要目的為何？", "A": "降低毒性", "B": "增加溶解度", "C": "延緩代謝", "D": "降低抗藥性", "answer": "C", "questions": "臨床上lopinavir常併用ritonavir，最主要目的為何？", "choices": ["降低毒性", "增加溶解度", "延緩代謝", "降低抗藥性"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上lopinavir常併用ritonavir，最主要目的為何？\nA. 降低毒性\nB. 增加溶解度\nC. 延緩代謝\nD. 降低抗藥性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上lopinavir常併用ritonavir，最主要目的為何？\nA. 降低毒性\nB. 增加溶解度\nC. 延緩代謝\nD. 降低抗藥性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上lopinavir常併用ritonavir，最主要目的為何？\nA. 降低毒性\nB. 增加溶解度\nC. 延緩代謝\nD. 降低抗藥性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上lopinavir常併用ritonavir，最主要目的為何？\nA. 降低毒性\nB. 增加溶解度\nC. 延緩代謝\nD. 降低抗藥性\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.28125", "False"]], [["-8.5", "False"]], [["-0.029052734375", "True"]], [["-4.28125", "False"]]], "filtered_resps": [["-4.28125", "False"], ["-8.5", "False"], ["-0.029052734375", "True"], ["-4.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4178fb52996c818c6e5f842e54aaa5c6fba1f203c5e1b40d045fbf7bedd5d907", "prompt_hash": "0399f2df2d48e767fb5e21cf66a8d4c963f8d1835ce1c277f455ba50438460da", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 404, "doc": {"question": "在藥物結構修飾中，加入一個phenyl基團對於藥物分子脂溶性的影響為何？", "A": "不改變", "B": "約增加100倍", "C": "約增加1倍", "D": "約增加10倍", "answer": "B", "questions": "在藥物結構修飾中，加入一個phenyl基團對於藥物分子脂溶性的影響為何？", "choices": ["不改變", "約增加100倍", "約增加1倍", "約增加10倍"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在藥物結構修飾中，加入一個phenyl基團對於藥物分子脂溶性的影響為何？\nA. 不改變\nB. 約增加100倍\nC. 約增加1倍\nD. 約增加10倍\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在藥物結構修飾中，加入一個phenyl基團對於藥物分子脂溶性的影響為何？\nA. 不改變\nB. 約增加100倍\nC. 約增加1倍\nD. 約增加10倍\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在藥物結構修飾中，加入一個phenyl基團對於藥物分子脂溶性的影響為何？\nA. 不改變\nB. 約增加100倍\nC. 約增加1倍\nD. 約增加10倍\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在藥物結構修飾中，加入一個phenyl基團對於藥物分子脂溶性的影響為何？\nA. 不改變\nB. 約增加100倍\nC. 約增加1倍\nD. 約增加10倍\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.21875", "False"]], [["-2.09375", "False"]], [["-2.84375", "False"]], [["-0.2216796875", "True"]]], "filtered_resps": [["-4.21875", "False"], ["-2.09375", "False"], ["-2.84375", "False"], ["-0.2216796875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "95969070049177a0931c11331fe5a0a48e6fc0710e1993a4610d6d3002ebcf64", "prompt_hash": "8406a4cc92f312f60f4680e18ab03f739eee279e2f8490a2cdb618b0e4b181b1", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 405, "doc": {"question": "下列可用於治療多發性硬化症（multiple sclerosis）的藥物中，何者為前驅藥？", "A": "ocrelizumab", "B": "dalfampridine", "C": "fingolimod", "D": "glatiramer", "answer": "C", "questions": "下列可用於治療多發性硬化症（multiple sclerosis）的藥物中，何者為前驅藥？", "choices": ["ocrelizumab", "dalfampridine", "fingolimod", "glatiramer"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列可用於治療多發性硬化症（multiple sclerosis）的藥物中，何者為前驅藥？\nA. ocrelizumab\nB. dalfampridine\nC. fingolimod\nD. glatiramer\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列可用於治療多發性硬化症（multiple sclerosis）的藥物中，何者為前驅藥？\nA. ocrelizumab\nB. dalfampridine\nC. fingolimod\nD. glatiramer\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列可用於治療多發性硬化症（multiple sclerosis）的藥物中，何者為前驅藥？\nA. ocrelizumab\nB. dalfampridine\nC. fingolimod\nD. glatiramer\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列可用於治療多發性硬化症（multiple sclerosis）的藥物中，何者為前驅藥？\nA. ocrelizumab\nB. dalfampridine\nC. fingolimod\nD. glatiramer\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.5", "False"]], [["-1.625", "False"]], [["-0.248046875", "True"]], [["-4.25", "False"]]], "filtered_resps": [["-5.5", "False"], ["-1.625", "False"], ["-0.248046875", "True"], ["-4.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "be35373e9e29c529f5200709225ff96cb7f562b6339fcf1e531f665838a67e5d", "prompt_hash": "322eb4b0fa5971ff75871af20e45db2e8c28c1bc5b74c0862a4d77700153bd17", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 406, "doc": {"question": "下列有關放射碘之敘述，何者錯誤？", "A": "131I可治療甲狀腺癌", "B": "131I與 125I衰變時皆會產生γ射線", "C": "125I可藉由電子補獲（electronic capture）衰變為125Te", "D": "131I半衰期為60天", "answer": "D", "questions": "下列有關放射碘之敘述，何者錯誤？", "choices": ["131I可治療甲狀腺癌", "131I與 125I衰變時皆會產生γ射線", "125I可藉由電子補獲（electronic capture）衰變為125Te", "131I半衰期為60天"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關放射碘之敘述，何者錯誤？\nA. 131I可治療甲狀腺癌\nB. 131I與 125I衰變時皆會產生γ射線\nC. 125I可藉由電子補獲（electronic capture）衰變為125Te\nD. 131I半衰期為60天\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關放射碘之敘述，何者錯誤？\nA. 131I可治療甲狀腺癌\nB. 131I與 125I衰變時皆會產生γ射線\nC. 125I可藉由電子補獲（electronic capture）衰變為125Te\nD. 131I半衰期為60天\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關放射碘之敘述，何者錯誤？\nA. 131I可治療甲狀腺癌\nB. 131I與 125I衰變時皆會產生γ射線\nC. 125I可藉由電子補獲（electronic capture）衰變為125Te\nD. 131I半衰期為60天\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關放射碘之敘述，何者錯誤？\nA. 131I可治療甲狀腺癌\nB. 131I與 125I衰變時皆會產生γ射線\nC. 125I可藉由電子補獲（electronic capture）衰變為125Te\nD. 131I半衰期為60天\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.5625", "False"]], [["-3.328125", "False"]], [["-3.703125", "False"]], [["-0.07373046875", "True"]]], "filtered_resps": [["-4.5625", "False"], ["-3.328125", "False"], ["-3.703125", "False"], ["-0.07373046875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e5814f6b48c41b7d2f8a2e2ce0c53b0009e7015130cf97f3e51ddb875a91c9bc", "prompt_hash": "4b1dede8b122e97f3b22ecba1211d36b49b389d6c57bbf81f97b860ce8b302d4", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 407, "doc": {"question": "下列何者不是毒蕈鹼受體拮抗劑（muscarinic antagonist）之治療用途？", "A": "動暈症（motion sickness）", "B": "慢性阻塞性肺病（chronic obstructive pulmonary disease）", "C": "帕金森氏症（Parkinson disease）", "D": "阿茲海默症（Alzheimer disease）", "answer": "D", "questions": "下列何者不是毒蕈鹼受體拮抗劑（muscarinic antagonist）之治療用途？", "choices": ["動暈症（motion sickness）", "慢性阻塞性肺病（chronic obstructive pulmonary disease）", "帕金森氏症（Parkinson disease）", "阿茲海默症（Alzheimer disease）"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是毒蕈鹼受體拮抗劑（muscarinic antagonist）之治療用途？\nA. 動暈症（motion sickness）\nB. 慢性阻塞性肺病（chronic obstructive pulmonary disease）\nC. 帕金森氏症（Parkinson disease）\nD. 阿茲海默症（Alzheimer disease）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是毒蕈鹼受體拮抗劑（muscarinic antagonist）之治療用途？\nA. 動暈症（motion sickness）\nB. 慢性阻塞性肺病（chronic obstructive pulmonary disease）\nC. 帕金森氏症（Parkinson disease）\nD. 阿茲海默症（Alzheimer disease）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是毒蕈鹼受體拮抗劑（muscarinic antagonist）之治療用途？\nA. 動暈症（motion sickness）\nB. 慢性阻塞性肺病（chronic obstructive pulmonary disease）\nC. 帕金森氏症（Parkinson disease）\nD. 阿茲海默症（Alzheimer disease）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是毒蕈鹼受體拮抗劑（muscarinic antagonist）之治療用途？\nA. 動暈症（motion sickness）\nB. 慢性阻塞性肺病（chronic obstructive pulmonary disease）\nC. 帕金森氏症（Parkinson disease）\nD. 阿茲海默症（Alzheimer disease）\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.78125", "False"]], [["-3.15625", "False"]], [["-0.158203125", "True"]], [["-2.40625", "False"]]], "filtered_resps": [["-4.78125", "False"], ["-3.15625", "False"], ["-0.158203125", "True"], ["-2.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ad088722003993536147a45fee723e9b85e89a582c2df2e8bf1cbc380860351f", "prompt_hash": "2ed733121f31ee8c025d3da83110fc57bac77923c02561b1e4769d2fe8c1df94", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 408, "doc": {"question": "下列有關caspofungin的敘述，何者錯誤？", "A": "靜脈注射給藥", "B": "半合成的echinocandin", "C": "可治療新生囊球菌（Cryptococcus neoformans）感染", "D": "抑制β-1,3-glucan synthase", "answer": "C", "questions": "下列有關caspofungin的敘述，何者錯誤？", "choices": ["靜脈注射給藥", "半合成的echinocandin", "可治療新生囊球菌（Cryptococcus neoformans）感染", "抑制β-1,3-glucan synthase"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關caspofungin的敘述，何者錯誤？\nA. 靜脈注射給藥\nB. 半合成的echinocandin\nC. 可治療新生囊球菌（Cryptococcus neoformans）感染\nD. 抑制β-1,3-glucan synthase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關caspofungin的敘述，何者錯誤？\nA. 靜脈注射給藥\nB. 半合成的echinocandin\nC. 可治療新生囊球菌（Cryptococcus neoformans）感染\nD. 抑制β-1,3-glucan synthase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關caspofungin的敘述，何者錯誤？\nA. 靜脈注射給藥\nB. 半合成的echinocandin\nC. 可治療新生囊球菌（Cryptococcus neoformans）感染\nD. 抑制β-1,3-glucan synthase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關caspofungin的敘述，何者錯誤？\nA. 靜脈注射給藥\nB. 半合成的echinocandin\nC. 可治療新生囊球菌（Cryptococcus neoformans）感染\nD. 抑制β-1,3-glucan synthase\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.75", "False"]], [["-5.0", "False"]], [["-0.01544189453125", "True"]], [["-5.875", "False"]]], "filtered_resps": [["-6.75", "False"], ["-5.0", "False"], ["-0.01544189453125", "True"], ["-5.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "dc36fed296f41f1ad80352f4408f08ab473ed6d7cd5e6aca87f9d2c3102a0225", "prompt_hash": "23849bb41e634c8bd0e01037c388f12844835ec5c145a9e8a6006579baa5ee9c", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 409, "doc": {"question": "下列口服降血糖藥物，何者可以抑制dipeptidyl peptidase 4，使內生性之glucagon-like peptide-1作用時間延長，而增加胰臟insulin釋放量？", "A": "canagliflozin", "B": "glimepiride", "C": "exenatide", "D": "saxagliptin", "answer": "D", "questions": "下列口服降血糖藥物，何者可以抑制dipeptidyl peptidase 4，使內生性之glucagon-like peptide-1作用時間延長，而增加胰臟insulin釋放量？", "choices": ["canagliflozin", "glimepiride", "exenatide", "saxagliptin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列口服降血糖藥物，何者可以抑制dipeptidyl peptidase 4，使內生性之glucagon-like peptide-1作用時間延長，而增加胰臟insulin釋放量？\nA. canagliflozin\nB. glimepiride\nC. exenatide\nD. saxagliptin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列口服降血糖藥物，何者可以抑制dipeptidyl peptidase 4，使內生性之glucagon-like peptide-1作用時間延長，而增加胰臟insulin釋放量？\nA. canagliflozin\nB. glimepiride\nC. exenatide\nD. saxagliptin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列口服降血糖藥物，何者可以抑制dipeptidyl peptidase 4，使內生性之glucagon-like peptide-1作用時間延長，而增加胰臟insulin釋放量？\nA. canagliflozin\nB. glimepiride\nC. exenatide\nD. saxagliptin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列口服降血糖藥物，何者可以抑制dipeptidyl peptidase 4，使內生性之glucagon-like peptide-1作用時間延長，而增加胰臟insulin釋放量？\nA. canagliflozin\nB. glimepiride\nC. exenatide\nD. saxagliptin\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.25", "False"]], [["-7.5", "False"]], [["-7.625", "False"]], [["-0.005126953125", "True"]]], "filtered_resps": [["-6.25", "False"], ["-7.5", "False"], ["-7.625", "False"], ["-0.005126953125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c14f6be092c7fc4b612d2f085e0807498edc12ec76e698a6456b71e2716459d1", "prompt_hash": "89d30bdb316ea98f0e9b12392bf0a0700bf4ce290f02c09031b612e3106471ed", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 410, "doc": {"question": "下列有關三環類抗憂鬱藥物的敘述，何者錯誤？", "A": "使用三環類抗憂鬱藥物會發生直立性低血壓（Orthostatic hypotension）的副作用", "B": "大部分的三環類抗憂鬱藥物都具有阻斷多巴胺（Dopamine）再回收的作用", "C": "三環類抗憂鬱藥物可以用來改善小孩遺尿（Enuresis）的現象", "D": "三環類抗憂鬱藥物大多具有高度的首渡效應（First-pass effect）", "answer": "B", "questions": "下列有關三環類抗憂鬱藥物的敘述，何者錯誤？", "choices": ["使用三環類抗憂鬱藥物會發生直立性低血壓（Orthostatic hypotension）的副作用", "大部分的三環類抗憂鬱藥物都具有阻斷多巴胺（Dopamine）再回收的作用", "三環類抗憂鬱藥物可以用來改善小孩遺尿（Enuresis）的現象", "三環類抗憂鬱藥物大多具有高度的首渡效應（First-pass effect）"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關三環類抗憂鬱藥物的敘述，何者錯誤？\nA. 使用三環類抗憂鬱藥物會發生直立性低血壓（Orthostatic hypotension）的副作用\nB. 大部分的三環類抗憂鬱藥物都具有阻斷多巴胺（Dopamine）再回收的作用\nC. 三環類抗憂鬱藥物可以用來改善小孩遺尿（Enuresis）的現象\nD. 三環類抗憂鬱藥物大多具有高度的首渡效應（First-pass effect）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關三環類抗憂鬱藥物的敘述，何者錯誤？\nA. 使用三環類抗憂鬱藥物會發生直立性低血壓（Orthostatic hypotension）的副作用\nB. 大部分的三環類抗憂鬱藥物都具有阻斷多巴胺（Dopamine）再回收的作用\nC. 三環類抗憂鬱藥物可以用來改善小孩遺尿（Enuresis）的現象\nD. 三環類抗憂鬱藥物大多具有高度的首渡效應（First-pass effect）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關三環類抗憂鬱藥物的敘述，何者錯誤？\nA. 使用三環類抗憂鬱藥物會發生直立性低血壓（Orthostatic hypotension）的副作用\nB. 大部分的三環類抗憂鬱藥物都具有阻斷多巴胺（Dopamine）再回收的作用\nC. 三環類抗憂鬱藥物可以用來改善小孩遺尿（Enuresis）的現象\nD. 三環類抗憂鬱藥物大多具有高度的首渡效應（First-pass effect）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關三環類抗憂鬱藥物的敘述，何者錯誤？\nA. 使用三環類抗憂鬱藥物會發生直立性低血壓（Orthostatic hypotension）的副作用\nB. 大部分的三環類抗憂鬱藥物都具有阻斷多巴胺（Dopamine）再回收的作用\nC. 三環類抗憂鬱藥物可以用來改善小孩遺尿（Enuresis）的現象\nD. 三環類抗憂鬱藥物大多具有高度的首渡效應（First-pass effect）\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.15625", "False"]], [["-1.5234375", "False"]], [["-4.15625", "False"]], [["-0.271484375", "True"]]], "filtered_resps": [["-6.15625", "False"], ["-1.5234375", "False"], ["-4.15625", "False"], ["-0.271484375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "41fb4ed59cd2997648e28b7e03d0c8ab97a28f01702d1476b53d18e08180b28e", "prompt_hash": "544a0895393a573289c69c6b8db55d90f90d68c0f12f8b7557850839ed4ef23e", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 411, "doc": {"question": "作用於亨利氏環之利尿劑furosemide在使用上可能發生不同種類之副作用，下列何者錯誤？", "A": "過敏反應（allergy）", "B": "代謝性鹼中毒（metabolic alkalosis）", "C": "高血鎂症（hypermagnesemia）", "D": "高尿酸症（hyperuricemia）", "answer": "C", "questions": "作用於亨利氏環之利尿劑furosemide在使用上可能發生不同種類之副作用，下列何者錯誤？", "choices": ["過敏反應（allergy）", "代謝性鹼中毒（metabolic alkalosis）", "高血鎂症（hypermagnesemia）", "高尿酸症（hyperuricemia）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n作用於亨利氏環之利尿劑furosemide在使用上可能發生不同種類之副作用，下列何者錯誤？\nA. 過敏反應（allergy）\nB. 代謝性鹼中毒（metabolic alkalosis）\nC. 高血鎂症（hypermagnesemia）\nD. 高尿酸症（hyperuricemia）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n作用於亨利氏環之利尿劑furosemide在使用上可能發生不同種類之副作用，下列何者錯誤？\nA. 過敏反應（allergy）\nB. 代謝性鹼中毒（metabolic alkalosis）\nC. 高血鎂症（hypermagnesemia）\nD. 高尿酸症（hyperuricemia）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n作用於亨利氏環之利尿劑furosemide在使用上可能發生不同種類之副作用，下列何者錯誤？\nA. 過敏反應（allergy）\nB. 代謝性鹼中毒（metabolic alkalosis）\nC. 高血鎂症（hypermagnesemia）\nD. 高尿酸症（hyperuricemia）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n作用於亨利氏環之利尿劑furosemide在使用上可能發生不同種類之副作用，下列何者錯誤？\nA. 過敏反應（allergy）\nB. 代謝性鹼中毒（metabolic alkalosis）\nC. 高血鎂症（hypermagnesemia）\nD. 高尿酸症（hyperuricemia）\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.53125", "False"]], [["-4.78125", "False"]], [["-0.0260009765625", "True"]], [["-4.40625", "False"]]], "filtered_resps": [["-6.53125", "False"], ["-4.78125", "False"], ["-0.0260009765625", "True"], ["-4.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ef735f87c152c130670b0c59643a778eb0cefa6a0789ffad79460c1412e1bf51", "prompt_hash": "da45e0ae57971e3d1a45d46bad7a5469eda32e74f12ee145c8deaade0602de48", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 412, "doc": {"question": "白三烯素前驅物主要自arachidonic acid經何種酵素氧化而得？", "A": "12-lipoxygenase", "B": "5-lipoxygenase", "C": "9-lipoxygenase", "D": "15-lipoxygenase", "answer": "B", "questions": "白三烯素前驅物主要自arachidonic acid經何種酵素氧化而得？", "choices": ["12-lipoxygenase", "5-lipoxygenase", "9-lipoxygenase", "15-lipoxygenase"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n白三烯素前驅物主要自arachidonic acid經何種酵素氧化而得？\nA. 12-lipoxygenase\nB. 5-lipoxygenase\nC. 9-lipoxygenase\nD. 15-lipoxygenase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n白三烯素前驅物主要自arachidonic acid經何種酵素氧化而得？\nA. 12-lipoxygenase\nB. 5-lipoxygenase\nC. 9-lipoxygenase\nD. 15-lipoxygenase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n白三烯素前驅物主要自arachidonic acid經何種酵素氧化而得？\nA. 12-lipoxygenase\nB. 5-lipoxygenase\nC. 9-lipoxygenase\nD. 15-lipoxygenase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n白三烯素前驅物主要自arachidonic acid經何種酵素氧化而得？\nA. 12-lipoxygenase\nB. 5-lipoxygenase\nC. 9-lipoxygenase\nD. 15-lipoxygenase\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.21875", "False"]], [["-0.337890625", "True"]], [["-3.21875", "False"]], [["-1.5859375", "False"]]], "filtered_resps": [["-3.21875", "False"], ["-0.337890625", "True"], ["-3.21875", "False"], ["-1.5859375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2f747195bd5be56717dd6c7d0541b5ba58181df4e08ede363859f71e8eb71121", "prompt_hash": "8f7cd7df7bf673eefac4c9447c07bf20c46ac183d1ec04ee59e3011b3067ca98", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 413, "doc": {"question": "Prontosil於活體內轉化成4-aminobenzenesulfonamide，其代謝反應係屬於：", "A": "還原", "B": "水解", "C": "共軛", "D": "氧化", "answer": "A", "questions": "Prontosil於活體內轉化成4-aminobenzenesulfonamide，其代謝反應係屬於：", "choices": ["還原", "水解", "共軛", "氧化"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nProntosil於活體內轉化成4-aminobenzenesulfonamide，其代謝反應係屬於：\nA. 還原\nB. 水解\nC. 共軛\nD. 氧化\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nProntosil於活體內轉化成4-aminobenzenesulfonamide，其代謝反應係屬於：\nA. 還原\nB. 水解\nC. 共軛\nD. 氧化\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nProntosil於活體內轉化成4-aminobenzenesulfonamide，其代謝反應係屬於：\nA. 還原\nB. 水解\nC. 共軛\nD. 氧化\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nProntosil於活體內轉化成4-aminobenzenesulfonamide，其代謝反應係屬於：\nA. 還原\nB. 水解\nC. 共軛\nD. 氧化\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.408203125", "True"]], [["-2.15625", "False"]], [["-2.65625", "False"]], [["-1.90625", "False"]]], "filtered_resps": [["-0.408203125", "True"], ["-2.15625", "False"], ["-2.65625", "False"], ["-1.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "cf5d0a39aea0983ad482f71248f6f75dcd509ab0ae30b1e0d50a660033a5b2fb", "prompt_hash": "8f8ac45b981748a2af950290ba261f579ab33bd7a0773948ee8fa972584e3b9c", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 414, "doc": {"question": "下列有關potency與efficacy的敘述，何者最正確？", "A": "efficacy與藥物-受體間的親和力較有關", "B": "一藥物之potency比其efficacy重要", "C": "efficacy與藥物的intrinsic activity較有關", "D": "potency與藥物的intrinsic activity較有關", "answer": "C", "questions": "下列有關potency與efficacy的敘述，何者最正確？", "choices": ["efficacy與藥物-受體間的親和力較有關", "一藥物之potency比其efficacy重要", "efficacy與藥物的intrinsic activity較有關", "potency與藥物的intrinsic activity較有關"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關potency與efficacy的敘述，何者最正確？\nA. efficacy與藥物-受體間的親和力較有關\nB. 一藥物之potency比其efficacy重要\nC. efficacy與藥物的intrinsic activity較有關\nD. potency與藥物的intrinsic activity較有關\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關potency與efficacy的敘述，何者最正確？\nA. efficacy與藥物-受體間的親和力較有關\nB. 一藥物之potency比其efficacy重要\nC. efficacy與藥物的intrinsic activity較有關\nD. potency與藥物的intrinsic activity較有關\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關potency與efficacy的敘述，何者最正確？\nA. efficacy與藥物-受體間的親和力較有關\nB. 一藥物之potency比其efficacy重要\nC. efficacy與藥物的intrinsic activity較有關\nD. potency與藥物的intrinsic activity較有關\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關potency與efficacy的敘述，何者最正確？\nA. efficacy與藥物-受體間的親和力較有關\nB. 一藥物之potency比其efficacy重要\nC. efficacy與藥物的intrinsic activity較有關\nD. potency與藥物的intrinsic activity較有關\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.375", "False"]], [["-6.625", "False"]], [["-0.01220703125", "True"]], [["-5.625", "False"]]], "filtered_resps": [["-5.375", "False"], ["-6.625", "False"], ["-0.01220703125", "True"], ["-5.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2d3142da7881ff56140566ab5eebf0077c8cd291943bee4d0046889726eab601", "prompt_hash": "faec26ba23bd0f8b56772bc38829e2aef948933670f5d9c29d9ea08924d3379c", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 415, "doc": {"question": "下列corticosteroids製劑中何者最容易發生明顯的生長抑制作用，所以不建議給兒童使用？", "A": "triamcinolone", "B": "dexamethasone", "C": "cortisol", "D": "fludrocortisone", "answer": "B", "questions": "下列corticosteroids製劑中何者最容易發生明顯的生長抑制作用，所以不建議給兒童使用？", "choices": ["triamcinolone", "dexamethasone", "cortisol", "fludrocortisone"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列corticosteroids製劑中何者最容易發生明顯的生長抑制作用，所以不建議給兒童使用？\nA. triamcinolone\nB. dexamethasone\nC. cortisol\nD. fludrocortisone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列corticosteroids製劑中何者最容易發生明顯的生長抑制作用，所以不建議給兒童使用？\nA. triamcinolone\nB. dexamethasone\nC. cortisol\nD. fludrocortisone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列corticosteroids製劑中何者最容易發生明顯的生長抑制作用，所以不建議給兒童使用？\nA. triamcinolone\nB. dexamethasone\nC. cortisol\nD. fludrocortisone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列corticosteroids製劑中何者最容易發生明顯的生長抑制作用，所以不建議給兒童使用？\nA. triamcinolone\nB. dexamethasone\nC. cortisol\nD. fludrocortisone\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.5", "False"]], [["-0.00384521484375", "True"]], [["-8.0", "False"]], [["-6.5", "False"]]], "filtered_resps": [["-6.5", "False"], ["-0.00384521484375", "True"], ["-8.0", "False"], ["-6.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0ac1a017adb2122e78d3ed82b04edf57938cacd82b5453b1d014dbd1c629406d", "prompt_hash": "ed709fac441bf9ebc95824adf3e26d2460c197a84c27c061cf86231484b98922", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 416, "doc": {"question": "下列藥物治療用途，何者錯誤？", "A": "midodrine可用於治療姿態性低血壓", "B": "oxymetazoline局部使用可治療鼻塞", "C": "clonidine可用於治療高血壓", "D": "moxonidine可用於治療氣喘", "answer": "D", "questions": "下列藥物治療用途，何者錯誤？", "choices": ["midodrine可用於治療姿態性低血壓", "oxymetazoline局部使用可治療鼻塞", "clonidine可用於治療高血壓", "moxonidine可用於治療氣喘"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物治療用途，何者錯誤？\nA. midodrine可用於治療姿態性低血壓\nB. oxymetazoline局部使用可治療鼻塞\nC. clonidine可用於治療高血壓\nD. moxonidine可用於治療氣喘\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物治療用途，何者錯誤？\nA. midodrine可用於治療姿態性低血壓\nB. oxymetazoline局部使用可治療鼻塞\nC. clonidine可用於治療高血壓\nD. moxonidine可用於治療氣喘\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物治療用途，何者錯誤？\nA. midodrine可用於治療姿態性低血壓\nB. oxymetazoline局部使用可治療鼻塞\nC. clonidine可用於治療高血壓\nD. moxonidine可用於治療氣喘\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物治療用途，何者錯誤？\nA. midodrine可用於治療姿態性低血壓\nB. oxymetazoline局部使用可治療鼻塞\nC. clonidine可用於治療高血壓\nD. moxonidine可用於治療氣喘\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.75", "False"]], [["-8.5", "False"]], [["-9.625", "False"]], [["-0.0021514892578125", "True"]]], "filtered_resps": [["-7.75", "False"], ["-8.5", "False"], ["-9.625", "False"], ["-0.0021514892578125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7a8995c5254cdc722e093576fe22fddc7b496a1fbc0372d81612eed0747c9c32", "prompt_hash": "03180313ef15fa7b7b1cbb691d394c06eb9b3418a68f988b1482b0621ac0f621", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 417, "doc": {"question": "手術結束後，使用 sugammadex 的藥理作用與目的，下列何者正確？", "A": "抑制去極化神經肌肉阻斷劑，恢復正常呼吸，減少低氧狀態", "B": "抑制非去極化神經肌肉阻斷劑，恢復正常呼吸", "C": "中樞興奮劑，減少全身麻醉的中樞抑制作用，使病人早點恢復意識", "D": "中樞鎮痛劑，減少手術後的疼痛", "answer": "B", "questions": "手術結束後，使用 sugammadex 的藥理作用與目的，下列何者正確？", "choices": ["抑制去極化神經肌肉阻斷劑，恢復正常呼吸，減少低氧狀態", "抑制非去極化神經肌肉阻斷劑，恢復正常呼吸", "中樞興奮劑，減少全身麻醉的中樞抑制作用，使病人早點恢復意識", "中樞鎮痛劑，減少手術後的疼痛"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n手術結束後，使用 sugammadex 的藥理作用與目的，下列何者正確？\nA. 抑制去極化神經肌肉阻斷劑，恢復正常呼吸，減少低氧狀態\nB. 抑制非去極化神經肌肉阻斷劑，恢復正常呼吸\nC. 中樞興奮劑，減少全身麻醉的中樞抑制作用，使病人早點恢復意識\nD. 中樞鎮痛劑，減少手術後的疼痛\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n手術結束後，使用 sugammadex 的藥理作用與目的，下列何者正確？\nA. 抑制去極化神經肌肉阻斷劑，恢復正常呼吸，減少低氧狀態\nB. 抑制非去極化神經肌肉阻斷劑，恢復正常呼吸\nC. 中樞興奮劑，減少全身麻醉的中樞抑制作用，使病人早點恢復意識\nD. 中樞鎮痛劑，減少手術後的疼痛\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n手術結束後，使用 sugammadex 的藥理作用與目的，下列何者正確？\nA. 抑制去極化神經肌肉阻斷劑，恢復正常呼吸，減少低氧狀態\nB. 抑制非去極化神經肌肉阻斷劑，恢復正常呼吸\nC. 中樞興奮劑，減少全身麻醉的中樞抑制作用，使病人早點恢復意識\nD. 中樞鎮痛劑，減少手術後的疼痛\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n手術結束後，使用 sugammadex 的藥理作用與目的，下列何者正確？\nA. 抑制去極化神經肌肉阻斷劑，恢復正常呼吸，減少低氧狀態\nB. 抑制非去極化神經肌肉阻斷劑，恢復正常呼吸\nC. 中樞興奮劑，減少全身麻醉的中樞抑制作用，使病人早點恢復意識\nD. 中樞鎮痛劑，減少手術後的疼痛\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.609375", "False"]], [["-0.486328125", "True"]], [["-2.734375", "False"]], [["-2.109375", "False"]]], "filtered_resps": [["-1.609375", "False"], ["-0.486328125", "True"], ["-2.734375", "False"], ["-2.109375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1e07c93ce52c60eb4106826f211cd29b95891ea5415f391950f3965052aa2131", "prompt_hash": "80138c7d6587b63bee633603147fa031a5bc014ffc138e6a3b0215b8819fdc7a", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 418, "doc": {"question": "下列有關ondansetron之敘述，何者正確？", "A": "主要用於治療懷孕時的噁心、嘔吐", "B": "具有carbazolone之結構", "C": "屬於5-HT3 agonist", "D": "半衰期比palonosetron長", "answer": "B", "questions": "下列有關ondansetron之敘述，何者正確？", "choices": ["主要用於治療懷孕時的噁心、嘔吐", "具有carbazolone之結構", "屬於5-HT3 agonist", "半衰期比palonosetron長"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ondansetron之敘述，何者正確？\nA. 主要用於治療懷孕時的噁心、嘔吐\nB. 具有carbazolone之結構\nC. 屬於5-HT3 agonist\nD. 半衰期比palonosetron長\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ondansetron之敘述，何者正確？\nA. 主要用於治療懷孕時的噁心、嘔吐\nB. 具有carbazolone之結構\nC. 屬於5-HT3 agonist\nD. 半衰期比palonosetron長\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ondansetron之敘述，何者正確？\nA. 主要用於治療懷孕時的噁心、嘔吐\nB. 具有carbazolone之結構\nC. 屬於5-HT3 agonist\nD. 半衰期比palonosetron長\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關ondansetron之敘述，何者正確？\nA. 主要用於治療懷孕時的噁心、嘔吐\nB. 具有carbazolone之結構\nC. 屬於5-HT3 agonist\nD. 半衰期比palonosetron長\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-0.0234375", "True"]], [["-6.40625", "False"]], [["-4.03125", "False"]]], "filtered_resps": [["-5.78125", "False"], ["-0.0234375", "True"], ["-6.40625", "False"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ce53e37d4fbce2ccdac07451287a8bf65d5300819d90f23b533d69d05560aa2e", "prompt_hash": "9aaf30c4264a2e48c2d75fcd3ab42671ca957b812e8f39f4f32dcdf580673066", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 419, "doc": {"question": "下列括弧內之吸入性麻醉劑參數（blood/gas partition ； minimum alveolar concentration），何者效價（potency）最強？", "A": "enflurane（1.91；1.68）", "B": "isoflurane（1.4；1.15）", "C": "desflurane（0.42；6.0）", "D": "sevoflurane（0.63；1.71）", "answer": "B", "questions": "下列括弧內之吸入性麻醉劑參數（blood/gas partition ； minimum alveolar concentration），何者效價（potency）最強？", "choices": ["enflurane（1.91；1.68）", "isoflurane（1.4；1.15）", "desflurane（0.42；6.0）", "sevoflurane（0.63；1.71）"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列括弧內之吸入性麻醉劑參數（blood/gas partition ； minimum alveolar concentration），何者效價（potency）最強？\nA. enflurane（1.91；1.68）\nB. isoflurane（1.4；1.15）\nC. desflurane（0.42；6.0）\nD. sevoflurane（0.63；1.71）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列括弧內之吸入性麻醉劑參數（blood/gas partition ； minimum alveolar concentration），何者效價（potency）最強？\nA. enflurane（1.91；1.68）\nB. isoflurane（1.4；1.15）\nC. desflurane（0.42；6.0）\nD. sevoflurane（0.63；1.71）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列括弧內之吸入性麻醉劑參數（blood/gas partition ； minimum alveolar concentration），何者效價（potency）最強？\nA. enflurane（1.91；1.68）\nB. isoflurane（1.4；1.15）\nC. desflurane（0.42；6.0）\nD. sevoflurane（0.63；1.71）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列括弧內之吸入性麻醉劑參數（blood/gas partition ； minimum alveolar concentration），何者效價（potency）最強？\nA. enflurane（1.91；1.68）\nB. isoflurane（1.4；1.15）\nC. desflurane（0.42；6.0）\nD. sevoflurane（0.63；1.71）\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.1875", "False"]], [["-2.5625", "False"]], [["-0.310546875", "True"]], [["-1.9375", "False"]]], "filtered_resps": [["-3.1875", "False"], ["-2.5625", "False"], ["-0.310546875", "True"], ["-1.9375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "284dbf5c8bd0c565cec8a884f8cc358b3bef2b2148ab66fd8192c71bd7c6505c", "prompt_hash": "d2c8ae571ced96bc1057bf992474aa671a2d5482d26087390c5f287fe7c0cedf", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 420, "doc": {"question": "下列那一個止痛藥物是屬於fenamates類型？", "A": "piroxicam", "B": "meclofenamic acid", "C": "ibuprofen", "D": "sulindac", "answer": "B", "questions": "下列那一個止痛藥物是屬於fenamates類型？", "choices": ["piroxicam", "meclofenamic acid", "ibuprofen", "sulindac"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一個止痛藥物是屬於fenamates類型？\nA. piroxicam\nB. meclofenamic acid\nC. ibuprofen\nD. sulindac\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一個止痛藥物是屬於fenamates類型？\nA. piroxicam\nB. meclofenamic acid\nC. ibuprofen\nD. sulindac\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一個止痛藥物是屬於fenamates類型？\nA. piroxicam\nB. meclofenamic acid\nC. ibuprofen\nD. sulindac\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一個止痛藥物是屬於fenamates類型？\nA. piroxicam\nB. meclofenamic acid\nC. ibuprofen\nD. sulindac\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.09375", "False"]], [["-0.0830078125", "True"]], [["-3.703125", "False"]], [["-3.328125", "False"]]], "filtered_resps": [["-4.09375", "False"], ["-0.0830078125", "True"], ["-3.703125", "False"], ["-3.328125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c3f27032220c86b652a8b4d210516adce07a3ef6766fd3074885a7ab1d908376", "prompt_hash": "886f367f6a392f98bf4ee3ed5e607f1a9364fbc1271adee95c2fea2e54a66bc6", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 421, "doc": {"question": "帕金森氏症患者主要病因為腦中basal ganglia-striatum系統多巴胺神經活性缺損所致，治療時除了處方多巴胺前驅物levodopa以外，倂用下列那一類藥物，對於改善病患之震顫和僵硬成效尤佳？", "A": "尼古丁受體拮抗劑", "B": "丁酰膽鹼酯酶抑制劑", "C": "毒蕈鹼受體拮抗劑", "D": "乙醯膽鹼酯酶抑制劑", "answer": "C", "questions": "帕金森氏症患者主要病因為腦中basal ganglia-striatum系統多巴胺神經活性缺損所致，治療時除了處方多巴胺前驅物levodopa以外，倂用下列那一類藥物，對於改善病患之震顫和僵硬成效尤佳？", "choices": ["尼古丁受體拮抗劑", "丁酰膽鹼酯酶抑制劑", "毒蕈鹼受體拮抗劑", "乙醯膽鹼酯酶抑制劑"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n帕金森氏症患者主要病因為腦中basal ganglia-striatum系統多巴胺神經活性缺損所致，治療時除了處方多巴胺前驅物levodopa以外，倂用下列那一類藥物，對於改善病患之震顫和僵硬成效尤佳？\nA. 尼古丁受體拮抗劑\nB. 丁酰膽鹼酯酶抑制劑\nC. 毒蕈鹼受體拮抗劑\nD. 乙醯膽鹼酯酶抑制劑\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n帕金森氏症患者主要病因為腦中basal ganglia-striatum系統多巴胺神經活性缺損所致，治療時除了處方多巴胺前驅物levodopa以外，倂用下列那一類藥物，對於改善病患之震顫和僵硬成效尤佳？\nA. 尼古丁受體拮抗劑\nB. 丁酰膽鹼酯酶抑制劑\nC. 毒蕈鹼受體拮抗劑\nD. 乙醯膽鹼酯酶抑制劑\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n帕金森氏症患者主要病因為腦中basal ganglia-striatum系統多巴胺神經活性缺損所致，治療時除了處方多巴胺前驅物levodopa以外，倂用下列那一類藥物，對於改善病患之震顫和僵硬成效尤佳？\nA. 尼古丁受體拮抗劑\nB. 丁酰膽鹼酯酶抑制劑\nC. 毒蕈鹼受體拮抗劑\nD. 乙醯膽鹼酯酶抑制劑\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n帕金森氏症患者主要病因為腦中basal ganglia-striatum系統多巴胺神經活性缺損所致，治療時除了處方多巴胺前驅物levodopa以外，倂用下列那一類藥物，對於改善病患之震顫和僵硬成效尤佳？\nA. 尼古丁受體拮抗劑\nB. 丁酰膽鹼酯酶抑制劑\nC. 毒蕈鹼受體拮抗劑\nD. 乙醯膽鹼酯酶抑制劑\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.1875", "False"]], [["-4.3125", "False"]], [["-0.060302734375", "True"]], [["-3.6875", "False"]]], "filtered_resps": [["-4.1875", "False"], ["-4.3125", "False"], ["-0.060302734375", "True"], ["-3.6875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "918eba2d6a4a795974fa5758430cfbd096d74e520a33555a0d20981bf8f68f83", "prompt_hash": "99cef5b5d0eb2d024aa87190ad85fc9c30392124a9f689145b554813bc4d7d36", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 422, "doc": {"question": "5α-Androstane之A/B，B/C，C/D環之立體結構為何？", "A": "cis，trans，cis", "B": "trans，cis，trans", "C": "all trans", "D": "all cis", "answer": "C", "questions": "5α-Androstane之A/B，B/C，C/D環之立體結構為何？", "choices": ["cis，trans，cis", "trans，cis，trans", "all trans", "all cis"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n5α-Androstane之A/B，B/C，C/D環之立體結構為何？\nA. cis，trans，cis\nB. trans，cis，trans\nC. all trans\nD. all cis\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n5α-Androstane之A/B，B/C，C/D環之立體結構為何？\nA. cis，trans，cis\nB. trans，cis，trans\nC. all trans\nD. all cis\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n5α-Androstane之A/B，B/C，C/D環之立體結構為何？\nA. cis，trans，cis\nB. trans，cis，trans\nC. all trans\nD. all cis\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n5α-Androstane之A/B，B/C，C/D環之立體結構為何？\nA. cis，trans，cis\nB. trans，cis，trans\nC. all trans\nD. all cis\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.3359375", "False"]], [["-0.70703125", "True"]], [["-2.328125", "False"]], [["-1.9609375", "False"]]], "filtered_resps": [["-1.3359375", "False"], ["-0.70703125", "True"], ["-2.328125", "False"], ["-1.9609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2d26596d6eaba6933ea8b4aab40755a17a32054a5d1619cde710f4f623c6b3b1", "prompt_hash": "ba855a6a375538905bc4a89b14a726aa40d419ca82af4a7e27a19fe930665da9", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 423, "doc": {"question": "下列何種藥可抑制LDL受體降解，而達到降血脂作用？", "A": "evolocumab", "B": "ezetimibe", "C": "cholestyramine", "D": "niacin", "answer": "A", "questions": "下列何種藥可抑制LDL受體降解，而達到降血脂作用？", "choices": ["evolocumab", "ezetimibe", "cholestyramine", "niacin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥可抑制LDL受體降解，而達到降血脂作用？\nA. evolocumab\nB. ezetimibe\nC. cholestyramine\nD. niacin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥可抑制LDL受體降解，而達到降血脂作用？\nA. evolocumab\nB. ezetimibe\nC. cholestyramine\nD. niacin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥可抑制LDL受體降解，而達到降血脂作用？\nA. evolocumab\nB. ezetimibe\nC. cholestyramine\nD. niacin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥可抑制LDL受體降解，而達到降血脂作用？\nA. evolocumab\nB. ezetimibe\nC. cholestyramine\nD. niacin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.03271484375", "True"]], [["-5.03125", "False"]], [["-5.15625", "False"]], [["-4.03125", "False"]]], "filtered_resps": [["-0.03271484375", "True"], ["-5.03125", "False"], ["-5.15625", "False"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3049aa97e425876b6dd07cbe64dccc95a8fa646f302cfb04c48f2b2abc1eae23", "prompt_hash": "d7bb20e225cd5e39fe04ef80bd34774db594e59b118b668d1b135de6a3fa6df4", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 424, "doc": {"question": "有關肺結核治療用藥與其主要副作用之配對，下列何者最為正確？", "A": "Rifampin–使尿液染成橙色", "B": "Isoniazid–暈眩、失去平衡", "C": "Ethambutol–肝毒性", "D": "Streptomycin–視神經炎", "answer": "A", "questions": "有關肺結核治療用藥與其主要副作用之配對，下列何者最為正確？", "choices": ["Rifampin–使尿液染成橙色", "Isoniazid–暈眩、失去平衡", "Ethambutol–肝毒性", "Streptomycin–視神經炎"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關肺結核治療用藥與其主要副作用之配對，下列何者最為正確？\nA. Rifampin–使尿液染成橙色\nB. Isoniazid–暈眩、失去平衡\nC. Ethambutol–肝毒性\nD. Streptomycin–視神經炎\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關肺結核治療用藥與其主要副作用之配對，下列何者最為正確？\nA. Rifampin–使尿液染成橙色\nB. Isoniazid–暈眩、失去平衡\nC. Ethambutol–肝毒性\nD. Streptomycin–視神經炎\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關肺結核治療用藥與其主要副作用之配對，下列何者最為正確？\nA. Rifampin–使尿液染成橙色\nB. Isoniazid–暈眩、失去平衡\nC. Ethambutol–肝毒性\nD. Streptomycin–視神經炎\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關肺結核治療用藥與其主要副作用之配對，下列何者最為正確？\nA. Rifampin–使尿液染成橙色\nB. Isoniazid–暈眩、失去平衡\nC. Ethambutol–肝毒性\nD. Streptomycin–視神經炎\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.84375", "False"]], [["-2.46875", "False"]], [["-3.34375", "False"]], [["-0.341796875", "True"]]], "filtered_resps": [["-1.84375", "False"], ["-2.46875", "False"], ["-3.34375", "False"], ["-0.341796875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c8c14101391f40c6914eb924335c0424365aa2a50415ba24a3ef53f62a4cde4b", "prompt_hash": "48914e964f3aa020fee1fde2f369f87b8c2cac5f0b580fba378e84f184937fed", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 425, "doc": {"question": "Acetaminophen在幼兒的尿液中，主要代謝物為何？", "A": "sulfate", "B": "glutathione conjugate", "C": "N-acetylimidoquinone", "D": "glucuronide", "answer": "A", "questions": "Acetaminophen在幼兒的尿液中，主要代謝物為何？", "choices": ["sulfate", "glutathione conjugate", "N-acetylimidoquinone", "glucuronide"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAcetaminophen在幼兒的尿液中，主要代謝物為何？\nA. sulfate\nB. glutathione conjugate\nC. N-acetylimidoquinone\nD. glucuronide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAcetaminophen在幼兒的尿液中，主要代謝物為何？\nA. sulfate\nB. glutathione conjugate\nC. N-acetylimidoquinone\nD. glucuronide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAcetaminophen在幼兒的尿液中，主要代謝物為何？\nA. sulfate\nB. glutathione conjugate\nC. N-acetylimidoquinone\nD. glucuronide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAcetaminophen在幼兒的尿液中，主要代謝物為何？\nA. sulfate\nB. glutathione conjugate\nC. N-acetylimidoquinone\nD. glucuronide\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1591796875", "True"]], [["-2.65625", "False"]], [["-4.28125", "False"]], [["-2.78125", "False"]]], "filtered_resps": [["-0.1591796875", "True"], ["-2.65625", "False"], ["-4.28125", "False"], ["-2.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bc2a5922d36f8bc7be134ac8dcf548c8229baa7458fbc34d31d36ad2043467de", "prompt_hash": "a047d40b5eb170168f7a3f7c53ac1560a0fb701790cd05c6691b9edb2791fd80", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 426, "doc": {"question": "有關抗腫瘤藥物cetuximab的敘述，下列何者錯誤？", "A": "適用於腫瘤基因RAS產生突變之病人", "B": "可與irinotecan併用於治療轉移性大腸直腸癌", "C": "可與放射線療法合併使用於治療局部性頭頸癌，但有極低比率（1%）可能造成病患猝死", "D": "是一種對抗EGFR的單株抗體用藥", "answer": "A", "questions": "有關抗腫瘤藥物cetuximab的敘述，下列何者錯誤？", "choices": ["適用於腫瘤基因RAS產生突變之病人", "可與irinotecan併用於治療轉移性大腸直腸癌", "可與放射線療法合併使用於治療局部性頭頸癌，但有極低比率（1%）可能造成病患猝死", "是一種對抗EGFR的單株抗體用藥"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗腫瘤藥物cetuximab的敘述，下列何者錯誤？\nA. 適用於腫瘤基因RAS產生突變之病人\nB. 可與irinotecan併用於治療轉移性大腸直腸癌\nC. 可與放射線療法合併使用於治療局部性頭頸癌，但有極低比率（1%）可能造成病患猝死\nD. 是一種對抗EGFR的單株抗體用藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗腫瘤藥物cetuximab的敘述，下列何者錯誤？\nA. 適用於腫瘤基因RAS產生突變之病人\nB. 可與irinotecan併用於治療轉移性大腸直腸癌\nC. 可與放射線療法合併使用於治療局部性頭頸癌，但有極低比率（1%）可能造成病患猝死\nD. 是一種對抗EGFR的單株抗體用藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗腫瘤藥物cetuximab的敘述，下列何者錯誤？\nA. 適用於腫瘤基因RAS產生突變之病人\nB. 可與irinotecan併用於治療轉移性大腸直腸癌\nC. 可與放射線療法合併使用於治療局部性頭頸癌，但有極低比率（1%）可能造成病患猝死\nD. 是一種對抗EGFR的單株抗體用藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗腫瘤藥物cetuximab的敘述，下列何者錯誤？\nA. 適用於腫瘤基因RAS產生突變之病人\nB. 可與irinotecan併用於治療轉移性大腸直腸癌\nC. 可與放射線療法合併使用於治療局部性頭頸癌，但有極低比率（1%）可能造成病患猝死\nD. 是一種對抗EGFR的單株抗體用藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.00927734375", "True"]], [["-6.0", "False"]], [["-5.125", "False"]], [["-10.125", "False"]]], "filtered_resps": [["-0.00927734375", "True"], ["-6.0", "False"], ["-5.125", "False"], ["-10.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d6f99b8955cd79b41af39bde4dd866a5df175f4e8184cf508bb9f645bcee3dc1", "prompt_hash": "44b74a9814db39b74f02d369a3a72e972fc21fddbcfc2b55f336952c4ec77c64", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 427, "doc": {"question": "下列何者結構的甲基置換成碘基後即為idoxuridine？", "A": "thymidine", "B": "adenosine", "C": "guanosine", "D": "cytidine", "answer": "A", "questions": "下列何者結構的甲基置換成碘基後即為idoxuridine？", "choices": ["thymidine", "adenosine", "guanosine", "cytidine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者結構的甲基置換成碘基後即為idoxuridine？\nA. thymidine\nB. adenosine\nC. guanosine\nD. cytidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者結構的甲基置換成碘基後即為idoxuridine？\nA. thymidine\nB. adenosine\nC. guanosine\nD. cytidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者結構的甲基置換成碘基後即為idoxuridine？\nA. thymidine\nB. adenosine\nC. guanosine\nD. cytidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者結構的甲基置換成碘基後即為idoxuridine？\nA. thymidine\nB. adenosine\nC. guanosine\nD. cytidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.054443359375", "True"]], [["-4.4375", "False"]], [["-5.0625", "False"]], [["-3.421875", "False"]]], "filtered_resps": [["-0.054443359375", "True"], ["-4.4375", "False"], ["-5.0625", "False"], ["-3.421875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b4432237e0c331efbc94588c09a2ca7d73d5912de463579b6aabe7e7671370fd", "prompt_hash": "81324d86b2b4ee32963bc3604bba91d36d6a87aa83df346cced24ce258705103", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 428, "doc": {"question": "下列那些抗癲癇藥物可用於治療失神性癲癇（absence seizures）？①phenytoin ②valproate ③ethosuximide ④gabapentin", "A": "③④", "B": "①②", "C": "①④", "D": "②③", "answer": "D", "questions": "下列那些抗癲癇藥物可用於治療失神性癲癇（absence seizures）？①phenytoin ②valproate ③ethosuximide ④gabapentin", "choices": ["③④", "①②", "①④", "②③"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那些抗癲癇藥物可用於治療失神性癲癇（absence seizures）？①phenytoin ②valproate ③ethosuximide ④gabapentin\nA. ③④\nB. ①②\nC. ①④\nD. ②③\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那些抗癲癇藥物可用於治療失神性癲癇（absence seizures）？①phenytoin ②valproate ③ethosuximide ④gabapentin\nA. ③④\nB. ①②\nC. ①④\nD. ②③\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那些抗癲癇藥物可用於治療失神性癲癇（absence seizures）？①phenytoin ②valproate ③ethosuximide ④gabapentin\nA. ③④\nB. ①②\nC. ①④\nD. ②③\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那些抗癲癇藥物可用於治療失神性癲癇（absence seizures）？①phenytoin ②valproate ③ethosuximide ④gabapentin\nA. ③④\nB. ①②\nC. ①④\nD. ②③\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.40625", "False"]], [["-4.53125", "False"]], [["-6.28125", "False"]], [["-0.017822265625", "True"]]], "filtered_resps": [["-5.40625", "False"], ["-4.53125", "False"], ["-6.28125", "False"], ["-0.017822265625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a508751a85efb54f62fb877bcdf91170c1228b44fe4b290dbd27b807131bb9c2", "prompt_hash": "55e060de3e932fe142718ed3b23a35a8f5440da02698127522ddeeb4731a0595", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 429, "doc": {"question": "下列何者可以口服用於多種重金屬，包括鉛、砷和汞中毒的治療？", "A": "Dimercaprol", "B": "Succimer", "C": "Deferoxamine", "D": "Penicillamine", "answer": "B", "questions": "下列何者可以口服用於多種重金屬，包括鉛、砷和汞中毒的治療？", "choices": ["Dimercaprol", "Succimer", "Deferoxamine", "Penicillamine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可以口服用於多種重金屬，包括鉛、砷和汞中毒的治療？\nA. Dimercaprol\nB. Succimer\nC. Deferoxamine\nD. Penicillamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可以口服用於多種重金屬，包括鉛、砷和汞中毒的治療？\nA. Dimercaprol\nB. Succimer\nC. Deferoxamine\nD. Penicillamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可以口服用於多種重金屬，包括鉛、砷和汞中毒的治療？\nA. Dimercaprol\nB. Succimer\nC. Deferoxamine\nD. Penicillamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可以口服用於多種重金屬，包括鉛、砷和汞中毒的治療？\nA. Dimercaprol\nB. Succimer\nC. Deferoxamine\nD. Penicillamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.03125", "False"]], [["-0.15625", "True"]], [["-5.65625", "False"]], [["-2.03125", "False"]]], "filtered_resps": [["-5.03125", "False"], ["-0.15625", "True"], ["-5.65625", "False"], ["-2.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1003e6e83b04fa103638ca8eb1d2e3587f4df2af1f9b79a24d25c5d3b96b2ea0", "prompt_hash": "d5bdca5213e266e05e56eda3b9675cf2708500694e55994459d86d835732a07f", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 430, "doc": {"question": "下列何種臨床症狀，不宜使用膽鹼受體阻斷劑治療？", "A": "一氧化碳氣體中毒", "B": "野生毒蘑菇中毒", "C": "有機磷農藥中毒", "D": "神經毒氣中毒", "answer": "A", "questions": "下列何種臨床症狀，不宜使用膽鹼受體阻斷劑治療？", "choices": ["一氧化碳氣體中毒", "野生毒蘑菇中毒", "有機磷農藥中毒", "神經毒氣中毒"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種臨床症狀，不宜使用膽鹼受體阻斷劑治療？\nA. 一氧化碳氣體中毒\nB. 野生毒蘑菇中毒\nC. 有機磷農藥中毒\nD. 神經毒氣中毒\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種臨床症狀，不宜使用膽鹼受體阻斷劑治療？\nA. 一氧化碳氣體中毒\nB. 野生毒蘑菇中毒\nC. 有機磷農藥中毒\nD. 神經毒氣中毒\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種臨床症狀，不宜使用膽鹼受體阻斷劑治療？\nA. 一氧化碳氣體中毒\nB. 野生毒蘑菇中毒\nC. 有機磷農藥中毒\nD. 神經毒氣中毒\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種臨床症狀，不宜使用膽鹼受體阻斷劑治療？\nA. 一氧化碳氣體中毒\nB. 野生毒蘑菇中毒\nC. 有機磷農藥中毒\nD. 神經毒氣中毒\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.26171875", "True"]], [["-1.6328125", "False"]], [["-5.75", "False"]], [["-3.515625", "False"]]], "filtered_resps": [["-0.26171875", "True"], ["-1.6328125", "False"], ["-5.75", "False"], ["-3.515625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5221364e17921ea3209a92fc142966e350abcdaeab41f360b3d5f3f5e06be9cb", "prompt_hash": "47e2fbef44b77e9de598ddb713c72a45424bc1d2b5b568019395c76cfee8bc59", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 431, "doc": {"question": "下列有關抗病毒藥oseltamivir的敘述，何者錯誤？", "A": "含guanidino官能基", "B": "是口服neuraminidase抑制劑", "C": "屬前驅藥", "D": "結構含cyclohexene環", "answer": "A", "questions": "下列有關抗病毒藥oseltamivir的敘述，何者錯誤？", "choices": ["含guanidino官能基", "是口服neuraminidase抑制劑", "屬前驅藥", "結構含cyclohexene環"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗病毒藥oseltamivir的敘述，何者錯誤？\nA. 含guanidino官能基\nB. 是口服neuraminidase抑制劑\nC. 屬前驅藥\nD. 結構含cyclohexene環\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗病毒藥oseltamivir的敘述，何者錯誤？\nA. 含guanidino官能基\nB. 是口服neuraminidase抑制劑\nC. 屬前驅藥\nD. 結構含cyclohexene環\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗病毒藥oseltamivir的敘述，何者錯誤？\nA. 含guanidino官能基\nB. 是口服neuraminidase抑制劑\nC. 屬前驅藥\nD. 結構含cyclohexene環\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗病毒藥oseltamivir的敘述，何者錯誤？\nA. 含guanidino官能基\nB. 是口服neuraminidase抑制劑\nC. 屬前驅藥\nD. 結構含cyclohexene環\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.171875", "False"]], [["-0.6796875", "True"]], [["-1.5546875", "False"]], [["-1.4296875", "False"]]], "filtered_resps": [["-3.171875", "False"], ["-0.6796875", "True"], ["-1.5546875", "False"], ["-1.4296875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1d463c2480768b6a6e50ad756ae30fc88176af57f96490e470f7c1db156d5a36", "prompt_hash": "74e255d6b2c70ea13337d69d7c3c41004332882743e1f529d260f30efeafe4ae", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 432, "doc": {"question": "有關thalidomide藥物可應用於抗發炎及免疫調節之敘述，下列何者錯誤？", "A": "具有降低嗜中性白血球之吞噬作用（phagocytosis）", "B": "具有抗血管新生作用", "C": "具有減少IL-10生成作用", "D": "可使用於多發性骨髓瘤（multiple myeloma）", "answer": "C", "questions": "有關thalidomide藥物可應用於抗發炎及免疫調節之敘述，下列何者錯誤？", "choices": ["具有降低嗜中性白血球之吞噬作用（phagocytosis）", "具有抗血管新生作用", "具有減少IL-10生成作用", "可使用於多發性骨髓瘤（multiple myeloma）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關thalidomide藥物可應用於抗發炎及免疫調節之敘述，下列何者錯誤？\nA. 具有降低嗜中性白血球之吞噬作用（phagocytosis）\nB. 具有抗血管新生作用\nC. 具有減少IL-10生成作用\nD. 可使用於多發性骨髓瘤（multiple myeloma）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關thalidomide藥物可應用於抗發炎及免疫調節之敘述，下列何者錯誤？\nA. 具有降低嗜中性白血球之吞噬作用（phagocytosis）\nB. 具有抗血管新生作用\nC. 具有減少IL-10生成作用\nD. 可使用於多發性骨髓瘤（multiple myeloma）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關thalidomide藥物可應用於抗發炎及免疫調節之敘述，下列何者錯誤？\nA. 具有降低嗜中性白血球之吞噬作用（phagocytosis）\nB. 具有抗血管新生作用\nC. 具有減少IL-10生成作用\nD. 可使用於多發性骨髓瘤（multiple myeloma）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關thalidomide藥物可應用於抗發炎及免疫調節之敘述，下列何者錯誤？\nA. 具有降低嗜中性白血球之吞噬作用（phagocytosis）\nB. 具有抗血管新生作用\nC. 具有減少IL-10生成作用\nD. 可使用於多發性骨髓瘤（multiple myeloma）\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.15625", "False"]], [["-6.65625", "False"]], [["-0.02099609375", "True"]], [["-6.40625", "False"]]], "filtered_resps": [["-4.15625", "False"], ["-6.65625", "False"], ["-0.02099609375", "True"], ["-6.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "be2ecb99cae6b15c524e90e72c4574ded23bf60c723c3f8dbee8317fcd7dd3e5", "prompt_hash": "ef93676e999d103e252de4a9e6e8e66bce8a243943d2914cd85597ca6b085b02", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 433, "doc": {"question": "下列何種抗癌藥作用機制，為造成有絲分裂停止（mitotic arrest）？", "A": "mitoxantrone", "B": "vinblastine", "C": "cytarabine", "D": "doxorubicin", "answer": "B", "questions": "下列何種抗癌藥作用機制，為造成有絲分裂停止（mitotic arrest）？", "choices": ["mitoxantrone", "vinblastine", "cytarabine", "doxorubicin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥作用機制，為造成有絲分裂停止（mitotic arrest）？\nA. mitoxantrone\nB. vinblastine\nC. cytarabine\nD. doxorubicin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥作用機制，為造成有絲分裂停止（mitotic arrest）？\nA. mitoxantrone\nB. vinblastine\nC. cytarabine\nD. doxorubicin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥作用機制，為造成有絲分裂停止（mitotic arrest）？\nA. mitoxantrone\nB. vinblastine\nC. cytarabine\nD. doxorubicin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗癌藥作用機制，為造成有絲分裂停止（mitotic arrest）？\nA. mitoxantrone\nB. vinblastine\nC. cytarabine\nD. doxorubicin\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.25", "False"]], [["-0.00439453125", "True"]], [["-7.625", "False"]], [["-6.875", "False"]]], "filtered_resps": [["-6.25", "False"], ["-0.00439453125", "True"], ["-7.625", "False"], ["-6.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b7b882c68d6d4f73229f8476085bceb9cb326692ad3866aa3ad87c63354b8ab8", "prompt_hash": "74bd740e422f8322b8a8d0dd8d686205f72a1dd6e844266fae99079915ca0862", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 434, "doc": {"question": "下列何者不是Proton pump抑制劑的特性？", "A": "主要經由胃部吸收", "B": "屬弱鹼性藥物", "C": "脂溶性高", "D": "大部分以prodrug型式使用", "answer": "A", "questions": "下列何者不是Proton pump抑制劑的特性？", "choices": ["主要經由胃部吸收", "屬弱鹼性藥物", "脂溶性高", "大部分以prodrug型式使用"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是Proton pump抑制劑的特性？\nA. 主要經由胃部吸收\nB. 屬弱鹼性藥物\nC. 脂溶性高\nD. 大部分以prodrug型式使用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是Proton pump抑制劑的特性？\nA. 主要經由胃部吸收\nB. 屬弱鹼性藥物\nC. 脂溶性高\nD. 大部分以prodrug型式使用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是Proton pump抑制劑的特性？\nA. 主要經由胃部吸收\nB. 屬弱鹼性藥物\nC. 脂溶性高\nD. 大部分以prodrug型式使用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是Proton pump抑制劑的特性？\nA. 主要經由胃部吸收\nB. 屬弱鹼性藥物\nC. 脂溶性高\nD. 大部分以prodrug型式使用\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.96484375", "True"]], [["-1.4609375", "False"]], [["-2.09375", "False"]], [["-1.3359375", "False"]]], "filtered_resps": [["-0.96484375", "True"], ["-1.4609375", "False"], ["-2.09375", "False"], ["-1.3359375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8acb98fa6d15a0353b18de6307deb9020338ab3a95e727c35410837d7c90bf75", "prompt_hash": "2d09950f8552a1663ff0afb95ab44883dc348c51fc2c912f367a4e17284be9a5", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 435, "doc": {"question": "Buspirone為新型抗焦慮藥物，其作用機轉為何？", "A": "GABAA受體拮抗劑", "B": "5-HT1A受體之部分致效劑", "C": "正腎上腺素/多巴胺再吸收抑制劑（norepinephrine-dopamine reuptake inhibitor）", "D": "鈉離子通道抑制劑", "answer": "B", "questions": "Buspirone為新型抗焦慮藥物，其作用機轉為何？", "choices": ["GABAA受體拮抗劑", "5-HT1A受體之部分致效劑", "正腎上腺素/多巴胺再吸收抑制劑（norepinephrine-dopamine reuptake inhibitor）", "鈉離子通道抑制劑"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBuspirone為新型抗焦慮藥物，其作用機轉為何？\nA. GABAA受體拮抗劑\nB. 5-HT1A受體之部分致效劑\nC. 正腎上腺素/多巴胺再吸收抑制劑（norepinephrine-dopamine reuptake inhibitor）\nD. 鈉離子通道抑制劑\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBuspirone為新型抗焦慮藥物，其作用機轉為何？\nA. GABAA受體拮抗劑\nB. 5-HT1A受體之部分致效劑\nC. 正腎上腺素/多巴胺再吸收抑制劑（norepinephrine-dopamine reuptake inhibitor）\nD. 鈉離子通道抑制劑\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBuspirone為新型抗焦慮藥物，其作用機轉為何？\nA. GABAA受體拮抗劑\nB. 5-HT1A受體之部分致效劑\nC. 正腎上腺素/多巴胺再吸收抑制劑（norepinephrine-dopamine reuptake inhibitor）\nD. 鈉離子通道抑制劑\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nBuspirone為新型抗焦慮藥物，其作用機轉為何？\nA. GABAA受體拮抗劑\nB. 5-HT1A受體之部分致效劑\nC. 正腎上腺素/多巴胺再吸收抑制劑（norepinephrine-dopamine reuptake inhibitor）\nD. 鈉離子通道抑制劑\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.875", "False"]], [["-0.0030517578125", "True"]], [["-6.75", "False"]], [["-7.25", "False"]]], "filtered_resps": [["-7.875", "False"], ["-0.0030517578125", "True"], ["-6.75", "False"], ["-7.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "41f8028af83b3f0076efa297a21bf50f33506b18714d72eb10102fc83366b85f", "prompt_hash": "bce9c9e7b5b5a0941b173972c5bf49c1ba324e0096990c48355365b546e758f7", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 436, "doc": {"question": "下列何種糖尿病治療用藥可以藉由關閉胰臟β細胞表面之ATP-sensitive potassium channels，進而促使 insulin釋放？", "A": "Metformin", "B": "Pioglitazone", "C": "Glipizide", "D": "Pramlintide", "answer": "C", "questions": "下列何種糖尿病治療用藥可以藉由關閉胰臟β細胞表面之ATP-sensitive potassium channels，進而促使 insulin釋放？", "choices": ["Metformin", "Pioglitazone", "Glipizide", "Pramlintide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種糖尿病治療用藥可以藉由關閉胰臟β細胞表面之ATP-sensitive potassium channels，進而促使 insulin釋放？\nA. Metformin\nB. Pioglitazone\nC. Glipizide\nD. Pramlintide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種糖尿病治療用藥可以藉由關閉胰臟β細胞表面之ATP-sensitive potassium channels，進而促使 insulin釋放？\nA. Metformin\nB. Pioglitazone\nC. Glipizide\nD. Pramlintide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種糖尿病治療用藥可以藉由關閉胰臟β細胞表面之ATP-sensitive potassium channels，進而促使 insulin釋放？\nA. Metformin\nB. Pioglitazone\nC. Glipizide\nD. Pramlintide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種糖尿病治療用藥可以藉由關閉胰臟β細胞表面之ATP-sensitive potassium channels，進而促使 insulin釋放？\nA. Metformin\nB. Pioglitazone\nC. Glipizide\nD. Pramlintide\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.6875", "False"]], [["-4.5625", "False"]], [["-0.054931640625", "True"]], [["-5.1875", "False"]]], "filtered_resps": [["-3.6875", "False"], ["-4.5625", "False"], ["-0.054931640625", "True"], ["-5.1875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8bf180d0ea61109fba8e0db47618685a843cd21f12fd53ec5b3401d945c93dfb", "prompt_hash": "6e39644fdd0375c8234dbcf73b1979d6ceac1247a98cc3ab7dd7cb016848e214", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 437, "doc": {"question": "藥物通過體內某一部分的擴散速率與下列何種因素成反比？", "A": "通透率係數", "B": "通過部位的厚度", "C": "濃度差", "D": "表面積", "answer": "B", "questions": "藥物通過體內某一部分的擴散速率與下列何種因素成反比？", "choices": ["通透率係數", "通過部位的厚度", "濃度差", "表面積"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n藥物通過體內某一部分的擴散速率與下列何種因素成反比？\nA. 通透率係數\nB. 通過部位的厚度\nC. 濃度差\nD. 表面積\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n藥物通過體內某一部分的擴散速率與下列何種因素成反比？\nA. 通透率係數\nB. 通過部位的厚度\nC. 濃度差\nD. 表面積\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n藥物通過體內某一部分的擴散速率與下列何種因素成反比？\nA. 通透率係數\nB. 通過部位的厚度\nC. 濃度差\nD. 表面積\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n藥物通過體內某一部分的擴散速率與下列何種因素成反比？\nA. 通透率係數\nB. 通過部位的厚度\nC. 濃度差\nD. 表面積\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-0.01025390625", "True"]], [["-5.875", "False"]], [["-5.5", "False"]]], "filtered_resps": [["-5.875", "False"], ["-0.01025390625", "True"], ["-5.875", "False"], ["-5.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6855f88af74cd1c13c99397e1b71936915425353b0b3137ce4316b80b553d123", "prompt_hash": "1ce5188a1f4ffa5390d669c0161a7d4364929de4cb6bdfd368d29f2362146330", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 438, "doc": {"question": "下列藥物，何者具有benzothiazepine結構？", "A": "clozapine", "B": "oxazepam", "C": "diltiazem", "D": "methdilazine", "answer": "C", "questions": "下列藥物，何者具有benzothiazepine結構？", "choices": ["clozapine", "oxazepam", "diltiazem", "methdilazine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者具有benzothiazepine結構？\nA. clozapine\nB. oxazepam\nC. diltiazem\nD. methdilazine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者具有benzothiazepine結構？\nA. clozapine\nB. oxazepam\nC. diltiazem\nD. methdilazine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者具有benzothiazepine結構？\nA. clozapine\nB. oxazepam\nC. diltiazem\nD. methdilazine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物，何者具有benzothiazepine結構？\nA. clozapine\nB. oxazepam\nC. diltiazem\nD. methdilazine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.0625", "False"]], [["-1.9296875", "False"]], [["-0.30859375", "True"]], [["-2.1875", "False"]]], "filtered_resps": [["-5.0625", "False"], ["-1.9296875", "False"], ["-0.30859375", "True"], ["-2.1875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fbc57f381fa592a6ef25671f62bb3aa00a7e2c68cca5fe781d6c04f33b3edf61", "prompt_hash": "54f918ead10c1ab8deacc5bc5295111cf7d5fb25f8f52c629dfc8e7b78ecbcd0", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 439, "doc": {"question": "Prednisolone的抗發炎活性約為hydrocortisone之四倍，而其鈉離子滯留則較低，主要是由於prednisolone：", "A": "在C-6和C-7間導入C=C雙鍵", "B": "在6α導入methyl取代基", "C": "在C-11位置以ketone取代hydrocortisone的hydroxy group", "D": "在C-1和C-2間導入C=C雙鍵", "answer": "D", "questions": "Prednisolone的抗發炎活性約為hydrocortisone之四倍，而其鈉離子滯留則較低，主要是由於prednisolone：", "choices": ["在C-6和C-7間導入C=C雙鍵", "在6α導入methyl取代基", "在C-11位置以ketone取代hydrocortisone的hydroxy group", "在C-1和C-2間導入C=C雙鍵"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPrednisolone的抗發炎活性約為hydrocortisone之四倍，而其鈉離子滯留則較低，主要是由於prednisolone：\nA. 在C-6和C-7間導入C=C雙鍵\nB. 在6α導入methyl取代基\nC. 在C-11位置以ketone取代hydrocortisone的hydroxy group\nD. 在C-1和C-2間導入C=C雙鍵\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPrednisolone的抗發炎活性約為hydrocortisone之四倍，而其鈉離子滯留則較低，主要是由於prednisolone：\nA. 在C-6和C-7間導入C=C雙鍵\nB. 在6α導入methyl取代基\nC. 在C-11位置以ketone取代hydrocortisone的hydroxy group\nD. 在C-1和C-2間導入C=C雙鍵\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPrednisolone的抗發炎活性約為hydrocortisone之四倍，而其鈉離子滯留則較低，主要是由於prednisolone：\nA. 在C-6和C-7間導入C=C雙鍵\nB. 在6α導入methyl取代基\nC. 在C-11位置以ketone取代hydrocortisone的hydroxy group\nD. 在C-1和C-2間導入C=C雙鍵\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPrednisolone的抗發炎活性約為hydrocortisone之四倍，而其鈉離子滯留則較低，主要是由於prednisolone：\nA. 在C-6和C-7間導入C=C雙鍵\nB. 在6α導入methyl取代基\nC. 在C-11位置以ketone取代hydrocortisone的hydroxy group\nD. 在C-1和C-2間導入C=C雙鍵\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.46875", "False"]], [["-1.96875", "False"]], [["-1.21875", "False"]], [["-1.09375", "True"]]], "filtered_resps": [["-1.46875", "False"], ["-1.96875", "False"], ["-1.21875", "False"], ["-1.09375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bed687b3084d92bfef46ffd44ef484279ce07c133d4614fb60b3cb03e6a1d998", "prompt_hash": "0ac1553f469ff85a3deef49a1b167ceae39ce43145eed835350f271396a1e09d", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 440, "doc": {"question": "Renin angiotensin system作用藥物用於治療高血壓時，下列敘述何者錯誤？", "A": "使用angiotensin II receptor blockers較少發生乾咳", "B": "enalapril是angiotensin-converting enzyme（ACE）的抑制劑", "C": "會產生高血鉀副作用", "D": "aliskiren可與valsartan併用可增加降壓效果且降低副作用", "answer": "D", "questions": "Renin angiotensin system作用藥物用於治療高血壓時，下列敘述何者錯誤？", "choices": ["使用angiotensin II receptor blockers較少發生乾咳", "enalapril是angiotensin-converting enzyme（ACE）的抑制劑", "會產生高血鉀副作用", "aliskiren可與valsartan併用可增加降壓效果且降低副作用"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRenin angiotensin system作用藥物用於治療高血壓時，下列敘述何者錯誤？\nA. 使用angiotensin II receptor blockers較少發生乾咳\nB. enalapril是angiotensin-converting enzyme（ACE）的抑制劑\nC. 會產生高血鉀副作用\nD. aliskiren可與valsartan併用可增加降壓效果且降低副作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRenin angiotensin system作用藥物用於治療高血壓時，下列敘述何者錯誤？\nA. 使用angiotensin II receptor blockers較少發生乾咳\nB. enalapril是angiotensin-converting enzyme（ACE）的抑制劑\nC. 會產生高血鉀副作用\nD. aliskiren可與valsartan併用可增加降壓效果且降低副作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRenin angiotensin system作用藥物用於治療高血壓時，下列敘述何者錯誤？\nA. 使用angiotensin II receptor blockers較少發生乾咳\nB. enalapril是angiotensin-converting enzyme（ACE）的抑制劑\nC. 會產生高血鉀副作用\nD. aliskiren可與valsartan併用可增加降壓效果且降低副作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRenin angiotensin system作用藥物用於治療高血壓時，下列敘述何者錯誤？\nA. 使用angiotensin II receptor blockers較少發生乾咳\nB. enalapril是angiotensin-converting enzyme（ACE）的抑制劑\nC. 會產生高血鉀副作用\nD. aliskiren可與valsartan併用可增加降壓效果且降低副作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.03125", "False"]], [["-4.15625", "False"]], [["-6.53125", "False"]], [["-0.03564453125", "True"]]], "filtered_resps": [["-4.03125", "False"], ["-4.15625", "False"], ["-6.53125", "False"], ["-0.03564453125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8db66ff4451ccfa6122e11180fe1ce150357c5a693ef18820e967f4ed88752c4", "prompt_hash": "d7245b18c16c5c0c5820fa5f5ad4d167bc2b918ffc45bb9cd8b25df367a8c697", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 441, "doc": {"question": "下列何種α1 -blockers在產生降壓作用時會引起最明顯的反射性心跳頻率增加？", "A": "Terazosin", "B": "Phentolamine", "C": "Prazosin", "D": "Doxazosin", "answer": "B", "questions": "下列何種α1 -blockers在產生降壓作用時會引起最明顯的反射性心跳頻率增加？", "choices": ["Terazosin", "Phentolamine", "Prazosin", "Doxazosin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種α1 -blockers在產生降壓作用時會引起最明顯的反射性心跳頻率增加？\nA. Terazosin\nB. Phentolamine\nC. Prazosin\nD. Doxazosin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種α1 -blockers在產生降壓作用時會引起最明顯的反射性心跳頻率增加？\nA. Terazosin\nB. Phentolamine\nC. Prazosin\nD. Doxazosin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種α1 -blockers在產生降壓作用時會引起最明顯的反射性心跳頻率增加？\nA. Terazosin\nB. Phentolamine\nC. Prazosin\nD. Doxazosin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種α1 -blockers在產生降壓作用時會引起最明顯的反射性心跳頻率增加？\nA. Terazosin\nB. Phentolamine\nC. Prazosin\nD. Doxazosin\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.03125", "False"]], [["-0.041015625", "True"]], [["-5.15625", "False"]], [["-3.671875", "False"]]], "filtered_resps": [["-5.03125", "False"], ["-0.041015625", "True"], ["-5.15625", "False"], ["-3.671875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "feed575765576c4ffd1ceef19608bc8fe56499f8d7cdfb1dea19a4df74f4aa5e", "prompt_hash": "e73cd37e2e31afb6942817723777a9e441d912c4e18ddffd1afea3fba2a6776e", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 442, "doc": {"question": "阿寬和同學慶祝生日喝酒到不省人事，產生所謂的“blackouts”，此時高濃度酒精的主要作用機制為何？", "A": "活化5-HT受體", "B": "抑制GABAA受體", "C": "活化NMDA受體", "D": "抑制NMDA受體", "answer": "D", "questions": "阿寬和同學慶祝生日喝酒到不省人事，產生所謂的“blackouts”，此時高濃度酒精的主要作用機制為何？", "choices": ["活化5-HT受體", "抑制GABAA受體", "活化NMDA受體", "抑制NMDA受體"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿寬和同學慶祝生日喝酒到不省人事，產生所謂的“blackouts”，此時高濃度酒精的主要作用機制為何？\nA. 活化5-HT受體\nB. 抑制GABAA受體\nC. 活化NMDA受體\nD. 抑制NMDA受體\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿寬和同學慶祝生日喝酒到不省人事，產生所謂的“blackouts”，此時高濃度酒精的主要作用機制為何？\nA. 活化5-HT受體\nB. 抑制GABAA受體\nC. 活化NMDA受體\nD. 抑制NMDA受體\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿寬和同學慶祝生日喝酒到不省人事，產生所謂的“blackouts”，此時高濃度酒精的主要作用機制為何？\nA. 活化5-HT受體\nB. 抑制GABAA受體\nC. 活化NMDA受體\nD. 抑制NMDA受體\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n阿寬和同學慶祝生日喝酒到不省人事，產生所謂的“blackouts”，此時高濃度酒精的主要作用機制為何？\nA. 活化5-HT受體\nB. 抑制GABAA受體\nC. 活化NMDA受體\nD. 抑制NMDA受體\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-5.78125", "False"]], [["-6.53125", "False"]], [["-0.0308837890625", "True"]]], "filtered_resps": [["-5.78125", "False"], ["-5.78125", "False"], ["-6.53125", "False"], ["-0.0308837890625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "cd59157fa17a27ba1d944b801233b9c51de0ad98cacd155c5293484966709fb1", "prompt_hash": "39ab5297cc0d917c87ef1af42ee6377f636f07340834e75bb9831d0d498853b1", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 443, "doc": {"question": "下列有關Osmotic diuretics之敘述，何者錯誤？", "A": "Urea為一種Osmotic diuretic，對有肝臟疾病之患者不宜使用", "B": "使心衰竭病人肺水腫更明顯", "C": "使血液鈉濃度降低，而引起頭疼、噁心等症狀", "D": "會使病人血糖降低", "answer": "D", "questions": "下列有關Osmotic diuretics之敘述，何者錯誤？", "choices": ["Urea為一種Osmotic diuretic，對有肝臟疾病之患者不宜使用", "使心衰竭病人肺水腫更明顯", "使血液鈉濃度降低，而引起頭疼、噁心等症狀", "會使病人血糖降低"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Osmotic diuretics之敘述，何者錯誤？\nA. Urea為一種Osmotic diuretic，對有肝臟疾病之患者不宜使用\nB. 使心衰竭病人肺水腫更明顯\nC. 使血液鈉濃度降低，而引起頭疼、噁心等症狀\nD. 會使病人血糖降低\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Osmotic diuretics之敘述，何者錯誤？\nA. Urea為一種Osmotic diuretic，對有肝臟疾病之患者不宜使用\nB. 使心衰竭病人肺水腫更明顯\nC. 使血液鈉濃度降低，而引起頭疼、噁心等症狀\nD. 會使病人血糖降低\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Osmotic diuretics之敘述，何者錯誤？\nA. Urea為一種Osmotic diuretic，對有肝臟疾病之患者不宜使用\nB. 使心衰竭病人肺水腫更明顯\nC. 使血液鈉濃度降低，而引起頭疼、噁心等症狀\nD. 會使病人血糖降低\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關Osmotic diuretics之敘述，何者錯誤？\nA. Urea為一種Osmotic diuretic，對有肝臟疾病之患者不宜使用\nB. 使心衰竭病人肺水腫更明顯\nC. 使血液鈉濃度降低，而引起頭疼、噁心等症狀\nD. 會使病人血糖降低\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.65625", "False"]], [["-4.65625", "False"]], [["-5.28125", "False"]], [["-0.02001953125", "True"]]], "filtered_resps": [["-5.65625", "False"], ["-4.65625", "False"], ["-5.28125", "False"], ["-0.02001953125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f161c3c0a68daf02c1cb5b7552720a56b6fac6e96523e937575c0e24a59f6e63", "prompt_hash": "4112235916810c3fe6899f45efaf0cbe40979629943640ef3857fbcaeaa227a2", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 444, "doc": {"question": "一般蛋白質或胜肽藥物half-life不長，原因與下列何者無關？", "A": "peptide bond hydrolysis", "B": "olefin epoxidation", "C": "disulfide bridge reduction", "D": "sulfur-containing residue oxidation", "answer": "B", "questions": "一般蛋白質或胜肽藥物half-life不長，原因與下列何者無關？", "choices": ["peptide bond hydrolysis", "olefin epoxidation", "disulfide bridge reduction", "sulfur-containing residue oxidation"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一般蛋白質或胜肽藥物half-life不長，原因與下列何者無關？\nA. peptide bond hydrolysis\nB. olefin epoxidation\nC. disulfide bridge reduction\nD. sulfur-containing residue oxidation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一般蛋白質或胜肽藥物half-life不長，原因與下列何者無關？\nA. peptide bond hydrolysis\nB. olefin epoxidation\nC. disulfide bridge reduction\nD. sulfur-containing residue oxidation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一般蛋白質或胜肽藥物half-life不長，原因與下列何者無關？\nA. peptide bond hydrolysis\nB. olefin epoxidation\nC. disulfide bridge reduction\nD. sulfur-containing residue oxidation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一般蛋白質或胜肽藥物half-life不長，原因與下列何者無關？\nA. peptide bond hydrolysis\nB. olefin epoxidation\nC. disulfide bridge reduction\nD. sulfur-containing residue oxidation\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.8125", "False"]], [["-0.052001953125", "True"]], [["-4.4375", "False"]], [["-3.421875", "False"]]], "filtered_resps": [["-5.8125", "False"], ["-0.052001953125", "True"], ["-4.4375", "False"], ["-3.421875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "128f816cc41491d31c91b508eea90e8b722aa3697e7460d32c367c69f569f5cd", "prompt_hash": "1893092e72e95f2b1a12b8500abfb9eccd77d4b9b519e9ec6d2446243c45ca5d", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 445, "doc": {"question": "下列治療痛風藥物，何者主要機轉為促進尿酸排除？", "A": "sulindac", "B": "colchicine", "C": "probenecid", "D": "allopurinol", "answer": "C", "questions": "下列治療痛風藥物，何者主要機轉為促進尿酸排除？", "choices": ["sulindac", "colchicine", "probenecid", "allopurinol"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療痛風藥物，何者主要機轉為促進尿酸排除？\nA. sulindac\nB. colchicine\nC. probenecid\nD. allopurinol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療痛風藥物，何者主要機轉為促進尿酸排除？\nA. sulindac\nB. colchicine\nC. probenecid\nD. allopurinol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療痛風藥物，何者主要機轉為促進尿酸排除？\nA. sulindac\nB. colchicine\nC. probenecid\nD. allopurinol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列治療痛風藥物，何者主要機轉為促進尿酸排除？\nA. sulindac\nB. colchicine\nC. probenecid\nD. allopurinol\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.90625", "False"]], [["-5.40625", "False"]], [["-0.023193359375", "True"]], [["-4.78125", "False"]]], "filtered_resps": [["-4.90625", "False"], ["-5.40625", "False"], ["-0.023193359375", "True"], ["-4.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "068a55df89bc789455e2460098e74d15239295a68d74cef852c41924c9459563", "prompt_hash": "4ec7cb02459e7a4fab0d2175a55668799cf204dd93012ccce0726533dd2915f9", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 446, "doc": {"question": "下列各項藥物與其副作用之配對中，何者錯誤？", "A": "Oprelvekin：貧血", "B": "Erythropoietin：低血壓", "C": "Ferrous sulfate：上胃部不舒服", "D": "Filgrastim：骨痛", "answer": "B", "questions": "下列各項藥物與其副作用之配對中，何者錯誤？", "choices": ["Oprelvekin：貧血", "Erythropoietin：低血壓", "Ferrous sulfate：上胃部不舒服", "Filgrastim：骨痛"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列各項藥物與其副作用之配對中，何者錯誤？\nA. Oprelvekin：貧血\nB. Erythropoietin：低血壓\nC. Ferrous sulfate：上胃部不舒服\nD. Filgrastim：骨痛\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列各項藥物與其副作用之配對中，何者錯誤？\nA. Oprelvekin：貧血\nB. Erythropoietin：低血壓\nC. Ferrous sulfate：上胃部不舒服\nD. Filgrastim：骨痛\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列各項藥物與其副作用之配對中，何者錯誤？\nA. Oprelvekin：貧血\nB. Erythropoietin：低血壓\nC. Ferrous sulfate：上胃部不舒服\nD. Filgrastim：骨痛\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列各項藥物與其副作用之配對中，何者錯誤？\nA. Oprelvekin：貧血\nB. Erythropoietin：低血壓\nC. Ferrous sulfate：上胃部不舒服\nD. Filgrastim：骨痛\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.5", "False"]], [["-1.5078125", "False"]], [["-0.3828125", "True"]], [["-4.625", "False"]]], "filtered_resps": [["-2.5", "False"], ["-1.5078125", "False"], ["-0.3828125", "True"], ["-4.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "af76b8c03720ca1e87ac1b534eec60b481fc4a49d73b683eb060de37ffaf8fb8", "prompt_hash": "d4d32a27ea650399a40f13ed772521ac6e9e590d130a4177abc4e2147140deda", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 447, "doc": {"question": "不同作用機制的利尿劑，雖作用區域不同，但其作用主要針對腎臟何種組織細胞？", "A": "系膜細胞（mesangial cells）", "B": "內皮細胞（endothelial cells）", "C": "上皮細胞（epithelial cells）", "D": "足細胞（podocyte）", "answer": "C", "questions": "不同作用機制的利尿劑，雖作用區域不同，但其作用主要針對腎臟何種組織細胞？", "choices": ["系膜細胞（mesangial cells）", "內皮細胞（endothelial cells）", "上皮細胞（epithelial cells）", "足細胞（podocyte）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n不同作用機制的利尿劑，雖作用區域不同，但其作用主要針對腎臟何種組織細胞？\nA. 系膜細胞（mesangial cells）\nB. 內皮細胞（endothelial cells）\nC. 上皮細胞（epithelial cells）\nD. 足細胞（podocyte）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n不同作用機制的利尿劑，雖作用區域不同，但其作用主要針對腎臟何種組織細胞？\nA. 系膜細胞（mesangial cells）\nB. 內皮細胞（endothelial cells）\nC. 上皮細胞（epithelial cells）\nD. 足細胞（podocyte）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n不同作用機制的利尿劑，雖作用區域不同，但其作用主要針對腎臟何種組織細胞？\nA. 系膜細胞（mesangial cells）\nB. 內皮細胞（endothelial cells）\nC. 上皮細胞（epithelial cells）\nD. 足細胞（podocyte）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n不同作用機制的利尿劑，雖作用區域不同，但其作用主要針對腎臟何種組織細胞？\nA. 系膜細胞（mesangial cells）\nB. 內皮細胞（endothelial cells）\nC. 上皮細胞（epithelial cells）\nD. 足細胞（podocyte）\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.0625", "False"]], [["-7.4375", "False"]], [["-0.068359375", "True"]], [["-3.0625", "False"]]], "filtered_resps": [["-4.0625", "False"], ["-7.4375", "False"], ["-0.068359375", "True"], ["-3.0625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ed2c0ab8679a1a770d5281f1dc9e422edf87014a65ca45d575596faa18bf9ba6", "prompt_hash": "2b4fba1a231c670ef2016765a5c412f8e29de30503c271e0f21b4685dddbb13a", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 448, "doc": {"question": "下列抗生素中，何者無法用於治療methicillin-resistant staphylococcus aureus（MRSA）之感染？", "A": "vancomycin", "B": "aztreonam", "C": "dalbavancin", "D": "ceftaroline", "answer": "B", "questions": "下列抗生素中，何者無法用於治療methicillin-resistant staphylococcus aureus（MRSA）之感染？", "choices": ["vancomycin", "aztreonam", "dalbavancin", "ceftaroline"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者無法用於治療methicillin-resistant staphylococcus aureus（MRSA）之感染？\nA. vancomycin\nB. aztreonam\nC. dalbavancin\nD. ceftaroline\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者無法用於治療methicillin-resistant staphylococcus aureus（MRSA）之感染？\nA. vancomycin\nB. aztreonam\nC. dalbavancin\nD. ceftaroline\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者無法用於治療methicillin-resistant staphylococcus aureus（MRSA）之感染？\nA. vancomycin\nB. aztreonam\nC. dalbavancin\nD. ceftaroline\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素中，何者無法用於治療methicillin-resistant staphylococcus aureus（MRSA）之感染？\nA. vancomycin\nB. aztreonam\nC. dalbavancin\nD. ceftaroline\nAnswer:", "arg_1": " D"}}, "resps": [[["-8.1875", "False"]], [["-0.016845703125", "True"]], [["-5.90625", "False"]], [["-4.40625", "False"]]], "filtered_resps": [["-8.1875", "False"], ["-0.016845703125", "True"], ["-5.90625", "False"], ["-4.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "057ea1522359ceaf1c398ccf3433f4e7c43bf6950f86b756d31352b3b9a4ce78", "prompt_hash": "6377a802ce0e96f8b899303ccd9bf31714665170605b4b05f85963d51362c13c", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 449, "doc": {"question": "Met-enkephalin是由幾個胺基酸組成？", "A": "3", "B": "10", "C": "8", "D": "5", "answer": "D", "questions": "Met-enkephalin是由幾個胺基酸組成？", "choices": ["3", "10", "8", "5"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMet-enkephalin是由幾個胺基酸組成？\nA. 3\nB. 10\nC. 8\nD. 5\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMet-enkephalin是由幾個胺基酸組成？\nA. 3\nB. 10\nC. 8\nD. 5\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMet-enkephalin是由幾個胺基酸組成？\nA. 3\nB. 10\nC. 8\nD. 5\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMet-enkephalin是由幾個胺基酸組成？\nA. 3\nB. 10\nC. 8\nD. 5\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.125", "False"]], [["-3.640625", "False"]], [["-0.1337890625", "True"]], [["-2.515625", "False"]]], "filtered_resps": [["-4.125", "False"], ["-3.640625", "False"], ["-0.1337890625", "True"], ["-2.515625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a96eea8c30b6416aebf4ae819a6bab609d8f9bac4b01a05c6c89467afd9f5115", "prompt_hash": "0c899df19c61542d338a03105ed717379238edded568c2fa30c83c7ede5bea38", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 450, "doc": {"question": "降血脂藥ezetimibe主要是減少小腸回收多種固醇類（phytosterols及cholesterol），且具有輔助statin藥物降低 LDL療效。下列何者為其作用標的？", "A": "transport protein NPC1L1", "B": "peroxisome proliferator-activated receptor", "C": "HMG-CoA reductase", "D": "microsomal triglyceride transfer protein（MTP）", "answer": "A", "questions": "降血脂藥ezetimibe主要是減少小腸回收多種固醇類（phytosterols及cholesterol），且具有輔助statin藥物降低 LDL療效。下列何者為其作用標的？", "choices": ["transport protein NPC1L1", "peroxisome proliferator-activated receptor", "HMG-CoA reductase", "microsomal triglyceride transfer protein（MTP）"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n降血脂藥ezetimibe主要是減少小腸回收多種固醇類（phytosterols及cholesterol），且具有輔助statin藥物降低 LDL療效。下列何者為其作用標的？\nA. transport protein NPC1L1\nB. peroxisome proliferator-activated receptor\nC. HMG-CoA reductase\nD. microsomal triglyceride transfer protein（MTP）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n降血脂藥ezetimibe主要是減少小腸回收多種固醇類（phytosterols及cholesterol），且具有輔助statin藥物降低 LDL療效。下列何者為其作用標的？\nA. transport protein NPC1L1\nB. peroxisome proliferator-activated receptor\nC. HMG-CoA reductase\nD. microsomal triglyceride transfer protein（MTP）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n降血脂藥ezetimibe主要是減少小腸回收多種固醇類（phytosterols及cholesterol），且具有輔助statin藥物降低 LDL療效。下列何者為其作用標的？\nA. transport protein NPC1L1\nB. peroxisome proliferator-activated receptor\nC. HMG-CoA reductase\nD. microsomal triglyceride transfer protein（MTP）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n降血脂藥ezetimibe主要是減少小腸回收多種固醇類（phytosterols及cholesterol），且具有輔助statin藥物降低 LDL療效。下列何者為其作用標的？\nA. transport protein NPC1L1\nB. peroxisome proliferator-activated receptor\nC. HMG-CoA reductase\nD. microsomal triglyceride transfer protein（MTP）\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.216796875", "True"]], [["-3.59375", "False"]], [["-3.71875", "False"]], [["-2.09375", "False"]]], "filtered_resps": [["-0.216796875", "True"], ["-3.59375", "False"], ["-3.71875", "False"], ["-2.09375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "dea70b2b08bfe27621f74debd50dd81f342e51eccfe59e326c159bc0aa816961", "prompt_hash": "b16154ff732d2c5606b39653c5736cf333a757f02a69e3e64f40e1df26d6ac11", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 451, "doc": {"question": "下列有關atropine與scopolamine之敘述，何者錯誤？", "A": "atropine即是(±)-hyoscyamine", "B": "二者皆屬於tropane類生物鹼", "C": "tropane為piperidine與pyrrolidine形成之雙環結構", "D": "scopolamine即是(±)-hyoscine", "answer": "D", "questions": "下列有關atropine與scopolamine之敘述，何者錯誤？", "choices": ["atropine即是(±)-hyoscyamine", "二者皆屬於tropane類生物鹼", "tropane為piperidine與pyrrolidine形成之雙環結構", "scopolamine即是(±)-hyoscine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關atropine與scopolamine之敘述，何者錯誤？\nA. atropine即是(±)-hyoscyamine\nB. 二者皆屬於tropane類生物鹼\nC. tropane為piperidine與pyrrolidine形成之雙環結構\nD. scopolamine即是(±)-hyoscine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關atropine與scopolamine之敘述，何者錯誤？\nA. atropine即是(±)-hyoscyamine\nB. 二者皆屬於tropane類生物鹼\nC. tropane為piperidine與pyrrolidine形成之雙環結構\nD. scopolamine即是(±)-hyoscine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關atropine與scopolamine之敘述，何者錯誤？\nA. atropine即是(±)-hyoscyamine\nB. 二者皆屬於tropane類生物鹼\nC. tropane為piperidine與pyrrolidine形成之雙環結構\nD. scopolamine即是(±)-hyoscine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關atropine與scopolamine之敘述，何者錯誤？\nA. atropine即是(±)-hyoscyamine\nB. 二者皆屬於tropane類生物鹼\nC. tropane為piperidine與pyrrolidine形成之雙環結構\nD. scopolamine即是(±)-hyoscine\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.28125", "False"]], [["-3.15625", "False"]], [["-0.28515625", "True"]], [["-2.28125", "False"]]], "filtered_resps": [["-2.28125", "False"], ["-3.15625", "False"], ["-0.28515625", "True"], ["-2.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c577cf606f2507561e4a522105f4bcd84c7b51f2ea330e3aafee48d36bb7a587", "prompt_hash": "7ee6416ea2492294b22d9b39798c9a93b29c2e151052e44c8d2f547079c0dea0", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 452, "doc": {"question": "下列有關gemfibrozil之敘述，何者錯誤？", "A": "與statin類藥物併用時，易產生橫紋肌溶解症", "B": "作用於PPARα", "C": "主要經CYP3A4代謝", "D": "含有羧酸基團，具極佳水溶性", "answer": "D", "questions": "下列有關gemfibrozil之敘述，何者錯誤？", "choices": ["與statin類藥物併用時，易產生橫紋肌溶解症", "作用於PPARα", "主要經CYP3A4代謝", "含有羧酸基團，具極佳水溶性"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關gemfibrozil之敘述，何者錯誤？\nA. 與statin類藥物併用時，易產生橫紋肌溶解症\nB. 作用於PPARα\nC. 主要經CYP3A4代謝\nD. 含有羧酸基團，具極佳水溶性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關gemfibrozil之敘述，何者錯誤？\nA. 與statin類藥物併用時，易產生橫紋肌溶解症\nB. 作用於PPARα\nC. 主要經CYP3A4代謝\nD. 含有羧酸基團，具極佳水溶性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關gemfibrozil之敘述，何者錯誤？\nA. 與statin類藥物併用時，易產生橫紋肌溶解症\nB. 作用於PPARα\nC. 主要經CYP3A4代謝\nD. 含有羧酸基團，具極佳水溶性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關gemfibrozil之敘述，何者錯誤？\nA. 與statin類藥物併用時，易產生橫紋肌溶解症\nB. 作用於PPARα\nC. 主要經CYP3A4代謝\nD. 含有羧酸基團，具極佳水溶性\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.5625", "False"]], [["-3.921875", "False"]], [["-4.0625", "False"]], [["-0.049560546875", "True"]]], "filtered_resps": [["-4.5625", "False"], ["-3.921875", "False"], ["-4.0625", "False"], ["-0.049560546875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "773bb62abf7644227137fe30c02bbe6e219a02d570a4a02a9b2fdc88cbfa529d", "prompt_hash": "76d9b3cd25f1306fa2b9f2ea350b013d9c571af3fa173caf5bb1bf19706850c1", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 453, "doc": {"question": "下列那一組抗生素併用可產生抑菌協同作用的原因是：(a)藥物可以減少(b)藥物被細菌所產生的酵素破壞？", "A": "(a) Sulbactam；(b) Ampicillin", "B": "(a) Amphotericin B；(b) Flucytocine", "C": ".(a) Imipenem；(b) Cilastatin", "D": "(a) Ticarcillin；(b) Kanamycin", "answer": "A", "questions": "下列那一組抗生素併用可產生抑菌協同作用的原因是：(a)藥物可以減少(b)藥物被細菌所產生的酵素破壞？", "choices": ["(a) Sulbactam；(b) Ampicillin", "(a) Amphotericin B；(b) Flucytocine", ".(a) Imipenem；(b) Cilastatin", "(a) Ticarcillin；(b) Kanamycin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一組抗生素併用可產生抑菌協同作用的原因是：(a)藥物可以減少(b)藥物被細菌所產生的酵素破壞？\nA. (a) Sulbactam；(b) Ampicillin\nB. (a) Amphotericin B；(b) Flucytocine\nC. .(a) Imipenem；(b) Cilastatin\nD. (a) Ticarcillin；(b) Kanamycin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一組抗生素併用可產生抑菌協同作用的原因是：(a)藥物可以減少(b)藥物被細菌所產生的酵素破壞？\nA. (a) Sulbactam；(b) Ampicillin\nB. (a) Amphotericin B；(b) Flucytocine\nC. .(a) Imipenem；(b) Cilastatin\nD. (a) Ticarcillin；(b) Kanamycin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一組抗生素併用可產生抑菌協同作用的原因是：(a)藥物可以減少(b)藥物被細菌所產生的酵素破壞？\nA. (a) Sulbactam；(b) Ampicillin\nB. (a) Amphotericin B；(b) Flucytocine\nC. .(a) Imipenem；(b) Cilastatin\nD. (a) Ticarcillin；(b) Kanamycin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一組抗生素併用可產生抑菌協同作用的原因是：(a)藥物可以減少(b)藥物被細菌所產生的酵素破壞？\nA. (a) Sulbactam；(b) Ampicillin\nB. (a) Amphotericin B；(b) Flucytocine\nC. .(a) Imipenem；(b) Cilastatin\nD. (a) Ticarcillin；(b) Kanamycin\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.0546875", "False"]], [["-3.921875", "False"]], [["-2.921875", "False"]], [["-0.55078125", "True"]]], "filtered_resps": [["-1.0546875", "False"], ["-3.921875", "False"], ["-2.921875", "False"], ["-0.55078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "40f816e4923c3483b59582546a88d51755052f4ce9744783dbc57a940ea12aa5", "prompt_hash": "55e574e6c59ed20f491d02ee027fe18ef76c5cc44cc40c55522d92295f0a6831", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 454, "doc": {"question": "下列何者最不可能為chlorpromazine的代謝方式？", "A": "hydrolysis", "B": "aromatic hydroxylation", "C": "N-demethylation", "D": "sulfoxidation", "answer": "A", "questions": "下列何者最不可能為chlorpromazine的代謝方式？", "choices": ["hydrolysis", "aromatic hydroxylation", "N-demethylation", "sulfoxidation"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者最不可能為chlorpromazine的代謝方式？\nA. hydrolysis\nB. aromatic hydroxylation\nC. N-demethylation\nD. sulfoxidation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者最不可能為chlorpromazine的代謝方式？\nA. hydrolysis\nB. aromatic hydroxylation\nC. N-demethylation\nD. sulfoxidation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者最不可能為chlorpromazine的代謝方式？\nA. hydrolysis\nB. aromatic hydroxylation\nC. N-demethylation\nD. sulfoxidation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者最不可能為chlorpromazine的代謝方式？\nA. hydrolysis\nB. aromatic hydroxylation\nC. N-demethylation\nD. sulfoxidation\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.181640625", "True"]], [["-5.1875", "False"]], [["-7.1875", "False"]], [["-1.9296875", "False"]]], "filtered_resps": [["-0.181640625", "True"], ["-5.1875", "False"], ["-7.1875", "False"], ["-1.9296875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "912efe4c5efe9dcbc1cd738bd090124225785c900b936a16587d386ebf0e42ad", "prompt_hash": "16c0455cf86b6a04f6b4a46a01a521ebecb51edd88feec7d900f79cf17d17b78", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 455, "doc": {"question": "臨床上以靜脈注射小劑量多巴胺增加腎臟的灌流，可改善少尿症，多巴胺最有可能透過那一型受體產生腎血管的舒張作用？", "A": "α", "B": "D3", "C": "D1", "D": "β1", "answer": "C", "questions": "臨床上以靜脈注射小劑量多巴胺增加腎臟的灌流，可改善少尿症，多巴胺最有可能透過那一型受體產生腎血管的舒張作用？", "choices": ["α", "D3", "D1", "β1"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上以靜脈注射小劑量多巴胺增加腎臟的灌流，可改善少尿症，多巴胺最有可能透過那一型受體產生腎血管的舒張作用？\nA. α\nB. D3\nC. D1\nD. β1\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上以靜脈注射小劑量多巴胺增加腎臟的灌流，可改善少尿症，多巴胺最有可能透過那一型受體產生腎血管的舒張作用？\nA. α\nB. D3\nC. D1\nD. β1\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上以靜脈注射小劑量多巴胺增加腎臟的灌流，可改善少尿症，多巴胺最有可能透過那一型受體產生腎血管的舒張作用？\nA. α\nB. D3\nC. D1\nD. β1\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n臨床上以靜脈注射小劑量多巴胺增加腎臟的灌流，可改善少尿症，多巴胺最有可能透過那一型受體產生腎血管的舒張作用？\nA. α\nB. D3\nC. D1\nD. β1\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.81640625", "True"]], [["-2.0625", "False"]], [["-1.3125", "False"]], [["-1.8125", "False"]]], "filtered_resps": [["-0.81640625", "True"], ["-2.0625", "False"], ["-1.3125", "False"], ["-1.8125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9d7720fbbf4ef2d281b8cc3748923e3ef373a01dd2dbee3b29e4a62c2f2a5129", "prompt_hash": "cccdb0491fd3c8f83758c7abed39926c533c8c67b421dcf35195f6ade7c22324", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 456, "doc": {"question": "口服小分子非胜肽藥eltrombopag可治療慢性免疫性血小板缺乏症（chronic immune thrombocytopenia），此藥 物為下列何種受體之致效劑？", "A": "interleukin（IL）-11", "B": "granulocyte colony-stimulating factor（G-CSF）", "C": "erythropoietin", "D": "thrombopoietin", "answer": "D", "questions": "口服小分子非胜肽藥eltrombopag可治療慢性免疫性血小板缺乏症（chronic immune thrombocytopenia），此藥 物為下列何種受體之致效劑？", "choices": ["interleukin（IL）-11", "granulocyte colony-stimulating factor（G-CSF）", "erythropoietin", "thrombopoietin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n口服小分子非胜肽藥eltrombopag可治療慢性免疫性血小板缺乏症（chronic immune thrombocytopenia），此藥 物為下列何種受體之致效劑？\nA. interleukin（IL）-11\nB. granulocyte colony-stimulating factor（G-CSF）\nC. erythropoietin\nD. thrombopoietin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n口服小分子非胜肽藥eltrombopag可治療慢性免疫性血小板缺乏症（chronic immune thrombocytopenia），此藥 物為下列何種受體之致效劑？\nA. interleukin（IL）-11\nB. granulocyte colony-stimulating factor（G-CSF）\nC. erythropoietin\nD. thrombopoietin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n口服小分子非胜肽藥eltrombopag可治療慢性免疫性血小板缺乏症（chronic immune thrombocytopenia），此藥 物為下列何種受體之致效劑？\nA. interleukin（IL）-11\nB. granulocyte colony-stimulating factor（G-CSF）\nC. erythropoietin\nD. thrombopoietin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n口服小分子非胜肽藥eltrombopag可治療慢性免疫性血小板缺乏症（chronic immune thrombocytopenia），此藥 物為下列何種受體之致效劑？\nA. interleukin（IL）-11\nB. granulocyte colony-stimulating factor（G-CSF）\nC. erythropoietin\nD. thrombopoietin\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.0", "False"]], [["-6.625", "False"]], [["-7.0", "False"]], [["-0.013671875", "True"]]], "filtered_resps": [["-5.0", "False"], ["-6.625", "False"], ["-7.0", "False"], ["-0.013671875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c8ef811c222a8750d972c56b883e4a8bc66e728272a2949279da952f12008718", "prompt_hash": "d1a5371dbf19bb130ab52d74352d38ae7585f789d09851e60c7b5f23425faaf3", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 457, "doc": {"question": "下列有關glimepiride之敘述，何者錯誤？", "A": "可結合至sulfonylurea receptor type I（SURI）", "B": "結構中含p-(β-arylcarboxyamidoethyl)，可增加受體結合力", "C": "屬於第二代sulfonylurea降血糖藥", "D": "主要經CYP3A4代謝", "answer": "D", "questions": "下列有關glimepiride之敘述，何者錯誤？", "choices": ["可結合至sulfonylurea receptor type I（SURI）", "結構中含p-(β-arylcarboxyamidoethyl)，可增加受體結合力", "屬於第二代sulfonylurea降血糖藥", "主要經CYP3A4代謝"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關glimepiride之敘述，何者錯誤？\nA. 可結合至sulfonylurea receptor type I（SURI）\nB. 結構中含p-(β-arylcarboxyamidoethyl)，可增加受體結合力\nC. 屬於第二代sulfonylurea降血糖藥\nD. 主要經CYP3A4代謝\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關glimepiride之敘述，何者錯誤？\nA. 可結合至sulfonylurea receptor type I（SURI）\nB. 結構中含p-(β-arylcarboxyamidoethyl)，可增加受體結合力\nC. 屬於第二代sulfonylurea降血糖藥\nD. 主要經CYP3A4代謝\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關glimepiride之敘述，何者錯誤？\nA. 可結合至sulfonylurea receptor type I（SURI）\nB. 結構中含p-(β-arylcarboxyamidoethyl)，可增加受體結合力\nC. 屬於第二代sulfonylurea降血糖藥\nD. 主要經CYP3A4代謝\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關glimepiride之敘述，何者錯誤？\nA. 可結合至sulfonylurea receptor type I（SURI）\nB. 結構中含p-(β-arylcarboxyamidoethyl)，可增加受體結合力\nC. 屬於第二代sulfonylurea降血糖藥\nD. 主要經CYP3A4代謝\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.59375", "False"]], [["-1.7265625", "False"]], [["-4.34375", "False"]], [["-0.2255859375", "True"]]], "filtered_resps": [["-4.59375", "False"], ["-1.7265625", "False"], ["-4.34375", "False"], ["-0.2255859375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "959c9323ae92e522eb35cdb36405ef11fdd3fb4f0f0cc70a81d77ef790011412", "prompt_hash": "acae6cd243cf78f4ddac0472572180eb772ab0b898c7162b5da5b55d13487144", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 458, "doc": {"question": "利尿劑acetazolamide為carbonic anhydrase抑制劑，可導致不同副作用，下列何者錯誤？", "A": "代謝性酸中毒（metabolic acidosis）", "B": "腎結石（renal stone）", "C": "感覺異常（paresthesia）", "D": "高血鉀症（hyperkalemia）", "answer": "D", "questions": "利尿劑acetazolamide為carbonic anhydrase抑制劑，可導致不同副作用，下列何者錯誤？", "choices": ["代謝性酸中毒（metabolic acidosis）", "腎結石（renal stone）", "感覺異常（paresthesia）", "高血鉀症（hyperkalemia）"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑acetazolamide為carbonic anhydrase抑制劑，可導致不同副作用，下列何者錯誤？\nA. 代謝性酸中毒（metabolic acidosis）\nB. 腎結石（renal stone）\nC. 感覺異常（paresthesia）\nD. 高血鉀症（hyperkalemia）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑acetazolamide為carbonic anhydrase抑制劑，可導致不同副作用，下列何者錯誤？\nA. 代謝性酸中毒（metabolic acidosis）\nB. 腎結石（renal stone）\nC. 感覺異常（paresthesia）\nD. 高血鉀症（hyperkalemia）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑acetazolamide為carbonic anhydrase抑制劑，可導致不同副作用，下列何者錯誤？\nA. 代謝性酸中毒（metabolic acidosis）\nB. 腎結石（renal stone）\nC. 感覺異常（paresthesia）\nD. 高血鉀症（hyperkalemia）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n利尿劑acetazolamide為carbonic anhydrase抑制劑，可導致不同副作用，下列何者錯誤？\nA. 代謝性酸中毒（metabolic acidosis）\nB. 腎結石（renal stone）\nC. 感覺異常（paresthesia）\nD. 高血鉀症（hyperkalemia）\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.53125", "False"]], [["-5.28125", "False"]], [["-5.90625", "False"]], [["-0.0194091796875", "True"]]], "filtered_resps": [["-4.53125", "False"], ["-5.28125", "False"], ["-5.90625", "False"], ["-0.0194091796875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2578ae4b155ad71e40f5788e8ca713e3a24230c36a56f4d52deba99e21429739", "prompt_hash": "3755ff5a33e2e5a069322d751ba5614da48606d51aed926acd99e0f09073d88b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 459, "doc": {"question": "下列何種藥物之適應症包括急性／慢性骨髓性白血病以及鐮刀型貧血症？", "A": "Cytarabine", "B": "Methotrexate", "C": "Daunorubicin", "D": "Hydroxyurea", "answer": "D", "questions": "下列何種藥物之適應症包括急性／慢性骨髓性白血病以及鐮刀型貧血症？", "choices": ["Cytarabine", "Methotrexate", "Daunorubicin", "Hydroxyurea"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之適應症包括急性／慢性骨髓性白血病以及鐮刀型貧血症？\nA. Cytarabine\nB. Methotrexate\nC. Daunorubicin\nD. Hydroxyurea\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之適應症包括急性／慢性骨髓性白血病以及鐮刀型貧血症？\nA. Cytarabine\nB. Methotrexate\nC. Daunorubicin\nD. Hydroxyurea\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之適應症包括急性／慢性骨髓性白血病以及鐮刀型貧血症？\nA. Cytarabine\nB. Methotrexate\nC. Daunorubicin\nD. Hydroxyurea\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物之適應症包括急性／慢性骨髓性白血病以及鐮刀型貧血症？\nA. Cytarabine\nB. Methotrexate\nC. Daunorubicin\nD. Hydroxyurea\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.0", "False"]], [["-5.875", "False"]], [["-8.125", "False"]], [["-0.005645751953125", "True"]]], "filtered_resps": [["-7.0", "False"], ["-5.875", "False"], ["-8.125", "False"], ["-0.005645751953125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2dea505dab17dbcf6023baeb789a5d6d291a105da6e83ed7110d59f7ca0bd797", "prompt_hash": "c83fa627d115922cde2b6bf7f4523dc5c637a9d9874572efedfef1e45c09a1b7", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 460, "doc": {"question": "下列利尿劑中，何者酸度最強？", "A": "amiloride", "B": "acetazolamide", "C": "furosemide", "D": "hydrochlorothiazide", "answer": "C", "questions": "下列利尿劑中，何者酸度最強？", "choices": ["amiloride", "acetazolamide", "furosemide", "hydrochlorothiazide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列利尿劑中，何者酸度最強？\nA. amiloride\nB. acetazolamide\nC. furosemide\nD. hydrochlorothiazide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列利尿劑中，何者酸度最強？\nA. amiloride\nB. acetazolamide\nC. furosemide\nD. hydrochlorothiazide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列利尿劑中，何者酸度最強？\nA. amiloride\nB. acetazolamide\nC. furosemide\nD. hydrochlorothiazide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列利尿劑中，何者酸度最強？\nA. amiloride\nB. acetazolamide\nC. furosemide\nD. hydrochlorothiazide\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.71875", "False"]], [["-1.2109375", "False"]], [["-0.58984375", "True"]], [["-2.09375", "False"]]], "filtered_resps": [["-3.71875", "False"], ["-1.2109375", "False"], ["-0.58984375", "True"], ["-2.09375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3cd44ecf908c3185274bccd9ab27e204c3786e4b4f4099303655199144bf8c85", "prompt_hash": "f4a99c9b76a8de9c06d15aa973feaeb6f28484435e19f8b6f2c0d3010a415bd1", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 461, "doc": {"question": "下列有關hydrocortisone酯類衍生物之敘述，何者正確？", "A": "hydrocortisone valerate可靜脈注射", "B": "hydrocortisone sodium succinate為水溶性", "C": "hydrocortisone sodium phosphate可口服", "D": "hydrocortisone cypionate為水溶性", "answer": "B", "questions": "下列有關hydrocortisone酯類衍生物之敘述，何者正確？", "choices": ["hydrocortisone valerate可靜脈注射", "hydrocortisone sodium succinate為水溶性", "hydrocortisone sodium phosphate可口服", "hydrocortisone cypionate為水溶性"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關hydrocortisone酯類衍生物之敘述，何者正確？\nA. hydrocortisone valerate可靜脈注射\nB. hydrocortisone sodium succinate為水溶性\nC. hydrocortisone sodium phosphate可口服\nD. hydrocortisone cypionate為水溶性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關hydrocortisone酯類衍生物之敘述，何者正確？\nA. hydrocortisone valerate可靜脈注射\nB. hydrocortisone sodium succinate為水溶性\nC. hydrocortisone sodium phosphate可口服\nD. hydrocortisone cypionate為水溶性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關hydrocortisone酯類衍生物之敘述，何者正確？\nA. hydrocortisone valerate可靜脈注射\nB. hydrocortisone sodium succinate為水溶性\nC. hydrocortisone sodium phosphate可口服\nD. hydrocortisone cypionate為水溶性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關hydrocortisone酯類衍生物之敘述，何者正確？\nA. hydrocortisone valerate可靜脈注射\nB. hydrocortisone sodium succinate為水溶性\nC. hydrocortisone sodium phosphate可口服\nD. hydrocortisone cypionate為水溶性\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-0.021240234375", "True"]], [["-5.40625", "False"]], [["-4.53125", "False"]]], "filtered_resps": [["-5.78125", "False"], ["-0.021240234375", "True"], ["-5.40625", "False"], ["-4.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "51650f64306d7dccccc3a083de88811b648696b458b75b9b73fd090cbfd34c98", "prompt_hash": "07859b4e178c8886b7b8a31738108062c41b3e8f7c7755311c2340f8d19671b3", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 462, "doc": {"question": "下列何者不是cocaine的水解產物？", "A": "benzoic acid", "B": "tropane", "C": "methanol", "D": "ecgonine", "answer": "B", "questions": "下列何者不是cocaine的水解產物？", "choices": ["benzoic acid", "tropane", "methanol", "ecgonine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是cocaine的水解產物？\nA. benzoic acid\nB. tropane\nC. methanol\nD. ecgonine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是cocaine的水解產物？\nA. benzoic acid\nB. tropane\nC. methanol\nD. ecgonine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是cocaine的水解產物？\nA. benzoic acid\nB. tropane\nC. methanol\nD. ecgonine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是cocaine的水解產物？\nA. benzoic acid\nB. tropane\nC. methanol\nD. ecgonine\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.375", "False"]], [["-0.01318359375", "True"]], [["-5.0", "False"]], [["-6.75", "False"]]], "filtered_resps": [["-6.375", "False"], ["-0.01318359375", "True"], ["-5.0", "False"], ["-6.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "30bae56f2c972af0bc48cc4ebdd2be5f5b865178d542b2f8255cba09617cf8be", "prompt_hash": "476082cb587d8aff152b1f235b6f51d09e463f8486596ef085f0aac5a6c1d661", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 463, "doc": {"question": "下列關於可以治療臉上皺紋之肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？", "A": "具切斷ACh之酵素活性", "B": "有多種免疫性各異的毒素，如BoNTs-A, B, C, D, E, F, G", "C": "可減少ACh的釋放", "D": "可以引起化學性去神經作用（chemodenervation）", "answer": "A", "questions": "下列關於可以治療臉上皺紋之肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？", "choices": ["具切斷ACh之酵素活性", "有多種免疫性各異的毒素，如BoNTs-A, B, C, D, E, F, G", "可減少ACh的釋放", "可以引起化學性去神經作用（chemodenervation）"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於可以治療臉上皺紋之肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？\nA. 具切斷ACh之酵素活性\nB. 有多種免疫性各異的毒素，如BoNTs-A, B, C, D, E, F, G\nC. 可減少ACh的釋放\nD. 可以引起化學性去神經作用（chemodenervation）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於可以治療臉上皺紋之肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？\nA. 具切斷ACh之酵素活性\nB. 有多種免疫性各異的毒素，如BoNTs-A, B, C, D, E, F, G\nC. 可減少ACh的釋放\nD. 可以引起化學性去神經作用（chemodenervation）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於可以治療臉上皺紋之肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？\nA. 具切斷ACh之酵素活性\nB. 有多種免疫性各異的毒素，如BoNTs-A, B, C, D, E, F, G\nC. 可減少ACh的釋放\nD. 可以引起化學性去神經作用（chemodenervation）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於可以治療臉上皺紋之肉毒桿菌毒素（botulinum toxin）的敘述，何者錯誤？\nA. 具切斷ACh之酵素活性\nB. 有多種免疫性各異的毒素，如BoNTs-A, B, C, D, E, F, G\nC. 可減少ACh的釋放\nD. 可以引起化學性去神經作用（chemodenervation）\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.8203125", "True"]], [["-1.6953125", "False"]], [["-1.0703125", "False"]], [["-3.4375", "False"]]], "filtered_resps": [["-0.8203125", "True"], ["-1.6953125", "False"], ["-1.0703125", "False"], ["-3.4375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3db5cdd5ece26e4571f5896acb88043e383639634228bc34100a9e4e453419ed", "prompt_hash": "0333d4f422eeb7df3041442fe0ccae958c4bc22b30d6f6827c779fe1c994d15e", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 464, "doc": {"question": "下列有關cevimeline之敘述，何者錯誤？", "A": "可治療Sjögren徵候群所產生之口乾症", "B": "其sulfoxide之代謝物不具活性", "C": "可作用於中樞及上皮組織之M1受體", "D": "含quinuclidine之結構", "answer": "C", "questions": "下列有關cevimeline之敘述，何者錯誤？", "choices": ["可治療Sjögren徵候群所產生之口乾症", "其sulfoxide之代謝物不具活性", "可作用於中樞及上皮組織之M1受體", "含quinuclidine之結構"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關cevimeline之敘述，何者錯誤？\nA. 可治療Sjögren徵候群所產生之口乾症\nB. 其sulfoxide之代謝物不具活性\nC. 可作用於中樞及上皮組織之M1受體\nD. 含quinuclidine之結構\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關cevimeline之敘述，何者錯誤？\nA. 可治療Sjögren徵候群所產生之口乾症\nB. 其sulfoxide之代謝物不具活性\nC. 可作用於中樞及上皮組織之M1受體\nD. 含quinuclidine之結構\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關cevimeline之敘述，何者錯誤？\nA. 可治療Sjögren徵候群所產生之口乾症\nB. 其sulfoxide之代謝物不具活性\nC. 可作用於中樞及上皮組織之M1受體\nD. 含quinuclidine之結構\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關cevimeline之敘述，何者錯誤？\nA. 可治療Sjögren徵候群所產生之口乾症\nB. 其sulfoxide之代謝物不具活性\nC. 可作用於中樞及上皮組織之M1受體\nD. 含quinuclidine之結構\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.796875", "False"]], [["-4.65625", "False"]], [["-0.041748046875", "True"]], [["-5.40625", "False"]]], "filtered_resps": [["-3.796875", "False"], ["-4.65625", "False"], ["-0.041748046875", "True"], ["-5.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6cae9041bc2601bfe1f92e9ac5f1531df0a1337ea017a8ddf56cc78ed71ae182", "prompt_hash": "dc8a00b15b2fe2e3ca22523fab879a6f60217907b413ffdd04dcb3544636214e", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 465, "doc": {"question": "下列有關pilocarpine之敘述，何者錯誤？", "A": "結構含imidazole環", "B": "可做成凝膠（gel）使用，但須貯於冷藏器（refrigerator）中", "C": "結構中含二個手性中心（chiral center）", "D": "於酸性條件下進行差向異構化（epimerization）形成isopilocarpine", "answer": "D", "questions": "下列有關pilocarpine之敘述，何者錯誤？", "choices": ["結構含imidazole環", "可做成凝膠（gel）使用，但須貯於冷藏器（refrigerator）中", "結構中含二個手性中心（chiral center）", "於酸性條件下進行差向異構化（epimerization）形成isopilocarpine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關pilocarpine之敘述，何者錯誤？\nA. 結構含imidazole環\nB. 可做成凝膠（gel）使用，但須貯於冷藏器（refrigerator）中\nC. 結構中含二個手性中心（chiral center）\nD. 於酸性條件下進行差向異構化（epimerization）形成isopilocarpine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關pilocarpine之敘述，何者錯誤？\nA. 結構含imidazole環\nB. 可做成凝膠（gel）使用，但須貯於冷藏器（refrigerator）中\nC. 結構中含二個手性中心（chiral center）\nD. 於酸性條件下進行差向異構化（epimerization）形成isopilocarpine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關pilocarpine之敘述，何者錯誤？\nA. 結構含imidazole環\nB. 可做成凝膠（gel）使用，但須貯於冷藏器（refrigerator）中\nC. 結構中含二個手性中心（chiral center）\nD. 於酸性條件下進行差向異構化（epimerization）形成isopilocarpine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關pilocarpine之敘述，何者錯誤？\nA. 結構含imidazole環\nB. 可做成凝膠（gel）使用，但須貯於冷藏器（refrigerator）中\nC. 結構中含二個手性中心（chiral center）\nD. 於酸性條件下進行差向異構化（epimerization）形成isopilocarpine\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.1875", "False"]], [["-0.68359375", "True"]], [["-1.9375", "False"]], [["-1.4375", "False"]]], "filtered_resps": [["-2.1875", "False"], ["-0.68359375", "True"], ["-1.9375", "False"], ["-1.4375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ca0123fd753674ed5d6a54cb5d458f7e10c65e451afee42d36487405f3acdadc", "prompt_hash": "1d43ca3330c9a0e86b4d286ce1472a8d7fca1ab7658dd17417fae48b7b49ec52", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 466, "doc": {"question": "下列何者為抗病毒藥 ganciclovir之主要副作用？", "A": "神經毒性", "B": "心毒性", "C": "血液毒性", "D": "腎毒性", "answer": "C", "questions": "下列何者為抗病毒藥 ganciclovir之主要副作用？", "choices": ["神經毒性", "心毒性", "血液毒性", "腎毒性"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗病毒藥 ganciclovir之主要副作用？\nA. 神經毒性\nB. 心毒性\nC. 血液毒性\nD. 腎毒性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗病毒藥 ganciclovir之主要副作用？\nA. 神經毒性\nB. 心毒性\nC. 血液毒性\nD. 腎毒性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗病毒藥 ganciclovir之主要副作用？\nA. 神經毒性\nB. 心毒性\nC. 血液毒性\nD. 腎毒性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗病毒藥 ganciclovir之主要副作用？\nA. 神經毒性\nB. 心毒性\nC. 血液毒性\nD. 腎毒性\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.25", "False"]], [["-6.0", "False"]], [["-0.11865234375", "True"]], [["-2.75", "False"]]], "filtered_resps": [["-3.25", "False"], ["-6.0", "False"], ["-0.11865234375", "True"], ["-2.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0ad6e78992340a93adfb120eaae9cd66a78cac2fbc27eced5b2b5e866f50398f", "prompt_hash": "953ca882170de2d5fa85d313ce759a423f19c30013f60d3cb8305833cc2bce81", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 467, "doc": {"question": "下列何者可透過阻斷鉀離子通道，而用於多發性硬化症（multiple sclerosis）的治療？", "A": "fingolimod", "B": "dalfampridine", "C": "glatiramer", "D": "ocrelizumab", "answer": "B", "questions": "下列何者可透過阻斷鉀離子通道，而用於多發性硬化症（multiple sclerosis）的治療？", "choices": ["fingolimod", "dalfampridine", "glatiramer", "ocrelizumab"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可透過阻斷鉀離子通道，而用於多發性硬化症（multiple sclerosis）的治療？\nA. fingolimod\nB. dalfampridine\nC. glatiramer\nD. ocrelizumab\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可透過阻斷鉀離子通道，而用於多發性硬化症（multiple sclerosis）的治療？\nA. fingolimod\nB. dalfampridine\nC. glatiramer\nD. ocrelizumab\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可透過阻斷鉀離子通道，而用於多發性硬化症（multiple sclerosis）的治療？\nA. fingolimod\nB. dalfampridine\nC. glatiramer\nD. ocrelizumab\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者可透過阻斷鉀離子通道，而用於多發性硬化症（multiple sclerosis）的治療？\nA. fingolimod\nB. dalfampridine\nC. glatiramer\nD. ocrelizumab\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.375", "False"]], [["-0.00787353515625", "True"]], [["-8.375", "False"]], [["-6.625", "False"]]], "filtered_resps": [["-5.375", "False"], ["-0.00787353515625", "True"], ["-8.375", "False"], ["-6.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0c5d2238769ef22b39ce22a803cdeefaac7ee920d79ea612fffd9c51a08757de", "prompt_hash": "504e30005fdc2321bb45c082e4b3ec0c472dfc35dcdb3e5e7119aba7d39ede00", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 468, "doc": {"question": "下列有關抗真菌藥ketoconazole的描述，何者錯誤？", "A": "可抑制CYP3A4", "B": "胃酸pH值越低，吸收越差", "C": "可口服投予", "D": "易被CYP3A4代謝", "answer": "B", "questions": "下列有關抗真菌藥ketoconazole的描述，何者錯誤？", "choices": ["可抑制CYP3A4", "胃酸pH值越低，吸收越差", "可口服投予", "易被CYP3A4代謝"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗真菌藥ketoconazole的描述，何者錯誤？\nA. 可抑制CYP3A4\nB. 胃酸pH值越低，吸收越差\nC. 可口服投予\nD. 易被CYP3A4代謝\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗真菌藥ketoconazole的描述，何者錯誤？\nA. 可抑制CYP3A4\nB. 胃酸pH值越低，吸收越差\nC. 可口服投予\nD. 易被CYP3A4代謝\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗真菌藥ketoconazole的描述，何者錯誤？\nA. 可抑制CYP3A4\nB. 胃酸pH值越低，吸收越差\nC. 可口服投予\nD. 易被CYP3A4代謝\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗真菌藥ketoconazole的描述，何者錯誤？\nA. 可抑制CYP3A4\nB. 胃酸pH值越低，吸收越差\nC. 可口服投予\nD. 易被CYP3A4代謝\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.671875", "False"]], [["-0.0458984375", "True"]], [["-5.53125", "False"]], [["-4.15625", "False"]]], "filtered_resps": [["-3.671875", "False"], ["-0.0458984375", "True"], ["-5.53125", "False"], ["-4.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b4768b1342dcfa877914373bcec43270e1cfeafbf4e7c05b4766e6968e275189", "prompt_hash": "69c4506985847a79be19b570753bfd7849c52fa8b0ba737defcf619394c0dff3", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 469, "doc": {"question": "在hydrocortisone結構中，那個位置導入氟原子，可增加其抗炎與鈉滯留活性？", "A": "21", "B": "2", "C": "9", "D": "11", "answer": "C", "questions": "在hydrocortisone結構中，那個位置導入氟原子，可增加其抗炎與鈉滯留活性？", "choices": ["21", "2", "9", "11"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在hydrocortisone結構中，那個位置導入氟原子，可增加其抗炎與鈉滯留活性？\nA. 21\nB. 2\nC. 9\nD. 11\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在hydrocortisone結構中，那個位置導入氟原子，可增加其抗炎與鈉滯留活性？\nA. 21\nB. 2\nC. 9\nD. 11\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在hydrocortisone結構中，那個位置導入氟原子，可增加其抗炎與鈉滯留活性？\nA. 21\nB. 2\nC. 9\nD. 11\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在hydrocortisone結構中，那個位置導入氟原子，可增加其抗炎與鈉滯留活性？\nA. 21\nB. 2\nC. 9\nD. 11\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.296875", "False"]], [["-3.171875", "False"]], [["-4.0625", "False"]], [["-0.173828125", "True"]]], "filtered_resps": [["-2.296875", "False"], ["-3.171875", "False"], ["-4.0625", "False"], ["-0.173828125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b9c3d8c2544395425f0736c975344c0ab590a91fefa957fc075c8584cf757883", "prompt_hash": "02adc1204d424a31b479315ed363137265c42eaebb8922dd1a0cd80482631006", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 470, "doc": {"question": "選擇性 COX-2 抑制劑之藥物設計，是利用是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異？活性中心何種胺基酸的差異", "A": "threonine 與 valine", "B": "serine 與 valine", "C": "isoleucine 與 valine", "D": "leucine 與 valine", "answer": "C", "questions": "選擇性 COX-2 抑制劑之藥物設計，是利用是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異？活性中心何種胺基酸的差異", "choices": ["threonine 與 valine", "serine 與 valine", "isoleucine 與 valine", "leucine 與 valine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性 COX-2 抑制劑之藥物設計，是利用是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異？活性中心何種胺基酸的差異\nA. threonine 與 valine\nB. serine 與 valine\nC. isoleucine 與 valine\nD. leucine 與 valine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性 COX-2 抑制劑之藥物設計，是利用是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異？活性中心何種胺基酸的差異\nA. threonine 與 valine\nB. serine 與 valine\nC. isoleucine 與 valine\nD. leucine 與 valine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性 COX-2 抑制劑之藥物設計，是利用是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異？活性中心何種胺基酸的差異\nA. threonine 與 valine\nB. serine 與 valine\nC. isoleucine 與 valine\nD. leucine 與 valine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性 COX-2 抑制劑之藥物設計，是利用是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異？活性中心何種胺基酸的差異\nA. threonine 與 valine\nB. serine 與 valine\nC. isoleucine 與 valine\nD. leucine 與 valine\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.296875", "False"]], [["-2.921875", "False"]], [["-1.796875", "False"]], [["-0.296875", "True"]]], "filtered_resps": [["-3.296875", "False"], ["-2.921875", "False"], ["-1.796875", "False"], ["-0.296875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8b6a961b4886fa3e2f725b3ad30282b06d3b81812c300ac1892b186fe0eb516a", "prompt_hash": "ae3c203b872d73ba5ef231e4a5e86d0f768515ec53c6be7f648b38b8ccf446ba", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 471, "doc": {"question": "下列何者為Digoxin用於治療心房纖維顫動的最主要藥理作用機轉？", "A": "增加心房的傳導時間", "B": "減少副交感神經的活性", "C": "減少心房的跳動速率", "D": "增加房室結的不反應期", "answer": "D", "questions": "下列何者為Digoxin用於治療心房纖維顫動的最主要藥理作用機轉？", "choices": ["增加心房的傳導時間", "減少副交感神經的活性", "減少心房的跳動速率", "增加房室結的不反應期"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為Digoxin用於治療心房纖維顫動的最主要藥理作用機轉？\nA. 增加心房的傳導時間\nB. 減少副交感神經的活性\nC. 減少心房的跳動速率\nD. 增加房室結的不反應期\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為Digoxin用於治療心房纖維顫動的最主要藥理作用機轉？\nA. 增加心房的傳導時間\nB. 減少副交感神經的活性\nC. 減少心房的跳動速率\nD. 增加房室結的不反應期\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為Digoxin用於治療心房纖維顫動的最主要藥理作用機轉？\nA. 增加心房的傳導時間\nB. 減少副交感神經的活性\nC. 減少心房的跳動速率\nD. 增加房室結的不反應期\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為Digoxin用於治療心房纖維顫動的最主要藥理作用機轉？\nA. 增加心房的傳導時間\nB. 減少副交感神經的活性\nC. 減少心房的跳動速率\nD. 增加房室結的不反應期\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.53125", "False"]], [["-6.28125", "False"]], [["-3.90625", "False"]], [["-0.03369140625", "True"]]], "filtered_resps": [["-4.53125", "False"], ["-6.28125", "False"], ["-3.90625", "False"], ["-0.03369140625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "07ae4ab9405034f923edc277eb4642223c2f09def88eae4ce449b0fe48ec9261", "prompt_hash": "076ea74733619eb7151ac403b3155a61ec2cbec77a4c04ba49280b2ae90841b0", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 472, "doc": {"question": "下列有關amantadine的敘述，何者錯誤？", "A": "屬於非對稱（asymmetric）結構", "B": "含有初級胺（primary amine）", "C": "可預防流感病毒感染", "D": "可用於帕金森氏症", "answer": "A", "questions": "下列有關amantadine的敘述，何者錯誤？", "choices": ["屬於非對稱（asymmetric）結構", "含有初級胺（primary amine）", "可預防流感病毒感染", "可用於帕金森氏症"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關amantadine的敘述，何者錯誤？\nA. 屬於非對稱（asymmetric）結構\nB. 含有初級胺（primary amine）\nC. 可預防流感病毒感染\nD. 可用於帕金森氏症\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關amantadine的敘述，何者錯誤？\nA. 屬於非對稱（asymmetric）結構\nB. 含有初級胺（primary amine）\nC. 可預防流感病毒感染\nD. 可用於帕金森氏症\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關amantadine的敘述，何者錯誤？\nA. 屬於非對稱（asymmetric）結構\nB. 含有初級胺（primary amine）\nC. 可預防流感病毒感染\nD. 可用於帕金森氏症\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關amantadine的敘述，何者錯誤？\nA. 屬於非對稱（asymmetric）結構\nB. 含有初級胺（primary amine）\nC. 可預防流感病毒感染\nD. 可用於帕金森氏症\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.546875", "True"]], [["-1.046875", "False"]], [["-3.046875", "False"]], [["-3.796875", "False"]]], "filtered_resps": [["-0.546875", "True"], ["-1.046875", "False"], ["-3.046875", "False"], ["-3.796875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7c48d4ce805a4636c08af6245b3ab0e667bf4c8a3c04107a0d10163e76196464", "prompt_hash": "5ff93c3593570d56d16d9b2644a648cc0bd1d678920e22f89f45543fe3dd769f", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 473, "doc": {"question": "下列有關 methenamine 之敘述，何者錯誤？", "A": "主要抗菌作用在低 pH 值環境", "B": "可由甲醛與強氨水合成", "C": "結構含 6 個氮原子", "D": "用於泌尿道感染", "answer": "C", "questions": "下列有關 methenamine 之敘述，何者錯誤？", "choices": ["主要抗菌作用在低 pH 值環境", "可由甲醛與強氨水合成", "結構含 6 個氮原子", "用於泌尿道感染"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 methenamine 之敘述，何者錯誤？\nA. 主要抗菌作用在低 pH 值環境\nB. 可由甲醛與強氨水合成\nC. 結構含 6 個氮原子\nD. 用於泌尿道感染\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 methenamine 之敘述，何者錯誤？\nA. 主要抗菌作用在低 pH 值環境\nB. 可由甲醛與強氨水合成\nC. 結構含 6 個氮原子\nD. 用於泌尿道感染\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 methenamine 之敘述，何者錯誤？\nA. 主要抗菌作用在低 pH 值環境\nB. 可由甲醛與強氨水合成\nC. 結構含 6 個氮原子\nD. 用於泌尿道感染\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 methenamine 之敘述，何者錯誤？\nA. 主要抗菌作用在低 pH 值環境\nB. 可由甲醛與強氨水合成\nC. 結構含 6 個氮原子\nD. 用於泌尿道感染\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.0625", "False"]], [["-2.0625", "False"]], [["-0.19140625", "True"]], [["-7.4375", "False"]]], "filtered_resps": [["-3.0625", "False"], ["-2.0625", "False"], ["-0.19140625", "True"], ["-7.4375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fb2b7c5878dcdfb1ad5e71af2ac111fe6ddfcfe59372c0362982589dfc858b6d", "prompt_hash": "8314371a00ecb9671d9c780f540edc8cc7b5496ca203cca9bbf714977d517c6d", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 474, "doc": {"question": "擬膽鹼作用劑（cholinomimetics）包含膽鹼受體激活作用劑與乙醯膽鹼酯酶抑制劑，但不可應用在下列何種疾病的治療？", "A": "眼疾，例如青光眼（glaucoma）", "B": "神經退化性疾病，例如帕金森氏症（Parkinson's disease）", "C": "腸胃道或泌尿道異常，例如手術後腸胃道或膀胱弛緩（postoperative atony）", "D": "神經肌肉聯會障礙，例如重症肌無力（myasthenia gravis）", "answer": "B", "questions": "擬膽鹼作用劑（cholinomimetics）包含膽鹼受體激活作用劑與乙醯膽鹼酯酶抑制劑，但不可應用在下列何種疾病的治療？", "choices": ["眼疾，例如青光眼（glaucoma）", "神經退化性疾病，例如帕金森氏症（Parkinson's disease）", "腸胃道或泌尿道異常，例如手術後腸胃道或膀胱弛緩（postoperative atony）", "神經肌肉聯會障礙，例如重症肌無力（myasthenia gravis）"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬膽鹼作用劑（cholinomimetics）包含膽鹼受體激活作用劑與乙醯膽鹼酯酶抑制劑，但不可應用在下列何種疾病的治療？\nA. 眼疾，例如青光眼（glaucoma）\nB. 神經退化性疾病，例如帕金森氏症（Parkinson's disease）\nC. 腸胃道或泌尿道異常，例如手術後腸胃道或膀胱弛緩（postoperative atony）\nD. 神經肌肉聯會障礙，例如重症肌無力（myasthenia gravis）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬膽鹼作用劑（cholinomimetics）包含膽鹼受體激活作用劑與乙醯膽鹼酯酶抑制劑，但不可應用在下列何種疾病的治療？\nA. 眼疾，例如青光眼（glaucoma）\nB. 神經退化性疾病，例如帕金森氏症（Parkinson's disease）\nC. 腸胃道或泌尿道異常，例如手術後腸胃道或膀胱弛緩（postoperative atony）\nD. 神經肌肉聯會障礙，例如重症肌無力（myasthenia gravis）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬膽鹼作用劑（cholinomimetics）包含膽鹼受體激活作用劑與乙醯膽鹼酯酶抑制劑，但不可應用在下列何種疾病的治療？\nA. 眼疾，例如青光眼（glaucoma）\nB. 神經退化性疾病，例如帕金森氏症（Parkinson's disease）\nC. 腸胃道或泌尿道異常，例如手術後腸胃道或膀胱弛緩（postoperative atony）\nD. 神經肌肉聯會障礙，例如重症肌無力（myasthenia gravis）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n擬膽鹼作用劑（cholinomimetics）包含膽鹼受體激活作用劑與乙醯膽鹼酯酶抑制劑，但不可應用在下列何種疾病的治療？\nA. 眼疾，例如青光眼（glaucoma）\nB. 神經退化性疾病，例如帕金森氏症（Parkinson's disease）\nC. 腸胃道或泌尿道異常，例如手術後腸胃道或膀胱弛緩（postoperative atony）\nD. 神經肌肉聯會障礙，例如重症肌無力（myasthenia gravis）\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.5", "False"]], [["-0.0115966796875", "True"]], [["-5.75", "False"]], [["-5.125", "False"]]], "filtered_resps": [["-6.5", "False"], ["-0.0115966796875", "True"], ["-5.75", "False"], ["-5.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e2a87043ad8b82689a7b18d545f2cb029bd0c507b62e2772c2bd7cecbef11b84", "prompt_hash": "4d55e19f222020990223d7e5399869da4370c8984214e2f576382ae3a195acd0", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 475, "doc": {"question": "下列何者為parecoxib和valdecoxib所共有的雜環？", "A": "pyrazole", "B": "furanone", "C": "isoxazole", "D": "pyridine", "answer": "C", "questions": "下列何者為parecoxib和valdecoxib所共有的雜環？", "choices": ["pyrazole", "furanone", "isoxazole", "pyridine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為parecoxib和valdecoxib所共有的雜環？\nA. pyrazole\nB. furanone\nC. isoxazole\nD. pyridine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為parecoxib和valdecoxib所共有的雜環？\nA. pyrazole\nB. furanone\nC. isoxazole\nD. pyridine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為parecoxib和valdecoxib所共有的雜環？\nA. pyrazole\nB. furanone\nC. isoxazole\nD. pyridine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為parecoxib和valdecoxib所共有的雜環？\nA. pyrazole\nB. furanone\nC. isoxazole\nD. pyridine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.03125", "False"]], [["-4.78125", "False"]], [["-0.0255126953125", "True"]], [["-4.90625", "False"]]], "filtered_resps": [["-5.03125", "False"], ["-4.78125", "False"], ["-0.0255126953125", "True"], ["-4.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "47deae288604e2d95809d43a9a7dde98ae96658fc406adcb1734f4f1151e00f6", "prompt_hash": "cb6af9f4a07a7b274d002f7f4fb9fcbb2dc6febec509c2516fe5f33d6415dee5", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 476, "doc": {"question": "下列何項利尿劑具有phthalimidine結構，且可開環形成benzophenone衍生物？", "A": "chlorthalidone", "B": "indapamide", "C": "metolazone", "D": "quinethazone", "answer": "A", "questions": "下列何項利尿劑具有phthalimidine結構，且可開環形成benzophenone衍生物？", "choices": ["chlorthalidone", "indapamide", "metolazone", "quinethazone"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何項利尿劑具有phthalimidine結構，且可開環形成benzophenone衍生物？\nA. chlorthalidone\nB. indapamide\nC. metolazone\nD. quinethazone\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何項利尿劑具有phthalimidine結構，且可開環形成benzophenone衍生物？\nA. chlorthalidone\nB. indapamide\nC. metolazone\nD. quinethazone\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何項利尿劑具有phthalimidine結構，且可開環形成benzophenone衍生物？\nA. chlorthalidone\nB. indapamide\nC. metolazone\nD. quinethazone\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何項利尿劑具有phthalimidine結構，且可開環形成benzophenone衍生物？\nA. chlorthalidone\nB. indapamide\nC. metolazone\nD. quinethazone\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.06591796875", "True"]], [["-3.9375", "False"]], [["-4.4375", "False"]], [["-3.5625", "False"]]], "filtered_resps": [["-0.06591796875", "True"], ["-3.9375", "False"], ["-4.4375", "False"], ["-3.5625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "da63d5c82f2bff0572027df329e6c529adc0f4ebd99324abb2cde49c9ed6aad1", "prompt_hash": "ab472f1e32b70c35bc3238c5ca18c6ad7a4f18ce000f8e24eebccd7c04283efc", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 477, "doc": {"question": "下列抗心律不整藥物中，何者屬bis-methanesulfonamide衍生物？", "A": "sotalol", "B": "procainamide", "C": "dofetilide", "D": "ibutilide", "answer": "C", "questions": "下列抗心律不整藥物中，何者屬bis-methanesulfonamide衍生物？", "choices": ["sotalol", "procainamide", "dofetilide", "ibutilide"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗心律不整藥物中，何者屬bis-methanesulfonamide衍生物？\nA. sotalol\nB. procainamide\nC. dofetilide\nD. ibutilide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗心律不整藥物中，何者屬bis-methanesulfonamide衍生物？\nA. sotalol\nB. procainamide\nC. dofetilide\nD. ibutilide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗心律不整藥物中，何者屬bis-methanesulfonamide衍生物？\nA. sotalol\nB. procainamide\nC. dofetilide\nD. ibutilide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗心律不整藥物中，何者屬bis-methanesulfonamide衍生物？\nA. sotalol\nB. procainamide\nC. dofetilide\nD. ibutilide\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.4453125", "False"]], [["-6.0625", "False"]], [["-0.3203125", "True"]], [["-3.328125", "False"]]], "filtered_resps": [["-1.4453125", "False"], ["-6.0625", "False"], ["-0.3203125", "True"], ["-3.328125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0e601025fb61a3d5e60dc64a229868551015304aa6e0ee4dcb427d9b7f4434fb", "prompt_hash": "79903a2f871c98d990fd0ffcb975f46af4b6e7fd1356b6a1e4dc045779bd4e59", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 478, "doc": {"question": "有關bismuth subsalicylate的敘述，下列何者錯誤？", "A": "bismuth具有抗菌作用", "B": "口服後在胃中分解出bismuth及salicylate，而二者再被吸收", "C": "salicylate可以抑制prostaglandin的分泌", "D": "bismuth具有保護胃壁的作用", "answer": "B", "questions": "有關bismuth subsalicylate的敘述，下列何者錯誤？", "choices": ["bismuth具有抗菌作用", "口服後在胃中分解出bismuth及salicylate，而二者再被吸收", "salicylate可以抑制prostaglandin的分泌", "bismuth具有保護胃壁的作用"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關bismuth subsalicylate的敘述，下列何者錯誤？\nA. bismuth具有抗菌作用\nB. 口服後在胃中分解出bismuth及salicylate，而二者再被吸收\nC. salicylate可以抑制prostaglandin的分泌\nD. bismuth具有保護胃壁的作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關bismuth subsalicylate的敘述，下列何者錯誤？\nA. bismuth具有抗菌作用\nB. 口服後在胃中分解出bismuth及salicylate，而二者再被吸收\nC. salicylate可以抑制prostaglandin的分泌\nD. bismuth具有保護胃壁的作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關bismuth subsalicylate的敘述，下列何者錯誤？\nA. bismuth具有抗菌作用\nB. 口服後在胃中分解出bismuth及salicylate，而二者再被吸收\nC. salicylate可以抑制prostaglandin的分泌\nD. bismuth具有保護胃壁的作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關bismuth subsalicylate的敘述，下列何者錯誤？\nA. bismuth具有抗菌作用\nB. 口服後在胃中分解出bismuth及salicylate，而二者再被吸收\nC. salicylate可以抑制prostaglandin的分泌\nD. bismuth具有保護胃壁的作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.625", "False"]], [["-0.006256103515625", "True"]], [["-5.75", "False"]], [["-6.5", "False"]]], "filtered_resps": [["-6.625", "False"], ["-0.006256103515625", "True"], ["-5.75", "False"], ["-6.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6819531b1eac3deb6ad3e9210b80f8964ace620b37de9343f516770f34cb4129", "prompt_hash": "cb4a7a1134b9ac48bd16481b7f17d77965562050dc5da93d69f221a55671f2b2", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 479, "doc": {"question": "下列藥物中，何者可抑制副交感神經元進行胞吐作用（exocytosis），減少乙醯膽鹼（acetylcholine）之釋出？", "A": "cocaine", "B": "reserpine", "C": "botulinum toxin", "D": "vesamicol", "answer": "C", "questions": "下列藥物中，何者可抑制副交感神經元進行胞吐作用（exocytosis），減少乙醯膽鹼（acetylcholine）之釋出？", "choices": ["cocaine", "reserpine", "botulinum toxin", "vesamicol"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者可抑制副交感神經元進行胞吐作用（exocytosis），減少乙醯膽鹼（acetylcholine）之釋出？\nA. cocaine\nB. reserpine\nC. botulinum toxin\nD. vesamicol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者可抑制副交感神經元進行胞吐作用（exocytosis），減少乙醯膽鹼（acetylcholine）之釋出？\nA. cocaine\nB. reserpine\nC. botulinum toxin\nD. vesamicol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者可抑制副交感神經元進行胞吐作用（exocytosis），減少乙醯膽鹼（acetylcholine）之釋出？\nA. cocaine\nB. reserpine\nC. botulinum toxin\nD. vesamicol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物中，何者可抑制副交感神經元進行胞吐作用（exocytosis），減少乙醯膽鹼（acetylcholine）之釋出？\nA. cocaine\nB. reserpine\nC. botulinum toxin\nD. vesamicol\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.03125", "False"]], [["-5.15625", "False"]], [["-0.037109375", "True"]], [["-3.65625", "False"]]], "filtered_resps": [["-6.03125", "False"], ["-5.15625", "False"], ["-0.037109375", "True"], ["-3.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "bc48fc86769d12798884424e84455c55f80311a99cee9fddd432dc6e15c71c76", "prompt_hash": "420b7a29de4611fff66ee645b46a765783f807e1283e71d211b23ca401064a97", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 480, "doc": {"question": "下列抗炎藥，何者具有chiral center？", "A": "oxaprozin", "B": "tolmetin", "C": "nabumetone", "D": "naproxen", "answer": "D", "questions": "下列抗炎藥，何者具有chiral center？", "choices": ["oxaprozin", "tolmetin", "nabumetone", "naproxen"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗炎藥，何者具有chiral center？\nA. oxaprozin\nB. tolmetin\nC. nabumetone\nD. naproxen\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗炎藥，何者具有chiral center？\nA. oxaprozin\nB. tolmetin\nC. nabumetone\nD. naproxen\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗炎藥，何者具有chiral center？\nA. oxaprozin\nB. tolmetin\nC. nabumetone\nD. naproxen\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗炎藥，何者具有chiral center？\nA. oxaprozin\nB. tolmetin\nC. nabumetone\nD. naproxen\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.0", "False"]], [["-6.25", "False"]], [["-7.625", "False"]], [["-0.008056640625", "True"]]], "filtered_resps": [["-6.0", "False"], ["-6.25", "False"], ["-7.625", "False"], ["-0.008056640625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ddd9936ef8d4f2180a18dbfe428569c632d60863f8ecf408e584a2cae9681e91", "prompt_hash": "ef9eb047bf1a7b9bb59b3dadcdc0ddc32985e52001fccf021a742657d24e95c6", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 481, "doc": {"question": "抗凝血藥物Fondaparinux為抑制那一個凝血因子？", "A": "Ⅱa", "B": "Ⅶa", "C": "Ⅸa", "D": "Ⅹa", "answer": "D", "questions": "抗凝血藥物Fondaparinux為抑制那一個凝血因子？", "choices": ["Ⅱa", "Ⅶa", "Ⅸa", "Ⅹa"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗凝血藥物Fondaparinux為抑制那一個凝血因子？\nA. Ⅱa\nB. Ⅶa\nC. Ⅸa\nD. Ⅹa\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗凝血藥物Fondaparinux為抑制那一個凝血因子？\nA. Ⅱa\nB. Ⅶa\nC. Ⅸa\nD. Ⅹa\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗凝血藥物Fondaparinux為抑制那一個凝血因子？\nA. Ⅱa\nB. Ⅶa\nC. Ⅸa\nD. Ⅹa\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗凝血藥物Fondaparinux為抑制那一個凝血因子？\nA. Ⅱa\nB. Ⅶa\nC. Ⅸa\nD. Ⅹa\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.375", "False"]], [["-5.125", "False"]], [["-5.625", "False"]], [["-0.01171875", "True"]]], "filtered_resps": [["-6.375", "False"], ["-5.125", "False"], ["-5.625", "False"], ["-0.01171875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "82ebd54744be4eaf64acafcc7b0d7e737fa9ceb0bad03a0716c38dd100231757", "prompt_hash": "fff20f47ff5bbad6c38d10fb42f0fad06b2fc7cc4daeb8e00c12cd969119bf42", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 482, "doc": {"question": "一位HIV檢測陽性，酗酒及胸部X光檢驗結果高度疑似肺結核之急診病患，下列有關此病患給藥的處置何者錯誤？", "A": "若用rifabutin可以與dolutegravir同時使用", "B": "以rifabutin, isoniazid, pyrazinamide及ethambutol開始治療", "C": "此病患使用isoniazid與pyrazinamide產生肝毒性風險會增加", "D": "HIV治療用藥atazanavir可以與rifampin同時使用", "answer": "D", "questions": "一位HIV檢測陽性，酗酒及胸部X光檢驗結果高度疑似肺結核之急診病患，下列有關此病患給藥的處置何者錯誤？", "choices": ["若用rifabutin可以與dolutegravir同時使用", "以rifabutin, isoniazid, pyrazinamide及ethambutol開始治療", "此病患使用isoniazid與pyrazinamide產生肝毒性風險會增加", "HIV治療用藥atazanavir可以與rifampin同時使用"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位HIV檢測陽性，酗酒及胸部X光檢驗結果高度疑似肺結核之急診病患，下列有關此病患給藥的處置何者錯誤？\nA. 若用rifabutin可以與dolutegravir同時使用\nB. 以rifabutin, isoniazid, pyrazinamide及ethambutol開始治療\nC. 此病患使用isoniazid與pyrazinamide產生肝毒性風險會增加\nD. HIV治療用藥atazanavir可以與rifampin同時使用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位HIV檢測陽性，酗酒及胸部X光檢驗結果高度疑似肺結核之急診病患，下列有關此病患給藥的處置何者錯誤？\nA. 若用rifabutin可以與dolutegravir同時使用\nB. 以rifabutin, isoniazid, pyrazinamide及ethambutol開始治療\nC. 此病患使用isoniazid與pyrazinamide產生肝毒性風險會增加\nD. HIV治療用藥atazanavir可以與rifampin同時使用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位HIV檢測陽性，酗酒及胸部X光檢驗結果高度疑似肺結核之急診病患，下列有關此病患給藥的處置何者錯誤？\nA. 若用rifabutin可以與dolutegravir同時使用\nB. 以rifabutin, isoniazid, pyrazinamide及ethambutol開始治療\nC. 此病患使用isoniazid與pyrazinamide產生肝毒性風險會增加\nD. HIV治療用藥atazanavir可以與rifampin同時使用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一位HIV檢測陽性，酗酒及胸部X光檢驗結果高度疑似肺結核之急診病患，下列有關此病患給藥的處置何者錯誤？\nA. 若用rifabutin可以與dolutegravir同時使用\nB. 以rifabutin, isoniazid, pyrazinamide及ethambutol開始治療\nC. 此病患使用isoniazid與pyrazinamide產生肝毒性風險會增加\nD. HIV治療用藥atazanavir可以與rifampin同時使用\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.0859375", "False"]], [["-2.71875", "False"]], [["-3.21875", "False"]], [["-0.5859375", "True"]]], "filtered_resps": [["-1.0859375", "False"], ["-2.71875", "False"], ["-3.21875", "False"], ["-0.5859375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1ebabfa5c46dcb6eef37de7b6d770bb31eb6093fb89b09bb328d223ed95e0ae4", "prompt_hash": "a1b2baca474bada82bf3baf7d6a56ad2bef3a3380ee017c9892415b4eaa7705b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 483, "doc": {"question": "Clorazepate經下列何種反應，可得到活性代謝物N-desmethyldiazepam？", "A": "hydrolysis", "B": "esterification", "C": "hydroxylation", "D": "decarboxylation", "answer": "D", "questions": "Clorazepate經下列何種反應，可得到活性代謝物N-desmethyldiazepam？", "choices": ["hydrolysis", "esterification", "hydroxylation", "decarboxylation"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClorazepate經下列何種反應，可得到活性代謝物N-desmethyldiazepam？\nA. hydrolysis\nB. esterification\nC. hydroxylation\nD. decarboxylation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClorazepate經下列何種反應，可得到活性代謝物N-desmethyldiazepam？\nA. hydrolysis\nB. esterification\nC. hydroxylation\nD. decarboxylation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClorazepate經下列何種反應，可得到活性代謝物N-desmethyldiazepam？\nA. hydrolysis\nB. esterification\nC. hydroxylation\nD. decarboxylation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nClorazepate經下列何種反應，可得到活性代謝物N-desmethyldiazepam？\nA. hydrolysis\nB. esterification\nC. hydroxylation\nD. decarboxylation\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.53125", "False"]], [["-2.40625", "False"]], [["-4.15625", "False"]], [["-0.15234375", "True"]]], "filtered_resps": [["-3.53125", "False"], ["-2.40625", "False"], ["-4.15625", "False"], ["-0.15234375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d2ba486d73c4ae5d8f65e8da99d732c7cab1f4e2a922af3312ab6548d5713ac5", "prompt_hash": "79951cb40f0cadab47ebe6d666f49efd8fd16e7fe2529824446db9e0895a2dfc", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 484, "doc": {"question": "有關insulin glargine之敘述，下列何者錯誤？", "A": "可製成澄清製劑並以靜脈注射給藥", "B": "將insulin的A21Asn修飾成Gly", "C": "此藥之等電點（isoelectric point）接近7", "D": "於insulin加入B31Arg與B32Arg", "answer": "A", "questions": "有關insulin glargine之敘述，下列何者錯誤？", "choices": ["可製成澄清製劑並以靜脈注射給藥", "將insulin的A21Asn修飾成Gly", "此藥之等電點（isoelectric point）接近7", "於insulin加入B31Arg與B32Arg"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關insulin glargine之敘述，下列何者錯誤？\nA. 可製成澄清製劑並以靜脈注射給藥\nB. 將insulin的A21Asn修飾成Gly\nC. 此藥之等電點（isoelectric point）接近7\nD. 於insulin加入B31Arg與B32Arg\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關insulin glargine之敘述，下列何者錯誤？\nA. 可製成澄清製劑並以靜脈注射給藥\nB. 將insulin的A21Asn修飾成Gly\nC. 此藥之等電點（isoelectric point）接近7\nD. 於insulin加入B31Arg與B32Arg\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關insulin glargine之敘述，下列何者錯誤？\nA. 可製成澄清製劑並以靜脈注射給藥\nB. 將insulin的A21Asn修飾成Gly\nC. 此藥之等電點（isoelectric point）接近7\nD. 於insulin加入B31Arg與B32Arg\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關insulin glargine之敘述，下列何者錯誤？\nA. 可製成澄清製劑並以靜脈注射給藥\nB. 將insulin的A21Asn修飾成Gly\nC. 此藥之等電點（isoelectric point）接近7\nD. 於insulin加入B31Arg與B32Arg\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.048828125", "True"]], [["-4.0625", "False"]], [["-5.4375", "False"]], [["-3.671875", "False"]]], "filtered_resps": [["-0.048828125", "True"], ["-4.0625", "False"], ["-5.4375", "False"], ["-3.671875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "33d03785a53206aee294709af79057d4cfa48485719db7c645f2ac446f0658f5", "prompt_hash": "92c03920110a32bdf0f34bba74c7b350e86c9ca508a44d4bc6c787f6c6f0b1f0", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 485, "doc": {"question": "下列有關 butyrophenone 類抗精神疾症藥之結構敘述，何者錯誤？類抗精神疾症藥之結構敘述", "A": "三個碳的碳鏈長度改變成二個碳的碳鏈三個碳的碳鏈長度改變成二個碳的碳鏈，對活性影響不大", "B": "在碳鏈上的含三級氮環狀結構是主要活性來源在碳鏈上的含三級氮環狀結構是主要活性來源", "C": "其苯環之對位導入氟原子，可提升活性可提升活性", "D": "其 keto 基團經還原後，活性降低", "answer": "A", "questions": "下列有關 butyrophenone 類抗精神疾症藥之結構敘述，何者錯誤？類抗精神疾症藥之結構敘述", "choices": ["三個碳的碳鏈長度改變成二個碳的碳鏈三個碳的碳鏈長度改變成二個碳的碳鏈，對活性影響不大", "在碳鏈上的含三級氮環狀結構是主要活性來源在碳鏈上的含三級氮環狀結構是主要活性來源", "其苯環之對位導入氟原子，可提升活性可提升活性", "其 keto 基團經還原後，活性降低"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 butyrophenone 類抗精神疾症藥之結構敘述，何者錯誤？類抗精神疾症藥之結構敘述\nA. 三個碳的碳鏈長度改變成二個碳的碳鏈三個碳的碳鏈長度改變成二個碳的碳鏈，對活性影響不大\nB. 在碳鏈上的含三級氮環狀結構是主要活性來源在碳鏈上的含三級氮環狀結構是主要活性來源\nC. 其苯環之對位導入氟原子，可提升活性可提升活性\nD. 其 keto 基團經還原後，活性降低\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 butyrophenone 類抗精神疾症藥之結構敘述，何者錯誤？類抗精神疾症藥之結構敘述\nA. 三個碳的碳鏈長度改變成二個碳的碳鏈三個碳的碳鏈長度改變成二個碳的碳鏈，對活性影響不大\nB. 在碳鏈上的含三級氮環狀結構是主要活性來源在碳鏈上的含三級氮環狀結構是主要活性來源\nC. 其苯環之對位導入氟原子，可提升活性可提升活性\nD. 其 keto 基團經還原後，活性降低\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 butyrophenone 類抗精神疾症藥之結構敘述，何者錯誤？類抗精神疾症藥之結構敘述\nA. 三個碳的碳鏈長度改變成二個碳的碳鏈三個碳的碳鏈長度改變成二個碳的碳鏈，對活性影響不大\nB. 在碳鏈上的含三級氮環狀結構是主要活性來源在碳鏈上的含三級氮環狀結構是主要活性來源\nC. 其苯環之對位導入氟原子，可提升活性可提升活性\nD. 其 keto 基團經還原後，活性降低\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 butyrophenone 類抗精神疾症藥之結構敘述，何者錯誤？類抗精神疾症藥之結構敘述\nA. 三個碳的碳鏈長度改變成二個碳的碳鏈三個碳的碳鏈長度改變成二個碳的碳鏈，對活性影響不大\nB. 在碳鏈上的含三級氮環狀結構是主要活性來源在碳鏈上的含三級氮環狀結構是主要活性來源\nC. 其苯環之對位導入氟原子，可提升活性可提升活性\nD. 其 keto 基團經還原後，活性降低\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.609375", "False"]], [["-0.23828125", "True"]], [["-3.109375", "False"]], [["-2.359375", "False"]]], "filtered_resps": [["-2.609375", "False"], ["-0.23828125", "True"], ["-3.109375", "False"], ["-2.359375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "44e124eff96e7da03c0fca6d1a723ab712678e238b507899ae3f21c9750ac4dc", "prompt_hash": "a12b3c24b7242c107a3ffd2095fc3c86f153c5e28f8224d263e1147f594ca4db", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 486, "doc": {"question": "一般合成之norprogesterone藥，是移除progesterone結構中那個位置的甲基而得？", "A": "18", "B": "19", "C": "17", "D": "21", "answer": "B", "questions": "一般合成之norprogesterone藥，是移除progesterone結構中那個位置的甲基而得？", "choices": ["18", "19", "17", "21"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一般合成之norprogesterone藥，是移除progesterone結構中那個位置的甲基而得？\nA. 18\nB. 19\nC. 17\nD. 21\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一般合成之norprogesterone藥，是移除progesterone結構中那個位置的甲基而得？\nA. 18\nB. 19\nC. 17\nD. 21\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一般合成之norprogesterone藥，是移除progesterone結構中那個位置的甲基而得？\nA. 18\nB. 19\nC. 17\nD. 21\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一般合成之norprogesterone藥，是移除progesterone結構中那個位置的甲基而得？\nA. 18\nB. 19\nC. 17\nD. 21\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.6640625", "False"]], [["-1.0390625", "False"]], [["-1.0390625", "True"]], [["-2.28125", "False"]]], "filtered_resps": [["-1.6640625", "False"], ["-1.0390625", "False"], ["-1.0390625", "True"], ["-2.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "26e43dd1ba16e3bfc2da363fb31917c5fa8877d5d65d0a2db2e22cf722cfeef7", "prompt_hash": "7406ab54b6f20ddf1dd0e9ab0dbe536f6c3a04fa9d91bab657e9904426eeac08", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 487, "doc": {"question": "下列有關peramivir的敘述，何者錯誤？", "A": "結構中有glycerol side chain", "B": "為神經胺酸酶抑制劑（neuraminidase inhibitor）", "C": "結構中有carboxylic acid group", "D": "結構中有cyclopentane ring", "answer": "A", "questions": "下列有關peramivir的敘述，何者錯誤？", "choices": ["結構中有glycerol side chain", "為神經胺酸酶抑制劑（neuraminidase inhibitor）", "結構中有carboxylic acid group", "結構中有cyclopentane ring"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關peramivir的敘述，何者錯誤？\nA. 結構中有glycerol side chain\nB. 為神經胺酸酶抑制劑（neuraminidase inhibitor）\nC. 結構中有carboxylic acid group\nD. 結構中有cyclopentane ring\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關peramivir的敘述，何者錯誤？\nA. 結構中有glycerol side chain\nB. 為神經胺酸酶抑制劑（neuraminidase inhibitor）\nC. 結構中有carboxylic acid group\nD. 結構中有cyclopentane ring\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關peramivir的敘述，何者錯誤？\nA. 結構中有glycerol side chain\nB. 為神經胺酸酶抑制劑（neuraminidase inhibitor）\nC. 結構中有carboxylic acid group\nD. 結構中有cyclopentane ring\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關peramivir的敘述，何者錯誤？\nA. 結構中有glycerol side chain\nB. 為神經胺酸酶抑制劑（neuraminidase inhibitor）\nC. 結構中有carboxylic acid group\nD. 結構中有cyclopentane ring\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.453125", "True"]], [["-3.453125", "False"]], [["-2.703125", "False"]], [["-1.328125", "False"]]], "filtered_resps": [["-0.453125", "True"], ["-3.453125", "False"], ["-2.703125", "False"], ["-1.328125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fcf48c768c76e17c9c964ee48407a1c308cb9baa79fa76fac02f3510c5c5a032", "prompt_hash": "d73b37da5439140d84f25d13f170140b70da35cb0e4ccc0449a48051806e4cb7", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 488, "doc": {"question": "通常蛋白藥物最適合的儲藏溫度為：", "A": "-80℃", "B": "20℃", "C": "-20℃", "D": "4℃", "answer": "D", "questions": "通常蛋白藥物最適合的儲藏溫度為：", "choices": ["-80℃", "20℃", "-20℃", "4℃"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n通常蛋白藥物最適合的儲藏溫度為：\nA. -80℃\nB. 20℃\nC. -20℃\nD. 4℃\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n通常蛋白藥物最適合的儲藏溫度為：\nA. -80℃\nB. 20℃\nC. -20℃\nD. 4℃\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n通常蛋白藥物最適合的儲藏溫度為：\nA. -80℃\nB. 20℃\nC. -20℃\nD. 4℃\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n通常蛋白藥物最適合的儲藏溫度為：\nA. -80℃\nB. 20℃\nC. -20℃\nD. 4℃\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.734375", "False"]], [["-3.609375", "False"]], [["-3.109375", "False"]], [["-0.10205078125", "True"]]], "filtered_resps": [["-3.734375", "False"], ["-3.609375", "False"], ["-3.109375", "False"], ["-0.10205078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c14e6015f38d2a1955381c24b74d287623b65df3c535f0114d8bfed759acbbe4", "prompt_hash": "4bf1aae6ce80111bc6714a14952ed276198ff37251520eefa90f605c38883334", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 489, "doc": {"question": "下列有關daptomycin的敘述，何者錯誤？", "A": "具殺菌作用", "B": "具cyclic lipopeptide結構", "C": "抑制細胞壁生合成", "D": "為發酵產物", "answer": "C", "questions": "下列有關daptomycin的敘述，何者錯誤？", "choices": ["具殺菌作用", "具cyclic lipopeptide結構", "抑制細胞壁生合成", "為發酵產物"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關daptomycin的敘述，何者錯誤？\nA. 具殺菌作用\nB. 具cyclic lipopeptide結構\nC. 抑制細胞壁生合成\nD. 為發酵產物\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關daptomycin的敘述，何者錯誤？\nA. 具殺菌作用\nB. 具cyclic lipopeptide結構\nC. 抑制細胞壁生合成\nD. 為發酵產物\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關daptomycin的敘述，何者錯誤？\nA. 具殺菌作用\nB. 具cyclic lipopeptide結構\nC. 抑制細胞壁生合成\nD. 為發酵產物\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關daptomycin的敘述，何者錯誤？\nA. 具殺菌作用\nB. 具cyclic lipopeptide結構\nC. 抑制細胞壁生合成\nD. 為發酵產物\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.84375", "False"]], [["-3.359375", "False"]], [["-0.103515625", "True"]], [["-2.984375", "False"]]], "filtered_resps": [["-4.84375", "False"], ["-3.359375", "False"], ["-0.103515625", "True"], ["-2.984375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b1b09935d6cf27473cd2e14e1ddd6e3282ca1403a3ebee461bf8e2a8dc76e588", "prompt_hash": "af046c51f059f0aa30dd89c41aabb796b982a512667e71255933017ca1dd5073", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 490, "doc": {"question": "Nitroglycerin（NTG）經由舌下或經皮膚（貼劑）給藥有下列何項優點？", "A": "作用緩和，藥效持久長達48小時", "B": "減少反射性心搏過速", "C": "避開肝臟代謝之首渡效應", "D": "減少低血壓之副作用", "answer": "C", "questions": "Nitroglycerin（NTG）經由舌下或經皮膚（貼劑）給藥有下列何項優點？", "choices": ["作用緩和，藥效持久長達48小時", "減少反射性心搏過速", "避開肝臟代謝之首渡效應", "減少低血壓之副作用"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNitroglycerin（NTG）經由舌下或經皮膚（貼劑）給藥有下列何項優點？\nA. 作用緩和，藥效持久長達48小時\nB. 減少反射性心搏過速\nC. 避開肝臟代謝之首渡效應\nD. 減少低血壓之副作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNitroglycerin（NTG）經由舌下或經皮膚（貼劑）給藥有下列何項優點？\nA. 作用緩和，藥效持久長達48小時\nB. 減少反射性心搏過速\nC. 避開肝臟代謝之首渡效應\nD. 減少低血壓之副作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNitroglycerin（NTG）經由舌下或經皮膚（貼劑）給藥有下列何項優點？\nA. 作用緩和，藥效持久長達48小時\nB. 減少反射性心搏過速\nC. 避開肝臟代謝之首渡效應\nD. 減少低血壓之副作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNitroglycerin（NTG）經由舌下或經皮膚（貼劑）給藥有下列何項優點？\nA. 作用緩和，藥效持久長達48小時\nB. 減少反射性心搏過速\nC. 避開肝臟代謝之首渡效應\nD. 減少低血壓之副作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.125", "False"]], [["-4.375", "False"]], [["-0.1337890625", "True"]], [["-2.265625", "False"]]], "filtered_resps": [["-6.125", "False"], ["-4.375", "False"], ["-0.1337890625", "True"], ["-2.265625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e3a2a57ce4f2df0ba271e3b213e06cac701d742ccf4db1cc689119f5e09ba058", "prompt_hash": "932474e81511fd9568846e7a3ee28f0b8af4e425025804d1f7a193c919d93b6b", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 491, "doc": {"question": "下列有關治療類風濕關節炎含金藥物的敘述，何者錯誤？", "A": "一價金離子比三價金離子有效", "B": "金與硫元素結合會失去活性", "C": "auranofin可口服使用", "D": "金離子在水溶液的半衰期短", "answer": "B", "questions": "下列有關治療類風濕關節炎含金藥物的敘述，何者錯誤？", "choices": ["一價金離子比三價金離子有效", "金與硫元素結合會失去活性", "auranofin可口服使用", "金離子在水溶液的半衰期短"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關治療類風濕關節炎含金藥物的敘述，何者錯誤？\nA. 一價金離子比三價金離子有效\nB. 金與硫元素結合會失去活性\nC. auranofin可口服使用\nD. 金離子在水溶液的半衰期短\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關治療類風濕關節炎含金藥物的敘述，何者錯誤？\nA. 一價金離子比三價金離子有效\nB. 金與硫元素結合會失去活性\nC. auranofin可口服使用\nD. 金離子在水溶液的半衰期短\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關治療類風濕關節炎含金藥物的敘述，何者錯誤？\nA. 一價金離子比三價金離子有效\nB. 金與硫元素結合會失去活性\nC. auranofin可口服使用\nD. 金離子在水溶液的半衰期短\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關治療類風濕關節炎含金藥物的敘述，何者錯誤？\nA. 一價金離子比三價金離子有效\nB. 金與硫元素結合會失去活性\nC. auranofin可口服使用\nD. 金離子在水溶液的半衰期短\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.875", "False"]], [["-0.369140625", "True"]], [["-3.625", "False"]], [["-1.4921875", "False"]]], "filtered_resps": [["-2.875", "False"], ["-0.369140625", "True"], ["-3.625", "False"], ["-1.4921875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3a7077a1e99499dc1a6358ea472a6d4188d072a2cc778a0a86351822d20069c6", "prompt_hash": "da803221b042ba8e81dfc8ea0e2ac2da092046bf83bfe9cb726b58d6906ae94b", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 492, "doc": {"question": "下列有關藥物Phase II代謝中的酵素與基質提供者的對應，何者錯誤？", "A": "glutathione S-transferase－glutathione", "B": "methyl transferase－S-adenosylmethionine", "C": "sulfotransferase－3-phosphoadenosine-5'-phosphate", "D": "acyl synthetase－glycine", "answer": "C", "questions": "下列有關藥物Phase II代謝中的酵素與基質提供者的對應，何者錯誤？", "choices": ["glutathione S-transferase－glutathione", "methyl transferase－S-adenosylmethionine", "sulfotransferase－3-phosphoadenosine-5'-phosphate", "acyl synthetase－glycine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關藥物Phase II代謝中的酵素與基質提供者的對應，何者錯誤？\nA. glutathione S-transferase－glutathione\nB. methyl transferase－S-adenosylmethionine\nC. sulfotransferase－3-phosphoadenosine-5'-phosphate\nD. acyl synthetase－glycine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關藥物Phase II代謝中的酵素與基質提供者的對應，何者錯誤？\nA. glutathione S-transferase－glutathione\nB. methyl transferase－S-adenosylmethionine\nC. sulfotransferase－3-phosphoadenosine-5'-phosphate\nD. acyl synthetase－glycine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關藥物Phase II代謝中的酵素與基質提供者的對應，何者錯誤？\nA. glutathione S-transferase－glutathione\nB. methyl transferase－S-adenosylmethionine\nC. sulfotransferase－3-phosphoadenosine-5'-phosphate\nD. acyl synthetase－glycine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關藥物Phase II代謝中的酵素與基質提供者的對應，何者錯誤？\nA. glutathione S-transferase－glutathione\nB. methyl transferase－S-adenosylmethionine\nC. sulfotransferase－3-phosphoadenosine-5'-phosphate\nD. acyl synthetase－glycine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.65625", "False"]], [["-5.53125", "False"]], [["-0.0225830078125", "True"]], [["-4.90625", "False"]]], "filtered_resps": [["-5.65625", "False"], ["-5.53125", "False"], ["-0.0225830078125", "True"], ["-4.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "05b6979ee6998bb7bbafae98d96a2030e999ac163b2a6dc27b80fa6334b0e432", "prompt_hash": "fe36272ddb50a97c6ce6ce6158a31921f9a24337a1b31e026b9ca281856067e3", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 493, "doc": {"question": "有關 acyclovir 敘述，下列何者正確？", "A": "acyclovir 對抗水痘帶狀疱疹病毒（VZV）能力比對抗單純疱疹病毒（HSV）強", "B": "acyclovir 需在宿主細胞內被磷酸化後才具抗病毒活性", "C": "當病人被投與 acyclovir，具活性的 acyclovir 代謝產物會出現在受感染及非受感染的宿主細胞中", "D": "若對 acyclovir 產生過敏或抗藥性者可以使用 ganciclovir", "answer": "B", "questions": "有關 acyclovir 敘述，下列何者正確？", "choices": ["acyclovir 對抗水痘帶狀疱疹病毒（VZV）能力比對抗單純疱疹病毒（HSV）強", "acyclovir 需在宿主細胞內被磷酸化後才具抗病毒活性", "當病人被投與 acyclovir，具活性的 acyclovir 代謝產物會出現在受感染及非受感染的宿主細胞中", "若對 acyclovir 產生過敏或抗藥性者可以使用 ganciclovir"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關 acyclovir 敘述，下列何者正確？\nA. acyclovir 對抗水痘帶狀疱疹病毒（VZV）能力比對抗單純疱疹病毒（HSV）強\nB. acyclovir 需在宿主細胞內被磷酸化後才具抗病毒活性\nC. 當病人被投與 acyclovir，具活性的 acyclovir 代謝產物會出現在受感染及非受感染的宿主細胞中\nD. 若對 acyclovir 產生過敏或抗藥性者可以使用 ganciclovir\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關 acyclovir 敘述，下列何者正確？\nA. acyclovir 對抗水痘帶狀疱疹病毒（VZV）能力比對抗單純疱疹病毒（HSV）強\nB. acyclovir 需在宿主細胞內被磷酸化後才具抗病毒活性\nC. 當病人被投與 acyclovir，具活性的 acyclovir 代謝產物會出現在受感染及非受感染的宿主細胞中\nD. 若對 acyclovir 產生過敏或抗藥性者可以使用 ganciclovir\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關 acyclovir 敘述，下列何者正確？\nA. acyclovir 對抗水痘帶狀疱疹病毒（VZV）能力比對抗單純疱疹病毒（HSV）強\nB. acyclovir 需在宿主細胞內被磷酸化後才具抗病毒活性\nC. 當病人被投與 acyclovir，具活性的 acyclovir 代謝產物會出現在受感染及非受感染的宿主細胞中\nD. 若對 acyclovir 產生過敏或抗藥性者可以使用 ganciclovir\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關 acyclovir 敘述，下列何者正確？\nA. acyclovir 對抗水痘帶狀疱疹病毒（VZV）能力比對抗單純疱疹病毒（HSV）強\nB. acyclovir 需在宿主細胞內被磷酸化後才具抗病毒活性\nC. 當病人被投與 acyclovir，具活性的 acyclovir 代謝產物會出現在受感染及非受感染的宿主細胞中\nD. 若對 acyclovir 產生過敏或抗藥性者可以使用 ganciclovir\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.3125", "False"]], [["-0.051025390625", "True"]], [["-3.671875", "False"]], [["-4.0625", "False"]]], "filtered_resps": [["-5.3125", "False"], ["-0.051025390625", "True"], ["-3.671875", "False"], ["-4.0625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "048e4b74c798f86e6070304dbeda2cf2aa5c81eee79fe5c1ee44e9130ed4210a", "prompt_hash": "4ac7799d876480ca027b75f934782d803233b87ec14ec37f2158a43f4bba0550", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 494, "doc": {"question": "下列何者為HMG-CoA還原酶抑制劑之必要結構？", "A": "3,5-dimethylheptanoic acid", "B": "3,5-dichloroheptanoic acid", "C": "3,5-dihydroxyheptanoic acid", "D": "3,5-diaminoheptanoic acid", "answer": "C", "questions": "下列何者為HMG-CoA還原酶抑制劑之必要結構？", "choices": ["3,5-dimethylheptanoic acid", "3,5-dichloroheptanoic acid", "3,5-dihydroxyheptanoic acid", "3,5-diaminoheptanoic acid"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為HMG-CoA還原酶抑制劑之必要結構？\nA. 3,5-dimethylheptanoic acid\nB. 3,5-dichloroheptanoic acid\nC. 3,5-dihydroxyheptanoic acid\nD. 3,5-diaminoheptanoic acid\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為HMG-CoA還原酶抑制劑之必要結構？\nA. 3,5-dimethylheptanoic acid\nB. 3,5-dichloroheptanoic acid\nC. 3,5-dihydroxyheptanoic acid\nD. 3,5-diaminoheptanoic acid\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為HMG-CoA還原酶抑制劑之必要結構？\nA. 3,5-dimethylheptanoic acid\nB. 3,5-dichloroheptanoic acid\nC. 3,5-dihydroxyheptanoic acid\nD. 3,5-diaminoheptanoic acid\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為HMG-CoA還原酶抑制劑之必要結構？\nA. 3,5-dimethylheptanoic acid\nB. 3,5-dichloroheptanoic acid\nC. 3,5-dihydroxyheptanoic acid\nD. 3,5-diaminoheptanoic acid\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.109375", "False"]], [["-3.109375", "False"]], [["-0.2373046875", "True"]], [["-3.234375", "False"]]], "filtered_resps": [["-2.109375", "False"], ["-3.109375", "False"], ["-0.2373046875", "True"], ["-3.234375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0e57d473b320536fddd7d04ca976c219a7b11d3ce1fd8a956ad1095ccd3eced3", "prompt_hash": "a5b5c6c7743f5658dae3e1cae37589f8e6f27b35217e92b7a31b5a006c012880", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 495, "doc": {"question": "下列何者是digoxin的結構？", "A": "digitoxose-digitoxose-digitoxose-digoxigenin", "B": "glucose-digitoxose-digitoxose-digoxigenin", "C": "3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin", "D": "glucose-3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin", "answer": "A", "questions": "下列何者是digoxin的結構？", "choices": ["digitoxose-digitoxose-digitoxose-digoxigenin", "glucose-digitoxose-digitoxose-digoxigenin", "3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin", "glucose-3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是digoxin的結構？\nA. digitoxose-digitoxose-digitoxose-digoxigenin\nB. glucose-digitoxose-digitoxose-digoxigenin\nC. 3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin\nD. glucose-3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是digoxin的結構？\nA. digitoxose-digitoxose-digitoxose-digoxigenin\nB. glucose-digitoxose-digitoxose-digoxigenin\nC. 3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin\nD. glucose-3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是digoxin的結構？\nA. digitoxose-digitoxose-digitoxose-digoxigenin\nB. glucose-digitoxose-digitoxose-digoxigenin\nC. 3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin\nD. glucose-3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是digoxin的結構？\nA. digitoxose-digitoxose-digitoxose-digoxigenin\nB. glucose-digitoxose-digitoxose-digoxigenin\nC. 3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin\nD. glucose-3-acetyldigitoxose-digitoxose-digitoxose-digoxigenin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.62109375", "True"]], [["-2.5", "False"]], [["-1.875", "False"]], [["-1.5", "False"]]], "filtered_resps": [["-0.62109375", "True"], ["-2.5", "False"], ["-1.875", "False"], ["-1.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d6ae40e660caf553ac63feb3e43744c80171bb6b8d6fe2ce27ab0ef1910da3b4", "prompt_hash": "87dc9b43e51eb6244a3e2711f6902dede0c9d4e671380efa03e17d71baaa0004", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 496, "doc": {"question": "有關抗反轉錄病毒藥物（antiretroviral agents）與作用機轉配對，下列何者錯誤？", "A": "didanosine為抑制病毒反轉錄酶活性進而阻斷病毒DNA合成", "B": "atazanavir為蛋白酶抑制劑可以阻斷病毒膜蛋白與宿主細胞膜融合以防止病毒進入", "C": "maraviroc結合到宿主細胞CCR5蛋白質而阻斷病毒的進入", "D": "dolutegravir結合到病毒嵌入酶而阻斷病毒DNA嵌合到宿主染色體", "answer": "B", "questions": "有關抗反轉錄病毒藥物（antiretroviral agents）與作用機轉配對，下列何者錯誤？", "choices": ["didanosine為抑制病毒反轉錄酶活性進而阻斷病毒DNA合成", "atazanavir為蛋白酶抑制劑可以阻斷病毒膜蛋白與宿主細胞膜融合以防止病毒進入", "maraviroc結合到宿主細胞CCR5蛋白質而阻斷病毒的進入", "dolutegravir結合到病毒嵌入酶而阻斷病毒DNA嵌合到宿主染色體"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗反轉錄病毒藥物（antiretroviral agents）與作用機轉配對，下列何者錯誤？\nA. didanosine為抑制病毒反轉錄酶活性進而阻斷病毒DNA合成\nB. atazanavir為蛋白酶抑制劑可以阻斷病毒膜蛋白與宿主細胞膜融合以防止病毒進入\nC. maraviroc結合到宿主細胞CCR5蛋白質而阻斷病毒的進入\nD. dolutegravir結合到病毒嵌入酶而阻斷病毒DNA嵌合到宿主染色體\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗反轉錄病毒藥物（antiretroviral agents）與作用機轉配對，下列何者錯誤？\nA. didanosine為抑制病毒反轉錄酶活性進而阻斷病毒DNA合成\nB. atazanavir為蛋白酶抑制劑可以阻斷病毒膜蛋白與宿主細胞膜融合以防止病毒進入\nC. maraviroc結合到宿主細胞CCR5蛋白質而阻斷病毒的進入\nD. dolutegravir結合到病毒嵌入酶而阻斷病毒DNA嵌合到宿主染色體\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗反轉錄病毒藥物（antiretroviral agents）與作用機轉配對，下列何者錯誤？\nA. didanosine為抑制病毒反轉錄酶活性進而阻斷病毒DNA合成\nB. atazanavir為蛋白酶抑制劑可以阻斷病毒膜蛋白與宿主細胞膜融合以防止病毒進入\nC. maraviroc結合到宿主細胞CCR5蛋白質而阻斷病毒的進入\nD. dolutegravir結合到病毒嵌入酶而阻斷病毒DNA嵌合到宿主染色體\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關抗反轉錄病毒藥物（antiretroviral agents）與作用機轉配對，下列何者錯誤？\nA. didanosine為抑制病毒反轉錄酶活性進而阻斷病毒DNA合成\nB. atazanavir為蛋白酶抑制劑可以阻斷病毒膜蛋白與宿主細胞膜融合以防止病毒進入\nC. maraviroc結合到宿主細胞CCR5蛋白質而阻斷病毒的進入\nD. dolutegravir結合到病毒嵌入酶而阻斷病毒DNA嵌合到宿主染色體\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.0", "False"]], [["-0.00994873046875", "True"]], [["-5.625", "False"]], [["-5.75", "False"]]], "filtered_resps": [["-7.0", "False"], ["-0.00994873046875", "True"], ["-5.625", "False"], ["-5.75", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e0841fc9fc7569c41cc701c1c2fb7e8c935185614c021e3a6fce373b4f9d5dfb", "prompt_hash": "bf3666a2c88fe7a3f6db264051951800c626bb9108e3e7b0a824bf25ddd01430", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 497, "doc": {"question": "下列有關骨質疏鬆治療用藥 denosumab 之敘述，何者錯誤？", "A": "為人類單株抗體製劑", "B": "主要是藉由拮抗 calcineurin 而產生藥效", "C": "以皮下注射方式給藥", "D": "抑制噬骨細胞活性", "answer": "B", "questions": "下列有關骨質疏鬆治療用藥 denosumab 之敘述，何者錯誤？", "choices": ["為人類單株抗體製劑", "主要是藉由拮抗 calcineurin 而產生藥效", "以皮下注射方式給藥", "抑制噬骨細胞活性"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關骨質疏鬆治療用藥 denosumab 之敘述，何者錯誤？\nA. 為人類單株抗體製劑\nB. 主要是藉由拮抗 calcineurin 而產生藥效\nC. 以皮下注射方式給藥\nD. 抑制噬骨細胞活性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關骨質疏鬆治療用藥 denosumab 之敘述，何者錯誤？\nA. 為人類單株抗體製劑\nB. 主要是藉由拮抗 calcineurin 而產生藥效\nC. 以皮下注射方式給藥\nD. 抑制噬骨細胞活性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關骨質疏鬆治療用藥 denosumab 之敘述，何者錯誤？\nA. 為人類單株抗體製劑\nB. 主要是藉由拮抗 calcineurin 而產生藥效\nC. 以皮下注射方式給藥\nD. 抑制噬骨細胞活性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關骨質疏鬆治療用藥 denosumab 之敘述，何者錯誤？\nA. 為人類單株抗體製劑\nB. 主要是藉由拮抗 calcineurin 而產生藥效\nC. 以皮下注射方式給藥\nD. 抑制噬骨細胞活性\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.75", "False"]], [["-0.00286865234375", "True"]], [["-8.375", "False"]], [["-8.375", "False"]]], "filtered_resps": [["-6.75", "False"], ["-0.00286865234375", "True"], ["-8.375", "False"], ["-8.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7c3754a6b6b85250a48e622e77a8eef630c83416b7d47c8609eb71e7d7df2863", "prompt_hash": "530409b772ec36f47e97c7ca0ff602387871ba3add09ddfe449e24b19fabdace", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 498, "doc": {"question": "下列何者具有µ-receptor agonism及norepinephrine reuptake inhibition雙效作用？", "A": "tapentadol", "B": "diphenoxylate", "C": "buprenorphine", "D": "levorphanol", "answer": "A", "questions": "下列何者具有µ-receptor agonism及norepinephrine reuptake inhibition雙效作用？", "choices": ["tapentadol", "diphenoxylate", "buprenorphine", "levorphanol"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者具有µ-receptor agonism及norepinephrine reuptake inhibition雙效作用？\nA. tapentadol\nB. diphenoxylate\nC. buprenorphine\nD. levorphanol\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者具有µ-receptor agonism及norepinephrine reuptake inhibition雙效作用？\nA. tapentadol\nB. diphenoxylate\nC. buprenorphine\nD. levorphanol\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者具有µ-receptor agonism及norepinephrine reuptake inhibition雙效作用？\nA. tapentadol\nB. diphenoxylate\nC. buprenorphine\nD. levorphanol\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者具有µ-receptor agonism及norepinephrine reuptake inhibition雙效作用？\nA. tapentadol\nB. diphenoxylate\nC. buprenorphine\nD. levorphanol\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.00811767578125", "True"]], [["-6.125", "False"]], [["-7.25", "False"]], [["-5.875", "False"]]], "filtered_resps": [["-0.00811767578125", "True"], ["-6.125", "False"], ["-7.25", "False"], ["-5.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "199e0e5f812db4519051322a5e7e3d8fd90c153d8a090526f761d7ab445a197e", "prompt_hash": "069a529c3b6dd47812496fb6ed26524eeaa3b9ad3da548c75403ff5ebcaa3b75", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 499, "doc": {"question": "當胃潰瘍病人仍必須使用NSAID時，較適合用下列何種藥物做治療？", "A": "omeprazole", "B": "ranitidine", "C": "calcium carbonate", "D": "famotidine", "answer": "A", "questions": "當胃潰瘍病人仍必須使用NSAID時，較適合用下列何種藥物做治療？", "choices": ["omeprazole", "ranitidine", "calcium carbonate", "famotidine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當胃潰瘍病人仍必須使用NSAID時，較適合用下列何種藥物做治療？\nA. omeprazole\nB. ranitidine\nC. calcium carbonate\nD. famotidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當胃潰瘍病人仍必須使用NSAID時，較適合用下列何種藥物做治療？\nA. omeprazole\nB. ranitidine\nC. calcium carbonate\nD. famotidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當胃潰瘍病人仍必須使用NSAID時，較適合用下列何種藥物做治療？\nA. omeprazole\nB. ranitidine\nC. calcium carbonate\nD. famotidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n當胃潰瘍病人仍必須使用NSAID時，較適合用下列何種藥物做治療？\nA. omeprazole\nB. ranitidine\nC. calcium carbonate\nD. famotidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.076171875", "True"]], [["-4.4375", "False"]], [["-4.0625", "False"]], [["-3.328125", "False"]]], "filtered_resps": [["-0.076171875", "True"], ["-4.4375", "False"], ["-4.0625", "False"], ["-3.328125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "368935a813d1bf6bcfbb95edda227e63f3814a9d8924d4876880a44d74621a81", "prompt_hash": "f3a2b896fa4f41e44b75933ef112605c7d33b69c6e902015a3e97caf661e4c20", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 500, "doc": {"question": "NSAIDs類藥物（例如indomethacin）可能會影響nephrotic syndrome或hepatic cirrhosis病人服用furosemide的利尿作用，其影響的機制為何？", "A": "抑制COX-1", "B": "抑制PGE2生成", "C": "抑制尿酸排除", "D": "抑制Na⁺/K⁺/2Cl⁻ transporter", "answer": "B", "questions": "NSAIDs類藥物（例如indomethacin）可能會影響nephrotic syndrome或hepatic cirrhosis病人服用furosemide的利尿作用，其影響的機制為何？", "choices": ["抑制COX-1", "抑制PGE2生成", "抑制尿酸排除", "抑制Na⁺/K⁺/2Cl⁻ transporter"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNSAIDs類藥物（例如indomethacin）可能會影響nephrotic syndrome或hepatic cirrhosis病人服用furosemide的利尿作用，其影響的機制為何？\nA. 抑制COX-1\nB. 抑制PGE2生成\nC. 抑制尿酸排除\nD. 抑制Na⁺/K⁺/2Cl⁻ transporter\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNSAIDs類藥物（例如indomethacin）可能會影響nephrotic syndrome或hepatic cirrhosis病人服用furosemide的利尿作用，其影響的機制為何？\nA. 抑制COX-1\nB. 抑制PGE2生成\nC. 抑制尿酸排除\nD. 抑制Na⁺/K⁺/2Cl⁻ transporter\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNSAIDs類藥物（例如indomethacin）可能會影響nephrotic syndrome或hepatic cirrhosis病人服用furosemide的利尿作用，其影響的機制為何？\nA. 抑制COX-1\nB. 抑制PGE2生成\nC. 抑制尿酸排除\nD. 抑制Na⁺/K⁺/2Cl⁻ transporter\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nNSAIDs類藥物（例如indomethacin）可能會影響nephrotic syndrome或hepatic cirrhosis病人服用furosemide的利尿作用，其影響的機制為何？\nA. 抑制COX-1\nB. 抑制PGE2生成\nC. 抑制尿酸排除\nD. 抑制Na⁺/K⁺/2Cl⁻ transporter\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.15625", "False"]], [["-1.3984375", "False"]], [["-1.1484375", "True"]], [["-1.1484375", "False"]]], "filtered_resps": [["-2.15625", "False"], ["-1.3984375", "False"], ["-1.1484375", "True"], ["-1.1484375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d76db4697a7e6741c1e9ec0da77589ebba6a9fca7baaab33c5979f0c6fade29d", "prompt_hash": "2756516e82d2e718432299d01ea2837b0a7b08ae08bea8508eb081125d6e420c", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 501, "doc": {"question": "腎自泌素（renal autacoids）為腎臟內細胞局部釋放之內生性活性成分，具有調節腎功能，也能影響利尿劑之作用。下列何者非上述腎自泌素？", "A": "PGE2", "B": "renin", "C": "adenosine", "D": "urodilatin", "answer": "B", "questions": "腎自泌素（renal autacoids）為腎臟內細胞局部釋放之內生性活性成分，具有調節腎功能，也能影響利尿劑之作用。下列何者非上述腎自泌素？", "choices": ["PGE2", "renin", "adenosine", "urodilatin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎自泌素（renal autacoids）為腎臟內細胞局部釋放之內生性活性成分，具有調節腎功能，也能影響利尿劑之作用。下列何者非上述腎自泌素？\nA. PGE2\nB. renin\nC. adenosine\nD. urodilatin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎自泌素（renal autacoids）為腎臟內細胞局部釋放之內生性活性成分，具有調節腎功能，也能影響利尿劑之作用。下列何者非上述腎自泌素？\nA. PGE2\nB. renin\nC. adenosine\nD. urodilatin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎自泌素（renal autacoids）為腎臟內細胞局部釋放之內生性活性成分，具有調節腎功能，也能影響利尿劑之作用。下列何者非上述腎自泌素？\nA. PGE2\nB. renin\nC. adenosine\nD. urodilatin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n腎自泌素（renal autacoids）為腎臟內細胞局部釋放之內生性活性成分，具有調節腎功能，也能影響利尿劑之作用。下列何者非上述腎自泌素？\nA. PGE2\nB. renin\nC. adenosine\nD. urodilatin\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-0.0281982421875", "True"]], [["-5.53125", "False"]], [["-3.90625", "False"]]], "filtered_resps": [["-5.78125", "False"], ["-0.0281982421875", "True"], ["-5.53125", "False"], ["-3.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "221ed6aa69063611d98d2cf050833bc8857ef9b67919660dc1b58ee24c9c70fa", "prompt_hash": "ff9d0ba26ad13b1f12781c3a3c277e5bc922f87cfdd52a05e04cc3a4ac0d00ec", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 502, "doc": {"question": "Fibrates可經由活化PPAR-α途徑增加三酸甘油酯等的脂質分解，常用來治療高三酸甘油酯血症（hypertriglyceridemia），其副作用不包括下列何者？", "A": "arrhythmias", "B": "hypoprothrombinemia", "C": "high blood levels of aminotransferases or alkaline phosphatase", "D": "myopathy", "answer": "B", "questions": "Fibrates可經由活化PPAR-α途徑增加三酸甘油酯等的脂質分解，常用來治療高三酸甘油酯血症（hypertriglyceridemia），其副作用不包括下列何者？", "choices": ["arrhythmias", "hypoprothrombinemia", "high blood levels of aminotransferases or alkaline phosphatase", "myopathy"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFibrates可經由活化PPAR-α途徑增加三酸甘油酯等的脂質分解，常用來治療高三酸甘油酯血症（hypertriglyceridemia），其副作用不包括下列何者？\nA. arrhythmias\nB. hypoprothrombinemia\nC. high blood levels of aminotransferases or alkaline phosphatase\nD. myopathy\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFibrates可經由活化PPAR-α途徑增加三酸甘油酯等的脂質分解，常用來治療高三酸甘油酯血症（hypertriglyceridemia），其副作用不包括下列何者？\nA. arrhythmias\nB. hypoprothrombinemia\nC. high blood levels of aminotransferases or alkaline phosphatase\nD. myopathy\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFibrates可經由活化PPAR-α途徑增加三酸甘油酯等的脂質分解，常用來治療高三酸甘油酯血症（hypertriglyceridemia），其副作用不包括下列何者？\nA. arrhythmias\nB. hypoprothrombinemia\nC. high blood levels of aminotransferases or alkaline phosphatase\nD. myopathy\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nFibrates可經由活化PPAR-α途徑增加三酸甘油酯等的脂質分解，常用來治療高三酸甘油酯血症（hypertriglyceridemia），其副作用不包括下列何者？\nA. arrhythmias\nB. hypoprothrombinemia\nC. high blood levels of aminotransferases or alkaline phosphatase\nD. myopathy\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.03125", "False"]], [["-0.03515625", "True"]], [["-4.53125", "False"]], [["-5.15625", "False"]]], "filtered_resps": [["-4.03125", "False"], ["-0.03515625", "True"], ["-4.53125", "False"], ["-5.15625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "0e406b3c952ddd7e03a9b36b813ca19c8b6760adc3f709826618dad7a374816f", "prompt_hash": "4e2db6d5ceb17fcc252ca2a3728c318e758f6d0bd63d53045f646568eccf14d7", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 503, "doc": {"question": "鈣離子管道阻斷劑、β-blockers或nitrates用於治療心絞痛時，對心臟產生的作用，何者錯誤？", "A": "nitrates可能會引起反射性心搏過速（reflex tachycardia）", "B": "鈣離子管道阻斷劑會增加心室舒張末期容積（ventricular end-diastolic volume）", "C": "nitrates會減少後負荷（afterload），增加心室射血時間（ventricular ejection time）", "D": "β-blockers會延長心室射血時間（ventricular ejection time）", "answer": "C", "questions": "鈣離子管道阻斷劑、β-blockers或nitrates用於治療心絞痛時，對心臟產生的作用，何者錯誤？", "choices": ["nitrates可能會引起反射性心搏過速（reflex tachycardia）", "鈣離子管道阻斷劑會增加心室舒張末期容積（ventricular end-diastolic volume）", "nitrates會減少後負荷（afterload），增加心室射血時間（ventricular ejection time）", "β-blockers會延長心室射血時間（ventricular ejection time）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n鈣離子管道阻斷劑、β-blockers或nitrates用於治療心絞痛時，對心臟產生的作用，何者錯誤？\nA. nitrates可能會引起反射性心搏過速（reflex tachycardia）\nB. 鈣離子管道阻斷劑會增加心室舒張末期容積（ventricular end-diastolic volume）\nC. nitrates會減少後負荷（afterload），增加心室射血時間（ventricular ejection time）\nD. β-blockers會延長心室射血時間（ventricular ejection time）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n鈣離子管道阻斷劑、β-blockers或nitrates用於治療心絞痛時，對心臟產生的作用，何者錯誤？\nA. nitrates可能會引起反射性心搏過速（reflex tachycardia）\nB. 鈣離子管道阻斷劑會增加心室舒張末期容積（ventricular end-diastolic volume）\nC. nitrates會減少後負荷（afterload），增加心室射血時間（ventricular ejection time）\nD. β-blockers會延長心室射血時間（ventricular ejection time）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n鈣離子管道阻斷劑、β-blockers或nitrates用於治療心絞痛時，對心臟產生的作用，何者錯誤？\nA. nitrates可能會引起反射性心搏過速（reflex tachycardia）\nB. 鈣離子管道阻斷劑會增加心室舒張末期容積（ventricular end-diastolic volume）\nC. nitrates會減少後負荷（afterload），增加心室射血時間（ventricular ejection time）\nD. β-blockers會延長心室射血時間（ventricular ejection time）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n鈣離子管道阻斷劑、β-blockers或nitrates用於治療心絞痛時，對心臟產生的作用，何者錯誤？\nA. nitrates可能會引起反射性心搏過速（reflex tachycardia）\nB. 鈣離子管道阻斷劑會增加心室舒張末期容積（ventricular end-diastolic volume）\nC. nitrates會減少後負荷（afterload），增加心室射血時間（ventricular ejection time）\nD. β-blockers會延長心室射血時間（ventricular ejection time）\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.53125", "False"]], [["-5.53125", "False"]], [["-0.028076171875", "True"]], [["-3.90625", "False"]]], "filtered_resps": [["-6.53125", "False"], ["-5.53125", "False"], ["-0.028076171875", "True"], ["-3.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4961596fce7cca46407888f61e38f9061fdd13c0766254203966f442a040c1c1", "prompt_hash": "eb0d80aa9f9aa78e5fcd357ebcdcaaff60a9ab8c5732ada224b92a694bcbe928", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 504, "doc": {"question": "Pyrazinamide在何種pH值時，其抗肺結核活性最佳？", "A": "6.5", "B": "8.5", "C": "7.5", "D": "5.5", "answer": "D", "questions": "Pyrazinamide在何種pH值時，其抗肺結核活性最佳？", "choices": ["6.5", "8.5", "7.5", "5.5"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPyrazinamide在何種pH值時，其抗肺結核活性最佳？\nA. 6.5\nB. 8.5\nC. 7.5\nD. 5.5\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPyrazinamide在何種pH值時，其抗肺結核活性最佳？\nA. 6.5\nB. 8.5\nC. 7.5\nD. 5.5\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPyrazinamide在何種pH值時，其抗肺結核活性最佳？\nA. 6.5\nB. 8.5\nC. 7.5\nD. 5.5\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nPyrazinamide在何種pH值時，其抗肺結核活性最佳？\nA. 6.5\nB. 8.5\nC. 7.5\nD. 5.5\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.015625", "False"]], [["-2.765625", "False"]], [["-3.390625", "False"]], [["-0.263671875", "True"]]], "filtered_resps": [["-2.015625", "False"], ["-2.765625", "False"], ["-3.390625", "False"], ["-0.263671875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "dd5ddc86fc3176ca651b1b290302ec3e756e066b8dd655905d8d6ccdb1d54f59", "prompt_hash": "69a1faccd8021677a9098b49895be4fbdc842486271f917938db7e5508e967c0", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 505, "doc": {"question": "下列有關鴉片類藥物作用之敘述，何者錯誤？", "A": "codeine具有良好的止咳效益，主要是codeine活化kappa接受器所致", "B": "naloxone是鴉片類藥物拮抗劑，可以用來治療急性鴉片中毒", "C": "fentanyl止痛效力約是morphine的100倍", "D": "morphine的強效止痛效力，主要是morphine活化mu接受器所致", "answer": "A", "questions": "下列有關鴉片類藥物作用之敘述，何者錯誤？", "choices": ["codeine具有良好的止咳效益，主要是codeine活化kappa接受器所致", "naloxone是鴉片類藥物拮抗劑，可以用來治療急性鴉片中毒", "fentanyl止痛效力約是morphine的100倍", "morphine的強效止痛效力，主要是morphine活化mu接受器所致"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關鴉片類藥物作用之敘述，何者錯誤？\nA. codeine具有良好的止咳效益，主要是codeine活化kappa接受器所致\nB. naloxone是鴉片類藥物拮抗劑，可以用來治療急性鴉片中毒\nC. fentanyl止痛效力約是morphine的100倍\nD. morphine的強效止痛效力，主要是morphine活化mu接受器所致\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關鴉片類藥物作用之敘述，何者錯誤？\nA. codeine具有良好的止咳效益，主要是codeine活化kappa接受器所致\nB. naloxone是鴉片類藥物拮抗劑，可以用來治療急性鴉片中毒\nC. fentanyl止痛效力約是morphine的100倍\nD. morphine的強效止痛效力，主要是morphine活化mu接受器所致\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關鴉片類藥物作用之敘述，何者錯誤？\nA. codeine具有良好的止咳效益，主要是codeine活化kappa接受器所致\nB. naloxone是鴉片類藥物拮抗劑，可以用來治療急性鴉片中毒\nC. fentanyl止痛效力約是morphine的100倍\nD. morphine的強效止痛效力，主要是morphine活化mu接受器所致\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關鴉片類藥物作用之敘述，何者錯誤？\nA. codeine具有良好的止咳效益，主要是codeine活化kappa接受器所致\nB. naloxone是鴉片類藥物拮抗劑，可以用來治療急性鴉片中毒\nC. fentanyl止痛效力約是morphine的100倍\nD. morphine的強效止痛效力，主要是morphine活化mu接受器所致\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.021484375", "True"]], [["-5.90625", "False"]], [["-4.28125", "False"]], [["-5.53125", "False"]]], "filtered_resps": [["-0.021484375", "True"], ["-5.90625", "False"], ["-4.28125", "False"], ["-5.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "92045b1c700fa51089aa2baa3e8eb700f05c41fc7af96be8a3acd138e6a5f2ed", "prompt_hash": "b5b2b31d5d8a325570722cf1ae3b4245cb1060037766cb1f5c1e1aec22cd3cbd", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 506, "doc": {"question": "下列有關boceprevir的敘述，何者錯誤？", "A": "結構中有urea moiety", "B": "可與pegylated interferon α-2b及ribavirin併用", "C": "可治療HCV感染", "D": "結構中有pyrazine ring", "answer": "D", "questions": "下列有關boceprevir的敘述，何者錯誤？", "choices": ["結構中有urea moiety", "可與pegylated interferon α-2b及ribavirin併用", "可治療HCV感染", "結構中有pyrazine ring"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關boceprevir的敘述，何者錯誤？\nA. 結構中有urea moiety\nB. 可與pegylated interferon α-2b及ribavirin併用\nC. 可治療HCV感染\nD. 結構中有pyrazine ring\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關boceprevir的敘述，何者錯誤？\nA. 結構中有urea moiety\nB. 可與pegylated interferon α-2b及ribavirin併用\nC. 可治療HCV感染\nD. 結構中有pyrazine ring\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關boceprevir的敘述，何者錯誤？\nA. 結構中有urea moiety\nB. 可與pegylated interferon α-2b及ribavirin併用\nC. 可治療HCV感染\nD. 結構中有pyrazine ring\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關boceprevir的敘述，何者錯誤？\nA. 結構中有urea moiety\nB. 可與pegylated interferon α-2b及ribavirin併用\nC. 可治療HCV感染\nD. 結構中有pyrazine ring\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.1875", "False"]], [["-3.8125", "False"]], [["-5.4375", "False"]], [["-0.06982421875", "True"]]], "filtered_resps": [["-3.1875", "False"], ["-3.8125", "False"], ["-5.4375", "False"], ["-0.06982421875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8b1b41758026cb7dba9d568c33b98d1d8928013e6c462ebe127a00d2d1c5d8e9", "prompt_hash": "a917096e62141d730e69e20ba93862e97348d3ae24702e4df183a536ddcff833", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 507, "doc": {"question": "下列何種非類固醇抗發炎藥物的結構，不屬於aryl- or heteroaryl- propionic acid類？", "A": "oxaprozin", "B": "ibuprofen", "C": "diclofenac", "D": "naproxen", "answer": "C", "questions": "下列何種非類固醇抗發炎藥物的結構，不屬於aryl- or heteroaryl- propionic acid類？", "choices": ["oxaprozin", "ibuprofen", "diclofenac", "naproxen"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種非類固醇抗發炎藥物的結構，不屬於aryl- or heteroaryl- propionic acid類？\nA. oxaprozin\nB. ibuprofen\nC. diclofenac\nD. naproxen\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種非類固醇抗發炎藥物的結構，不屬於aryl- or heteroaryl- propionic acid類？\nA. oxaprozin\nB. ibuprofen\nC. diclofenac\nD. naproxen\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種非類固醇抗發炎藥物的結構，不屬於aryl- or heteroaryl- propionic acid類？\nA. oxaprozin\nB. ibuprofen\nC. diclofenac\nD. naproxen\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種非類固醇抗發炎藥物的結構，不屬於aryl- or heteroaryl- propionic acid類？\nA. oxaprozin\nB. ibuprofen\nC. diclofenac\nD. naproxen\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.0625", "False"]], [["-2.8125", "False"]], [["-0.310546875", "True"]], [["-2.5625", "False"]]], "filtered_resps": [["-2.0625", "False"], ["-2.8125", "False"], ["-0.310546875", "True"], ["-2.5625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "fda801dd499433141c80c9ab56169e3a8ea074f5a8d8df70033476ba6abf6b7d", "prompt_hash": "65b6e32ac5f19e1aaecbbc695e60cb0d564bd6e35bfac81cbe2cabe288418dd1", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 508, "doc": {"question": "下列何者為抗心律不整藥amiodarone最主要的代謝途徑？", "A": "hydroxylation", "B": "N-deethylation", "C": "deiodination", "D": "bis-N-deethylation", "answer": "B", "questions": "下列何者為抗心律不整藥amiodarone最主要的代謝途徑？", "choices": ["hydroxylation", "N-deethylation", "deiodination", "bis-N-deethylation"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗心律不整藥amiodarone最主要的代謝途徑？\nA. hydroxylation\nB. N-deethylation\nC. deiodination\nD. bis-N-deethylation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗心律不整藥amiodarone最主要的代謝途徑？\nA. hydroxylation\nB. N-deethylation\nC. deiodination\nD. bis-N-deethylation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗心律不整藥amiodarone最主要的代謝途徑？\nA. hydroxylation\nB. N-deethylation\nC. deiodination\nD. bis-N-deethylation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗心律不整藥amiodarone最主要的代謝途徑？\nA. hydroxylation\nB. N-deethylation\nC. deiodination\nD. bis-N-deethylation\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.484375", "False"]], [["-0.73828125", "True"]], [["-0.98828125", "False"]], [["-2.734375", "False"]]], "filtered_resps": [["-2.484375", "False"], ["-0.73828125", "True"], ["-0.98828125", "False"], ["-2.734375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "99a1bdc229df9337f0e6a941f0ec18a18cbe8a558c91e8a83c88ae6b2530d976", "prompt_hash": "90f9282102309d04914a6bd107a123e9427867a6b6a55ccfa96681a41bab53ac", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 509, "doc": {"question": "下列有關 hydroxyzine 的敘述，何者錯誤？", "A": "結構具 carboxylic acid", "B": "結構具 Cl 原子", "C": "結構具 piperazine 環", "D": "可用於治療搔癢症（pruritus）", "answer": "A", "questions": "下列有關 hydroxyzine 的敘述，何者錯誤？", "choices": ["結構具 carboxylic acid", "結構具 Cl 原子", "結構具 piperazine 環", "可用於治療搔癢症（pruritus）"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 hydroxyzine 的敘述，何者錯誤？\nA. 結構具 carboxylic acid\nB. 結構具 Cl 原子\nC. 結構具 piperazine 環\nD. 可用於治療搔癢症（pruritus）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 hydroxyzine 的敘述，何者錯誤？\nA. 結構具 carboxylic acid\nB. 結構具 Cl 原子\nC. 結構具 piperazine 環\nD. 可用於治療搔癢症（pruritus）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 hydroxyzine 的敘述，何者錯誤？\nA. 結構具 carboxylic acid\nB. 結構具 Cl 原子\nC. 結構具 piperazine 環\nD. 可用於治療搔癢症（pruritus）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關 hydroxyzine 的敘述，何者錯誤？\nA. 結構具 carboxylic acid\nB. 結構具 Cl 原子\nC. 結構具 piperazine 環\nD. 可用於治療搔癢症（pruritus）\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1474609375", "True"]], [["-2.515625", "False"]], [["-4.40625", "False"]], [["-3.140625", "False"]]], "filtered_resps": [["-0.1474609375", "True"], ["-2.515625", "False"], ["-4.40625", "False"], ["-3.140625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "126b87ae6dd78e0d72daba7d2a1d24c8f4941a52417573498a3f43b76470c118", "prompt_hash": "8dd0452ac57c56331edb91dca397f88a672f35ca923e592f3e5c36bb9f9e98c4", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 510, "doc": {"question": "下列何者為使用Quinidine常見的副作用？", "A": "金雞納中毒", "B": "類紅斑性狼瘡", "C": "甲狀腺機能亢進", "D": "便秘", "answer": "A", "questions": "下列何者為使用Quinidine常見的副作用？", "choices": ["金雞納中毒", "類紅斑性狼瘡", "甲狀腺機能亢進", "便秘"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為使用Quinidine常見的副作用？\nA. 金雞納中毒\nB. 類紅斑性狼瘡\nC. 甲狀腺機能亢進\nD. 便秘\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為使用Quinidine常見的副作用？\nA. 金雞納中毒\nB. 類紅斑性狼瘡\nC. 甲狀腺機能亢進\nD. 便秘\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為使用Quinidine常見的副作用？\nA. 金雞納中毒\nB. 類紅斑性狼瘡\nC. 甲狀腺機能亢進\nD. 便秘\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為使用Quinidine常見的副作用？\nA. 金雞納中毒\nB. 類紅斑性狼瘡\nC. 甲狀腺機能亢進\nD. 便秘\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.17578125", "True"]], [["-2.921875", "False"]], [["-3.546875", "False"]], [["-2.546875", "False"]]], "filtered_resps": [["-0.17578125", "True"], ["-2.921875", "False"], ["-3.546875", "False"], ["-2.546875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d9594290699753ff08916249dd3fdb88d6d84a7935ac70472c7ed8870f95ce6e", "prompt_hash": "f322d3ac79457c1edc256b311e8307a15dbe9592154287465fc5e7d9d67b4bc6", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 511, "doc": {"question": "長期服用β-blockers治療高血壓，病人若突然停藥，常見的戒斷症狀為何？", "A": "tachycardia", "B": "decreased intensity of angina", "C": "sexual dysfunction", "D": "bradycardia", "answer": "A", "questions": "長期服用β-blockers治療高血壓，病人若突然停藥，常見的戒斷症狀為何？", "choices": ["tachycardia", "decreased intensity of angina", "sexual dysfunction", "bradycardia"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n長期服用β-blockers治療高血壓，病人若突然停藥，常見的戒斷症狀為何？\nA. tachycardia\nB. decreased intensity of angina\nC. sexual dysfunction\nD. bradycardia\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n長期服用β-blockers治療高血壓，病人若突然停藥，常見的戒斷症狀為何？\nA. tachycardia\nB. decreased intensity of angina\nC. sexual dysfunction\nD. bradycardia\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n長期服用β-blockers治療高血壓，病人若突然停藥，常見的戒斷症狀為何？\nA. tachycardia\nB. decreased intensity of angina\nC. sexual dysfunction\nD. bradycardia\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n長期服用β-blockers治療高血壓，病人若突然停藥，常見的戒斷症狀為何？\nA. tachycardia\nB. decreased intensity of angina\nC. sexual dysfunction\nD. bradycardia\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.062255859375", "True"]], [["-3.4375", "False"]], [["-5.8125", "False"]], [["-3.8125", "False"]]], "filtered_resps": [["-0.062255859375", "True"], ["-3.4375", "False"], ["-5.8125", "False"], ["-3.8125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "459f5e9922aa3c4abd2669c1873add790af306566866ed08f933d8ba0c1aa6c7", "prompt_hash": "1e9d433e671017f72f55aa97b3c6d3a65db0a457a843a024803cd207dd6aa02e", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 512, "doc": {"question": "α-Methyldopa可經下列何種反應，而產生活性代謝物？", "A": "先α-hydroxylation再decarboxylation", "B": "先decarboxylation再α-hydroxylation", "C": "先decarboxylation再β-hydroxylation", "D": "先β-hydroxylation再decarboxylation", "answer": "C", "questions": "α-Methyldopa可經下列何種反應，而產生活性代謝物？", "choices": ["先α-hydroxylation再decarboxylation", "先decarboxylation再α-hydroxylation", "先decarboxylation再β-hydroxylation", "先β-hydroxylation再decarboxylation"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nα-Methyldopa可經下列何種反應，而產生活性代謝物？\nA. 先α-hydroxylation再decarboxylation\nB. 先decarboxylation再α-hydroxylation\nC. 先decarboxylation再β-hydroxylation\nD. 先β-hydroxylation再decarboxylation\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nα-Methyldopa可經下列何種反應，而產生活性代謝物？\nA. 先α-hydroxylation再decarboxylation\nB. 先decarboxylation再α-hydroxylation\nC. 先decarboxylation再β-hydroxylation\nD. 先β-hydroxylation再decarboxylation\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nα-Methyldopa可經下列何種反應，而產生活性代謝物？\nA. 先α-hydroxylation再decarboxylation\nB. 先decarboxylation再α-hydroxylation\nC. 先decarboxylation再β-hydroxylation\nD. 先β-hydroxylation再decarboxylation\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nα-Methyldopa可經下列何種反應，而產生活性代謝物？\nA. 先α-hydroxylation再decarboxylation\nB. 先decarboxylation再α-hydroxylation\nC. 先decarboxylation再β-hydroxylation\nD. 先β-hydroxylation再decarboxylation\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.15625", "False"]], [["-0.53125", "True"]], [["-3.78125", "False"]], [["-2.78125", "False"]]], "filtered_resps": [["-1.15625", "False"], ["-0.53125", "True"], ["-3.78125", "False"], ["-2.78125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "620d448e8754c5779c8990300d5816429870510ca88b53bc24d9cca856c51d01", "prompt_hash": "613c0279c6e7a4c2c74463fd64633563acfb1f24da6afed589587f25d1fedd4d", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 513, "doc": {"question": "下列何者不是使用prednisolone之藥理作用？", "A": "抑制發炎作用", "B": "降低免疫能力", "C": "降低糖質新生（gluconeogenesis）", "D": "增加肝醣生成（glycogen synthesis）", "answer": "C", "questions": "下列何者不是使用prednisolone之藥理作用？", "choices": ["抑制發炎作用", "降低免疫能力", "降低糖質新生（gluconeogenesis）", "增加肝醣生成（glycogen synthesis）"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是使用prednisolone之藥理作用？\nA. 抑制發炎作用\nB. 降低免疫能力\nC. 降低糖質新生（gluconeogenesis）\nD. 增加肝醣生成（glycogen synthesis）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是使用prednisolone之藥理作用？\nA. 抑制發炎作用\nB. 降低免疫能力\nC. 降低糖質新生（gluconeogenesis）\nD. 增加肝醣生成（glycogen synthesis）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是使用prednisolone之藥理作用？\nA. 抑制發炎作用\nB. 降低免疫能力\nC. 降低糖質新生（gluconeogenesis）\nD. 增加肝醣生成（glycogen synthesis）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者不是使用prednisolone之藥理作用？\nA. 抑制發炎作用\nB. 降低免疫能力\nC. 降低糖質新生（gluconeogenesis）\nD. 增加肝醣生成（glycogen synthesis）\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.9375", "False"]], [["-4.1875", "False"]], [["-0.07470703125", "True"]], [["-2.953125", "False"]]], "filtered_resps": [["-5.9375", "False"], ["-4.1875", "False"], ["-0.07470703125", "True"], ["-2.953125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2796c182daaa1a9fbaeaf14ee748b2edad329b4027fdbfc8e6dd548a363aa5de", "prompt_hash": "72dd0a6e37c673aff97a3b2b013b2eb06aec620d4a008abbcf2b6e33984cb149", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 514, "doc": {"question": "下列何種阿片類止痛劑結構，不含piperidine環？", "A": "nalbuphine", "B": "levorphanol", "C": "methadone", "D": "meperidine", "answer": "C", "questions": "下列何種阿片類止痛劑結構，不含piperidine環？", "choices": ["nalbuphine", "levorphanol", "methadone", "meperidine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種阿片類止痛劑結構，不含piperidine環？\nA. nalbuphine\nB. levorphanol\nC. methadone\nD. meperidine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種阿片類止痛劑結構，不含piperidine環？\nA. nalbuphine\nB. levorphanol\nC. methadone\nD. meperidine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種阿片類止痛劑結構，不含piperidine環？\nA. nalbuphine\nB. levorphanol\nC. methadone\nD. meperidine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種阿片類止痛劑結構，不含piperidine環？\nA. nalbuphine\nB. levorphanol\nC. methadone\nD. meperidine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.546875", "True"]], [["-1.046875", "False"]], [["-3.421875", "False"]], [["-3.296875", "False"]]], "filtered_resps": [["-0.546875", "True"], ["-1.046875", "False"], ["-3.421875", "False"], ["-3.296875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8b3fb4b5b5ac28bab5029192bbeac0d49647d7f5a4e79bd10ca284f5cd098df0", "prompt_hash": "cec9e637bddce7ff8e1d28e6d67a6e23f8e882b40d705ac1ded7914c85f65e7c", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 515, "doc": {"question": "有關類風濕性關節炎（rheumatoid arthritis; RA）之用藥，下列敘述何者錯誤？", "A": "methotrexate可用於治療 RA", "B": "A77-1726為 leflunomide之活性代謝產物", "C": "6-thioguanine為 azathioprine之活性代謝產物", "D": "infliximab與 rituximab皆為TNF-α阻斷劑", "answer": "D", "questions": "有關類風濕性關節炎（rheumatoid arthritis; RA）之用藥，下列敘述何者錯誤？", "choices": ["methotrexate可用於治療 RA", "A77-1726為 leflunomide之活性代謝產物", "6-thioguanine為 azathioprine之活性代謝產物", "infliximab與 rituximab皆為TNF-α阻斷劑"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關類風濕性關節炎（rheumatoid arthritis; RA）之用藥，下列敘述何者錯誤？\nA. methotrexate可用於治療 RA\nB. A77-1726為 leflunomide之活性代謝產物\nC. 6-thioguanine為 azathioprine之活性代謝產物\nD. infliximab與 rituximab皆為TNF-α阻斷劑\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關類風濕性關節炎（rheumatoid arthritis; RA）之用藥，下列敘述何者錯誤？\nA. methotrexate可用於治療 RA\nB. A77-1726為 leflunomide之活性代謝產物\nC. 6-thioguanine為 azathioprine之活性代謝產物\nD. infliximab與 rituximab皆為TNF-α阻斷劑\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關類風濕性關節炎（rheumatoid arthritis; RA）之用藥，下列敘述何者錯誤？\nA. methotrexate可用於治療 RA\nB. A77-1726為 leflunomide之活性代謝產物\nC. 6-thioguanine為 azathioprine之活性代謝產物\nD. infliximab與 rituximab皆為TNF-α阻斷劑\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關類風濕性關節炎（rheumatoid arthritis; RA）之用藥，下列敘述何者錯誤？\nA. methotrexate可用於治療 RA\nB. A77-1726為 leflunomide之活性代謝產物\nC. 6-thioguanine為 azathioprine之活性代謝產物\nD. infliximab與 rituximab皆為TNF-α阻斷劑\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.78125", "False"]], [["-4.40625", "False"]], [["-4.15625", "False"]], [["-0.032958984375", "True"]]], "filtered_resps": [["-5.78125", "False"], ["-4.40625", "False"], ["-4.15625", "False"], ["-0.032958984375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2c9e891b3f9d32bd9a28346cf58630ad833f1b900c915daf661c14f09c2e2a4f", "prompt_hash": "7359dbcd2ef77081f11a95dd9a9796258b2d6947f152068b9ad53b6cf8e95cff", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 516, "doc": {"question": "下列何種藥物不適用於治療Legionella pneumonia之感染？", "A": "Rifampin", "B": "Ciprofloxacin", "C": "Erythromycin", "D": "Gentamicin", "answer": "D", "questions": "下列何種藥物不適用於治療Legionella pneumonia之感染？", "choices": ["Rifampin", "Ciprofloxacin", "Erythromycin", "Gentamicin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適用於治療Legionella pneumonia之感染？\nA. Rifampin\nB. Ciprofloxacin\nC. Erythromycin\nD. Gentamicin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適用於治療Legionella pneumonia之感染？\nA. Rifampin\nB. Ciprofloxacin\nC. Erythromycin\nD. Gentamicin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適用於治療Legionella pneumonia之感染？\nA. Rifampin\nB. Ciprofloxacin\nC. Erythromycin\nD. Gentamicin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適用於治療Legionella pneumonia之感染？\nA. Rifampin\nB. Ciprofloxacin\nC. Erythromycin\nD. Gentamicin\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.25", "False"]], [["-5.875", "False"]], [["-7.75", "False"]], [["-0.005828857421875", "True"]]], "filtered_resps": [["-6.25", "False"], ["-5.875", "False"], ["-7.75", "False"], ["-0.005828857421875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e8de7965ecf9f3028036cee982942e1dde4f7538e3e2d6bccbf806ecd2221187", "prompt_hash": "b7700960c1d3d75223d2ce56cb13560b7f203ee863b7932fa1d984bbd6acbaf6", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 517, "doc": {"question": "下列關於擬交感神經作用劑之敘述，何者錯誤？", "A": "midodrine可以治療姿態性低血壓", "B": "atomoxetine可以治療注意力缺陷過動障礙", "C": "droxidopa可以治療姿態性低血壓", "D": "dobutamine可以治療敗血性休克", "answer": "D", "questions": "下列關於擬交感神經作用劑之敘述，何者錯誤？", "choices": ["midodrine可以治療姿態性低血壓", "atomoxetine可以治療注意力缺陷過動障礙", "droxidopa可以治療姿態性低血壓", "dobutamine可以治療敗血性休克"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於擬交感神經作用劑之敘述，何者錯誤？\nA. midodrine可以治療姿態性低血壓\nB. atomoxetine可以治療注意力缺陷過動障礙\nC. droxidopa可以治療姿態性低血壓\nD. dobutamine可以治療敗血性休克\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於擬交感神經作用劑之敘述，何者錯誤？\nA. midodrine可以治療姿態性低血壓\nB. atomoxetine可以治療注意力缺陷過動障礙\nC. droxidopa可以治療姿態性低血壓\nD. dobutamine可以治療敗血性休克\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於擬交感神經作用劑之敘述，何者錯誤？\nA. midodrine可以治療姿態性低血壓\nB. atomoxetine可以治療注意力缺陷過動障礙\nC. droxidopa可以治療姿態性低血壓\nD. dobutamine可以治療敗血性休克\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列關於擬交感神經作用劑之敘述，何者錯誤？\nA. midodrine可以治療姿態性低血壓\nB. atomoxetine可以治療注意力缺陷過動障礙\nC. droxidopa可以治療姿態性低血壓\nD. dobutamine可以治療敗血性休克\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.625", "False"]], [["-5.0", "False"]], [["-5.5", "False"]], [["-0.01495361328125", "True"]]], "filtered_resps": [["-5.625", "False"], ["-5.0", "False"], ["-5.5", "False"], ["-0.01495361328125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6af9e85e1031f80ddf60033ac84cf26f056590d26b9d3e8780df92bb5ab91d52", "prompt_hash": "20038b86d0ffb187018120b71adbbf98227098922399cf504e616d850b1d5142", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 518, "doc": {"question": "下列那一種抗癲癇藥物，為治療癲癇重積症（status epilepticus）的第一線用藥？", "A": "ethosuximide", "B": "diazepam", "C": "valproic acid", "D": "carbamazepine", "answer": "B", "questions": "下列那一種抗癲癇藥物，為治療癲癇重積症（status epilepticus）的第一線用藥？", "choices": ["ethosuximide", "diazepam", "valproic acid", "carbamazepine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種抗癲癇藥物，為治療癲癇重積症（status epilepticus）的第一線用藥？\nA. ethosuximide\nB. diazepam\nC. valproic acid\nD. carbamazepine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種抗癲癇藥物，為治療癲癇重積症（status epilepticus）的第一線用藥？\nA. ethosuximide\nB. diazepam\nC. valproic acid\nD. carbamazepine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種抗癲癇藥物，為治療癲癇重積症（status epilepticus）的第一線用藥？\nA. ethosuximide\nB. diazepam\nC. valproic acid\nD. carbamazepine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種抗癲癇藥物，為治療癲癇重積症（status epilepticus）的第一線用藥？\nA. ethosuximide\nB. diazepam\nC. valproic acid\nD. carbamazepine\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.125", "False"]], [["-0.006439208984375", "True"]], [["-6.625", "False"]], [["-5.625", "False"]]], "filtered_resps": [["-7.125", "False"], ["-0.006439208984375", "True"], ["-6.625", "False"], ["-5.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d141b7c3dc9f562ac1a076c8fe3c83104b2500a0a4cf3bc535d022665aeef173", "prompt_hash": "5496b835fa49f8e49f614b9c40ed7784bf757507e583203113859baad7c6fcd7", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 519, "doc": {"question": "甲狀腺生合成釋出的甲狀腺素中，下列何者最多？", "A": "L-thyroxine（T4）", "B": "L-triiodothyronine（T3）", "C": "diiodo-L-tyrosine（DIT）", "D": "monoiodo-L-tyrosine（MIT）", "answer": "A", "questions": "甲狀腺生合成釋出的甲狀腺素中，下列何者最多？", "choices": ["L-thyroxine（T4）", "L-triiodothyronine（T3）", "diiodo-L-tyrosine（DIT）", "monoiodo-L-tyrosine（MIT）"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n甲狀腺生合成釋出的甲狀腺素中，下列何者最多？\nA. L-thyroxine（T4）\nB. L-triiodothyronine（T3）\nC. diiodo-L-tyrosine（DIT）\nD. monoiodo-L-tyrosine（MIT）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n甲狀腺生合成釋出的甲狀腺素中，下列何者最多？\nA. L-thyroxine（T4）\nB. L-triiodothyronine（T3）\nC. diiodo-L-tyrosine（DIT）\nD. monoiodo-L-tyrosine（MIT）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n甲狀腺生合成釋出的甲狀腺素中，下列何者最多？\nA. L-thyroxine（T4）\nB. L-triiodothyronine（T3）\nC. diiodo-L-tyrosine（DIT）\nD. monoiodo-L-tyrosine（MIT）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n甲狀腺生合成釋出的甲狀腺素中，下列何者最多？\nA. L-thyroxine（T4）\nB. L-triiodothyronine（T3）\nC. diiodo-L-tyrosine（DIT）\nD. monoiodo-L-tyrosine（MIT）\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0791015625", "True"]], [["-3.953125", "False"]], [["-3.328125", "False"]], [["-3.953125", "False"]]], "filtered_resps": [["-0.0791015625", "True"], ["-3.953125", "False"], ["-3.328125", "False"], ["-3.953125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "007a1c0fdb500326041259503db7c26e20dcc24d593e42b702e3a590ad14d239", "prompt_hash": "0de3398cc8e65dbac537e9e7fdbaa994b17b480b727286dcab3a6a8f545d8fa4", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 520, "doc": {"question": "下列有關galantamine之敘述，何者正確？", "A": "具有butyrylcholinesterase抑制作用", "B": "屬於irreversible acetylcholinesterase 抑制劑", "C": "具有quaternary ammonium結構", "D": "可治療Alzheimer's disease", "answer": "D", "questions": "下列有關galantamine之敘述，何者正確？", "choices": ["具有butyrylcholinesterase抑制作用", "屬於irreversible acetylcholinesterase 抑制劑", "具有quaternary ammonium結構", "可治療Alzheimer's disease"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關galantamine之敘述，何者正確？\nA. 具有butyrylcholinesterase抑制作用\nB. 屬於irreversible acetylcholinesterase 抑制劑\nC. 具有quaternary ammonium結構\nD. 可治療Alzheimer's disease\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關galantamine之敘述，何者正確？\nA. 具有butyrylcholinesterase抑制作用\nB. 屬於irreversible acetylcholinesterase 抑制劑\nC. 具有quaternary ammonium結構\nD. 可治療Alzheimer's disease\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關galantamine之敘述，何者正確？\nA. 具有butyrylcholinesterase抑制作用\nB. 屬於irreversible acetylcholinesterase 抑制劑\nC. 具有quaternary ammonium結構\nD. 可治療Alzheimer's disease\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關galantamine之敘述，何者正確？\nA. 具有butyrylcholinesterase抑制作用\nB. 屬於irreversible acetylcholinesterase 抑制劑\nC. 具有quaternary ammonium結構\nD. 可治療Alzheimer's disease\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.0", "False"]], [["-4.0", "False"]], [["-2.625", "False"]], [["-0.11865234375", "True"]]], "filtered_resps": [["-4.0", "False"], ["-4.0", "False"], ["-2.625", "False"], ["-0.11865234375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "40a452fd19b5bf69ed1a0d4b5c1bf27b300eeb214754f28ab9784d46ddc8effa", "prompt_hash": "9e452de597f856f2d2060c6dcd2fa2a25ec4559a2f97998fc4948c643697985d", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 521, "doc": {"question": "下列何種藥物不適合作為偏頭痛（migraine）用藥？", "A": "amitriptyline", "B": "propranolol", "C": "flunarizine", "D": "dexfenfluramine", "answer": "D", "questions": "下列何種藥物不適合作為偏頭痛（migraine）用藥？", "choices": ["amitriptyline", "propranolol", "flunarizine", "dexfenfluramine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適合作為偏頭痛（migraine）用藥？\nA. amitriptyline\nB. propranolol\nC. flunarizine\nD. dexfenfluramine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適合作為偏頭痛（migraine）用藥？\nA. amitriptyline\nB. propranolol\nC. flunarizine\nD. dexfenfluramine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適合作為偏頭痛（migraine）用藥？\nA. amitriptyline\nB. propranolol\nC. flunarizine\nD. dexfenfluramine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適合作為偏頭痛（migraine）用藥？\nA. amitriptyline\nB. propranolol\nC. flunarizine\nD. dexfenfluramine\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.125", "False"]], [["-7.25", "False"]], [["-6.875", "False"]], [["-0.003875732421875", "True"]]], "filtered_resps": [["-7.125", "False"], ["-7.25", "False"], ["-6.875", "False"], ["-0.003875732421875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "00d369fcf3b6f4caebe747b8c8de54dc89add2d87775b08fcc1f9b0c04772f53", "prompt_hash": "d1f4bfc13ecbda44ff9f5e8279a80f8f7758e68489acf190f14e5e88dc75cc3b", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 522, "doc": {"question": "下列全身麻醉劑中，何者在體內代謝的百分比最高？", "A": "CF3 CHFOCHF2", "B": "CF3 CHBrCl", "C": "CF3 CHClOCHF2", "D": "CHCl2 CF2OCH3", "answer": "D", "questions": "下列全身麻醉劑中，何者在體內代謝的百分比最高？", "choices": ["CF3 CHFOCHF2", "CF3 CHBrCl", "CF3 CHClOCHF2", "CHCl2 CF2OCH3"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者在體內代謝的百分比最高？\nA. CF3 CHFOCHF2\nB. CF3 CHBrCl\nC. CF3 CHClOCHF2\nD. CHCl2 CF2OCH3\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者在體內代謝的百分比最高？\nA. CF3 CHFOCHF2\nB. CF3 CHBrCl\nC. CF3 CHClOCHF2\nD. CHCl2 CF2OCH3\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者在體內代謝的百分比最高？\nA. CF3 CHFOCHF2\nB. CF3 CHBrCl\nC. CF3 CHClOCHF2\nD. CHCl2 CF2OCH3\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列全身麻醉劑中，何者在體內代謝的百分比最高？\nA. CF3 CHFOCHF2\nB. CF3 CHBrCl\nC. CF3 CHClOCHF2\nD. CHCl2 CF2OCH3\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.453125", "False"]], [["-2.078125", "False"]], [["-0.83203125", "True"]], [["-1.578125", "False"]]], "filtered_resps": [["-1.453125", "False"], ["-2.078125", "False"], ["-0.83203125", "True"], ["-1.578125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "077435c7564e4602c39a553480464c2f19e3d9bd81557ff3974ce71f135de904", "prompt_hash": "335f6a7aac7c0bc975675bc79c843e4fb45946cc0514fbc86e4e43d9d0107c65", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 523, "doc": {"question": "Glulisine是短效型胰島素，其正確結構為何？", "A": "A21Gly/B31Arg/B32 Arg-human insulin", "B": "B28 Lys/B29 Pro-human insulin", "C": "B28 Asp-human insulin", "D": "B3 Lys/B29 Glu-human insulin", "answer": "D", "questions": "Glulisine是短效型胰島素，其正確結構為何？", "choices": ["A21Gly/B31Arg/B32 Arg-human insulin", "B28 Lys/B29 Pro-human insulin", "B28 Asp-human insulin", "B3 Lys/B29 Glu-human insulin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGlulisine是短效型胰島素，其正確結構為何？\nA. A21Gly/B31Arg/B32 Arg-human insulin\nB. B28 Lys/B29 Pro-human insulin\nC. B28 Asp-human insulin\nD. B3 Lys/B29 Glu-human insulin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGlulisine是短效型胰島素，其正確結構為何？\nA. A21Gly/B31Arg/B32 Arg-human insulin\nB. B28 Lys/B29 Pro-human insulin\nC. B28 Asp-human insulin\nD. B3 Lys/B29 Glu-human insulin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGlulisine是短效型胰島素，其正確結構為何？\nA. A21Gly/B31Arg/B32 Arg-human insulin\nB. B28 Lys/B29 Pro-human insulin\nC. B28 Asp-human insulin\nD. B3 Lys/B29 Glu-human insulin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nGlulisine是短效型胰島素，其正確結構為何？\nA. A21Gly/B31Arg/B32 Arg-human insulin\nB. B28 Lys/B29 Pro-human insulin\nC. B28 Asp-human insulin\nD. B3 Lys/B29 Glu-human insulin\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.203125", "False"]], [["-2.453125", "False"]], [["-3.078125", "False"]], [["-0.578125", "True"]]], "filtered_resps": [["-1.203125", "False"], ["-2.453125", "False"], ["-3.078125", "False"], ["-0.578125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c612afac4795d9cc3cbfc8621c410cb77a2465a2e5e0e8e4a08331eaa8d3b1fb", "prompt_hash": "ed9070338b1845bed5067688b3804fd9e8b20b160dd3e3363660e6f74e71f6d7", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 524, "doc": {"question": "下列受體的訊息傳遞，何者是活化 Gq 蛋白？", "A": "mu-opioid receptor", "B": "alpha2-adrenoceptor", "C": "beta2-adrenoceptor", "D": "5HT2 serotonin receptor", "answer": "D", "questions": "下列受體的訊息傳遞，何者是活化 Gq 蛋白？", "choices": ["mu-opioid receptor", "alpha2-adrenoceptor", "beta2-adrenoceptor", "5HT2 serotonin receptor"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列受體的訊息傳遞，何者是活化 Gq 蛋白？\nA. mu-opioid receptor\nB. alpha2-adrenoceptor\nC. beta2-adrenoceptor\nD. 5HT2 serotonin receptor\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列受體的訊息傳遞，何者是活化 Gq 蛋白？\nA. mu-opioid receptor\nB. alpha2-adrenoceptor\nC. beta2-adrenoceptor\nD. 5HT2 serotonin receptor\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列受體的訊息傳遞，何者是活化 Gq 蛋白？\nA. mu-opioid receptor\nB. alpha2-adrenoceptor\nC. beta2-adrenoceptor\nD. 5HT2 serotonin receptor\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列受體的訊息傳遞，何者是活化 Gq 蛋白？\nA. mu-opioid receptor\nB. alpha2-adrenoceptor\nC. beta2-adrenoceptor\nD. 5HT2 serotonin receptor\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.90625", "False"]], [["-5.15625", "False"]], [["-5.65625", "False"]], [["-0.0186767578125", "True"]]], "filtered_resps": [["-4.90625", "False"], ["-5.15625", "False"], ["-5.65625", "False"], ["-0.0186767578125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "449a286ef525c598562a0bca9dbc64bf0edeed3f716db9a50dca3447f470ca1b", "prompt_hash": "06e1ea0b391a81de0453f234cd60c909f612601c9f576ebaa9d931211d831ea6", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 525, "doc": {"question": "Paricalcitol是維生素D活化物，其結構中具有幾個不飽和鍵？", "A": "4", "B": "3", "C": "2", "D": "5", "answer": "B", "questions": "Paricalcitol是維生素D活化物，其結構中具有幾個不飽和鍵？", "choices": ["4", "3", "2", "5"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nParicalcitol是維生素D活化物，其結構中具有幾個不飽和鍵？\nA. 4\nB. 3\nC. 2\nD. 5\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nParicalcitol是維生素D活化物，其結構中具有幾個不飽和鍵？\nA. 4\nB. 3\nC. 2\nD. 5\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nParicalcitol是維生素D活化物，其結構中具有幾個不飽和鍵？\nA. 4\nB. 3\nC. 2\nD. 5\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nParicalcitol是維生素D活化物，其結構中具有幾個不飽和鍵？\nA. 4\nB. 3\nC. 2\nD. 5\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.2109375", "False"]], [["-0.95703125", "True"]], [["-1.4609375", "False"]], [["-2.453125", "False"]]], "filtered_resps": [["-1.2109375", "False"], ["-0.95703125", "True"], ["-1.4609375", "False"], ["-2.453125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "805878983b319088b24c68f7d774cc0ccb8222248b96ef22fc032bd8d0de95fa", "prompt_hash": "71bc72bb21a7395b23ca385f974bab1b76448cac471da8326fa5a1ce33ff618b", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 526, "doc": {"question": "下列有關安非他命（Amphetamine）藥理作用的敘述，何者錯誤？", "A": "濫用會對多巴胺神經造成傷害", "B": "會促進食慾，進而引起暴食症", "C": "會誘發類精神分裂症狀", "D": "可以用來改善注意力不集中症候群（Attention deficit syndrome）", "answer": "B", "questions": "下列有關安非他命（Amphetamine）藥理作用的敘述，何者錯誤？", "choices": ["濫用會對多巴胺神經造成傷害", "會促進食慾，進而引起暴食症", "會誘發類精神分裂症狀", "可以用來改善注意力不集中症候群（Attention deficit syndrome）"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關安非他命（Amphetamine）藥理作用的敘述，何者錯誤？\nA. 濫用會對多巴胺神經造成傷害\nB. 會促進食慾，進而引起暴食症\nC. 會誘發類精神分裂症狀\nD. 可以用來改善注意力不集中症候群（Attention deficit syndrome）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關安非他命（Amphetamine）藥理作用的敘述，何者錯誤？\nA. 濫用會對多巴胺神經造成傷害\nB. 會促進食慾，進而引起暴食症\nC. 會誘發類精神分裂症狀\nD. 可以用來改善注意力不集中症候群（Attention deficit syndrome）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關安非他命（Amphetamine）藥理作用的敘述，何者錯誤？\nA. 濫用會對多巴胺神經造成傷害\nB. 會促進食慾，進而引起暴食症\nC. 會誘發類精神分裂症狀\nD. 可以用來改善注意力不集中症候群（Attention deficit syndrome）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關安非他命（Amphetamine）藥理作用的敘述，何者錯誤？\nA. 濫用會對多巴胺神經造成傷害\nB. 會促進食慾，進而引起暴食症\nC. 會誘發類精神分裂症狀\nD. 可以用來改善注意力不集中症候群（Attention deficit syndrome）\nAnswer:", "arg_1": " D"}}, "resps": [[["-8.0", "False"]], [["-0.00153350830078125", "True"]], [["-8.5", "False"]], [["-7.125", "False"]]], "filtered_resps": [["-8.0", "False"], ["-0.00153350830078125", "True"], ["-8.5", "False"], ["-7.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "50a2b2ee7bef6f9a55345591d907fefa89cea941812aae856f263e5d86b8a4b0", "prompt_hash": "4eeba940985af3e2e8e76aab0bbed4fe1cb489f1e73b47a9e28df8cf0cc7c36c", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 527, "doc": {"question": "Angiotensin II receptor（AT1 receptor）inhibitors的降血壓機制，不包括下列何者？", "A": "抑制bradykinin代謝", "B": "抑制血管收縮", "C": "減少交感神經活化", "D": "減少前負荷（preload）", "answer": "A", "questions": "Angiotensin II receptor（AT1 receptor）inhibitors的降血壓機制，不包括下列何者？", "choices": ["抑制bradykinin代謝", "抑制血管收縮", "減少交感神經活化", "減少前負荷（preload）"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAngiotensin II receptor（AT1 receptor）inhibitors的降血壓機制，不包括下列何者？\nA. 抑制bradykinin代謝\nB. 抑制血管收縮\nC. 減少交感神經活化\nD. 減少前負荷（preload）\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAngiotensin II receptor（AT1 receptor）inhibitors的降血壓機制，不包括下列何者？\nA. 抑制bradykinin代謝\nB. 抑制血管收縮\nC. 減少交感神經活化\nD. 減少前負荷（preload）\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAngiotensin II receptor（AT1 receptor）inhibitors的降血壓機制，不包括下列何者？\nA. 抑制bradykinin代謝\nB. 抑制血管收縮\nC. 減少交感神經活化\nD. 減少前負荷（preload）\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nAngiotensin II receptor（AT1 receptor）inhibitors的降血壓機制，不包括下列何者？\nA. 抑制bradykinin代謝\nB. 抑制血管收縮\nC. 減少交感神經活化\nD. 減少前負荷（preload）\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.703125", "False"]], [["-5.84375", "False"]], [["-5.21875", "False"]], [["-0.0791015625", "True"]]], "filtered_resps": [["-2.703125", "False"], ["-5.84375", "False"], ["-5.21875", "False"], ["-0.0791015625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "35a0ddb4fef497c28236d1d8ba12e45bcf3f7945c928f9be5bfd2564fac03320", "prompt_hash": "28fed599a81f0119db0ec19a30c749468706e17f407a06d5580ae6bfc64ffdea", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 528, "doc": {"question": "Raloxifene是選擇性雌激素受體調節劑（SERM），其結構不包含下列何者？", "A": "pyridine", "B": "benzene", "C": "piperidine", "D": "benzothiophene", "answer": "A", "questions": "Raloxifene是選擇性雌激素受體調節劑（SERM），其結構不包含下列何者？", "choices": ["pyridine", "benzene", "piperidine", "benzothiophene"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRaloxifene是選擇性雌激素受體調節劑（SERM），其結構不包含下列何者？\nA. pyridine\nB. benzene\nC. piperidine\nD. benzothiophene\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRaloxifene是選擇性雌激素受體調節劑（SERM），其結構不包含下列何者？\nA. pyridine\nB. benzene\nC. piperidine\nD. benzothiophene\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRaloxifene是選擇性雌激素受體調節劑（SERM），其結構不包含下列何者？\nA. pyridine\nB. benzene\nC. piperidine\nD. benzothiophene\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nRaloxifene是選擇性雌激素受體調節劑（SERM），其結構不包含下列何者？\nA. pyridine\nB. benzene\nC. piperidine\nD. benzothiophene\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.90625", "False"]], [["-2.15625", "False"]], [["-0.78125", "True"]], [["-0.90625", "False"]]], "filtered_resps": [["-3.90625", "False"], ["-2.15625", "False"], ["-0.78125", "True"], ["-0.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "aa0675b69915aa91cca33af5db5010dddd4dd87d46261aa61b2f4ea684641e7b", "prompt_hash": "bc5010adb7f6b2c709d83cce9a806c96000a423476f81e6b959f838ea7057d38", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 529, "doc": {"question": "下列有關利尿劑triamterene與amiloride的結構比較，何者錯誤？", "A": "amiloride主結構為aminopyrazine", "B": "triamterene鹼性較強", "C": "兩者具相同氮原子數量", "D": "triamterene主結構為pteridine", "answer": "B", "questions": "下列有關利尿劑triamterene與amiloride的結構比較，何者錯誤？", "choices": ["amiloride主結構為aminopyrazine", "triamterene鹼性較強", "兩者具相同氮原子數量", "triamterene主結構為pteridine"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關利尿劑triamterene與amiloride的結構比較，何者錯誤？\nA. amiloride主結構為aminopyrazine\nB. triamterene鹼性較強\nC. 兩者具相同氮原子數量\nD. triamterene主結構為pteridine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關利尿劑triamterene與amiloride的結構比較，何者錯誤？\nA. amiloride主結構為aminopyrazine\nB. triamterene鹼性較強\nC. 兩者具相同氮原子數量\nD. triamterene主結構為pteridine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關利尿劑triamterene與amiloride的結構比較，何者錯誤？\nA. amiloride主結構為aminopyrazine\nB. triamterene鹼性較強\nC. 兩者具相同氮原子數量\nD. triamterene主結構為pteridine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關利尿劑triamterene與amiloride的結構比較，何者錯誤？\nA. amiloride主結構為aminopyrazine\nB. triamterene鹼性較強\nC. 兩者具相同氮原子數量\nD. triamterene主結構為pteridine\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.828125", "False"]], [["-0.8359375", "False"]], [["-0.8359375", "True"]], [["-2.203125", "False"]]], "filtered_resps": [["-3.828125", "False"], ["-0.8359375", "False"], ["-0.8359375", "True"], ["-2.203125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "1b4c45cb4011cc5644acc8ce3c2eeaa2b88bf83aafd54d0c08c738450396dc16", "prompt_hash": "0c08823f88e3c4f0f0333458d5c54660f711403e41e806695e07c0c146af9093", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 530, "doc": {"question": "下列何種抗憂鬱藥物對抑制正腎上腺素轉運體的作用最小？", "A": "sertraline", "B": "desipramine", "C": "maprotiline", "D": "protriptyline", "answer": "A", "questions": "下列何種抗憂鬱藥物對抑制正腎上腺素轉運體的作用最小？", "choices": ["sertraline", "desipramine", "maprotiline", "protriptyline"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗憂鬱藥物對抑制正腎上腺素轉運體的作用最小？\nA. sertraline\nB. desipramine\nC. maprotiline\nD. protriptyline\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗憂鬱藥物對抑制正腎上腺素轉運體的作用最小？\nA. sertraline\nB. desipramine\nC. maprotiline\nD. protriptyline\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗憂鬱藥物對抑制正腎上腺素轉運體的作用最小？\nA. sertraline\nB. desipramine\nC. maprotiline\nD. protriptyline\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗憂鬱藥物對抑制正腎上腺素轉運體的作用最小？\nA. sertraline\nB. desipramine\nC. maprotiline\nD. protriptyline\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.031982421875", "True"]], [["-4.65625", "False"]], [["-5.53125", "False"]], [["-4.03125", "False"]]], "filtered_resps": [["-0.031982421875", "True"], ["-4.65625", "False"], ["-5.53125", "False"], ["-4.03125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "225f88b970a63eeeaf025bdd6e71751b98bd5633db8ab64b19333de43142d32e", "prompt_hash": "9002350872d680abb27c768321bf2a5876001e575ec511f539cb8afd2dd97893", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 531, "doc": {"question": "Procainamide為會產生延長心臟動作電位期間之第一類抗心律不整藥物，其延長動作電位期間的作用機制為何？", "A": "代謝物N-acetoxylprocainamide能抑制鉀離子管道", "B": "procainamide能抑制鉀離子管道", "C": "procainamide能減慢鉀離子管道活化", "D": "代謝物N-acetylprocainamide能抑制鉀離子管道", "answer": "D", "questions": "Procainamide為會產生延長心臟動作電位期間之第一類抗心律不整藥物，其延長動作電位期間的作用機制為何？", "choices": ["代謝物N-acetoxylprocainamide能抑制鉀離子管道", "procainamide能抑制鉀離子管道", "procainamide能減慢鉀離子管道活化", "代謝物N-acetylprocainamide能抑制鉀離子管道"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nProcainamide為會產生延長心臟動作電位期間之第一類抗心律不整藥物，其延長動作電位期間的作用機制為何？\nA. 代謝物N-acetoxylprocainamide能抑制鉀離子管道\nB. procainamide能抑制鉀離子管道\nC. procainamide能減慢鉀離子管道活化\nD. 代謝物N-acetylprocainamide能抑制鉀離子管道\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nProcainamide為會產生延長心臟動作電位期間之第一類抗心律不整藥物，其延長動作電位期間的作用機制為何？\nA. 代謝物N-acetoxylprocainamide能抑制鉀離子管道\nB. procainamide能抑制鉀離子管道\nC. procainamide能減慢鉀離子管道活化\nD. 代謝物N-acetylprocainamide能抑制鉀離子管道\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nProcainamide為會產生延長心臟動作電位期間之第一類抗心律不整藥物，其延長動作電位期間的作用機制為何？\nA. 代謝物N-acetoxylprocainamide能抑制鉀離子管道\nB. procainamide能抑制鉀離子管道\nC. procainamide能減慢鉀離子管道活化\nD. 代謝物N-acetylprocainamide能抑制鉀離子管道\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nProcainamide為會產生延長心臟動作電位期間之第一類抗心律不整藥物，其延長動作電位期間的作用機制為何？\nA. 代謝物N-acetoxylprocainamide能抑制鉀離子管道\nB. procainamide能抑制鉀離子管道\nC. procainamide能減慢鉀離子管道活化\nD. 代謝物N-acetylprocainamide能抑制鉀離子管道\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.859375", "False"]], [["-1.234375", "False"]], [["-1.734375", "False"]], [["-0.984375", "True"]]], "filtered_resps": [["-1.859375", "False"], ["-1.234375", "False"], ["-1.734375", "False"], ["-0.984375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "a11bd901031c785a22b316ae72a2d23f10b03d199d63547c9d648a4ebab58bfe", "prompt_hash": "1df4ab0be33ff9e9f8df83bc7eb6ff2ffd2cef637ce2638dd131987d87a0a6f8", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 532, "doc": {"question": "下列何種抗憂鬱藥具oxime ether結構，其溶液製劑經光照後易失去活性，故須避光保存？", "A": "citalopram", "B": "sertraline", "C": "trazodone", "D": "fluvoxamine", "answer": "D", "questions": "下列何種抗憂鬱藥具oxime ether結構，其溶液製劑經光照後易失去活性，故須避光保存？", "choices": ["citalopram", "sertraline", "trazodone", "fluvoxamine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗憂鬱藥具oxime ether結構，其溶液製劑經光照後易失去活性，故須避光保存？\nA. citalopram\nB. sertraline\nC. trazodone\nD. fluvoxamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗憂鬱藥具oxime ether結構，其溶液製劑經光照後易失去活性，故須避光保存？\nA. citalopram\nB. sertraline\nC. trazodone\nD. fluvoxamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗憂鬱藥具oxime ether結構，其溶液製劑經光照後易失去活性，故須避光保存？\nA. citalopram\nB. sertraline\nC. trazodone\nD. fluvoxamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗憂鬱藥具oxime ether結構，其溶液製劑經光照後易失去活性，故須避光保存？\nA. citalopram\nB. sertraline\nC. trazodone\nD. fluvoxamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-5.875", "False"]], [["-7.75", "False"]], [["-0.006591796875", "True"]]], "filtered_resps": [["-5.875", "False"], ["-5.875", "False"], ["-7.75", "False"], ["-0.006591796875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "d0a8f95b0f810c2704efbc7259692c7dbb00d18843433b3b58be7d115abaaead", "prompt_hash": "5f76071788643c6823abba1f0bfa79c25822ce1a4e22fff722b803c407cbd92e", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 533, "doc": {"question": "下列何種 HMG-CoA 還原酶抑制劑具活性代謝物？", "A": "fluvastatin", "B": "pravastatin", "C": "atorvastatin", "D": "pitavastatin", "answer": "C", "questions": "下列何種 HMG-CoA 還原酶抑制劑具活性代謝物？", "choices": ["fluvastatin", "pravastatin", "atorvastatin", "pitavastatin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種 HMG-CoA 還原酶抑制劑具活性代謝物？\nA. fluvastatin\nB. pravastatin\nC. atorvastatin\nD. pitavastatin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種 HMG-CoA 還原酶抑制劑具活性代謝物？\nA. fluvastatin\nB. pravastatin\nC. atorvastatin\nD. pitavastatin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種 HMG-CoA 還原酶抑制劑具活性代謝物？\nA. fluvastatin\nB. pravastatin\nC. atorvastatin\nD. pitavastatin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種 HMG-CoA 還原酶抑制劑具活性代謝物？\nA. fluvastatin\nB. pravastatin\nC. atorvastatin\nD. pitavastatin\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.0", "False"]], [["-6.375", "False"]], [["-0.01239013671875", "True"]], [["-5.125", "False"]]], "filtered_resps": [["-6.0", "False"], ["-6.375", "False"], ["-0.01239013671875", "True"], ["-5.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e1ad39e609f6b9e8b74123066093b5e78fe988b0f0e70e32c0059ea8616cdf93", "prompt_hash": "3672d1d3759213a5b68d647375a189d6d451e91f2c01d0eb821cf95963a888b4", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 534, "doc": {"question": "下列有關protamine的敘述，何者錯誤？", "A": "會與heparin競爭antithrombin III結合區", "B": "副作用可能引起anaphylaxis", "C": "會與fibrinogen、血小板產生交互作用", "D": "為富含arginine的蛋白質", "answer": "A", "questions": "下列有關protamine的敘述，何者錯誤？", "choices": ["會與heparin競爭antithrombin III結合區", "副作用可能引起anaphylaxis", "會與fibrinogen、血小板產生交互作用", "為富含arginine的蛋白質"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關protamine的敘述，何者錯誤？\nA. 會與heparin競爭antithrombin III結合區\nB. 副作用可能引起anaphylaxis\nC. 會與fibrinogen、血小板產生交互作用\nD. 為富含arginine的蛋白質\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關protamine的敘述，何者錯誤？\nA. 會與heparin競爭antithrombin III結合區\nB. 副作用可能引起anaphylaxis\nC. 會與fibrinogen、血小板產生交互作用\nD. 為富含arginine的蛋白質\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關protamine的敘述，何者錯誤？\nA. 會與heparin競爭antithrombin III結合區\nB. 副作用可能引起anaphylaxis\nC. 會與fibrinogen、血小板產生交互作用\nD. 為富含arginine的蛋白質\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關protamine的敘述，何者錯誤？\nA. 會與heparin競爭antithrombin III結合區\nB. 副作用可能引起anaphylaxis\nC. 會與fibrinogen、血小板產生交互作用\nD. 為富含arginine的蛋白質\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.54296875", "True"]], [["-3.546875", "False"]], [["-1.1640625", "False"]], [["-2.546875", "False"]]], "filtered_resps": [["-0.54296875", "True"], ["-3.546875", "False"], ["-1.1640625", "False"], ["-2.546875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2faf461326dc9d7df72e62ec10687372a0c2864e90065befb3d258eebec58b2b", "prompt_hash": "8e54a3f264ed435462a9eff159054d1e016ad00e2b0f3bfac578d2f777961fd5", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 535, "doc": {"question": "下列何者並非Corticosterone之作用？", "A": "抑制免疫作用", "B": "產生精神異常", "C": "使腦下垂體釋放生長激素及甲狀腺促進激素", "D": "減少發炎之現象", "answer": "C", "questions": "下列何者並非Corticosterone之作用？", "choices": ["抑制免疫作用", "產生精神異常", "使腦下垂體釋放生長激素及甲狀腺促進激素", "減少發炎之現象"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非Corticosterone之作用？\nA. 抑制免疫作用\nB. 產生精神異常\nC. 使腦下垂體釋放生長激素及甲狀腺促進激素\nD. 減少發炎之現象\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非Corticosterone之作用？\nA. 抑制免疫作用\nB. 產生精神異常\nC. 使腦下垂體釋放生長激素及甲狀腺促進激素\nD. 減少發炎之現象\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非Corticosterone之作用？\nA. 抑制免疫作用\nB. 產生精神異常\nC. 使腦下垂體釋放生長激素及甲狀腺促進激素\nD. 減少發炎之現象\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者並非Corticosterone之作用？\nA. 抑制免疫作用\nB. 產生精神異常\nC. 使腦下垂體釋放生長激素及甲狀腺促進激素\nD. 減少發炎之現象\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.875", "False"]], [["-0.01434326171875", "True"]], [["-5.0", "False"]], [["-5.5", "False"]]], "filtered_resps": [["-5.875", "False"], ["-0.01434326171875", "True"], ["-5.0", "False"], ["-5.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ab6c5a7eba410623d9a4210cf7ed368165f673aaafef7f3446be2c9c5007346f", "prompt_hash": "361f6090e908011dec274a1715495488f82a9a9414f4ebfb77fc9f820b061f04", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 536, "doc": {"question": "下列利尿劑中，何者具有sulfonylurea結構？", "A": "bumetanide", "B": "torsemide", "C": "indapamide", "D": "furosemide", "answer": "B", "questions": "下列利尿劑中，何者具有sulfonylurea結構？", "choices": ["bumetanide", "torsemide", "indapamide", "furosemide"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列利尿劑中，何者具有sulfonylurea結構？\nA. bumetanide\nB. torsemide\nC. indapamide\nD. furosemide\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列利尿劑中，何者具有sulfonylurea結構？\nA. bumetanide\nB. torsemide\nC. indapamide\nD. furosemide\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列利尿劑中，何者具有sulfonylurea結構？\nA. bumetanide\nB. torsemide\nC. indapamide\nD. furosemide\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列利尿劑中，何者具有sulfonylurea結構？\nA. bumetanide\nB. torsemide\nC. indapamide\nD. furosemide\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.734375", "False"]], [["-0.357421875", "True"]], [["-2.859375", "False"]], [["-2.734375", "False"]]], "filtered_resps": [["-1.734375", "False"], ["-0.357421875", "True"], ["-2.859375", "False"], ["-2.734375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e00222f2b5dc5977b3252036982b0dcdb8bc4b9f365920cceebb8fa05cbb6496", "prompt_hash": "0f7aceafab2c6e78b8cb06f190c73703c21552570c15fa93979a338f8ba612b1", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 537, "doc": {"question": "下列藥物在血中，何者主要會與α1 -acid glycoprotein結合？", "A": "prazosin", "B": "barbiturates", "C": "amphotericin B", "D": "tetracycline", "answer": "A", "questions": "下列藥物在血中，何者主要會與α1 -acid glycoprotein結合？", "choices": ["prazosin", "barbiturates", "amphotericin B", "tetracycline"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物在血中，何者主要會與α1 -acid glycoprotein結合？\nA. prazosin\nB. barbiturates\nC. amphotericin B\nD. tetracycline\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物在血中，何者主要會與α1 -acid glycoprotein結合？\nA. prazosin\nB. barbiturates\nC. amphotericin B\nD. tetracycline\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物在血中，何者主要會與α1 -acid glycoprotein結合？\nA. prazosin\nB. barbiturates\nC. amphotericin B\nD. tetracycline\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物在血中，何者主要會與α1 -acid glycoprotein結合？\nA. prazosin\nB. barbiturates\nC. amphotericin B\nD. tetracycline\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.09326171875", "True"]], [["-2.71875", "False"]], [["-6.21875", "False"]], [["-3.96875", "False"]]], "filtered_resps": [["-0.09326171875", "True"], ["-2.71875", "False"], ["-6.21875", "False"], ["-3.96875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b3852f148bc6ca97d86391f5fd5a7a548e5e8a50ed74d2f16cfad3d68366b79c", "prompt_hash": "08efe815e1f1c33eee198f87f6ee8f9023caf88f72b40bf826c999bdc51118c0", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 538, "doc": {"question": "下列抗生素之吸收何者較不受食物之影響？", "A": "Ampicillin", "B": "Amoxicillin", "C": "Dicloxacillin", "D": "Oxacillin", "answer": "B", "questions": "下列抗生素之吸收何者較不受食物之影響？", "choices": ["Ampicillin", "Amoxicillin", "Dicloxacillin", "Oxacillin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素之吸收何者較不受食物之影響？\nA. Ampicillin\nB. Amoxicillin\nC. Dicloxacillin\nD. Oxacillin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素之吸收何者較不受食物之影響？\nA. Ampicillin\nB. Amoxicillin\nC. Dicloxacillin\nD. Oxacillin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素之吸收何者較不受食物之影響？\nA. Ampicillin\nB. Amoxicillin\nC. Dicloxacillin\nD. Oxacillin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗生素之吸收何者較不受食物之影響？\nA. Ampicillin\nB. Amoxicillin\nC. Dicloxacillin\nD. Oxacillin\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.40625", "False"]], [["-0.1572265625", "True"]], [["-3.15625", "False"]], [["-2.40625", "False"]]], "filtered_resps": [["-4.40625", "False"], ["-0.1572265625", "True"], ["-3.15625", "False"], ["-2.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "cae317cf1f8d1bb1a5172b85c885e54e5cc9e3952b729fd9feb41f5ef7e4415f", "prompt_hash": "284eba619a6e0625a73b68932399b73246b788e73e9f30d896aca5ca24cdcaef", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 539, "doc": {"question": "下列有關抗結核藥ethambutol的敘述，何者正確？", "A": "具光學活性", "B": "具明顯聽神經毒性", "C": "屬脂溶性藥", "D": "含兩個三級胺結構", "answer": "A", "questions": "下列有關抗結核藥ethambutol的敘述，何者正確？", "choices": ["具光學活性", "具明顯聽神經毒性", "屬脂溶性藥", "含兩個三級胺結構"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗結核藥ethambutol的敘述，何者正確？\nA. 具光學活性\nB. 具明顯聽神經毒性\nC. 屬脂溶性藥\nD. 含兩個三級胺結構\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗結核藥ethambutol的敘述，何者正確？\nA. 具光學活性\nB. 具明顯聽神經毒性\nC. 屬脂溶性藥\nD. 含兩個三級胺結構\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗結核藥ethambutol的敘述，何者正確？\nA. 具光學活性\nB. 具明顯聽神經毒性\nC. 屬脂溶性藥\nD. 含兩個三級胺結構\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關抗結核藥ethambutol的敘述，何者正確？\nA. 具光學活性\nB. 具明顯聽神經毒性\nC. 屬脂溶性藥\nD. 含兩個三級胺結構\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.3671875", "False"]], [["-0.98828125", "True"]], [["-1.1171875", "False"]], [["-3.109375", "False"]]], "filtered_resps": [["-1.3671875", "False"], ["-0.98828125", "True"], ["-1.1171875", "False"], ["-3.109375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8628346eb4528f839e391ae76fb04331acc32e917f03ee1620df2e052757f959", "prompt_hash": "6f5932abc3575c2e9aa64eaad59be4c9d9a57d7790fd9d9a9d70ebdf38d19394", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 540, "doc": {"question": "下列有關性功能障礙用藥sildenafil與vardenafil之比較，何者錯誤？", "A": "vardenafil對PDE5的抑制活性較強", "B": "主要代謝酵素均為CYP3A4", "C": "結構均具piperazine環", "D": "sildenafil之N-demethyl代謝物不具活性", "answer": "D", "questions": "下列有關性功能障礙用藥sildenafil與vardenafil之比較，何者錯誤？", "choices": ["vardenafil對PDE5的抑制活性較強", "主要代謝酵素均為CYP3A4", "結構均具piperazine環", "sildenafil之N-demethyl代謝物不具活性"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關性功能障礙用藥sildenafil與vardenafil之比較，何者錯誤？\nA. vardenafil對PDE5的抑制活性較強\nB. 主要代謝酵素均為CYP3A4\nC. 結構均具piperazine環\nD. sildenafil之N-demethyl代謝物不具活性\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關性功能障礙用藥sildenafil與vardenafil之比較，何者錯誤？\nA. vardenafil對PDE5的抑制活性較強\nB. 主要代謝酵素均為CYP3A4\nC. 結構均具piperazine環\nD. sildenafil之N-demethyl代謝物不具活性\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關性功能障礙用藥sildenafil與vardenafil之比較，何者錯誤？\nA. vardenafil對PDE5的抑制活性較強\nB. 主要代謝酵素均為CYP3A4\nC. 結構均具piperazine環\nD. sildenafil之N-demethyl代謝物不具活性\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關性功能障礙用藥sildenafil與vardenafil之比較，何者錯誤？\nA. vardenafil對PDE5的抑制活性較強\nB. 主要代謝酵素均為CYP3A4\nC. 結構均具piperazine環\nD. sildenafil之N-demethyl代謝物不具活性\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.5625", "False"]], [["-1.4296875", "False"]], [["-3.4375", "False"]], [["-0.4296875", "True"]]], "filtered_resps": [["-2.5625", "False"], ["-1.4296875", "False"], ["-3.4375", "False"], ["-0.4296875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8b187dd51055c9cc25310a726929ab56db0ca2b3b7061701802fab14c8648383", "prompt_hash": "7630035c2ab54e035d93c3b31cf57349035f129c7a2f94ba091466c54bef183e", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 541, "doc": {"question": "下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子何者結構中含硫原子？", "A": "pamidronate", "B": "ibandronate", "C": "risedronate", "D": "tiludronate", "answer": "D", "questions": "下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子何者結構中含硫原子？", "choices": ["pamidronate", "ibandronate", "risedronate", "tiludronate"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子何者結構中含硫原子？\nA. pamidronate\nB. ibandronate\nC. risedronate\nD. tiludronate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子何者結構中含硫原子？\nA. pamidronate\nB. ibandronate\nC. risedronate\nD. tiludronate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子何者結構中含硫原子？\nA. pamidronate\nB. ibandronate\nC. risedronate\nD. tiludronate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列雙膦酸鹽（bisphosphonates），何者結構中含硫原子何者結構中含硫原子？\nA. pamidronate\nB. ibandronate\nC. risedronate\nD. tiludronate\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.8125", "False"]], [["-5.3125", "False"]], [["-6.0625", "False"]], [["-0.06396484375", "True"]]], "filtered_resps": [["-5.8125", "False"], ["-5.3125", "False"], ["-6.0625", "False"], ["-0.06396484375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e6701bbd1d68a86a7c4d3e376dc53da8e929ed893812923dc0a99d62c555721c", "prompt_hash": "1c824cf5ae0d75729444a57ad842674cdb3160ed28040d4a1338a2e253862017", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 542, "doc": {"question": "下列何種藥物不適用於失眠？", "A": "Melatonin", "B": "Benzodiazepine", "C": "Buspirone", "D": "Antihistamines", "answer": "C", "questions": "下列何種藥物不適用於失眠？", "choices": ["Melatonin", "Benzodiazepine", "Buspirone", "Antihistamines"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適用於失眠？\nA. Melatonin\nB. Benzodiazepine\nC. Buspirone\nD. Antihistamines\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適用於失眠？\nA. Melatonin\nB. Benzodiazepine\nC. Buspirone\nD. Antihistamines\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適用於失眠？\nA. Melatonin\nB. Benzodiazepine\nC. Buspirone\nD. Antihistamines\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物不適用於失眠？\nA. Melatonin\nB. Benzodiazepine\nC. Buspirone\nD. Antihistamines\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.5", "False"]], [["-7.5", "False"]], [["-0.0106201171875", "True"]], [["-5.25", "False"]]], "filtered_resps": [["-6.5", "False"], ["-7.5", "False"], ["-0.0106201171875", "True"], ["-5.25", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "c7d05b4feef88d5dbaff458ae185aefdc9e49ee9b1f1a22cacfec220cb59ea99", "prompt_hash": "de725d1a8959d37c05f62cbbd3e6008861aa2f69ee1697a0e1f7c25984bb9da5", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 543, "doc": {"question": "眼科病患常常需要先使用藥物產生瞳孔擴散（mydriasis），以利眼科醫師進行相關檢查。下列藥物何者具瞳孔擴散作用？", "A": "尼古丁受體致效劑", "B": "毒蕈鹼受體拮抗劑", "C": "乙醯膽鹼酯酶抑制劑", "D": "毒蕈鹼受體致效劑", "answer": "B", "questions": "眼科病患常常需要先使用藥物產生瞳孔擴散（mydriasis），以利眼科醫師進行相關檢查。下列藥物何者具瞳孔擴散作用？", "choices": ["尼古丁受體致效劑", "毒蕈鹼受體拮抗劑", "乙醯膽鹼酯酶抑制劑", "毒蕈鹼受體致效劑"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n眼科病患常常需要先使用藥物產生瞳孔擴散（mydriasis），以利眼科醫師進行相關檢查。下列藥物何者具瞳孔擴散作用？\nA. 尼古丁受體致效劑\nB. 毒蕈鹼受體拮抗劑\nC. 乙醯膽鹼酯酶抑制劑\nD. 毒蕈鹼受體致效劑\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n眼科病患常常需要先使用藥物產生瞳孔擴散（mydriasis），以利眼科醫師進行相關檢查。下列藥物何者具瞳孔擴散作用？\nA. 尼古丁受體致效劑\nB. 毒蕈鹼受體拮抗劑\nC. 乙醯膽鹼酯酶抑制劑\nD. 毒蕈鹼受體致效劑\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n眼科病患常常需要先使用藥物產生瞳孔擴散（mydriasis），以利眼科醫師進行相關檢查。下列藥物何者具瞳孔擴散作用？\nA. 尼古丁受體致效劑\nB. 毒蕈鹼受體拮抗劑\nC. 乙醯膽鹼酯酶抑制劑\nD. 毒蕈鹼受體致效劑\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n眼科病患常常需要先使用藥物產生瞳孔擴散（mydriasis），以利眼科醫師進行相關檢查。下列藥物何者具瞳孔擴散作用？\nA. 尼古丁受體致效劑\nB. 毒蕈鹼受體拮抗劑\nC. 乙醯膽鹼酯酶抑制劑\nD. 毒蕈鹼受體致效劑\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.3125", "False"]], [["-0.048583984375", "True"]], [["-5.5625", "False"]], [["-3.296875", "False"]]], "filtered_resps": [["-5.3125", "False"], ["-0.048583984375", "True"], ["-5.5625", "False"], ["-3.296875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ae66c6722e358d410e840d77472a3c72711aa5592f16a8665ccadf7de8dad5ec", "prompt_hash": "a2542391810f8c1494709e645e6f7a8b34a215570a4fc1a2e0150387be41d720", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 544, "doc": {"question": "長期使用phenytoin時會產生軟骨症（Osteomalacia），係由於下列那一種維生素代謝異常所造成的？", "A": "B6", "B": "E", "C": "A", "D": "D", "answer": "D", "questions": "長期使用phenytoin時會產生軟骨症（Osteomalacia），係由於下列那一種維生素代謝異常所造成的？", "choices": ["B6", "E", "A", "D"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n長期使用phenytoin時會產生軟骨症（Osteomalacia），係由於下列那一種維生素代謝異常所造成的？\nA. B6\nB. E\nC. A\nD. D\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n長期使用phenytoin時會產生軟骨症（Osteomalacia），係由於下列那一種維生素代謝異常所造成的？\nA. B6\nB. E\nC. A\nD. D\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n長期使用phenytoin時會產生軟骨症（Osteomalacia），係由於下列那一種維生素代謝異常所造成的？\nA. B6\nB. E\nC. A\nD. D\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n長期使用phenytoin時會產生軟骨症（Osteomalacia），係由於下列那一種維生素代謝異常所造成的？\nA. B6\nB. E\nC. A\nD. D\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.375", "False"]], [["-6.375", "False"]], [["-7.25", "False"]], [["-0.00421142578125", "True"]]], "filtered_resps": [["-6.375", "False"], ["-6.375", "False"], ["-7.25", "False"], ["-0.00421142578125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6f3b2a0d0887b573b1d68b5eff854f784d93ba6647e2e78b5eab3f0bff25507a", "prompt_hash": "7499ec55c992fdb7c797b4bb0f22aba7afb01a6103302d7302d1e4202e2824bb", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 545, "doc": {"question": "下列有關sodium nitroprusside之敘述，何者正確？", "A": "製劑溶液可加入保存劑，以增加安定性", "B": "製劑溶液由藍色轉變為紅棕色時，表示已變質", "C": "結構含三價鐵", "D": "製劑溶液若有銅存在時，會加速其降解", "answer": "D", "questions": "下列有關sodium nitroprusside之敘述，何者正確？", "choices": ["製劑溶液可加入保存劑，以增加安定性", "製劑溶液由藍色轉變為紅棕色時，表示已變質", "結構含三價鐵", "製劑溶液若有銅存在時，會加速其降解"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關sodium nitroprusside之敘述，何者正確？\nA. 製劑溶液可加入保存劑，以增加安定性\nB. 製劑溶液由藍色轉變為紅棕色時，表示已變質\nC. 結構含三價鐵\nD. 製劑溶液若有銅存在時，會加速其降解\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關sodium nitroprusside之敘述，何者正確？\nA. 製劑溶液可加入保存劑，以增加安定性\nB. 製劑溶液由藍色轉變為紅棕色時，表示已變質\nC. 結構含三價鐵\nD. 製劑溶液若有銅存在時，會加速其降解\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關sodium nitroprusside之敘述，何者正確？\nA. 製劑溶液可加入保存劑，以增加安定性\nB. 製劑溶液由藍色轉變為紅棕色時，表示已變質\nC. 結構含三價鐵\nD. 製劑溶液若有銅存在時，會加速其降解\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關sodium nitroprusside之敘述，何者正確？\nA. 製劑溶液可加入保存劑，以增加安定性\nB. 製劑溶液由藍色轉變為紅棕色時，表示已變質\nC. 結構含三價鐵\nD. 製劑溶液若有銅存在時，會加速其降解\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.078125", "False"]], [["-2.328125", "False"]], [["-1.953125", "False"]], [["-0.455078125", "True"]]], "filtered_resps": [["-2.078125", "False"], ["-2.328125", "False"], ["-1.953125", "False"], ["-0.455078125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4751060b09908a3b3706f0d6fb25c48d52e54b18ff48f92bb12ec04ada1c900c", "prompt_hash": "e472eef48e1f3c977e780c70773fb703a88b1f8a286089c8fedde1536ccf7cd5", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 546, "doc": {"question": "Telithromycin產生膽鹼拮抗作用，與結構中下列何種基團有關？", "A": "pyrimidine", "B": "pyrrolidine", "C": "piperidine", "D": "pyridine", "answer": "D", "questions": "Telithromycin產生膽鹼拮抗作用，與結構中下列何種基團有關？", "choices": ["pyrimidine", "pyrrolidine", "piperidine", "pyridine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nTelithromycin產生膽鹼拮抗作用，與結構中下列何種基團有關？\nA. pyrimidine\nB. pyrrolidine\nC. piperidine\nD. pyridine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nTelithromycin產生膽鹼拮抗作用，與結構中下列何種基團有關？\nA. pyrimidine\nB. pyrrolidine\nC. piperidine\nD. pyridine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nTelithromycin產生膽鹼拮抗作用，與結構中下列何種基團有關？\nA. pyrimidine\nB. pyrrolidine\nC. piperidine\nD. pyridine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nTelithromycin產生膽鹼拮抗作用，與結構中下列何種基團有關？\nA. pyrimidine\nB. pyrrolidine\nC. piperidine\nD. pyridine\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.78125", "False"]], [["-3.921875", "False"]], [["-4.65625", "False"]], [["-0.045166015625", "True"]]], "filtered_resps": [["-4.78125", "False"], ["-3.921875", "False"], ["-4.65625", "False"], ["-0.045166015625", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9d4a532a07f92689cdf5d776a4b625402139f072180171eba97dd88410219e39", "prompt_hash": "7c4ba6e68ec845721b0976334cd0752196056190341820fdace3a201047c0cbc", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 547, "doc": {"question": "下列那一種吸入性全身麻醉劑的溶解度（血液/氣體分配係數）最低？", "A": "halothane", "B": "isoflurane", "C": "desflurane", "D": "enflurane", "answer": "C", "questions": "下列那一種吸入性全身麻醉劑的溶解度（血液/氣體分配係數）最低？", "choices": ["halothane", "isoflurane", "desflurane", "enflurane"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種吸入性全身麻醉劑的溶解度（血液/氣體分配係數）最低？\nA. halothane\nB. isoflurane\nC. desflurane\nD. enflurane\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種吸入性全身麻醉劑的溶解度（血液/氣體分配係數）最低？\nA. halothane\nB. isoflurane\nC. desflurane\nD. enflurane\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種吸入性全身麻醉劑的溶解度（血液/氣體分配係數）最低？\nA. halothane\nB. isoflurane\nC. desflurane\nD. enflurane\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種吸入性全身麻醉劑的溶解度（血液/氣體分配係數）最低？\nA. halothane\nB. isoflurane\nC. desflurane\nD. enflurane\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.0625", "False"]], [["-6.0625", "False"]], [["-0.048095703125", "True"]], [["-3.171875", "False"]]], "filtered_resps": [["-6.0625", "False"], ["-6.0625", "False"], ["-0.048095703125", "True"], ["-3.171875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "88cd4710880f281923383bb956c7b3d3f4ce301db45b43b36756d54e658cf1af", "prompt_hash": "61e1421cd6fad5b83093f833134e57a8a554e463e3c3f86563fee85980834204", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 548, "doc": {"question": "下列那一種安眠藥（Hypnotics）最不會影響人體正常睡眠狀態？", "A": "Triazolam", "B": "Zolpidem", "C": "Phenobarbital", "D": "Diazepam", "answer": "B", "questions": "下列那一種安眠藥（Hypnotics）最不會影響人體正常睡眠狀態？", "choices": ["Triazolam", "Zolpidem", "Phenobarbital", "Diazepam"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種安眠藥（Hypnotics）最不會影響人體正常睡眠狀態？\nA. Triazolam\nB. Zolpidem\nC. Phenobarbital\nD. Diazepam\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種安眠藥（Hypnotics）最不會影響人體正常睡眠狀態？\nA. Triazolam\nB. Zolpidem\nC. Phenobarbital\nD. Diazepam\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種安眠藥（Hypnotics）最不會影響人體正常睡眠狀態？\nA. Triazolam\nB. Zolpidem\nC. Phenobarbital\nD. Diazepam\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列那一種安眠藥（Hypnotics）最不會影響人體正常睡眠狀態？\nA. Triazolam\nB. Zolpidem\nC. Phenobarbital\nD. Diazepam\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.0", "False"]], [["-0.01043701171875", "True"]], [["-5.875", "False"]], [["-6.125", "False"]]], "filtered_resps": [["-6.0", "False"], ["-0.01043701171875", "True"], ["-5.875", "False"], ["-6.125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "dea57eb0f19d5e8e98d2ecbc82775bcab7815909f875146084f4dbdc4b5e00c5", "prompt_hash": "ac1da9ae957a255f4d1196eab6347b7282f8dceaf7b158495aacd9f68b83b35f", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 549, "doc": {"question": "下列有關diazoxide的敘述，何者錯誤？", "A": "結構中含有sulfonamide基團", "B": "可直接作用於血管平滑肌細胞，造成鉀離子通道開啟", "C": "氧化為其主要的代謝途徑", "D": "可降血糖", "answer": "D", "questions": "下列有關diazoxide的敘述，何者錯誤？", "choices": ["結構中含有sulfonamide基團", "可直接作用於血管平滑肌細胞，造成鉀離子通道開啟", "氧化為其主要的代謝途徑", "可降血糖"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關diazoxide的敘述，何者錯誤？\nA. 結構中含有sulfonamide基團\nB. 可直接作用於血管平滑肌細胞，造成鉀離子通道開啟\nC. 氧化為其主要的代謝途徑\nD. 可降血糖\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關diazoxide的敘述，何者錯誤？\nA. 結構中含有sulfonamide基團\nB. 可直接作用於血管平滑肌細胞，造成鉀離子通道開啟\nC. 氧化為其主要的代謝途徑\nD. 可降血糖\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關diazoxide的敘述，何者錯誤？\nA. 結構中含有sulfonamide基團\nB. 可直接作用於血管平滑肌細胞，造成鉀離子通道開啟\nC. 氧化為其主要的代謝途徑\nD. 可降血糖\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關diazoxide的敘述，何者錯誤？\nA. 結構中含有sulfonamide基團\nB. 可直接作用於血管平滑肌細胞，造成鉀離子通道開啟\nC. 氧化為其主要的代謝途徑\nD. 可降血糖\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.40625", "False"]], [["-4.78125", "False"]], [["-5.28125", "False"]], [["-0.028564453125", "True"]]], "filtered_resps": [["-4.40625", "False"], ["-4.78125", "False"], ["-5.28125", "False"], ["-0.028564453125", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "332b75fe006ee2597bf619bdb160117e469622ac0af4be6e005771efc9d0ed39", "prompt_hash": "ad438b7122a6476e26265a65eb40681c6ccacc354b5a7c26be47b943dfb11d89", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 550, "doc": {"question": "下列何者之受體不屬於G-蛋白耦合受體（G-protein-coupled receptors, GPCRs）？", "A": "histamine", "B": "dopamine", "C": "testosterone", "D": "enkephalin", "answer": "C", "questions": "下列何者之受體不屬於G-蛋白耦合受體（G-protein-coupled receptors, GPCRs）？", "choices": ["histamine", "dopamine", "testosterone", "enkephalin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者之受體不屬於G-蛋白耦合受體（G-protein-coupled receptors, GPCRs）？\nA. histamine\nB. dopamine\nC. testosterone\nD. enkephalin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者之受體不屬於G-蛋白耦合受體（G-protein-coupled receptors, GPCRs）？\nA. histamine\nB. dopamine\nC. testosterone\nD. enkephalin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者之受體不屬於G-蛋白耦合受體（G-protein-coupled receptors, GPCRs）？\nA. histamine\nB. dopamine\nC. testosterone\nD. enkephalin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者之受體不屬於G-蛋白耦合受體（G-protein-coupled receptors, GPCRs）？\nA. histamine\nB. dopamine\nC. testosterone\nD. enkephalin\nAnswer:", "arg_1": " D"}}, "resps": [[["-7.15625", "False"]], [["-7.03125", "False"]], [["-0.0177001953125", "True"]], [["-4.65625", "False"]]], "filtered_resps": [["-7.15625", "False"], ["-7.03125", "False"], ["-0.0177001953125", "True"], ["-4.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6d6e62e717fc04abf6fee980e4f3d41fa5614408e69d995b23dac43fc0d856e6", "prompt_hash": "3392cc17a31eaf05cd3c6ffd67c0a2bd7abde01888b8af3ac95e272d72adef5f", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 551, "doc": {"question": "下列胺糖苷類（aminoglycosides）抗生素，何者結構中具有D-ribose基團？", "A": "kanamycin", "B": "neomycin", "C": "gentamicin", "D": "tobramycin", "answer": "B", "questions": "下列胺糖苷類（aminoglycosides）抗生素，何者結構中具有D-ribose基團？", "choices": ["kanamycin", "neomycin", "gentamicin", "tobramycin"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列胺糖苷類（aminoglycosides）抗生素，何者結構中具有D-ribose基團？\nA. kanamycin\nB. neomycin\nC. gentamicin\nD. tobramycin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列胺糖苷類（aminoglycosides）抗生素，何者結構中具有D-ribose基團？\nA. kanamycin\nB. neomycin\nC. gentamicin\nD. tobramycin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列胺糖苷類（aminoglycosides）抗生素，何者結構中具有D-ribose基團？\nA. kanamycin\nB. neomycin\nC. gentamicin\nD. tobramycin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列胺糖苷類（aminoglycosides）抗生素，何者結構中具有D-ribose基團？\nA. kanamycin\nB. neomycin\nC. gentamicin\nD. tobramycin\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.78125", "False"]], [["-0.1572265625", "True"]], [["-3.15625", "False"]], [["-2.53125", "False"]]], "filtered_resps": [["-3.78125", "False"], ["-0.1572265625", "True"], ["-3.15625", "False"], ["-2.53125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "3722b101201d108d775c188fa3dd5c2fb1224572cb06536da39d4ece0652af04", "prompt_hash": "d0f0c3c55d043e45e88dbdaaa766fc0908e9f6654cc43d5003eab23897d4e719", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 552, "doc": {"question": "Sulindac經代謝後活化之結構，具有何種官能基？", "A": "sulfone", "B": "sulfide", "C": "sulfoxide", "D": "sulfate", "answer": "B", "questions": "Sulindac經代謝後活化之結構，具有何種官能基？", "choices": ["sulfone", "sulfide", "sulfoxide", "sulfate"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSulindac經代謝後活化之結構，具有何種官能基？\nA. sulfone\nB. sulfide\nC. sulfoxide\nD. sulfate\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSulindac經代謝後活化之結構，具有何種官能基？\nA. sulfone\nB. sulfide\nC. sulfoxide\nD. sulfate\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSulindac經代謝後活化之結構，具有何種官能基？\nA. sulfone\nB. sulfide\nC. sulfoxide\nD. sulfate\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nSulindac經代謝後活化之結構，具有何種官能基？\nA. sulfone\nB. sulfide\nC. sulfoxide\nD. sulfate\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.75", "False"]], [["-0.01275634765625", "True"]], [["-5.5", "False"]], [["-5.625", "False"]]], "filtered_resps": [["-5.75", "False"], ["-0.01275634765625", "True"], ["-5.5", "False"], ["-5.625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "ea4dd6e1114a2624ae9917334ed94503e0e96e57242ee991096cad6bfbfcdc6d", "prompt_hash": "53a0eb3694f2928ed5be403619bfa42e65105bc5add22dfca96d137a860234c9", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 553, "doc": {"question": "下列何種酵素可將codeine代謝成morphine？", "A": "CYP2C19", "B": "CYP2C9", "C": "CYP3A4", "D": "CYP2D6", "answer": "D", "questions": "下列何種酵素可將codeine代謝成morphine？", "choices": ["CYP2C19", "CYP2C9", "CYP3A4", "CYP2D6"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種酵素可將codeine代謝成morphine？\nA. CYP2C19\nB. CYP2C9\nC. CYP3A4\nD. CYP2D6\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種酵素可將codeine代謝成morphine？\nA. CYP2C19\nB. CYP2C9\nC. CYP3A4\nD. CYP2D6\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種酵素可將codeine代謝成morphine？\nA. CYP2C19\nB. CYP2C9\nC. CYP3A4\nD. CYP2D6\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種酵素可將codeine代謝成morphine？\nA. CYP2C19\nB. CYP2C9\nC. CYP3A4\nD. CYP2D6\nAnswer:", "arg_1": " D"}}, "resps": [[["-8.0", "False"]], [["-6.25", "False"]], [["-6.875", "False"]], [["-0.004486083984375", "True"]]], "filtered_resps": [["-8.0", "False"], ["-6.25", "False"], ["-6.875", "False"], ["-0.004486083984375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "8d0a52f495992f8c425bb1be69026eb46d915283bfc81ec769b46c7ee4263d1d", "prompt_hash": "df239d80ca8db85156473088374394f16f6121f757563eea4ec09da5de93bd53", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 554, "doc": {"question": "關於erythromycin的敘述，下列何者錯誤？", "A": "可以有效抑制肺炎黴漿菌", "B": "因為抑制cytochrome P450酵素活性而會增加warfarin血中濃度", "C": "在酸性環境中能增加其藥效", "D": "經由結合到50S核糖體RNA達到抑制細菌生存", "answer": "C", "questions": "關於erythromycin的敘述，下列何者錯誤？", "choices": ["可以有效抑制肺炎黴漿菌", "因為抑制cytochrome P450酵素活性而會增加warfarin血中濃度", "在酸性環境中能增加其藥效", "經由結合到50S核糖體RNA達到抑制細菌生存"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於erythromycin的敘述，下列何者錯誤？\nA. 可以有效抑制肺炎黴漿菌\nB. 因為抑制cytochrome P450酵素活性而會增加warfarin血中濃度\nC. 在酸性環境中能增加其藥效\nD. 經由結合到50S核糖體RNA達到抑制細菌生存\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於erythromycin的敘述，下列何者錯誤？\nA. 可以有效抑制肺炎黴漿菌\nB. 因為抑制cytochrome P450酵素活性而會增加warfarin血中濃度\nC. 在酸性環境中能增加其藥效\nD. 經由結合到50S核糖體RNA達到抑制細菌生存\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於erythromycin的敘述，下列何者錯誤？\nA. 可以有效抑制肺炎黴漿菌\nB. 因為抑制cytochrome P450酵素活性而會增加warfarin血中濃度\nC. 在酸性環境中能增加其藥效\nD. 經由結合到50S核糖體RNA達到抑制細菌生存\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n關於erythromycin的敘述，下列何者錯誤？\nA. 可以有效抑制肺炎黴漿菌\nB. 因為抑制cytochrome P450酵素活性而會增加warfarin血中濃度\nC. 在酸性環境中能增加其藥效\nD. 經由結合到50S核糖體RNA達到抑制細菌生存\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.875", "False"]], [["-4.0", "False"]], [["-0.126953125", "True"]], [["-2.375", "False"]]], "filtered_resps": [["-4.875", "False"], ["-4.0", "False"], ["-0.126953125", "True"], ["-2.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "105d58f0e42fc7cbe76d81ac11d047398bd740e15ea1d9821adddd10a351e655", "prompt_hash": "5687c49ae03a17913e9e58f00eba738c65fa666cf920f0856c76a5085e6cb103", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 555, "doc": {"question": "下列有關cisplatin的敘述，何者錯誤？", "A": "Saline或mannitol利尿劑可加速藥物的排泄", "B": "使用sodium thiosulfate無法減少其腎毒性", "C": "其monoaquo form及diaquo form均為活性型", "D": "為結構最簡單的含鉑抗癌藥", "answer": "B", "questions": "下列有關cisplatin的敘述，何者錯誤？", "choices": ["Saline或mannitol利尿劑可加速藥物的排泄", "使用sodium thiosulfate無法減少其腎毒性", "其monoaquo form及diaquo form均為活性型", "為結構最簡單的含鉑抗癌藥"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關cisplatin的敘述，何者錯誤？\nA. Saline或mannitol利尿劑可加速藥物的排泄\nB. 使用sodium thiosulfate無法減少其腎毒性\nC. 其monoaquo form及diaquo form均為活性型\nD. 為結構最簡單的含鉑抗癌藥\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關cisplatin的敘述，何者錯誤？\nA. Saline或mannitol利尿劑可加速藥物的排泄\nB. 使用sodium thiosulfate無法減少其腎毒性\nC. 其monoaquo form及diaquo form均為活性型\nD. 為結構最簡單的含鉑抗癌藥\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關cisplatin的敘述，何者錯誤？\nA. Saline或mannitol利尿劑可加速藥物的排泄\nB. 使用sodium thiosulfate無法減少其腎毒性\nC. 其monoaquo form及diaquo form均為活性型\nD. 為結構最簡單的含鉑抗癌藥\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關cisplatin的敘述，何者錯誤？\nA. Saline或mannitol利尿劑可加速藥物的排泄\nB. 使用sodium thiosulfate無法減少其腎毒性\nC. 其monoaquo form及diaquo form均為活性型\nD. 為結構最簡單的含鉑抗癌藥\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.65625", "False"]], [["-0.0247802734375", "True"]], [["-4.03125", "False"]], [["-5.28125", "False"]]], "filtered_resps": [["-6.65625", "False"], ["-0.0247802734375", "True"], ["-4.03125", "False"], ["-5.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "dae375299531aa8d48f8f86ef64d834235832d7eab3c14d9e65a1bc9902519d5", "prompt_hash": "6e2da5d6212b3c2d19596a145bf4a515f7ac844b382ba9b5fe6afe988cb3d4ec", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 556, "doc": {"question": "下列有關影響麻醉誘導速率因素的敘述，何者錯誤？", "A": "增加心輸出量時，誘導速率會加速", "B": "肺泡換氣速率增加時，誘導速率會加速", "C": "提高氣體混合中吸入性麻醉劑比例時，誘導速率會加速", "D": "麻醉劑溶解度高時，誘導速率慢", "answer": "A", "questions": "下列有關影響麻醉誘導速率因素的敘述，何者錯誤？", "choices": ["增加心輸出量時，誘導速率會加速", "肺泡換氣速率增加時，誘導速率會加速", "提高氣體混合中吸入性麻醉劑比例時，誘導速率會加速", "麻醉劑溶解度高時，誘導速率慢"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關影響麻醉誘導速率因素的敘述，何者錯誤？\nA. 增加心輸出量時，誘導速率會加速\nB. 肺泡換氣速率增加時，誘導速率會加速\nC. 提高氣體混合中吸入性麻醉劑比例時，誘導速率會加速\nD. 麻醉劑溶解度高時，誘導速率慢\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關影響麻醉誘導速率因素的敘述，何者錯誤？\nA. 增加心輸出量時，誘導速率會加速\nB. 肺泡換氣速率增加時，誘導速率會加速\nC. 提高氣體混合中吸入性麻醉劑比例時，誘導速率會加速\nD. 麻醉劑溶解度高時，誘導速率慢\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關影響麻醉誘導速率因素的敘述，何者錯誤？\nA. 增加心輸出量時，誘導速率會加速\nB. 肺泡換氣速率增加時，誘導速率會加速\nC. 提高氣體混合中吸入性麻醉劑比例時，誘導速率會加速\nD. 麻醉劑溶解度高時，誘導速率慢\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關影響麻醉誘導速率因素的敘述，何者錯誤？\nA. 增加心輸出量時，誘導速率會加速\nB. 肺泡換氣速率增加時，誘導速率會加速\nC. 提高氣體混合中吸入性麻醉劑比例時，誘導速率會加速\nD. 麻醉劑溶解度高時，誘導速率慢\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.2421875", "False"]], [["-1.2421875", "False"]], [["-2.359375", "False"]], [["-1.1171875", "True"]]], "filtered_resps": [["-1.2421875", "False"], ["-1.2421875", "False"], ["-2.359375", "False"], ["-1.1171875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "14f7581d96d41b530a3310c6a5b739505c60c317319ab7ce1ae459898c38553d", "prompt_hash": "466a8b5aa3e6899313e3422d105fc17670e0cc9287ba1b723c63cefe5dd78062", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 557, "doc": {"question": "有關副交感神經致效劑所產生之反應，下列何者錯誤？", "A": "支氣管收縮作用", "B": "唾液腺分泌增加", "C": "睫狀肌舒張作用", "D": "逼尿肌收縮作用", "answer": "C", "questions": "有關副交感神經致效劑所產生之反應，下列何者錯誤？", "choices": ["支氣管收縮作用", "唾液腺分泌增加", "睫狀肌舒張作用", "逼尿肌收縮作用"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關副交感神經致效劑所產生之反應，下列何者錯誤？\nA. 支氣管收縮作用\nB. 唾液腺分泌增加\nC. 睫狀肌舒張作用\nD. 逼尿肌收縮作用\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關副交感神經致效劑所產生之反應，下列何者錯誤？\nA. 支氣管收縮作用\nB. 唾液腺分泌增加\nC. 睫狀肌舒張作用\nD. 逼尿肌收縮作用\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關副交感神經致效劑所產生之反應，下列何者錯誤？\nA. 支氣管收縮作用\nB. 唾液腺分泌增加\nC. 睫狀肌舒張作用\nD. 逼尿肌收縮作用\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關副交感神經致效劑所產生之反應，下列何者錯誤？\nA. 支氣管收縮作用\nB. 唾液腺分泌增加\nC. 睫狀肌舒張作用\nD. 逼尿肌收縮作用\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.9296875", "False"]], [["-4.8125", "False"]], [["-4.6875", "False"]], [["-0.1787109375", "True"]]], "filtered_resps": [["-1.9296875", "False"], ["-4.8125", "False"], ["-4.6875", "False"], ["-0.1787109375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "95efd8aa0300b45767e66a95759bf524c0276e9906638e55bc30d97af91b32af", "prompt_hash": "781461ad15634697a0a7a245d9abd794cd8c6b334005fbb9391f16a05552fffd", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 558, "doc": {"question": "抗癌藥物procarbazine是經由何種中間體抑制DNA？", "A": "hydroxy radical", "B": "aziridinium ion", "C": "superoxide anion", "D": "methyl radical", "answer": "D", "questions": "抗癌藥物procarbazine是經由何種中間體抑制DNA？", "choices": ["hydroxy radical", "aziridinium ion", "superoxide anion", "methyl radical"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗癌藥物procarbazine是經由何種中間體抑制DNA？\nA. hydroxy radical\nB. aziridinium ion\nC. superoxide anion\nD. methyl radical\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗癌藥物procarbazine是經由何種中間體抑制DNA？\nA. hydroxy radical\nB. aziridinium ion\nC. superoxide anion\nD. methyl radical\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗癌藥物procarbazine是經由何種中間體抑制DNA？\nA. hydroxy radical\nB. aziridinium ion\nC. superoxide anion\nD. methyl radical\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n抗癌藥物procarbazine是經由何種中間體抑制DNA？\nA. hydroxy radical\nB. aziridinium ion\nC. superoxide anion\nD. methyl radical\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.5625", "False"]], [["-3.546875", "False"]], [["-5.4375", "False"]], [["-0.049560546875", "True"]]], "filtered_resps": [["-4.5625", "False"], ["-3.546875", "False"], ["-5.4375", "False"], ["-0.049560546875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "cc03327ae65ad859af72d2a1b3b61eaf6094c99395b7cc11a30d234d32bea8e5", "prompt_hash": "7af98cf1beb6ee387bc02ec52013d664bea3f80e1e32acd0b8871bb51295095d", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 559, "doc": {"question": "下列何種藥物，不具有sulfonamide基團？", "A": "rofecoxib", "B": "acetazolamide", "C": "probenecid", "D": "prontosil", "answer": "A", "questions": "下列何種藥物，不具有sulfonamide基團？", "choices": ["rofecoxib", "acetazolamide", "probenecid", "prontosil"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物，不具有sulfonamide基團？\nA. rofecoxib\nB. acetazolamide\nC. probenecid\nD. prontosil\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物，不具有sulfonamide基團？\nA. rofecoxib\nB. acetazolamide\nC. probenecid\nD. prontosil\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物，不具有sulfonamide基團？\nA. rofecoxib\nB. acetazolamide\nC. probenecid\nD. prontosil\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種藥物，不具有sulfonamide基團？\nA. rofecoxib\nB. acetazolamide\nC. probenecid\nD. prontosil\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.0322265625", "True"]], [["-6.65625", "False"]], [["-4.28125", "False"]], [["-4.28125", "False"]]], "filtered_resps": [["-0.0322265625", "True"], ["-6.65625", "False"], ["-4.28125", "False"], ["-4.28125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "50544df26e242bcab4dc045b43c5424365f20c493c5aee1b5e6e12122dd2f1b0", "prompt_hash": "24b59b0945eed15e84ed3b7ed71f91b6c723805852e5c06d1fe5f22ea281079f", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 560, "doc": {"question": "下列何者是 magnesium hydroxide 治療酸性消化性疾病的副作用？", "A": "滲透性腹瀉", "B": "打嗝", "C": "水腫", "D": "代謝性鹼中毒", "answer": "A", "questions": "下列何者是 magnesium hydroxide 治療酸性消化性疾病的副作用？", "choices": ["滲透性腹瀉", "打嗝", "水腫", "代謝性鹼中毒"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是 magnesium hydroxide 治療酸性消化性疾病的副作用？\nA. 滲透性腹瀉\nB. 打嗝\nC. 水腫\nD. 代謝性鹼中毒\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是 magnesium hydroxide 治療酸性消化性疾病的副作用？\nA. 滲透性腹瀉\nB. 打嗝\nC. 水腫\nD. 代謝性鹼中毒\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是 magnesium hydroxide 治療酸性消化性疾病的副作用？\nA. 滲透性腹瀉\nB. 打嗝\nC. 水腫\nD. 代謝性鹼中毒\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者是 magnesium hydroxide 治療酸性消化性疾病的副作用？\nA. 滲透性腹瀉\nB. 打嗝\nC. 水腫\nD. 代謝性鹼中毒\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.62890625", "True"]], [["-1.5", "False"]], [["-3.875", "False"]], [["-1.5", "False"]]], "filtered_resps": [["-0.62890625", "True"], ["-1.5", "False"], ["-3.875", "False"], ["-1.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4689b7baeda7eb1958b9da2f043d705a21d14a67088dc7eee94e51ce5f99b239", "prompt_hash": "73a7e6719229f8713391e158fcce787fedbbcc8fb970758d42b36252de009a30", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 561, "doc": {"question": "選擇性 COX-2 抑制劑之藥物設計，是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異?", "A": "serine 與 valine", "B": "threonine 與 valine", "C": "leucine 與 valine", "D": "isoleucine 與 valine", "answer": "D", "questions": "選擇性 COX-2 抑制劑之藥物設計，是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異?", "choices": ["serine 與 valine", "threonine 與 valine", "leucine 與 valine", "isoleucine 與 valine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性 COX-2 抑制劑之藥物設計，是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異?\nA. serine 與 valine\nB. threonine 與 valine\nC. leucine 與 valine\nD. isoleucine 與 valine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性 COX-2 抑制劑之藥物設計，是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異?\nA. serine 與 valine\nB. threonine 與 valine\nC. leucine 與 valine\nD. isoleucine 與 valine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性 COX-2 抑制劑之藥物設計，是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異?\nA. serine 與 valine\nB. threonine 與 valine\nC. leucine 與 valine\nD. isoleucine 與 valine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n選擇性 COX-2 抑制劑之藥物設計，是利用 COX-1 與 COX-2 活性中心何種胺基酸的差異?\nA. serine 與 valine\nB. threonine 與 valine\nC. leucine 與 valine\nD. isoleucine 與 valine\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.53125", "False"]], [["-2.40625", "False"]], [["-3.03125", "False"]], [["-0.162109375", "True"]]], "filtered_resps": [["-4.53125", "False"], ["-2.40625", "False"], ["-3.03125", "False"], ["-0.162109375", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "4eb2f7613d2389dcdf4cc5c7d0fbe6e425b2d45d4922ccd8e56d260bbf8dc20d", "prompt_hash": "4e1e782198d0db0cddeb33851aa8fc142c166b03e6fd49823fb4c9f63428b166", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 562, "doc": {"question": "一名男性精神病患服用醫師處方之抗精神病類藥物（antipsychotics）治療疾病，回診時卻抱怨使用該藥物導致其性功能障礙，尤其是產生了顯著射精障礙。該名病患最有可能使用下列那一項抗精神病類藥物？", "A": "haloperidol", "B": "butyrophenone", "C": "fluphenazine", "D": "chlorpromazine", "answer": "D", "questions": "一名男性精神病患服用醫師處方之抗精神病類藥物（antipsychotics）治療疾病，回診時卻抱怨使用該藥物導致其性功能障礙，尤其是產生了顯著射精障礙。該名病患最有可能使用下列那一項抗精神病類藥物？", "choices": ["haloperidol", "butyrophenone", "fluphenazine", "chlorpromazine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一名男性精神病患服用醫師處方之抗精神病類藥物（antipsychotics）治療疾病，回診時卻抱怨使用該藥物導致其性功能障礙，尤其是產生了顯著射精障礙。該名病患最有可能使用下列那一項抗精神病類藥物？\nA. haloperidol\nB. butyrophenone\nC. fluphenazine\nD. chlorpromazine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一名男性精神病患服用醫師處方之抗精神病類藥物（antipsychotics）治療疾病，回診時卻抱怨使用該藥物導致其性功能障礙，尤其是產生了顯著射精障礙。該名病患最有可能使用下列那一項抗精神病類藥物？\nA. haloperidol\nB. butyrophenone\nC. fluphenazine\nD. chlorpromazine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一名男性精神病患服用醫師處方之抗精神病類藥物（antipsychotics）治療疾病，回診時卻抱怨使用該藥物導致其性功能障礙，尤其是產生了顯著射精障礙。該名病患最有可能使用下列那一項抗精神病類藥物？\nA. haloperidol\nB. butyrophenone\nC. fluphenazine\nD. chlorpromazine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n一名男性精神病患服用醫師處方之抗精神病類藥物（antipsychotics）治療疾病，回診時卻抱怨使用該藥物導致其性功能障礙，尤其是產生了顯著射精障礙。該名病患最有可能使用下列那一項抗精神病類藥物？\nA. haloperidol\nB. butyrophenone\nC. fluphenazine\nD. chlorpromazine\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.65625", "False"]], [["-0.404296875", "True"]], [["-2.65625", "False"]], [["-1.65625", "False"]]], "filtered_resps": [["-2.65625", "False"], ["-0.404296875", "True"], ["-2.65625", "False"], ["-1.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "aa53a431928715192be94f8844e18edcc3fef033d5e633c33e5bf166d973150b", "prompt_hash": "b0ff45d73031140deacd8c2fbc6a03785656c55192a74a7156a6fbc606131b38", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 563, "doc": {"question": "Mitoxantrone在體內之代謝反應，不會經由下列何種途徑？", "A": "N-dealkylation", "B": "glucuronide conjugation", "C": "reduction", "D": "oxidative deamination", "answer": "C", "questions": "Mitoxantrone在體內之代謝反應，不會經由下列何種途徑？", "choices": ["N-dealkylation", "glucuronide conjugation", "reduction", "oxidative deamination"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMitoxantrone在體內之代謝反應，不會經由下列何種途徑？\nA. N-dealkylation\nB. glucuronide conjugation\nC. reduction\nD. oxidative deamination\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMitoxantrone在體內之代謝反應，不會經由下列何種途徑？\nA. N-dealkylation\nB. glucuronide conjugation\nC. reduction\nD. oxidative deamination\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMitoxantrone在體內之代謝反應，不會經由下列何種途徑？\nA. N-dealkylation\nB. glucuronide conjugation\nC. reduction\nD. oxidative deamination\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMitoxantrone在體內之代謝反應，不會經由下列何種途徑？\nA. N-dealkylation\nB. glucuronide conjugation\nC. reduction\nD. oxidative deamination\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.625", "False"]], [["-3.75", "False"]], [["-0.3828125", "True"]], [["-1.5078125", "False"]]], "filtered_resps": [["-2.625", "False"], ["-3.75", "False"], ["-0.3828125", "True"], ["-1.5078125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "2befaa93142b33e133bfbbfca27bbee0258d2a22bce0f604376a98f53ca792f5", "prompt_hash": "1827c07a917e8e30e29de4c43bdcaf7e313cb8255ca346d9e0c94f3299fcb753", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 564, "doc": {"question": "Methyldopa的最終活性代謝物，與下列何藥的作用機制最相似？", "A": "propranolol", "B": "guanethidine", "C": "clonidine", "D": "prazosin", "answer": "C", "questions": "Methyldopa的最終活性代謝物，與下列何藥的作用機制最相似？", "choices": ["propranolol", "guanethidine", "clonidine", "prazosin"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethyldopa的最終活性代謝物，與下列何藥的作用機制最相似？\nA. propranolol\nB. guanethidine\nC. clonidine\nD. prazosin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethyldopa的最終活性代謝物，與下列何藥的作用機制最相似？\nA. propranolol\nB. guanethidine\nC. clonidine\nD. prazosin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethyldopa的最終活性代謝物，與下列何藥的作用機制最相似？\nA. propranolol\nB. guanethidine\nC. clonidine\nD. prazosin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nMethyldopa的最終活性代謝物，與下列何藥的作用機制最相似？\nA. propranolol\nB. guanethidine\nC. clonidine\nD. prazosin\nAnswer:", "arg_1": " D"}}, "resps": [[["-5.8125", "False"]], [["-6.9375", "False"]], [["-0.056396484375", "True"]], [["-6.8125", "False"]]], "filtered_resps": [["-5.8125", "False"], ["-6.9375", "False"], ["-0.056396484375", "True"], ["-6.8125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "33c2a411f57f596b064bfac8bcec6ce006e0be79a97b3b1f40fd0b0d3650f45e", "prompt_hash": "123af165b73e2e5898c58b6fb9e765266702fe43dc2aec488573dae2b177a264", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 565, "doc": {"question": "Leflunomide的何種基團，能形成具α-cyanoenol之活性代謝物？", "A": "oxazole", "B": "oxazoline", "C": "isoxazole", "D": "isoxazoline", "answer": "C", "questions": "Leflunomide的何種基團，能形成具α-cyanoenol之活性代謝物？", "choices": ["oxazole", "oxazoline", "isoxazole", "isoxazoline"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLeflunomide的何種基團，能形成具α-cyanoenol之活性代謝物？\nA. oxazole\nB. oxazoline\nC. isoxazole\nD. isoxazoline\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLeflunomide的何種基團，能形成具α-cyanoenol之活性代謝物？\nA. oxazole\nB. oxazoline\nC. isoxazole\nD. isoxazoline\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLeflunomide的何種基團，能形成具α-cyanoenol之活性代謝物？\nA. oxazole\nB. oxazoline\nC. isoxazole\nD. isoxazoline\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nLeflunomide的何種基團，能形成具α-cyanoenol之活性代謝物？\nA. oxazole\nB. oxazoline\nC. isoxazole\nD. isoxazoline\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.25390625", "True"]], [["-3.625", "False"]], [["-2.25", "False"]], [["-2.375", "False"]]], "filtered_resps": [["-0.25390625", "True"], ["-3.625", "False"], ["-2.25", "False"], ["-2.375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "951b1b8927769e86de2847de74d58f1a15ffbd45560e96e2271e456e068a6a0d", "prompt_hash": "2bb5cb7d82d8e49ad8c4723835084244eb94bb3bfaf794eafac8f94cb5126010", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 566, "doc": {"question": "在鹼性條件下，蛋白藥物結構中之何種胺基酸殘基最易發生消旋反應？", "A": "L-threonine", "B": "L-lysine", "C": "L-aspartic acid", "D": "L-tyrosine", "answer": "C", "questions": "在鹼性條件下，蛋白藥物結構中之何種胺基酸殘基最易發生消旋反應？", "choices": ["L-threonine", "L-lysine", "L-aspartic acid", "L-tyrosine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在鹼性條件下，蛋白藥物結構中之何種胺基酸殘基最易發生消旋反應？\nA. L-threonine\nB. L-lysine\nC. L-aspartic acid\nD. L-tyrosine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在鹼性條件下，蛋白藥物結構中之何種胺基酸殘基最易發生消旋反應？\nA. L-threonine\nB. L-lysine\nC. L-aspartic acid\nD. L-tyrosine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在鹼性條件下，蛋白藥物結構中之何種胺基酸殘基最易發生消旋反應？\nA. L-threonine\nB. L-lysine\nC. L-aspartic acid\nD. L-tyrosine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n在鹼性條件下，蛋白藥物結構中之何種胺基酸殘基最易發生消旋反應？\nA. L-threonine\nB. L-lysine\nC. L-aspartic acid\nD. L-tyrosine\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.453125", "False"]], [["-0.1953125", "True"]], [["-3.078125", "False"]], [["-2.328125", "False"]]], "filtered_resps": [["-3.453125", "False"], ["-0.1953125", "True"], ["-3.078125", "False"], ["-2.328125", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "5e216f35d2d75b1a0cae4852947137503729939197a63e162ea71483afad87dc", "prompt_hash": "1a29319a67c22d2ca0fef78795df489b969b41fc4180556b3965b98b65e84653", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 0.0, "acc_norm": 0.0}
{"doc_id": 567, "doc": {"question": "帕金森氏症的發生係下列那兩種神經傳遞物質的平衡失調所造成的？", "A": "Glutamate/GABA", "B": "Norepinephrine/Epinephrine", "C": "Dopamine/Acetylcholine", "D": "Serotonin/Dopamine", "answer": "C", "questions": "帕金森氏症的發生係下列那兩種神經傳遞物質的平衡失調所造成的？", "choices": ["Glutamate/GABA", "Norepinephrine/Epinephrine", "Dopamine/Acetylcholine", "Serotonin/Dopamine"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n帕金森氏症的發生係下列那兩種神經傳遞物質的平衡失調所造成的？\nA. Glutamate/GABA\nB. Norepinephrine/Epinephrine\nC. Dopamine/Acetylcholine\nD. Serotonin/Dopamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n帕金森氏症的發生係下列那兩種神經傳遞物質的平衡失調所造成的？\nA. Glutamate/GABA\nB. Norepinephrine/Epinephrine\nC. Dopamine/Acetylcholine\nD. Serotonin/Dopamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n帕金森氏症的發生係下列那兩種神經傳遞物質的平衡失調所造成的？\nA. Glutamate/GABA\nB. Norepinephrine/Epinephrine\nC. Dopamine/Acetylcholine\nD. Serotonin/Dopamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n帕金森氏症的發生係下列那兩種神經傳遞物質的平衡失調所造成的？\nA. Glutamate/GABA\nB. Norepinephrine/Epinephrine\nC. Dopamine/Acetylcholine\nD. Serotonin/Dopamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.125", "False"]], [["-8.0", "False"]], [["-0.012939453125", "True"]], [["-5.5", "False"]]], "filtered_resps": [["-6.125", "False"], ["-8.0", "False"], ["-0.012939453125", "True"], ["-5.5", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "6af8efc2f5162bfd692dfdc04166d59d271bddc3dc2c613ccd79d5c4fcfc482d", "prompt_hash": "f01be68d1a644b80de88ae5cf0bc033752aed682d4b4776a75e1b99e4845bd7b", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 568, "doc": {"question": "下列何者為抗病毒藥foscarnet sodium之作用標的？", "A": "RNA polymerase", "B": "DNA polymerase", "C": "thymidylate synthase", "D": "thymidine kinase", "answer": "B", "questions": "下列何者為抗病毒藥foscarnet sodium之作用標的？", "choices": ["RNA polymerase", "DNA polymerase", "thymidylate synthase", "thymidine kinase"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗病毒藥foscarnet sodium之作用標的？\nA. RNA polymerase\nB. DNA polymerase\nC. thymidylate synthase\nD. thymidine kinase\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗病毒藥foscarnet sodium之作用標的？\nA. RNA polymerase\nB. DNA polymerase\nC. thymidylate synthase\nD. thymidine kinase\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗病毒藥foscarnet sodium之作用標的？\nA. RNA polymerase\nB. DNA polymerase\nC. thymidylate synthase\nD. thymidine kinase\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何者為抗病毒藥foscarnet sodium之作用標的？\nA. RNA polymerase\nB. DNA polymerase\nC. thymidylate synthase\nD. thymidine kinase\nAnswer:", "arg_1": " D"}}, "resps": [[["-6.25", "False"]], [["-0.013427734375", "True"]], [["-6.0", "False"]], [["-4.875", "False"]]], "filtered_resps": [["-6.25", "False"], ["-0.013427734375", "True"], ["-6.0", "False"], ["-4.875", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "eb29299774576fcda7cc313c980dcb8de88a57a53ae058fbbde5002767648d56", "prompt_hash": "4a7d2a9c5f5ad303b4120b78f66f9ed5d49e750a477cb33f5aa8a3d58ddabbe8", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 569, "doc": {"question": "CYP2D6 基因型為 CYP2D6*4 等位基因（allele）者，對於使用 tamoxifen 或 tolterodine 治療的影響，分別為何？", "A": "tamoxifen 療效增加、tolterodine 副作用增加", "B": "tamoxifen 療效減弱、tolterodine 副作用增加", "C": "tamoxifen 療效增加、tolterodine 副作用降低", "D": "tamoxifen 療效減弱、tolterodine 副作用降低", "answer": "B", "questions": "CYP2D6 基因型為 CYP2D6*4 等位基因（allele）者，對於使用 tamoxifen 或 tolterodine 治療的影響，分別為何？", "choices": ["tamoxifen 療效增加、tolterodine 副作用增加", "tamoxifen 療效減弱、tolterodine 副作用增加", "tamoxifen 療效增加、tolterodine 副作用降低", "tamoxifen 療效減弱、tolterodine 副作用降低"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCYP2D6 基因型為 CYP2D6*4 等位基因（allele）者，對於使用 tamoxifen 或 tolterodine 治療的影響，分別為何？\nA. tamoxifen 療效增加、tolterodine 副作用增加\nB. tamoxifen 療效減弱、tolterodine 副作用增加\nC. tamoxifen 療效增加、tolterodine 副作用降低\nD. tamoxifen 療效減弱、tolterodine 副作用降低\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCYP2D6 基因型為 CYP2D6*4 等位基因（allele）者，對於使用 tamoxifen 或 tolterodine 治療的影響，分別為何？\nA. tamoxifen 療效增加、tolterodine 副作用增加\nB. tamoxifen 療效減弱、tolterodine 副作用增加\nC. tamoxifen 療效增加、tolterodine 副作用降低\nD. tamoxifen 療效減弱、tolterodine 副作用降低\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCYP2D6 基因型為 CYP2D6*4 等位基因（allele）者，對於使用 tamoxifen 或 tolterodine 治療的影響，分別為何？\nA. tamoxifen 療效增加、tolterodine 副作用增加\nB. tamoxifen 療效減弱、tolterodine 副作用增加\nC. tamoxifen 療效增加、tolterodine 副作用降低\nD. tamoxifen 療效減弱、tolterodine 副作用降低\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\nCYP2D6 基因型為 CYP2D6*4 等位基因（allele）者，對於使用 tamoxifen 或 tolterodine 治療的影響，分別為何？\nA. tamoxifen 療效增加、tolterodine 副作用增加\nB. tamoxifen 療效減弱、tolterodine 副作用增加\nC. tamoxifen 療效增加、tolterodine 副作用降低\nD. tamoxifen 療效減弱、tolterodine 副作用降低\nAnswer:", "arg_1": " D"}}, "resps": [[["-3.28125", "False"]], [["-0.158203125", "True"]], [["-4.15625", "False"]], [["-2.40625", "False"]]], "filtered_resps": [["-3.28125", "False"], ["-0.158203125", "True"], ["-4.15625", "False"], ["-2.40625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "e3d7a01884044996653c314f3d8397560d005402ce831ef5938f818685ca1910", "prompt_hash": "984fac5d2a757b2f81c78a95e1bef3e4e4754e76e9fc80cc170628acb6ba9254", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 570, "doc": {"question": "下列何種抗生素結構含有N-methylpyrrolidine？", "A": "lincomycin", "B": "amikacin", "C": "chloramphenicol", "D": "bacitracin", "answer": "A", "questions": "下列何種抗生素結構含有N-methylpyrrolidine？", "choices": ["lincomycin", "amikacin", "chloramphenicol", "bacitracin"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗生素結構含有N-methylpyrrolidine？\nA. lincomycin\nB. amikacin\nC. chloramphenicol\nD. bacitracin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗生素結構含有N-methylpyrrolidine？\nA. lincomycin\nB. amikacin\nC. chloramphenicol\nD. bacitracin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗生素結構含有N-methylpyrrolidine？\nA. lincomycin\nB. amikacin\nC. chloramphenicol\nD. bacitracin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種抗生素結構含有N-methylpyrrolidine？\nA. lincomycin\nB. amikacin\nC. chloramphenicol\nD. bacitracin\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.1064453125", "True"]], [["-4.34375", "False"]], [["-4.34375", "False"]], [["-2.609375", "False"]]], "filtered_resps": [["-0.1064453125", "True"], ["-4.34375", "False"], ["-4.34375", "False"], ["-2.609375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "9b031052a963f624da9431038e5c1d087653f32a74aedd807542da9ca9775101", "prompt_hash": "3ff023d76a870e8a64f0d1e673cfcf2756623e8818a24c0b736bb340e89838f0", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 571, "doc": {"question": "有關免疫檢查點抑制劑（immune checkpoint inhibitor），下列何者錯誤？", "A": "avelumab與pembrolizumab皆可阻斷PD-1與PD-L1的結合", "B": "belimumab可有效的阻斷T細胞上CD2的活化", "C": "有針對腫瘤或免疫T細胞上受體作用之抑制劑", "D": "比起傳統化療藥物例如alkylating agents副作用小", "answer": "B", "questions": "有關免疫檢查點抑制劑（immune checkpoint inhibitor），下列何者錯誤？", "choices": ["avelumab與pembrolizumab皆可阻斷PD-1與PD-L1的結合", "belimumab可有效的阻斷T細胞上CD2的活化", "有針對腫瘤或免疫T細胞上受體作用之抑制劑", "比起傳統化療藥物例如alkylating agents副作用小"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關免疫檢查點抑制劑（immune checkpoint inhibitor），下列何者錯誤？\nA. avelumab與pembrolizumab皆可阻斷PD-1與PD-L1的結合\nB. belimumab可有效的阻斷T細胞上CD2的活化\nC. 有針對腫瘤或免疫T細胞上受體作用之抑制劑\nD. 比起傳統化療藥物例如alkylating agents副作用小\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關免疫檢查點抑制劑（immune checkpoint inhibitor），下列何者錯誤？\nA. avelumab與pembrolizumab皆可阻斷PD-1與PD-L1的結合\nB. belimumab可有效的阻斷T細胞上CD2的活化\nC. 有針對腫瘤或免疫T細胞上受體作用之抑制劑\nD. 比起傳統化療藥物例如alkylating agents副作用小\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關免疫檢查點抑制劑（immune checkpoint inhibitor），下列何者錯誤？\nA. avelumab與pembrolizumab皆可阻斷PD-1與PD-L1的結合\nB. belimumab可有效的阻斷T細胞上CD2的活化\nC. 有針對腫瘤或免疫T細胞上受體作用之抑制劑\nD. 比起傳統化療藥物例如alkylating agents副作用小\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n有關免疫檢查點抑制劑（immune checkpoint inhibitor），下列何者錯誤？\nA. avelumab與pembrolizumab皆可阻斷PD-1與PD-L1的結合\nB. belimumab可有效的阻斷T細胞上CD2的活化\nC. 有針對腫瘤或免疫T細胞上受體作用之抑制劑\nD. 比起傳統化療藥物例如alkylating agents副作用小\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.65625", "False"]], [["-0.021484375", "True"]], [["-6.78125", "False"]], [["-4.65625", "False"]]], "filtered_resps": [["-4.65625", "False"], ["-0.021484375", "True"], ["-6.78125", "False"], ["-4.65625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "f099082dcc255fc3023cf2698c17e107af4fd229579036b5609f794d878d14be", "prompt_hash": "90e8e10b86260bf816f055485edfd178c1cd880db1af6ffdd8345ce3787e678a", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 572, "doc": {"question": "下列中草藥中，何者具有促進prolactin產生之藥理活性，因此傳統上可促進哺乳婦女乳汁分泌？", "A": "St. John's wort", "B": "milk thistle", "C": "ginseng", "D": "ginkgo", "answer": "B", "questions": "下列中草藥中，何者具有促進prolactin產生之藥理活性，因此傳統上可促進哺乳婦女乳汁分泌？", "choices": ["St. John's wort", "milk thistle", "ginseng", "ginkgo"], "goal": 1}, "target": "B", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中草藥中，何者具有促進prolactin產生之藥理活性，因此傳統上可促進哺乳婦女乳汁分泌？\nA. St. John's wort\nB. milk thistle\nC. ginseng\nD. ginkgo\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中草藥中，何者具有促進prolactin產生之藥理活性，因此傳統上可促進哺乳婦女乳汁分泌？\nA. St. John's wort\nB. milk thistle\nC. ginseng\nD. ginkgo\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中草藥中，何者具有促進prolactin產生之藥理活性，因此傳統上可促進哺乳婦女乳汁分泌？\nA. St. John's wort\nB. milk thistle\nC. ginseng\nD. ginkgo\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列中草藥中，何者具有促進prolactin產生之藥理活性，因此傳統上可促進哺乳婦女乳汁分泌？\nA. St. John's wort\nB. milk thistle\nC. ginseng\nD. ginkgo\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.53125", "False"]], [["-0.0228271484375", "True"]], [["-4.90625", "False"]], [["-5.90625", "False"]]], "filtered_resps": [["-4.53125", "False"], ["-0.0228271484375", "True"], ["-4.90625", "False"], ["-5.90625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "dbabbfdf660b903379d933e82fe1a6354a4660b41e03f9c486248ce29b09fe39", "prompt_hash": "b4c6289f5838e304dcc023f6d166c24badfdc2ce3e581061e07f6aa7d6330204", "target_hash": "df7e70e5021544f4834bbee64a9e3789febc4be81470df629cad6ddb03320a5c", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 573, "doc": {"question": "下列有關esmolol之敘述，何者錯誤？", "A": "屬於長效性作用藥物", "B": "選擇性作用於β1受體", "C": "適用於上心室心搏過速（supraventricular tachycardia）之患者", "D": "結構之骨架為aryloxypropanolamine", "answer": "A", "questions": "下列有關esmolol之敘述，何者錯誤？", "choices": ["屬於長效性作用藥物", "選擇性作用於β1受體", "適用於上心室心搏過速（supraventricular tachycardia）之患者", "結構之骨架為aryloxypropanolamine"], "goal": 0}, "target": "A", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關esmolol之敘述，何者錯誤？\nA. 屬於長效性作用藥物\nB. 選擇性作用於β1受體\nC. 適用於上心室心搏過速（supraventricular tachycardia）之患者\nD. 結構之骨架為aryloxypropanolamine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關esmolol之敘述，何者錯誤？\nA. 屬於長效性作用藥物\nB. 選擇性作用於β1受體\nC. 適用於上心室心搏過速（supraventricular tachycardia）之患者\nD. 結構之骨架為aryloxypropanolamine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關esmolol之敘述，何者錯誤？\nA. 屬於長效性作用藥物\nB. 選擇性作用於β1受體\nC. 適用於上心室心搏過速（supraventricular tachycardia）之患者\nD. 結構之骨架為aryloxypropanolamine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列有關esmolol之敘述，何者錯誤？\nA. 屬於長效性作用藥物\nB. 選擇性作用於β1受體\nC. 適用於上心室心搏過速（supraventricular tachycardia）之患者\nD. 結構之骨架為aryloxypropanolamine\nAnswer:", "arg_1": " D"}}, "resps": [[["-0.06298828125", "True"]], [["-2.8125", "False"]], [["-8.8125", "False"]], [["-7.4375", "False"]]], "filtered_resps": [["-0.06298828125", "True"], ["-2.8125", "False"], ["-8.8125", "False"], ["-7.4375", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "7eaf9297a475952d9e0f1934aaec89eb90fe0a3118a6d4bb7ea5f592f8f30a3a", "prompt_hash": "2c3b5f3cc654cb7951395c03ff7ed0ccf25d66342f6ab92ab91b3449176cfeed", "target_hash": "559aead08264d5795d3909718cdd05abd49572e84fe55590eef31a88a08fdffd", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 574, "doc": {"question": "下列抗癌藥中，何者具有胺醣（amino sugar）結構？", "A": "mitomycin", "B": "mitoxantrone", "C": "dactinomycin", "D": "daunorubicin", "answer": "D", "questions": "下列抗癌藥中，何者具有胺醣（amino sugar）結構？", "choices": ["mitomycin", "mitoxantrone", "dactinomycin", "daunorubicin"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌藥中，何者具有胺醣（amino sugar）結構？\nA. mitomycin\nB. mitoxantrone\nC. dactinomycin\nD. daunorubicin\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌藥中，何者具有胺醣（amino sugar）結構？\nA. mitomycin\nB. mitoxantrone\nC. dactinomycin\nD. daunorubicin\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌藥中，何者具有胺醣（amino sugar）結構？\nA. mitomycin\nB. mitoxantrone\nC. dactinomycin\nD. daunorubicin\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列抗癌藥中，何者具有胺醣（amino sugar）結構？\nA. mitomycin\nB. mitoxantrone\nC. dactinomycin\nD. daunorubicin\nAnswer:", "arg_1": " D"}}, "resps": [[["-4.78125", "False"]], [["-4.78125", "False"]], [["-4.65625", "False"]], [["-0.0301513671875", "True"]]], "filtered_resps": [["-4.78125", "False"], ["-4.78125", "False"], ["-4.65625", "False"], ["-0.0301513671875", "True"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "11bb7d40826df6d8dcdd2119cc544cb8d82b2f969f2a8246c434c7da81fe2d27", "prompt_hash": "e00840b16b4be20b87e4cd8b96a92be5ba0cd8d13444124de62a4935aad4c846", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 575, "doc": {"question": "下列藥物分子與受體的結合中，何者通常較能延長藥物作用時間？", "A": "氫鍵", "B": "凡得瓦爾力", "C": "共價鍵", "D": "離子鍵", "answer": "C", "questions": "下列藥物分子與受體的結合中，何者通常較能延長藥物作用時間？", "choices": ["氫鍵", "凡得瓦爾力", "共價鍵", "離子鍵"], "goal": 2}, "target": "C", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物分子與受體的結合中，何者通常較能延長藥物作用時間？\nA. 氫鍵\nB. 凡得瓦爾力\nC. 共價鍵\nD. 離子鍵\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物分子與受體的結合中，何者通常較能延長藥物作用時間？\nA. 氫鍵\nB. 凡得瓦爾力\nC. 共價鍵\nD. 離子鍵\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物分子與受體的結合中，何者通常較能延長藥物作用時間？\nA. 氫鍵\nB. 凡得瓦爾力\nC. 共價鍵\nD. 離子鍵\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列藥物分子與受體的結合中，何者通常較能延長藥物作用時間？\nA. 氫鍵\nB. 凡得瓦爾力\nC. 共價鍵\nD. 離子鍵\nAnswer:", "arg_1": " D"}}, "resps": [[["-1.6640625", "False"]], [["-2.53125", "False"]], [["-0.7890625", "True"]], [["-1.2890625", "False"]]], "filtered_resps": [["-1.6640625", "False"], ["-2.53125", "False"], ["-0.7890625", "True"], ["-1.2890625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "05254d2d991690030104fc00cd3dbcdf9612487938973e99c80931743fb6adb5", "prompt_hash": "f5034cfb139676bf4f395d63fbbae76a884c573134eb6449c62a09599e6ad4f3", "target_hash": "6b23c0d5f35d1b11f9b683f0b0a617355deb11277d91ae091d399c655b87940d", "acc": 1.0, "acc_norm": 1.0}
{"doc_id": 576, "doc": {"question": "下列何種麻醉藥結構不屬於amino amide-type？", "A": "ropivacaine", "B": "mepivacaine", "C": "lidocaine", "D": "tetracaine", "answer": "D", "questions": "下列何種麻醉藥結構不屬於amino amide-type？", "choices": ["ropivacaine", "mepivacaine", "lidocaine", "tetracaine"], "goal": 3}, "target": "D", "arguments": {"gen_args_0": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種麻醉藥結構不屬於amino amide-type？\nA. ropivacaine\nB. mepivacaine\nC. lidocaine\nD. tetracaine\nAnswer:", "arg_1": " A"}, "gen_args_1": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種麻醉藥結構不屬於amino amide-type？\nA. ropivacaine\nB. mepivacaine\nC. lidocaine\nD. tetracaine\nAnswer:", "arg_1": " B"}, "gen_args_2": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種麻醉藥結構不屬於amino amide-type？\nA. ropivacaine\nB. mepivacaine\nC. lidocaine\nD. tetracaine\nAnswer:", "arg_1": " C"}, "gen_args_3": {"arg_0": "以下為藥理學的單選題，請提供正確答案的選項。\n\n下列何種麻醉藥結構不屬於amino amide-type？\nA. ropivacaine\nB. mepivacaine\nC. lidocaine\nD. tetracaine\nAnswer:", "arg_1": " D"}}, "resps": [[["-2.140625", "False"]], [["-0.388671875", "True"]], [["-3.640625", "False"]], [["-1.765625", "False"]]], "filtered_resps": [["-2.140625", "False"], ["-0.388671875", "True"], ["-3.640625", "False"], ["-1.765625", "False"]], "filter": "none", "metrics": ["acc", "acc_norm"], "doc_hash": "b61d3fe57c4480d06f150400653f7a21d912147ab93ea13864cc1338efda9ac5", "prompt_hash": "09f546e317e3a0783cb6639e6f0ca5788eaa6677fc6b071cde264e87c2b7e2a6", "target_hash": "3f39d5c348e5b79d06e842c114e6cc571583bbf44e4b0ebfda1a01ec05745d43", "acc": 0.0, "acc_norm": 0.0}
